Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
in	O
a	O
sporadic	B-Disease
T	I-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
.	O

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
is	O
a	O
recessive	B-Disease
multi	I-Disease
-	I-Disease
system	I-Disease
disorder	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
.	O

The	O
risk	O
of	O
cancer	B-Disease
,	O
especially	O
lymphoid	B-Disease
neoplasias	I-Disease
,	O
is	O
substantially	O
elevated	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O

By	O
analysing	O
tumour	B-Disease
DNA	O
from	O
patients	O
with	O
sporadic	B-Disease
T	I-Disease
-	I-Disease
cell	I-Disease
prolymphocytic	I-Disease
leukaemia	I-Disease
(	O
T	B-Disease
-	I-Disease
PLL	I-Disease
)	O
,	O
a	O
rare	O
clonal	B-Disease
malignancy	I-Disease
with	O
similarities	O
to	O
a	O
mature	B-Disease
T	I-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
seen	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T	B-Disease
-	I-Disease
PLL	I-Disease
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B-Disease
were	O
missense	O
mutations	O
.	O

These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
.	O
<EOS>	B-X
The	B-X
combined	B-X
structural	B-X
modeling	B-X
,	B-X
steady	B-X
-	B-X
state	B-X
kinetics	B-X
,	B-X
and	B-X
mutational	B-X
analyses	B-X
lead	B-X
to	B-X
the	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
substrate	B-X
recognition	B-X
of	B-X
BlsG	B-X
<EOS>	B-X
Based	B-X
on	B-X
a	B-X
generalized	B-X
,	B-X
CYP3A4	B-X
-	B-X
related	B-X
construct	B-X
,	B-X
the	B-X
sum	B-X
of	B-X
critical	B-X
elements	B-X
from	B-X
diverse	B-X
target	B-X
enzymes	B-X
was	B-X
found	B-X
to	B-X
cluster	B-X
within	B-X
the	B-X
known	B-X
substrate	B-X
recognition	B-X
sites	B-X
<EOS>	B-X
The	B-X
strength	B-X
of	B-X
anion	B-X
-	B-X
Ï€	B-X
interactions	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
electric	B-X
fields	B-X
on	B-X
the	B-X
electrode	B-X
<EOS>	B-X
Key	B-X
regulators	B-X
in	B-X
the	B-X
architecture	B-X
of	B-X
substrate	B-X
access	B-X
/	B-X
egress	B-X
channels	B-X
in	B-X
mammalian	B-X
cytochromes	B-X
P450	B-X
governing	B-X
flexibility	B-X
in	B-X
substrate	B-X
oxyfunctionalization	B-X
.	B-X

Two	O
of	O
seventeen	O
mutated	O
T	B-Disease
-	I-Disease
PLL	I-Disease
samples	O
had	O
a	O
previously	O
reported	O
A	B-Disease
-	I-Disease
T	I-Disease
allele	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B-Disease
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B-Disease
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
p53	B-X
gene	B-X
mutation	B-X
has	B-X
been	B-X
rarely	B-X
detected	B-X
in	B-X
feline	B-X
malignancies	B-X
,	B-X
and	B-X
most	B-X
feline	B-X
malignancies	B-X
conceivably	B-X
retain	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
p53	B-X
(	B-X
wt	B-X
-	B-X
p53	B-X
)	B-X
gene	B-X
<EOS>	B-X
Thus	B-X
,	B-X
a	B-X
mechanism	B-X
for	B-X
direct	B-X
p53	B-X
-	B-X
dependent	B-X
transcriptional	B-X
repression	B-X
is	B-X
not	B-X
supported	B-X
by	B-X
the	B-X
data	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
EGFR	B-X
mutation	B-X
rates	B-X
were	B-X
not	B-X
significantly	B-X
associated	B-X
with	B-X
staging	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
TP53	B-X
mutation	B-X
was	B-X
absent	B-X
(	B-X
0	B-X
/	B-X
4	B-X
)	B-X
in	B-X
MLH1	B-X
-	B-X
negative	B-X
small	B-X
intramucosal	B-X
carcinoma	B-X
(	B-X
8	B-X
-	B-X
24	B-X
mm	B-X
)	B-X

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	O
in	O
tumour	B-Disease
DNA	O
from	O
patients	O
with	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkins	I-Disease
lymphomas	I-Disease
(	O
B	B-Disease
-	I-Disease
NHL	I-Disease
)	O
and	O
a	O
B	B-Disease
-	I-Disease
NHL	I-Disease
cell	O
line	O
.	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B-Disease
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-Disease
T	I-Disease
-	I-Disease
PLL	I-Disease
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	B-Disease
suppressor	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B-Disease
-	I-Disease
PLL	I-Disease
will	O
require	O
further	O
investigation	O
.	O
.	O
<EOS>	B-X
The	B-X
constitution	B-X
of	B-X
bioactive	B-X
anticancer	B-X
nanoconjugates	B-X
from	B-X
natural	B-X
derivatives	B-X
,	B-X
e	B-X
<EOS>	B-X
Next	B-X
-	B-X
generation	B-X
diagnostics	B-X
adds	B-X
robust	B-X
and	B-X
relevant	B-X
information	B-X
on	B-X
diagnosis	B-X
,	B-X
actionable	B-X
alterations	B-X
and	B-X
cancer	B-X
predisposition	B-X
syndromes	B-X
even	B-X
when	B-X
tissue	B-X
from	B-X
the	B-X
current	B-X
disease	B-X
episode	B-X
is	B-X
limited	B-X
<EOS>	B-X
Retrospective	B-X
chart	B-X
and	B-X
imaging	B-X
review	B-X
of	B-X
patients	B-X
with	B-X
primary	B-X
aortic	B-X
infection	B-X
<EOS>	B-X
Dysfunctions	B-X
in	B-X
mismatch	B-X
repair	B-X
lead	B-X
to	B-X
a	B-X
predisposition	B-X
to	B-X
cancer	B-X

Myotonic	B-Disease
dystrophy	I-Disease
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
protein	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
the	B-X
Ca2+	B-X
homeostasis	B-X
in	B-X
skeletal	B-X
muscle	B-X
cells	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
myotonic	B-X
dystrophy	B-X
protein	B-X
kinase	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
Ca2+	B-X
homeostasis	B-X
in	B-X
cardiac	B-X
myofibres	B-X
<EOS>	B-X
Confocal	B-X
images	B-X
of	B-X
the	B-X
protein	B-X
kinase	B-X
immunostaining	B-X
showed	B-X
striated	B-X
banding	B-X
patterns	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
skeletal	B-X
muscles	B-X
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
protein	B-X
kinase	B-X
has	B-X
been	B-X
examined	B-X
in	B-X
human	B-X
cardiac	B-X
muscles	B-X
with	B-X
confocal	B-X
laser	B-X
-	B-X
scanning	B-X
microscopy	B-X
and	B-X
electron	B-X
microscopy	B-X

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
,	O
the	O
most	O
prevalent	O
muscular	B-Disease
disorder	I-Disease
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B-Disease
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O
.	O
<EOS>	B-X
In	B-X
vitro	B-X
-	B-X
differentiated	B-X
DMPK	B-X
[	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
]	B-X
myotubes	B-X
exhibit	B-X
a	B-X
higher	B-X
resting	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
than	B-X
do	B-X
wild	B-X
-	B-X
type	B-X
myotubes	B-X
because	B-X
of	B-X
an	B-X
altered	B-X
open	B-X
probability	B-X
of	B-X
voltage	B-X
-	B-X
dependent	B-X
l	B-X
-	B-X
type	B-X
Ca2+	B-X
and	B-X
Na+	B-X
channels	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
these	B-X
Ca2+	B-X
transients	B-X
partially	B-X
result	B-X
from	B-X
an	B-X
influx	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
through	B-X
the	B-X
l	B-X
-	B-X
type	B-X
Ca2+	B-X
channel	B-X
<EOS>	B-X
To	B-X
obtain	B-X
clues	B-X
to	B-X
the	B-X
normal	B-X
biological	B-X
role	B-X
of	B-X
DMPK	B-X
in	B-X
cellular	B-X
ion	B-X
homeostasis	B-X
,	B-X
we	B-X
have	B-X
compared	B-X
the	B-X
resting	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
,	B-X
the	B-X
amplitude	B-X
and	B-X
shape	B-X
of	B-X
depolarization	B-X
-	B-X
induced	B-X
Ca2+	B-X
transients	B-X
,	B-X
and	B-X
the	B-X
content	B-X
of	B-X
ATP	B-X
-	B-X
driven	B-X
ion	B-X
pumps	B-X
in	B-X
cultured	B-X
skeletal	B-X
muscle	B-X
cells	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
and	B-X
DMPK	B-X
[	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
]	B-X
knockout	B-X
mice	B-X
<EOS>	B-X
The	B-X
mutant	B-X
myotubes	B-X
exhibit	B-X
smaller	B-X
and	B-X
slower	B-X
Ca2+	B-X
responses	B-X
upon	B-X
triggering	B-X
by	B-X
acetylcholine	B-X
or	B-X
high	B-X
external	B-X
K+	B-X

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O
<EOS>	B-X
When	B-X
divided	B-X
into	B-X
strength	B-X
groups	B-X
,	B-X
correlations	B-X
between	B-X
strength	B-X
and	B-X
total	B-X
pitches	B-X
were	B-X
nonsignificant	B-X
for	B-X
the	B-X
high	B-X
-	B-X
strength	B-X
group	B-X
but	B-X
were	B-X
strong	B-X
for	B-X
both	B-X
external	B-X
rotation	B-X
(	B-X
r	B-X
=	B-X
	B-X
-	B-X
0	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
changes	B-X
between	B-X
prestrength	B-X
and	B-X
poststrength	B-X
assessments	B-X
in	B-X
external	B-X
rotation	B-X
strength	B-X
or	B-X
internal	B-X
rotation	B-X
strength	B-X
for	B-X
the	B-X
entire	B-X
group	B-X
<EOS>	B-X
The	B-X
training	B-X
set	B-X
was	B-X
composed	B-X
of	B-X
data	B-X
from	B-X
Taipei	B-X
Medical	B-X
University	B-X
Hospital	B-X
and	B-X
Wan	B-X
Fang	B-X
Hospital	B-X
,	B-X
while	B-X
data	B-X
from	B-X
Taipei	B-X
Medical	B-X
University	B-X
Shuang	B-X
Ho	B-X
Hospital	B-X
were	B-X
used	B-X
as	B-X
the	B-X
external	B-X
test	B-X
set	B-X
<EOS>	B-X
The	B-X
diurnal	B-X
cycle	B-X
of	B-X
hygroscopicity	B-X
showed	B-X
a	B-X
prominent	B-X
peak	B-X
during	B-X
the	B-X
midnight	B-X
to	B-X
early	B-X
morning	B-X
hours	B-X
followed	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
forenoon	B-X
hours	B-X
and	B-X
a	B-X
secondary	B-X
peak	B-X
in	B-X
the	B-X
afternoon	B-X
hours	B-X

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O
<EOS>	B-X
Neither	B-X
the	B-X
content	B-X
nor	B-X
the	B-X
activity	B-X
of	B-X
Na+	B-X
/	B-X
K+	B-X
ATPase	B-X
and	B-X
sarcoplasmic	B-X
reticulum	B-X
Ca2+	B-X
-	B-X
ATPase	B-X
are	B-X
affected	B-X
by	B-X
DMPK	B-X
absence	B-X
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
,	B-X
the	B-X
most	B-X
prevalent	B-X
muscular	B-X
disorder	B-X
in	B-X
adults	B-X
,	B-X
is	B-X
caused	B-X
by	B-X
(	B-X
CTG	B-X
)	B-X
n	B-X
-	B-X
repeat	B-X
expansion	B-X
in	B-X
a	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
kinase	B-X
(	B-X
DM	B-X
protein	B-X
kinase	B-X
;	B-X
DMPK	B-X
)	B-X
and	B-X
involves	B-X
changes	B-X
in	B-X
cytoarchitecture	B-X
and	B-X
ion	B-X
homeostasis	B-X
<EOS>	B-X
To	B-X
obtain	B-X
clues	B-X
to	B-X
the	B-X
normal	B-X
biological	B-X
role	B-X
of	B-X
DMPK	B-X
in	B-X
cellular	B-X
ion	B-X
homeostasis	B-X
,	B-X
we	B-X
have	B-X
compared	B-X
the	B-X
resting	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
,	B-X
the	B-X
amplitude	B-X
and	B-X
shape	B-X
of	B-X
depolarization	B-X
-	B-X
induced	B-X
Ca2+	B-X
transients	B-X
,	B-X
and	B-X
the	B-X
content	B-X
of	B-X
ATP	B-X
-	B-X
driven	B-X
ion	B-X
pumps	B-X
in	B-X
cultured	B-X
skeletal	B-X
muscle	B-X
cells	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
and	B-X
DMPK	B-X
[	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
]	B-X
knockout	B-X
mice	B-X
<EOS>	B-X
The	B-X
mutant	B-X
myotubes	B-X
exhibit	B-X
smaller	B-X
and	B-X
slower	B-X
Ca2+	B-X
responses	B-X
upon	B-X
triggering	B-X
by	B-X
acetylcholine	B-X
or	B-X
high	B-X
external	B-X
K+	B-X

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
DMPK	B-X
is	B-X
involved	B-X
in	B-X
modulating	B-X
the	B-X
initial	B-X
events	B-X
of	B-X
excitation	B-X
-	B-X
contraction	B-X
coupling	B-X
in	B-X
skeletal	B-X
muscle	B-X
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
protein	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
the	B-X
Ca2+	B-X
homeostasis	B-X
in	B-X
skeletal	B-X
muscle	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
obtain	B-X
clues	B-X
to	B-X
the	B-X
normal	B-X
biological	B-X
role	B-X
of	B-X
DMPK	B-X
in	B-X
cellular	B-X
ion	B-X
homeostasis	B-X
,	B-X
we	B-X
have	B-X
compared	B-X
the	B-X
resting	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
,	B-X
the	B-X
amplitude	B-X
and	B-X
shape	B-X
of	B-X
depolarization	B-X
-	B-X
induced	B-X
Ca2+	B-X
transients	B-X
,	B-X
and	B-X
the	B-X
content	B-X
of	B-X
ATP	B-X
-	B-X
driven	B-X
ion	B-X
pumps	B-X
in	B-X
cultured	B-X
skeletal	B-X
muscle	B-X
cells	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
and	B-X
DMPK	B-X
[	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
]	B-X
knockout	B-X
mice	B-X
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
,	B-X
the	B-X
most	B-X
prevalent	B-X
muscular	B-X
disorder	B-X
in	B-X
adults	B-X
,	B-X
is	B-X
caused	B-X
by	B-X
(	B-X
CTG	B-X
)	B-X
n	B-X
-	B-X
repeat	B-X
expansion	B-X
in	B-X
a	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
kinase	B-X
(	B-X
DM	B-X
protein	B-X
kinase	B-X
;	B-X
DMPK	B-X
)	B-X
and	B-X
involves	B-X
changes	B-X
in	B-X
cytoarchitecture	B-X
and	B-X
ion	B-X
homeostasis	B-X

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	I-Disease
.	O
<EOS>	B-X
Constitutional	B-X
RB1	B-X
-	B-X
gene	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
.	B-X
<EOS>	B-X
Constitutional	B-X
Rb	B-X
-	B-X
1	B-X
gene	B-X
mutations	B-X
were	B-X
studied	B-X
in	B-X
a	B-X
series	B-X
of	B-X
17	B-X
families	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
patients	B-X
<EOS>	B-X
No	B-X
association	B-X
between	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
constitutional	B-X
RB1	B-X
gene	B-X
mutation	B-X
and	B-X
age	B-X
in	B-X
68	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
.	B-X
<EOS>	B-X
Frequency	B-X
and	B-X
nature	B-X
of	B-X
germline	B-X
Rb	B-X
-	B-X
1	B-X
gene	B-X
mutations	B-X
in	B-X
a	B-X
series	B-X
of	B-X
patients	B-X
with	B-X
sporadic	B-X
unilateral	B-X
retinoblastoma	B-X
.	B-X

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	I-Disease
,	O
tumor	B-Disease
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O
<EOS>	B-X
In	B-X
most	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
,	B-X
tumor	B-X
development	B-X
is	B-X
initiated	B-X
by	B-X
somatic	B-X
inactivation	B-X
of	B-X
both	B-X
alleles	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
emphasize	B-X
that	B-X
the	B-X
manifestation	B-X
and	B-X
transmissibility	B-X
of	B-X
retinoblastoma	B-X
depend	B-X
on	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
first	B-X
mutation	B-X
,	B-X
its	B-X
time	B-X
in	B-X
development	B-X
,	B-X
and	B-X
the	B-X
number	B-X
and	B-X
types	B-X
of	B-X
cells	B-X
that	B-X
are	B-X
affected	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
DNA	B-X
from	B-X
tumor	B-X
tissue	B-X
and	B-X
peripheral	B-X
blood	B-X
of	B-X
a	B-X
unilateral	B-X
retinoblastoma	B-X
patient	B-X
to	B-X
determine	B-X
the	B-X
RB1	B-X
mutation	B-X
status	B-X
and	B-X
to	B-X
provide	B-X
an	B-X
accurate	B-X
genetic	B-X
counseling	B-X
<EOS>	B-X
In	B-X
1	B-X
patient	B-X
,	B-X
somatic	B-X
mosaicism	B-X
was	B-X
demonstrated	B-X
by	B-X
molecular	B-X
analysis	B-X
of	B-X
DNA	B-X
and	B-X
RNA	B-X
from	B-X
peripheral	B-X
blood	B-X

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B-Disease
predisposition	O
to	O
their	O
offspring	O
.	O
<EOS>	B-X
However	B-X
,	B-X
some	B-X
of	B-X
these	B-X
patients	B-X
can	B-X
transmit	B-X
retinoblastoma	B-X
predisposition	B-X
to	B-X
their	B-X
offspring	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
phenotypic	B-X
expression	B-X
of	B-X
hereditary	B-X
retinoblastoma	B-X
is	B-X
subject	B-X
to	B-X
genetic	B-X
modification	B-X
<EOS>	B-X
This	B-X
is	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
they	B-X
have	B-X
inherited	B-X
only	B-X
one	B-X
functional	B-X
copy	B-X
compared	B-X
to	B-X
persons	B-X
with	B-X
no	B-X
predisposition	B-X
who	B-X
have	B-X
two	B-X
copies	B-X
<EOS>	B-X
Three	B-X
of	B-X
13	B-X
uninformative	B-X
patients	B-X
had	B-X
constitutional	B-X
deletions	B-X

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-Disease
retinoblastoma	I-Disease
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B-Disease
tissue	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
frequency	B-X
and	B-X
nature	B-X
of	B-X
constitutional	B-X
RB1	B-X
-	B-X
gene	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
,	B-X
we	B-X
analyzed	B-X
DNA	B-X
from	B-X
peripheral	B-X
blood	B-X
and	B-X
from	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
Constitutional	B-X
RB1	B-X
-	B-X
gene	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
.	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
constitutional	B-X
mutation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
early	B-X
age	B-X
at	B-X
treatment	B-X
<EOS>	B-X
In	B-X
1	B-X
patient	B-X
,	B-X
somatic	B-X
mosaicism	B-X
was	B-X
demonstrated	B-X
by	B-X
molecular	B-X
analysis	B-X
of	B-X
DNA	B-X
and	B-X
RNA	B-X
from	B-X
peripheral	B-X
blood	B-X

The	O
analysis	O
of	O
tumors	B-Disease
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
.	O
<EOS>	B-X
Three	B-X
of	B-X
13	B-X
uninformative	B-X
patients	B-X
had	B-X
constitutional	B-X
deletions	B-X
<EOS>	B-X
The	B-X
analysis	B-X
of	B-X
tumors	B-X
from	B-X
54	B-X
(	B-X
71	B-X
%	B-X
)	B-X
of	B-X
76	B-X
informative	B-X
patients	B-X
showed	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
(	B-X
LOH	B-X
)	B-X
at	B-X
intragenic	B-X
loci	B-X
<EOS>	B-X
Constitutional	B-X
RB1	B-X
-	B-X
gene	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
.	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
constitutional	B-X
mutation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
early	B-X
age	B-X
at	B-X
treatment	B-X

For	O
39	O
randomly	O
selected	O
tumors	B-Disease
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O
<EOS>	B-X
For	B-X
39	B-X
randomly	B-X
selected	B-X
tumors	B-X
,	B-X
SSCP	B-X
,	B-X
hetero	B-X
-	B-X
duplex	B-X
analysis	B-X
,	B-X
sequencing	B-X
,	B-X
and	B-X
Southern	B-X
blot	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
identify	B-X
mutations	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
frequency	B-X
and	B-X
nature	B-X
of	B-X
constitutional	B-X
RB1	B-X
-	B-X
gene	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
,	B-X
we	B-X
analyzed	B-X
DNA	B-X
from	B-X
peripheral	B-X
blood	B-X
and	B-X
from	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
constitutional	B-X
mutation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
early	B-X
age	B-X
at	B-X
treatment	B-X
<EOS>	B-X
In	B-X
6	B-X
(	B-X
38	B-X
%	B-X
)	B-X
of	B-X
16	B-X
tumors	B-X
without	B-X
LOH	B-X
,	B-X
one	B-X
mutation	B-X
was	B-X
detected	B-X
,	B-X
and	B-X
in	B-X
9	B-X
(	B-X
56	B-X
%	B-X
)	B-X
of	B-X
the	B-X
tumors	B-X
without	B-X
LOH	B-X
,	B-X
both	B-X
mutations	B-X
were	B-X
found	B-X

Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	B-Disease
with	O
LOH	O
.	O
<EOS>	B-X
Mutations	B-X
were	B-X
detected	B-X
in	B-X
21	B-X
(	B-X
91	B-X
%	B-X
)	B-X
of	B-X
23	B-X
tumors	B-X
with	B-X
LOH	B-X
<EOS>	B-X
Genetic	B-X
p53	B-X
alterations	B-X
were	B-X
associated	B-X
with	B-X
advanced	B-X
tumor	B-X
stage	B-X
and	B-X
tumor	B-X
differentiation	B-X
<EOS>	B-X
In	B-X
6	B-X
(	B-X
38	B-X
%	B-X
)	B-X
of	B-X
16	B-X
tumors	B-X
without	B-X
LOH	B-X
,	B-X
one	B-X
mutation	B-X
was	B-X
detected	B-X
,	B-X
and	B-X
in	B-X
9	B-X
(	B-X
56	B-X
%	B-X
)	B-X
of	B-X
the	B-X
tumors	B-X
without	B-X
LOH	B-X
,	B-X
both	B-X
mutations	B-X
were	B-X
found	B-X
<EOS>	B-X
3	B-X
%	B-X
)	B-X
were	B-X
associated	B-X
with	B-X
presence	B-X
of	B-X
serum	B-X
p53	B-X
-	B-X
Ab	B-X

In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B-Disease
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B-Disease
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
.	O

Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B-Disease
of	O
36	O
patients	O
.	O
<EOS>	B-X
Eighteen	B-X
articles	B-X
with	B-X
a	B-X
total	B-X
of	B-X
4,535	B-X
patients	B-X
were	B-X
included	B-X
in	B-X
this	B-X
meta	B-X
-	B-X
analysis	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
45	B-X
cases	B-X
of	B-X
cervical	B-X
LCNEC	B-X
were	B-X
identified	B-X
with	B-X
a	B-X
median	B-X
age	B-X
of	B-X
36	B-X
years	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
214	B-X
020	B-X
participants	B-X
were	B-X
identified	B-X
,	B-X
including	B-X
23	B-X
544	B-X
in	B-X
eMERGEseq	B-X
cohort	B-X
(	B-X
mean	B-X
[	B-X
SD	B-X
]	B-X
age	B-X
,	B-X
47	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
13	B-X
genome	B-X
regions	B-X
,	B-X
comprising	B-X
14	B-X
alterations	B-X
,	B-X
were	B-X
identified	B-X
as	B-X
significantly	B-X
risk	B-X
associated	B-X

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O
<EOS>	B-X
In	B-X
6	B-X
(	B-X
17	B-X
%	B-X
)	B-X
of	B-X
the	B-X
36	B-X
patients	B-X
,	B-X
a	B-X
mutation	B-X
was	B-X
detected	B-X
in	B-X
constitutional	B-X
DNA	B-X
,	B-X
and	B-X
1	B-X
of	B-X
these	B-X
mutations	B-X
is	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
reduced	B-X
expressivity	B-X
<EOS>	B-X
In	B-X
6	B-X
(	B-X
38	B-X
%	B-X
)	B-X
of	B-X
16	B-X
tumors	B-X
without	B-X
LOH	B-X
,	B-X
one	B-X
mutation	B-X
was	B-X
detected	B-X
,	B-X
and	B-X
in	B-X
9	B-X
(	B-X
56	B-X
%	B-X
)	B-X
of	B-X
the	B-X
tumors	B-X
without	B-X
LOH	B-X
,	B-X
both	B-X
mutations	B-X
were	B-X
found	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
constitutional	B-X
mutation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
an	B-X
early	B-X
age	B-X
at	B-X
treatment	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
emphasize	B-X
that	B-X
the	B-X
manifestation	B-X
and	B-X
transmissibility	B-X
of	B-X
retinoblastoma	B-X
depend	B-X
on	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
first	B-X
mutation	B-X
,	B-X
its	B-X
time	B-X
in	B-X
development	B-X
,	B-X
and	B-X
the	B-X
number	B-X
and	B-X
types	B-X
of	B-X
cells	B-X
that	B-X
are	B-X
affected	B-X

The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
.	O
<EOS>	B-X
Type	B-X
1	B-X
/	B-X
like	B-X
CALR	B-X
mutation	B-X
is	B-X
associated	B-X
with	B-X
superior	B-X
survival	B-X
<EOS>	B-X
High	B-X
Prevalence	B-X
of	B-X
Constitutional	B-X
Mismatch	B-X
Repair	B-X
Deficiency	B-X
in	B-X
a	B-X
Pediatric	B-X
T	B-X
-	B-X
cell	B-X
Lymphoblastic	B-X
Lymphoma	B-X
Cohort	B-X
.	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
tumour	B-X
plop	B-X
and	B-X
change	B-X
of	B-X
the	B-X
physical	B-X
findings	B-X
with	B-X
changing	B-X
position	B-X
may	B-X
help	B-X
differentiation	B-X
between	B-X
the	B-X
two	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
deletions	B-X
within	B-X
the	B-X
5'untranslated	B-X
region	B-X
of	B-X
the	B-X
TAZ	B-X
gene	B-X
and	B-X
/	B-X
or	B-X
the	B-X
noncoding	B-X
regions	B-X
of	B-X
the	B-X
DNASE1L1	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
several	B-X
tissues	B-X

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O
<EOS>	B-X
In	B-X
1	B-X
patient	B-X
,	B-X
somatic	B-X
mosaicism	B-X
was	B-X
demonstrated	B-X
by	B-X
molecular	B-X
analysis	B-X
of	B-X
DNA	B-X
and	B-X
RNA	B-X
from	B-X
peripheral	B-X
blood	B-X
<EOS>	B-X
In	B-X
vivo	B-X
somatic	B-X
mosaicism	B-X
was	B-X
demonstrated	B-X
in	B-X
genomic	B-X
DNA	B-X
from	B-X
peripheral	B-X
blood	B-X
cells	B-X
obtained	B-X
at	B-X
16	B-X
years	B-X
of	B-X
age	B-X
,	B-X
in	B-X
that	B-X
less	B-X
than	B-X
half	B-X
the	B-X
DNA	B-X
carried	B-X
the	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
(	B-X
P	B-X
<	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
frequency	B-X
and	B-X
nature	B-X
of	B-X
constitutional	B-X
RB1	B-X
-	B-X
gene	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
,	B-X
we	B-X
analyzed	B-X
DNA	B-X
from	B-X
peripheral	B-X
blood	B-X
and	B-X
from	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
Thirty	B-X
-	B-X
nine	B-X
of	B-X
the	B-X
mutations	B-X
-	B-X
including	B-X
34	B-X
small	B-X
mutations	B-X
,	B-X
2	B-X
large	B-X
structural	B-X
alterations	B-X
,	B-X
and	B-X
hypermethylation	B-X
in	B-X
3	B-X
tumors	B-X
-	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
corresponding	B-X
peripheral	B-X
blood	B-X
DNA	B-X

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	B-Disease
and	O
the	O
other	O
later	O
developed	O
bilateral	B-Disease
retinoblastoma	I-Disease
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B-Disease
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
.	O
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
emphasize	B-X
that	B-X
the	B-X
manifestation	B-X
and	B-X
transmissibility	B-X
of	B-X
retinoblastoma	B-X
depend	B-X
on	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
first	B-X
mutation	B-X
,	B-X
its	B-X
time	B-X
in	B-X
development	B-X
,	B-X
and	B-X
the	B-X
number	B-X
and	B-X
types	B-X
of	B-X
cells	B-X
that	B-X
are	B-X
affected	B-X
<EOS>	B-X
In	B-X
most	B-X
patients	B-X
with	B-X
isolated	B-X
unilateral	B-X
retinoblastoma	B-X
,	B-X
tumor	B-X
development	B-X
is	B-X
initiated	B-X
by	B-X
somatic	B-X
inactivation	B-X
of	B-X
both	B-X
alleles	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
<EOS>	B-X
In	B-X
6	B-X
(	B-X
17	B-X
%	B-X
)	B-X
of	B-X
the	B-X
36	B-X
patients	B-X
,	B-X
a	B-X
mutation	B-X
was	B-X
detected	B-X
in	B-X
constitutional	B-X
DNA	B-X
,	B-X
and	B-X
1	B-X
of	B-X
these	B-X
mutations	B-X
is	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
reduced	B-X
expressivity	B-X
<EOS>	B-X
In	B-X
2	B-X
patients	B-X
without	B-X
a	B-X
detectable	B-X
mutation	B-X
in	B-X
peripheral	B-X
blood	B-X
,	B-X
mosaicism	B-X
was	B-X
suggested	B-X
because	B-X
1	B-X
of	B-X
the	B-X
patients	B-X
showed	B-X
multifocal	B-X
tumors	B-X
and	B-X
the	B-X
other	B-X
later	B-X
developed	B-X
bilateral	B-X
retinoblastoma	B-X

Hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
in	O
man	O
.	O
<EOS>	B-X
Hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
in	B-X
man	B-X
.	B-X
I	B-X
.	B-X
Clinical	B-X
,	B-X
immunochemical	B-X
,	B-X
and	B-X
family	B-X
studies	B-X
.	B-X
<EOS>	B-X
Hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
in	B-X
man	B-X
.	B-X
II	B-X
.	B-X
Biological	B-X
properties	B-X
of	B-X
C5	B-X
-	B-X
deficient	B-X
human	B-X
serum	B-X
.	B-X
<EOS>	B-X
The	B-X
first	B-X
recognized	B-X
human	B-X
kindred	B-X
with	B-X
hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
(	B-X
C5	B-X
)	B-X
is	B-X
described	B-X
<EOS>	B-X
The	B-X
first	B-X
known	B-X
human	B-X
kindred	B-X
with	B-X
hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
(	B-X
C5	B-X
)	B-X
was	B-X
documented	B-X
in	B-X
the	B-X
accompanying	B-X
report	B-X

I	O
.	O

Clinical	O
,	O
immunochemical	O
,	O
and	O
family	O
studies	O
.	O
<EOS>	B-X
Most	B-X
interval	B-X
CRCs	B-X
develop	B-X
from	B-X
fecal	B-X
immunochemical	B-X
test	B-X
(	B-X
FIT	B-X
)	B-X
	B-X
-	B-X
negative	B-X
CRC	B-X
<EOS>	B-X
Single	B-X
urban	B-X
academic	B-X
healthcare	B-X
system	B-X
<EOS>	B-X
Mailed	B-X
fecal	B-X
immunochemical	B-X
test	B-X
(	B-X
FIT	B-X
)	B-X
outreach	B-X
can	B-X
improve	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
screening	B-X
rates	B-X
<EOS>	B-X
The	B-X
mtFIT	B-X
measures	B-X
three	B-X
protein	B-X
markers	B-X
:	B-X
hemoglobin	B-X
,	B-X
calprotectin	B-X
,	B-X
and	B-X
serpin	B-X
family	B-X
F	B-X
member	B-X
2	B-X

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B-Disease
deficiency	I-Disease
of	I-Disease
the	I-Disease
fifth	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C5	O
)	O
is	O
described	O
.	O
<EOS>	B-X
The	B-X
first	B-X
recognized	B-X
human	B-X
kindred	B-X
with	B-X
hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
(	B-X
C5	B-X
)	B-X
is	B-X
described	B-X
<EOS>	B-X
The	B-X
proband	B-X
,	B-X
a	B-X
20	B-X
-	B-X
year	B-X
-	B-X
old	B-X
black	B-X
female	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
since	B-X
age	B-X
11	B-X
,	B-X
lacked	B-X
serum	B-X
hemolytic	B-X
complement	B-X
activity	B-X
,	B-X
even	B-X
during	B-X
remission	B-X
<EOS>	B-X
Hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
in	B-X
man	B-X
.	B-X
I	B-X
.	B-X
Clinical	B-X
,	B-X
immunochemical	B-X
,	B-X
and	B-X
family	B-X
studies	B-X
.	B-X
<EOS>	B-X
Other	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
C5D	B-X
state	B-X
is	B-X
compatible	B-X
with	B-X
normal	B-X
coagulation	B-X
function	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
mount	B-X
a	B-X
neutrophilic	B-X
leukocytosis	B-X
during	B-X
pyogenic	B-X
infection	B-X

The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O
<EOS>	B-X
The	B-X
proband	B-X
,	B-X
a	B-X
20	B-X
-	B-X
year	B-X
-	B-X
old	B-X
black	B-X
female	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
since	B-X
age	B-X
11	B-X
,	B-X
lacked	B-X
serum	B-X
hemolytic	B-X
complement	B-X
activity	B-X
,	B-X
even	B-X
during	B-X
remission	B-X
<EOS>	B-X
The	B-X
first	B-X
recognized	B-X
human	B-X
kindred	B-X
with	B-X
hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
(	B-X
C5	B-X
)	B-X
is	B-X
described	B-X
<EOS>	B-X
In	B-X
specific	B-X
C5	B-X
titrations	B-X
,	B-X
however	B-X
,	B-X
it	B-X
was	B-X
noted	B-X
that	B-X
when	B-X
limited	B-X
amounts	B-X
of	B-X
C5	B-X
were	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
low	B-X
dilutions	B-X
of	B-X
either	B-X
C5D	B-X
serum	B-X
,	B-X
curving	B-X
rather	B-X
than	B-X
linear	B-X
dose	B-X
-	B-X
response	B-X
plots	B-X
were	B-X
consistently	B-X
obtained	B-X
,	B-X
suggesting	B-X
some	B-X
inhibitory	B-X
effect	B-X
<EOS>	B-X
Of	B-X
clinical	B-X
interest	B-X
are	B-X
(	B-X
a	B-X
)	B-X
the	B-X
documentation	B-X
of	B-X
membranous	B-X
glomerulonephritis	B-X
,	B-X
vasculitis	B-X
,	B-X
and	B-X
arthritis	B-X
in	B-X
an	B-X
individual	B-X
lacking	B-X
C5	B-X
(	B-X
and	B-X
its	B-X
biologic	B-X
functions	B-X
)	B-X
,	B-X
and	B-X
(	B-X
b	B-X
)	B-X
a	B-X
remarkable	B-X
propensity	B-X
to	B-X
bacterial	B-X
infections	B-X
in	B-X
the	B-X
proband	B-X
,	B-X
even	B-X
during	B-X
periods	B-X
of	B-X
low	B-X
-	B-X
dose	B-X
or	B-X
alternate	B-X
-	B-X
day	B-X
corticosteroid	B-X
therapy	B-X

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
.	O
<EOS>	B-X
C5	B-X
was	B-X
undetectable	B-X
in	B-X
her	B-X
serum	B-X
by	B-X
both	B-X
immunodiffusion	B-X
and	B-X
hemolytic	B-X
assays	B-X
<EOS>	B-X
Normal	B-X
hemolytic	B-X
titers	B-X
were	B-X
restored	B-X
to	B-X
both	B-X
homozygous	B-X
C5	B-X
-	B-X
deficient	B-X
(	B-X
C5D	B-X
)	B-X
sera	B-X
by	B-X
addition	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
C5	B-X
<EOS>	B-X
By	B-X
hemolytic	B-X
assay	B-X
,	B-X
she	B-X
exhibited	B-X
1	B-X
-	B-X
2	B-X
%	B-X
of	B-X
the	B-X
normal	B-X
serum	B-X
C5	B-X
level	B-X
and	B-X
normal	B-X
concentrations	B-X
of	B-X
other	B-X
complement	B-X
components	B-X
<EOS>	B-X
Other	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
C5D	B-X
state	B-X
is	B-X
compatible	B-X
with	B-X
normal	B-X
coagulation	B-X
function	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
mount	B-X
a	B-X
neutrophilic	B-X
leukocytosis	B-X
during	B-X
pyogenic	B-X
infection	B-X

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations	O
.	O
<EOS>	B-X
Other	B-X
complement	B-X
components	B-X
were	B-X
normal	B-X
during	B-X
remission	B-X
of	B-X
lupus	B-X
,	B-X
but	B-X
C1	B-X
,	B-X
C4	B-X
,	B-X
C2	B-X
,	B-X
and	B-X
C3	B-X
levels	B-X
fell	B-X
during	B-X
exacerbations	B-X
<EOS>	B-X
Other	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
C5D	B-X
state	B-X
is	B-X
compatible	B-X
with	B-X
normal	B-X
coagulation	B-X
function	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
mount	B-X
a	B-X
neutrophilic	B-X
leukocytosis	B-X
during	B-X
pyogenic	B-X
infection	B-X
<EOS>	B-X
C5	B-X
levels	B-X
of	B-X
other	B-X
family	B-X
members	B-X
were	B-X
either	B-X
normal	B-X
or	B-X
approximately	B-X
half	B-X
-	B-X
normal	B-X
,	B-X
consistent	B-X
with	B-X
autosomal	B-X
codominant	B-X
inheritance	B-X
of	B-X
the	B-X
gene	B-X
determining	B-X
C5	B-X
deficiency	B-X
<EOS>	B-X
Further	B-X
studies	B-X
suggested	B-X
that	B-X
low	B-X
dilutions	B-X
of	B-X
C5D	B-X
serum	B-X
contain	B-X
a	B-X
factor	B-X
(	B-X
or	B-X
factors	B-X
)	B-X
interfering	B-X
at	B-X
some	B-X
step	B-X
in	B-X
the	B-X
hemolytic	B-X
assay	B-X
of	B-X
C5	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
true	B-X
C5	B-X
inhibitor	B-X
or	B-X
inactivator	B-X

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5	O
.	O
<EOS>	B-X
A	B-X
younger	B-X
half	B-X
-	B-X
sister	B-X
,	B-X
who	B-X
had	B-X
no	B-X
underlying	B-X
disease	B-X
,	B-X
was	B-X
also	B-X
found	B-X
to	B-X
lack	B-X
immunochemically	B-X
detectable	B-X
C5	B-X
<EOS>	B-X
C5	B-X
levels	B-X
of	B-X
other	B-X
family	B-X
members	B-X
were	B-X
either	B-X
normal	B-X
or	B-X
approximately	B-X
half	B-X
-	B-X
normal	B-X
,	B-X
consistent	B-X
with	B-X
autosomal	B-X
codominant	B-X
inheritance	B-X
of	B-X
the	B-X
gene	B-X
determining	B-X
C5	B-X
deficiency	B-X
<EOS>	B-X
Hereditary	B-X
deficiency	B-X
of	B-X
the	B-X
fifth	B-X
component	B-X
of	B-X
complement	B-X
in	B-X
man	B-X
.	B-X
I	B-X
.	B-X
Clinical	B-X
,	B-X
immunochemical	B-X
,	B-X
and	B-X
family	B-X
studies	B-X
.	B-X
<EOS>	B-X
Other	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
C5D	B-X
state	B-X
is	B-X
compatible	B-X
with	B-X
normal	B-X
coagulation	B-X
function	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
mount	B-X
a	B-X
neutrophilic	B-X
leukocytosis	B-X
during	B-X
pyogenic	B-X
infection	B-X

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O
components	O
.	O
<EOS>	B-X
By	B-X
hemolytic	B-X
assay	B-X
,	B-X
she	B-X
exhibited	B-X
1	B-X
-	B-X
2	B-X
%	B-X
of	B-X
the	B-X
normal	B-X
serum	B-X
C5	B-X
level	B-X
and	B-X
normal	B-X
concentrations	B-X
of	B-X
other	B-X
complement	B-X
components	B-X
<EOS>	B-X
C5	B-X
levels	B-X
of	B-X
other	B-X
family	B-X
members	B-X
were	B-X
either	B-X
normal	B-X
or	B-X
approximately	B-X
half	B-X
-	B-X
normal	B-X
,	B-X
consistent	B-X
with	B-X
autosomal	B-X
codominant	B-X
inheritance	B-X
of	B-X
the	B-X
gene	B-X
determining	B-X
C5	B-X
deficiency	B-X
<EOS>	B-X
Normal	B-X
hemolytic	B-X
titers	B-X
were	B-X
restored	B-X
to	B-X
both	B-X
homozygous	B-X
C5	B-X
-	B-X
deficient	B-X
(	B-X
C5D	B-X
)	B-X
sera	B-X
by	B-X
addition	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
C5	B-X
<EOS>	B-X
Other	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
C5D	B-X
state	B-X
is	B-X
compatible	B-X
with	B-X
normal	B-X
coagulation	B-X
function	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
mount	B-X
a	B-X
neutrophilic	B-X
leukocytosis	B-X
during	B-X
pyogenic	B-X
infection	B-X

C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B-Disease
deficiency	I-Disease
.	O
<EOS>	B-X
C5	B-X
levels	B-X
of	B-X
other	B-X
family	B-X
members	B-X
were	B-X
either	B-X
normal	B-X
or	B-X
approximately	B-X
half	B-X
-	B-X
normal	B-X
,	B-X
consistent	B-X
with	B-X
autosomal	B-X
codominant	B-X
inheritance	B-X
of	B-X
the	B-X
gene	B-X
determining	B-X
C5	B-X
deficiency	B-X
<EOS>	B-X
Sera	B-X
from	B-X
all	B-X
family	B-X
members	B-X
showed	B-X
normal	B-X
IIP	B-X
values	B-X
,	B-X
with	B-X
exception	B-X
of	B-X
the	B-X
subject	B-X
with	B-X
combined	B-X
partial	B-X
deficiency	B-X
in	B-X
C4A	B-X
,	B-X
C4B	B-X
,	B-X
and	B-X
complete	B-X
deficiency	B-X
in	B-X
C5	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
an	B-X
autosomal	B-X
codominant	B-X
mode	B-X
of	B-X
inheritance	B-X
of	B-X
C5	B-X
deficiency	B-X
<EOS>	B-X
The	B-X
asymptomatic	B-X
first	B-X
degree	B-X
family	B-X
members	B-X
had	B-X
C5	B-X
levels	B-X
compatible	B-X
with	B-X
a	B-X
heterozygous	B-X
state	B-X
of	B-X
C5	B-X
deficiency	B-X

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B-Disease
-	I-Disease
deficient	I-Disease
(	O
C5D	B-Disease
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
.	O
<EOS>	B-X
Normal	B-X
hemolytic	B-X
titers	B-X
were	B-X
restored	B-X
to	B-X
both	B-X
homozygous	B-X
C5	B-X
-	B-X
deficient	B-X
(	B-X
C5D	B-X
)	B-X
sera	B-X
by	B-X
addition	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
C5	B-X
<EOS>	B-X
By	B-X
hemolytic	B-X
assay	B-X
,	B-X
she	B-X
exhibited	B-X
1	B-X
-	B-X
2	B-X
%	B-X
of	B-X
the	B-X
normal	B-X
serum	B-X
C5	B-X
level	B-X
and	B-X
normal	B-X
concentrations	B-X
of	B-X
other	B-X
complement	B-X
components	B-X
<EOS>	B-X
C5	B-X
levels	B-X
of	B-X
other	B-X
family	B-X
members	B-X
were	B-X
either	B-X
normal	B-X
or	B-X
approximately	B-X
half	B-X
-	B-X
normal	B-X
,	B-X
consistent	B-X
with	B-X
autosomal	B-X
codominant	B-X
inheritance	B-X
of	B-X
the	B-X
gene	B-X
determining	B-X
C5	B-X
deficiency	B-X
<EOS>	B-X
C5	B-X
was	B-X
undetectable	B-X
in	B-X
her	B-X
serum	B-X
by	B-X
both	B-X
immunodiffusion	B-X
and	B-X
hemolytic	B-X
assays	B-X

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B-Disease
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O
<EOS>	B-X
In	B-X
specific	B-X
C5	B-X
titrations	B-X
,	B-X
however	B-X
,	B-X
it	B-X
was	B-X
noted	B-X
that	B-X
when	B-X
limited	B-X
amounts	B-X
of	B-X
C5	B-X
were	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
low	B-X
dilutions	B-X
of	B-X
either	B-X
C5D	B-X
serum	B-X
,	B-X
curving	B-X
rather	B-X
than	B-X
linear	B-X
dose	B-X
-	B-X
response	B-X
plots	B-X
were	B-X
consistently	B-X
obtained	B-X
,	B-X
suggesting	B-X
some	B-X
inhibitory	B-X
effect	B-X
<EOS>	B-X
Further	B-X
studies	B-X
suggested	B-X
that	B-X
low	B-X
dilutions	B-X
of	B-X
C5D	B-X
serum	B-X
contain	B-X
a	B-X
factor	B-X
(	B-X
or	B-X
factors	B-X
)	B-X
interfering	B-X
at	B-X
some	B-X
step	B-X
in	B-X
the	B-X
hemolytic	B-X
assay	B-X
of	B-X
C5	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
true	B-X
C5	B-X
inhibitor	B-X
or	B-X
inactivator	B-X
<EOS>	B-X
Other	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
C5D	B-X
state	B-X
is	B-X
compatible	B-X
with	B-X
normal	B-X
coagulation	B-X
function	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
mount	B-X
a	B-X
neutrophilic	B-X
leukocytosis	B-X
during	B-X
pyogenic	B-X
infection	B-X
<EOS>	B-X
C5	B-X
levels	B-X
of	B-X
other	B-X
family	B-X
members	B-X
were	B-X
either	B-X
normal	B-X
or	B-X
approximately	B-X
half	B-X
-	B-X
normal	B-X
,	B-X
consistent	B-X
with	B-X
autosomal	B-X
codominant	B-X
inheritance	B-X
of	B-X
the	B-X
gene	B-X
determining	B-X
C5	B-X
deficiency	B-X

Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	B-Disease
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B-Disease
,	O
vasculitis	B-Disease
,	O
and	O
arthritis	B-Disease
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B-Disease
infections	I-Disease
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
alternate	B-X
-	B-X
day	B-X
GC	B-X
therapy	B-X
on	B-X
glucocorticoid	B-X
toxicity	B-X
index	B-X
(	B-X
GTI	B-X
)	B-X
score	B-X
was	B-X
evaluated	B-X
using	B-X
multilinear	B-X
analysis	B-X
with	B-X
adjustments	B-X
for	B-X
cumulative	B-X
GC	B-X
doses	B-X
until	B-X
each	B-X
assessment	B-X
point	B-X
and	B-X
propensity	B-X
scores	B-X
(	B-X
PS	B-X
)	B-X
for	B-X
alternate	B-X
-	B-X
day	B-X
GC	B-X
therapy	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
vitamin	B-X
E	B-X
and	B-X
selenium	B-X
along	B-X
with	B-X
glycerol	B-X
had	B-X
the	B-X
best	B-X
effect	B-X
in	B-X
the	B-X
reduction	B-X
of	B-X
blood	B-X
cortisol	B-X
level	B-X
in	B-X
heat	B-X
-	B-X
stressed	B-X
buffaloes	B-X
<EOS>	B-X
This	B-X
was	B-X
a	B-X
multicenter	B-X
study	B-X
(	B-X
33	B-X
referral	B-X
centers	B-X
in	B-X
11	B-X
countries	B-X
)	B-X
and	B-X
included	B-X
boys	B-X
4	B-X
to	B-X
younger	B-X
than	B-X
7	B-X
years	B-X
of	B-X
age	B-X
with	B-X
genetically	B-X
confirmed	B-X
DMD	B-X
not	B-X
previously	B-X
treated	B-X
with	B-X
corticosteroids	B-X
<EOS>	B-X
We	B-X
could	B-X
not	B-X
perform	B-X
contrast	B-X
-	B-X
enhanced	B-X
CT	B-X
because	B-X
the	B-X
patient	B-X
had	B-X
a	B-X
history	B-X
of	B-X
contrast	B-X
allergy	B-X
and	B-X
refused	B-X
to	B-X
undergo	B-X
premedicated	B-X
contrast	B-X
CT	B-X
with	B-X
anti	B-X
-	B-X
histamine	B-X
and	B-X
/	B-X
or	B-X
corticosteroid	B-X

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B-Disease
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B-Disease
infection	I-Disease
.	O
.	O

Susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O
<EOS>	B-X
Susceptibility	B-X
to	B-X
ankylosing	B-X
spondylitis	B-X
in	B-X
twins	B-X
:	B-X
the	B-X
role	B-X
of	B-X
genes	B-X
,	B-X
HLA	B-X
,	B-X
and	B-X
the	B-X
environment	B-X
.	B-X
<EOS>	B-X
Susceptibility	B-X
to	B-X
AS	B-X
is	B-X
largely	B-X
genetically	B-X
determined	B-X
,	B-X
and	B-X
the	B-X
environmental	B-X
trigger	B-X
for	B-X
the	B-X
disease	B-X
is	B-X
probably	B-X
ubiquitous	B-X
<EOS>	B-X
Genetic	B-X
and	B-X
environmental	B-X
variance	B-X
components	B-X
were	B-X
assessed	B-X
with	B-X
the	B-X
program	B-X
Mx	B-X
,	B-X
using	B-X
data	B-X
from	B-X
this	B-X
and	B-X
previous	B-X
studies	B-X
of	B-X
twins	B-X
with	B-X
AS	B-X
<EOS>	B-X
Nonsignificant	B-X
increases	B-X
in	B-X
similarity	B-X
with	B-X
regard	B-X
to	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
and	B-X
all	B-X
of	B-X
the	B-X
disease	B-X
severity	B-X
scores	B-X
assessed	B-X
were	B-X
noted	B-X
in	B-X
disease	B-X
-	B-X
concordant	B-X
MZ	B-X
twins	B-X
compared	B-X
with	B-X
concordant	B-X
DZ	B-X
twins	B-X

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B-Disease
spondylitis	I-Disease
(	O
AS	B-Disease
)	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
relative	B-X
effects	B-X
of	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
in	B-X
susceptibility	B-X
to	B-X
ankylosing	B-X
spondylitis	B-X
(	B-X
AS	B-X
)	B-X
<EOS>	B-X
Additive	B-X
genetic	B-X
effects	B-X
were	B-X
estimated	B-X
to	B-X
contribute	B-X
97	B-X
%	B-X
of	B-X
the	B-X
population	B-X
variance	B-X
<EOS>	B-X
The	B-X
susceptibility	B-X
genes	B-X
of	B-X
these	B-X
co	B-X
-	B-X
disorders	B-X
appear	B-X
to	B-X
overlap	B-X
with	B-X
each	B-X
other	B-X
and	B-X
with	B-X
AS	B-X
:	B-X
1	B-X
<EOS>	B-X
HLA	B-X
-	B-X
B27	B-X
accounts	B-X
for	B-X
a	B-X
minority	B-X
of	B-X
the	B-X
overall	B-X
genetic	B-X
susceptibility	B-X
to	B-X
AS	B-X

METHODS	O
Twins	O
with	O
AS	B-Disease
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B-Disease
Diseases	I-Disease
database	O
.	O
<EOS>	B-X
Twins	B-X
with	B-X
AS	B-X
were	B-X
identified	B-X
from	B-X
the	B-X
Royal	B-X
National	B-X
Hospital	B-X
for	B-X
Rheumatic	B-X
Diseases	B-X
database	B-X
<EOS>	B-X
Susceptibility	B-X
to	B-X
AS	B-X
is	B-X
largely	B-X
genetically	B-X
determined	B-X
,	B-X
and	B-X
the	B-X
environmental	B-X
trigger	B-X
for	B-X
the	B-X
disease	B-X
is	B-X
probably	B-X
ubiquitous	B-X
<EOS>	B-X
Additive	B-X
genetic	B-X
effects	B-X
were	B-X
estimated	B-X
to	B-X
contribute	B-X
97	B-X
%	B-X
of	B-X
the	B-X
population	B-X
variance	B-X
<EOS>	B-X
Genetic	B-X
and	B-X
environmental	B-X
variance	B-X
components	B-X
were	B-X
assessed	B-X
with	B-X
the	B-X
program	B-X
Mx	B-X
,	B-X
using	B-X
data	B-X
from	B-X
this	B-X
and	B-X
previous	B-X
studies	B-X
of	B-X
twins	B-X
with	B-X
AS	B-X

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O
<EOS>	B-X
Clinical	B-X
and	B-X
radiographic	B-X
examinations	B-X
were	B-X
performed	B-X
to	B-X
establish	B-X
diagnoses	B-X
,	B-X
and	B-X
disease	B-X
severity	B-X
was	B-X
assessed	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
validated	B-X
scoring	B-X
systems	B-X
<EOS>	B-X
Nonsignificant	B-X
increases	B-X
in	B-X
similarity	B-X
with	B-X
regard	B-X
to	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
and	B-X
all	B-X
of	B-X
the	B-X
disease	B-X
severity	B-X
scores	B-X
assessed	B-X
were	B-X
noted	B-X
in	B-X
disease	B-X
-	B-X
concordant	B-X
MZ	B-X
twins	B-X
compared	B-X
with	B-X
concordant	B-X
DZ	B-X
twins	B-X
<EOS>	B-X
Genetic	B-X
and	B-X
environmental	B-X
variance	B-X
components	B-X
were	B-X
assessed	B-X
with	B-X
the	B-X
program	B-X
Mx	B-X
,	B-X
using	B-X
data	B-X
from	B-X
this	B-X
and	B-X
previous	B-X
studies	B-X
of	B-X
twins	B-X
with	B-X
AS	B-X
<EOS>	B-X
Additive	B-X
genetic	B-X
effects	B-X
were	B-X
estimated	B-X
to	B-X
contribute	B-X
97	B-X
%	B-X
of	B-X
the	B-X
population	B-X
variance	B-X

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
.	O
<EOS>	B-X
HLA	B-X
typing	B-X
for	B-X
HLA	B-X
-	B-X
B27	B-X
,	B-X
HLA	B-X
-	B-X
B60	B-X
,	B-X
and	B-X
HLA	B-X
-	B-X
DR1	B-X
was	B-X
performed	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
with	B-X
sequence	B-X
-	B-X
specific	B-X
primers	B-X
,	B-X
and	B-X
zygosity	B-X
was	B-X
assessed	B-X
using	B-X
microsatellite	B-X
markers	B-X
<EOS>	B-X
Clinical	B-X
and	B-X
radiographic	B-X
examinations	B-X
were	B-X
performed	B-X
to	B-X
establish	B-X
diagnoses	B-X
,	B-X
and	B-X
disease	B-X
severity	B-X
was	B-X
assessed	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
validated	B-X
scoring	B-X
systems	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
relative	B-X
effects	B-X
of	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
in	B-X
susceptibility	B-X
to	B-X
ankylosing	B-X
spondylitis	B-X
(	B-X
AS	B-X
)	B-X
<EOS>	B-X
Susceptibility	B-X
to	B-X
AS	B-X
is	B-X
largely	B-X
genetically	B-X
determined	B-X
,	B-X
and	B-X
the	B-X
environmental	B-X
trigger	B-X
for	B-X
the	B-X
disease	B-X
is	B-X
probably	B-X
ubiquitous	B-X

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	B-Disease
.	O
<EOS>	B-X
Genetic	B-X
and	B-X
environmental	B-X
variance	B-X
components	B-X
were	B-X
assessed	B-X
with	B-X
the	B-X
program	B-X
Mx	B-X
,	B-X
using	B-X
data	B-X
from	B-X
this	B-X
and	B-X
previous	B-X
studies	B-X
of	B-X
twins	B-X
with	B-X
AS	B-X
<EOS>	B-X
Additive	B-X
genetic	B-X
effects	B-X
were	B-X
estimated	B-X
to	B-X
contribute	B-X
97	B-X
%	B-X
of	B-X
the	B-X
population	B-X
variance	B-X
<EOS>	B-X
Nonsignificant	B-X
increases	B-X
in	B-X
similarity	B-X
with	B-X
regard	B-X
to	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
and	B-X
all	B-X
of	B-X
the	B-X
disease	B-X
severity	B-X
scores	B-X
assessed	B-X
were	B-X
noted	B-X
in	B-X
disease	B-X
-	B-X
concordant	B-X
MZ	B-X
twins	B-X
compared	B-X
with	B-X
concordant	B-X
DZ	B-X
twins	B-X
<EOS>	B-X
HLA	B-X
-	B-X
B27	B-X
and	B-X
B60	B-X
were	B-X
associated	B-X
with	B-X
the	B-X
disease	B-X
in	B-X
probands	B-X
,	B-X
and	B-X
the	B-X
rate	B-X
of	B-X
disease	B-X
concordance	B-X
was	B-X
significantly	B-X
increased	B-X
among	B-X
DZ	B-X
twin	B-X
pairs	B-X
in	B-X
which	B-X
the	B-X
co	B-X
-	B-X
twin	B-X
was	B-X
positive	B-X
for	B-X
both	B-X
B27	B-X
and	B-X
DR1	B-X

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O
<EOS>	B-X
HLA	B-X
-	B-X
B27	B-X
and	B-X
B60	B-X
were	B-X
associated	B-X
with	B-X
the	B-X
disease	B-X
in	B-X
probands	B-X
,	B-X
and	B-X
the	B-X
rate	B-X
of	B-X
disease	B-X
concordance	B-X
was	B-X
significantly	B-X
increased	B-X
among	B-X
DZ	B-X
twin	B-X
pairs	B-X
in	B-X
which	B-X
the	B-X
co	B-X
-	B-X
twin	B-X
was	B-X
positive	B-X
for	B-X
both	B-X
B27	B-X
and	B-X
DR1	B-X
<EOS>	B-X
Six	B-X
of	B-X
8	B-X
monozygotic	B-X
(	B-X
MZ	B-X
)	B-X
twin	B-X
pairs	B-X
were	B-X
disease	B-X
concordant	B-X
,	B-X
compared	B-X
with	B-X
4	B-X
of	B-X
15	B-X
B27	B-X
-	B-X
positive	B-X
dizygotic	B-X
(	B-X
DZ	B-X
)	B-X
twin	B-X
pairs	B-X
(	B-X
27	B-X
%	B-X
)	B-X
and	B-X
4	B-X
of	B-X
32	B-X
DZ	B-X
twin	B-X
pairs	B-X
overall	B-X
(	B-X
12	B-X
<EOS>	B-X
Nonsignificant	B-X
increases	B-X
in	B-X
similarity	B-X
with	B-X
regard	B-X
to	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
and	B-X
all	B-X
of	B-X
the	B-X
disease	B-X
severity	B-X
scores	B-X
assessed	B-X
were	B-X
noted	B-X
in	B-X
disease	B-X
-	B-X
concordant	B-X
MZ	B-X
twins	B-X
compared	B-X
with	B-X
concordant	B-X
DZ	B-X
twins	B-X
<EOS>	B-X
Genetic	B-X
and	B-X
environmental	B-X
variance	B-X
components	B-X
were	B-X
assessed	B-X
with	B-X
the	B-X
program	B-X
Mx	B-X
,	B-X
using	B-X
data	B-X
from	B-X
this	B-X
and	B-X
previous	B-X
studies	B-X
of	B-X
twins	B-X
with	B-X
AS	B-X

Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O
<EOS>	B-X
Additive	B-X
genetic	B-X
effects	B-X
were	B-X
estimated	B-X
to	B-X
contribute	B-X
97	B-X
%	B-X
of	B-X
the	B-X
population	B-X
variance	B-X
<EOS>	B-X
The	B-X
differential	B-X
effects	B-X
of	B-X
the	B-X
BMI	B-X
methylation	B-X
profiles	B-X
by	B-X
age	B-X
support	B-X
previous	B-X
observations	B-X
of	B-X
age	B-X
modulation	B-X
of	B-X
genetic	B-X
contributions	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
relative	B-X
effects	B-X
of	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
in	B-X
susceptibility	B-X
to	B-X
ankylosing	B-X
spondylitis	B-X
(	B-X
AS	B-X
)	B-X
<EOS>	B-X
Contribution	B-X
of	B-X
genetics	B-X
and	B-X
environment	B-X
to	B-X
craniofacial	B-X
anthropometric	B-X
phenotypes	B-X
in	B-X
Belgian	B-X
nuclear	B-X
families	B-X
.	B-X

CONCLUSION	O
Susceptibility	O
to	O
AS	B-Disease
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

HLA	O
-	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	B-Disease
.	O

Cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O
<EOS>	B-X
Cell	B-X
cycle	B-X
-	B-X
dependent	B-X
colocalization	B-X
of	B-X
BARD1	B-X
and	B-X
BRCA1	B-X
proteins	B-X
in	B-X
discrete	B-X
nuclear	B-X
domains	B-X
.	B-X
<EOS>	B-X
This	B-X
cell	B-X
cycle	B-X
-	B-X
dependent	B-X
colocalization	B-X
of	B-X
BARD1	B-X
and	B-X
BRCA1	B-X
indicates	B-X
a	B-X
role	B-X
for	B-X
BARD1	B-X
in	B-X
BRCA1	B-X
-	B-X
mediated	B-X
tumor	B-X
suppression	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BARD1	B-X
,	B-X
unlike	B-X
those	B-X
of	B-X
BRCA1	B-X
,	B-X
remain	B-X
relatively	B-X
constant	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
progression	B-X
to	B-X
S	B-X
phase	B-X
is	B-X
accompanied	B-X
by	B-X
the	B-X
aggregation	B-X
of	B-X
nuclear	B-X
BARD1	B-X
polypeptides	B-X
into	B-X
BRCA1	B-X
nuclear	B-X
dots	B-X

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B-Disease
suppressor	O
.	O
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
mutations	B-X
of	B-X
the	B-X
BRCA1	B-X
gene	B-X
predispose	B-X
women	B-X
to	B-X
early	B-X
-	B-X
onset	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
by	B-X
compromising	B-X
the	B-X
gene	B-X
's	B-X
presumptive	B-X
function	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
<EOS>	B-X
This	B-X
cell	B-X
cycle	B-X
-	B-X
dependent	B-X
colocalization	B-X
of	B-X
BARD1	B-X
and	B-X
BRCA1	B-X
indicates	B-X
a	B-X
role	B-X
for	B-X
BARD1	B-X
in	B-X
BRCA1	B-X
-	B-X
mediated	B-X
tumor	B-X
suppression	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BARD1	B-X
,	B-X
unlike	B-X
those	B-X
of	B-X
BRCA1	B-X
,	B-X
remain	B-X
relatively	B-X
constant	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
in	B-X
S	B-X
phase	B-X
cells	B-X
,	B-X
BRCA1	B-X
polypeptides	B-X
are	B-X
hyperphosphorylated	B-X
and	B-X
accumulate	B-X
into	B-X
discrete	B-X
subnuclear	B-X
foci	B-X
termed	B-X
``	B-X
BRCA1	B-X
nuclear	B-X
dots	B-X

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O
<EOS>	B-X
While	B-X
these	B-X
findings	B-X
are	B-X
indicative	B-X
that	B-X
BRIP1	B-X
is	B-X
a	B-X
potential	B-X
BARD1	B-X
binding	B-X
partner	B-X
,	B-X
it	B-X
becomes	B-X
evident	B-X
that	B-X
in	B-X
vitro	B-X
binding	B-X
assays	B-X
involving	B-X
the	B-X
entire	B-X
BARD1	B-X
protein	B-X
and	B-X
in	B-X
vivo	B-X
experiments	B-X
are	B-X
also	B-X
needed	B-X
to	B-X
establish	B-X
its	B-X
binding	B-X
partners	B-X
and	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
tumor	B-X
suppression	B-X
pathways	B-X
<EOS>	B-X
5	B-X
kcal	B-X
/	B-X
mol	B-X
and	B-X
isothermal	B-X
titration	B-X
calorimetry	B-X
(	B-X
ITC	B-X
)	B-X
experiments	B-X
at	B-X
this	B-X
lower	B-X
temperature	B-X
showed	B-X
binding	B-X
to	B-X
the	B-X
BRIP1	B-X
phosphopeptide	B-X
via	B-X
an	B-X
enthalpy	B-X
-	B-X
driven	B-X
interaction	B-X
,	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
the	B-X
pSer	B-X
-	B-X
X	B-X
-	B-X
X	B-X
-	B-X
Phe	B-X
peptide	B-X
-	B-X
binding	B-X
motif	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
and	B-X
intrinsic	B-X
tryptophan	B-X
fluorescence	B-X
experiments	B-X
also	B-X
demonstrate	B-X
that	B-X
,	B-X
although	B-X
intrinsically	B-X
disordered	B-X
,	B-X
polypeptides	B-X
from	B-X
the	B-X
central	B-X
region	B-X
are	B-X
able	B-X
to	B-X
mediate	B-X
interactions	B-X
with	B-X
DNA	B-X
and	B-X
p53	B-X
with	B-X
affinities	B-X
in	B-X
the	B-X
low	B-X
micromolar	B-X
range	B-X
<EOS>	B-X
Substitution	B-X
of	B-X
either	B-X
pSer	B-X
at	B-X
position	B-X
0	B-X
with	B-X
Ser	B-X
(	B-X
non	B-X
-	B-X
phosphorylated	B-X
peptide	B-X
)	B-X
or	B-X
Phe	B-X
with	B-X
Val	B-X
at	B-X
position	B-X
+3	B-X
,	B-X
leads	B-X
to	B-X
no	B-X
-	B-X
binding	B-X
ITC	B-X
results	B-X

When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O
dots	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1	O
.	O
<EOS>	B-X
``	B-X
BRCA1	B-X
associates	B-X
in	B-X
vivo	B-X
with	B-X
a	B-X
structurally	B-X
related	B-X
protein	B-X
termed	B-X
BARD1	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
in	B-X
S	B-X
phase	B-X
cells	B-X
,	B-X
BRCA1	B-X
polypeptides	B-X
are	B-X
hyperphosphorylated	B-X
and	B-X
accumulate	B-X
into	B-X
discrete	B-X
subnuclear	B-X
foci	B-X
termed	B-X
``	B-X
BRCA1	B-X
nuclear	B-X
dots	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BARD1	B-X
,	B-X
unlike	B-X
those	B-X
of	B-X
BRCA1	B-X
,	B-X
remain	B-X
relatively	B-X
constant	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
When	B-X
resting	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
proliferate	B-X
,	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BRCA1	B-X
increase	B-X
in	B-X
late	B-X
G1	B-X
and	B-X
reach	B-X
a	B-X
maximum	B-X
during	B-X
S	B-X
phase	B-X

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BARD1	B-X
,	B-X
unlike	B-X
those	B-X
of	B-X
BRCA1	B-X
,	B-X
remain	B-X
relatively	B-X
constant	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Cell	B-X
cycle	B-X
-	B-X
dependent	B-X
colocalization	B-X
of	B-X
BARD1	B-X
and	B-X
BRCA1	B-X
proteins	B-X
in	B-X
discrete	B-X
nuclear	B-X
domains	B-X
.	B-X
<EOS>	B-X
Although	B-X
the	B-X
biochemical	B-X
properties	B-X
of	B-X
BRCA1	B-X
polypeptides	B-X
are	B-X
not	B-X
understood	B-X
,	B-X
their	B-X
expression	B-X
pattern	B-X
and	B-X
subcellular	B-X
localization	B-X
suggest	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
-	B-X
cycle	B-X
regulation	B-X
<EOS>	B-X
When	B-X
resting	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
proliferate	B-X
,	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BRCA1	B-X
increase	B-X
in	B-X
late	B-X
G1	B-X
and	B-X
reach	B-X
a	B-X
maximum	B-X
during	B-X
S	B-X
phase	B-X

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
S	O
-	O
phase	O
cells	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
BARD1	B-X
polypeptides	B-X
are	B-X
found	B-X
exclusively	B-X
in	B-X
the	B-X
nuclear	B-X
fractions	B-X
of	B-X
both	B-X
G1	B-X
-	B-X
	B-X
and	B-X
S	B-X
-	B-X
phase	B-X
cells	B-X
<EOS>	B-X
Although	B-X
the	B-X
biochemical	B-X
properties	B-X
of	B-X
BRCA1	B-X
polypeptides	B-X
are	B-X
not	B-X
understood	B-X
,	B-X
their	B-X
expression	B-X
pattern	B-X
and	B-X
subcellular	B-X
localization	B-X
suggest	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
-	B-X
cycle	B-X
regulation	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
in	B-X
S	B-X
phase	B-X
cells	B-X
,	B-X
BRCA1	B-X
polypeptides	B-X
are	B-X
hyperphosphorylated	B-X
and	B-X
accumulate	B-X
into	B-X
discrete	B-X
subnuclear	B-X
foci	B-X
termed	B-X
``	B-X
BRCA1	B-X
nuclear	B-X
dots	B-X
<EOS>	B-X
However	B-X
,	B-X
immunostaining	B-X
revealed	B-X
that	B-X
BARD1	B-X
resides	B-X
within	B-X
BRCA1	B-X
nuclear	B-X
dots	B-X
during	B-X
S	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
but	B-X
not	B-X
during	B-X
the	B-X
G1	B-X
phase	B-X

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
mediated	O
tumor	B-Disease
suppression	O
.	O
<EOS>	B-X
This	B-X
cell	B-X
cycle	B-X
-	B-X
dependent	B-X
colocalization	B-X
of	B-X
BARD1	B-X
and	B-X
BRCA1	B-X
indicates	B-X
a	B-X
role	B-X
for	B-X
BARD1	B-X
in	B-X
BRCA1	B-X
-	B-X
mediated	B-X
tumor	B-X
suppression	B-X
<EOS>	B-X
Cell	B-X
cycle	B-X
-	B-X
dependent	B-X
colocalization	B-X
of	B-X
BARD1	B-X
and	B-X
BRCA1	B-X
proteins	B-X
in	B-X
discrete	B-X
nuclear	B-X
domains	B-X
.	B-X
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
mutations	B-X
of	B-X
the	B-X
BRCA1	B-X
gene	B-X
predispose	B-X
women	B-X
to	B-X
early	B-X
-	B-X
onset	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
by	B-X
compromising	B-X
the	B-X
gene	B-X
's	B-X
presumptive	B-X
function	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
<EOS>	B-X
When	B-X
resting	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
proliferate	B-X
,	B-X
the	B-X
steady	B-X
-	B-X
state	B-X
levels	B-X
of	B-X
BRCA1	B-X
increase	B-X
in	B-X
late	B-X
G1	B-X
and	B-X
reach	B-X
a	B-X
maximum	B-X
during	B-X
S	B-X
phase	B-X

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O
<EOS>	B-X
Ethnic	B-X
differences	B-X
in	B-X
the	B-X
HFE	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
in	B-X
different	B-X
ethnic	B-X
groups	B-X
<EOS>	B-X
Population	B-X
studies	B-X
of	B-X
this	B-X
polymorphism	B-X
are	B-X
facilitated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
Cys282Tyr	B-X
mutation	B-X
creates	B-X
a	B-X
Rsal	B-X
restriction	B-X
site	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
observations	B-X
the	B-X
Tyr	B-X
allele	B-X
appeared	B-X
to	B-X
be	B-X
rare	B-X
or	B-X
absent	B-X
in	B-X
Asiatic	B-X
(	B-X
Indian	B-X
,	B-X
Chinese	B-X
)	B-X
populations	B-X

Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
hereditary	B-X
hemochromatosis	B-X
(	B-X
HH	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
homozygosity	B-X
for	B-X
a	B-X
Cys282Tyr	B-X
mutation	B-X
in	B-X
the	B-X
HFE	B-X
gene	B-X
located	B-X
4	B-X
<EOS>	B-X
Population	B-X
studies	B-X
of	B-X
this	B-X
polymorphism	B-X
are	B-X
facilitated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
Cys282Tyr	B-X
mutation	B-X
creates	B-X
a	B-X
Rsal	B-X
restriction	B-X
site	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
observations	B-X
the	B-X
Tyr	B-X
allele	B-X
appeared	B-X
to	B-X
be	B-X
rare	B-X
or	B-X
absent	B-X
in	B-X
Asiatic	B-X
(	B-X
Indian	B-X
,	B-X
Chinese	B-X
)	B-X
populations	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
in	B-X
different	B-X
ethnic	B-X
groups	B-X

5	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O
<EOS>	B-X
5	B-X
Mb	B-X
telomeric	B-X
to	B-X
HLA	B-X
-	B-X
A	B-X
<EOS>	B-X
0	B-X
Mb	B-X
telomeric	B-X
to	B-X
HLA	B-X
-	B-X
A	B-X
)	B-X
<EOS>	B-X
5	B-X
-	B-X
Mb	B-X
telomeric	B-X
of	B-X
HLA	B-X
-	B-X
A	B-X
,	B-X
was	B-X
tested	B-X
<EOS>	B-X
3	B-X
is	B-X
related	B-X
to	B-X
the	B-X
MHC	B-X

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O
<EOS>	B-X
Population	B-X
studies	B-X
of	B-X
this	B-X
polymorphism	B-X
are	B-X
facilitated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
Cys282Tyr	B-X
mutation	B-X
creates	B-X
a	B-X
Rsal	B-X
restriction	B-X
site	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
hereditary	B-X
hemochromatosis	B-X
(	B-X
HH	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
homozygosity	B-X
for	B-X
a	B-X
Cys282Tyr	B-X
mutation	B-X
in	B-X
the	B-X
HFE	B-X
gene	B-X
located	B-X
4	B-X
<EOS>	B-X
The	B-X
newly	B-X
described	B-X
HFE	B-X
marker	B-X
provides	B-X
a	B-X
new	B-X
approach	B-X
to	B-X
the	B-X
screening	B-X
of	B-X
HH	B-X
as	B-X
well	B-X
as	B-X
studies	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
HFE	B-X
Tyr	B-X
allele	B-X
and	B-X
different	B-X
disorders	B-X
including	B-X
cancer	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
in	B-X
different	B-X
ethnic	B-X
groups	B-X

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
in	B-X
different	B-X
ethnic	B-X
groups	B-X
<EOS>	B-X
Ethnic	B-X
differences	B-X
in	B-X
the	B-X
HFE	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
.	B-X
<EOS>	B-X
Population	B-X
studies	B-X
of	B-X
this	B-X
polymorphism	B-X
are	B-X
facilitated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
Cys282Tyr	B-X
mutation	B-X
creates	B-X
a	B-X
Rsal	B-X
restriction	B-X
site	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
hereditary	B-X
hemochromatosis	B-X
(	B-X
HH	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
homozygosity	B-X
for	B-X
a	B-X
Cys282Tyr	B-X
mutation	B-X
in	B-X
the	B-X
HFE	B-X
gene	B-X
located	B-X
4	B-X

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
observations	B-X
the	B-X
Tyr	B-X
allele	B-X
appeared	B-X
to	B-X
be	B-X
rare	B-X
or	B-X
absent	B-X
in	B-X
Asiatic	B-X
(	B-X
Indian	B-X
,	B-X
Chinese	B-X
)	B-X
populations	B-X
<EOS>	B-X
The	B-X
newly	B-X
described	B-X
HFE	B-X
marker	B-X
provides	B-X
a	B-X
new	B-X
approach	B-X
to	B-X
the	B-X
screening	B-X
of	B-X
HH	B-X
as	B-X
well	B-X
as	B-X
studies	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
HFE	B-X
Tyr	B-X
allele	B-X
and	B-X
different	B-X
disorders	B-X
including	B-X
cancer	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
hereditary	B-X
hemochromatosis	B-X
(	B-X
HH	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
homozygosity	B-X
for	B-X
a	B-X
Cys282Tyr	B-X
mutation	B-X
in	B-X
the	B-X
HFE	B-X
gene	B-X
located	B-X
4	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
codon	B-X
282	B-X
(	B-X
Cys	B-X
/	B-X
Tyr	B-X
)	B-X
polymorphism	B-X
in	B-X
different	B-X
ethnic	B-X
groups	B-X

The	O
highest	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O
<EOS>	B-X
The	B-X
highest	B-X
allele	B-X
frequency	B-X
(	B-X
7	B-X
<EOS>	B-X
5	B-X
%	B-X
)	B-X
was	B-X
found	B-X
in	B-X
Swedes	B-X
<EOS>	B-X
The	B-X
encountered	B-X
hurdles	B-X
to	B-X
implement	B-X
the	B-X
gene	B-X
flow	B-X
index	B-X
and	B-X
proposals	B-X
to	B-X
acquire	B-X
the	B-X
missing	B-X
data	B-X
are	B-X
discussed	B-X
<EOS>	B-X
Comparisons	B-X
with	B-X
allele	B-X
frequencies	B-X
based	B-X
on	B-X
prevalence	B-X
estimates	B-X
of	B-X
HH	B-X
showed	B-X
some	B-X
disagreements	B-X
with	B-X
the	B-X
RFLP	B-X
data	B-X
,	B-X
particularly	B-X
in	B-X
Finns	B-X

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B-Disease
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O
<EOS>	B-X
Comparisons	B-X
with	B-X
allele	B-X
frequencies	B-X
based	B-X
on	B-X
prevalence	B-X
estimates	B-X
of	B-X
HH	B-X
showed	B-X
some	B-X
disagreements	B-X
with	B-X
the	B-X
RFLP	B-X
data	B-X
,	B-X
particularly	B-X
in	B-X
Finns	B-X
<EOS>	B-X
The	B-X
newly	B-X
described	B-X
HFE	B-X
marker	B-X
provides	B-X
a	B-X
new	B-X
approach	B-X
to	B-X
the	B-X
screening	B-X
of	B-X
HH	B-X
as	B-X
well	B-X
as	B-X
studies	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
HFE	B-X
Tyr	B-X
allele	B-X
and	B-X
different	B-X
disorders	B-X
including	B-X
cancer	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
previous	B-X
observations	B-X
the	B-X
Tyr	B-X
allele	B-X
appeared	B-X
to	B-X
be	B-X
rare	B-X
or	B-X
absent	B-X
in	B-X
Asiatic	B-X
(	B-X
Indian	B-X
,	B-X
Chinese	B-X
)	B-X
populations	B-X
<EOS>	B-X
Population	B-X
studies	B-X
of	B-X
this	B-X
polymorphism	B-X
are	B-X
facilitated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
Cys282Tyr	B-X
mutation	B-X
creates	B-X
a	B-X
Rsal	B-X
restriction	B-X
site	B-X

The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	B-Disease
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B-Disease

Autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
II	O
.	O
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
associated	B-X
with	B-X
a	B-X
missense	B-X
mutation	B-X
encoding	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
in	B-X
neurophysin	B-X
II	B-X
.	B-X
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
(	B-X
ADNDI	B-X
)	B-X
is	B-X
an	B-X
inherited	B-X
disease	B-X
caused	B-X
by	B-X
progressive	B-X
degeneration	B-X
of	B-X
the	B-X
magnocellular	B-X
neurons	B-X
of	B-X
the	B-X
hypothalamus	B-X
leading	B-X
to	B-X
decreased	B-X
ability	B-X
to	B-X
produce	B-X
the	B-X
hormone	B-X
arginine	B-X
vasopressin	B-X
(	B-X
AVP	B-X
)	B-X
<EOS>	B-X
An	B-X
affected	B-X
girl	B-X
who	B-X
presented	B-X
at	B-X
9	B-X
months	B-X
of	B-X
age	B-X
and	B-X
her	B-X
similarly	B-X
affected	B-X
younger	B-X
brother	B-X
and	B-X
father	B-X
were	B-X
all	B-X
found	B-X
to	B-X
have	B-X
a	B-X
novel	B-X
missense	B-X
mutation	B-X
(	B-X
G1758	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
T	B-X
)	B-X
encoding	B-X
the	B-X
amino	B-X
acid	B-X
substitution	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
within	B-X
NPII	B-X
<EOS>	B-X
This	B-X
mutation	B-X
may	B-X
be	B-X
valuable	B-X
for	B-X
developing	B-X
models	B-X
of	B-X
dominantly	B-X
inherited	B-X
neurodegeneration	B-X
,	B-X
as	B-X
the	B-X
early	B-X
age	B-X
of	B-X
onset	B-X
of	B-X
symptoms	B-X
suggests	B-X
that	B-X
this	B-X
mutation	B-X
may	B-X
be	B-X
particularly	B-X
deleterious	B-X
to	B-X
the	B-X
magnocellular	B-X
neuron	B-X

Autosomal	B-Disease
dominant	I-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
ADNDI	B-Disease
)	O
is	O
an	O
inherited	B-Disease
disease	I-Disease
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
(	B-X
ADNDI	B-X
)	B-X
is	B-X
an	B-X
inherited	B-X
disease	B-X
caused	B-X
by	B-X
progressive	B-X
degeneration	B-X
of	B-X
the	B-X
magnocellular	B-X
neurons	B-X
of	B-X
the	B-X
hypothalamus	B-X
leading	B-X
to	B-X
decreased	B-X
ability	B-X
to	B-X
produce	B-X
the	B-X
hormone	B-X
arginine	B-X
vasopressin	B-X
(	B-X
AVP	B-X
)	B-X
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
associated	B-X
with	B-X
a	B-X
missense	B-X
mutation	B-X
encoding	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
in	B-X
neurophysin	B-X
II	B-X
.	B-X
<EOS>	B-X
This	B-X
mutation	B-X
may	B-X
be	B-X
valuable	B-X
for	B-X
developing	B-X
models	B-X
of	B-X
dominantly	B-X
inherited	B-X
neurodegeneration	B-X
,	B-X
as	B-X
the	B-X
early	B-X
age	B-X
of	B-X
onset	B-X
of	B-X
symptoms	B-X
suggests	B-X
that	B-X
this	B-X
mutation	B-X
may	B-X
be	B-X
particularly	B-X
deleterious	B-X
to	B-X
the	B-X
magnocellular	B-X
neuron	B-X
<EOS>	B-X
The	B-X
genetic	B-X
locus	B-X
of	B-X
the	B-X
disease	B-X
is	B-X
the	B-X
AVP	B-X
-	B-X
neurophysin	B-X
II	B-X
(	B-X
NPII	B-X
)	B-X
gene	B-X
,	B-X
and	B-X
mutations	B-X
that	B-X
cause	B-X
ADNDI	B-X
have	B-X
been	B-X
found	B-X
in	B-X
both	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
the	B-X
prepro	B-X
-	B-X
AVP	B-X
-	B-X
NPII	B-X
precursor	B-X
and	B-X
within	B-X
NPII	B-X
itself	B-X

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B-Disease
insipidus	I-Disease
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O
<EOS>	B-X
7	B-X
%	B-X
were	B-X
classified	B-X
as	B-X
symptomatic	B-X
,	B-X
with	B-X
prevalence	B-X
increasing	B-X
with	B-X
age	B-X
<EOS>	B-X
The	B-X
study	B-X
's	B-X
objective	B-X
was	B-X
to	B-X
compare	B-X
symptomatic	B-X
versus	B-X
asymptomatic	B-X
women	B-X
with	B-X
X	B-X
-	B-X
ALD	B-X
regarding	B-X
their	B-X
physical	B-X
and	B-X
mental	B-X
well	B-X
-	B-X
being	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
<EOS>	B-X
Differences	B-X
between	B-X
male	B-X
and	B-X
female	B-X
children	B-X
were	B-X
not	B-X
generally	B-X
significant	B-X
but	B-X
increased	B-X
dentine	B-X
exposure	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
lower	B-X
molars	B-X
of	B-X
younger	B-X
female	B-X
children	B-X
<EOS>	B-X
Patients	B-X
'	B-X
Individualized	B-X
Care	B-X
Perceptions	B-X
and	B-X
Health	B-X
Literacy	B-X
Using	B-X
an	B-X
Interactive	B-X
App	B-X
During	B-X
Breast	B-X
and	B-X
Prostate	B-X
Cancer	B-X
Treatment	B-X
:	B-X
Two	B-X
Parallel	B-X
Randomized	B-X
Controlled	B-X
Trials	B-X
.	B-X

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	B-Disease
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O
<EOS>	B-X
The	B-X
genetic	B-X
locus	B-X
of	B-X
the	B-X
disease	B-X
is	B-X
the	B-X
AVP	B-X
-	B-X
neurophysin	B-X
II	B-X
(	B-X
NPII	B-X
)	B-X
gene	B-X
,	B-X
and	B-X
mutations	B-X
that	B-X
cause	B-X
ADNDI	B-X
have	B-X
been	B-X
found	B-X
in	B-X
both	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
the	B-X
prepro	B-X
-	B-X
AVP	B-X
-	B-X
NPII	B-X
precursor	B-X
and	B-X
within	B-X
NPII	B-X
itself	B-X
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
associated	B-X
with	B-X
a	B-X
missense	B-X
mutation	B-X
encoding	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
in	B-X
neurophysin	B-X
II	B-X
.	B-X
<EOS>	B-X
A	B-X
T1	B-X
-	B-X
weighted	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
of	B-X
the	B-X
father	B-X
's	B-X
pituitary	B-X
gland	B-X
demonstrates	B-X
an	B-X
attenuated	B-X
posterior	B-X
pituitary	B-X
bright	B-X
spot	B-X
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
(	B-X
ADNDI	B-X
)	B-X
is	B-X
an	B-X
inherited	B-X
disease	B-X
caused	B-X
by	B-X
progressive	B-X
degeneration	B-X
of	B-X
the	B-X
magnocellular	B-X
neurons	B-X
of	B-X
the	B-X
hypothalamus	B-X
leading	B-X
to	B-X
decreased	B-X
ability	B-X
to	B-X
produce	B-X
the	B-X
hormone	B-X
arginine	B-X
vasopressin	B-X
(	B-X
AVP	B-X
)	B-X

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
within	O
NPII	O
.	O
<EOS>	B-X
An	B-X
affected	B-X
girl	B-X
who	B-X
presented	B-X
at	B-X
9	B-X
months	B-X
of	B-X
age	B-X
and	B-X
her	B-X
similarly	B-X
affected	B-X
younger	B-X
brother	B-X
and	B-X
father	B-X
were	B-X
all	B-X
found	B-X
to	B-X
have	B-X
a	B-X
novel	B-X
missense	B-X
mutation	B-X
(	B-X
G1758	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
T	B-X
)	B-X
encoding	B-X
the	B-X
amino	B-X
acid	B-X
substitution	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
within	B-X
NPII	B-X
<EOS>	B-X
Autosomal	B-X
dominant	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
associated	B-X
with	B-X
a	B-X
missense	B-X
mutation	B-X
encoding	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
in	B-X
neurophysin	B-X
II	B-X
.	B-X
<EOS>	B-X
A	B-X
T1	B-X
-	B-X
weighted	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
of	B-X
the	B-X
father	B-X
's	B-X
pituitary	B-X
gland	B-X
demonstrates	B-X
an	B-X
attenuated	B-X
posterior	B-X
pituitary	B-X
bright	B-X
spot	B-X
<EOS>	B-X
The	B-X
genetic	B-X
locus	B-X
of	B-X
the	B-X
disease	B-X
is	B-X
the	B-X
AVP	B-X
-	B-X
neurophysin	B-X
II	B-X
(	B-X
NPII	B-X
)	B-X
gene	B-X
,	B-X
and	B-X
mutations	B-X
that	B-X
cause	B-X
ADNDI	B-X
have	B-X
been	B-X
found	B-X
in	B-X
both	B-X
the	B-X
signal	B-X
peptide	B-X
of	B-X
the	B-X
prepro	B-X
-	B-X
AVP	B-X
-	B-X
NPII	B-X
precursor	B-X
and	B-X
within	B-X
NPII	B-X
itself	B-X

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O
<EOS>	B-X
Detected	B-X
mutations	B-X
were	B-X
confirmed	B-X
by	B-X
restriction	B-X
enzymes	B-X
<EOS>	B-X
Hb	B-X
E	B-X
-	B-X
Saskatoon	B-X
was	B-X
confirmed	B-X
by	B-X
amplification	B-X
of	B-X
the	B-X
HBB	B-X
gene	B-X
,	B-X
followed	B-X
by	B-X
sequence	B-X
analysis	B-X
<EOS>	B-X
Kpn2I	B-X
is	B-X
an	B-X
orthodox	B-X
Type	B-X
IIP	B-X
restriction	B-X
endonuclease	B-X
,	B-X
which	B-X
acts	B-X
as	B-X
a	B-X
dimer	B-X
<EOS>	B-X
Crystal	B-X
structure	B-X
of	B-X
restriction	B-X
endonuclease	B-X
Kpn2I	B-X
of	B-X
CCGG	B-X
-	B-X
family	B-X
.	B-X

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O
<EOS>	B-X
A	B-X
T1	B-X
-	B-X
weighted	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
of	B-X
the	B-X
father	B-X
's	B-X
pituitary	B-X
gland	B-X
demonstrates	B-X
an	B-X
attenuated	B-X
posterior	B-X
pituitary	B-X
bright	B-X
spot	B-X
<EOS>	B-X
Affected	B-X
individuals	B-X
are	B-X
not	B-X
symptomatic	B-X
at	B-X
birth	B-X
,	B-X
but	B-X
usually	B-X
develop	B-X
diabetes	B-X
insipidus	B-X
at	B-X
1	B-X
-	B-X
6	B-X
yr	B-X
of	B-X
age	B-X
<EOS>	B-X
An	B-X
affected	B-X
girl	B-X
who	B-X
presented	B-X
at	B-X
9	B-X
months	B-X
of	B-X
age	B-X
and	B-X
her	B-X
similarly	B-X
affected	B-X
younger	B-X
brother	B-X
and	B-X
father	B-X
were	B-X
all	B-X
found	B-X
to	B-X
have	B-X
a	B-X
novel	B-X
missense	B-X
mutation	B-X
(	B-X
G1758	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
T	B-X
)	B-X
encoding	B-X
the	B-X
amino	B-X
acid	B-X
substitution	B-X
Gly23	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Val	B-X
within	B-X
NPII	B-X
<EOS>	B-X
This	B-X
mutation	B-X
may	B-X
be	B-X
valuable	B-X
for	B-X
developing	B-X
models	B-X
of	B-X
dominantly	B-X
inherited	B-X
neurodegeneration	B-X
,	B-X
as	B-X
the	B-X
early	B-X
age	B-X
of	B-X
onset	B-X
of	B-X
symptoms	B-X
suggests	B-X
that	B-X
this	B-X
mutation	B-X
may	B-X
be	B-X
particularly	B-X
deleterious	B-X
to	B-X
the	B-X
magnocellular	B-X
neuron	B-X

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B-Disease
inherited	I-Disease
neurodegeneration	I-Disease
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Frequent	B-X
inactivation	B-X
of	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
in	B-X
primary	B-X
prostate	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Frequent	B-X
inactivation	B-X
of	B-X
PTEN	B-X
in	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
xenografts	B-X
.	B-X
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
second	B-X
mutational	B-X
event	B-X
in	B-X
10	B-X
(	B-X
43	B-X
%	B-X
)	B-X
tumors	B-X
establishes	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
as	B-X
a	B-X
main	B-X
inactivation	B-X
target	B-X
of	B-X
10q	B-X
loss	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

Sporadic	B-Disease
prostate	I-Disease
carcinoma	I-Disease
is	O
the	O
most	O
common	O
male	B-Disease
cancer	I-Disease
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B-Disease
remain	O
to	O
be	O
elucidated	O
.	O
<EOS>	B-X
Sporadic	B-X
prostate	B-X
carcinoma	B-X
is	B-X
the	B-X
most	B-X
common	B-X
male	B-X
cancer	B-X
in	B-X
the	B-X
Western	B-X
world	B-X
,	B-X
yet	B-X
many	B-X
of	B-X
the	B-X
major	B-X
genetic	B-X
events	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
this	B-X
often	B-X
fatal	B-X
cancer	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
Deletion	B-X
mapping	B-X
studies	B-X
have	B-X
unambiguously	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
the	B-X
minimal	B-X
area	B-X
of	B-X
loss	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
second	B-X
mutational	B-X
event	B-X
in	B-X
10	B-X
(	B-X
43	B-X
%	B-X
)	B-X
tumors	B-X
establishes	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
as	B-X
a	B-X
main	B-X
inactivation	B-X
target	B-X
of	B-X
10q	B-X
loss	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
second	B-X
mutational	B-X
event	B-X
in	B-X
10	B-X
(	B-X
43	B-X
%	B-X
)	B-X
tumors	B-X
establishes	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
as	B-X
a	B-X
main	B-X
inactivation	B-X
target	B-X
of	B-X
10q	B-X
loss	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
Deletion	B-X
mapping	B-X
studies	B-X
have	B-X
unambiguously	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
the	B-X
minimal	B-X
area	B-X
of	B-X
loss	B-X
<EOS>	B-X
We	B-X
screened	B-X
80	B-X
prostate	B-X
tumors	B-X
by	B-X
microsatellite	B-X
analysis	B-X
and	B-X
found	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
deleted	B-X
in	B-X
23	B-X
cases	B-X

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
.	O
<EOS>	B-X
Deletion	B-X
mapping	B-X
studies	B-X
have	B-X
unambiguously	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
the	B-X
minimal	B-X
area	B-X
of	B-X
loss	B-X
<EOS>	B-X
A	B-X
new	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
,	B-X
was	B-X
isolated	B-X
recently	B-X
at	B-X
this	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
and	B-X
found	B-X
to	B-X
be	B-X
inactivated	B-X
by	B-X
mutation	B-X
in	B-X
three	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
<EOS>	B-X
We	B-X
screened	B-X
80	B-X
prostate	B-X
tumors	B-X
by	B-X
microsatellite	B-X
analysis	B-X
and	B-X
found	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
deleted	B-X
in	B-X
23	B-X
cases	B-X
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

A	O
new	O
tumor	B-Disease
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B-Disease
cancer	I-Disease
cell	O
lines	O
.	O
<EOS>	B-X
A	B-X
new	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
,	B-X
was	B-X
isolated	B-X
recently	B-X
at	B-X
this	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
and	B-X
found	B-X
to	B-X
be	B-X
inactivated	B-X
by	B-X
mutation	B-X
in	B-X
three	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Deletion	B-X
mapping	B-X
studies	B-X
have	B-X
unambiguously	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
the	B-X
minimal	B-X
area	B-X
of	B-X
loss	B-X
<EOS>	B-X
We	B-X
screened	B-X
80	B-X
prostate	B-X
tumors	B-X
by	B-X
microsatellite	B-X
analysis	B-X
and	B-X
found	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
deleted	B-X
in	B-X
23	B-X
cases	B-X
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

We	O
screened	O
80	O
prostate	B-Disease
tumors	I-Disease
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O
<EOS>	B-X
We	B-X
screened	B-X
80	B-X
prostate	B-X
tumors	B-X
by	B-X
microsatellite	B-X
analysis	B-X
and	B-X
found	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
deleted	B-X
in	B-X
23	B-X
cases	B-X
<EOS>	B-X
Deletion	B-X
mapping	B-X
studies	B-X
have	B-X
unambiguously	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
the	B-X
minimal	B-X
area	B-X
of	B-X
loss	B-X
<EOS>	B-X
A	B-X
new	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
,	B-X
was	B-X
isolated	B-X
recently	B-X
at	B-X
this	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
and	B-X
found	B-X
to	B-X
be	B-X
inactivated	B-X
by	B-X
mutation	B-X
in	B-X
three	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O
<EOS>	B-X
We	B-X
then	B-X
proceeded	B-X
with	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
entire	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
coding	B-X
region	B-X
and	B-X
tested	B-X
for	B-X
homozygous	B-X
deletion	B-X
with	B-X
new	B-X
intragenic	B-X
markers	B-X
in	B-X
these	B-X
23	B-X
cases	B-X
with	B-X
10q23	B-X
loss	B-X
of	B-X
heterozygosity	B-X
<EOS>	B-X
We	B-X
screened	B-X
80	B-X
prostate	B-X
tumors	B-X
by	B-X
microsatellite	B-X
analysis	B-X
and	B-X
found	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
deleted	B-X
in	B-X
23	B-X
cases	B-X
<EOS>	B-X
Deletion	B-X
mapping	B-X
studies	B-X
have	B-X
unambiguously	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
to	B-X
be	B-X
the	B-X
minimal	B-X
area	B-X
of	B-X
loss	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
second	B-X
mutational	B-X
event	B-X
in	B-X
10	B-X
(	B-X
43	B-X
%	B-X
)	B-X
tumors	B-X
establishes	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
as	B-X
a	B-X
main	B-X
inactivation	B-X
target	B-X
of	B-X
10q	B-X
loss	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B-Disease
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B-Disease
prostate	I-Disease
cancer	I-Disease
.	O
.	O
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
second	B-X
mutational	B-X
event	B-X
in	B-X
10	B-X
(	B-X
43	B-X
%	B-X
)	B-X
tumors	B-X
establishes	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
as	B-X
a	B-X
main	B-X
inactivation	B-X
target	B-X
of	B-X
10q	B-X
loss	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
Numerous	B-X
cytogenetic	B-X
and	B-X
allelotype	B-X
studies	B-X
have	B-X
reported	B-X
frequent	B-X
loss	B-X
of	B-X
heterozygosity	B-X
on	B-X
chromosomal	B-X
arm	B-X
10q	B-X
in	B-X
sporadic	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
Frequent	B-X
inactivation	B-X
of	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
in	B-X
primary	B-X
prostate	B-X
cancer	B-X
.	B-X
<EOS>	B-X
A	B-X
new	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
,	B-X
was	B-X
isolated	B-X
recently	B-X
at	B-X
this	B-X
region	B-X
of	B-X
chromosome	B-X
10q23	B-X
and	B-X
found	B-X
to	B-X
be	B-X
inactivated	B-X
by	B-X
mutation	B-X
in	B-X
three	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B-Disease
disease	I-Disease
.	O
<EOS>	B-X
Risk	B-X
reversals	B-X
in	B-X
predictive	B-X
testing	B-X
for	B-X
Huntington	B-X
disease	B-X
.	B-X
<EOS>	B-X
Testing	B-X
the	B-X
test	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
why	B-X
pursue	B-X
a	B-X
better	B-X
test	B-X
for	B-X
Huntington	B-X
disease	B-X
?	B-X
<EOS>	B-X
No	B-X
risk	B-X
reversals	B-X
were	B-X
revealed	B-X
by	B-X
this	B-X
study	B-X
<EOS>	B-X
Predictive	B-X
testing	B-X
for	B-X
Huntington	B-X
's	B-X
disease	B-X
:	B-X
after	B-X
the	B-X
gene	B-X
.	B-X
The	B-X
United	B-X
Kingdom	B-X
Huntington	B-X
's	B-X
Disease	B-X
Prediction	B-X
Consortium	B-X
.	B-X

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	B-Disease
.	O
<EOS>	B-X
The	B-X
first	B-X
predictive	B-X
testing	B-X
for	B-X
Huntington	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
was	B-X
based	B-X
on	B-X
analysis	B-X
of	B-X
linked	B-X
polymorphic	B-X
DNA	B-X
markers	B-X
to	B-X
estimate	B-X
the	B-X
likelihood	B-X
of	B-X
inheriting	B-X
the	B-X
mutation	B-X
for	B-X
HD	B-X
<EOS>	B-X
With	B-X
direct	B-X
tests	B-X
for	B-X
the	B-X
HD	B-X
mutation	B-X
,	B-X
we	B-X
have	B-X
assessed	B-X
the	B-X
accuracy	B-X
of	B-X
results	B-X
obtained	B-X
by	B-X
linkage	B-X
approaches	B-X
when	B-X
requested	B-X
to	B-X
do	B-X
so	B-X
by	B-X
the	B-X
test	B-X
individuals	B-X
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
potential	B-X
reasons	B-X
for	B-X
these	B-X
changes	B-X
in	B-X
results	B-X
and	B-X
impact	B-X
of	B-X
these	B-X
risk	B-X
reversals	B-X
on	B-X
both	B-X
patients	B-X
and	B-X
the	B-X
counseling	B-X
team	B-X
can	B-X
assist	B-X
in	B-X
the	B-X
development	B-X
of	B-X
strategies	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
,	B-X
where	B-X
necessary	B-X
,	B-X
management	B-X
of	B-X
a	B-X
risk	B-X
reversal	B-X
in	B-X
any	B-X
predictive	B-X
testing	B-X
program	B-X
<EOS>	B-X
Three	B-X
went	B-X
from	B-X
a	B-X
decreased	B-X
risk	B-X
to	B-X
an	B-X
increased	B-X
risk	B-X
,	B-X
while	B-X
in	B-X
another	B-X
three	B-X
the	B-X
risk	B-X
was	B-X
decreased	B-X

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O
<EOS>	B-X
Limits	B-X
to	B-X
accuracy	B-X
included	B-X
recombination	B-X
between	B-X
the	B-X
DNA	B-X
markers	B-X
and	B-X
the	B-X
mutation	B-X
,	B-X
pedigree	B-X
structure	B-X
,	B-X
and	B-X
whether	B-X
DNA	B-X
samples	B-X
were	B-X
available	B-X
from	B-X
family	B-X
members	B-X
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
potential	B-X
reasons	B-X
for	B-X
these	B-X
changes	B-X
in	B-X
results	B-X
and	B-X
impact	B-X
of	B-X
these	B-X
risk	B-X
reversals	B-X
on	B-X
both	B-X
patients	B-X
and	B-X
the	B-X
counseling	B-X
team	B-X
can	B-X
assist	B-X
in	B-X
the	B-X
development	B-X
of	B-X
strategies	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
,	B-X
where	B-X
necessary	B-X
,	B-X
management	B-X
of	B-X
a	B-X
risk	B-X
reversal	B-X
in	B-X
any	B-X
predictive	B-X
testing	B-X
program	B-X
<EOS>	B-X
Three	B-X
went	B-X
from	B-X
a	B-X
decreased	B-X
risk	B-X
to	B-X
an	B-X
increased	B-X
risk	B-X
,	B-X
while	B-X
in	B-X
another	B-X
three	B-X
the	B-X
risk	B-X
was	B-X
decreased	B-X
<EOS>	B-X
With	B-X
direct	B-X
tests	B-X
for	B-X
the	B-X
HD	B-X
mutation	B-X
,	B-X
we	B-X
have	B-X
assessed	B-X
the	B-X
accuracy	B-X
of	B-X
results	B-X
obtained	B-X
by	B-X
linkage	B-X
approaches	B-X
when	B-X
requested	B-X
to	B-X
do	B-X
so	B-X
by	B-X
the	B-X
test	B-X
individuals	B-X

With	O
direct	O
tests	O
for	O
the	O
HD	B-Disease
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O
.	O
<EOS>	B-X
95	B-X
)	B-X
,	B-X
and	B-X
the	B-X
severity	B-X
of	B-X
pneumonitis	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
Hispanics	B-X
and	B-X
NHWs	B-X
(	B-X
P=0	B-X
<EOS>	B-X
Italian	B-X
people	B-X
were	B-X
overall	B-X
satisfied	B-X
with	B-X
HCS	B-X
although	B-X
with	B-X
significant	B-X
different	B-X
perceptions	B-X
between	B-X
regions	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicated	B-X
no	B-X
significant	B-X
difference	B-X
between	B-X
the	B-X
groups	B-X
in	B-X
terms	B-X
of	B-X
mental	B-X
health	B-X
or	B-X
stress	B-X
<EOS>	B-X
55	B-X
%	B-X
of	B-X
all	B-X
interviewees	B-X
felt	B-X
they	B-X
were	B-X
adequately	B-X
informed	B-X
about	B-X
cancer	B-X
,	B-X
with	B-X
no	B-X
disparities	B-X
between	B-X
regions	B-X

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O
.	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
potential	B-X
reasons	B-X
for	B-X
these	B-X
changes	B-X
in	B-X
results	B-X
and	B-X
impact	B-X
of	B-X
these	B-X
risk	B-X
reversals	B-X
on	B-X
both	B-X
patients	B-X
and	B-X
the	B-X
counseling	B-X
team	B-X
can	B-X
assist	B-X
in	B-X
the	B-X
development	B-X
of	B-X
strategies	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
,	B-X
where	B-X
necessary	B-X
,	B-X
management	B-X
of	B-X
a	B-X
risk	B-X
reversal	B-X
in	B-X
any	B-X
predictive	B-X
testing	B-X
program	B-X
<EOS>	B-X
With	B-X
direct	B-X
tests	B-X
for	B-X
the	B-X
HD	B-X
mutation	B-X
,	B-X
we	B-X
have	B-X
assessed	B-X
the	B-X
accuracy	B-X
of	B-X
results	B-X
obtained	B-X
by	B-X
linkage	B-X
approaches	B-X
when	B-X
requested	B-X
to	B-X
do	B-X
so	B-X
by	B-X
the	B-X
test	B-X
individuals	B-X
<EOS>	B-X
The	B-X
first	B-X
predictive	B-X
testing	B-X
for	B-X
Huntington	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
was	B-X
based	B-X
on	B-X
analysis	B-X
of	B-X
linked	B-X
polymorphic	B-X
DNA	B-X
markers	B-X
to	B-X
estimate	B-X
the	B-X
likelihood	B-X
of	B-X
inheriting	B-X
the	B-X
mutation	B-X
for	B-X
HD	B-X
<EOS>	B-X
Limits	B-X
to	B-X
accuracy	B-X
included	B-X
recombination	B-X
between	B-X
the	B-X
DNA	B-X
markers	B-X
and	B-X
the	B-X
mutation	B-X
,	B-X
pedigree	B-X
structure	B-X
,	B-X
and	B-X
whether	B-X
DNA	B-X
samples	B-X
were	B-X
available	B-X
from	B-X
family	B-X
members	B-X

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B-Disease
IVA	I-Disease
.	O

Mucopolysaccharidosis	B-Disease
IVA	I-Disease
(	O
MPS	B-Disease
IVA	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
lysosomal	I-Disease
storage	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
genetic	B-Disease
defect	I-Disease
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
.	O
<EOS>	B-X
In	B-X
previous	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
found	B-X
two	B-X
common	B-X
mutations	B-X
in	B-X
Caucasians	B-X
and	B-X
Japanese	B-X
,	B-X
respectively	B-X
<EOS>	B-X
No	B-X
CYP2D6A	B-X
or	B-X
CYP2D6B	B-X
alleles	B-X
,	B-X
two	B-X
of	B-X
the	B-X
most	B-X
common	B-X
defect	B-X
alleles	B-X
among	B-X
Caucasians	B-X
,	B-X
were	B-X
found	B-X
among	B-X
the	B-X
Oriental	B-X
subjects	B-X
<EOS>	B-X
Genetic	B-X
analysis	B-X
of	B-X
the	B-X
CYP2D	B-X
locus	B-X
in	B-X
relation	B-X
to	B-X
debrisoquine	B-X
hydroxylation	B-X
capacity	B-X
in	B-X
Korean	B-X
,	B-X
Japanese	B-X
and	B-X
Chinese	B-X
subjects	B-X
.	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
present	B-X
pilot	B-X
study	B-X
revealed	B-X
major	B-X
similarities	B-X
in	B-X
the	B-X
polymorphic	B-X
CYP2D	B-X
locus	B-X
between	B-X
Korean	B-X
,	B-X
Japanese	B-X
and	B-X
Chinese	B-X
populations	B-X

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	B-Disease
IVA	I-Disease
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
mutational	B-X
spectrum	B-X
in	B-X
various	B-X
ethnic	B-X
groups	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
in	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
patients	B-X
were	B-X
investigated	B-X
,	B-X
and	B-X
genetic	B-X
backgrounds	B-X
were	B-X
extensively	B-X
analyzed	B-X
to	B-X
identify	B-X
racial	B-X
origin	B-X
,	B-X
based	B-X
on	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
lineages	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
the	B-X
genetic	B-X
background	B-X
by	B-X
means	B-X
of	B-X
mtDNA	B-X
lineages	B-X
indicate	B-X
that	B-X
all	B-X
our	B-X
patients	B-X
are	B-X
probably	B-X
of	B-X
native	B-X
American	B-X
descent	B-X
<EOS>	B-X
The	B-X
skewed	B-X
prevalence	B-X
of	B-X
G301C	B-X
in	B-X
only	B-X
Colombian	B-X
patients	B-X
and	B-X
haplotype	B-X
analysis	B-X
by	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphisms	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
suggest	B-X
that	B-X
G301C	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X
<EOS>	B-X
Three	B-X
novel	B-X
missense	B-X
mutations	B-X
never	B-X
identified	B-X
previously	B-X
in	B-X
other	B-X
populations	B-X
and	B-X
found	B-X
in	B-X
16	B-X
out	B-X
of	B-X
19	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
unrelated	B-X
alleles	B-X
account	B-X
for	B-X
84	B-X

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	B-Disease
IVA	I-Disease
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
.	O
<EOS>	B-X
The	B-X
genotyping	B-X
of	B-X
the	B-X
animals	B-X
revealed	B-X
four	B-X
SNPs	B-X
at	B-X
the	B-X
183	B-X
<EOS>	B-X
Most	B-X
of	B-X
the	B-X
available	B-X
genotyping	B-X
methods	B-X
were	B-X
applied	B-X
and	B-X
evaluated	B-X
in	B-X
<EOS>	B-X
A	B-X
study	B-X
on	B-X
the	B-X
design	B-X
of	B-X
an	B-X
<EOS>	B-X
Eighty	B-X
BD	B-X
cases	B-X
and	B-X
80	B-X
controls	B-X
were	B-X
recruited	B-X
in	B-X
the	B-X
study	B-X

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
.	O
<EOS>	B-X
The	B-X
G301C	B-X
and	B-X
S162F	B-X
mutations	B-X
account	B-X
for	B-X
68	B-X
<EOS>	B-X
In	B-X
previous	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
found	B-X
two	B-X
common	B-X
mutations	B-X
in	B-X
Caucasians	B-X
and	B-X
Japanese	B-X
,	B-X
respectively	B-X
<EOS>	B-X
A	B-X
novel	B-X
common	B-X
missense	B-X
mutation	B-X
G301C	B-X
in	B-X
the	B-X
N	B-X
-	B-X
acetylgalactosamine	B-X
-	B-X
6	B-X
-	B-X
sulfate	B-X
sulfatase	B-X
gene	B-X
in	B-X
mucopolysaccharidosis	B-X
IVA	B-X
.	B-X
<EOS>	B-X
Three	B-X
novel	B-X
missense	B-X
mutations	B-X
never	B-X
identified	B-X
previously	B-X
in	B-X
other	B-X
populations	B-X
and	B-X
found	B-X
in	B-X
16	B-X
out	B-X
of	B-X
19	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
unrelated	B-X
alleles	B-X
account	B-X
for	B-X
84	B-X

4	O
%	O
and	O
10	O
.	O
<EOS>	B-X
5	B-X
Â±	B-X
10	B-X
<EOS>	B-X
4	B-X
;	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
45	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
0	B-X
<EOS>	B-X
4	B-X
Â±	B-X
1	B-X

5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O
<EOS>	B-X
5	B-X
%	B-X
of	B-X
mutations	B-X
,	B-X
respectively	B-X
,	B-X
whereas	B-X
the	B-X
remaining	B-X
F69V	B-X
is	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
allele	B-X
<EOS>	B-X
Three	B-X
novel	B-X
missense	B-X
mutations	B-X
never	B-X
identified	B-X
previously	B-X
in	B-X
other	B-X
populations	B-X
and	B-X
found	B-X
in	B-X
16	B-X
out	B-X
of	B-X
19	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
unrelated	B-X
alleles	B-X
account	B-X
for	B-X
84	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
the	B-X
genetic	B-X
background	B-X
by	B-X
means	B-X
of	B-X
mtDNA	B-X
lineages	B-X
indicate	B-X
that	B-X
all	B-X
our	B-X
patients	B-X
are	B-X
probably	B-X
of	B-X
native	B-X
American	B-X
descent	B-X
<EOS>	B-X
The	B-X
skewed	B-X
prevalence	B-X
of	B-X
G301C	B-X
in	B-X
only	B-X
Colombian	B-X
patients	B-X
and	B-X
haplotype	B-X
analysis	B-X
by	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphisms	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
suggest	B-X
that	B-X
G301C	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O
<EOS>	B-X
The	B-X
skewed	B-X
prevalence	B-X
of	B-X
G301C	B-X
in	B-X
only	B-X
Colombian	B-X
patients	B-X
and	B-X
haplotype	B-X
analysis	B-X
by	B-X
restriction	B-X
fragment	B-X
length	B-X
polymorphisms	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
suggest	B-X
that	B-X
G301C	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
mutational	B-X
spectrum	B-X
in	B-X
various	B-X
ethnic	B-X
groups	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
in	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
patients	B-X
were	B-X
investigated	B-X
,	B-X
and	B-X
genetic	B-X
backgrounds	B-X
were	B-X
extensively	B-X
analyzed	B-X
to	B-X
identify	B-X
racial	B-X
origin	B-X
,	B-X
based	B-X
on	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
lineages	B-X
<EOS>	B-X
Three	B-X
novel	B-X
missense	B-X
mutations	B-X
never	B-X
identified	B-X
previously	B-X
in	B-X
other	B-X
populations	B-X
and	B-X
found	B-X
in	B-X
16	B-X
out	B-X
of	B-X
19	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
unrelated	B-X
alleles	B-X
account	B-X
for	B-X
84	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
the	B-X
genetic	B-X
background	B-X
by	B-X
means	B-X
of	B-X
mtDNA	B-X
lineages	B-X
indicate	B-X
that	B-X
all	B-X
our	B-X
patients	B-X
are	B-X
probably	B-X
of	B-X
native	B-X
American	B-X
descent	B-X

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O
American	O
descent	O
<EOS>	B-X
Investigation	B-X
of	B-X
the	B-X
genetic	B-X
background	B-X
by	B-X
means	B-X
of	B-X
mtDNA	B-X
lineages	B-X
indicate	B-X
that	B-X
all	B-X
our	B-X
patients	B-X
are	B-X
probably	B-X
of	B-X
native	B-X
American	B-X
descent	B-X
<EOS>	B-X
In	B-X
previous	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
found	B-X
two	B-X
common	B-X
mutations	B-X
in	B-X
Caucasians	B-X
and	B-X
Japanese	B-X
,	B-X
respectively	B-X
<EOS>	B-X
5	B-X
%	B-X
of	B-X
mutations	B-X
,	B-X
respectively	B-X
,	B-X
whereas	B-X
the	B-X
remaining	B-X
F69V	B-X
is	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
allele	B-X
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
mutational	B-X
spectrum	B-X
in	B-X
various	B-X
ethnic	B-X
groups	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
in	B-X
Colombian	B-X
MPS	B-X
IVA	B-X
patients	B-X
were	B-X
investigated	B-X
,	B-X
and	B-X
genetic	B-X
backgrounds	B-X
were	B-X
extensively	B-X
analyzed	B-X
to	B-X
identify	B-X
racial	B-X
origin	B-X
,	B-X
based	B-X
on	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
lineages	B-X

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
<EOS>	B-X
Low	B-X
frequency	B-X
of	B-X
BRCA1	B-X
germline	B-X
mutations	B-X
in	B-X
45	B-X
German	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
We	B-X
identified	B-X
four	B-X
germline	B-X
mutations	B-X
in	B-X
three	B-X
breast	B-X
cancer	B-X
families	B-X
and	B-X
in	B-X
one	B-X
breast	B-X
-	B-X
ovarian	B-X
cancer	B-X
family	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
45	B-X
German	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
for	B-X
germline	B-X
mutations	B-X
in	B-X
the	B-X
BRCA1	B-X
gene	B-X
<EOS>	B-X
These	B-X
findings	B-X
show	B-X
that	B-X
BRCA1	B-X
is	B-X
implicated	B-X
in	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
another	B-X
susceptibility	B-X
gene	B-X
(	B-X
s	B-X
)	B-X

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
45	B-X
German	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
for	B-X
germline	B-X
mutations	B-X
in	B-X
the	B-X
BRCA1	B-X
gene	B-X
<EOS>	B-X
These	B-X
findings	B-X
show	B-X
that	B-X
BRCA1	B-X
is	B-X
implicated	B-X
in	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
another	B-X
susceptibility	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
<EOS>	B-X
We	B-X
identified	B-X
four	B-X
germline	B-X
mutations	B-X
in	B-X
three	B-X
breast	B-X
cancer	B-X
families	B-X
and	B-X
in	B-X
one	B-X
breast	B-X
-	B-X
ovarian	B-X
cancer	B-X
family	B-X
<EOS>	B-X
The	B-X
average	B-X
age	B-X
of	B-X
disease	B-X
onset	B-X
in	B-X
those	B-X
families	B-X
harbouring	B-X
causative	B-X
mutations	B-X
was	B-X
between	B-X
32	B-X

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B-Disease
cancer	I-Disease
families	O
and	O
in	O
one	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
family	O
.	O
among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O
<EOS>	B-X
among	B-X
these	B-X
were	B-X
one	B-X
frameshift	B-X
mutation	B-X
,	B-X
one	B-X
nonsense	B-X
mutation	B-X
,	B-X
one	B-X
novel	B-X
splice	B-X
site	B-X
mutation	B-X
,	B-X
and	B-X
one	B-X
missense	B-X
mutation	B-X
<EOS>	B-X
We	B-X
identified	B-X
four	B-X
germline	B-X
mutations	B-X
in	B-X
three	B-X
breast	B-X
cancer	B-X
families	B-X
and	B-X
in	B-X
one	B-X
breast	B-X
-	B-X
ovarian	B-X
cancer	B-X
family	B-X
<EOS>	B-X
All	B-X
but	B-X
one	B-X
of	B-X
the	B-X
mutations	B-X
are	B-X
predicted	B-X
to	B-X
give	B-X
rise	B-X
to	B-X
premature	B-X
translation	B-X
termination	B-X
and	B-X
include	B-X
seven	B-X
frameshift	B-X
insertions	B-X
or	B-X
deletions	B-X
,	B-X
a	B-X
nonsense	B-X
mutation	B-X
,	B-X
and	B-X
a	B-X
splice	B-X
acceptor	B-X
site	B-X
mutation	B-X
<EOS>	B-X
Nine	B-X
different	B-X
germ	B-X
-	B-X
line	B-X
mutations	B-X
in	B-X
the	B-X
BRCA1	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
susceptibility	B-X
gene	B-X
were	B-X
identified	B-X
in	B-X
15	B-X
of	B-X
47	B-X
kindreds	B-X
from	B-X
southern	B-X
Sweden	B-X
,	B-X
by	B-X
use	B-X
of	B-X
SSCP	B-X
and	B-X
heteroduplex	B-X
analysis	B-X
of	B-X
all	B-X
exons	B-X
and	B-X
flanking	B-X
intron	B-X
region	B-X
and	B-X
by	B-X
a	B-X
protein	B-X
-	B-X
truncation	B-X
test	B-X
for	B-X
exon	B-X
11	B-X
,	B-X
followed	B-X
by	B-X
direct	B-X
sequencing	B-X

The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
.	O
<EOS>	B-X
Missense	B-X
Mutations	B-X
were	B-X
detected	B-X
in	B-X
0	B-X
<EOS>	B-X
242A	B-X
>	B-X
G	B-X
missense	B-X
mutation	B-X
that	B-X
results	B-X
in	B-X
a	B-X
nonsynonymous	B-X
p	B-X
<EOS>	B-X
Point	B-X
mutations	B-X
,	B-X
Nonsense	B-X
mutations	B-X
and	B-X
small	B-X
mutations	B-X
have	B-X
a	B-X
least	B-X
accountability	B-X
<EOS>	B-X
R201H	B-X
)	B-X
missense	B-X
variant	B-X
in	B-X
exon	B-X
8	B-X
of	B-X
the	B-X
GNAS	B-X
gene	B-X

8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O
<EOS>	B-X
Outpatient	B-X
billing	B-X
information	B-X
suggesting	B-X
that	B-X
these	B-X
cases	B-X
were	B-X
billed	B-X
as	B-X
outpatients	B-X
,	B-X
was	B-X
found	B-X
in	B-X
0	B-X
<EOS>	B-X
Most	B-X
of	B-X
the	B-X
patients	B-X
hospitalized	B-X
due	B-X
to	B-X
eye	B-X
diseases	B-X
were	B-X
females	B-X
(	B-X
59	B-X
<EOS>	B-X
2	B-X
%	B-X
,	B-X
the	B-X
negative	B-X
predictive	B-X
value	B-X
increased	B-X
from	B-X
73	B-X
<EOS>	B-X
16	B-X
)	B-X
of	B-X
the	B-X
variation	B-X
were	B-X
attributable	B-X
to	B-X
between	B-X
-	B-X
anesthesiologist	B-X
and	B-X
between	B-X
-	B-X
hospital	B-X
differences	B-X
,	B-X
respectively	B-X

The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
.	O
<EOS>	B-X
The	B-X
average	B-X
age	B-X
of	B-X
disease	B-X
onset	B-X
in	B-X
those	B-X
families	B-X
harbouring	B-X
causative	B-X
mutations	B-X
was	B-X
between	B-X
32	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
45	B-X
German	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
for	B-X
germline	B-X
mutations	B-X
in	B-X
the	B-X
BRCA1	B-X
gene	B-X
<EOS>	B-X
Those	B-X
families	B-X
included	B-X
202	B-X
KRIT1	B-X
mutation	B-X
carriers	B-X
<EOS>	B-X
Alterations	B-X
of	B-X
candidate	B-X
genes	B-X
at	B-X
these	B-X
loci	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
TAAD	B-X

3	O
and	O
37	O
.	O
<EOS>	B-X
1	B-X
and	B-X
	B-X
-	B-X
1	B-X
<EOS>	B-X
2	B-X
)	B-X
and	B-X
50	B-X
(	B-X
SD	B-X
12	B-X
<EOS>	B-X
37	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
0	B-X
<EOS>	B-X
93	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
2	B-X

4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
.	O
<EOS>	B-X
4	B-X
years	B-X
,	B-X
whereas	B-X
the	B-X
family	B-X
harbouring	B-X
the	B-X
missense	B-X
mutation	B-X
had	B-X
an	B-X
average	B-X
age	B-X
of	B-X
onset	B-X
of	B-X
51	B-X
<EOS>	B-X
among	B-X
these	B-X
were	B-X
one	B-X
frameshift	B-X
mutation	B-X
,	B-X
one	B-X
nonsense	B-X
mutation	B-X
,	B-X
one	B-X
novel	B-X
splice	B-X
site	B-X
mutation	B-X
,	B-X
and	B-X
one	B-X
missense	B-X
mutation	B-X
<EOS>	B-X
The	B-X
missense	B-X
mutation	B-X
was	B-X
also	B-X
found	B-X
in	B-X
2	B-X
<EOS>	B-X
The	B-X
average	B-X
age	B-X
of	B-X
disease	B-X
onset	B-X
in	B-X
those	B-X
families	B-X
harbouring	B-X
causative	B-X
mutations	B-X
was	B-X
between	B-X
32	B-X

2	O
years	O
.	O
<EOS>	B-X
8	B-X
years	B-X
,	B-X
with	B-X
9	B-X
<EOS>	B-X
8	B-X
years	B-X
were	B-X
included	B-X
<EOS>	B-X
2	B-X
%	B-X
,	B-X
aOR	B-X
2	B-X
<EOS>	B-X
2	B-X
to	B-X
3	B-X

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

Paternal	O
transmission	O
of	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	I-Disease
.	O
<EOS>	B-X
[	B-X
Premutation	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
]	B-X
.	B-X
<EOS>	B-X
Paternal	B-X
transmission	B-X
of	B-X
the	B-X
congenital	B-X
form	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
type	B-X
1	B-X
:	B-X
a	B-X
new	B-X
case	B-X
and	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
.	B-X
<EOS>	B-X
CpG	B-X
Methylation	B-X
,	B-X
a	B-X
Parent	B-X
-	B-X
of	B-X
-	B-X
Origin	B-X
Effect	B-X
for	B-X
Maternal	B-X
-	B-X
Biased	B-X
Transmission	B-X
of	B-X
Congenital	B-X
Myotonic	B-X
Dystrophy	B-X
.	B-X
<EOS>	B-X
Sibship	B-X
stability	B-X
of	B-X
genotype	B-X
and	B-X
phenotype	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
.	B-X

We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
.	O
<EOS>	B-X
We	B-X
report	B-X
a	B-X
rare	B-X
case	B-X
of	B-X
paternally	B-X
transmitted	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
<EOS>	B-X
Paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Only	B-X
six	B-X
other	B-X
cases	B-X
of	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
have	B-X
been	B-X
reported	B-X
recently	B-X
<EOS>	B-X
We	B-X
review	B-X
the	B-X
sex	B-X
related	B-X
effects	B-X
on	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B-Disease
retarded	I-Disease
male	O
who	O
suffers	O
severe	O
muscular	B-Disease
weakness	I-Disease
.	O
<EOS>	B-X
The	B-X
proband	B-X
is	B-X
a	B-X
23	B-X
year	B-X
old	B-X
,	B-X
mentally	B-X
retarded	B-X
male	B-X
who	B-X
suffers	B-X
severe	B-X
muscular	B-X
weakness	B-X
<EOS>	B-X
Their	B-X
late	B-X
father	B-X
had	B-X
the	B-X
adult	B-X
type	B-X
of	B-X
DM	B-X
,	B-X
with	B-X
onset	B-X
around	B-X
30	B-X
years	B-X
<EOS>	B-X
Also	B-X
the	B-X
fathers	B-X
of	B-X
the	B-X
reported	B-X
congenitally	B-X
affected	B-X
children	B-X
showed	B-X
,	B-X
on	B-X
average	B-X
,	B-X
shorter	B-X
CTG	B-X
repeat	B-X
lengths	B-X
and	B-X
hence	B-X
less	B-X
severe	B-X
clinical	B-X
symptoms	B-X
than	B-X
the	B-X
mothers	B-X
of	B-X
children	B-X
with	B-X
congenital	B-X
DM	B-X
<EOS>	B-X
He	B-X
presented	B-X
with	B-X
respiratory	B-X
and	B-X
feeding	B-X
difficulties	B-X
at	B-X
birth	B-X

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
.	O
<EOS>	B-X
He	B-X
presented	B-X
with	B-X
respiratory	B-X
and	B-X
feeding	B-X
difficulties	B-X
at	B-X
birth	B-X
<EOS>	B-X
He	B-X
had	B-X
hypothyroidism	B-X
and	B-X
experienced	B-X
feeding	B-X
difficulties	B-X
and	B-X
irritability	B-X
<EOS>	B-X
We	B-X
present	B-X
the	B-X
case	B-X
of	B-X
a	B-X
5	B-X
-	B-X
month	B-X
-	B-X
old	B-X
male	B-X
with	B-X
hypertrophic	B-X
cardiomyopathy	B-X
,	B-X
hypotony	B-X
,	B-X
feeding	B-X
difficulties	B-X
,	B-X
and	B-X
oxygen	B-X
requirement	B-X
since	B-X
birth	B-X
<EOS>	B-X
We	B-X
present	B-X
a	B-X
Chinese	B-X
KS	B-X
patient	B-X
with	B-X
a	B-X
novel	B-X

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B-Disease
.	O
<EOS>	B-X
His	B-X
two	B-X
sibs	B-X
suffer	B-X
from	B-X
childhood	B-X
onset	B-X
DM	B-X
<EOS>	B-X
We	B-X
review	B-X
the	B-X
sex	B-X
related	B-X
effects	B-X
on	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
<EOS>	B-X
We	B-X
report	B-X
a	B-X
rare	B-X
case	B-X
of	B-X
paternally	B-X
transmitted	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
<EOS>	B-X
Only	B-X
six	B-X
other	B-X
cases	B-X
of	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
have	B-X
been	B-X
reported	B-X
recently	B-X

Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B-Disease
,	O
with	O
onset	O
around	O
30	O
years	O
.	O
<EOS>	B-X
Their	B-X
late	B-X
father	B-X
had	B-X
the	B-X
adult	B-X
type	B-X
of	B-X
DM	B-X
,	B-X
with	B-X
onset	B-X
around	B-X
30	B-X
years	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
is	B-X
rare	B-X
and	B-X
preferentially	B-X
occurs	B-X
with	B-X
onset	B-X
of	B-X
DM	B-X
past	B-X
30	B-X
years	B-X
in	B-X
the	B-X
father	B-X
<EOS>	B-X
The	B-X
proband	B-X
is	B-X
a	B-X
23	B-X
year	B-X
old	B-X
,	B-X
mentally	B-X
retarded	B-X
male	B-X
who	B-X
suffers	B-X
severe	B-X
muscular	B-X
weakness	B-X
<EOS>	B-X
We	B-X
review	B-X
the	B-X
sex	B-X
related	B-X
effects	B-X
on	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B-Disease
DM	I-Disease
have	O
been	O
reported	O
recently	O
.	O
<EOS>	B-X
Only	B-X
six	B-X
other	B-X
cases	B-X
of	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
have	B-X
been	B-X
reported	B-X
recently	B-X
<EOS>	B-X
Paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
We	B-X
report	B-X
a	B-X
rare	B-X
case	B-X
of	B-X
paternally	B-X
transmitted	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
is	B-X
rare	B-X
and	B-X
preferentially	B-X
occurs	B-X
with	B-X
onset	B-X
of	B-X
DM	B-X
past	B-X
30	B-X
years	B-X
in	B-X
the	B-X
father	B-X

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B-Disease
DM	I-Disease
.	O
<EOS>	B-X
We	B-X
review	B-X
the	B-X
sex	B-X
related	B-X
effects	B-X
on	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
<EOS>	B-X
Only	B-X
six	B-X
other	B-X
cases	B-X
of	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
have	B-X
been	B-X
reported	B-X
recently	B-X
<EOS>	B-X
We	B-X
report	B-X
a	B-X
rare	B-X
case	B-X
of	B-X
paternally	B-X
transmitted	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
<EOS>	B-X
His	B-X
two	B-X
sibs	B-X
suffer	B-X
from	B-X
childhood	B-X
onset	B-X
DM	B-X

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B-Disease
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B-Disease
DM	I-Disease
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B-Disease
DM	I-Disease
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B-Disease
DM	I-Disease
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B-Disease
past	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
is	B-X
rare	B-X
and	B-X
preferentially	B-X
occurs	B-X
with	B-X
onset	B-X
of	B-X
DM	B-X
past	B-X
30	B-X
years	B-X
in	B-X
the	B-X
father	B-X
<EOS>	B-X
Only	B-X
six	B-X
other	B-X
cases	B-X
of	B-X
paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
DM	B-X
have	B-X
been	B-X
reported	B-X
recently	B-X
<EOS>	B-X
Paternal	B-X
transmission	B-X
of	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Their	B-X
late	B-X
father	B-X
had	B-X
the	B-X
adult	B-X
type	B-X
of	B-X
DM	B-X
,	B-X
with	B-X
onset	B-X
around	B-X
30	B-X
years	B-X

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B-Disease
intracranial	I-Disease
retinoblastoma	I-Disease
.	O

The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B-Disease
intracranial	I-Disease
retinoblastoma	I-Disease
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B-Disease
and	I-Disease
retinal	I-Disease
tumours	I-Disease
of	O
the	O
patient	O
.	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B-Disease
and	I-Disease
the	I-Disease
pineal	I-Disease
tumours	I-Disease
.	O
<EOS>	B-X
A	B-X
nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
17	B-X
(	B-X
codon	B-X
556	B-X
)	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
was	B-X
found	B-X
to	B-X
be	B-X
present	B-X
homozygously	B-X
in	B-X
both	B-X
the	B-X
retinal	B-X
and	B-X
the	B-X
pineal	B-X
tumours	B-X
<EOS>	B-X
The	B-X
RB1	B-X
gene	B-X
mutation	B-X
was	B-X
investigated	B-X
in	B-X
a	B-X
child	B-X
with	B-X
ectopic	B-X
intracranial	B-X
retinoblastoma	B-X
using	B-X
DNA	B-X
obtained	B-X
from	B-X
both	B-X
the	B-X
pineal	B-X
and	B-X
retinal	B-X
tumours	B-X
of	B-X
the	B-X
patient	B-X
<EOS>	B-X
The	B-X
mutation	B-X
is	B-X
in	B-X
an	B-X
area	B-X
of	B-X
the	B-X
gene	B-X
that	B-X
encodes	B-X
the	B-X
protein	B-X
-	B-X
binding	B-X
region	B-X
known	B-X
as	B-X
the	B-X
'pocket	B-X
'	B-X
region	B-X
and	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
other	B-X
cases	B-X
of	B-X
retinoblastoma	B-X
<EOS>	B-X
The	B-X
RB1	B-X
gene	B-X
mutation	B-X
in	B-X
a	B-X
child	B-X
with	B-X
ectopic	B-X
intracranial	B-X
retinoblastoma	B-X
.	B-X

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin	O
.	O
<EOS>	B-X
The	B-X
same	B-X
mutation	B-X
was	B-X
present	B-X
heterozygously	B-X
in	B-X
the	B-X
DNA	B-X
from	B-X
the	B-X
constitutional	B-X
cells	B-X
of	B-X
the	B-X
patient	B-X
,	B-X
proving	B-X
it	B-X
to	B-X
be	B-X
of	B-X
germline	B-X
origin	B-X
<EOS>	B-X
The	B-X
RB1	B-X
gene	B-X
mutation	B-X
was	B-X
investigated	B-X
in	B-X
a	B-X
child	B-X
with	B-X
ectopic	B-X
intracranial	B-X
retinoblastoma	B-X
using	B-X
DNA	B-X
obtained	B-X
from	B-X
both	B-X
the	B-X
pineal	B-X
and	B-X
retinal	B-X
tumours	B-X
of	B-X
the	B-X
patient	B-X
<EOS>	B-X
The	B-X
initial	B-X
mutation	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
occurred	B-X
in	B-X
the	B-X
paternally	B-X
derived	B-X
RB1	B-X
allele	B-X
<EOS>	B-X
The	B-X
mutation	B-X
is	B-X
in	B-X
an	B-X
area	B-X
of	B-X
the	B-X
gene	B-X
that	B-X
encodes	B-X
the	B-X
protein	B-X
-	B-X
binding	B-X
region	B-X
known	B-X
as	B-X
the	B-X
'pocket	B-X
'	B-X
region	B-X
and	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
other	B-X
cases	B-X
of	B-X
retinoblastoma	B-X

The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O
<EOS>	B-X
The	B-X
initial	B-X
mutation	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
occurred	B-X
in	B-X
the	B-X
paternally	B-X
derived	B-X
RB1	B-X
allele	B-X
<EOS>	B-X
The	B-X
RB1	B-X
gene	B-X
mutation	B-X
in	B-X
a	B-X
child	B-X
with	B-X
ectopic	B-X
intracranial	B-X
retinoblastoma	B-X
.	B-X
<EOS>	B-X
The	B-X
same	B-X
mutation	B-X
was	B-X
present	B-X
heterozygously	B-X
in	B-X
the	B-X
DNA	B-X
from	B-X
the	B-X
constitutional	B-X
cells	B-X
of	B-X
the	B-X
patient	B-X
,	B-X
proving	B-X
it	B-X
to	B-X
be	B-X
of	B-X
germline	B-X
origin	B-X
<EOS>	B-X
The	B-X
RB1	B-X
gene	B-X
mutation	B-X
was	B-X
investigated	B-X
in	B-X
a	B-X
child	B-X
with	B-X
ectopic	B-X
intracranial	B-X
retinoblastoma	B-X
using	B-X
DNA	B-X
obtained	B-X
from	B-X
both	B-X
the	B-X
pineal	B-X
and	B-X
retinal	B-X
tumours	B-X
of	B-X
the	B-X
patient	B-X

The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B-Disease
.	O
.	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O
<EOS>	B-X
Low	B-X
levels	B-X
of	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
in	B-X
healthy	B-X
individuals	B-X
with	B-X
apparent	B-X
deficiency	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
<EOS>	B-X
Appreciable	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
(	B-X
hex	B-X
A	B-X
)	B-X
activity	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
and	B-X
melanoma	B-X
tissue	B-X
from	B-X
healthy	B-X
individuals	B-X
previously	B-X
reported	B-X
as	B-X
having	B-X
deficiency	B-X
of	B-X
hex	B-X
A	B-X
activity	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
<EOS>	B-X
9	B-X
%	B-X
of	B-X
total	B-X
beta	B-X
hexosaminidase	B-X
activity	B-X
,	B-X
has	B-X
been	B-X
obtained	B-X
by	B-X
cellulose	B-X
acetate	B-X
gel	B-X
electrophoresis	B-X
,	B-X
DEAE	B-X
-	B-X
cellulose	B-X
ion	B-X
-	B-X
exchange	B-X
chromatography	B-X
,	B-X
radial	B-X
immunodiffusion	B-X
,	B-X
and	B-X
radioimmunoassay	B-X
<EOS>	B-X
However	B-X
,	B-X
direct	B-X
visualization	B-X
and	B-X
quantitation	B-X
of	B-X
hex	B-X
A	B-X
by	B-X
the	B-X
methods	B-X
described	B-X
may	B-X
prevent	B-X
false	B-X
-	B-X
positive	B-X
prenatal	B-X
diagnosis	B-X
of	B-X
TSD	B-X
in	B-X
fetuses	B-X
having	B-X
the	B-X
incomplete	B-X
hex	B-X
A	B-X
deficiency	B-X
of	B-X
the	B-X
type	B-X
described	B-X
in	B-X
the	B-X
four	B-X
healthy	B-X
individuals	B-X

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B-Disease
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B-Disease
of	I-Disease
hex	I-Disease
A	I-Disease
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
.	O
<EOS>	B-X
Appreciable	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
(	B-X
hex	B-X
A	B-X
)	B-X
activity	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
and	B-X
melanoma	B-X
tissue	B-X
from	B-X
healthy	B-X
individuals	B-X
previously	B-X
reported	B-X
as	B-X
having	B-X
deficiency	B-X
of	B-X
hex	B-X
A	B-X
activity	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
<EOS>	B-X
9	B-X
%	B-X
of	B-X
total	B-X
beta	B-X
hexosaminidase	B-X
activity	B-X
,	B-X
has	B-X
been	B-X
obtained	B-X
by	B-X
cellulose	B-X
acetate	B-X
gel	B-X
electrophoresis	B-X
,	B-X
DEAE	B-X
-	B-X
cellulose	B-X
ion	B-X
-	B-X
exchange	B-X
chromatography	B-X
,	B-X
radial	B-X
immunodiffusion	B-X
,	B-X
and	B-X
radioimmunoassay	B-X
<EOS>	B-X
Low	B-X
levels	B-X
of	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
in	B-X
healthy	B-X
individuals	B-X
with	B-X
apparent	B-X
deficiency	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
direct	B-X
visualization	B-X
and	B-X
quantitation	B-X
of	B-X
hex	B-X
A	B-X
by	B-X
the	B-X
methods	B-X
described	B-X
may	B-X
prevent	B-X
false	B-X
-	B-X
positive	B-X
prenatal	B-X
diagnosis	B-X
of	B-X
TSD	B-X
in	B-X
fetuses	B-X
having	B-X
the	B-X
incomplete	B-X
hex	B-X
A	B-X
deficiency	B-X
of	B-X
the	B-X
type	B-X
described	B-X
in	B-X
the	B-X
four	B-X
healthy	B-X
individuals	B-X

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O
<EOS>	B-X
Identification	B-X
and	B-X
quantitation	B-X
of	B-X
hex	B-X
A	B-X
,	B-X
amounting	B-X
to	B-X
3	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
postulated	B-X
rate	B-X
mutant	B-X
gene	B-X
appears	B-X
to	B-X
code	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
low	B-X
amounts	B-X
of	B-X
hex	B-X
A	B-X
<EOS>	B-X
Heterozygotes	B-X
for	B-X
the	B-X
rare	B-X
mutant	B-X
may	B-X
be	B-X
indistinguishable	B-X
from	B-X
heterozygotes	B-X
for	B-X
the	B-X
common	B-X
TSD	B-X
mutant	B-X
<EOS>	B-X
Low	B-X
levels	B-X
of	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
in	B-X
healthy	B-X
individuals	B-X
with	B-X
apparent	B-X
deficiency	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X

5	O
%	O
-	O
6	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O
<EOS>	B-X
9	B-X
%	B-X
of	B-X
total	B-X
beta	B-X
hexosaminidase	B-X
activity	B-X
,	B-X
has	B-X
been	B-X
obtained	B-X
by	B-X
cellulose	B-X
acetate	B-X
gel	B-X
electrophoresis	B-X
,	B-X
DEAE	B-X
-	B-X
cellulose	B-X
ion	B-X
-	B-X
exchange	B-X
chromatography	B-X
,	B-X
radial	B-X
immunodiffusion	B-X
,	B-X
and	B-X
radioimmunoassay	B-X
<EOS>	B-X
Appreciable	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
(	B-X
hex	B-X
A	B-X
)	B-X
activity	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
and	B-X
melanoma	B-X
tissue	B-X
from	B-X
healthy	B-X
individuals	B-X
previously	B-X
reported	B-X
as	B-X
having	B-X
deficiency	B-X
of	B-X
hex	B-X
A	B-X
activity	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
<EOS>	B-X
Low	B-X
levels	B-X
of	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
in	B-X
healthy	B-X
individuals	B-X
with	B-X
apparent	B-X
deficiency	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
postulated	B-X
rate	B-X
mutant	B-X
gene	B-X
appears	B-X
to	B-X
code	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
low	B-X
amounts	B-X
of	B-X
hex	B-X
A	B-X

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B-Disease
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
postulated	B-X
rate	B-X
mutant	B-X
gene	B-X
appears	B-X
to	B-X
code	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
low	B-X
amounts	B-X
of	B-X
hex	B-X
A	B-X
<EOS>	B-X
Identification	B-X
and	B-X
quantitation	B-X
of	B-X
hex	B-X
A	B-X
,	B-X
amounting	B-X
to	B-X
3	B-X
<EOS>	B-X
Previous	B-X
family	B-X
studies	B-X
suggested	B-X
that	B-X
these	B-X
individuals	B-X
may	B-X
be	B-X
compound	B-X
heterozygotes	B-X
for	B-X
the	B-X
common	B-X
mutant	B-X
TSD	B-X
gene	B-X
and	B-X
a	B-X
rare	B-X
(	B-X
allelic	B-X
)	B-X
mutant	B-X
gene	B-X
<EOS>	B-X
Heterozygotes	B-X
for	B-X
the	B-X
rare	B-X
mutant	B-X
may	B-X
be	B-X
indistinguishable	B-X
from	B-X
heterozygotes	B-X
for	B-X
the	B-X
common	B-X
TSD	B-X
mutant	B-X

Heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B-Disease
mutant	O
.	O
<EOS>	B-X
Heterozygotes	B-X
for	B-X
the	B-X
rare	B-X
mutant	B-X
may	B-X
be	B-X
indistinguishable	B-X
from	B-X
heterozygotes	B-X
for	B-X
the	B-X
common	B-X
TSD	B-X
mutant	B-X
<EOS>	B-X
Previous	B-X
family	B-X
studies	B-X
suggested	B-X
that	B-X
these	B-X
individuals	B-X
may	B-X
be	B-X
compound	B-X
heterozygotes	B-X
for	B-X
the	B-X
common	B-X
mutant	B-X
TSD	B-X
gene	B-X
and	B-X
a	B-X
rare	B-X
(	B-X
allelic	B-X
)	B-X
mutant	B-X
gene	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
postulated	B-X
rate	B-X
mutant	B-X
gene	B-X
appears	B-X
to	B-X
code	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
low	B-X
amounts	B-X
of	B-X
hex	B-X
A	B-X
<EOS>	B-X
However	B-X
,	B-X
direct	B-X
visualization	B-X
and	B-X
quantitation	B-X
of	B-X
hex	B-X
A	B-X
by	B-X
the	B-X
methods	B-X
described	B-X
may	B-X
prevent	B-X
false	B-X
-	B-X
positive	B-X
prenatal	B-X
diagnosis	B-X
of	B-X
TSD	B-X
in	B-X
fetuses	B-X
having	B-X
the	B-X
incomplete	B-X
hex	B-X
A	B-X
deficiency	B-X
of	B-X
the	B-X
type	B-X
described	B-X
in	B-X
the	B-X
four	B-X
healthy	B-X
individuals	B-X

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B-Disease
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B-Disease
A	I-Disease
deficiency	I-Disease
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O
<EOS>	B-X
However	B-X
,	B-X
direct	B-X
visualization	B-X
and	B-X
quantitation	B-X
of	B-X
hex	B-X
A	B-X
by	B-X
the	B-X
methods	B-X
described	B-X
may	B-X
prevent	B-X
false	B-X
-	B-X
positive	B-X
prenatal	B-X
diagnosis	B-X
of	B-X
TSD	B-X
in	B-X
fetuses	B-X
having	B-X
the	B-X
incomplete	B-X
hex	B-X
A	B-X
deficiency	B-X
of	B-X
the	B-X
type	B-X
described	B-X
in	B-X
the	B-X
four	B-X
healthy	B-X
individuals	B-X
<EOS>	B-X
Low	B-X
levels	B-X
of	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
in	B-X
healthy	B-X
individuals	B-X
with	B-X
apparent	B-X
deficiency	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
<EOS>	B-X
Appreciable	B-X
beta	B-X
hexosaminidase	B-X
A	B-X
(	B-X
hex	B-X
A	B-X
)	B-X
activity	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
and	B-X
melanoma	B-X
tissue	B-X
from	B-X
healthy	B-X
individuals	B-X
previously	B-X
reported	B-X
as	B-X
having	B-X
deficiency	B-X
of	B-X
hex	B-X
A	B-X
activity	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
<EOS>	B-X
Previous	B-X
family	B-X
studies	B-X
suggested	B-X
that	B-X
these	B-X
individuals	B-X
may	B-X
be	B-X
compound	B-X
heterozygotes	B-X
for	B-X
the	B-X
common	B-X
mutant	B-X
TSD	B-X
gene	B-X
and	B-X
a	B-X
rare	B-X
(	B-X
allelic	B-X
)	B-X
mutant	B-X
gene	B-X

The	O
tumor	B-Disease
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
Smad4	B-X
/	B-X
Dpc4	B-X
is	B-X
required	B-X
for	B-X
gastrulation	B-X
and	B-X
later	B-X
for	B-X
anterior	B-X
development	B-X
of	B-X
the	B-X
mouse	B-X
embryo	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Smad4	B-X
is	B-X
initially	B-X
required	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
visceral	B-X
endoderm	B-X
and	B-X
that	B-X
the	B-X
gastrulation	B-X
defect	B-X
in	B-X
the	B-X
epiblast	B-X
is	B-X
secondary	B-X
and	B-X
non	B-X
-	B-X
cell	B-X
autonomous	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
SMAD4	B-X
/	B-X
DPC4	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
a	B-X
key	B-X
signal	B-X
transducer	B-X
in	B-X
most	B-X
TGFbeta	B-X
-	B-X
related	B-X
pathways	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
50	B-X
%	B-X
of	B-X
pancreatic	B-X
cancers	B-X
<EOS>	B-X
Rescued	B-X
embryos	B-X
show	B-X
severe	B-X
anterior	B-X
truncations	B-X
,	B-X
indicating	B-X
a	B-X
second	B-X
important	B-X
role	B-X
for	B-X
Smad4	B-X
in	B-X
anterior	B-X
patterning	B-X
during	B-X
embryogenesis	B-X

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B-Disease
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B-Disease
cancers	I-Disease
.	O
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
SMAD4	B-X
/	B-X
DPC4	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
a	B-X
key	B-X
signal	B-X
transducer	B-X
in	B-X
most	B-X
TGFbeta	B-X
-	B-X
related	B-X
pathways	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
50	B-X
%	B-X
of	B-X
pancreatic	B-X
cancers	B-X
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
Smad4	B-X
/	B-X
Dpc4	B-X
is	B-X
required	B-X
for	B-X
gastrulation	B-X
and	B-X
later	B-X
for	B-X
anterior	B-X
development	B-X
of	B-X
the	B-X
mouse	B-X
embryo	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Smad4	B-X
is	B-X
initially	B-X
required	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
visceral	B-X
endoderm	B-X
and	B-X
that	B-X
the	B-X
gastrulation	B-X
defect	B-X
in	B-X
the	B-X
epiblast	B-X
is	B-X
secondary	B-X
and	B-X
non	B-X
-	B-X
cell	B-X
autonomous	B-X
<EOS>	B-X
Growth	B-X
retardation	B-X
of	B-X
the	B-X
Smad4	B-X
-	B-X
deficient	B-X
embryos	B-X
results	B-X
from	B-X
reduced	B-X
cell	B-X
proliferation	B-X
rather	B-X
than	B-X
increased	B-X
apoptosis	B-X

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O
<EOS>	B-X
Homozygous	B-X
Smad4	B-X
mutant	B-X
mice	B-X
die	B-X
before	B-X
day	B-X
7	B-X
<EOS>	B-X
Aggregation	B-X
of	B-X
mutant	B-X
Smad4	B-X
ES	B-X
cells	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
tetraploid	B-X
morulae	B-X
rescues	B-X
the	B-X
gastrulation	B-X
defect	B-X
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
Smad4	B-X
/	B-X
Dpc4	B-X
is	B-X
required	B-X
for	B-X
gastrulation	B-X
and	B-X
later	B-X
for	B-X
anterior	B-X
development	B-X
of	B-X
the	B-X
mouse	B-X
embryo	B-X
.	B-X
<EOS>	B-X
Growth	B-X
retardation	B-X
of	B-X
the	B-X
Smad4	B-X
-	B-X
deficient	B-X
embryos	B-X
results	B-X
from	B-X
reduced	B-X
cell	B-X
proliferation	B-X
rather	B-X
than	B-X
increased	B-X
apoptosis	B-X

5	O
of	O
embryogenesis	O
.	O
<EOS>	B-X
5	B-X
)	B-X
were	B-X
evaluated	B-X
,	B-X
respectively	B-X
<EOS>	B-X
5	B-X
anterior	B-X
palate	B-X
<EOS>	B-X
5	B-X
mouse	B-X
embryos	B-X
and	B-X
were	B-X
enriched	B-X
by	B-X
4	B-X
-	B-X
day	B-X
incubation	B-X
with	B-X
FGF2	B-X
<EOS>	B-X
5	B-X
,	B-X
around	B-X
the	B-X
time	B-X
of	B-X
neural	B-X
tube	B-X
closure	B-X

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development	O
.	O
<EOS>	B-X
Mutant	B-X
embryos	B-X
have	B-X
reduced	B-X
size	B-X
,	B-X
fail	B-X
to	B-X
gastrulate	B-X
or	B-X
express	B-X
a	B-X
mesodermal	B-X
marker	B-X
,	B-X
and	B-X
show	B-X
abnormal	B-X
visceral	B-X
endoderm	B-X
development	B-X
<EOS>	B-X
Several	B-X
vertebrate	B-X
relatives	B-X
of	B-X
tinman	B-X
,	B-X
many	B-X
of	B-X
which	B-X
are	B-X
predominately	B-X
expressed	B-X
in	B-X
the	B-X
very	B-X
early	B-X
cardiac	B-X
progenitors	B-X
(	B-X
and	B-X
pharyngeal	B-X
endoderm	B-X
)	B-X
,	B-X
also	B-X
seem	B-X
to	B-X
promote	B-X
heart	B-X
development	B-X
<EOS>	B-X
Variant	B-X
hepatocyte	B-X
nuclear	B-X
factor	B-X
1	B-X
is	B-X
required	B-X
for	B-X
visceral	B-X
endoderm	B-X
specification	B-X
.	B-X
<EOS>	B-X
Mutant	B-X
embryos	B-X
show	B-X
a	B-X
decrease	B-X
in	B-X
cellular	B-X
proliferation	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
but	B-X
no	B-X
increase	B-X
in	B-X
apoptosis	B-X

Growth	B-Disease
retardation	I-Disease
of	O
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O
<EOS>	B-X
Growth	B-X
retardation	B-X
of	B-X
the	B-X
Smad4	B-X
-	B-X
deficient	B-X
embryos	B-X
results	B-X
from	B-X
reduced	B-X
cell	B-X
proliferation	B-X
rather	B-X
than	B-X
increased	B-X
apoptosis	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Smad4	B-X
is	B-X
initially	B-X
required	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
visceral	B-X
endoderm	B-X
and	B-X
that	B-X
the	B-X
gastrulation	B-X
defect	B-X
in	B-X
the	B-X
epiblast	B-X
is	B-X
secondary	B-X
and	B-X
non	B-X
-	B-X
cell	B-X
autonomous	B-X
<EOS>	B-X
Aggregation	B-X
of	B-X
mutant	B-X
Smad4	B-X
ES	B-X
cells	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
tetraploid	B-X
morulae	B-X
rescues	B-X
the	B-X
gastrulation	B-X
defect	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
SMAD4	B-X
/	B-X
DPC4	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
a	B-X
key	B-X
signal	B-X
transducer	B-X
in	B-X
most	B-X
TGFbeta	B-X
-	B-X
related	B-X
pathways	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
50	B-X
%	B-X
of	B-X
pancreatic	B-X
cancers	B-X

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B-Disease
defect	I-Disease
.	O
<EOS>	B-X
Aggregation	B-X
of	B-X
mutant	B-X
Smad4	B-X
ES	B-X
cells	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
tetraploid	B-X
morulae	B-X
rescues	B-X
the	B-X
gastrulation	B-X
defect	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Smad4	B-X
is	B-X
initially	B-X
required	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
visceral	B-X
endoderm	B-X
and	B-X
that	B-X
the	B-X
gastrulation	B-X
defect	B-X
in	B-X
the	B-X
epiblast	B-X
is	B-X
secondary	B-X
and	B-X
non	B-X
-	B-X
cell	B-X
autonomous	B-X
<EOS>	B-X
Growth	B-X
retardation	B-X
of	B-X
the	B-X
Smad4	B-X
-	B-X
deficient	B-X
embryos	B-X
results	B-X
from	B-X
reduced	B-X
cell	B-X
proliferation	B-X
rather	B-X
than	B-X
increased	B-X
apoptosis	B-X
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
Smad4	B-X
/	B-X
Dpc4	B-X
is	B-X
required	B-X
for	B-X
gastrulation	B-X
and	B-X
later	B-X
for	B-X
anterior	B-X
development	B-X
of	B-X
the	B-X
mouse	B-X
embryo	B-X
.	B-X

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B-Disease
defect	I-Disease
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Smad4	B-X
is	B-X
initially	B-X
required	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
visceral	B-X
endoderm	B-X
and	B-X
that	B-X
the	B-X
gastrulation	B-X
defect	B-X
in	B-X
the	B-X
epiblast	B-X
is	B-X
secondary	B-X
and	B-X
non	B-X
-	B-X
cell	B-X
autonomous	B-X
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
Smad4	B-X
/	B-X
Dpc4	B-X
is	B-X
required	B-X
for	B-X
gastrulation	B-X
and	B-X
later	B-X
for	B-X
anterior	B-X
development	B-X
of	B-X
the	B-X
mouse	B-X
embryo	B-X
.	B-X
<EOS>	B-X
Growth	B-X
retardation	B-X
of	B-X
the	B-X
Smad4	B-X
-	B-X
deficient	B-X
embryos	B-X
results	B-X
from	B-X
reduced	B-X
cell	B-X
proliferation	B-X
rather	B-X
than	B-X
increased	B-X
apoptosis	B-X
<EOS>	B-X
Rescued	B-X
embryos	B-X
show	B-X
severe	B-X
anterior	B-X
truncations	B-X
,	B-X
indicating	B-X
a	B-X
second	B-X
important	B-X
role	B-X
for	B-X
Smad4	B-X
in	B-X
anterior	B-X
patterning	B-X
during	B-X
embryogenesis	B-X

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O
<EOS>	B-X
Rescued	B-X
embryos	B-X
show	B-X
severe	B-X
anterior	B-X
truncations	B-X
,	B-X
indicating	B-X
a	B-X
second	B-X
important	B-X
role	B-X
for	B-X
Smad4	B-X
in	B-X
anterior	B-X
patterning	B-X
during	B-X
embryogenesis	B-X
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
Smad4	B-X
/	B-X
Dpc4	B-X
is	B-X
required	B-X
for	B-X
gastrulation	B-X
and	B-X
later	B-X
for	B-X
anterior	B-X
development	B-X
of	B-X
the	B-X
mouse	B-X
embryo	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Smad4	B-X
is	B-X
initially	B-X
required	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
visceral	B-X
endoderm	B-X
and	B-X
that	B-X
the	B-X
gastrulation	B-X
defect	B-X
in	B-X
the	B-X
epiblast	B-X
is	B-X
secondary	B-X
and	B-X
non	B-X
-	B-X
cell	B-X
autonomous	B-X
<EOS>	B-X
Mutant	B-X
embryos	B-X
have	B-X
reduced	B-X
size	B-X
,	B-X
fail	B-X
to	B-X
gastrulate	B-X
or	B-X
express	B-X
a	B-X
mesodermal	B-X
marker	B-X
,	B-X
and	B-X
show	B-X
abnormal	B-X
visceral	B-X
endoderm	B-X
development	B-X

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B-Disease
-	O
prone	O
families	O
in	O
France	O
.	O
<EOS>	B-X
Prevalence	B-X
of	B-X
p16	B-X
and	B-X
CDK4	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
in	B-X
France	B-X
.	B-X
The	B-X
French	B-X
Familial	B-X
Melanoma	B-X
Study	B-X
Group	B-X
.	B-X
<EOS>	B-X
Germline	B-X
mutations	B-X
in	B-X
the	B-X
p16	B-X
and	B-X
CDK4	B-X
genes	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
melanoma	B-X
pedigrees	B-X
,	B-X
but	B-X
their	B-X
prevalence	B-X
is	B-X
not	B-X
well	B-X
known	B-X
<EOS>	B-X
Sixteen	B-X
different	B-X
p16	B-X
germline	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
21	B-X
families	B-X
,	B-X
while	B-X
one	B-X
germline	B-X
mutation	B-X
,	B-X
Arg24His	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
CDK4	B-X
gene	B-X
<EOS>	B-X
The	B-X
frequency	B-X
of	B-X
p16	B-X
gene	B-X
mutation	B-X
in	B-X
our	B-X
sample	B-X
(	B-X
44	B-X
%	B-X
)	B-X
is	B-X
among	B-X
the	B-X
highest	B-X
rates	B-X
yet	B-X
reported	B-X
and	B-X
the	B-X
CDK4	B-X
mutation	B-X
is	B-X
the	B-X
second	B-X
mutation	B-X
detected	B-X
in	B-X
this	B-X
gene	B-X
worldwide	B-X

The	O
French	O
Familial	B-Disease
Melanoma	I-Disease
Study	O
Group	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B-Disease
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B-Disease
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O
<EOS>	B-X
We	B-X
searched	B-X
for	B-X
such	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
French	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
selected	B-X
according	B-X
to	B-X
two	B-X
major	B-X
criteria	B-X
:	B-X
families	B-X
with	B-X
at	B-X
least	B-X
three	B-X
affected	B-X
members	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
or	B-X
families	B-X
with	B-X
two	B-X
affected	B-X
members	B-X
,	B-X
one	B-X
of	B-X
them	B-X
affected	B-X
before	B-X
the	B-X
age	B-X
of	B-X
50	B-X
(	B-X
n	B-X
=	B-X
28	B-X
)	B-X
,	B-X
and	B-X
one	B-X
additional	B-X
minor	B-X
criterion	B-X
<EOS>	B-X
The	B-X
frequency	B-X
of	B-X
p16	B-X
gene	B-X
mutation	B-X
in	B-X
our	B-X
sample	B-X
(	B-X
44	B-X
%	B-X
)	B-X
is	B-X
among	B-X
the	B-X
highest	B-X
rates	B-X
yet	B-X
reported	B-X
and	B-X
the	B-X
CDK4	B-X
mutation	B-X
is	B-X
the	B-X
second	B-X
mutation	B-X
detected	B-X
in	B-X
this	B-X
gene	B-X
worldwide	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
show	B-X
frequent	B-X
involvement	B-X
of	B-X
the	B-X
p16	B-X
gene	B-X
in	B-X
familial	B-X
melanoma	B-X
and	B-X
confirm	B-X
the	B-X
role	B-X
of	B-X
the	B-X
CDK4	B-X
gene	B-X
as	B-X
a	B-X
melanoma	B-X
-	B-X
predisposing	B-X
gene	B-X
<EOS>	B-X
Prevalence	B-X
of	B-X
p16	B-X
and	B-X
CDK4	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
in	B-X
France	B-X
.	B-X
The	B-X
French	B-X
Familial	B-X
Melanoma	B-X
Study	B-X
Group	B-X
.	B-X

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O
<EOS>	B-X
Sixteen	B-X
different	B-X
p16	B-X
germline	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
21	B-X
families	B-X
,	B-X
while	B-X
one	B-X
germline	B-X
mutation	B-X
,	B-X
Arg24His	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
CDK4	B-X
gene	B-X
<EOS>	B-X
The	B-X
frequency	B-X
of	B-X
p16	B-X
gene	B-X
mutation	B-X
in	B-X
our	B-X
sample	B-X
(	B-X
44	B-X
%	B-X
)	B-X
is	B-X
among	B-X
the	B-X
highest	B-X
rates	B-X
yet	B-X
reported	B-X
and	B-X
the	B-X
CDK4	B-X
mutation	B-X
is	B-X
the	B-X
second	B-X
mutation	B-X
detected	B-X
in	B-X
this	B-X
gene	B-X
worldwide	B-X
<EOS>	B-X
Prevalence	B-X
of	B-X
p16	B-X
and	B-X
CDK4	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
in	B-X
France	B-X
.	B-X
The	B-X
French	B-X
Familial	B-X
Melanoma	B-X
Study	B-X
Group	B-X
.	B-X
<EOS>	B-X
We	B-X
searched	B-X
for	B-X
such	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
French	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
selected	B-X
according	B-X
to	B-X
two	B-X
major	B-X
criteria	B-X
:	B-X
families	B-X
with	B-X
at	B-X
least	B-X
three	B-X
affected	B-X
members	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
or	B-X
families	B-X
with	B-X
two	B-X
affected	B-X
members	B-X
,	B-X
one	B-X
of	B-X
them	B-X
affected	B-X
before	B-X
the	B-X
age	B-X
of	B-X
50	B-X
(	B-X
n	B-X
=	B-X
28	B-X
)	B-X
,	B-X
and	B-X
one	B-X
additional	B-X
minor	B-X
criterion	B-X

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O
<EOS>	B-X
The	B-X
frequency	B-X
of	B-X
p16	B-X
gene	B-X
mutation	B-X
in	B-X
our	B-X
sample	B-X
(	B-X
44	B-X
%	B-X
)	B-X
is	B-X
among	B-X
the	B-X
highest	B-X
rates	B-X
yet	B-X
reported	B-X
and	B-X
the	B-X
CDK4	B-X
mutation	B-X
is	B-X
the	B-X
second	B-X
mutation	B-X
detected	B-X
in	B-X
this	B-X
gene	B-X
worldwide	B-X
<EOS>	B-X
Sixteen	B-X
different	B-X
p16	B-X
germline	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
21	B-X
families	B-X
,	B-X
while	B-X
one	B-X
germline	B-X
mutation	B-X
,	B-X
Arg24His	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
CDK4	B-X
gene	B-X
<EOS>	B-X
Germline	B-X
mutations	B-X
in	B-X
the	B-X
p16	B-X
and	B-X
CDK4	B-X
genes	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
melanoma	B-X
pedigrees	B-X
,	B-X
but	B-X
their	B-X
prevalence	B-X
is	B-X
not	B-X
well	B-X
known	B-X
<EOS>	B-X
We	B-X
searched	B-X
for	B-X
such	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
French	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
selected	B-X
according	B-X
to	B-X
two	B-X
major	B-X
criteria	B-X
:	B-X
families	B-X
with	B-X
at	B-X
least	B-X
three	B-X
affected	B-X
members	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
or	B-X
families	B-X
with	B-X
two	B-X
affected	B-X
members	B-X
,	B-X
one	B-X
of	B-X
them	B-X
affected	B-X
before	B-X
the	B-X
age	B-X
of	B-X
50	B-X
(	B-X
n	B-X
=	B-X
28	B-X
)	B-X
,	B-X
and	B-X
one	B-X
additional	B-X
minor	B-X
criterion	B-X

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B-Disease
melanoma	I-Disease
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	B-Disease
-	O
predisposing	O
gene	O
.	O
.	O
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
show	B-X
frequent	B-X
involvement	B-X
of	B-X
the	B-X
p16	B-X
gene	B-X
in	B-X
familial	B-X
melanoma	B-X
and	B-X
confirm	B-X
the	B-X
role	B-X
of	B-X
the	B-X
CDK4	B-X
gene	B-X
as	B-X
a	B-X
melanoma	B-X
-	B-X
predisposing	B-X
gene	B-X
<EOS>	B-X
We	B-X
searched	B-X
for	B-X
such	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
French	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
selected	B-X
according	B-X
to	B-X
two	B-X
major	B-X
criteria	B-X
:	B-X
families	B-X
with	B-X
at	B-X
least	B-X
three	B-X
affected	B-X
members	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
or	B-X
families	B-X
with	B-X
two	B-X
affected	B-X
members	B-X
,	B-X
one	B-X
of	B-X
them	B-X
affected	B-X
before	B-X
the	B-X
age	B-X
of	B-X
50	B-X
(	B-X
n	B-X
=	B-X
28	B-X
)	B-X
,	B-X
and	B-X
one	B-X
additional	B-X
minor	B-X
criterion	B-X
<EOS>	B-X
Prevalence	B-X
of	B-X
p16	B-X
and	B-X
CDK4	B-X
germline	B-X
mutations	B-X
in	B-X
48	B-X
melanoma	B-X
-	B-X
prone	B-X
families	B-X
in	B-X
France	B-X
.	B-X
The	B-X
French	B-X
Familial	B-X
Melanoma	B-X
Study	B-X
Group	B-X
.	B-X
<EOS>	B-X
Sixteen	B-X
different	B-X
p16	B-X
germline	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
21	B-X
families	B-X
,	B-X
while	B-X
one	B-X
germline	B-X
mutation	B-X
,	B-X
Arg24His	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
CDK4	B-X
gene	B-X

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
.	O
<EOS>	B-X
Progression	B-X
of	B-X
somatic	B-X
CTG	B-X
repeat	B-X
length	B-X
heterogeneity	B-X
in	B-X
the	B-X
blood	B-X
cells	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
a	B-X
direct	B-X
progression	B-X
of	B-X
the	B-X
size	B-X
heterogeneity	B-X
over	B-X
time	B-X
related	B-X
to	B-X
initial	B-X
CTG	B-X
repeat	B-X
size	B-X
and	B-X
the	B-X
time	B-X
interval	B-X
and	B-X
always	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
further	B-X
characterize	B-X
the	B-X
dynamics	B-X
of	B-X
DM	B-X
CTG	B-X
repeat	B-X
somatic	B-X
instability	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
repeat	B-X
length	B-X
changes	B-X
over	B-X
time	B-X
in	B-X
111	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
with	B-X
varying	B-X
clinical	B-X
severity	B-X
and	B-X
CTG	B-X
repeat	B-X
size	B-X
over	B-X
time	B-X
intervals	B-X
of	B-X
1	B-X
-	B-X
7	B-X
years	B-X
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
the	B-X
expansion	B-X
of	B-X
an	B-X
unstable	B-X
CTG	B-X
repeat	B-X
in	B-X
the	B-X
34	B-X
UTR	B-X
of	B-X
the	B-X
DM	B-X
protein	B-X
kinase	B-X
gene	B-X
on	B-X
chromosome	B-X
19	B-X

The	O
genetic	O
basis	O
of	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	B-Disease
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
the	B-X
expansion	B-X
of	B-X
an	B-X
unstable	B-X
CTG	B-X
repeat	B-X
in	B-X
the	B-X
34	B-X
UTR	B-X
of	B-X
the	B-X
DM	B-X
protein	B-X
kinase	B-X
gene	B-X
on	B-X
chromosome	B-X
19	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
a	B-X
direct	B-X
progression	B-X
of	B-X
the	B-X
size	B-X
heterogeneity	B-X
over	B-X
time	B-X
related	B-X
to	B-X
initial	B-X
CTG	B-X
repeat	B-X
size	B-X
and	B-X
the	B-X
time	B-X
interval	B-X
and	B-X
always	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X
<EOS>	B-X
This	B-X
instability	B-X
appears	B-X
to	B-X
be	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X
and	B-X
continuous	B-X
throughout	B-X
the	B-X
life	B-X
of	B-X
an	B-X
individual	B-X
,	B-X
features	B-X
that	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
progressive	B-X
nature	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
Progression	B-X
of	B-X
somatic	B-X
CTG	B-X
repeat	B-X
length	B-X
heterogeneity	B-X
in	B-X
the	B-X
blood	B-X
cells	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
.	B-X

One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	B-Disease
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O
<EOS>	B-X
This	B-X
instability	B-X
appears	B-X
to	B-X
be	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X
and	B-X
continuous	B-X
throughout	B-X
the	B-X
life	B-X
of	B-X
an	B-X
individual	B-X
,	B-X
features	B-X
that	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
progressive	B-X
nature	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
the	B-X
expansion	B-X
of	B-X
an	B-X
unstable	B-X
CTG	B-X
repeat	B-X
in	B-X
the	B-X
34	B-X
UTR	B-X
of	B-X
the	B-X
DM	B-X
protein	B-X
kinase	B-X
gene	B-X
on	B-X
chromosome	B-X
19	B-X
<EOS>	B-X
Although	B-X
increasing	B-X
measured	B-X
allele	B-X
size	B-X
between	B-X
patients	B-X
clearly	B-X
correlates	B-X
with	B-X
an	B-X
increased	B-X
severity	B-X
of	B-X
symptoms	B-X
and	B-X
an	B-X
earlier	B-X
age	B-X
of	B-X
onset	B-X
,	B-X
this	B-X
correlation	B-X
is	B-X
not	B-X
precise	B-X
and	B-X
measured	B-X
allele	B-X
length	B-X
can	B-X
not	B-X
be	B-X
used	B-X
as	B-X
an	B-X
accurate	B-X
predictor	B-X
of	B-X
age	B-X
of	B-X
onset	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
a	B-X
direct	B-X
progression	B-X
of	B-X
the	B-X
size	B-X
heterogeneity	B-X
over	B-X
time	B-X
related	B-X
to	B-X
initial	B-X
CTG	B-X
repeat	B-X
size	B-X
and	B-X
the	B-X
time	B-X
interval	B-X
and	B-X
always	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B-Disease
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
further	B-X
characterize	B-X
the	B-X
dynamics	B-X
of	B-X
DM	B-X
CTG	B-X
repeat	B-X
somatic	B-X
instability	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
repeat	B-X
length	B-X
changes	B-X
over	B-X
time	B-X
in	B-X
111	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
with	B-X
varying	B-X
clinical	B-X
severity	B-X
and	B-X
CTG	B-X
repeat	B-X
size	B-X
over	B-X
time	B-X
intervals	B-X
of	B-X
1	B-X
-	B-X
7	B-X
years	B-X
<EOS>	B-X
Attempts	B-X
to	B-X
mathematically	B-X
model	B-X
the	B-X
dynamics	B-X
have	B-X
proved	B-X
only	B-X
partially	B-X
successful	B-X
suggesting	B-X
that	B-X
individual	B-X
specific	B-X
genetic	B-X
and	B-X
/	B-X
or	B-X
environmental	B-X
factors	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
somatic	B-X
mosaicism	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
a	B-X
direct	B-X
progression	B-X
of	B-X
the	B-X
size	B-X
heterogeneity	B-X
over	B-X
time	B-X
related	B-X
to	B-X
initial	B-X
CTG	B-X
repeat	B-X
size	B-X
and	B-X
the	B-X
time	B-X
interval	B-X
and	B-X
always	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X
<EOS>	B-X
Progression	B-X
of	B-X
somatic	B-X
CTG	B-X
repeat	B-X
length	B-X
heterogeneity	B-X
in	B-X
the	B-X
blood	B-X
cells	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
.	B-X

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
a	B-X
direct	B-X
progression	B-X
of	B-X
the	B-X
size	B-X
heterogeneity	B-X
over	B-X
time	B-X
related	B-X
to	B-X
initial	B-X
CTG	B-X
repeat	B-X
size	B-X
and	B-X
the	B-X
time	B-X
interval	B-X
and	B-X
always	B-X
biased	B-X
towards	B-X
further	B-X
expansion	B-X
<EOS>	B-X
Progression	B-X
of	B-X
somatic	B-X
CTG	B-X
repeat	B-X
length	B-X
heterogeneity	B-X
in	B-X
the	B-X
blood	B-X
cells	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
.	B-X
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
the	B-X
expansion	B-X
of	B-X
an	B-X
unstable	B-X
CTG	B-X
repeat	B-X
in	B-X
the	B-X
34	B-X
UTR	B-X
of	B-X
the	B-X
DM	B-X
protein	B-X
kinase	B-X
gene	B-X
on	B-X
chromosome	B-X
19	B-X
<EOS>	B-X
Although	B-X
increasing	B-X
measured	B-X
allele	B-X
size	B-X
between	B-X
patients	B-X
clearly	B-X
correlates	B-X
with	B-X
an	B-X
increased	B-X
severity	B-X
of	B-X
symptoms	B-X
and	B-X
an	B-X
earlier	B-X
age	B-X
of	B-X
onset	B-X
,	B-X
this	B-X
correlation	B-X
is	B-X
not	B-X
precise	B-X
and	B-X
measured	B-X
allele	B-X
length	B-X
can	B-X
not	B-X
be	B-X
used	B-X
as	B-X
an	B-X
accurate	B-X
predictor	B-X
of	B-X
age	B-X
of	B-X
onset	B-X

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
.	O
<EOS>	B-X
Attempts	B-X
to	B-X
mathematically	B-X
model	B-X
the	B-X
dynamics	B-X
have	B-X
proved	B-X
only	B-X
partially	B-X
successful	B-X
suggesting	B-X
that	B-X
individual	B-X
specific	B-X
genetic	B-X
and	B-X
/	B-X
or	B-X
environmental	B-X
factors	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
somatic	B-X
mosaicism	B-X
<EOS>	B-X
If	B-X
the	B-X
hypothesis	B-X
is	B-X
correct	B-X
,	B-X
whole	B-X
genome	B-X
sequencing	B-X
or	B-X
copy	B-X
number	B-X
variation	B-X
studies	B-X
at	B-X
individual	B-X
cell	B-X
level	B-X
should	B-X
allow	B-X
to	B-X
identify	B-X
the	B-X
expected	B-X
low	B-X
level	B-X
of	B-X
genetic	B-X
mosaicism	B-X
<EOS>	B-X
Paradoxically	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
biliary	B-X
atresia	B-X
has	B-X
neither	B-X
a	B-X
genetic	B-X
nor	B-X
an	B-X
environmental	B-X
cause	B-X
<EOS>	B-X
We	B-X
present	B-X
a	B-X
thorough	B-X
genetic	B-X
characterization	B-X
of	B-X
the	B-X
sequenced	B-X
individuals	B-X
but	B-X
detected	B-X
no	B-X
consistent	B-X
differences	B-X
within	B-X
the	B-X
twin	B-X
pairs	B-X

Aspartylglucosaminuria	B-Disease
among	O
Palestinian	O
Arabs	O
.	O
<EOS>	B-X
Aspartylglucosaminuria	B-X
among	B-X
Palestinian	B-X
Arabs	B-X
.	B-X
<EOS>	B-X
Aspartylglucosaminuria	B-X
(	B-X
AGU	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
disorder	B-X
of	B-X
glycoprotein	B-X
metabolism	B-X
caused	B-X
by	B-X
the	B-X
deficiency	B-X
of	B-X
the	B-X
lysosomal	B-X
enzyme	B-X
aspartylglucosaminidase	B-X
(	B-X
AGA	B-X
)	B-X
<EOS>	B-X
However	B-X
,	B-X
since	B-X
these	B-X
patients	B-X
excrete	B-X
early	B-X
large	B-X
amounts	B-X
of	B-X
aspartylglucosamine	B-X
in	B-X
urine	B-X
,	B-X
biochemical	B-X
screening	B-X
is	B-X
easy	B-X
by	B-X
urine	B-X
chromatography	B-X
<EOS>	B-X
AGU	B-X
is	B-X
inherited	B-X
as	B-X
an	B-X
autosomal	B-X
recessive	B-X
trait	B-X
and	B-X
occurs	B-X
with	B-X
a	B-X
high	B-X
frequency	B-X
in	B-X
Finland	B-X
because	B-X
of	B-X
a	B-X
founder	B-X
effect	B-X

Aspartylglucosaminuria	B-Disease
(	O
AGU	B-Disease
)	O
is	O
a	O
rare	O
disorder	B-Disease
of	I-Disease
glycoprotein	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
lysosomal	I-Disease
enzyme	I-Disease
aspartylglucosaminidase	I-Disease
(	O
AGA	O
)	O
.	O
<EOS>	B-X
Aspartylglucosaminuria	B-X
(	B-X
AGU	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
disorder	B-X
of	B-X
glycoprotein	B-X
metabolism	B-X
caused	B-X
by	B-X
the	B-X
deficiency	B-X
of	B-X
the	B-X
lysosomal	B-X
enzyme	B-X
aspartylglucosaminidase	B-X
(	B-X
AGA	B-X
)	B-X
<EOS>	B-X
Aspartylglucosaminuria	B-X
(	B-X
AGU	B-X
)	B-X
is	B-X
exceptional	B-X
among	B-X
lysosomal	B-X
storage	B-X
diseases	B-X
since	B-X
it	B-X
represents	B-X
the	B-X
only	B-X
known	B-X
amidase	B-X
deficiency	B-X
in	B-X
man	B-X
,	B-X
being	B-X
caused	B-X
by	B-X
an	B-X
inadequate	B-X
function	B-X
of	B-X
aspartylglucosaminidase	B-X
(	B-X
AGA	B-X
,	B-X
E	B-X
<EOS>	B-X
Aspartylglucosaminuria	B-X
(	B-X
AGU	B-X
)	B-X
,	B-X
a	B-X
recessively	B-X
inherited	B-X
lysosomal	B-X
storage	B-X
disease	B-X
,	B-X
is	B-X
the	B-X
most	B-X
common	B-X
disorder	B-X
of	B-X
glycoprotein	B-X
degradation	B-X
with	B-X
a	B-X
high	B-X
prevalence	B-X
in	B-X
the	B-X
Finnish	B-X
population	B-X
<EOS>	B-X
A	B-X
single	B-X
nucleotide	B-X
change	B-X
in	B-X
the	B-X
AGA	B-X
gene	B-X
resulting	B-X
in	B-X
a	B-X
cysteine	B-X
to	B-X
serine	B-X
substitution	B-X
(	B-X
C163S	B-X
)	B-X
in	B-X
the	B-X
AGA	B-X
enzyme	B-X
protein	B-X
causes	B-X
the	B-X
deficiency	B-X
of	B-X
the	B-X
glycosylasparaginase	B-X
activity	B-X
in	B-X
the	B-X
Finnish	B-X
population	B-X

AGU	B-Disease
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B-Disease
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O
<EOS>	B-X
While	B-X
very	B-X
few	B-X
patients	B-X
with	B-X
AGU	B-X
have	B-X
been	B-X
reported	B-X
from	B-X
non	B-X
-	B-X
Finnish	B-X
origin	B-X
,	B-X
we	B-X
diagnosed	B-X
the	B-X
disorder	B-X
in	B-X
8	B-X
patients	B-X
originating	B-X
from	B-X
3	B-X
unrelated	B-X
families	B-X
,	B-X
all	B-X
Palestinian	B-X
Arabs	B-X
from	B-X
the	B-X
region	B-X
of	B-X
Jerusalem	B-X
<EOS>	B-X
The	B-X
clinical	B-X
diagnosis	B-X
of	B-X
AGU	B-X
is	B-X
often	B-X
difficult	B-X
,	B-X
in	B-X
particular	B-X
early	B-X
in	B-X
the	B-X
course	B-X
of	B-X
the	B-X
disease	B-X
,	B-X
and	B-X
most	B-X
of	B-X
the	B-X
patients	B-X
are	B-X
diagnosed	B-X
after	B-X
the	B-X
age	B-X
of	B-X
5	B-X
years	B-X
<EOS>	B-X
However	B-X
,	B-X
since	B-X
these	B-X
patients	B-X
excrete	B-X
early	B-X
large	B-X
amounts	B-X
of	B-X
aspartylglucosamine	B-X
in	B-X
urine	B-X
,	B-X
biochemical	B-X
screening	B-X
is	B-X
easy	B-X
by	B-X
urine	B-X
chromatography	B-X
<EOS>	B-X
AGU	B-X
is	B-X
inherited	B-X
as	B-X
an	B-X
autosomal	B-X
recessive	B-X
trait	B-X
and	B-X
occurs	B-X
with	B-X
a	B-X
high	B-X
frequency	B-X
in	B-X
Finland	B-X
because	B-X
of	B-X
a	B-X
founder	B-X
effect	B-X

The	O
clinical	O
diagnosis	O
of	O
AGU	B-Disease
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O
.	O
.	O
<EOS>	B-X
However	B-X
,	B-X
since	B-X
these	B-X
patients	B-X
excrete	B-X
early	B-X
large	B-X
amounts	B-X
of	B-X
aspartylglucosamine	B-X
in	B-X
urine	B-X
,	B-X
biochemical	B-X
screening	B-X
is	B-X
easy	B-X
by	B-X
urine	B-X
chromatography	B-X
<EOS>	B-X
While	B-X
very	B-X
few	B-X
patients	B-X
with	B-X
AGU	B-X
have	B-X
been	B-X
reported	B-X
from	B-X
non	B-X
-	B-X
Finnish	B-X
origin	B-X
,	B-X
we	B-X
diagnosed	B-X
the	B-X
disorder	B-X
in	B-X
8	B-X
patients	B-X
originating	B-X
from	B-X
3	B-X
unrelated	B-X
families	B-X
,	B-X
all	B-X
Palestinian	B-X
Arabs	B-X
from	B-X
the	B-X
region	B-X
of	B-X
Jerusalem	B-X
<EOS>	B-X
Aspartylglucosaminuria	B-X
among	B-X
Palestinian	B-X
Arabs	B-X
.	B-X
<EOS>	B-X
AGU	B-X
is	B-X
inherited	B-X
as	B-X
an	B-X
autosomal	B-X
recessive	B-X
trait	B-X
and	B-X
occurs	B-X
with	B-X
a	B-X
high	B-X
frequency	B-X
in	B-X
Finland	B-X
because	B-X
of	B-X
a	B-X
founder	B-X
effect	B-X

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O
<EOS>	B-X
Detection	B-X
of	B-X
heterozygous	B-X
carriers	B-X
of	B-X
the	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
ATM	B-X
)	B-X
gene	B-X
by	B-X
G2	B-X
phase	B-X
chromosomal	B-X
radiosensitivity	B-X
of	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
G2	B-X
-	B-X
phase	B-X
chromosomal	B-X
radiosensitivity	B-X
assay	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
A	B-X
-	B-X
T	B-X
heterozygotes	B-X
<EOS>	B-X
In	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
A	B-X
-	B-X
T	B-X
)	B-X
patients	B-X
,	B-X
mutations	B-X
in	B-X
a	B-X
single	B-X
gene	B-X
,	B-X
ATM	B-X
,	B-X
result	B-X
in	B-X
an	B-X
autosomal	B-X
recessive	B-X
syndrome	B-X
that	B-X
embraces	B-X
a	B-X
variety	B-X
of	B-X
clinical	B-X
features	B-X
and	B-X
manifests	B-X
extreme	B-X
radiosensitivity	B-X
and	B-X
a	B-X
strong	B-X
pre	B-X
-	B-X
disposition	B-X
to	B-X
malignancy	B-X
<EOS>	B-X
In	B-X
combination	B-X
with	B-X
molecular	B-X
genetic	B-X
analyses	B-X
,	B-X
this	B-X
test	B-X
may	B-X
be	B-X
of	B-X
value	B-X
in	B-X
studies	B-X
of	B-X
familial	B-X
and	B-X
sporadic	B-X
cancers	B-X
aimed	B-X
at	B-X
determination	B-X
of	B-X
the	B-X
potential	B-X
involvement	B-X
of	B-X
ATM	B-X
mutations	B-X
in	B-X
tumor	B-X
risk	B-X
or	B-X
development	B-X

In	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B-Disease
.	O

Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
but	O
may	O
be	O
cancer	B-Disease
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
,	O
13	O
obligate	O
A	B-Disease
-	I-Disease
T	I-Disease
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

Both	O
A	B-Disease
-	I-Disease
T	I-Disease
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
heterozygotes	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B-Disease
and	I-Disease
sporadic	I-Disease
cancers	I-Disease
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B-Disease
risk	O
or	O
development	O
.	O
.	O
<EOS>	B-X
Many	B-X
different	B-X
mental	B-X
states	B-X
have	B-X
been	B-X
investigated	B-X
,	B-X
including	B-X
fatigue	B-X
,	B-X
attention	B-X
and	B-X
various	B-X
emotions	B-X
,	B-X
however	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
studied	B-X
states	B-X
is	B-X
mental	B-X
workload	B-X
,	B-X
i	B-X
<EOS>	B-X
The	B-X
emphasis	B-X
of	B-X
mental	B-X
workload	B-X
studies	B-X
to	B-X
date	B-X
has	B-X
been	B-X
almost	B-X
exclusively	B-X
on	B-X
detecting	B-X
and	B-X
predicting	B-X
the	B-X
``	B-X
level	B-X
''	B-X
of	B-X
cognitive	B-X
resources	B-X
required	B-X
(	B-X
e	B-X
<EOS>	B-X
Induction	B-X
of	B-X
the	B-X
multipolar	B-X
phenotype	B-X
was	B-X
shown	B-X
in	B-X
centrosome	B-X
-	B-X
amplified	B-X
human	B-X
cancer	B-X
cells	B-X
treated	B-X
with	B-X
these	B-X
inhibitors	B-X
<EOS>	B-X
Accurate	B-X
in	B-X
vitro	B-X
models	B-X
are	B-X
necessary	B-X
to	B-X
detect	B-X
early	B-X
toxicity	B-X
kinetics	B-X
,	B-X
investigate	B-X
disease	B-X
etiology	B-X
,	B-X
and	B-X
develop	B-X
preclinical	B-X
models	B-X
for	B-X
new	B-X
therapies	B-X

Ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O
<EOS>	B-X
Ataxia	B-X
-	B-X
telangiectasia	B-X
:	B-X
identification	B-X
and	B-X
detection	B-X
of	B-X
founder	B-X
-	B-X
effect	B-X
mutations	B-X
in	B-X
the	B-X
ATM	B-X
gene	B-X
in	B-X
ethnic	B-X
populations	B-X
.	B-X
<EOS>	B-X
The	B-X
haplotyping	B-X
of	B-X
patients	B-X
with	B-X
identical	B-X
mutations	B-X
indicates	B-X
that	B-X
almost	B-X
all	B-X
of	B-X
these	B-X
represent	B-X
common	B-X
ancestry	B-X
and	B-X
that	B-X
very	B-X
few	B-X
spontaneously	B-X
recurring	B-X
ATM	B-X
mutations	B-X
exist	B-X
<EOS>	B-X
5	B-X
%	B-X
carried	B-X
a	B-X
PV	B-X
in	B-X
a	B-X
cancer	B-X
susceptibility	B-X
gene	B-X
,	B-X
increasing	B-X
understanding	B-X
of	B-X
hereditary	B-X
BC	B-X
in	B-X
this	B-X
population	B-X
<EOS>	B-X
To	B-X
facilitate	B-X
the	B-X
evaluation	B-X
of	B-X
ATM	B-X
heterozygotes	B-X
for	B-X
susceptibility	B-X
to	B-X
other	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
define	B-X
the	B-X
most	B-X
common	B-X
mutations	B-X
and	B-X
their	B-X
frequencies	B-X
in	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
A	B-X
-	B-X
T	B-X
)	B-X
homozygotes	B-X
from	B-X
10	B-X
ethnic	B-X
populations	B-X

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B-Disease
cancer	I-Disease
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
most	B-X
ABCA3	B-X
variants	B-X
identified	B-X
in	B-X
patients	B-X
have	B-X
not	B-X
been	B-X
characterized	B-X
at	B-X
the	B-X
RNA	B-X
level	B-X
<EOS>	B-X
Eighty	B-X
abnormalities	B-X
were	B-X
found	B-X
using	B-X
standard	B-X
techniques	B-X
of	B-X
which	B-X
72	B-X
(	B-X
90	B-X
%	B-X
)	B-X
were	B-X
correctly	B-X
detected	B-X
using	B-X
OGM	B-X
<EOS>	B-X
Thus	B-X
,	B-X
OGM	B-X
represents	B-X
a	B-X
promising	B-X
alternative	B-X
to	B-X
cytogenetic	B-X
techniques	B-X
currently	B-X
performed	B-X
for	B-X
ALL	B-X
characterization	B-X
<EOS>	B-X
However	B-X
,	B-X
such	B-X
technologies	B-X
are	B-X
limited	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
make	B-X
targeted	B-X
large	B-X
deletions	B-X

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened	O
.	O
<EOS>	B-X
Protein	B-X
-	B-X
truncation	B-X
testing	B-X
of	B-X
the	B-X
entire	B-X
ATM	B-X
cDNA	B-X
detected	B-X
92	B-X
(	B-X
66	B-X
%	B-X
)	B-X
truncating	B-X
mutations	B-X
in	B-X
140	B-X
mutant	B-X
alleles	B-X
screened	B-X
<EOS>	B-X
Ataxia	B-X
-	B-X
telangiectasia	B-X
:	B-X
identification	B-X
and	B-X
detection	B-X
of	B-X
founder	B-X
-	B-X
effect	B-X
mutations	B-X
in	B-X
the	B-X
ATM	B-X
gene	B-X
in	B-X
ethnic	B-X
populations	B-X
.	B-X
<EOS>	B-X
To	B-X
facilitate	B-X
the	B-X
evaluation	B-X
of	B-X
ATM	B-X
heterozygotes	B-X
for	B-X
susceptibility	B-X
to	B-X
other	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
define	B-X
the	B-X
most	B-X
common	B-X
mutations	B-X
and	B-X
their	B-X
frequencies	B-X
in	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
A	B-X
-	B-X
T	B-X
)	B-X
homozygotes	B-X
from	B-X
10	B-X
ethnic	B-X
populations	B-X
<EOS>	B-X
These	B-X
rapid	B-X
assays	B-X
detected	B-X
mutations	B-X
in	B-X
76	B-X
%	B-X
of	B-X
Costa	B-X
Rican	B-X
patients	B-X
(	B-X
3	B-X
)	B-X
,	B-X
50	B-X
%	B-X
of	B-X
Norwegian	B-X
patients	B-X
(	B-X
1	B-X
)	B-X
,	B-X
25	B-X
%	B-X
of	B-X
Polish	B-X
patients	B-X
(	B-X
4	B-X
)	B-X
,	B-X
and	B-X
14	B-X
%	B-X
of	B-X
Italian	B-X
patients	B-X
(	B-X
1	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
patients	B-X
of	B-X
Amish	B-X
/	B-X
Mennonite	B-X
and	B-X
Irish	B-X
English	B-X
backgrounds	B-X

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O
<EOS>	B-X
The	B-X
haplotyping	B-X
of	B-X
patients	B-X
with	B-X
identical	B-X
mutations	B-X
indicates	B-X
that	B-X
almost	B-X
all	B-X
of	B-X
these	B-X
represent	B-X
common	B-X
ancestry	B-X
and	B-X
that	B-X
very	B-X
few	B-X
spontaneously	B-X
recurring	B-X
ATM	B-X
mutations	B-X
exist	B-X
<EOS>	B-X
Ataxia	B-X
-	B-X
telangiectasia	B-X
:	B-X
identification	B-X
and	B-X
detection	B-X
of	B-X
founder	B-X
-	B-X
effect	B-X
mutations	B-X
in	B-X
the	B-X
ATM	B-X
gene	B-X
in	B-X
ethnic	B-X
populations	B-X
.	B-X
<EOS>	B-X
To	B-X
facilitate	B-X
the	B-X
evaluation	B-X
of	B-X
ATM	B-X
heterozygotes	B-X
for	B-X
susceptibility	B-X
to	B-X
other	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
,	B-X
we	B-X
have	B-X
attempted	B-X
to	B-X
define	B-X
the	B-X
most	B-X
common	B-X
mutations	B-X
and	B-X
their	B-X
frequencies	B-X
in	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
A	B-X
-	B-X
T	B-X
)	B-X
homozygotes	B-X
from	B-X
10	B-X
ethnic	B-X
populations	B-X
<EOS>	B-X
Assays	B-X
requiring	B-X
minimal	B-X
amounts	B-X
of	B-X
genomic	B-X
DNA	B-X
were	B-X
designed	B-X
to	B-X
allow	B-X
rapid	B-X
screening	B-X
for	B-X
common	B-X
ethnic	B-X
mutations	B-X

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O
<EOS>	B-X
Assays	B-X
requiring	B-X
minimal	B-X
amounts	B-X
of	B-X
genomic	B-X
DNA	B-X
were	B-X
designed	B-X
to	B-X
allow	B-X
rapid	B-X
screening	B-X
for	B-X
common	B-X
ethnic	B-X
mutations	B-X
<EOS>	B-X
The	B-X
haplotyping	B-X
of	B-X
patients	B-X
with	B-X
identical	B-X
mutations	B-X
indicates	B-X
that	B-X
almost	B-X
all	B-X
of	B-X
these	B-X
represent	B-X
common	B-X
ancestry	B-X
and	B-X
that	B-X
very	B-X
few	B-X
spontaneously	B-X
recurring	B-X
ATM	B-X
mutations	B-X
exist	B-X
<EOS>	B-X
Additional	B-X
mutations	B-X
were	B-X
observed	B-X
in	B-X
Japanese	B-X
,	B-X
Utah	B-X
Mormon	B-X
,	B-X
and	B-X
African	B-X
American	B-X
patients	B-X
<EOS>	B-X
Ataxia	B-X
-	B-X
telangiectasia	B-X
:	B-X
identification	B-X
and	B-X
detection	B-X
of	B-X
founder	B-X
-	B-X
effect	B-X
mutations	B-X
in	B-X
the	B-X
ATM	B-X
gene	B-X
in	B-X
ethnic	B-X
populations	B-X
.	B-X

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

Additional	O
mutations	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O
<EOS>	B-X
Additional	B-X
mutations	B-X
were	B-X
observed	B-X
in	B-X
Japanese	B-X
,	B-X
Utah	B-X
Mormon	B-X
,	B-X
and	B-X
African	B-X
American	B-X
patients	B-X
<EOS>	B-X
Ataxia	B-X
-	B-X
telangiectasia	B-X
:	B-X
identification	B-X
and	B-X
detection	B-X
of	B-X
founder	B-X
-	B-X
effect	B-X
mutations	B-X
in	B-X
the	B-X
ATM	B-X
gene	B-X
in	B-X
ethnic	B-X
populations	B-X
.	B-X
<EOS>	B-X
Both	B-X
genomic	B-X
mutations	B-X
and	B-X
their	B-X
effects	B-X
on	B-X
cDNA	B-X
were	B-X
characterized	B-X
<EOS>	B-X
The	B-X
haplotyping	B-X
of	B-X
patients	B-X
with	B-X
identical	B-X
mutations	B-X
indicates	B-X
that	B-X
almost	B-X
all	B-X
of	B-X
these	B-X
represent	B-X
common	B-X
ancestry	B-X
and	B-X
that	B-X
very	B-X
few	B-X
spontaneously	B-X
recurring	B-X
ATM	B-X
mutations	B-X
exist	B-X

These	O
assays	O
should	O
facilitate	O
screening	O
for	O
A	B-Disease
-	I-Disease
T	I-Disease
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
.	O

The	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
tumor	I-Disease
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
inactivation	O
of	O
the	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	I-Disease
VHL	I-Disease
)	I-Disease
tumor	I-Disease
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B-Disease
cancer	I-Disease
syndrome	I-Disease
and	O
is	O
associated	O
with	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
(	O
RCC	B-Disease
)	O
and	O
brain	B-Disease
hemangioblastomas	I-Disease
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B-Disease
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	B-Disease
.	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
.	O
<EOS>	B-X
Remarkably	B-X
,	B-X
this	B-X
occurs	B-X
without	B-X
affecting	B-X
the	B-X
growth	B-X
rate	B-X
and	B-X
cell	B-X
cycle	B-X
profile	B-X
of	B-X
these	B-X
cells	B-X
in	B-X
culture	B-X
<EOS>	B-X
This	B-X
is	B-X
corrected	B-X
by	B-X
the	B-X
reintroduction	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
,	B-X
implicating	B-X
VHL	B-X
as	B-X
the	B-X
first	B-X
tumor	B-X
suppressor	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
exit	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
gatekeeper	B-X
function	B-X
in	B-X
the	B-X
kidney	B-X
<EOS>	B-X
Here	B-X
,	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
reintroduction	B-X
of	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
restores	B-X
the	B-X
ability	B-X
of	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cancer	B-X
cells	B-X
to	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
enter	B-X
G0	B-X
/	B-X
quiescence	B-X
in	B-X
low	B-X
serum	B-X
<EOS>	B-X
Both	B-X
VHL	B-X
-	B-X
positive	B-X
and	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cells	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
by	B-X
contact	B-X
inhibition	B-X

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B-Disease
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B-Disease
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B-Disease
cancer	I-Disease
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
reintroduction	B-X
of	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
restores	B-X
the	B-X
ability	B-X
of	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cancer	B-X
cells	B-X
to	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
enter	B-X
G0	B-X
/	B-X
quiescence	B-X
in	B-X
low	B-X
serum	B-X
<EOS>	B-X
This	B-X
is	B-X
corrected	B-X
by	B-X
the	B-X
reintroduction	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
,	B-X
implicating	B-X
VHL	B-X
as	B-X
the	B-X
first	B-X
tumor	B-X
suppressor	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
exit	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
gatekeeper	B-X
function	B-X
in	B-X
the	B-X
kidney	B-X
<EOS>	B-X
Both	B-X
VHL	B-X
-	B-X
positive	B-X
and	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cells	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
by	B-X
contact	B-X
inhibition	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
results	B-X
in	B-X
a	B-X
specific	B-X
cellular	B-X
defect	B-X
in	B-X
serum	B-X
-	B-X
dependent	B-X
growth	B-X
control	B-X
,	B-X
which	B-X
may	B-X
initiate	B-X
tumor	B-X
formation	B-X

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	B-Disease
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O
<EOS>	B-X
Both	B-X
VHL	B-X
-	B-X
positive	B-X
and	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cells	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
by	B-X
contact	B-X
inhibition	B-X
<EOS>	B-X
Here	B-X
,	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
reintroduction	B-X
of	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
restores	B-X
the	B-X
ability	B-X
of	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cancer	B-X
cells	B-X
to	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
enter	B-X
G0	B-X
/	B-X
quiescence	B-X
in	B-X
low	B-X
serum	B-X
<EOS>	B-X
The	B-X
786	B-X
-	B-X
0	B-X
cell	B-X
line	B-X
,	B-X
like	B-X
many	B-X
cancer	B-X
cells	B-X
,	B-X
fails	B-X
to	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
upon	B-X
serum	B-X
withdrawal	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
results	B-X
in	B-X
a	B-X
specific	B-X
cellular	B-X
defect	B-X
in	B-X
serum	B-X
-	B-X
dependent	B-X
growth	B-X
control	B-X
,	B-X
which	B-X
may	B-X
initiate	B-X
tumor	B-X
formation	B-X

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	B-Disease
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
The	B-X
cyclin	B-X
-	B-X
dependent	B-X
kinase	B-X
inhibitor	B-X
,	B-X
p27	B-X
,	B-X
accumulates	B-X
upon	B-X
serum	B-X
withdrawal	B-X
,	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VHL	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
stabilization	B-X
of	B-X
the	B-X
protein	B-X
<EOS>	B-X
This	B-X
is	B-X
corrected	B-X
by	B-X
the	B-X
reintroduction	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
,	B-X
implicating	B-X
VHL	B-X
as	B-X
the	B-X
first	B-X
tumor	B-X
suppressor	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
exit	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
gatekeeper	B-X
function	B-X
in	B-X
the	B-X
kidney	B-X
<EOS>	B-X
VHL	B-X
-	B-X
negative	B-X
786	B-X
-	B-X
0	B-X
RCC	B-X
cells	B-X
are	B-X
tumorigenic	B-X
in	B-X
nude	B-X
mice	B-X
which	B-X
is	B-X
suppressed	B-X
by	B-X
the	B-X
reintroduction	B-X
of	B-X
VHL	B-X
<EOS>	B-X
The	B-X
inactivation	B-X
of	B-X
the	B-X
von	B-X
Hippel	B-X
-	B-X
Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
predisposes	B-X
affected	B-X
individuals	B-X
to	B-X
the	B-X
human	B-X
VHL	B-X
cancer	B-X
syndrome	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
sporadic	B-X
renal	B-X
cell	B-X
carcinomas	B-X
(	B-X
RCC	B-X
)	B-X
and	B-X
brain	B-X
hemangioblastomas	B-X

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B-Disease
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B-Disease
formation	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B-Disease
,	O
implicating	O
VHL	B-Disease
as	O
the	O
first	O
tumor	B-Disease
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
.	O
.	O
<EOS>	B-X
This	B-X
is	B-X
corrected	B-X
by	B-X
the	B-X
reintroduction	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
,	B-X
implicating	B-X
VHL	B-X
as	B-X
the	B-X
first	B-X
tumor	B-X
suppressor	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
exit	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
its	B-X
gatekeeper	B-X
function	B-X
in	B-X
the	B-X
kidney	B-X
<EOS>	B-X
Here	B-X
,	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
reintroduction	B-X
of	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
restores	B-X
the	B-X
ability	B-X
of	B-X
VHL	B-X
-	B-X
negative	B-X
RCC	B-X
cancer	B-X
cells	B-X
to	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
enter	B-X
G0	B-X
/	B-X
quiescence	B-X
in	B-X
low	B-X
serum	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
gene	B-X
results	B-X
in	B-X
a	B-X
specific	B-X
cellular	B-X
defect	B-X
in	B-X
serum	B-X
-	B-X
dependent	B-X
growth	B-X
control	B-X
,	B-X
which	B-X
may	B-X
initiate	B-X
tumor	B-X
formation	B-X
<EOS>	B-X
The	B-X
von	B-X
Hippel	B-X
-	B-X
Lindau	B-X
tumor	B-X
suppressor	B-X
gene	B-X
is	B-X
required	B-X
for	B-X
cell	B-X
cycle	B-X
exit	B-X
upon	B-X
serum	B-X
withdrawal	B-X
.	B-X

Piebaldism	B-Disease
with	O
deafness	B-Disease
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O
<EOS>	B-X
Piebaldism	B-X
with	B-X
deafness	B-X
:	B-X
molecular	B-X
evidence	B-X
for	B-X
an	B-X
expanded	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Though	B-X
auditory	B-X
anomalies	B-X
have	B-X
been	B-X
observed	B-X
in	B-X
mice	B-X
with	B-X
dominant	B-X
white	B-X
spotting	B-X
(	B-X
W	B-X
)	B-X
due	B-X
to	B-X
KIT	B-X
mutations	B-X
,	B-X
deafness	B-X
is	B-X
not	B-X
typical	B-X
in	B-X
human	B-X
piebaldism	B-X
<EOS>	B-X
In	B-X
a	B-X
South	B-X
African	B-X
girl	B-X
of	B-X
Xhosa	B-X
stock	B-X
with	B-X
severe	B-X
piebaldism	B-X
and	B-X
profound	B-X
congenital	B-X
sensorineural	B-X
deafness	B-X
we	B-X
identified	B-X
a	B-X
novel	B-X
missense	B-X
substitution	B-X
at	B-X
a	B-X
highly	B-X
conserved	B-X
residue	B-X
in	B-X
the	B-X
intracellular	B-X
kinase	B-X
domain	B-X
of	B-X
the	B-X
KIT	B-X
proto	B-X
-	B-X
oncogene	B-X
,	B-X
R796G	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
occurrence	B-X
of	B-X
sensorineural	B-X
deafness	B-X
in	B-X
this	B-X
patient	B-X
extends	B-X
considerably	B-X
the	B-X
phenotypic	B-X
range	B-X
of	B-X
piebaldism	B-X
due	B-X
to	B-X
KIT	B-X
gene	B-X
mutation	B-X
in	B-X
humans	B-X
and	B-X
tightens	B-X
the	B-X
clinical	B-X
similarity	B-X
between	B-X
piebaldism	B-X
and	B-X
the	B-X
various	B-X
forms	B-X
of	B-X
Waardenburg	B-X
syndrome	B-X

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B-Disease
and	O
profound	O
congenital	O
sensorineural	B-Disease
deafness	I-Disease
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

Though	O
auditory	B-Disease
anomalies	I-Disease
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	B-Disease
is	O
not	O
typical	O
in	O
human	O
piebaldism	B-Disease
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B-Disease
deafness	I-Disease
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B-Disease
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B-Disease
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B-Disease
syndrome	I-Disease
.	O
.	O

Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
.	O

Patients	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
often	B-X
show	B-X
decreased	B-X
expression	B-X
of	B-X
type	B-X
XVII	B-X
collagen	B-X
,	B-X
a	B-X
transmembrane	B-X
hemidesmosomal	B-X
protein	B-X
encoded	B-X
by	B-X
COL17A1	B-X
<EOS>	B-X
This	B-X
report	B-X
documents	B-X
a	B-X
novel	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
and	B-X
applies	B-X
a	B-X
new	B-X
methodology	B-X
to	B-X
define	B-X
and	B-X
characterize	B-X
the	B-X
resulting	B-X
mRNA	B-X
splice	B-X
variants	B-X
<EOS>	B-X
This	B-X
acceptor	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
led	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
aberrant	B-X
transcripts	B-X
present	B-X
at	B-X
extremely	B-X
low	B-X
levels	B-X
<EOS>	B-X
Based	B-X
on	B-X
our	B-X
recent	B-X
finding	B-X
that	B-X
cycloheximide	B-X
stabilized	B-X
mutant	B-X
COL17A1	B-X
transcripts	B-X
in	B-X
keratinocytes	B-X
homozygous	B-X
for	B-X
a	B-X
frameshift	B-X
mutation	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
on	B-X
splicing	B-X
of	B-X
COL17A1	B-X
transcripts	B-X
were	B-X
determined	B-X
using	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
of	B-X
total	B-X
RNA	B-X
from	B-X
keratinocytes	B-X
incubated	B-X
for	B-X
2	B-X

This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
position	O
of	O
exon	O
32	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
our	B-X
recent	B-X
finding	B-X
that	B-X
cycloheximide	B-X
stabilized	B-X
mutant	B-X
COL17A1	B-X
transcripts	B-X
in	B-X
keratinocytes	B-X
homozygous	B-X
for	B-X
a	B-X
frameshift	B-X
mutation	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
on	B-X
splicing	B-X
of	B-X
COL17A1	B-X
transcripts	B-X
were	B-X
determined	B-X
using	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
of	B-X
total	B-X
RNA	B-X
from	B-X
keratinocytes	B-X
incubated	B-X
for	B-X
2	B-X
<EOS>	B-X
Cycloheximide	B-X
facilitates	B-X
the	B-X
identification	B-X
of	B-X
aberrant	B-X
transcripts	B-X
resulting	B-X
from	B-X
a	B-X
novel	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
usefulness	B-X
of	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
evaluating	B-X
the	B-X
abnormal	B-X
processing	B-X
of	B-X
mRNA	B-X
due	B-X
to	B-X
splice	B-X
-	B-X
site	B-X
mutations	B-X
,	B-X
because	B-X
:	B-X
(	B-X
i	B-X
)	B-X
aberrant	B-X
splicing	B-X
often	B-X
generates	B-X
a	B-X
premature	B-X
termination	B-X
codon	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
transcripts	B-X
with	B-X
premature	B-X
termination	B-X
codons	B-X
can	B-X
occur	B-X
at	B-X
low	B-X
or	B-X
undetectable	B-X
levels	B-X
due	B-X
to	B-X
nonsense	B-X
-	B-X
mediated	B-X
mRNA	B-X
decay	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
the	B-X
levels	B-X
of	B-X
these	B-X
transcripts	B-X
can	B-X
be	B-X
increased	B-X
by	B-X
cycloheximide	B-X
<EOS>	B-X
This	B-X
report	B-X
documents	B-X
a	B-X
novel	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
and	B-X
applies	B-X
a	B-X
new	B-X
methodology	B-X
to	B-X
define	B-X
and	B-X
characterize	B-X
the	B-X
resulting	B-X
mRNA	B-X
splice	B-X
variants	B-X

5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O
<EOS>	B-X
5	B-X
h	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
10	B-X
microg	B-X
cycloheximide	B-X
per	B-X
ml	B-X
<EOS>	B-X
The	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
lysozyme	B-X
are	B-X
independent	B-X
of	B-X
the	B-X
production	B-X
of	B-X
macrophage	B-X
acid	B-X
hydrolases	B-X
<EOS>	B-X
Production	B-X
by	B-X
the	B-X
mouse	B-X
macrophage	B-X
increases	B-X
threefold	B-X
on	B-X
the	B-X
2nd	B-X
day	B-X
in	B-X
culture	B-X
and	B-X
then	B-X
remains	B-X
linear	B-X
with	B-X
time	B-X
<EOS>	B-X
Three	B-X
other	B-X
splice	B-X
variants	B-X
,	B-X
including	B-X
one	B-X
derived	B-X
from	B-X
the	B-X
skipping	B-X
of	B-X
exon	B-X
32	B-X
,	B-X
were	B-X
also	B-X
identified	B-X

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
.	O
<EOS>	B-X
Three	B-X
other	B-X
splice	B-X
variants	B-X
,	B-X
including	B-X
one	B-X
derived	B-X
from	B-X
the	B-X
skipping	B-X
of	B-X
exon	B-X
32	B-X
,	B-X
were	B-X
also	B-X
identified	B-X
<EOS>	B-X
Using	B-X
this	B-X
approach	B-X
,	B-X
an	B-X
abnormally	B-X
spliced	B-X
transcript	B-X
was	B-X
identified	B-X
that	B-X
contains	B-X
an	B-X
extra	B-X
264	B-X
bases	B-X
upstream	B-X
from	B-X
exon	B-X
32	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
premature	B-X
termination	B-X
codon	B-X
27	B-X
bp	B-X
downstream	B-X
from	B-X
the	B-X
cryptic	B-X
splice	B-X
site	B-X
<EOS>	B-X
This	B-X
report	B-X
documents	B-X
a	B-X
novel	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
and	B-X
applies	B-X
a	B-X
new	B-X
methodology	B-X
to	B-X
define	B-X
and	B-X
characterize	B-X
the	B-X
resulting	B-X
mRNA	B-X
splice	B-X
variants	B-X
<EOS>	B-X
Patients	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
often	B-X
show	B-X
decreased	B-X
expression	B-X
of	B-X
type	B-X
XVII	B-X
collagen	B-X
,	B-X
a	B-X
transmembrane	B-X
hemidesmosomal	B-X
protein	B-X
encoded	B-X
by	B-X
COL17A1	B-X

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
usefulness	B-X
of	B-X
cycloheximide	B-X
treatment	B-X
in	B-X
evaluating	B-X
the	B-X
abnormal	B-X
processing	B-X
of	B-X
mRNA	B-X
due	B-X
to	B-X
splice	B-X
-	B-X
site	B-X
mutations	B-X
,	B-X
because	B-X
:	B-X
(	B-X
i	B-X
)	B-X
aberrant	B-X
splicing	B-X
often	B-X
generates	B-X
a	B-X
premature	B-X
termination	B-X
codon	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
transcripts	B-X
with	B-X
premature	B-X
termination	B-X
codons	B-X
can	B-X
occur	B-X
at	B-X
low	B-X
or	B-X
undetectable	B-X
levels	B-X
due	B-X
to	B-X
nonsense	B-X
-	B-X
mediated	B-X
mRNA	B-X
decay	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
the	B-X
levels	B-X
of	B-X
these	B-X
transcripts	B-X
can	B-X
be	B-X
increased	B-X
by	B-X
cycloheximide	B-X
<EOS>	B-X
Based	B-X
on	B-X
our	B-X
recent	B-X
finding	B-X
that	B-X
cycloheximide	B-X
stabilized	B-X
mutant	B-X
COL17A1	B-X
transcripts	B-X
in	B-X
keratinocytes	B-X
homozygous	B-X
for	B-X
a	B-X
frameshift	B-X
mutation	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
on	B-X
splicing	B-X
of	B-X
COL17A1	B-X
transcripts	B-X
were	B-X
determined	B-X
using	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
of	B-X
total	B-X
RNA	B-X
from	B-X
keratinocytes	B-X
incubated	B-X
for	B-X
2	B-X
<EOS>	B-X
Using	B-X
this	B-X
approach	B-X
,	B-X
an	B-X
abnormally	B-X
spliced	B-X
transcript	B-X
was	B-X
identified	B-X
that	B-X
contains	B-X
an	B-X
extra	B-X
264	B-X
bases	B-X
upstream	B-X
from	B-X
exon	B-X
32	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
premature	B-X
termination	B-X
codon	B-X
27	B-X
bp	B-X
downstream	B-X
from	B-X
the	B-X
cryptic	B-X
splice	B-X
site	B-X
<EOS>	B-X
This	B-X
report	B-X
documents	B-X
a	B-X
novel	B-X
splice	B-X
-	B-X
site	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
and	B-X
applies	B-X
a	B-X
new	B-X
methodology	B-X
to	B-X
define	B-X
and	B-X
characterize	B-X
the	B-X
resulting	B-X
mRNA	B-X
splice	B-X
variants	B-X

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O
<EOS>	B-X
A	B-X
deletion	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
represents	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
who	B-X
share	B-X
the	B-X
same	B-X
COL17A1	B-X
mutation	B-X
<EOS>	B-X
Patients	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
a	B-X
usually	B-X
nonlethal	B-X
form	B-X
of	B-X
junctional	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
have	B-X
generalized	B-X
blistering	B-X
,	B-X
nail	B-X
dystrophy	B-X
,	B-X
patchy	B-X
alopecia	B-X
,	B-X
and	B-X
dental	B-X
abnormalities	B-X
<EOS>	B-X
To	B-X
determine	B-X
if	B-X
the	B-X
occurrence	B-X
of	B-X
4003delTC	B-X
in	B-X
these	B-X
unrelated	B-X
families	B-X
signifies	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
or	B-X
a	B-X
mutational	B-X
hot	B-X
spot	B-X
,	B-X
haplotypes	B-X
were	B-X
determined	B-X
for	B-X
polymorphisms	B-X
both	B-X
within	B-X
and	B-X
flanking	B-X
COL17A1	B-X

Patients	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
have	O
generalized	O
blistering	B-Disease
,	O
nail	B-Disease
dystrophy	I-Disease
,	O
patchy	B-Disease
alopecia	I-Disease
,	O
and	O
dental	B-Disease
abnormalities	I-Disease
.	O
<EOS>	B-X
Patients	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
a	B-X
usually	B-X
nonlethal	B-X
form	B-X
of	B-X
junctional	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
have	B-X
generalized	B-X
blistering	B-X
,	B-X
nail	B-X
dystrophy	B-X
,	B-X
patchy	B-X
alopecia	B-X
,	B-X
and	B-X
dental	B-X
abnormalities	B-X
<EOS>	B-X
A	B-X
deletion	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
represents	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
who	B-X
share	B-X
the	B-X
same	B-X
COL17A1	B-X
mutation	B-X
<EOS>	B-X
Affected	B-X
individuals	B-X
in	B-X
three	B-X
families	B-X
are	B-X
homozygous	B-X
for	B-X
4003delTC	B-X
,	B-X
whereas	B-X
those	B-X
in	B-X
two	B-X
others	B-X
are	B-X
compound	B-X
heterozygotes	B-X

Skin	B-Disease
fragility	I-Disease
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O
<EOS>	B-X
Skin	B-X
fragility	B-X
in	B-X
most	B-X
cases	B-X
is	B-X
due	B-X
to	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
type	B-X
XVII	B-X
collagen	B-X
(	B-X
COL17A1	B-X
)	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
cases	B-X
are	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
COL17A1	B-X
gene	B-X
coding	B-X
for	B-X
type	B-X
XVII	B-X
collagen	B-X
(	B-X
or	B-X
the	B-X
180	B-X
kDa	B-X
bullous	B-X
pemphigoid	B-X
antigen	B-X
)	B-X
<EOS>	B-X
Compound	B-X
heterozygosity	B-X
for	B-X
a	B-X
point	B-X
mutation	B-X
and	B-X
a	B-X
deletion	B-X
located	B-X
at	B-X
splice	B-X
acceptor	B-X
sites	B-X
in	B-X
the	B-X
LAMB3	B-X
gene	B-X
leads	B-X
to	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
who	B-X
share	B-X
the	B-X
same	B-X
COL17A1	B-X
mutation	B-X

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B-Disease
benign	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
who	B-X
share	B-X
the	B-X
same	B-X
COL17A1	B-X
mutation	B-X
<EOS>	B-X
A	B-X
deletion	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
represents	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
.	B-X
<EOS>	B-X
Patients	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
a	B-X
usually	B-X
nonlethal	B-X
form	B-X
of	B-X
junctional	B-X
epidermolysis	B-X
bullosa	B-X
,	B-X
have	B-X
generalized	B-X
blistering	B-X
,	B-X
nail	B-X
dystrophy	B-X
,	B-X
patchy	B-X
alopecia	B-X
,	B-X
and	B-X
dental	B-X
abnormalities	B-X
<EOS>	B-X
Skin	B-X
fragility	B-X
in	B-X
most	B-X
cases	B-X
is	B-X
due	B-X
to	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
type	B-X
XVII	B-X
collagen	B-X
(	B-X
COL17A1	B-X
)	B-X

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
.	O
<EOS>	B-X
Affected	B-X
individuals	B-X
in	B-X
three	B-X
families	B-X
are	B-X
homozygous	B-X
for	B-X
4003delTC	B-X
,	B-X
whereas	B-X
those	B-X
in	B-X
two	B-X
others	B-X
are	B-X
compound	B-X
heterozygotes	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
4003delTC	B-X
occurs	B-X
on	B-X
a	B-X
single	B-X
ancestral	B-X
allele	B-X
<EOS>	B-X
A	B-X
deletion	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
represents	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
.	B-X
<EOS>	B-X
Five	B-X
intragenic	B-X
polymorphisms	B-X
were	B-X
chosen	B-X
based	B-X
on	B-X
their	B-X
informativeness	B-X

To	O
determine	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
if	B-X
the	B-X
occurrence	B-X
of	B-X
4003delTC	B-X
in	B-X
these	B-X
unrelated	B-X
families	B-X
signifies	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
or	B-X
a	B-X
mutational	B-X
hot	B-X
spot	B-X
,	B-X
haplotypes	B-X
were	B-X
determined	B-X
for	B-X
polymorphisms	B-X
both	B-X
within	B-X
and	B-X
flanking	B-X
COL17A1	B-X
<EOS>	B-X
A	B-X
deletion	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
represents	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
.	B-X
<EOS>	B-X
Fourteen	B-X
microsatellite	B-X
polymorphisms	B-X
were	B-X
selected	B-X
based	B-X
on	B-X
their	B-X
high	B-X
heterozygosity	B-X
and	B-X
their	B-X
location	B-X
within	B-X
10q23	B-X
-	B-X
q25	B-X
near	B-X
COL17A1	B-X
<EOS>	B-X
All	B-X
the	B-X
4003delTC	B-X
alleles	B-X
showed	B-X
the	B-X
same	B-X
haplotype	B-X
for	B-X
these	B-X
five	B-X
polymorphic	B-X
markers	B-X

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
.	O
<EOS>	B-X
Five	B-X
intragenic	B-X
polymorphisms	B-X
were	B-X
chosen	B-X
based	B-X
on	B-X
their	B-X
informativeness	B-X
<EOS>	B-X
Fourteen	B-X
microsatellite	B-X
polymorphisms	B-X
were	B-X
selected	B-X
based	B-X
on	B-X
their	B-X
high	B-X
heterozygosity	B-X
and	B-X
their	B-X
location	B-X
within	B-X
10q23	B-X
-	B-X
q25	B-X
near	B-X
COL17A1	B-X
<EOS>	B-X
Three	B-X
families	B-X
shared	B-X
microsatellite	B-X
polymorphisms	B-X
covering	B-X
at	B-X
most	B-X
19	B-X
cM	B-X
,	B-X
whereas	B-X
the	B-X
others	B-X
shared	B-X
smaller	B-X
regions	B-X
consistent	B-X
with	B-X
cross	B-X
-	B-X
over	B-X
events	B-X
during	B-X
passage	B-X
of	B-X
this	B-X
mutation	B-X
through	B-X
several	B-X
generations	B-X
<EOS>	B-X
One	B-X
of	B-X
these	B-X
,	B-X
not	B-X
previously	B-X
reported	B-X
,	B-X
was	B-X
2988	B-X
A	B-X
or	B-X
C	B-X
that	B-X
introduces	B-X
a	B-X
new	B-X
restriction	B-X
site	B-X
for	B-X
Eco0109	B-X
I	B-X

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I	O
.	O
<EOS>	B-X
Further	B-X
,	B-X
justice	B-X
perceptions	B-X
predicted	B-X
increased	B-X
reports	B-X
of	B-X
abuse	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
may	B-X
be	B-X
a	B-X
circular	B-X
relationship	B-X
instead	B-X
of	B-X
a	B-X
unidirectional	B-X
one	B-X
<EOS>	B-X
We	B-X
used	B-X
propensity	B-X
score	B-X
matching	B-X
and	B-X
Cox	B-X
hazard	B-X
models	B-X
to	B-X
estimate	B-X
the	B-X
risk	B-X
of	B-X
DME	B-X
<EOS>	B-X
The	B-X
average	B-X
initial	B-X
wound	B-X
size	B-X
was	B-X
not	B-X
statistically	B-X
different	B-X
between	B-X
the	B-X
groups	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
the	B-X
basis	B-X
for	B-X
monitoring	B-X
high	B-X
-	B-X
quality	B-X
nutritional	B-X
nursing	B-X
care	B-X

All	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	O
<EOS>	B-X
All	B-X
the	B-X
4003delTC	B-X
alleles	B-X
showed	B-X
the	B-X
same	B-X
haplotype	B-X
for	B-X
these	B-X
five	B-X
polymorphic	B-X
markers	B-X
<EOS>	B-X
To	B-X
determine	B-X
if	B-X
the	B-X
occurrence	B-X
of	B-X
4003delTC	B-X
in	B-X
these	B-X
unrelated	B-X
families	B-X
signifies	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
or	B-X
a	B-X
mutational	B-X
hot	B-X
spot	B-X
,	B-X
haplotypes	B-X
were	B-X
determined	B-X
for	B-X
polymorphisms	B-X
both	B-X
within	B-X
and	B-X
flanking	B-X
COL17A1	B-X
<EOS>	B-X
Five	B-X
intragenic	B-X
polymorphisms	B-X
were	B-X
chosen	B-X
based	B-X
on	B-X
their	B-X
informativeness	B-X
<EOS>	B-X
Fourteen	B-X
microsatellite	B-X
polymorphisms	B-X
were	B-X
selected	B-X
based	B-X
on	B-X
their	B-X
high	B-X
heterozygosity	B-X
and	B-X
their	B-X
location	B-X
within	B-X
10q23	B-X
-	B-X
q25	B-X
near	B-X
COL17A1	B-X

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
COL17A1	O
.	O
<EOS>	B-X
Fourteen	B-X
microsatellite	B-X
polymorphisms	B-X
were	B-X
selected	B-X
based	B-X
on	B-X
their	B-X
high	B-X
heterozygosity	B-X
and	B-X
their	B-X
location	B-X
within	B-X
10q23	B-X
-	B-X
q25	B-X
near	B-X
COL17A1	B-X
<EOS>	B-X
Five	B-X
intragenic	B-X
polymorphisms	B-X
were	B-X
chosen	B-X
based	B-X
on	B-X
their	B-X
informativeness	B-X
<EOS>	B-X
Three	B-X
families	B-X
shared	B-X
microsatellite	B-X
polymorphisms	B-X
covering	B-X
at	B-X
most	B-X
19	B-X
cM	B-X
,	B-X
whereas	B-X
the	B-X
others	B-X
shared	B-X
smaller	B-X
regions	B-X
consistent	B-X
with	B-X
cross	B-X
-	B-X
over	B-X
events	B-X
during	B-X
passage	B-X
of	B-X
this	B-X
mutation	B-X
through	B-X
several	B-X
generations	B-X
<EOS>	B-X
Skin	B-X
fragility	B-X
in	B-X
most	B-X
cases	B-X
is	B-X
due	B-X
to	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
type	B-X
XVII	B-X
collagen	B-X
(	B-X
COL17A1	B-X
)	B-X

Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
.	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
4003delTC	B-X
occurs	B-X
on	B-X
a	B-X
single	B-X
ancestral	B-X
allele	B-X
<EOS>	B-X
Affected	B-X
individuals	B-X
in	B-X
three	B-X
families	B-X
are	B-X
homozygous	B-X
for	B-X
4003delTC	B-X
,	B-X
whereas	B-X
those	B-X
in	B-X
two	B-X
others	B-X
are	B-X
compound	B-X
heterozygotes	B-X
<EOS>	B-X
A	B-X
deletion	B-X
mutation	B-X
in	B-X
COL17A1	B-X
in	B-X
five	B-X
Austrian	B-X
families	B-X
with	B-X
generalized	B-X
atrophic	B-X
benign	B-X
epidermolysis	B-X
bullosa	B-X
represents	B-X
propagation	B-X
of	B-X
an	B-X
ancestral	B-X
allele	B-X
.	B-X
<EOS>	B-X
Skin	B-X
fragility	B-X
in	B-X
most	B-X
cases	B-X
is	B-X
due	B-X
to	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
type	B-X
XVII	B-X
collagen	B-X
(	B-X
COL17A1	B-X
)	B-X

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B-Disease
.	O
<EOS>	B-X
The	B-X
haptoglobin	B-X
-	B-X
gene	B-X
deletion	B-X
responsible	B-X
for	B-X
anhaptoglobinemia	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
an	B-X
allelic	B-X
deletion	B-X
of	B-X
the	B-X
haptoglobin	B-X
(	B-X
Hp	B-X
)	B-X
gene	B-X
from	B-X
an	B-X
individual	B-X
with	B-X
anhaptoglobinemia	B-X
<EOS>	B-X
The	B-X
haptoglobin	B-X
(	B-X
HP	B-X
)	B-X
gene	B-X
deletion	B-X
allele	B-X
(	B-X
HP	B-X
(	B-X
del	B-X
)	B-X
)	B-X
is	B-X
responsible	B-X
for	B-X
anhaptoglobinemia	B-X
and	B-X
a	B-X
genetic	B-X
risk	B-X
factor	B-X
for	B-X
anaphylaxis	B-X
reaction	B-X
after	B-X
transfusion	B-X
due	B-X
to	B-X
production	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
HP	B-X
antibody	B-X
<EOS>	B-X
The	B-X
present	B-X
result	B-X
suggested	B-X
that	B-X
this	B-X
deletion	B-X
allele	B-X
is	B-X
restricted	B-X
to	B-X
East	B-X
and	B-X
Southeast	B-X
Asians	B-X

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B-Disease
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
an	B-X
allelic	B-X
deletion	B-X
of	B-X
the	B-X
haptoglobin	B-X
(	B-X
Hp	B-X
)	B-X
gene	B-X
from	B-X
an	B-X
individual	B-X
with	B-X
anhaptoglobinemia	B-X
<EOS>	B-X
The	B-X
haptoglobin	B-X
-	B-X
gene	B-X
deletion	B-X
responsible	B-X
for	B-X
anhaptoglobinemia	B-X
.	B-X
<EOS>	B-X
We	B-X
examined	B-X
her	B-X
genetic	B-X
phenotype	B-X
and	B-X
detected	B-X
anhaptoglobinemia	B-X
,	B-X
which	B-X
occurs	B-X
because	B-X
of	B-X
an	B-X
allelic	B-X
deletion	B-X
in	B-X
the	B-X
Hp	B-X
gene	B-X
cluster	B-X
<EOS>	B-X
The	B-X
Hp	B-X
gene	B-X
cluster	B-X
consists	B-X
of	B-X
coding	B-X
regions	B-X
of	B-X
the	B-X
alpha	B-X
chain	B-X
and	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
haptoglobin	B-X
gene	B-X
(	B-X
Hp	B-X
)	B-X
and	B-X
of	B-X
the	B-X
alpha	B-X
chain	B-X
and	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
haptoglobin	B-X
-	B-X
related	B-X
gene	B-X
(	B-X
Hpr	B-X
)	B-X
,	B-X
in	B-X
tandem	B-X
from	B-X
the	B-X
5	B-X
'	B-X
side	B-X

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
5	O
side	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B-Disease
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B-Disease
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
found	B-X
seven	B-X
individuals	B-X
with	B-X
hypohaptoglobinemia	B-X
in	B-X
three	B-X
families	B-X
,	B-X
and	B-X
the	B-X
genotypes	B-X
of	B-X
six	B-X
of	B-X
the	B-X
seven	B-X
individuals	B-X
were	B-X
found	B-X
to	B-X
be	B-X
Hp2	B-X
/	B-X
Hpdel	B-X
<EOS>	B-X
Southern	B-X
blot	B-X
and	B-X
PCR	B-X
analyses	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
individual	B-X
with	B-X
anhaptoglobinemia	B-X
was	B-X
homozygous	B-X
for	B-X
the	B-X
gene	B-X
deletion	B-X
and	B-X
that	B-X
the	B-X
gene	B-X
deletion	B-X
was	B-X
included	B-X
at	B-X
least	B-X
from	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
Hp	B-X
to	B-X
Hpr	B-X
alpha	B-X
but	B-X
not	B-X
to	B-X
Hpr	B-X
beta	B-X
(	B-X
Hpdel	B-X
)	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
an	B-X
allelic	B-X
deletion	B-X
of	B-X
the	B-X
haptoglobin	B-X
(	B-X
Hp	B-X
)	B-X
gene	B-X
from	B-X
an	B-X
individual	B-X
with	B-X
anhaptoglobinemia	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
anhaptoglobinemia	B-X
and	B-X
the	B-X
mechanism	B-X
of	B-X
anomalous	B-X
inheritance	B-X
of	B-X
Hp	B-X
phenotypes	B-X
were	B-X
well	B-X
explained	B-X

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B-Disease
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B-Disease
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O
<EOS>	B-X
The	B-X
phenotypes	B-X
and	B-X
genotypes	B-X
in	B-X
one	B-X
of	B-X
these	B-X
three	B-X
families	B-X
showed	B-X
the	B-X
father	B-X
to	B-X
be	B-X
hypohaptoglobinemic	B-X
(	B-X
Hp2	B-X
)	B-X
and	B-X
Hp2	B-X
/	B-X
Hpdel	B-X
,	B-X
the	B-X
mother	B-X
to	B-X
be	B-X
Hp2	B-X
-	B-X
1	B-X
and	B-X
Hp1	B-X
/	B-X
Hp2	B-X
,	B-X
one	B-X
of	B-X
the	B-X
two	B-X
children	B-X
to	B-X
be	B-X
hypohaptoglobinemic	B-X
(	B-X
Hp2	B-X
)	B-X
and	B-X
Hp2	B-X
/	B-X
Hpdel	B-X
,	B-X
and	B-X
the	B-X
other	B-X
child	B-X
to	B-X
be	B-X
Hp1	B-X
and	B-X
Hp1	B-X
/	B-X
Hpdel	B-X
,	B-X
showing	B-X
an	B-X
anomalous	B-X
inheritance	B-X
of	B-X
Hp	B-X
phenotypes	B-X
in	B-X
the	B-X
child	B-X
with	B-X
Hp1	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
anhaptoglobinemia	B-X
and	B-X
the	B-X
mechanism	B-X
of	B-X
anomalous	B-X
inheritance	B-X
of	B-X
Hp	B-X
phenotypes	B-X
were	B-X
well	B-X
explained	B-X
<EOS>	B-X
The	B-X
Hp	B-X
gene	B-X
cluster	B-X
consists	B-X
of	B-X
coding	B-X
regions	B-X
of	B-X
the	B-X
alpha	B-X
chain	B-X
and	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
haptoglobin	B-X
gene	B-X
(	B-X
Hp	B-X
)	B-X
and	B-X
of	B-X
the	B-X
alpha	B-X
chain	B-X
and	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
haptoglobin	B-X
-	B-X
related	B-X
gene	B-X
(	B-X
Hpr	B-X
)	B-X
,	B-X
in	B-X
tandem	B-X
from	B-X
the	B-X
5	B-X
'	B-X
side	B-X
<EOS>	B-X
Southern	B-X
blot	B-X
and	B-X
PCR	B-X
analyses	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
individual	B-X
with	B-X
anhaptoglobinemia	B-X
was	B-X
homozygous	B-X
for	B-X
the	B-X
gene	B-X
deletion	B-X
and	B-X
that	B-X
the	B-X
gene	B-X
deletion	B-X
was	B-X
included	B-X
at	B-X
least	B-X
from	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
Hp	B-X
to	B-X
Hpr	B-X
alpha	B-X
but	B-X
not	B-X
to	B-X
Hpr	B-X
beta	B-X
(	B-X
Hpdel	B-X
)	B-X

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
other	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B-Disease
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B-Disease
remains	O
unknown	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
hypohaptoglobinemia	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
anhaptoglobinemia	B-X
and	B-X
the	B-X
mechanism	B-X
of	B-X
anomalous	B-X
inheritance	B-X
of	B-X
Hp	B-X
phenotypes	B-X
were	B-X
well	B-X
explained	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
an	B-X
allelic	B-X
deletion	B-X
of	B-X
the	B-X
haptoglobin	B-X
(	B-X
Hp	B-X
)	B-X
gene	B-X
from	B-X
an	B-X
individual	B-X
with	B-X
anhaptoglobinemia	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
found	B-X
seven	B-X
individuals	B-X
with	B-X
hypohaptoglobinemia	B-X
in	B-X
three	B-X
families	B-X
,	B-X
and	B-X
the	B-X
genotypes	B-X
of	B-X
six	B-X
of	B-X
the	B-X
seven	B-X
individuals	B-X
were	B-X
found	B-X
to	B-X
be	B-X
Hp2	B-X
/	B-X
Hpdel	B-X

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B-Disease
,	O
lymphoma	B-Disease
,	O
and	O
breast	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
ATM	B-X
mutations	B-X
and	B-X
phenotypes	B-X
in	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
families	B-X
in	B-X
the	B-X
British	B-X
Isles	B-X
:	B-X
expression	B-X
of	B-X
mutant	B-X
ATM	B-X
and	B-X
the	B-X
risk	B-X
of	B-X
leukemia	B-X
,	B-X
lymphoma	B-X
,	B-X
and	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Of	B-X
51	B-X
ATM	B-X
mutations	B-X
identified	B-X
in	B-X
families	B-X
native	B-X
to	B-X
the	B-X
British	B-X
Isles	B-X
,	B-X
11	B-X
were	B-X
founder	B-X
mutations	B-X
,	B-X
and	B-X
2	B-X
of	B-X
these	B-X
11	B-X
conferred	B-X
a	B-X
milder	B-X
clinical	B-X
phenotype	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
cerebellar	B-X
degeneration	B-X
and	B-X
cellular	B-X
features	B-X
<EOS>	B-X
A	B-X
wide	B-X
variety	B-X
of	B-X
ATM	B-X
mutation	B-X
types	B-X
,	B-X
including	B-X
missense	B-X
mutations	B-X
and	B-X
in	B-X
-	B-X
frame	B-X
deletions	B-X
,	B-X
were	B-X
seen	B-X
in	B-X
these	B-X
patients	B-X
<EOS>	B-X
0025	B-X
)	B-X
,	B-X
although	B-X
there	B-X
is	B-X
a	B-X
less	B-X
severe	B-X
A	B-X
-	B-X
T	B-X
phenotype	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
degree	B-X
of	B-X
cerebellar	B-X
degeneration	B-X

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B-Disease
degeneration	I-Disease
and	O
cellular	O
features	O
.	O

We	O
report	O
,	O
in	O
two	O
A	B-Disease
-	I-Disease
T	I-Disease
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
A	B-Disease
-	I-Disease
T	I-Disease
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B-Disease
degeneration	I-Disease
.	O

This	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O
.	O

In	O
addition	O
,	O
we	O
have	O
studied	O
18	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B-Disease
,	O
lymphoma	B-Disease
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B-Disease
lymphoma	I-Disease
,	O
mostly	O
in	O
childhood	O
.	O
<EOS>	B-X
Delayed	B-X
infection	B-X
hypothesis	B-X
has	B-X
been	B-X
used	B-X
to	B-X
provide	B-X
explanation	B-X
for	B-X
the	B-X
early	B-X
childhood	B-X
peak	B-X
in	B-X
leukemias	B-X
and	B-X
lymphomas	B-X
,	B-X
whereas	B-X
the	B-X
peak	B-X
at	B-X
an	B-X
older	B-X
age	B-X
is	B-X
associated	B-X
with	B-X
accumulation	B-X
of	B-X
protooncogenes	B-X
and	B-X
weakened	B-X
immune	B-X
system	B-X
<EOS>	B-X
Survival	B-X
remained	B-X
stable	B-X
for	B-X
osteosarcomas	B-X
,	B-X
Ewing	B-X
sarcoma	B-X
,	B-X
Burkitt	B-X
lymphoma	B-X
,	B-X
non	B-X
-	B-X
Hodgkin	B-X
lymphomas	B-X
,	B-X
and	B-X
rhabdomyoscarcomas	B-X
<EOS>	B-X
SACCSG	B-X
HL	B-X
-	B-X
2018	B-X
.	B-X
Barriers	B-X
and	B-X
enablers	B-X
of	B-X
a	B-X
harmonized	B-X
treatment	B-X
protocol	B-X
for	B-X
childhood	B-X
and	B-X
adolescent	B-X
Hodgkin	B-X
lymphoma	B-X
in	B-X
South	B-X
Africa	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
HL	B-X
,	B-X
the	B-X
authors	B-X
show	B-X
here	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
survivors	B-X
of	B-X
Wilms	B-X
tumor	B-X
,	B-X
leukemia	B-X
,	B-X
and	B-X
bone	B-X
sarcoma	B-X
are	B-X
at	B-X
risk	B-X
of	B-X
NHL	B-X

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O
<EOS>	B-X
A	B-X
wide	B-X
variety	B-X
of	B-X
ATM	B-X
mutation	B-X
types	B-X
,	B-X
including	B-X
missense	B-X
mutations	B-X
and	B-X
in	B-X
-	B-X
frame	B-X
deletions	B-X
,	B-X
were	B-X
seen	B-X
in	B-X
these	B-X
patients	B-X
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
25	B-X
%	B-X
of	B-X
all	B-X
A	B-X
-	B-X
T	B-X
patients	B-X
carried	B-X
in	B-X
-	B-X
frame	B-X
deletions	B-X
or	B-X
missense	B-X
mutations	B-X
,	B-X
many	B-X
of	B-X
which	B-X
were	B-X
also	B-X
associated	B-X
with	B-X
expression	B-X
of	B-X
mutant	B-X
ATM	B-X
protein	B-X
<EOS>	B-X
We	B-X
report	B-X
,	B-X
in	B-X
two	B-X
A	B-X
-	B-X
T	B-X
families	B-X
,	B-X
an	B-X
ATM	B-X
mutation	B-X
(	B-X
7271T	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
G	B-X
)	B-X
that	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
both	B-X
homozygotes	B-X
and	B-X
heterozygotes	B-X
(	B-X
relative	B-X
risk	B-X
12	B-X
<EOS>	B-X
Of	B-X
51	B-X
ATM	B-X
mutations	B-X
identified	B-X
in	B-X
families	B-X
native	B-X
to	B-X
the	B-X
British	B-X
Isles	B-X
,	B-X
11	B-X
were	B-X
founder	B-X
mutations	B-X
,	B-X
and	B-X
2	B-X
of	B-X
these	B-X
11	B-X
conferred	B-X
a	B-X
milder	B-X
clinical	B-X
phenotype	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
cerebellar	B-X
degeneration	B-X
and	B-X
cellular	B-X
features	B-X

We	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
.	O
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
25	B-X
%	B-X
of	B-X
all	B-X
A	B-X
-	B-X
T	B-X
patients	B-X
carried	B-X
in	B-X
-	B-X
frame	B-X
deletions	B-X
or	B-X
missense	B-X
mutations	B-X
,	B-X
many	B-X
of	B-X
which	B-X
were	B-X
also	B-X
associated	B-X
with	B-X
expression	B-X
of	B-X
mutant	B-X
ATM	B-X
protein	B-X
<EOS>	B-X
A	B-X
wide	B-X
variety	B-X
of	B-X
ATM	B-X
mutation	B-X
types	B-X
,	B-X
including	B-X
missense	B-X
mutations	B-X
and	B-X
in	B-X
-	B-X
frame	B-X
deletions	B-X
,	B-X
were	B-X
seen	B-X
in	B-X
these	B-X
patients	B-X
<EOS>	B-X
Of	B-X
51	B-X
ATM	B-X
mutations	B-X
identified	B-X
in	B-X
families	B-X
native	B-X
to	B-X
the	B-X
British	B-X
Isles	B-X
,	B-X
11	B-X
were	B-X
founder	B-X
mutations	B-X
,	B-X
and	B-X
2	B-X
of	B-X
these	B-X
11	B-X
conferred	B-X
a	B-X
milder	B-X
clinical	B-X
phenotype	B-X
with	B-X
respect	B-X
to	B-X
both	B-X
cerebellar	B-X
degeneration	B-X
and	B-X
cellular	B-X
features	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
spectrum	B-X
of	B-X
59	B-X
ATM	B-X
mutations	B-X
observed	B-X
in	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
A	B-X
-	B-X
T	B-X
)	B-X
patients	B-X
in	B-X
the	B-X
British	B-X
Isles	B-X

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B-Disease
dystrophy	I-Disease
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
showing	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O
<EOS>	B-X
Using	B-X
methylation	B-X
-	B-X
sensitive	B-X
restriction	B-X
enzymes	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
methylation	B-X
pattern	B-X
on	B-X
the	B-X
5	B-X
'	B-X
side	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
the	B-X
DMPK	B-X
gene	B-X
of	B-X
normal	B-X
individuals	B-X
and	B-X
of	B-X
patients	B-X
affected	B-X
with	B-X
myotonic	B-X
dystrophy	B-X
,	B-X
showing	B-X
expansions	B-X
of	B-X
the	B-X
repetitive	B-X
sequence	B-X
<EOS>	B-X
There	B-X
is	B-X
constitutive	B-X
methylation	B-X
in	B-X
intron	B-X
12	B-X
at	B-X
restriction	B-X
sites	B-X
of	B-X
SacII	B-X
and	B-X
HhaI	B-X
,	B-X
localized	B-X
1,159	B-X
-	B-X
1,232	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
,	B-X
whereas	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
other	B-X
sites	B-X
of	B-X
SacII	B-X
,	B-X
HhaI	B-X
,	B-X
and	B-X
HpaII	B-X
in	B-X
this	B-X
region	B-X
are	B-X
unmethylated	B-X
,	B-X
in	B-X
normal	B-X
individuals	B-X
and	B-X
most	B-X
of	B-X
the	B-X
patients	B-X
<EOS>	B-X
In	B-X
a	B-X
number	B-X
of	B-X
young	B-X
and	B-X
severely	B-X
affected	B-X
patients	B-X
,	B-X
however	B-X
,	B-X
complete	B-X
methylation	B-X
of	B-X
these	B-X
restriction	B-X
sites	B-X
was	B-X
found	B-X
in	B-X
the	B-X
mutated	B-X
allele	B-X
<EOS>	B-X
The	B-X
DMPK	B-X
gene	B-X
of	B-X
severely	B-X
affected	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
is	B-X
hypermethylated	B-X
proximal	B-X
to	B-X
the	B-X
largely	B-X
expanded	B-X
CTG	B-X
repeat	B-X
.	B-X

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
.	O
<EOS>	B-X
There	B-X
is	B-X
constitutive	B-X
methylation	B-X
in	B-X
intron	B-X
12	B-X
at	B-X
restriction	B-X
sites	B-X
of	B-X
SacII	B-X
and	B-X
HhaI	B-X
,	B-X
localized	B-X
1,159	B-X
-	B-X
1,232	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
,	B-X
whereas	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
other	B-X
sites	B-X
of	B-X
SacII	B-X
,	B-X
HhaI	B-X
,	B-X
and	B-X
HpaII	B-X
in	B-X
this	B-X
region	B-X
are	B-X
unmethylated	B-X
,	B-X
in	B-X
normal	B-X
individuals	B-X
and	B-X
most	B-X
of	B-X
the	B-X
patients	B-X
<EOS>	B-X
Using	B-X
methylation	B-X
-	B-X
sensitive	B-X
restriction	B-X
enzymes	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
methylation	B-X
pattern	B-X
on	B-X
the	B-X
5	B-X
'	B-X
side	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
the	B-X
DMPK	B-X
gene	B-X
of	B-X
normal	B-X
individuals	B-X
and	B-X
of	B-X
patients	B-X
affected	B-X
with	B-X
myotonic	B-X
dystrophy	B-X
,	B-X
showing	B-X
expansions	B-X
of	B-X
the	B-X
repetitive	B-X
sequence	B-X
<EOS>	B-X
Preliminary	B-X
in	B-X
vivo	B-X
footprinting	B-X
data	B-X
gave	B-X
evidence	B-X
for	B-X
protein	B-X
-	B-X
DNA	B-X
contact	B-X
in	B-X
normal	B-X
genes	B-X
at	B-X
an	B-X
Sp1	B-X
consensus	B-X
binding	B-X
site	B-X
upstream	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
and	B-X
for	B-X
a	B-X
significant	B-X
reduction	B-X
of	B-X
this	B-X
interaction	B-X
in	B-X
cells	B-X
with	B-X
a	B-X
hypermethylated	B-X
DMPK	B-X
gene	B-X
<EOS>	B-X
In	B-X
a	B-X
number	B-X
of	B-X
young	B-X
and	B-X
severely	B-X
affected	B-X
patients	B-X
,	B-X
however	B-X
,	B-X
complete	B-X
methylation	B-X
of	B-X
these	B-X
restriction	B-X
sites	B-X
was	B-X
found	B-X
in	B-X
the	B-X
mutated	B-X
allele	B-X

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
.	O
.	O
<EOS>	B-X
Preliminary	B-X
in	B-X
vivo	B-X
footprinting	B-X
data	B-X
gave	B-X
evidence	B-X
for	B-X
protein	B-X
-	B-X
DNA	B-X
contact	B-X
in	B-X
normal	B-X
genes	B-X
at	B-X
an	B-X
Sp1	B-X
consensus	B-X
binding	B-X
site	B-X
upstream	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
and	B-X
for	B-X
a	B-X
significant	B-X
reduction	B-X
of	B-X
this	B-X
interaction	B-X
in	B-X
cells	B-X
with	B-X
a	B-X
hypermethylated	B-X
DMPK	B-X
gene	B-X
<EOS>	B-X
In	B-X
a	B-X
number	B-X
of	B-X
young	B-X
and	B-X
severely	B-X
affected	B-X
patients	B-X
,	B-X
however	B-X
,	B-X
complete	B-X
methylation	B-X
of	B-X
these	B-X
restriction	B-X
sites	B-X
was	B-X
found	B-X
in	B-X
the	B-X
mutated	B-X
allele	B-X
<EOS>	B-X
There	B-X
is	B-X
constitutive	B-X
methylation	B-X
in	B-X
intron	B-X
12	B-X
at	B-X
restriction	B-X
sites	B-X
of	B-X
SacII	B-X
and	B-X
HhaI	B-X
,	B-X
localized	B-X
1,159	B-X
-	B-X
1,232	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
,	B-X
whereas	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
other	B-X
sites	B-X
of	B-X
SacII	B-X
,	B-X
HhaI	B-X
,	B-X
and	B-X
HpaII	B-X
in	B-X
this	B-X
region	B-X
are	B-X
unmethylated	B-X
,	B-X
in	B-X
normal	B-X
individuals	B-X
and	B-X
most	B-X
of	B-X
the	B-X
patients	B-X
<EOS>	B-X
The	B-X
DMPK	B-X
gene	B-X
of	B-X
severely	B-X
affected	B-X
myotonic	B-X
dystrophy	B-X
patients	B-X
is	B-X
hypermethylated	B-X
proximal	B-X
to	B-X
the	B-X
largely	B-X
expanded	B-X
CTG	B-X
repeat	B-X
.	B-X

The	O
hemochromatosis	B-Disease
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O
<EOS>	B-X
The	B-X
hemochromatosis	B-X
gene	B-X
product	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
and	B-X
lowers	B-X
its	B-X
affinity	B-X
for	B-X
ligand	B-X
binding	B-X
.	B-X
<EOS>	B-X
HFE	B-X
and	B-X
transferrin	B-X
directly	B-X
compete	B-X
for	B-X
transferrin	B-X
receptor	B-X
in	B-X
solution	B-X
and	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
<EOS>	B-X
Studies	B-X
on	B-X
cell	B-X
-	B-X
associated	B-X
transferrin	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
suggest	B-X
that	B-X
the	B-X
overexpressed	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
protein	B-X
decreases	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
,	B-X
the	B-X
added	B-X
soluble	B-X
complex	B-X
of	B-X
HFE	B-X
/	B-X
beta2m	B-X
inhibited	B-X
binding	B-X
of	B-X
transferrin	B-X
to	B-X
HeLa	B-X
cell	B-X
TfR	B-X
in	B-X
a	B-X
concentration	B-X
-	B-X
dependent	B-X
manner	B-X

We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B-Disease
hemochromatosis	I-Disease
called	O
HFE	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
the	B-X
positional	B-X
cloning	B-X
of	B-X
a	B-X
candidate	B-X
gene	B-X
for	B-X
hereditary	B-X
hemochromatosis	B-X
called	B-X
HFE	B-X
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
the	B-X
positional	B-X
cloning	B-X
of	B-X
a	B-X
candidate	B-X
gene	B-X
for	B-X
hereditary	B-X
hemochromatosis	B-X
(	B-X
HH	B-X
)	B-X
,	B-X
called	B-X
HLA	B-X
-	B-X
H	B-X
,	B-X
which	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
family	B-X
<EOS>	B-X
The	B-X
overexpressed	B-X
H63D	B-X
protein	B-X
does	B-X
not	B-X
have	B-X
this	B-X
effect	B-X
,	B-X
providing	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
for	B-X
a	B-X
functional	B-X
consequence	B-X
of	B-X
the	B-X
H63D	B-X
mutation	B-X
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
the	B-X
first	B-X
functional	B-X
significance	B-X
of	B-X
the	B-X
C282Y	B-X
mutation	B-X
by	B-X
suggesting	B-X
that	B-X
an	B-X
abnormality	B-X
in	B-X
protein	B-X
trafficking	B-X
and	B-X
/	B-X
or	B-X
cell	B-X
-	B-X
surface	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
H	B-X
leads	B-X
to	B-X
HH	B-X
disease	B-X

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O
<EOS>	B-X
This	B-X
mutation	B-X
eliminates	B-X
the	B-X
ability	B-X
of	B-X
HFE	B-X
to	B-X
associate	B-X
with	B-X
beta2	B-X
-	B-X
microglobulin	B-X
(	B-X
beta2m	B-X
)	B-X
and	B-X
prevents	B-X
cell	B-X
-	B-X
surface	B-X
expression	B-X
<EOS>	B-X
A	B-X
second	B-X
mutation	B-X
that	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
beta2m	B-X
association	B-X
,	B-X
H63D	B-X
,	B-X
was	B-X
found	B-X
in	B-X
eight	B-X
out	B-X
of	B-X
nine	B-X
patients	B-X
heterozygous	B-X
for	B-X
the	B-X
C282Y	B-X
mutant	B-X
<EOS>	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
molecular	B-X
link	B-X
between	B-X
HFE	B-X
and	B-X
a	B-X
key	B-X
protein	B-X
involved	B-X
in	B-X
iron	B-X
transport	B-X
,	B-X
the	B-X
TfR	B-X
,	B-X
and	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
alterations	B-X
in	B-X
this	B-X
regulatory	B-X
mechanism	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
hereditary	B-X
hemochromatosis	B-X
<EOS>	B-X
The	B-X
hemochromatosis	B-X
gene	B-X
product	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
and	B-X
lowers	B-X
its	B-X
affinity	B-X
for	B-X
ligand	B-X
binding	B-X
.	B-X

A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O
<EOS>	B-X
A	B-X
second	B-X
mutation	B-X
that	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
beta2m	B-X
association	B-X
,	B-X
H63D	B-X
,	B-X
was	B-X
found	B-X
in	B-X
eight	B-X
out	B-X
of	B-X
nine	B-X
patients	B-X
heterozygous	B-X
for	B-X
the	B-X
C282Y	B-X
mutant	B-X
<EOS>	B-X
This	B-X
mutation	B-X
eliminates	B-X
the	B-X
ability	B-X
of	B-X
HFE	B-X
to	B-X
associate	B-X
with	B-X
beta2	B-X
-	B-X
microglobulin	B-X
(	B-X
beta2m	B-X
)	B-X
and	B-X
prevents	B-X
cell	B-X
-	B-X
surface	B-X
expression	B-X
<EOS>	B-X
The	B-X
C282Y	B-X
mutation	B-X
nearly	B-X
completely	B-X
prevents	B-X
the	B-X
association	B-X
of	B-X
the	B-X
mutant	B-X
HFE	B-X
protein	B-X
with	B-X
the	B-X
TfR	B-X
<EOS>	B-X
These	B-X
results	B-X
establish	B-X
a	B-X
molecular	B-X
link	B-X
between	B-X
HFE	B-X
and	B-X
a	B-X
key	B-X
protein	B-X
involved	B-X
in	B-X
iron	B-X
transport	B-X
,	B-X
the	B-X
TfR	B-X
,	B-X
and	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
alterations	B-X
in	B-X
this	B-X
regulatory	B-X
mechanism	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
hereditary	B-X
hemochromatosis	B-X

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
cultured	B-X
293	B-X
cells	B-X
overexpressing	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
mutant	B-X
HFE	B-X
proteins	B-X
that	B-X
both	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
and	B-X
H63D	B-X
HFE	B-X
proteins	B-X
form	B-X
stable	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
(	B-X
TfR	B-X
)	B-X
<EOS>	B-X
Studies	B-X
on	B-X
cell	B-X
-	B-X
associated	B-X
transferrin	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
suggest	B-X
that	B-X
the	B-X
overexpressed	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
protein	B-X
decreases	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
All	B-X
three	B-X
methods	B-X
demonstrated	B-X
predominant	B-X
plasma	B-X
membrane	B-X
localization	B-X
of	B-X
both	B-X
V174A	B-X
-	B-X
	B-X
and	B-X
WT	B-X
-	B-X
OATP1B1	B-X
in	B-X
human	B-X
liver	B-X
tissue	B-X
and	B-X
in	B-X
cell	B-X
culture	B-X
<EOS>	B-X
The	B-X
studies	B-X
presented	B-X
here	B-X
serve	B-X
to	B-X
underscore	B-X
the	B-X
importance	B-X
of	B-X
amino	B-X
-	B-X
acid	B-X
482	B-X
in	B-X
defining	B-X
the	B-X
substrate	B-X
specificity	B-X
of	B-X
the	B-X
ABCG2	B-X
protein	B-X
and	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
amino	B-X
-	B-X
acid	B-X
482	B-X
mutations	B-X
in	B-X
human	B-X
cancers	B-X
could	B-X
affect	B-X
the	B-X
clinical	B-X
application	B-X
of	B-X
antagonists	B-X
for	B-X
ABCG2	B-X

The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O
<EOS>	B-X
The	B-X
C282Y	B-X
mutation	B-X
nearly	B-X
completely	B-X
prevents	B-X
the	B-X
association	B-X
of	B-X
the	B-X
mutant	B-X
HFE	B-X
protein	B-X
with	B-X
the	B-X
TfR	B-X
<EOS>	B-X
A	B-X
second	B-X
mutation	B-X
that	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
beta2m	B-X
association	B-X
,	B-X
H63D	B-X
,	B-X
was	B-X
found	B-X
in	B-X
eight	B-X
out	B-X
of	B-X
nine	B-X
patients	B-X
heterozygous	B-X
for	B-X
the	B-X
C282Y	B-X
mutant	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
cultured	B-X
293	B-X
cells	B-X
overexpressing	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
mutant	B-X
HFE	B-X
proteins	B-X
that	B-X
both	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
and	B-X
H63D	B-X
HFE	B-X
proteins	B-X
form	B-X
stable	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
(	B-X
TfR	B-X
)	B-X
<EOS>	B-X
The	B-X
gene	B-X
product	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
-	B-X
like	B-X
family	B-X
,	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
mutation	B-X
,	B-X
Cys	B-X
-	B-X
282	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Tyr	B-X
(	B-X
C282Y	B-X
)	B-X
,	B-X
in	B-X
85	B-X
%	B-X
of	B-X
patient	B-X
chromosomes	B-X

Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
transferrin	O
.	O
<EOS>	B-X
Studies	B-X
on	B-X
cell	B-X
-	B-X
associated	B-X
transferrin	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
suggest	B-X
that	B-X
the	B-X
overexpressed	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
protein	B-X
decreases	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
Scatchard	B-X
plots	B-X
of	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
added	B-X
heterodimer	B-X
substantially	B-X
reduced	B-X
the	B-X
affinity	B-X
of	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
The	B-X
hemochromatosis	B-X
gene	B-X
product	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
and	B-X
lowers	B-X
its	B-X
affinity	B-X
for	B-X
ligand	B-X
binding	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
cultured	B-X
293	B-X
cells	B-X
overexpressing	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
mutant	B-X
HFE	B-X
proteins	B-X
that	B-X
both	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
and	B-X
H63D	B-X
HFE	B-X
proteins	B-X
form	B-X
stable	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
(	B-X
TfR	B-X
)	B-X

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O
<EOS>	B-X
In	B-X
the	B-X
current	B-X
work	B-X
,	B-X
we	B-X
have	B-X
used	B-X
HeLa	B-X
cells	B-X
carrying	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
Q283P	B-X
-	B-X
mutant	B-X
HFE	B-X
cDNA	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
tetracycline	B-X
-	B-X
sensitive	B-X
promoter	B-X
to	B-X
functionally	B-X
characterise	B-X
the	B-X
Q283P	B-X
mutation	B-X
<EOS>	B-X
Several	B-X
studies	B-X
have	B-X
now	B-X
shown	B-X
that	B-X
iron	B-X
overload	B-X
phenotypes	B-X
in	B-X
such	B-X
patients	B-X
can	B-X
be	B-X
associated	B-X
with	B-X
uncommon	B-X
HFE	B-X
mutations	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
283P	B-X
HFE	B-X
protein	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
limited	B-X
effect	B-X
on	B-X
the	B-X
major	B-X
cellular	B-X
iron	B-X
uptake	B-X
pathway	B-X
<EOS>	B-X
However	B-X
,	B-X
superdonors	B-X
heterozygous	B-X
for	B-X
the	B-X
H63D	B-X
mutation	B-X
in	B-X
HFE	B-X
had	B-X
significantly	B-X
decreased	B-X
hepcidin	B-X
:	B-X
ferritin	B-X
ratios	B-X
demonstrating	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
the	B-X
heterozygous	B-X
state	B-X
for	B-X
HFE	B-X
mutations	B-X
is	B-X
associated	B-X
with	B-X
alterations	B-X
in	B-X
hepcidin	B-X
expression	B-X

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells	O
.	O
<EOS>	B-X
Addition	B-X
of	B-X
soluble	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
/	B-X
beta2m	B-X
heterodimers	B-X
to	B-X
cultured	B-X
cells	B-X
also	B-X
decreased	B-X
the	B-X
apparent	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
its	B-X
ligand	B-X
under	B-X
steady	B-X
-	B-X
state	B-X
conditions	B-X
,	B-X
both	B-X
in	B-X
293	B-X
cells	B-X
and	B-X
in	B-X
HeLa	B-X
cells	B-X
<EOS>	B-X
Scatchard	B-X
plots	B-X
of	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
added	B-X
heterodimer	B-X
substantially	B-X
reduced	B-X
the	B-X
affinity	B-X
of	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
Studies	B-X
on	B-X
cell	B-X
-	B-X
associated	B-X
transferrin	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
suggest	B-X
that	B-X
the	B-X
overexpressed	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
protein	B-X
decreases	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
The	B-X
hemochromatosis	B-X
gene	B-X
product	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
and	B-X
lowers	B-X
its	B-X
affinity	B-X
for	B-X
ligand	B-X
binding	B-X
.	B-X

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O
<EOS>	B-X
Scatchard	B-X
plots	B-X
of	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
added	B-X
heterodimer	B-X
substantially	B-X
reduced	B-X
the	B-X
affinity	B-X
of	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
Studies	B-X
on	B-X
cell	B-X
-	B-X
associated	B-X
transferrin	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
suggest	B-X
that	B-X
the	B-X
overexpressed	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
protein	B-X
decreases	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
transferrin	B-X
<EOS>	B-X
The	B-X
hemochromatosis	B-X
gene	B-X
product	B-X
complexes	B-X
with	B-X
the	B-X
transferrin	B-X
receptor	B-X
and	B-X
lowers	B-X
its	B-X
affinity	B-X
for	B-X
ligand	B-X
binding	B-X
.	B-X
<EOS>	B-X
Addition	B-X
of	B-X
soluble	B-X
wild	B-X
-	B-X
type	B-X
HFE	B-X
/	B-X
beta2m	B-X
heterodimers	B-X
to	B-X
cultured	B-X
cells	B-X
also	B-X
decreased	B-X
the	B-X
apparent	B-X
affinity	B-X
of	B-X
the	B-X
TfR	B-X
for	B-X
its	B-X
ligand	B-X
under	B-X
steady	B-X
-	B-X
state	B-X
conditions	B-X
,	B-X
both	B-X
in	B-X
293	B-X
cells	B-X
and	B-X
in	B-X
HeLa	B-X
cells	B-X

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
.	O
.	O

Genomic	O
organization	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O
<EOS>	B-X
Genomic	B-X
organization	B-X
of	B-X
the	B-X
UBE3A	B-X
/	B-X
E6	B-X
-	B-X
AP	B-X
gene	B-X
and	B-X
related	B-X
pseudogenes	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
established	B-X
the	B-X
genomic	B-X
organization	B-X
of	B-X
UBE3A	B-X
and	B-X
the	B-X
sequence	B-X
of	B-X
intron	B-X
-	B-X
exon	B-X
borders	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
mapped	B-X
two	B-X
highly	B-X
homologous	B-X
processed	B-X
pseudogenes	B-X
,	B-X
UBE3AP1	B-X
and	B-X
UBE3AP2	B-X
,	B-X
to	B-X
chromosomes	B-X
2	B-X
and	B-X
21	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
determined	B-X
their	B-X
genomic	B-X
organization	B-X
<EOS>	B-X
6	B-X
kb	B-X
and	B-X
a	B-X
3'	B-X
-	B-X
untranslated	B-X
region	B-X
(	B-X
UTR	B-X
)	B-X
of	B-X
<	B-X
50	B-X
bp	B-X
,	B-X
whereas	B-X
Northern	B-X
analysis	B-X
has	B-X
indicated	B-X
mRNA	B-X
sizes	B-X
of	B-X
5	B-X
-	B-X
8	B-X
kb	B-X

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B-Disease
syndrome	I-Disease
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B-Disease
disomy	I-Disease
.	O
<EOS>	B-X
This	B-X
study	B-X
included	B-X
134	B-X
patients	B-X
with	B-X
PWS	B-X
(	B-X
115	B-X
patients	B-X
with	B-X
15q11	B-X
-	B-X
q13	B-X
deletion	B-X
and	B-X
19	B-X
with	B-X
maternal	B-X
uniparental	B-X
disomy	B-X
)	B-X
<EOS>	B-X
Blended	B-X
phenotype	B-X
of	B-X
combination	B-X
of	B-X
HERC2	B-X
and	B-X
AP3B2	B-X
deficiency	B-X
and	B-X
Angelman	B-X
syndrome	B-X
caused	B-X
by	B-X
paternal	B-X
isodisomy	B-X
of	B-X
chromosome	B-X
15	B-X
.	B-X
<EOS>	B-X
We	B-X
successfully	B-X
diagnosed	B-X
4	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
patients	B-X
and	B-X
3	B-X
Angelman	B-X
syndrome	B-X
patients	B-X
by	B-X
targeting	B-X
differentially	B-X
methylated	B-X
regions	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
first	B-X
prenatal	B-X
case	B-X
of	B-X
paternal	B-X
isodisomy	B-X
for	B-X
chromosome	B-X
14	B-X
associated	B-X
with	B-X
a	B-X
de	B-X
novo	B-X
SSMC	B-X
originating	B-X
from	B-X
chromosome	B-X
15	B-X
and	B-X
revealed	B-X
by	B-X
KOS	B-X

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O
.	O
<EOS>	B-X
Previous	B-X
UBE3A	B-X
cDNA	B-X
analysis	B-X
has	B-X
shown	B-X
a	B-X
coding	B-X
region	B-X
of	B-X
approximately	B-X
2	B-X
<EOS>	B-X
These	B-X
results	B-X
will	B-X
form	B-X
the	B-X
basis	B-X
for	B-X
studies	B-X
of	B-X
mutation	B-X
and	B-X
imprinting	B-X
of	B-X
UBE3A	B-X
<EOS>	B-X
We	B-X
have	B-X
analyzed	B-X
additional	B-X
cDNA	B-X
clones	B-X
and	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
0	B-X
<EOS>	B-X
The	B-X
UBE3A	B-X
gene	B-X
encodes	B-X
the	B-X
E6	B-X
-	B-X
AP	B-X
ubiquitin	B-X
-	B-X
protein	B-X
ligase	B-X
and	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mutated	B-X
in	B-X
Angelman	B-X
syndrome	B-X
patients	B-X
who	B-X
lack	B-X
15q11	B-X
-	B-X
q13	B-X
deletions	B-X
or	B-X
chromosome	B-X
15	B-X
paternal	B-X
uniparental	B-X
disomy	B-X

6	O
kb	O
and	O
a	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O

5	O
kb	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kb	O
of	O
3	O
-	O
UTR	O
.	O
<EOS>	B-X
3	B-X
kb	B-X
in	B-X
length	B-X
flanked	B-X
by	B-X
untranslated	B-X
regions	B-X
at	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
end	B-X
<EOS>	B-X
The	B-X
HCV	B-X
5	B-X
'	B-X
UTR	B-X
was	B-X
sequenced	B-X
using	B-X
the	B-X
Sanger	B-X
method	B-X
<EOS>	B-X
6	B-X
kb	B-X
genome	B-X
,	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
causes	B-X
of	B-X
liver	B-X
diseases	B-X
<EOS>	B-X
This	B-X
could	B-X
lead	B-X
to	B-X
new	B-X
treatments	B-X
for	B-X
viruses	B-X
like	B-X
PRRSV	B-X

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O
<EOS>	B-X
We	B-X
have	B-X
established	B-X
the	B-X
genomic	B-X
organization	B-X
of	B-X
UBE3A	B-X
and	B-X
the	B-X
sequence	B-X
of	B-X
intron	B-X
-	B-X
exon	B-X
borders	B-X
<EOS>	B-X
Genomic	B-X
organization	B-X
of	B-X
the	B-X
UBE3A	B-X
/	B-X
E6	B-X
-	B-X
AP	B-X
gene	B-X
and	B-X
related	B-X
pseudogenes	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
analyzed	B-X
additional	B-X
cDNA	B-X
clones	B-X
and	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
0	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
mapped	B-X
two	B-X
highly	B-X
homologous	B-X
processed	B-X
pseudogenes	B-X
,	B-X
UBE3AP1	B-X
and	B-X
UBE3AP2	B-X
,	B-X
to	B-X
chromosomes	B-X
2	B-X
and	B-X
21	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
determined	B-X
their	B-X
genomic	B-X
organization	B-X

We	O
have	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O
<EOS>	B-X
We	B-X
have	B-X
also	B-X
mapped	B-X
two	B-X
highly	B-X
homologous	B-X
processed	B-X
pseudogenes	B-X
,	B-X
UBE3AP1	B-X
and	B-X
UBE3AP2	B-X
,	B-X
to	B-X
chromosomes	B-X
2	B-X
and	B-X
21	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
determined	B-X
their	B-X
genomic	B-X
organization	B-X
<EOS>	B-X
We	B-X
have	B-X
established	B-X
the	B-X
genomic	B-X
organization	B-X
of	B-X
UBE3A	B-X
and	B-X
the	B-X
sequence	B-X
of	B-X
intron	B-X
-	B-X
exon	B-X
borders	B-X
<EOS>	B-X
We	B-X
have	B-X
analyzed	B-X
additional	B-X
cDNA	B-X
clones	B-X
and	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
0	B-X
<EOS>	B-X
Genomic	B-X
organization	B-X
of	B-X
the	B-X
UBE3A	B-X
/	B-X
E6	B-X
-	B-X
AP	B-X
gene	B-X
and	B-X
related	B-X
pseudogenes	B-X
.	B-X

These	O
results	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O
<EOS>	B-X
These	B-X
results	B-X
will	B-X
form	B-X
the	B-X
basis	B-X
for	B-X
studies	B-X
of	B-X
mutation	B-X
and	B-X
imprinting	B-X
of	B-X
UBE3A	B-X
<EOS>	B-X
We	B-X
have	B-X
established	B-X
the	B-X
genomic	B-X
organization	B-X
of	B-X
UBE3A	B-X
and	B-X
the	B-X
sequence	B-X
of	B-X
intron	B-X
-	B-X
exon	B-X
borders	B-X
<EOS>	B-X
Previous	B-X
UBE3A	B-X
cDNA	B-X
analysis	B-X
has	B-X
shown	B-X
a	B-X
coding	B-X
region	B-X
of	B-X
approximately	B-X
2	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
mapped	B-X
two	B-X
highly	B-X
homologous	B-X
processed	B-X
pseudogenes	B-X
,	B-X
UBE3AP1	B-X
and	B-X
UBE3AP2	B-X
,	B-X
to	B-X
chromosomes	B-X
2	B-X
and	B-X
21	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
determined	B-X
their	B-X
genomic	B-X
organization	B-X

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B-Disease
disease	I-Disease
and	O
Bannayan	B-Disease
-	I-Disease
Zonana	I-Disease
syndrome	I-Disease
,	O
two	O
hamartoma	B-Disease
syndromes	I-Disease
with	O
germline	O
PTEN	O
mutation	O
.	O
<EOS>	B-X
Mutation	B-X
spectrum	B-X
and	B-X
genotype	B-X
-	B-X
phenotype	B-X
analyses	B-X
in	B-X
Cowden	B-X
disease	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
syndrome	B-X
,	B-X
two	B-X
hamartoma	B-X
syndromes	B-X
with	B-X
germline	B-X
PTEN	B-X
mutation	B-X
.	B-X
<EOS>	B-X
PTEN	B-X
mutation	B-X
spectrum	B-X
and	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
Bannayan	B-X
-	B-X
Riley	B-X
-	B-X
Ruvalcaba	B-X
syndrome	B-X
suggest	B-X
a	B-X
single	B-X
entity	B-X
with	B-X
Cowden	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Constitutive	B-X
DNA	B-X
from	B-X
37	B-X
CD	B-X
families	B-X
and	B-X
seven	B-X
BZS	B-X
families	B-X
was	B-X
screened	B-X
for	B-X
germline	B-X
PTEN	B-X
mutations	B-X
<EOS>	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
30	B-X
of	B-X
37	B-X
(	B-X
81	B-X
%	B-X
)	B-X
CD	B-X
families	B-X
,	B-X
including	B-X
missense	B-X
and	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
a	B-X
deletion	B-X
/	B-X
insertion	B-X
and	B-X
splice	B-X
site	B-X
mutations	B-X

The	O
tumour	B-Disease
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O
<EOS>	B-X
The	B-X
tumour	B-X
suppressor	B-X
gene	B-X
PTEN	B-X
,	B-X
which	B-X
maps	B-X
to	B-X
10q23	B-X
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
PTEN	B-X
gene	B-X
maps	B-X
to	B-X
chromosome	B-X
10q23	B-X
<EOS>	B-X
The	B-X
PTEN	B-X
/	B-X
MMAC1	B-X
/	B-X
TEP1	B-X
tumor	B-X
-	B-X
suppressor	B-X
gene	B-X
,	B-X
which	B-X
maps	B-X
to	B-X
chromosome	B-X
10q23	B-X
<EOS>	B-X
The	B-X
CS	B-X
gene	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X
as	B-X
PTEN	B-X
,	B-X
which	B-X
maps	B-X
at	B-X
10q23	B-X

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B-Disease
.	O
<EOS>	B-X
3	B-X
and	B-X
encodes	B-X
a	B-X
403	B-X
amino	B-X
acid	B-X
dual	B-X
specificity	B-X
phosphatase	B-X
(	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
;	B-X
PTPase	B-X
)	B-X
,	B-X
was	B-X
shown	B-X
recently	B-X
to	B-X
play	B-X
a	B-X
broad	B-X
role	B-X
in	B-X
human	B-X
malignancy	B-X
<EOS>	B-X
These	B-X
mutations	B-X
were	B-X
scattered	B-X
over	B-X
the	B-X
entire	B-X
length	B-X
of	B-X
PTEN	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
first	B-X
,	B-X
fourth	B-X
and	B-X
last	B-X
exons	B-X
<EOS>	B-X
Somatic	B-X
PTEN	B-X
deletions	B-X
and	B-X
mutations	B-X
were	B-X
observed	B-X
in	B-X
sporadic	B-X
breast	B-X
,	B-X
brain	B-X
,	B-X
prostate	B-X
and	B-X
kidney	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
in	B-X
several	B-X
primary	B-X
tumours	B-X
such	B-X
as	B-X
endometrial	B-X
carcinomas	B-X
,	B-X
malignant	B-X
melanoma	B-X
and	B-X
thyroid	B-X
tumours	B-X
<EOS>	B-X
Secondly	B-X
,	B-X
there	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
interdependent	B-X
association	B-X
between	B-X
mutations	B-X
upstream	B-X
and	B-X
within	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
core	B-X
motif	B-X
containing	B-X
the	B-X
majority	B-X
of	B-X
missense	B-X
mutations	B-X
,	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
all	B-X
major	B-X
organ	B-X
systems	B-X
(	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
thyroid	B-X
,	B-X
breast	B-X
,	B-X
skin	B-X
and	B-X
gastrointestinal	B-X
tract	B-X
)	B-X

Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B-Disease
breast	I-Disease
,	I-Disease
brain	I-Disease
,	I-Disease
prostate	I-Disease
and	I-Disease
kidney	I-Disease
cancer	I-Disease
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B-Disease
such	O
as	O
endometrial	B-Disease
carcinomas	I-Disease
,	O
malignant	B-Disease
melanoma	I-Disease
and	O
thyroid	B-Disease
tumours	I-Disease
.	O
<EOS>	B-X
Somatic	B-X
PTEN	B-X
deletions	B-X
and	B-X
mutations	B-X
were	B-X
observed	B-X
in	B-X
sporadic	B-X
breast	B-X
,	B-X
brain	B-X
,	B-X
prostate	B-X
and	B-X
kidney	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
in	B-X
several	B-X
primary	B-X
tumours	B-X
such	B-X
as	B-X
endometrial	B-X
carcinomas	B-X
,	B-X
malignant	B-X
melanoma	B-X
and	B-X
thyroid	B-X
tumours	B-X
<EOS>	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
30	B-X
of	B-X
37	B-X
(	B-X
81	B-X
%	B-X
)	B-X
CD	B-X
families	B-X
,	B-X
including	B-X
missense	B-X
and	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
a	B-X
deletion	B-X
/	B-X
insertion	B-X
and	B-X
splice	B-X
site	B-X
mutations	B-X
<EOS>	B-X
Mutation	B-X
spectrum	B-X
and	B-X
genotype	B-X
-	B-X
phenotype	B-X
analyses	B-X
in	B-X
Cowden	B-X
disease	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
syndrome	B-X
,	B-X
two	B-X
hamartoma	B-X
syndromes	B-X
with	B-X
germline	B-X
PTEN	B-X
mutation	B-X
.	B-X
<EOS>	B-X
Specifically	B-X
and	B-X
more	B-X
directly	B-X
,	B-X
an	B-X
association	B-X
was	B-X
also	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B-Disease
syndromes	I-Disease
Cowden	B-Disease
disease	I-Disease
(	O
CD	B-Disease
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B-Disease
-	I-Disease
Zonana	I-Disease
(	I-Disease
BZS	I-Disease
)	I-Disease
or	I-Disease
Ruvalcaba	I-Disease
-	I-Disease
Riley	I-Disease
-	I-Disease
Smith	I-Disease
syndrome	I-Disease
(	O
MIM	O
153480	O
)	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
PTEN	B-X
was	B-X
identified	B-X
as	B-X
the	B-X
susceptibility	B-X
gene	B-X
for	B-X
two	B-X
hamartoma	B-X
syndromes	B-X
:	B-X
Cowden	B-X
disease	B-X
(	B-X
CD	B-X
;	B-X
MIM	B-X
158350	B-X
)	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
(	B-X
BZS	B-X
)	B-X
or	B-X
Ruvalcaba	B-X
-	B-X
Riley	B-X
-	B-X
Smith	B-X
syndrome	B-X
(	B-X
MIM	B-X
153480	B-X
)	B-X
<EOS>	B-X
Gastrointestinal	B-X
hamartomatous	B-X
polyps	B-X
are	B-X
also	B-X
present	B-X
in	B-X
Cowden	B-X
syndrome	B-X
(	B-X
CS	B-X
;	B-X
MIM	B-X
158350	B-X
)	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
syndrome	B-X
(	B-X
BZS	B-X
;	B-X
also	B-X
called	B-X
Ruvalcaba	B-X
-	B-X
Myhre	B-X
-	B-X
Smith	B-X
syndrome	B-X
;	B-X
MIM	B-X
153480	B-X
)	B-X
<EOS>	B-X
Mutation	B-X
spectrum	B-X
and	B-X
genotype	B-X
-	B-X
phenotype	B-X
analyses	B-X
in	B-X
Cowden	B-X
disease	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
syndrome	B-X
,	B-X
two	B-X
hamartoma	B-X
syndromes	B-X
with	B-X
germline	B-X
PTEN	B-X
mutation	B-X
.	B-X
<EOS>	B-X
Exclusion	B-X
of	B-X
PTEN	B-X
and	B-X
10q22	B-X
-	B-X
24	B-X
as	B-X
the	B-X
susceptibility	B-X
locus	B-X
for	B-X
juvenile	B-X
polyposis	B-X
syndrome	B-X
.	B-X

Constitutive	O
DNA	O
from	O
37	O
CD	B-Disease
families	O
and	O
seven	O
BZS	B-Disease
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O
<EOS>	B-X
Constitutive	B-X
DNA	B-X
from	B-X
37	B-X
CD	B-X
families	B-X
and	B-X
seven	B-X
BZS	B-X
families	B-X
was	B-X
screened	B-X
for	B-X
germline	B-X
PTEN	B-X
mutations	B-X
<EOS>	B-X
Mutation	B-X
spectrum	B-X
and	B-X
genotype	B-X
-	B-X
phenotype	B-X
analyses	B-X
in	B-X
Cowden	B-X
disease	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
syndrome	B-X
,	B-X
two	B-X
hamartoma	B-X
syndromes	B-X
with	B-X
germline	B-X
PTEN	B-X
mutation	B-X
.	B-X
<EOS>	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
30	B-X
of	B-X
37	B-X
(	B-X
81	B-X
%	B-X
)	B-X
CD	B-X
families	B-X
,	B-X
including	B-X
missense	B-X
and	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
a	B-X
deletion	B-X
/	B-X
insertion	B-X
and	B-X
splice	B-X
site	B-X
mutations	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
none	B-X
of	B-X
these	B-X
mutations	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
CD	B-Disease
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
.	O
<EOS>	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
30	B-X
of	B-X
37	B-X
(	B-X
81	B-X
%	B-X
)	B-X
CD	B-X
families	B-X
,	B-X
including	B-X
missense	B-X
and	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
a	B-X
deletion	B-X
/	B-X
insertion	B-X
and	B-X
splice	B-X
site	B-X
mutations	B-X
<EOS>	B-X
Mutation	B-X
spectrum	B-X
and	B-X
genotype	B-X
-	B-X
phenotype	B-X
analyses	B-X
in	B-X
Cowden	B-X
disease	B-X
and	B-X
Bannayan	B-X
-	B-X
Zonana	B-X
syndrome	B-X
,	B-X
two	B-X
hamartoma	B-X
syndromes	B-X
with	B-X
germline	B-X
PTEN	B-X
mutation	B-X
.	B-X
<EOS>	B-X
Constitutive	B-X
DNA	B-X
from	B-X
37	B-X
CD	B-X
families	B-X
and	B-X
seven	B-X
BZS	B-X
families	B-X
was	B-X
screened	B-X
for	B-X
germline	B-X
PTEN	B-X
mutations	B-X
<EOS>	B-X
These	B-X
mutations	B-X
were	B-X
scattered	B-X
over	B-X
the	B-X
entire	B-X
length	B-X
of	B-X
PTEN	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
first	B-X
,	B-X
fourth	B-X
and	B-X
last	B-X
exons	B-X

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O
exons	O
.	O
<EOS>	B-X
These	B-X
mutations	B-X
were	B-X
scattered	B-X
over	B-X
the	B-X
entire	B-X
length	B-X
of	B-X
PTEN	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
first	B-X
,	B-X
fourth	B-X
and	B-X
last	B-X
exons	B-X
<EOS>	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
30	B-X
of	B-X
37	B-X
(	B-X
81	B-X
%	B-X
)	B-X
CD	B-X
families	B-X
,	B-X
including	B-X
missense	B-X
and	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
a	B-X
deletion	B-X
/	B-X
insertion	B-X
and	B-X
splice	B-X
site	B-X
mutations	B-X
<EOS>	B-X
A	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
/	B-X
absence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
the	B-X
type	B-X
of	B-X
breast	B-X
involvement	B-X
(	B-X
unaffected	B-X
versus	B-X
benign	B-X
versus	B-X
malignant	B-X
)	B-X
<EOS>	B-X
Seven	B-X
of	B-X
30	B-X
(	B-X
23	B-X
%	B-X
)	B-X
were	B-X
within	B-X
the	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
majority	B-X
(	B-X
five	B-X
of	B-X
seven	B-X
)	B-X
of	B-X
which	B-X
were	B-X
missense	B-X
mutations	B-X
,	B-X
possibly	B-X
pointing	B-X
to	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
this	B-X
region	B-X

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	B-Disease
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B-Disease
mutations	O
identified	O
in	O
this	O
exon	O
.	O
<EOS>	B-X
A	B-X
'hot	B-X
spot	B-X
'	B-X
for	B-X
PTEN	B-X
mutation	B-X
in	B-X
CD	B-X
was	B-X
identified	B-X
in	B-X
exon	B-X
5	B-X
that	B-X
contains	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
with	B-X
13	B-X
of	B-X
30	B-X
(	B-X
43	B-X
%	B-X
)	B-X
CD	B-X
mutations	B-X
identified	B-X
in	B-X
this	B-X
exon	B-X
<EOS>	B-X
These	B-X
mutations	B-X
were	B-X
scattered	B-X
over	B-X
the	B-X
entire	B-X
length	B-X
of	B-X
PTEN	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
first	B-X
,	B-X
fourth	B-X
and	B-X
last	B-X
exons	B-X
<EOS>	B-X
Germline	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
four	B-X
of	B-X
seven	B-X
(	B-X
57	B-X
%	B-X
)	B-X
BZS	B-X
families	B-X
studied	B-X
<EOS>	B-X
Secondly	B-X
,	B-X
there	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
interdependent	B-X
association	B-X
between	B-X
mutations	B-X
upstream	B-X
and	B-X
within	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
core	B-X
motif	B-X
containing	B-X
the	B-X
majority	B-X
of	B-X
missense	B-X
mutations	B-X
,	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
all	B-X
major	B-X
organ	B-X
systems	B-X
(	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
thyroid	B-X
,	B-X
breast	B-X
,	B-X
skin	B-X
and	B-X
gastrointestinal	B-X
tract	B-X
)	B-X

Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B-Disease
families	O
studied	O
.	O
<EOS>	B-X
Germline	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
four	B-X
of	B-X
seven	B-X
(	B-X
57	B-X
%	B-X
)	B-X
BZS	B-X
families	B-X
studied	B-X
<EOS>	B-X
A	B-X
'hot	B-X
spot	B-X
'	B-X
for	B-X
PTEN	B-X
mutation	B-X
in	B-X
CD	B-X
was	B-X
identified	B-X
in	B-X
exon	B-X
5	B-X
that	B-X
contains	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
with	B-X
13	B-X
of	B-X
30	B-X
(	B-X
43	B-X
%	B-X
)	B-X
CD	B-X
mutations	B-X
identified	B-X
in	B-X
this	B-X
exon	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
studies	B-X
were	B-X
not	B-X
performed	B-X
on	B-X
this	B-X
small	B-X
group	B-X
of	B-X
BZS	B-X
families	B-X
<EOS>	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
30	B-X
of	B-X
37	B-X
(	B-X
81	B-X
%	B-X
)	B-X
CD	B-X
families	B-X
,	B-X
including	B-X
missense	B-X
and	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
a	B-X
deletion	B-X
/	B-X
insertion	B-X
and	B-X
splice	B-X
site	B-X
mutations	B-X

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
none	B-X
of	B-X
these	B-X
mutations	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
<EOS>	B-X
It	B-X
is	B-X
also	B-X
worthy	B-X
of	B-X
note	B-X
that	B-X
a	B-X
single	B-X
nonsense	B-X
point	B-X
mutation	B-X
,	B-X
R233X	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
germline	B-X
DNA	B-X
from	B-X
two	B-X
unrelated	B-X
CD	B-X
families	B-X
and	B-X
one	B-X
BZS	B-X
family	B-X
<EOS>	B-X
Specifically	B-X
and	B-X
more	B-X
directly	B-X
,	B-X
an	B-X
association	B-X
was	B-X
also	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X
<EOS>	B-X
Constitutive	B-X
DNA	B-X
from	B-X
37	B-X
CD	B-X
families	B-X
and	B-X
seven	B-X
BZS	B-X
families	B-X
was	B-X
screened	B-X
for	B-X
germline	B-X
PTEN	B-X
mutations	B-X

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B-Disease
families	O
and	O
one	O
BZS	B-Disease
family	O
.	O
<EOS>	B-X
It	B-X
is	B-X
also	B-X
worthy	B-X
of	B-X
note	B-X
that	B-X
a	B-X
single	B-X
nonsense	B-X
point	B-X
mutation	B-X
,	B-X
R233X	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
germline	B-X
DNA	B-X
from	B-X
two	B-X
unrelated	B-X
CD	B-X
families	B-X
and	B-X
one	B-X
BZS	B-X
family	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
none	B-X
of	B-X
these	B-X
mutations	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
<EOS>	B-X
The	B-X
first	B-X
was	B-X
an	B-X
association	B-X
noted	B-X
in	B-X
the	B-X
group	B-X
of	B-X
CD	B-X
families	B-X
with	B-X
breast	B-X
disease	B-X
<EOS>	B-X
Specifically	B-X
and	B-X
more	B-X
directly	B-X
,	B-X
an	B-X
association	B-X
was	B-X
also	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X

Genotype	O
-	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	B-Disease
families	O
.	O
<EOS>	B-X
Genotype	B-X
imputation	B-X
,	B-X
process	B-X
of	B-X
inferring	B-X
unobserved	B-X
genotypes	B-X
,	B-X
is	B-X
a	B-X
statistical	B-X
technique	B-X
and	B-X
thus	B-X
deals	B-X
with	B-X
probabilities	B-X
<EOS>	B-X
ESBL	B-X
genes	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
occur	B-X
also	B-X
on	B-X
plasmids	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
genotypes	B-X
of	B-X
the	B-X
two	B-X
hot	B-X
spot	B-X
regions	B-X
of	B-X
the	B-X
vssc	B-X
gene	B-X
were	B-X
determined	B-X
by	B-X
melting	B-X
curve	B-X
analysis	B-X
of	B-X
amplicons	B-X
<EOS>	B-X
Genome	B-X
-	B-X
wide	B-X
association	B-X
studies	B-X
(	B-X
GWAS	B-X
)	B-X
have	B-X
identified	B-X
thousands	B-X
of	B-X
variants	B-X
for	B-X
disease	B-X
risk	B-X

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B-Disease
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O
<EOS>	B-X
However	B-X
,	B-X
genotype	B-X
-	B-X
phenotype	B-X
analysis	B-X
inthe	B-X
group	B-X
of	B-X
CD	B-X
families	B-X
revealed	B-X
two	B-X
possible	B-X
associations	B-X
worthy	B-X
of	B-X
follow	B-X
-	B-X
up	B-X
in	B-X
independent	B-X
analyses	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
studies	B-X
were	B-X
not	B-X
performed	B-X
on	B-X
this	B-X
small	B-X
group	B-X
of	B-X
BZS	B-X
families	B-X
<EOS>	B-X
The	B-X
first	B-X
was	B-X
an	B-X
association	B-X
noted	B-X
in	B-X
the	B-X
group	B-X
of	B-X
CD	B-X
families	B-X
with	B-X
breast	B-X
disease	B-X
<EOS>	B-X
However	B-X
,	B-X
these	B-X
observations	B-X
would	B-X
need	B-X
to	B-X
be	B-X
confirmed	B-X
by	B-X
studying	B-X
a	B-X
larger	B-X
number	B-X
of	B-X
CD	B-X
families	B-X

The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B-Disease
families	O
with	O
breast	B-Disease
disease	I-Disease
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O
<EOS>	B-X
A	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
/	B-X
absence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
the	B-X
type	B-X
of	B-X
breast	B-X
involvement	B-X
(	B-X
unaffected	B-X
versus	B-X
benign	B-X
versus	B-X
malignant	B-X
)	B-X
<EOS>	B-X
These	B-X
mutations	B-X
were	B-X
scattered	B-X
over	B-X
the	B-X
entire	B-X
length	B-X
of	B-X
PTEN	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
first	B-X
,	B-X
fourth	B-X
and	B-X
last	B-X
exons	B-X
<EOS>	B-X
Secondly	B-X
,	B-X
there	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
interdependent	B-X
association	B-X
between	B-X
mutations	B-X
upstream	B-X
and	B-X
within	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
core	B-X
motif	B-X
containing	B-X
the	B-X
majority	B-X
of	B-X
missense	B-X
mutations	B-X
,	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
all	B-X
major	B-X
organ	B-X
systems	B-X
(	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
thyroid	B-X
,	B-X
breast	B-X
,	B-X
skin	B-X
and	B-X
gastrointestinal	B-X
tract	B-X
)	B-X
<EOS>	B-X
Somatic	B-X
PTEN	B-X
deletions	B-X
and	B-X
mutations	B-X
were	B-X
observed	B-X
in	B-X
sporadic	B-X
breast	B-X
,	B-X
brain	B-X
,	B-X
prostate	B-X
and	B-X
kidney	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
in	B-X
several	B-X
primary	B-X
tumours	B-X
such	B-X
as	B-X
endometrial	B-X
carcinomas	B-X
,	B-X
malignant	B-X
melanoma	B-X
and	B-X
thyroid	B-X
tumours	B-X

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B-Disease
breast	I-Disease
disease	I-Disease
.	O
<EOS>	B-X
Specifically	B-X
and	B-X
more	B-X
directly	B-X
,	B-X
an	B-X
association	B-X
was	B-X
also	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X
<EOS>	B-X
The	B-X
first	B-X
was	B-X
an	B-X
association	B-X
noted	B-X
in	B-X
the	B-X
group	B-X
of	B-X
CD	B-X
families	B-X
with	B-X
breast	B-X
disease	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
none	B-X
of	B-X
these	B-X
mutations	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
<EOS>	B-X
Secondly	B-X
,	B-X
there	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
interdependent	B-X
association	B-X
between	B-X
mutations	B-X
upstream	B-X
and	B-X
within	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
core	B-X
motif	B-X
containing	B-X
the	B-X
majority	B-X
of	B-X
missense	B-X
mutations	B-X
,	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
all	B-X
major	B-X
organ	B-X
systems	B-X
(	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
thyroid	B-X
,	B-X
breast	B-X
,	B-X
skin	B-X
and	B-X
gastrointestinal	B-X
tract	B-X
)	B-X

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O
<EOS>	B-X
Secondly	B-X
,	B-X
there	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
interdependent	B-X
association	B-X
between	B-X
mutations	B-X
upstream	B-X
and	B-X
within	B-X
the	B-X
PTPase	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
core	B-X
motif	B-X
containing	B-X
the	B-X
majority	B-X
of	B-X
missense	B-X
mutations	B-X
,	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
all	B-X
major	B-X
organ	B-X
systems	B-X
(	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
thyroid	B-X
,	B-X
breast	B-X
,	B-X
skin	B-X
and	B-X
gastrointestinal	B-X
tract	B-X
)	B-X
<EOS>	B-X
A	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
/	B-X
absence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
the	B-X
type	B-X
of	B-X
breast	B-X
involvement	B-X
(	B-X
unaffected	B-X
versus	B-X
benign	B-X
versus	B-X
malignant	B-X
)	B-X
<EOS>	B-X
Seven	B-X
of	B-X
30	B-X
(	B-X
23	B-X
%	B-X
)	B-X
were	B-X
within	B-X
the	B-X
core	B-X
motif	B-X
,	B-X
the	B-X
majority	B-X
(	B-X
five	B-X
of	B-X
seven	B-X
)	B-X
of	B-X
which	B-X
were	B-X
missense	B-X
mutations	B-X
,	B-X
possibly	B-X
pointing	B-X
to	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
this	B-X
region	B-X
<EOS>	B-X
Specifically	B-X
and	B-X
more	B-X
directly	B-X
,	B-X
an	B-X
association	B-X
was	B-X
also	B-X
observed	B-X
between	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
PTEN	B-X
mutation	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B-Disease
families	O
.	O
<EOS>	B-X
However	B-X
,	B-X
these	B-X
observations	B-X
would	B-X
need	B-X
to	B-X
be	B-X
confirmed	B-X
by	B-X
studying	B-X
a	B-X
larger	B-X
number	B-X
of	B-X
CD	B-X
families	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
studies	B-X
were	B-X
not	B-X
performed	B-X
on	B-X
this	B-X
small	B-X
group	B-X
of	B-X
BZS	B-X
families	B-X
<EOS>	B-X
Germline	B-X
PTEN	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
four	B-X
of	B-X
seven	B-X
(	B-X
57	B-X
%	B-X
)	B-X
BZS	B-X
families	B-X
studied	B-X
<EOS>	B-X
However	B-X
,	B-X
genotype	B-X
-	B-X
phenotype	B-X
analysis	B-X
inthe	B-X
group	B-X
of	B-X
CD	B-X
families	B-X
revealed	B-X
two	B-X
possible	B-X
associations	B-X
worthy	B-X
of	B-X
follow	B-X
-	B-X
up	B-X
in	B-X
independent	B-X
analyses	B-X

Molecular	O
defects	O
leading	O
to	O
human	O
complement	B-Disease
component	I-Disease
C6	I-Disease
deficiency	I-Disease
in	O
an	O
African	O
-	O
American	O
family	O
.	O

Complement	B-Disease
component	I-Disease
C6	I-Disease
deficiency	I-Disease
(	O
C6D	B-Disease
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B-Disease
meningitis	I-Disease
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B-Disease
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B-Disease
or	O
other	O
neisserial	B-Disease
infection	I-Disease
.	O
<EOS>	B-X
Among	B-X
the	B-X
4	B-X
patients	B-X
(	B-X
2	B-X
girls	B-X
)	B-X
,	B-X
2	B-X
had	B-X
previous	B-X
risk	B-X
factors	B-X
for	B-X
IMD	B-X
(	B-X
recurrent	B-X
bacterial	B-X
meningitis	B-X
of	B-X
unknown	B-X
origin	B-X
and	B-X
treatment	B-X
with	B-X
eculizumab	B-X
)	B-X
<EOS>	B-X
Gram	B-X
-	B-X
negative	B-X
bacteria	B-X
cause	B-X
the	B-X
majority	B-X
of	B-X
highly	B-X
drug	B-X
-	B-X
resistant	B-X
bacterial	B-X
infections	B-X
<EOS>	B-X
Patients	B-X
with	B-X
high	B-X
-	B-X
risk	B-X
behaviours	B-X
and	B-X
their	B-X
partners	B-X
should	B-X
also	B-X
be	B-X
screened	B-X
for	B-X
gonococcal	B-X
infection	B-X
<EOS>	B-X
meningitidis	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
impact	B-X
the	B-X
other	B-X
commensal	B-X
species	B-X
of	B-X
Neisseria	B-X

By	O
using	O
exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O
<EOS>	B-X
By	B-X
using	B-X
exon	B-X
-	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
	B-X
/	B-X
single	B-X
-	B-X
strand	B-X
conformation	B-X
polymorphism	B-X
as	B-X
a	B-X
screening	B-X
step	B-X
and	B-X
nucleotide	B-X
sequencing	B-X
of	B-X
target	B-X
exons	B-X
,	B-X
we	B-X
determined	B-X
that	B-X
the	B-X
proband	B-X
was	B-X
a	B-X
compound	B-X
heterozygote	B-X
for	B-X
two	B-X
C6	B-X
gene	B-X
mutations	B-X
<EOS>	B-X
Allele	B-X
-	B-X
specific	B-X
PCR	B-X
indicated	B-X
that	B-X
the	B-X
proband	B-X
's	B-X
two	B-X
brothers	B-X
also	B-X
inherited	B-X
the	B-X
1195delC	B-X
mutation	B-X
from	B-X
their	B-X
heterozygous	B-X
mother	B-X
and	B-X
the	B-X
1936delG	B-X
mutation	B-X
from	B-X
their	B-X
homozygous	B-X
father	B-X
<EOS>	B-X
The	B-X
first	B-X
,	B-X
1195delC	B-X
located	B-X
in	B-X
exon	B-X
7	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
mutation	B-X
,	B-X
while	B-X
the	B-X
second	B-X
,	B-X
1936delG	B-X
in	B-X
exon	B-X
12	B-X
,	B-X
has	B-X
been	B-X
described	B-X
before	B-X
to	B-X
cause	B-X
C6D	B-X
in	B-X
an	B-X
unrelated	B-X
African	B-X
-	B-X
American	B-X
individual	B-X
<EOS>	B-X
The	B-X
patient	B-X
's	B-X
father	B-X
and	B-X
two	B-X
brothers	B-X
also	B-X
had	B-X
C6D	B-X
,	B-X
but	B-X
gave	B-X
no	B-X
history	B-X
of	B-X
meningitis	B-X
or	B-X
other	B-X
neisserial	B-X
infection	B-X

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B-Disease
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
null	O
alleles	O
.	O
<EOS>	B-X
Both	B-X
mutations	B-X
result	B-X
in	B-X
premature	B-X
termination	B-X
codons	B-X
and	B-X
C6	B-X
null	B-X
alleles	B-X
<EOS>	B-X
The	B-X
patient	B-X
's	B-X
father	B-X
and	B-X
two	B-X
brothers	B-X
also	B-X
had	B-X
C6D	B-X
,	B-X
but	B-X
gave	B-X
no	B-X
history	B-X
of	B-X
meningitis	B-X
or	B-X
other	B-X
neisserial	B-X
infection	B-X
<EOS>	B-X
Molecular	B-X
defects	B-X
leading	B-X
to	B-X
human	B-X
complement	B-X
component	B-X
C6	B-X
deficiency	B-X
in	B-X
an	B-X
African	B-X
-	B-X
American	B-X
family	B-X
.	B-X
<EOS>	B-X
Allele	B-X
-	B-X
specific	B-X
PCR	B-X
indicated	B-X
that	B-X
the	B-X
proband	B-X
's	B-X
two	B-X
brothers	B-X
also	B-X
inherited	B-X
the	B-X
1195delC	B-X
mutation	B-X
from	B-X
their	B-X
heterozygous	B-X
mother	B-X
and	B-X
the	B-X
1936delG	B-X
mutation	B-X
from	B-X
their	B-X
homozygous	B-X
father	B-X

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O
<EOS>	B-X
Allele	B-X
-	B-X
specific	B-X
PCR	B-X
indicated	B-X
that	B-X
the	B-X
proband	B-X
's	B-X
two	B-X
brothers	B-X
also	B-X
inherited	B-X
the	B-X
1195delC	B-X
mutation	B-X
from	B-X
their	B-X
heterozygous	B-X
mother	B-X
and	B-X
the	B-X
1936delG	B-X
mutation	B-X
from	B-X
their	B-X
homozygous	B-X
father	B-X
<EOS>	B-X
The	B-X
patient	B-X
's	B-X
father	B-X
and	B-X
two	B-X
brothers	B-X
also	B-X
had	B-X
C6D	B-X
,	B-X
but	B-X
gave	B-X
no	B-X
history	B-X
of	B-X
meningitis	B-X
or	B-X
other	B-X
neisserial	B-X
infection	B-X
<EOS>	B-X
By	B-X
using	B-X
exon	B-X
-	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
	B-X
/	B-X
single	B-X
-	B-X
strand	B-X
conformation	B-X
polymorphism	B-X
as	B-X
a	B-X
screening	B-X
step	B-X
and	B-X
nucleotide	B-X
sequencing	B-X
of	B-X
target	B-X
exons	B-X
,	B-X
we	B-X
determined	B-X
that	B-X
the	B-X
proband	B-X
was	B-X
a	B-X
compound	B-X
heterozygote	B-X
for	B-X
two	B-X
C6	B-X
gene	B-X
mutations	B-X
<EOS>	B-X
Molecular	B-X
defects	B-X
leading	B-X
to	B-X
human	B-X
complement	B-X
component	B-X
C6	B-X
deficiency	B-X
in	B-X
an	B-X
African	B-X
-	B-X
American	B-X
family	B-X
.	B-X

PAX6	O
mutations	O
reviewed	O
.	O
<EOS>	B-X
PAX6	B-X
mutation	B-X
was	B-X
found	B-X
in	B-X
56	B-X
patients	B-X
(	B-X
77	B-X
%	B-X
)	B-X
<EOS>	B-X
All	B-X
participants	B-X
underwent	B-X
genetic	B-X
testing	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
three	B-X
genes	B-X
were	B-X
identified	B-X
in	B-X
69	B-X
<EOS>	B-X
Nystagmus	B-X
was	B-X
recorded	B-X
in	B-X
87	B-X

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B-Disease
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B-Disease
anomaly	I-Disease
,	O
with	O
congenital	B-Disease
cataracts	I-Disease
,	O
with	O
autosomal	B-Disease
dominant	I-Disease
keratitis	I-Disease
,	O
and	O
with	O
isolated	B-Disease
foveal	I-Disease
hypoplasia	I-Disease
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B-Disease
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
.	O
<EOS>	B-X
Perioperative	B-X
lumbar	B-X
interbody	B-X
cage	B-X
malfunctions	B-X
are	B-X
underreported	B-X
events	B-X
in	B-X
the	B-X
spine	B-X
literature	B-X
and	B-X
may	B-X
result	B-X
in	B-X
complications	B-X
<EOS>	B-X
Notably	B-X
,	B-X
it	B-X
is	B-X
also	B-X
applicable	B-X
to	B-X
quantify	B-X
structural	B-X
variation	B-X
in	B-X
special	B-X
RNA	B-X
editing	B-X
events	B-X
(	B-X
SNVs	B-X
or	B-X
SNPs	B-X
,	B-X
fragment	B-X
insertion	B-X
or	B-X
deletion	B-X
,	B-X
etc	B-X
<EOS>	B-X
T2	B-X
-	B-X
weighted	B-X
MRI	B-X
scans	B-X
were	B-X
obtained	B-X
every	B-X
15	B-X
min	B-X
up	B-X
to	B-X
a	B-X
maximum	B-X
of	B-X
105	B-X
min	B-X
in	B-X
order	B-X
to	B-X
calculate	B-X
the	B-X
volume	B-X
of	B-X
distribution	B-X
(	B-X
Vd	B-X
)	B-X
<EOS>	B-X
As	B-X
a	B-X
common	B-X
adverse	B-X
environmental	B-X
factor	B-X
,	B-X
heat	B-X
stress	B-X
(	B-X
HS	B-X
)	B-X
not	B-X
only	B-X
drastically	B-X
changes	B-X
the	B-X
plant	B-X
transcriptome	B-X
at	B-X
the	B-X
transcription	B-X
level	B-X
but	B-X
also	B-X
increases	B-X
alternative	B-X
splicing	B-X
(	B-X
AS	B-X
)	B-X
,	B-X
especially	B-X
intron	B-X
retention	B-X
(	B-X
IR	B-X
)	B-X
events	B-X

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O
<EOS>	B-X
There	B-X
is	B-X
a	B-X
noticeably	B-X
elevated	B-X
level	B-X
of	B-X
mutation	B-X
in	B-X
the	B-X
paired	B-X
domain	B-X
compared	B-X
with	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Very	B-X
nearly	B-X
all	B-X
mutations	B-X
appear	B-X
to	B-X
cause	B-X
loss	B-X
of	B-X
function	B-X
of	B-X
the	B-X
mutant	B-X
allele	B-X
,	B-X
and	B-X
more	B-X
than	B-X
80	B-X
%	B-X
of	B-X
exonic	B-X
substitutions	B-X
result	B-X
in	B-X
nonsense	B-X
codons	B-X
<EOS>	B-X
Twenty	B-X
-	B-X
eight	B-X
percent	B-X
of	B-X
identified	B-X
PAX6	B-X
mutations	B-X
are	B-X
C	B-X
-	B-X
T	B-X
changes	B-X
at	B-X
CpG	B-X
dinucleotides	B-X
,	B-X
20	B-X
%	B-X
are	B-X
splicing	B-X
errors	B-X
,	B-X
and	B-X
more	B-X
than	B-X
30	B-X
%	B-X
are	B-X
deletion	B-X
or	B-X
insertion	B-X
events	B-X
<EOS>	B-X
In	B-X
a	B-X
gene	B-X
with	B-X
such	B-X
extraordinarily	B-X
high	B-X
sequence	B-X
conservation	B-X
throughout	B-X
evolution	B-X
,	B-X
there	B-X
are	B-X
presumed	B-X
undiscovered	B-X
missense	B-X
mutations	B-X
,	B-X
these	B-X
are	B-X
hypothesized	B-X
to	B-X
exist	B-X
in	B-X
as	B-X
-	B-X
yet	B-X
unidentified	B-X
phenotypes	B-X

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O
<EOS>	B-X
Increased	B-X
mutation	B-X
in	B-X
the	B-X
homeodomain	B-X
is	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
hypermutable	B-X
CpG	B-X
dinucleotide	B-X
in	B-X
codon	B-X
240	B-X
<EOS>	B-X
Very	B-X
nearly	B-X
all	B-X
mutations	B-X
appear	B-X
to	B-X
cause	B-X
loss	B-X
of	B-X
function	B-X
of	B-X
the	B-X
mutant	B-X
allele	B-X
,	B-X
and	B-X
more	B-X
than	B-X
80	B-X
%	B-X
of	B-X
exonic	B-X
substitutions	B-X
result	B-X
in	B-X
nonsense	B-X
codons	B-X
<EOS>	B-X
Twenty	B-X
-	B-X
eight	B-X
percent	B-X
of	B-X
identified	B-X
PAX6	B-X
mutations	B-X
are	B-X
C	B-X
-	B-X
T	B-X
changes	B-X
at	B-X
CpG	B-X
dinucleotides	B-X
,	B-X
20	B-X
%	B-X
are	B-X
splicing	B-X
errors	B-X
,	B-X
and	B-X
more	B-X
than	B-X
30	B-X
%	B-X
are	B-X
deletion	B-X
or	B-X
insertion	B-X
events	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
PAX6	B-X
are	B-X
responsible	B-X
for	B-X
human	B-X
aniridia	B-X
and	B-X
have	B-X
also	B-X
been	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
Peter	B-X
's	B-X
anomaly	B-X
,	B-X
with	B-X
congenital	B-X
cataracts	B-X
,	B-X
with	B-X
autosomal	B-X
dominant	B-X
keratitis	B-X
,	B-X
and	B-X
with	B-X
isolated	B-X
foveal	B-X
hypoplasia	B-X

Very	O
nearly	O
all	O
mutations	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O
.	O
<EOS>	B-X
Very	B-X
nearly	B-X
all	B-X
mutations	B-X
appear	B-X
to	B-X
cause	B-X
loss	B-X
of	B-X
function	B-X
of	B-X
the	B-X
mutant	B-X
allele	B-X
,	B-X
and	B-X
more	B-X
than	B-X
80	B-X
%	B-X
of	B-X
exonic	B-X
substitutions	B-X
result	B-X
in	B-X
nonsense	B-X
codons	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
noticeably	B-X
elevated	B-X
level	B-X
of	B-X
mutation	B-X
in	B-X
the	B-X
paired	B-X
domain	B-X
compared	B-X
with	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Increased	B-X
mutation	B-X
in	B-X
the	B-X
homeodomain	B-X
is	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
hypermutable	B-X
CpG	B-X
dinucleotide	B-X
in	B-X
codon	B-X
240	B-X
<EOS>	B-X
Twenty	B-X
-	B-X
eight	B-X
percent	B-X
of	B-X
identified	B-X
PAX6	B-X
mutations	B-X
are	B-X
C	B-X
-	B-X
T	B-X
changes	B-X
at	B-X
CpG	B-X
dinucleotides	B-X
,	B-X
20	B-X
%	B-X
are	B-X
splicing	B-X
errors	B-X
,	B-X
and	B-X
more	B-X
than	B-X
30	B-X
%	B-X
are	B-X
deletion	B-X
or	B-X
insertion	B-X
events	B-X

In	O
a	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
.	O

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B-Disease
cancer	I-Disease
families	O
.	O
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
and	B-X
penetrance	B-X
analysis	B-X
of	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
genes	B-X
in	B-X
breast	B-X
cancer	B-X
families	B-X
.	B-X
The	B-X
Breast	B-X
Cancer	B-X
Linkage	B-X
Consortium	B-X
.	B-X
<EOS>	B-X
Genome	B-X
-	B-X
wide	B-X
scanning	B-X
for	B-X
linkage	B-X
in	B-X
Finnish	B-X
breast	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
BRCA2	B-X
mutation	B-X
analysis	B-X
of	B-X
87	B-X
Spanish	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
results	B-X
from	B-X
a	B-X
genome	B-X
-	B-X
wide	B-X
linkage	B-X
analysis	B-X
of	B-X
14	B-X
high	B-X
-	B-X
risk	B-X
breast	B-X
cancer	B-X
families	B-X
from	B-X
Finland	B-X

The	O
Breast	B-Disease
Cancer	I-Disease
Linkage	O
Consortium	O
.	O
<EOS>	B-X
The	B-X
etiology	B-X
of	B-X
male	B-X
breast	B-X
cancer	B-X
(	B-X
MBC	B-X
)	B-X
is	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
Hereditary	B-X
Diffuse	B-X
Gastric	B-X
Cancer	B-X
-	B-X
Update	B-X
Based	B-X
on	B-X
the	B-X
Current	B-X
Consort	B-X
Recommendations	B-X
.	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
cancer	B-X
detection	B-X
rate	B-X
(	B-X
4	B-X
<EOS>	B-X
Fine	B-X
-	B-X
Mapping	B-X
of	B-X
the	B-X
1p11.2	B-X
Breast	B-X
Cancer	B-X
Susceptibility	B-X
Locus	B-X
.	B-X

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
collected	O
by	O
the	O
Breast	B-Disease
Cancer	I-Disease
Linkage	O
Consortium	O
.	O
<EOS>	B-X
The	B-X
contribution	B-X
of	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
to	B-X
inherited	B-X
breast	B-X
cancer	B-X
was	B-X
assessed	B-X
by	B-X
linkage	B-X
and	B-X
mutation	B-X
analysis	B-X
in	B-X
237	B-X
families	B-X
,	B-X
each	B-X
with	B-X
at	B-X
least	B-X
four	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
,	B-X
collected	B-X
by	B-X
the	B-X
Breast	B-X
Cancer	B-X
Linkage	B-X
Consortium	B-X
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
and	B-X
penetrance	B-X
analysis	B-X
of	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
genes	B-X
in	B-X
breast	B-X
cancer	B-X
families	B-X
.	B-X
The	B-X
Breast	B-X
Cancer	B-X
Linkage	B-X
Consortium	B-X
.	B-X
<EOS>	B-X
The	B-X
largest	B-X
proportion	B-X
(	B-X
67	B-X
%	B-X
)	B-X
of	B-X
families	B-X
due	B-X
to	B-X
other	B-X
genes	B-X
was	B-X
found	B-X
in	B-X
families	B-X
with	B-X
four	B-X
or	B-X
five	B-X
cases	B-X
of	B-X
female	B-X
breast	B-X
cancer	B-X
only	B-X
<EOS>	B-X
The	B-X
penetrance	B-X
of	B-X
BRCA2	B-X
was	B-X
estimated	B-X
by	B-X
maximizing	B-X
the	B-X
LOD	B-X
score	B-X
in	B-X
BRCA2	B-X
-	B-X
mutation	B-X
families	B-X
,	B-X
over	B-X
all	B-X
possible	B-X
penetrance	B-X
functions	B-X

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B-Disease
or	I-Disease
other	I-Disease
cancers	I-Disease
.	O
<EOS>	B-X
The	B-X
immunological	B-X
and	B-X
stromal	B-X
scores	B-X
were	B-X
computed	B-X
using	B-X
the	B-X
ESTIMATE	B-X
algorithm	B-X
,	B-X
and	B-X
the	B-X
data	B-X
revealed	B-X
,	B-X
the	B-X
low	B-X
-	B-X
risk	B-X
group	B-X
had	B-X
a	B-X
higher	B-X
score	B-X
<EOS>	B-X
ORN	B-X
cases	B-X
were	B-X
identified	B-X
from	B-X
the	B-X
records	B-X
of	B-X
LA	B-X
-	B-X
NPCs	B-X
who	B-X
had	B-X
oral	B-X
exams	B-X
before	B-X
and	B-X
after	B-X
CCRT	B-X
<EOS>	B-X
Although	B-X
effective	B-X
multimodal	B-X
therapies	B-X
significantly	B-X
decline	B-X
mortality	B-X
rates	B-X
,	B-X
breast	B-X
cancer	B-X
remains	B-X
one	B-X
of	B-X
the	B-X
leading	B-X
causes	B-X
of	B-X
cancer	B-X
death	B-X
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
incidence	B-X
of	B-X
mediastinal	B-X
LN	B-X
recurrence	B-X
in	B-X
the	B-X
MIE	B-X
group	B-X
was	B-X
significantly	B-X
lower	B-X
than	B-X
that	B-X
in	B-X
the	B-X
OE	B-X
group	B-X
(	B-X
16	B-X
%	B-X
vs	B-X

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O
genes	O
.	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B-Disease
and	I-Disease
female	I-Disease
breast	I-Disease
cancer	I-Disease
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O
<EOS>	B-X
Conversely	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
families	B-X
with	B-X
male	B-X
and	B-X
female	B-X
breast	B-X
cancer	B-X
were	B-X
due	B-X
to	B-X
BRCA2	B-X
(	B-X
76	B-X
%	B-X
)	B-X
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
and	B-X
penetrance	B-X
analysis	B-X
of	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
genes	B-X
in	B-X
breast	B-X
cancer	B-X
families	B-X
.	B-X
The	B-X
Breast	B-X
Cancer	B-X
Linkage	B-X
Consortium	B-X
.	B-X
<EOS>	B-X
The	B-X
majority	B-X
(	B-X
81	B-X
%	B-X
)	B-X
of	B-X
the	B-X
breast	B-X
-	B-X
ovarian	B-X
cancer	B-X
families	B-X
were	B-X
due	B-X
to	B-X
BRCA1	B-X
,	B-X
with	B-X
most	B-X
others	B-X
(	B-X
14	B-X
%	B-X
)	B-X
due	B-X
to	B-X
BRCA2	B-X
<EOS>	B-X
The	B-X
largest	B-X
proportion	B-X
(	B-X
67	B-X
%	B-X
)	B-X
of	B-X
families	B-X
due	B-X
to	B-X
other	B-X
genes	B-X
was	B-X
found	B-X
in	B-X
families	B-X
with	B-X
four	B-X
or	B-X
five	B-X
cases	B-X
of	B-X
female	B-X
breast	B-X
cancer	B-X
only	B-X

The	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B-Disease
cancer	I-Disease
only	O
.	O
<EOS>	B-X
97	B-X
)	B-X
,	B-X
and	B-X
in	B-X
the	B-X
UK	B-X
Biobank	B-X
greater	B-X
risk	B-X
of	B-X
female	B-X
breast	B-X
cancer	B-X
(	B-X
1	B-X
<EOS>	B-X
In	B-X
observational	B-X
analyses	B-X
,	B-X
milk	B-X
consumption	B-X
was	B-X
associated	B-X
with	B-X
higher	B-X
risk	B-X
of	B-X
bladder	B-X
and	B-X
urinary	B-X
tract	B-X
cancer	B-X
(	B-X
OR	B-X
1	B-X
<EOS>	B-X
The	B-X
patients	B-X
who	B-X
had	B-X
mastectomy	B-X
with	B-X
sentinel	B-X
lymph	B-X
node	B-X
biopsy	B-X
as	B-X
a	B-X
rule	B-X
had	B-X
a	B-X
clinical	B-X
diagnosis	B-X
of	B-X
T2	B-X
-	B-X
T3N0M0	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Underreporting	B-X
may	B-X
also	B-X
be	B-X
a	B-X
contributing	B-X
factor	B-X
to	B-X
the	B-X
unknown	B-X
incidence	B-X
of	B-X
VC	B-X
in	B-X
pregnancy	B-X

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
this	B-X
tutorial	B-X
will	B-X
provide	B-X
clinicians	B-X
with	B-X
an	B-X
overview	B-X
of	B-X
what	B-X
an	B-X
RCT	B-X
is	B-X
,	B-X
the	B-X
various	B-X
types	B-X
of	B-X
RCTs	B-X
,	B-X
when	B-X
RCTs	B-X
are	B-X
appropriate	B-X
to	B-X
conduct	B-X
and	B-X
/	B-X
or	B-X
use	B-X
to	B-X
inform	B-X
clinical	B-X
practice	B-X
,	B-X
and	B-X
the	B-X
advantages	B-X
and	B-X
limitations	B-X
of	B-X
RCTs	B-X
<EOS>	B-X
The	B-X
tasks	B-X
were	B-X
designed	B-X
to	B-X
be	B-X
as	B-X
similar	B-X
as	B-X
possible	B-X
to	B-X
one	B-X
another	B-X
except	B-X
for	B-X
the	B-X
type	B-X
of	B-X
attentional	B-X
resources	B-X
required	B-X
<EOS>	B-X
Cauterization	B-X
of	B-X
neovessels	B-X
and	B-X
removal	B-X
of	B-X
the	B-X
vascular	B-X
pannus	B-X
were	B-X
followed	B-X
by	B-X
partial	B-X
excision	B-X
of	B-X
Tenon	B-X
's	B-X
capsule	B-X
<EOS>	B-X
A	B-X
passive	B-X
brain	B-X
-	B-X
computer	B-X
interface	B-X
(	B-X
pBCI	B-X
)	B-X
is	B-X
a	B-X
system	B-X
that	B-X
enhances	B-X
a	B-X
human	B-X
-	B-X
machine	B-X
interaction	B-X
by	B-X
monitoring	B-X
the	B-X
mental	B-X
state	B-X
of	B-X
the	B-X
user	B-X
and	B-X
,	B-X
based	B-X
on	B-X
this	B-X
implicit	B-X
information	B-X
,	B-X
making	B-X
appropriate	B-X
modifications	B-X
to	B-X
the	B-X
interaction	B-X

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O
<EOS>	B-X
Among	B-X
those	B-X
families	B-X
with	B-X
disease	B-X
due	B-X
to	B-X
BRCA1	B-X
that	B-X
were	B-X
tested	B-X
by	B-X
one	B-X
of	B-X
the	B-X
standard	B-X
screening	B-X
methods	B-X
,	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
coding	B-X
sequence	B-X
or	B-X
splice	B-X
sites	B-X
in	B-X
an	B-X
estimated	B-X
63	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
51	B-X
%	B-X
	B-X
-	B-X
77	B-X
%	B-X
)	B-X
<EOS>	B-X
These	B-X
estimates	B-X
were	B-X
not	B-X
substantially	B-X
affected	B-X
either	B-X
by	B-X
changing	B-X
the	B-X
assumed	B-X
penetrance	B-X
model	B-X
for	B-X
BRCA1	B-X
or	B-X
by	B-X
including	B-X
or	B-X
excluding	B-X
BRCA1	B-X
mutation	B-X
data	B-X
<EOS>	B-X
The	B-X
penetrance	B-X
of	B-X
BRCA2	B-X
was	B-X
estimated	B-X
by	B-X
maximizing	B-X
the	B-X
LOD	B-X
score	B-X
in	B-X
BRCA2	B-X
-	B-X
mutation	B-X
families	B-X
,	B-X
over	B-X
all	B-X
possible	B-X
penetrance	B-X
functions	B-X
<EOS>	B-X
The	B-X
lifetime	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
appears	B-X
similar	B-X
to	B-X
the	B-X
risk	B-X
in	B-X
BRCA1	B-X
carriers	B-X
,	B-X
but	B-X
there	B-X
was	B-X
some	B-X
suggestion	B-X
of	B-X
a	B-X
lower	B-X
risk	B-X
in	B-X
BRCA2	B-X
carriers	B-X
<	B-X
50	B-X
years	B-X
of	B-X
age	B-X

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O
<EOS>	B-X
The	B-X
estimated	B-X
sensitivity	B-X
was	B-X
identical	B-X
for	B-X
direct	B-X
sequencing	B-X
and	B-X
other	B-X
techniques	B-X
<EOS>	B-X
The	B-X
specificity	B-X
of	B-X
the	B-X
PCRs	B-X
was	B-X
confirmed	B-X
using	B-X
genomic	B-X
DNA	B-X
from	B-X
related	B-X
parasites	B-X
,	B-X
including	B-X
genomic	B-X
DNA	B-X
of	B-X
Besnoitia	B-X
spp	B-X
<EOS>	B-X
Quantitative	B-X
real	B-X
time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
assays	B-X
for	B-X
the	B-X
sensitive	B-X
detection	B-X
of	B-X
Besnoitia	B-X
besnoiti	B-X
infection	B-X
in	B-X
cattle	B-X
.	B-X
<EOS>	B-X
These	B-X
estimates	B-X
were	B-X
not	B-X
substantially	B-X
affected	B-X
either	B-X
by	B-X
changing	B-X
the	B-X
assumed	B-X
penetrance	B-X
model	B-X
for	B-X
BRCA1	B-X
or	B-X
by	B-X
including	B-X
or	B-X
excluding	B-X
BRCA1	B-X
mutation	B-X
data	B-X

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O
<EOS>	B-X
The	B-X
penetrance	B-X
of	B-X
BRCA2	B-X
was	B-X
estimated	B-X
by	B-X
maximizing	B-X
the	B-X
LOD	B-X
score	B-X
in	B-X
BRCA2	B-X
-	B-X
mutation	B-X
families	B-X
,	B-X
over	B-X
all	B-X
possible	B-X
penetrance	B-X
functions	B-X
<EOS>	B-X
The	B-X
contribution	B-X
of	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
to	B-X
inherited	B-X
breast	B-X
cancer	B-X
was	B-X
assessed	B-X
by	B-X
linkage	B-X
and	B-X
mutation	B-X
analysis	B-X
in	B-X
237	B-X
families	B-X
,	B-X
each	B-X
with	B-X
at	B-X
least	B-X
four	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
,	B-X
collected	B-X
by	B-X
the	B-X
Breast	B-X
Cancer	B-X
Linkage	B-X
Consortium	B-X
<EOS>	B-X
Among	B-X
those	B-X
families	B-X
with	B-X
disease	B-X
due	B-X
to	B-X
BRCA1	B-X
that	B-X
were	B-X
tested	B-X
by	B-X
one	B-X
of	B-X
the	B-X
standard	B-X
screening	B-X
methods	B-X
,	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
coding	B-X
sequence	B-X
or	B-X
splice	B-X
sites	B-X
in	B-X
an	B-X
estimated	B-X
63	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
51	B-X
%	B-X
	B-X
-	B-X
77	B-X
%	B-X
)	B-X
<EOS>	B-X
Overall	B-X
,	B-X
disease	B-X
was	B-X
linked	B-X
to	B-X
BRCA1	B-X
in	B-X
an	B-X
estimated	B-X
52	B-X
%	B-X
of	B-X
families	B-X
,	B-X
to	B-X
BRCA2	B-X
in	B-X
32	B-X
%	B-X
of	B-X
families	B-X
,	B-X
and	B-X
to	B-X
neither	B-X
gene	B-X
in	B-X
16	B-X
%	B-X
(	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
[	B-X
CI	B-X
]	B-X
6	B-X
%	B-X
	B-X
-	B-X
28	B-X
%	B-X
)	B-X
,	B-X
suggesting	B-X
other	B-X
predisposition	B-X
genes	B-X

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O
<EOS>	B-X
The	B-X
estimated	B-X
cumulative	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
reached	B-X
28	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
9	B-X
%	B-X
	B-X
-	B-X
44	B-X
%	B-X
)	B-X
by	B-X
age	B-X
50	B-X
years	B-X
and	B-X
84	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
43	B-X
%	B-X
	B-X
-	B-X
95	B-X
%	B-X
)	B-X
by	B-X
age	B-X
70	B-X
years	B-X
<EOS>	B-X
4	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
0	B-X
%	B-X
	B-X
-	B-X
1	B-X
%	B-X
)	B-X
by	B-X
age	B-X
50	B-X
years	B-X
and	B-X
27	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
0	B-X
%	B-X
	B-X
-	B-X
47	B-X
%	B-X
)	B-X
by	B-X
age	B-X
70	B-X
years	B-X
<EOS>	B-X
The	B-X
lifetime	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
appears	B-X
similar	B-X
to	B-X
the	B-X
risk	B-X
in	B-X
BRCA1	B-X
carriers	B-X
,	B-X
but	B-X
there	B-X
was	B-X
some	B-X
suggestion	B-X
of	B-X
a	B-X
lower	B-X
risk	B-X
in	B-X
BRCA2	B-X
carriers	B-X
<	B-X
50	B-X
years	B-X
of	B-X
age	B-X
<EOS>	B-X
The	B-X
contribution	B-X
of	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
to	B-X
inherited	B-X
breast	B-X
cancer	B-X
was	B-X
assessed	B-X
by	B-X
linkage	B-X
and	B-X
mutation	B-X
analysis	B-X
in	B-X
237	B-X
families	B-X
,	B-X
each	B-X
with	B-X
at	B-X
least	B-X
four	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
,	B-X
collected	B-X
by	B-X
the	B-X
Breast	B-X
Cancer	B-X
Linkage	B-X
Consortium	B-X

The	O
corresponding	O
ovarian	B-Disease
cancer	I-Disease
risks	O
were	O
0	O
.	O

4	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

Eye	B-Disease
movement	I-Disease
abnormalities	I-Disease
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
I	I-Disease
.	O
<EOS>	B-X
Eye	B-X
movement	B-X
abnormalities	B-X
correlate	B-X
with	B-X
genotype	B-X
in	B-X
autosomal	B-X
dominant	B-X
cerebellar	B-X
ataxia	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
Two	B-X
novel	B-X
missense	B-X
variants	B-X
in	B-X
SPTBN2	B-X
likely	B-X
associated	B-X
with	B-X
spinocerebellar	B-X
ataxia	B-X
type	B-X
5	B-X
.	B-X
<EOS>	B-X
These	B-X
sizes	B-X
correlated	B-X
inversely	B-X
with	B-X
age	B-X
at	B-X
onset	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
errors	B-X
in	B-X
antisaccades	B-X
was	B-X
greatly	B-X
increased	B-X
and	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B-Disease
ataxias	I-Disease
type	I-Disease
I	I-Disease
spinocerebellar	B-Disease
ataxias	I-Disease
1	I-Disease
and	I-Disease
2	I-Disease
(	O
SCA1	B-Disease
,	O
n	O
=	O
11	O
;	O
SCA2	B-Disease
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B-Disease
/	O
Machado	B-Disease
-	I-Disease
Joseph	I-Disease
disease	I-Disease
(	O
MJD	B-Disease
)	O
(	O
n	O
=	O
16	O
)	O
.	O
<EOS>	B-X
We	B-X
compared	B-X
horizontal	B-X
eye	B-X
movements	B-X
(	B-X
visually	B-X
guided	B-X
saccades	B-X
,	B-X
antisaccades	B-X
,	B-X
and	B-X
smooth	B-X
pursuit	B-X
)	B-X
in	B-X
control	B-X
subjects	B-X
(	B-X
n	B-X
=	B-X
14	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
three	B-X
forms	B-X
of	B-X
autosomal	B-X
dominant	B-X
cerebellar	B-X
ataxias	B-X
type	B-X
I	B-X
:	B-X
spinocerebellar	B-X
ataxias	B-X
1	B-X
and	B-X
2	B-X
(	B-X
SCA1	B-X
,	B-X
n	B-X
=	B-X
11	B-X
;	B-X
SCA2	B-X
,	B-X
n	B-X
=	B-X
10	B-X
)	B-X
and	B-X
SCA3	B-X
/	B-X
Machado	B-X
-	B-X
Joseph	B-X
disease	B-X
(	B-X
MJD	B-X
)	B-X
(	B-X
n	B-X
=	B-X
16	B-X
)	B-X
<EOS>	B-X
Eye	B-X
movement	B-X
abnormalities	B-X
correlate	B-X
with	B-X
genotype	B-X
in	B-X
autosomal	B-X
dominant	B-X
cerebellar	B-X
ataxia	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
errors	B-X
in	B-X
antisaccades	B-X
was	B-X
greatly	B-X
increased	B-X
and	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
<EOS>	B-X
Three	B-X
major	B-X
criteria	B-X
,	B-X
saccade	B-X
amplitude	B-X
,	B-X
saccade	B-X
velocity	B-X
,	B-X
and	B-X
presence	B-X
of	B-X
gaze	B-X
-	B-X
evoked	B-X
nystagmus	B-X
,	B-X
permitted	B-X
the	B-X
correct	B-X
assignment	B-X
of	B-X
90	B-X
%	B-X
of	B-X
the	B-X
SCA1	B-X
,	B-X
90	B-X
%	B-X
of	B-X
the	B-X
SCA2	B-X
,	B-X
and	B-X
93	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
with	B-X
SCA3	B-X
to	B-X
their	B-X
genetically	B-X
confirmed	B-X
patient	B-X
group	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
may	B-X
help	B-X
orient	B-X
diagnoses	B-X
of	B-X
SCA1	B-X
,	B-X
SCA2	B-X
,	B-X
and	B-X
SCA3	B-X
at	B-X
early	B-X
clinical	B-X
stages	B-X
of	B-X
the	B-X
diseases	B-X

In	O
SCA1	B-Disease
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B-Disease
.	O
<EOS>	B-X
In	B-X
SCA1	B-X
,	B-X
saccade	B-X
amplitude	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
resulting	B-X
in	B-X
hypermetria	B-X
<EOS>	B-X
In	B-X
SCA2	B-X
,	B-X
saccade	B-X
velocity	B-X
was	B-X
markedly	B-X
decreased	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
errors	B-X
in	B-X
antisaccades	B-X
was	B-X
greatly	B-X
increased	B-X
and	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
<EOS>	B-X
In	B-X
SCA3	B-X
,	B-X
gaze	B-X
-	B-X
evoked	B-X
nystagmus	B-X
was	B-X
often	B-X
present	B-X
as	B-X
was	B-X
saccade	B-X
hypometria	B-X
and	B-X
smooth	B-X
pursuit	B-X
gain	B-X
was	B-X
markedly	B-X
decreased	B-X

The	O
smooth	O
pursuit	O
gain	O
was	O
decreased	O
.	O
<EOS>	B-X
Smooth	B-X
pursuit	B-X
gains	B-X
increased	B-X
with	B-X
increased	B-X
age	B-X
<EOS>	B-X
The	B-X
target	B-X
was	B-X
a	B-X
0	B-X
<EOS>	B-X
Eye	B-X
,	B-X
head	B-X
,	B-X
and	B-X
gaze	B-X
contributions	B-X
to	B-X
smooth	B-X
pursuit	B-X
in	B-X
macular	B-X
degeneration	B-X
.	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
our	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
VEM	B-X
performance	B-X
in	B-X
SZ	B-X
and	B-X
BD	B-X

In	O
SCA2	B-Disease
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O
<EOS>	B-X
In	B-X
SCA2	B-X
,	B-X
saccade	B-X
velocity	B-X
was	B-X
markedly	B-X
decreased	B-X
<EOS>	B-X
In	B-X
SCA1	B-X
,	B-X
saccade	B-X
amplitude	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
resulting	B-X
in	B-X
hypermetria	B-X
<EOS>	B-X
The	B-X
smooth	B-X
pursuit	B-X
gain	B-X
was	B-X
decreased	B-X
<EOS>	B-X
In	B-X
SCA3	B-X
,	B-X
gaze	B-X
-	B-X
evoked	B-X
nystagmus	B-X
was	B-X
often	B-X
present	B-X
as	B-X
was	B-X
saccade	B-X
hypometria	B-X
and	B-X
smooth	B-X
pursuit	B-X
gain	B-X
was	B-X
markedly	B-X
decreased	B-X

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
.	O
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
errors	B-X
in	B-X
antisaccades	B-X
was	B-X
greatly	B-X
increased	B-X
and	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
age	B-X
at	B-X
disease	B-X
onset	B-X
<EOS>	B-X
In	B-X
SCA1	B-X
,	B-X
saccade	B-X
amplitude	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
resulting	B-X
in	B-X
hypermetria	B-X
<EOS>	B-X
Eye	B-X
movement	B-X
abnormalities	B-X
correlate	B-X
with	B-X
genotype	B-X
in	B-X
autosomal	B-X
dominant	B-X
cerebellar	B-X
ataxia	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
We	B-X
compared	B-X
horizontal	B-X
eye	B-X
movements	B-X
(	B-X
visually	B-X
guided	B-X
saccades	B-X
,	B-X
antisaccades	B-X
,	B-X
and	B-X
smooth	B-X
pursuit	B-X
)	B-X
in	B-X
control	B-X
subjects	B-X
(	B-X
n	B-X
=	B-X
14	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
three	B-X
forms	B-X
of	B-X
autosomal	B-X
dominant	B-X
cerebellar	B-X
ataxias	B-X
type	B-X
I	B-X
:	B-X
spinocerebellar	B-X
ataxias	B-X
1	B-X
and	B-X
2	B-X
(	B-X
SCA1	B-X
,	B-X
n	B-X
=	B-X
11	B-X
;	B-X
SCA2	B-X
,	B-X
n	B-X
=	B-X
10	B-X
)	B-X
and	B-X
SCA3	B-X
/	B-X
Machado	B-X
-	B-X
Joseph	B-X
disease	B-X
(	B-X
MJD	B-X
)	B-X
(	B-X
n	B-X
=	B-X
16	B-X
)	B-X

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
correlation	B-X
between	B-X
smooth	B-X
pursuit	B-X
gain	B-X
and	B-X
the	B-X
number	B-X
of	B-X
trinucleotide	B-X
repeats	B-X
was	B-X
found	B-X
<EOS>	B-X
The	B-X
smooth	B-X
pursuit	B-X
gain	B-X
was	B-X
decreased	B-X
<EOS>	B-X
Eye	B-X
movement	B-X
abnormalities	B-X
correlate	B-X
with	B-X
genotype	B-X
in	B-X
autosomal	B-X
dominant	B-X
cerebellar	B-X
ataxia	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
In	B-X
SCA1	B-X
,	B-X
saccade	B-X
amplitude	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
resulting	B-X
in	B-X
hypermetria	B-X

In	O
SCA3	B-Disease
,	O
gaze	B-Disease
-	I-Disease
evoked	I-Disease
nystagmus	I-Disease
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O
<EOS>	B-X
In	B-X
SCA3	B-X
,	B-X
gaze	B-X
-	B-X
evoked	B-X
nystagmus	B-X
was	B-X
often	B-X
present	B-X
as	B-X
was	B-X
saccade	B-X
hypometria	B-X
and	B-X
smooth	B-X
pursuit	B-X
gain	B-X
was	B-X
markedly	B-X
decreased	B-X
<EOS>	B-X
In	B-X
SCA2	B-X
,	B-X
saccade	B-X
velocity	B-X
was	B-X
markedly	B-X
decreased	B-X
<EOS>	B-X
The	B-X
smooth	B-X
pursuit	B-X
gain	B-X
was	B-X
decreased	B-X
<EOS>	B-X
In	B-X
SCA1	B-X
,	B-X
saccade	B-X
amplitude	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
resulting	B-X
in	B-X
hypermetria	B-X

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B-Disease
-	I-Disease
evoked	I-Disease
nystagmus	I-Disease
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B-Disease
,	O
90	O
%	O
of	O
the	O
SCA2	B-Disease
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B-Disease
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B-Disease
,	O
SCA2	B-Disease
,	O
and	O
SCA3	B-Disease
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
.	O

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	I-Disease
.	O
<EOS>	B-X
Genetic	B-X
basis	B-X
and	B-X
molecular	B-X
mechanism	B-X
for	B-X
idiopathic	B-X
ventricular	B-X
fibrillation	B-X
.	B-X
<EOS>	B-X
Genetic	B-X
basis	B-X
and	B-X
molecular	B-X
mechanism	B-X
for	B-X
idiopathic	B-X
ventricular	B-X
fibrillation	B-X
<EOS>	B-X
Generally	B-X
,	B-X
it	B-X
is	B-X
arrhythmic	B-X
death	B-X
due	B-X
to	B-X
ventricular	B-X
tachyarrythmias	B-X
	B-X
-	B-X
	B-X
sustained	B-X
ventricular	B-X
tachycardia	B-X
(	B-X
VT	B-X
)	B-X
or	B-X
ventricular	B-X
fibrillation	B-X
(	B-X
VF	B-X
)	B-X
<EOS>	B-X
Unique	B-X
cardiac	B-X
Purkinje	B-X
fiber	B-X
transient	B-X
outward	B-X
current	B-X
Î²	B-X
-	B-X
subunit	B-X
composition	B-X
:	B-X
a	B-X
potential	B-X
molecular	B-X
link	B-X
to	B-X
idiopathic	B-X
ventricular	B-X
fibrillation	B-X
.	B-X

Ventricular	B-Disease
fibrillation	I-Disease
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O
<EOS>	B-X
Ventricular	B-X
fibrillation	B-X
causes	B-X
more	B-X
than	B-X
300,000	B-X
sudden	B-X
deaths	B-X
each	B-X
year	B-X
in	B-X
the	B-X
USA	B-X
alone	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
small	B-X
size	B-X
of	B-X
most	B-X
pedigrees	B-X
and	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
sudden	B-X
death	B-X
,	B-X
however	B-X
,	B-X
molecular	B-X
genetic	B-X
studies	B-X
of	B-X
IVF	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
done	B-X
<EOS>	B-X
Genetic	B-X
basis	B-X
and	B-X
molecular	B-X
mechanism	B-X
for	B-X
idiopathic	B-X
ventricular	B-X
fibrillation	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
now	B-X
identified	B-X
a	B-X
missense	B-X
mutation	B-X
,	B-X
a	B-X
splice	B-X
-	B-X
donor	B-X
mutation	B-X
,	B-X
and	B-X
a	B-X
frameshift	B-X
mutation	B-X
in	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
SCN5A	B-X
in	B-X
three	B-X
IVF	B-X
families	B-X

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B-Disease
ventricular	I-Disease
fibrillation	I-Disease
(	O
IVF	B-Disease
)	O
.	O
<EOS>	B-X
Approximately	B-X
40	B-X
-	B-X
60	B-X
%	B-X
of	B-X
patients	B-X
are	B-X
positive	B-X
to	B-X
pANCA	B-X
(	B-X
9	B-X
)	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
these	B-X
antibodies	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
EGPA	B-X
remains	B-X
unclear	B-X
<EOS>	B-X
Primary	B-X
outcomes	B-X
were	B-X
survival	B-X
to	B-X
hospital	B-X
discharge	B-X
in	B-X
all	B-X
patients	B-X
and	B-X
in	B-X
the	B-X
subgroup	B-X
with	B-X
witnessed	B-X
ventricular	B-X
fibrillation	B-X
/	B-X
pulseless	B-X
ventricular	B-X
tachycardia	B-X
(	B-X
VF	B-X
/	B-X
VT	B-X
)	B-X
<EOS>	B-X
In	B-X
Canada	B-X
each	B-X
year	B-X
more	B-X
than	B-X
40,000	B-X
people	B-X
die	B-X
from	B-X
a	B-X
cardiovascular	B-X
related	B-X
cause	B-X
;	B-X
approximately	B-X
half	B-X
of	B-X
these	B-X
deaths	B-X
are	B-X
attributable	B-X
to	B-X
SCD	B-X
<EOS>	B-X
4	B-X
%	B-X
of	B-X
patients	B-X
met	B-X
all	B-X
three	B-X
histopathological	B-X
criteria	B-X
,	B-X
and	B-X
the	B-X
diagnosis	B-X
of	B-X
the	B-X
disease	B-X
was	B-X
frequently	B-X
delayed	B-X
despite	B-X
of	B-X
its	B-X
overt	B-X
clinical	B-X
picture	B-X
(	B-X
2	B-X
)	B-X

A	O
distinct	O
group	O
of	O
IVF	B-Disease
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O
<EOS>	B-X
A	B-X
distinct	B-X
group	B-X
of	B-X
IVF	B-X
patients	B-X
has	B-X
been	B-X
found	B-X
to	B-X
present	B-X
with	B-X
a	B-X
characteristic	B-X
electrocardiographic	B-X
pattern	B-X
<EOS>	B-X
Genetic	B-X
basis	B-X
and	B-X
molecular	B-X
mechanism	B-X
for	B-X
idiopathic	B-X
ventricular	B-X
fibrillation	B-X
.	B-X
<EOS>	B-X
In	B-X
approximately	B-X
5	B-X
-	B-X
12	B-X
%	B-X
of	B-X
these	B-X
cases	B-X
,	B-X
there	B-X
are	B-X
no	B-X
demonstrable	B-X
cardiac	B-X
or	B-X
non	B-X
-	B-X
cardiac	B-X
causes	B-X
to	B-X
account	B-X
for	B-X
the	B-X
episode	B-X
,	B-X
which	B-X
is	B-X
therefore	B-X
classified	B-X
as	B-X
idiopathic	B-X
ventricular	B-X
fibrillation	B-X
(	B-X
IVF	B-X
)	B-X
<EOS>	B-X
Ventricular	B-X
fibrillation	B-X
causes	B-X
more	B-X
than	B-X
300,000	B-X
sudden	B-X
deaths	B-X
each	B-X
year	B-X
in	B-X
the	B-X
USA	B-X
alone	B-X

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B-Disease
death	I-Disease
,	O
however	O
,	O
molecular	O
genetic	O
studies	O
of	O
IVF	B-Disease
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
IVF	B-Disease
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O
<EOS>	B-X
Because	B-X
IVF	B-X
causes	B-X
cardiac	B-X
rhythm	B-X
disturbance	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
malfunction	B-X
of	B-X
ion	B-X
channels	B-X
could	B-X
cause	B-X
the	B-X
disorder	B-X
by	B-X
studying	B-X
mutations	B-X
in	B-X
the	B-X
cardiac	B-X
sodium	B-X
channel	B-X
gene	B-X
SCN5A	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
mutations	B-X
in	B-X
cardiac	B-X
ion	B-X
-	B-X
channel	B-X
genes	B-X
contribute	B-X
to	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
IVF	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
sodium	B-X
channels	B-X
with	B-X
the	B-X
missense	B-X
mutation	B-X
recover	B-X
from	B-X
inactivation	B-X
more	B-X
rapidly	B-X
than	B-X
normal	B-X
and	B-X
that	B-X
the	B-X
frameshift	B-X
mutation	B-X
causes	B-X
the	B-X
sodium	B-X
channel	B-X
to	B-X
be	B-X
non	B-X
-	B-X
functional	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
small	B-X
size	B-X
of	B-X
most	B-X
pedigrees	B-X
and	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
sudden	B-X
death	B-X
,	B-X
however	B-X
,	B-X
molecular	B-X
genetic	B-X
studies	B-X
of	B-X
IVF	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
done	B-X

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B-Disease
families	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
sodium	B-X
channels	B-X
with	B-X
the	B-X
missense	B-X
mutation	B-X
recover	B-X
from	B-X
inactivation	B-X
more	B-X
rapidly	B-X
than	B-X
normal	B-X
and	B-X
that	B-X
the	B-X
frameshift	B-X
mutation	B-X
causes	B-X
the	B-X
sodium	B-X
channel	B-X
to	B-X
be	B-X
non	B-X
-	B-X
functional	B-X
<EOS>	B-X
We	B-X
have	B-X
now	B-X
identified	B-X
a	B-X
missense	B-X
mutation	B-X
,	B-X
a	B-X
splice	B-X
-	B-X
donor	B-X
mutation	B-X
,	B-X
and	B-X
a	B-X
frameshift	B-X
mutation	B-X
in	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
SCN5A	B-X
in	B-X
three	B-X
IVF	B-X
families	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
mutations	B-X
in	B-X
cardiac	B-X
ion	B-X
-	B-X
channel	B-X
genes	B-X
contribute	B-X
to	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
IVF	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
small	B-X
size	B-X
of	B-X
most	B-X
pedigrees	B-X
and	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
sudden	B-X
death	B-X
,	B-X
however	B-X
,	B-X
molecular	B-X
genetic	B-X
studies	B-X
of	B-X
IVF	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
done	B-X

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B-Disease
.	O
.	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B-Disease
IVA	I-Disease
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O
<EOS>	B-X
Molecular	B-X
heterogeneity	B-X
in	B-X
mucopolysaccharidosis	B-X
IVA	B-X
in	B-X
Australia	B-X
and	B-X
Northern	B-X
Ireland	B-X
:	B-X
nine	B-X
novel	B-X
mutations	B-X
including	B-X
T312S	B-X
,	B-X
a	B-X
common	B-X
allele	B-X
that	B-X
confers	B-X
a	B-X
mild	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
We	B-X
studied	B-X
mutations	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
from	B-X
23	B-X
additional	B-X
MPS	B-X
IVA	B-X
patients	B-X
(	B-X
15	B-X
from	B-X
Australia	B-X
,	B-X
8	B-X
from	B-X
Northern	B-X
Ireland	B-X
)	B-X
,	B-X
with	B-X
various	B-X
clinical	B-X
phenotypes	B-X
(	B-X
severe	B-X
,	B-X
16	B-X
cases	B-X
;	B-X
intermediate	B-X
,	B-X
4	B-X
cases	B-X
;	B-X
mild	B-X
,	B-X
3	B-X
cases	B-X
)	B-X
<EOS>	B-X
The	B-X
distribution	B-X
and	B-X
relative	B-X
frequencies	B-X
of	B-X
the	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
in	B-X
Australia	B-X
corresponded	B-X
to	B-X
those	B-X
observed	B-X
in	B-X
Northern	B-X
Ireland	B-X
and	B-X
are	B-X
unique	B-X
to	B-X
these	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
mutations	B-X
were	B-X
probably	B-X
introduced	B-X
to	B-X
Australia	B-X
by	B-X
Irish	B-X
migrants	B-X
during	B-X
the	B-X
19th	B-X
century	B-X
<EOS>	B-X
Haplotype	B-X
analysis	B-X
using	B-X
6	B-X
RFLPs	B-X
provides	B-X
additional	B-X
data	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X

Previous	O
studies	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B-Disease
IVA	I-Disease
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
of	B-X
patients	B-X
from	B-X
a	B-X
British	B-X
-	B-X
Irish	B-X
population	B-X
showed	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
single	B-X
mutation	B-X
among	B-X
MPS	B-X
IVA	B-X
patients	B-X
and	B-X
produces	B-X
a	B-X
severe	B-X
clinical	B-X
phenotype	B-X
<EOS>	B-X
Haplotype	B-X
analysis	B-X
using	B-X
6	B-X
RFLPs	B-X
provides	B-X
additional	B-X
data	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X
<EOS>	B-X
The	B-X
other	B-X
is	B-X
the	B-X
previously	B-X
described	B-X
I113F	B-X
that	B-X
produces	B-X
a	B-X
severe	B-X
phenotype	B-X
<EOS>	B-X
The	B-X
distribution	B-X
and	B-X
relative	B-X
frequencies	B-X
of	B-X
the	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
in	B-X
Australia	B-X
corresponded	B-X
to	B-X
those	B-X
observed	B-X
in	B-X
Northern	B-X
Ireland	B-X
and	B-X
are	B-X
unique	B-X
to	B-X
these	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
mutations	B-X
were	B-X
probably	B-X
introduced	B-X
to	B-X
Australia	B-X
by	B-X
Irish	B-X
migrants	B-X
during	B-X
the	B-X
19th	B-X
century	B-X

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B-Disease
IVA	I-Disease
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
mutations	B-X
in	B-X
the	B-X
GALNS	B-X
gene	B-X
from	B-X
23	B-X
additional	B-X
MPS	B-X
IVA	B-X
patients	B-X
(	B-X
15	B-X
from	B-X
Australia	B-X
,	B-X
8	B-X
from	B-X
Northern	B-X
Ireland	B-X
)	B-X
,	B-X
with	B-X
various	B-X
clinical	B-X
phenotypes	B-X
(	B-X
severe	B-X
,	B-X
16	B-X
cases	B-X
;	B-X
intermediate	B-X
,	B-X
4	B-X
cases	B-X
;	B-X
mild	B-X
,	B-X
3	B-X
cases	B-X
)	B-X
<EOS>	B-X
Molecular	B-X
heterogeneity	B-X
in	B-X
mucopolysaccharidosis	B-X
IVA	B-X
in	B-X
Australia	B-X
and	B-X
Northern	B-X
Ireland	B-X
:	B-X
nine	B-X
novel	B-X
mutations	B-X
including	B-X
T312S	B-X
,	B-X
a	B-X
common	B-X
allele	B-X
that	B-X
confers	B-X
a	B-X
mild	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
The	B-X
distribution	B-X
and	B-X
relative	B-X
frequencies	B-X
of	B-X
the	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
in	B-X
Australia	B-X
corresponded	B-X
to	B-X
those	B-X
observed	B-X
in	B-X
Northern	B-X
Ireland	B-X
and	B-X
are	B-X
unique	B-X
to	B-X
these	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
mutations	B-X
were	B-X
probably	B-X
introduced	B-X
to	B-X
Australia	B-X
by	B-X
Irish	B-X
migrants	B-X
during	B-X
the	B-X
19th	B-X
century	B-X
<EOS>	B-X
Haplotype	B-X
analysis	B-X
using	B-X
6	B-X
RFLPs	B-X
provides	B-X
additional	B-X
data	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O
<EOS>	B-X
We	B-X
found	B-X
two	B-X
common	B-X
mutations	B-X
that	B-X
together	B-X
accounted	B-X
for	B-X
32	B-X
%	B-X
of	B-X
the	B-X
44	B-X
unrelated	B-X
alleles	B-X
in	B-X
these	B-X
patients	B-X
<EOS>	B-X
The	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
accounted	B-X
for	B-X
8	B-X
(	B-X
18	B-X
%	B-X
)	B-X
and	B-X
6	B-X
(	B-X
14	B-X
%	B-X
)	B-X
of	B-X
44	B-X
unrelated	B-X
alleles	B-X
,	B-X
respectively	B-X
<EOS>	B-X
One	B-X
is	B-X
the	B-X
T312S	B-X
mutation	B-X
,	B-X
a	B-X
novel	B-X
mutation	B-X
found	B-X
exclusively	B-X
in	B-X
milder	B-X
patients	B-X
<EOS>	B-X
The	B-X
other	B-X
9	B-X
novel	B-X
mutations	B-X
identified	B-X
in	B-X
these	B-X
23	B-X
patients	B-X
were	B-X
each	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
family	B-X

One	O
is	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O
<EOS>	B-X
One	B-X
is	B-X
the	B-X
T312S	B-X
mutation	B-X
,	B-X
a	B-X
novel	B-X
mutation	B-X
found	B-X
exclusively	B-X
in	B-X
milder	B-X
patients	B-X
<EOS>	B-X
We	B-X
found	B-X
two	B-X
common	B-X
mutations	B-X
that	B-X
together	B-X
accounted	B-X
for	B-X
32	B-X
%	B-X
of	B-X
the	B-X
44	B-X
unrelated	B-X
alleles	B-X
in	B-X
these	B-X
patients	B-X
<EOS>	B-X
The	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
accounted	B-X
for	B-X
8	B-X
(	B-X
18	B-X
%	B-X
)	B-X
and	B-X
6	B-X
(	B-X
14	B-X
%	B-X
)	B-X
of	B-X
44	B-X
unrelated	B-X
alleles	B-X
,	B-X
respectively	B-X
<EOS>	B-X
The	B-X
other	B-X
9	B-X
novel	B-X
mutations	B-X
identified	B-X
in	B-X
these	B-X
23	B-X
patients	B-X
were	B-X
each	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
family	B-X

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O
.	O
<EOS>	B-X
The	B-X
other	B-X
is	B-X
the	B-X
previously	B-X
described	B-X
I113F	B-X
that	B-X
produces	B-X
a	B-X
severe	B-X
phenotype	B-X
<EOS>	B-X
The	B-X
other	B-X
9	B-X
novel	B-X
mutations	B-X
identified	B-X
in	B-X
these	B-X
23	B-X
patients	B-X
were	B-X
each	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
family	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
of	B-X
patients	B-X
from	B-X
a	B-X
British	B-X
-	B-X
Irish	B-X
population	B-X
showed	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
single	B-X
mutation	B-X
among	B-X
MPS	B-X
IVA	B-X
patients	B-X
and	B-X
produces	B-X
a	B-X
severe	B-X
clinical	B-X
phenotype	B-X
<EOS>	B-X
The	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
accounted	B-X
for	B-X
8	B-X
(	B-X
18	B-X
%	B-X
)	B-X
and	B-X
6	B-X
(	B-X
14	B-X
%	B-X
)	B-X
of	B-X
44	B-X
unrelated	B-X
alleles	B-X
,	B-X
respectively	B-X

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O
<EOS>	B-X
The	B-X
relatively	B-X
high	B-X
residual	B-X
GALNS	B-X
activity	B-X
seen	B-X
when	B-X
the	B-X
T312S	B-X
mutant	B-X
cDNA	B-X
is	B-X
overexpressed	B-X
in	B-X
mutant	B-X
cells	B-X
provides	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
mild	B-X
phenotype	B-X
in	B-X
patients	B-X
with	B-X
this	B-X
mutation	B-X
<EOS>	B-X
One	B-X
is	B-X
the	B-X
T312S	B-X
mutation	B-X
,	B-X
a	B-X
novel	B-X
mutation	B-X
found	B-X
exclusively	B-X
in	B-X
milder	B-X
patients	B-X
<EOS>	B-X
The	B-X
distribution	B-X
and	B-X
relative	B-X
frequencies	B-X
of	B-X
the	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
in	B-X
Australia	B-X
corresponded	B-X
to	B-X
those	B-X
observed	B-X
in	B-X
Northern	B-X
Ireland	B-X
and	B-X
are	B-X
unique	B-X
to	B-X
these	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
mutations	B-X
were	B-X
probably	B-X
introduced	B-X
to	B-X
Australia	B-X
by	B-X
Irish	B-X
migrants	B-X
during	B-X
the	B-X
19th	B-X
century	B-X
<EOS>	B-X
We	B-X
found	B-X
two	B-X
common	B-X
mutations	B-X
that	B-X
together	B-X
accounted	B-X
for	B-X
32	B-X
%	B-X
of	B-X
the	B-X
44	B-X
unrelated	B-X
alleles	B-X
in	B-X
these	B-X
patients	B-X

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O
.	O
<EOS>	B-X
The	B-X
distribution	B-X
and	B-X
relative	B-X
frequencies	B-X
of	B-X
the	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
in	B-X
Australia	B-X
corresponded	B-X
to	B-X
those	B-X
observed	B-X
in	B-X
Northern	B-X
Ireland	B-X
and	B-X
are	B-X
unique	B-X
to	B-X
these	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
mutations	B-X
were	B-X
probably	B-X
introduced	B-X
to	B-X
Australia	B-X
by	B-X
Irish	B-X
migrants	B-X
during	B-X
the	B-X
19th	B-X
century	B-X
<EOS>	B-X
Molecular	B-X
heterogeneity	B-X
in	B-X
mucopolysaccharidosis	B-X
IVA	B-X
in	B-X
Australia	B-X
and	B-X
Northern	B-X
Ireland	B-X
:	B-X
nine	B-X
novel	B-X
mutations	B-X
including	B-X
T312S	B-X
,	B-X
a	B-X
common	B-X
allele	B-X
that	B-X
confers	B-X
a	B-X
mild	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
further	B-X
evidence	B-X
for	B-X
extensive	B-X
allelic	B-X
heterogeneity	B-X
in	B-X
MPS	B-X
IVA	B-X
in	B-X
British	B-X
-	B-X
Irish	B-X
patients	B-X
and	B-X
provide	B-X
evidence	B-X
for	B-X
their	B-X
transmission	B-X
to	B-X
Australia	B-X
by	B-X
British	B-X
-	B-X
Irish	B-X
migrants	B-X
<EOS>	B-X
The	B-X
relatively	B-X
high	B-X
residual	B-X
GALNS	B-X
activity	B-X
seen	B-X
when	B-X
the	B-X
T312S	B-X
mutant	B-X
cDNA	B-X
is	B-X
overexpressed	B-X
in	B-X
mutant	B-X
cells	B-X
provides	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
mild	B-X
phenotype	B-X
in	B-X
patients	B-X
with	B-X
this	B-X
mutation	B-X

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O
<EOS>	B-X
Haplotype	B-X
analysis	B-X
using	B-X
6	B-X
RFLPs	B-X
provides	B-X
additional	B-X
data	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
originated	B-X
from	B-X
a	B-X
common	B-X
ancestor	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
of	B-X
patients	B-X
from	B-X
a	B-X
British	B-X
-	B-X
Irish	B-X
population	B-X
showed	B-X
that	B-X
the	B-X
I113F	B-X
mutation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
single	B-X
mutation	B-X
among	B-X
MPS	B-X
IVA	B-X
patients	B-X
and	B-X
produces	B-X
a	B-X
severe	B-X
clinical	B-X
phenotype	B-X
<EOS>	B-X
Molecular	B-X
heterogeneity	B-X
in	B-X
mucopolysaccharidosis	B-X
IVA	B-X
in	B-X
Australia	B-X
and	B-X
Northern	B-X
Ireland	B-X
:	B-X
nine	B-X
novel	B-X
mutations	B-X
including	B-X
T312S	B-X
,	B-X
a	B-X
common	B-X
allele	B-X
that	B-X
confers	B-X
a	B-X
mild	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
The	B-X
other	B-X
is	B-X
the	B-X
previously	B-X
described	B-X
I113F	B-X
that	B-X
produces	B-X
a	B-X
severe	B-X
phenotype	B-X

The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
.	O
<EOS>	B-X
The	B-X
other	B-X
9	B-X
novel	B-X
mutations	B-X
identified	B-X
in	B-X
these	B-X
23	B-X
patients	B-X
were	B-X
each	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
family	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
characterized	B-X
mutations	B-X
in	B-X
KRT5	B-X
and	B-X
KRT14	B-X
genes	B-X
in	B-X
patients	B-X
with	B-X
EBS	B-X
and	B-X
investigated	B-X
their	B-X
possible	B-X
structure	B-X
-	B-X
function	B-X
correlations	B-X
<EOS>	B-X
One	B-X
is	B-X
the	B-X
T312S	B-X
mutation	B-X
,	B-X
a	B-X
novel	B-X
mutation	B-X
found	B-X
exclusively	B-X
in	B-X
milder	B-X
patients	B-X
<EOS>	B-X
The	B-X
other	B-X
is	B-X
the	B-X
previously	B-X
described	B-X
I113F	B-X
that	B-X
produces	B-X
a	B-X
severe	B-X
phenotype	B-X

These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B-Disease
IVA	I-Disease
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
.	O
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
further	B-X
evidence	B-X
for	B-X
extensive	B-X
allelic	B-X
heterogeneity	B-X
in	B-X
MPS	B-X
IVA	B-X
in	B-X
British	B-X
-	B-X
Irish	B-X
patients	B-X
and	B-X
provide	B-X
evidence	B-X
for	B-X
their	B-X
transmission	B-X
to	B-X
Australia	B-X
by	B-X
British	B-X
-	B-X
Irish	B-X
migrants	B-X
<EOS>	B-X
The	B-X
distribution	B-X
and	B-X
relative	B-X
frequencies	B-X
of	B-X
the	B-X
I113F	B-X
and	B-X
T312S	B-X
mutations	B-X
in	B-X
Australia	B-X
corresponded	B-X
to	B-X
those	B-X
observed	B-X
in	B-X
Northern	B-X
Ireland	B-X
and	B-X
are	B-X
unique	B-X
to	B-X
these	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
mutations	B-X
were	B-X
probably	B-X
introduced	B-X
to	B-X
Australia	B-X
by	B-X
Irish	B-X
migrants	B-X
during	B-X
the	B-X
19th	B-X
century	B-X
<EOS>	B-X
The	B-X
other	B-X
9	B-X
novel	B-X
mutations	B-X
identified	B-X
in	B-X
these	B-X
23	B-X
patients	B-X
were	B-X
each	B-X
limited	B-X
to	B-X
a	B-X
single	B-X
family	B-X
<EOS>	B-X
The	B-X
relatively	B-X
high	B-X
residual	B-X
GALNS	B-X
activity	B-X
seen	B-X
when	B-X
the	B-X
T312S	B-X
mutant	B-X
cDNA	B-X
is	B-X
overexpressed	B-X
in	B-X
mutant	B-X
cells	B-X
provides	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
mild	B-X
phenotype	B-X
in	B-X
patients	B-X
with	B-X
this	B-X
mutation	B-X

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
constitutional	B-X
WT1	B-X
mutations	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
diffuse	B-X
mesangial	B-X
sclerosis	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
genotype	B-X
/	B-X
phenotype	B-X
correlations	B-X
by	B-X
use	B-X
of	B-X
a	B-X
computerized	B-X
mutation	B-X
database	B-X
.	B-X
<EOS>	B-X
No	B-X
WT1	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
six	B-X
other	B-X
IDMS	B-X
patients	B-X
,	B-X
suggesting	B-X
genetic	B-X
heterogeneity	B-X
of	B-X
this	B-X
disease	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
a	B-X
series	B-X
of	B-X
24	B-X
patients	B-X
,	B-X
10	B-X
with	B-X
isolated	B-X
DMS	B-X
(	B-X
IDMS	B-X
)	B-X
,	B-X
10	B-X
with	B-X
DDS	B-X
,	B-X
and	B-X
4	B-X
with	B-X
urogenital	B-X
abnormalities	B-X
and	B-X
/	B-X
or	B-X
WT	B-X
<EOS>	B-X
Most	B-X
mutations	B-X
in	B-X
DDS	B-X
patients	B-X
lie	B-X
in	B-X
exon	B-X
8	B-X
or	B-X
exon	B-X
9	B-X
,	B-X
encoding	B-X
zinc	B-X
finger	B-X
2	B-X
or	B-X
zinc	B-X
finger	B-X
3	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
a	B-X
hot	B-X
spot	B-X
(	B-X
R394W	B-X
)	B-X
in	B-X
exon	B-X
9	B-X

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	B-Disease
)	O
,	O
or	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
(	O
DMS	B-Disease
)	O
associated	O
with	O
pseudohermaphroditism	B-Disease
and	O
/	O
or	O
Wilms	B-Disease
tumor	I-Disease
(	O
WT	B-Disease
)	O
.	O
<EOS>	B-X
Cranial	B-X
and	B-X
accessory	B-X
lobes	B-X
extracted	B-X
from	B-X
KO	B-X
embryonic	B-X
lungs	B-X
fused	B-X
ex	B-X
vivo	B-X
when	B-X
cultured	B-X
in	B-X
juxtaposition	B-X
,	B-X
with	B-X
the	B-X
area	B-X
of	B-X
fusion	B-X
showing	B-X
loss	B-X
of	B-X
the	B-X
mesothelial	B-X
marker	B-X
Wilms	B-X
tumor	B-X
1	B-X
<EOS>	B-X
Survival	B-X
extrapolation	B-X
is	B-X
often	B-X
performed	B-X
by	B-X
fitting	B-X
one	B-X
or	B-X
two	B-X
parametric	B-X
models	B-X
selected	B-X
based	B-X
on	B-X
experience	B-X
or	B-X
selecting	B-X
a	B-X
model	B-X
based	B-X
on	B-X
some	B-X
goodness	B-X
of	B-X
fit	B-X
statistics	B-X
from	B-X
a	B-X
predefined	B-X
collection	B-X
of	B-X
models	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
retrospectively	B-X
analyse	B-X
outcomes	B-X
in	B-X
patients	B-X
with	B-X
stage	B-X
III	B-X
due	B-X
to	B-X
positive	B-X
resection	B-X
margins	B-X
(	B-X
RM	B-X
)	B-X
only	B-X
,	B-X
sub	B-X
-	B-X
grouped	B-X
in	B-X
RM	B-X
with	B-X
viable	B-X
(	B-X
RM	B-X
-	B-X
v	B-X
)	B-X
and	B-X
nonviable	B-X
(	B-X
RM	B-X
-	B-X
nv	B-X
)	B-X
tumour	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
miR	B-X
-	B-X
143	B-X
-	B-X
3p	B-X
was	B-X
significantly	B-X
downregulated	B-X
in	B-X
WT	B-X
tissues	B-X
and	B-X
its	B-X
expression	B-X
levels	B-X
were	B-X
closely	B-X
associated	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X

Most	O
mutations	O
in	O
DDS	B-Disease
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O
<EOS>	B-X
Germline	B-X
WT1	B-X
missense	B-X
mutations	B-X
located	B-X
in	B-X
exons	B-X
8	B-X
or	B-X
9	B-X
coding	B-X
for	B-X
zinc	B-X
fingers	B-X
2	B-X
or	B-X
3	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
nearly	B-X
all	B-X
patients	B-X
with	B-X
Denys	B-X
-	B-X
Drash	B-X
syndrome	B-X
and	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
isolated	B-X
diffuse	B-X
mesangial	B-X
sclerosis	B-X
<EOS>	B-X
Monoallelic	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
receptor	B-X
2	B-X
(	B-X
Bmpr2	B-X
)	B-X
are	B-X
the	B-X
main	B-X
genetic	B-X
risk	B-X
factor	B-X
for	B-X
heritable	B-X
pulmonary	B-X
arterial	B-X
hypertension	B-X
(	B-X
PAH	B-X
)	B-X
with	B-X
incomplete	B-X
penetrance	B-X
<EOS>	B-X
These	B-X
data	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
inclusion	B-X
of	B-X
WT1	B-X
gene	B-X
mutational	B-X
analysis	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
nephrotic	B-X
proteinuria	B-X
,	B-X
especially	B-X
when	B-X
similar	B-X
conditions	B-X
are	B-X
referred	B-X
to	B-X
the	B-X
family	B-X
<EOS>	B-X
This	B-X
mutation	B-X
was	B-X
inherited	B-X
from	B-X
her	B-X
mother	B-X
,	B-X
who	B-X
had	B-X
undergone	B-X
kidney	B-X
transplant	B-X
due	B-X
to	B-X
FSGS	B-X

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B-Disease
DMS	I-Disease
(	O
IDMS	B-Disease
)	O
,	O
10	O
with	O
DDS	B-Disease
,	O
and	O
4	O
with	O
urogenital	B-Disease
abnormalities	I-Disease
and	O
/	O
or	O
WT	B-Disease
.	O
<EOS>	B-X
However	B-X
,	B-X
to	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
for	B-X
the	B-X
case	B-X
of	B-X
SARS	B-X
-	B-X
CoV	B-X
-	B-X
2	B-X
such	B-X
analyses	B-X
were	B-X
mainly	B-X
conducted	B-X
with	B-X
the	B-X
use	B-X
of	B-X
viral	B-X
load	B-X
data	B-X
and	B-X
for	B-X
the	B-X
wild	B-X
type	B-X
(	B-X
WT	B-X
)	B-X
variant	B-X
of	B-X
the	B-X
virus	B-X
<EOS>	B-X
Female	B-X
,	B-X
not	B-X
male	B-X
,	B-X
KO	B-X
mice	B-X
weighed	B-X
less	B-X
than	B-X
WT	B-X
mice	B-X
,	B-X
had	B-X
reduced	B-X
body	B-X
fat	B-X
percentage	B-X
,	B-X
white	B-X
fat	B-X
mass	B-X
,	B-X
and	B-X
adipocyte	B-X
diameter	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
changes	B-X
in	B-X
metabolic	B-X
rate	B-X
<EOS>	B-X
Testing	B-X
the	B-X
nonclinical	B-X
Comprehensive	B-X
In	B-X
Vitro	B-X
Proarrhythmia	B-X
Assay	B-X
(	B-X
CiPA	B-X
)	B-X
paradigm	B-X
with	B-X
an	B-X
established	B-X
anti	B-X
-	B-X
seizure	B-X
medication	B-X
:	B-X
Levetiracetam	B-X
case	B-X
study	B-X
.	B-X
<EOS>	B-X
The	B-X
C	B-X
-	B-X
terminal	B-X
region	B-X
(	B-X
CTR	B-X
)	B-X
of	B-X
NSP2	B-X
(	B-X
residues	B-X
291	B-X
to	B-X
317	B-X
)	B-X
is	B-X
flexible	B-X
,	B-X
allowing	B-X
it	B-X
to	B-X
participate	B-X
in	B-X
domain	B-X
-	B-X
swapping	B-X
interactions	B-X
that	B-X
promote	B-X
interoctamer	B-X
interactions	B-X
and	B-X
,	B-X
presumably	B-X
,	B-X
viroplasm	B-X
formation	B-X

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B-Disease
.	O
<EOS>	B-X
We	B-X
report	B-X
WT1	B-X
heterozygous	B-X
mutations	B-X
in	B-X
16	B-X
patients	B-X
,	B-X
4	B-X
of	B-X
whom	B-X
presented	B-X
with	B-X
IDMS	B-X
<EOS>	B-X
No	B-X
WT1	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
six	B-X
other	B-X
IDMS	B-X
patients	B-X
,	B-X
suggesting	B-X
genetic	B-X
heterogeneity	B-X
of	B-X
this	B-X
disease	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
a	B-X
series	B-X
of	B-X
24	B-X
patients	B-X
,	B-X
10	B-X
with	B-X
isolated	B-X
DMS	B-X
(	B-X
IDMS	B-X
)	B-X
,	B-X
10	B-X
with	B-X
DDS	B-X
,	B-X
and	B-X
4	B-X
with	B-X
urogenital	B-X
abnormalities	B-X
and	B-X
/	B-X
or	B-X
WT	B-X
<EOS>	B-X
Identification	B-X
of	B-X
constitutional	B-X
WT1	B-X
mutations	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
diffuse	B-X
mesangial	B-X
sclerosis	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
genotype	B-X
/	B-X
phenotype	B-X
correlations	B-X
by	B-X
use	B-X
of	B-X
a	B-X
computerized	B-X
mutation	B-X
database	B-X
.	B-X

One	O
male	O
and	O
two	O
female	O
IDMS	B-Disease
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O
<EOS>	B-X
One	B-X
male	B-X
and	B-X
two	B-X
female	B-X
IDMS	B-X
patients	B-X
with	B-X
WT1	B-X
mutations	B-X
underwent	B-X
normal	B-X
puberty	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
a	B-X
series	B-X
of	B-X
24	B-X
patients	B-X
,	B-X
10	B-X
with	B-X
isolated	B-X
DMS	B-X
(	B-X
IDMS	B-X
)	B-X
,	B-X
10	B-X
with	B-X
DDS	B-X
,	B-X
and	B-X
4	B-X
with	B-X
urogenital	B-X
abnormalities	B-X
and	B-X
/	B-X
or	B-X
WT	B-X
<EOS>	B-X
No	B-X
WT1	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
six	B-X
other	B-X
IDMS	B-X
patients	B-X
,	B-X
suggesting	B-X
genetic	B-X
heterogeneity	B-X
of	B-X
this	B-X
disease	B-X
<EOS>	B-X
Identification	B-X
of	B-X
constitutional	B-X
WT1	B-X
mutations	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
diffuse	B-X
mesangial	B-X
sclerosis	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
genotype	B-X
/	B-X
phenotype	B-X
correlations	B-X
by	B-X
use	B-X
of	B-X
a	B-X
computerized	B-X
mutation	B-X
database	B-X
.	B-X

Two	O
mutations	O
associated	O
with	O
IDMS	B-Disease
are	O
different	O
from	O
those	O
described	O
in	O
DDS	B-Disease
patients	O
.	O
<EOS>	B-X
Two	B-X
mutations	B-X
associated	B-X
with	B-X
IDMS	B-X
are	B-X
different	B-X
from	B-X
those	B-X
described	B-X
in	B-X
DDS	B-X
patients	B-X
<EOS>	B-X
No	B-X
WT1	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
six	B-X
other	B-X
IDMS	B-X
patients	B-X
,	B-X
suggesting	B-X
genetic	B-X
heterogeneity	B-X
of	B-X
this	B-X
disease	B-X
<EOS>	B-X
Most	B-X
mutations	B-X
in	B-X
DDS	B-X
patients	B-X
lie	B-X
in	B-X
exon	B-X
8	B-X
or	B-X
exon	B-X
9	B-X
,	B-X
encoding	B-X
zinc	B-X
finger	B-X
2	B-X
or	B-X
zinc	B-X
finger	B-X
3	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
a	B-X
hot	B-X
spot	B-X
(	B-X
R394W	B-X
)	B-X
in	B-X
exon	B-X
9	B-X
<EOS>	B-X
Identification	B-X
of	B-X
constitutional	B-X
WT1	B-X
mutations	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
isolated	B-X
diffuse	B-X
mesangial	B-X
sclerosis	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
genotype	B-X
/	B-X
phenotype	B-X
correlations	B-X
by	B-X
use	B-X
of	B-X
a	B-X
computerized	B-X
mutation	B-X
database	B-X
.	B-X

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B-Disease
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O
<EOS>	B-X
No	B-X
WT1	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
six	B-X
other	B-X
IDMS	B-X
patients	B-X
,	B-X
suggesting	B-X
genetic	B-X
heterogeneity	B-X
of	B-X
this	B-X
disease	B-X
<EOS>	B-X
Two	B-X
mutations	B-X
associated	B-X
with	B-X
IDMS	B-X
are	B-X
different	B-X
from	B-X
those	B-X
described	B-X
in	B-X
DDS	B-X
patients	B-X
<EOS>	B-X
One	B-X
male	B-X
and	B-X
two	B-X
female	B-X
IDMS	B-X
patients	B-X
with	B-X
WT1	B-X
mutations	B-X
underwent	B-X
normal	B-X
puberty	B-X
<EOS>	B-X
Most	B-X
mutations	B-X
in	B-X
DDS	B-X
patients	B-X
lie	B-X
in	B-X
exon	B-X
8	B-X
or	B-X
exon	B-X
9	B-X
,	B-X
encoding	B-X
zinc	B-X
finger	B-X
2	B-X
or	B-X
zinc	B-X
finger	B-X
3	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
a	B-X
hot	B-X
spot	B-X
(	B-X
R394W	B-X
)	B-X
in	B-X
exon	B-X
9	B-X

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
the	O
different	O
symptoms	O
.	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B-Disease
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B-Disease
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
.	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
in	O
the	O
general	O
population	O
.	O
<EOS>	B-X
The	B-X
185delAG	B-X
mutation	B-X
in	B-X
BRCA1	B-X
is	B-X
detected	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
both	B-X
in	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
and	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
Unique	B-X
germline	B-X
mutations	B-X
in	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
account	B-X
for	B-X
inherited	B-X
predisposition	B-X
to	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
in	B-X
high	B-X
-	B-X
risk	B-X
families	B-X
<EOS>	B-X
An	B-X
identical	B-X
novel	B-X
mutation	B-X
in	B-X
BRCA1	B-X
and	B-X
a	B-X
common	B-X
haplotype	B-X
in	B-X
familial	B-X
ovarian	B-X
cancer	B-X
in	B-X
non	B-X
-	B-X
Ashkenazi	B-X
Jews	B-X
.	B-X
<EOS>	B-X
Objective	B-X
:	B-X
Assessing	B-X
the	B-X
occurrence	B-X
rate	B-X
of	B-X
the	B-X
Tyr978X	B-X
BRCA1	B-X
germline	B-X
mutation	B-X
in	B-X
Jewish	B-X
non	B-X
-	B-X
Ashkenazi	B-X
individuals	B-X
:	B-X
high	B-X
-	B-X
risk	B-X
familial	B-X
cases	B-X
,	B-X
unselected	B-X
ovarian	B-X
cancer	B-X
patients	B-X
and	B-X
the	B-X
general	B-X
average	B-X
risk	B-X
Jewish	B-X
Iraqi	B-X
population	B-X

All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O
<EOS>	B-X
All	B-X
tested	B-X
Ashkenazi	B-X
mutation	B-X
carriers	B-X
share	B-X
the	B-X
same	B-X
allelic	B-X
pattern	B-X
at	B-X
the	B-X
BRCA1	B-X
locus	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
185delAG	B-X
BRCA1	B-X
mutation	B-X
occurs	B-X
in	B-X
some	B-X
non	B-X
-	B-X
Ashkenazi	B-X
populations	B-X
at	B-X
rates	B-X
comparable	B-X
with	B-X
that	B-X
of	B-X
Ashkenazim	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
BRCA1	B-X
mutation	B-X
originated	B-X
before	B-X
the	B-X
dispersion	B-X
of	B-X
Jews	B-X
in	B-X
the	B-X
diaspora	B-X
and	B-X
is	B-X
not	B-X
limited	B-X
to	B-X
Ashkenazim	B-X
.	B-X
<EOS>	B-X
Six	B-X
non	B-X
-	B-X
Ashkenazi	B-X
individuals	B-X
shared	B-X
the	B-X
common	B-X
'Ashkenazi	B-X
haplotype	B-X
'	B-X
,	B-X
four	B-X
had	B-X
a	B-X
closely	B-X
related	B-X
pattern	B-X
,	B-X
and	B-X
the	B-X
rest	B-X
(	B-X
n	B-X
=	B-X
6	B-X
)	B-X
displayed	B-X
a	B-X
distinct	B-X
BRCA1	B-X
allelic	B-X
pattern	B-X

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
showed	B-X
that	B-X
this	B-X
'Ashkenazi	B-X
'	B-X
mutation	B-X
also	B-X
occurs	B-X
in	B-X
Iraqi	B-X
Jews	B-X
with	B-X
a	B-X
similar	B-X
allelic	B-X
pattern	B-X
<EOS>	B-X
Six	B-X
non	B-X
-	B-X
Ashkenazi	B-X
individuals	B-X
shared	B-X
the	B-X
common	B-X
'Ashkenazi	B-X
haplotype	B-X
'	B-X
,	B-X
four	B-X
had	B-X
a	B-X
closely	B-X
related	B-X
pattern	B-X
,	B-X
and	B-X
the	B-X
rest	B-X
(	B-X
n	B-X
=	B-X
6	B-X
)	B-X
displayed	B-X
a	B-X
distinct	B-X
BRCA1	B-X
allelic	B-X
pattern	B-X
<EOS>	B-X
All	B-X
tested	B-X
Ashkenazi	B-X
mutation	B-X
carriers	B-X
share	B-X
the	B-X
same	B-X
allelic	B-X
pattern	B-X
at	B-X
the	B-X
BRCA1	B-X
locus	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
mutation	B-X
in	B-X
BRCA1	B-X
is	B-X
detected	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
both	B-X
in	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
and	B-X
in	B-X
the	B-X
general	B-X
population	B-X

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews	O
.	O
<EOS>	B-X
We	B-X
extended	B-X
our	B-X
analysis	B-X
to	B-X
other	B-X
non	B-X
-	B-X
Ashkenazi	B-X
subsets	B-X
:	B-X
354	B-X
of	B-X
Moroccan	B-X
origin	B-X
,	B-X
200	B-X
Yemenites	B-X
and	B-X
150	B-X
Iranian	B-X
Jews	B-X
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
showed	B-X
that	B-X
this	B-X
'Ashkenazi	B-X
'	B-X
mutation	B-X
also	B-X
occurs	B-X
in	B-X
Iraqi	B-X
Jews	B-X
with	B-X
a	B-X
similar	B-X
allelic	B-X
pattern	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
mutation	B-X
in	B-X
BRCA1	B-X
is	B-X
detected	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
both	B-X
in	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
and	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
Heteroduplex	B-X
analysis	B-X
complemented	B-X
by	B-X
direct	B-X
DNA	B-X
sequencing	B-X
of	B-X
abnormally	B-X
migrating	B-X
bands	B-X
were	B-X
employed	B-X

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O
<EOS>	B-X
Heteroduplex	B-X
analysis	B-X
complemented	B-X
by	B-X
direct	B-X
DNA	B-X
sequencing	B-X
of	B-X
abnormally	B-X
migrating	B-X
bands	B-X
were	B-X
employed	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
mutation	B-X
in	B-X
BRCA1	B-X
is	B-X
detected	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
both	B-X
in	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
and	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
BRCA1	B-X
mutation	B-X
originated	B-X
before	B-X
the	B-X
dispersion	B-X
of	B-X
Jews	B-X
in	B-X
the	B-X
diaspora	B-X
and	B-X
is	B-X
not	B-X
limited	B-X
to	B-X
Ashkenazim	B-X
.	B-X
<EOS>	B-X
We	B-X
extended	B-X
our	B-X
analysis	B-X
to	B-X
other	B-X
non	B-X
-	B-X
Ashkenazi	B-X
subsets	B-X
:	B-X
354	B-X
of	B-X
Moroccan	B-X
origin	B-X
,	B-X
200	B-X
Yemenites	B-X
and	B-X
150	B-X
Iranian	B-X
Jews	B-X

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O
<EOS>	B-X
1	B-X
%	B-X
)	B-X
and	B-X
none	B-X
of	B-X
the	B-X
Yemenites	B-X
or	B-X
Iranians	B-X
was	B-X
a	B-X
carrier	B-X
of	B-X
the	B-X
185delAG	B-X
mutation	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
mutation	B-X
in	B-X
BRCA1	B-X
is	B-X
detected	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
both	B-X
in	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
and	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
Unique	B-X
germline	B-X
mutations	B-X
in	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
account	B-X
for	B-X
inherited	B-X
predisposition	B-X
to	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
in	B-X
high	B-X
-	B-X
risk	B-X
families	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
different	B-X
allelic	B-X
pattern	B-X
at	B-X
the	B-X
BRCA1	B-X
locus	B-X
even	B-X
in	B-X
some	B-X
Jewish	B-X
mutation	B-X
carriers	B-X
,	B-X
might	B-X
suggest	B-X
that	B-X
the	B-X
mutation	B-X
arose	B-X
independently	B-X

BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
<EOS>	B-X
BRCA1	B-X
allelic	B-X
patterns	B-X
were	B-X
determined	B-X
for	B-X
four	B-X
of	B-X
these	B-X
individuals	B-X
and	B-X
for	B-X
12	B-X
additional	B-X
non	B-X
-	B-X
Ashkenazi	B-X
185delAG	B-X
mutation	B-X
carriers	B-X
who	B-X
had	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
<EOS>	B-X
1	B-X
%	B-X
)	B-X
and	B-X
none	B-X
of	B-X
the	B-X
Yemenites	B-X
or	B-X
Iranians	B-X
was	B-X
a	B-X
carrier	B-X
of	B-X
the	B-X
185delAG	B-X
mutation	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
185delAG	B-X
BRCA1	B-X
mutation	B-X
occurs	B-X
in	B-X
some	B-X
non	B-X
-	B-X
Ashkenazi	B-X
populations	B-X
at	B-X
rates	B-X
comparable	B-X
with	B-X
that	B-X
of	B-X
Ashkenazim	B-X
<EOS>	B-X
We	B-X
extended	B-X
our	B-X
analysis	B-X
to	B-X
other	B-X
non	B-X
-	B-X
Ashkenazi	B-X
subsets	B-X
:	B-X
354	B-X
of	B-X
Moroccan	B-X
origin	B-X
,	B-X
200	B-X
Yemenites	B-X
and	B-X
150	B-X
Iranian	B-X
Jews	B-X

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
185delAG	B-X
BRCA1	B-X
mutation	B-X
occurs	B-X
in	B-X
some	B-X
non	B-X
-	B-X
Ashkenazi	B-X
populations	B-X
at	B-X
rates	B-X
comparable	B-X
with	B-X
that	B-X
of	B-X
Ashkenazim	B-X
<EOS>	B-X
The	B-X
185delAG	B-X
BRCA1	B-X
mutation	B-X
originated	B-X
before	B-X
the	B-X
dispersion	B-X
of	B-X
Jews	B-X
in	B-X
the	B-X
diaspora	B-X
and	B-X
is	B-X
not	B-X
limited	B-X
to	B-X
Ashkenazim	B-X
.	B-X
<EOS>	B-X
All	B-X
tested	B-X
Ashkenazi	B-X
mutation	B-X
carriers	B-X
share	B-X
the	B-X
same	B-X
allelic	B-X
pattern	B-X
at	B-X
the	B-X
BRCA1	B-X
locus	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
Jewish	B-X
185delAG	B-X
mutation	B-X
carriers	B-X
have	B-X
a	B-X
common	B-X
allelic	B-X
pattern	B-X
,	B-X
supporting	B-X
the	B-X
founder	B-X
effect	B-X
notion	B-X
,	B-X
but	B-X
dating	B-X
the	B-X
mutation	B-X
's	B-X
origin	B-X
to	B-X
an	B-X
earlier	B-X
date	B-X
than	B-X
currently	B-X
estimated	B-X

The	O
majority	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O
.	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
different	B-X
allelic	B-X
pattern	B-X
at	B-X
the	B-X
BRCA1	B-X
locus	B-X
even	B-X
in	B-X
some	B-X
Jewish	B-X
mutation	B-X
carriers	B-X
,	B-X
might	B-X
suggest	B-X
that	B-X
the	B-X
mutation	B-X
arose	B-X
independently	B-X
<EOS>	B-X
All	B-X
tested	B-X
Ashkenazi	B-X
mutation	B-X
carriers	B-X
share	B-X
the	B-X
same	B-X
allelic	B-X
pattern	B-X
at	B-X
the	B-X
BRCA1	B-X
locus	B-X
<EOS>	B-X
1	B-X
%	B-X
)	B-X
and	B-X
none	B-X
of	B-X
the	B-X
Yemenites	B-X
or	B-X
Iranians	B-X
was	B-X
a	B-X
carrier	B-X
of	B-X
the	B-X
185delAG	B-X
mutation	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
Jewish	B-X
185delAG	B-X
mutation	B-X
carriers	B-X
have	B-X
a	B-X
common	B-X
allelic	B-X
pattern	B-X
,	B-X
supporting	B-X
the	B-X
founder	B-X
effect	B-X
notion	B-X
,	B-X
but	B-X
dating	B-X
the	B-X
mutation	B-X
's	B-X
origin	B-X
to	B-X
an	B-X
earlier	B-X
date	B-X
than	B-X
currently	B-X
estimated	B-X

Crystal	O
structure	O
of	O
the	O
hemochromatosis	B-Disease
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O
<EOS>	B-X
Crystal	B-X
structure	B-X
of	B-X
the	B-X
hemochromatosis	B-X
protein	B-X
HFE	B-X
and	B-X
characterization	B-X
of	B-X
its	B-X
interaction	B-X
with	B-X
transferrin	B-X
receptor	B-X
.	B-X
<EOS>	B-X
6	B-X
A	B-X
crystal	B-X
structure	B-X
of	B-X
HFE	B-X
reveals	B-X
the	B-X
locations	B-X
of	B-X
hemochromatosis	B-X
mutations	B-X
and	B-X
a	B-X
patch	B-X
of	B-X
histidines	B-X
that	B-X
could	B-X
be	B-X
involved	B-X
in	B-X
pH	B-X
-	B-X
dependent	B-X
interactions	B-X
<EOS>	B-X
TfR	B-X
:	B-X
HFE	B-X
stoichiometry	B-X
(	B-X
2:1	B-X
)	B-X
differs	B-X
from	B-X
TfR	B-X
:	B-X
transferrin	B-X
stoichiometry	B-X
(	B-X
2:2	B-X
)	B-X
,	B-X
implying	B-X
a	B-X
different	B-X
mode	B-X
of	B-X
binding	B-X
for	B-X
HFE	B-X
and	B-X
transferrin	B-X
to	B-X
TfR	B-X
,	B-X
consistent	B-X
with	B-X
our	B-X
demonstration	B-X
that	B-X
HFE	B-X
,	B-X
transferrin	B-X
,	B-X
and	B-X
TfR	B-X
form	B-X
a	B-X
ternary	B-X
complex	B-X
<EOS>	B-X
Mutational	B-X
analysis	B-X
of	B-X
the	B-X
transferrin	B-X
receptor	B-X
reveals	B-X
overlapping	B-X
HFE	B-X
and	B-X
transferrin	B-X
binding	B-X
sites	B-X
.	B-X

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B-Disease
-	I-Disease
overload	I-Disease
disease	I-Disease
hereditary	B-Disease
hemochromatosis	I-Disease
.	O
<EOS>	B-X
HFE	B-X
is	B-X
related	B-X
to	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
I	B-X
proteins	B-X
and	B-X
is	B-X
mutated	B-X
in	B-X
the	B-X
iron	B-X
-	B-X
overload	B-X
disease	B-X
hereditary	B-X
haemochromatosis	B-X
<EOS>	B-X
The	B-X
C282Y	B-X
mutation	B-X
of	B-X
HFE	B-X
accounts	B-X
for	B-X
the	B-X
majority	B-X
of	B-X
cases	B-X
of	B-X
the	B-X
iron	B-X
overload	B-X
disease	B-X
Hereditary	B-X
Hemochromatosis	B-X
(	B-X
HH	B-X
)	B-X
<EOS>	B-X
HFE	B-X
is	B-X
a	B-X
class	B-X
-	B-X
I	B-X
MHC	B-X
related	B-X
protein	B-X
which	B-X
carries	B-X
the	B-X
C282Y	B-X
mutation	B-X
in	B-X
most	B-X
patients	B-X
with	B-X
hereditary	B-X
hemochromatosis	B-X
,	B-X
an	B-X
iron	B-X
overload	B-X
disease	B-X
<EOS>	B-X
The	B-X
unfolded	B-X
protein	B-X
response	B-X
in	B-X
hereditary	B-X
haemochromatosis	B-X
.	B-X

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	O
.	O
<EOS>	B-X
HFE	B-X
binds	B-X
to	B-X
transferrin	B-X
receptor	B-X
(	B-X
TfR	B-X
)	B-X
and	B-X
reduces	B-X
its	B-X
affinity	B-X
for	B-X
iron	B-X
-	B-X
loaded	B-X
transferrin	B-X
,	B-X
implicating	B-X
HFE	B-X
in	B-X
iron	B-X
metabolism	B-X
<EOS>	B-X
TfR	B-X
:	B-X
HFE	B-X
stoichiometry	B-X
(	B-X
2:1	B-X
)	B-X
differs	B-X
from	B-X
TfR	B-X
:	B-X
transferrin	B-X
stoichiometry	B-X
(	B-X
2:2	B-X
)	B-X
,	B-X
implying	B-X
a	B-X
different	B-X
mode	B-X
of	B-X
binding	B-X
for	B-X
HFE	B-X
and	B-X
transferrin	B-X
to	B-X
TfR	B-X
,	B-X
consistent	B-X
with	B-X
our	B-X
demonstration	B-X
that	B-X
HFE	B-X
,	B-X
transferrin	B-X
,	B-X
and	B-X
TfR	B-X
form	B-X
a	B-X
ternary	B-X
complex	B-X
<EOS>	B-X
HFE	B-X
is	B-X
an	B-X
MHC	B-X
-	B-X
related	B-X
protein	B-X
that	B-X
is	B-X
mutated	B-X
in	B-X
the	B-X
iron	B-X
-	B-X
overload	B-X
disease	B-X
hereditary	B-X
hemochromatosis	B-X
<EOS>	B-X
6	B-X
A	B-X
crystal	B-X
structure	B-X
of	B-X
HFE	B-X
reveals	B-X
the	B-X
locations	B-X
of	B-X
hemochromatosis	B-X
mutations	B-X
and	B-X
a	B-X
patch	B-X
of	B-X
histidines	B-X
that	B-X
could	B-X
be	B-X
involved	B-X
in	B-X
pH	B-X
-	B-X
dependent	B-X
interactions	B-X

The	O
2	O
.	O
<EOS>	B-X
Window	B-X
into	B-X
the	B-X
Future	B-X
.	B-X
<EOS>	B-X
The	B-X
specific	B-X
capacitance	B-X
is	B-X
18	B-X
<EOS>	B-X
986	B-X
;	B-X
95	B-X
%	B-X
CI,1	B-X
<EOS>	B-X
Using	B-X
the	B-X
PET	B-X
radiotracer	B-X
[	B-X

6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B-Disease
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B-Disease
disease	I-Disease
.	O

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B-Disease
disease	I-Disease
.	O
<EOS>	B-X
Four	B-X
mutations	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
R778L	B-X
,	B-X
A874V	B-X
,	B-X
L1083F	B-X
,	B-X
and	B-X
2304delC	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
in	B-X
the	B-X
copper	B-X
-	B-X
transporting	B-X
enzyme	B-X
,	B-X
P	B-X
-	B-X
type	B-X
ATPase	B-X
(	B-X
ATP7B	B-X
)	B-X
,	B-X
were	B-X
identified	B-X
in	B-X
Korean	B-X
Patients	B-X
with	B-X
Wilson	B-X
disease	B-X
<EOS>	B-X
Identification	B-X
of	B-X
three	B-X
novel	B-X
mutations	B-X
and	B-X
a	B-X
high	B-X
frequency	B-X
of	B-X
the	B-X
Arg778Leu	B-X
mutation	B-X
in	B-X
Korean	B-X
patients	B-X
with	B-X
Wilson	B-X
disease	B-X
.	B-X
<EOS>	B-X
Since	B-X
a	B-X
mutation	B-X
at	B-X
cDNA	B-X
nucleotide	B-X
2302	B-X
(	B-X
2302insC	B-X
)	B-X
had	B-X
been	B-X
previously	B-X
described	B-X
,	B-X
this	B-X
region	B-X
of	B-X
the	B-X
ATP7B	B-X
gene	B-X
may	B-X
be	B-X
susceptible	B-X
to	B-X
gene	B-X
rearrangements	B-X
causing	B-X
Wilson	B-X
disease	B-X
<EOS>	B-X
Arg778Leu	B-X
,	B-X
the	B-X
most	B-X
frequently	B-X
reported	B-X
mutation	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
was	B-X
found	B-X
in	B-X
six	B-X
of	B-X
eight	B-X
unrelated	B-X
patients	B-X
studied	B-X
,	B-X
an	B-X
allele	B-X
frequency	B-X
of	B-X
37	B-X

Arg778Leu	O
,	O
the	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O
<EOS>	B-X
Arg778Leu	B-X
,	B-X
the	B-X
most	B-X
frequently	B-X
reported	B-X
mutation	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
was	B-X
found	B-X
in	B-X
six	B-X
of	B-X
eight	B-X
unrelated	B-X
patients	B-X
studied	B-X
,	B-X
an	B-X
allele	B-X
frequency	B-X
of	B-X
37	B-X
<EOS>	B-X
The	B-X
novel	B-X
single	B-X
nucleotide	B-X
deletion	B-X
,	B-X
2304delC	B-X
,	B-X
was	B-X
found	B-X
in	B-X
one	B-X
patient	B-X
<EOS>	B-X
Identification	B-X
of	B-X
three	B-X
novel	B-X
mutations	B-X
and	B-X
a	B-X
high	B-X
frequency	B-X
of	B-X
the	B-X
Arg778Leu	B-X
mutation	B-X
in	B-X
Korean	B-X
patients	B-X
with	B-X
Wilson	B-X
disease	B-X
.	B-X
<EOS>	B-X
Since	B-X
a	B-X
mutation	B-X
at	B-X
cDNA	B-X
nucleotide	B-X
2302	B-X
(	B-X
2302insC	B-X
)	B-X
had	B-X
been	B-X
previously	B-X
described	B-X
,	B-X
this	B-X
region	B-X
of	B-X
the	B-X
ATP7B	B-X
gene	B-X
may	B-X
be	B-X
susceptible	B-X
to	B-X
gene	B-X
rearrangements	B-X
causing	B-X
Wilson	B-X
disease	B-X

5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O
<EOS>	B-X
The	B-X
frequency	B-X
of	B-X
Huntington	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
may	B-X
vary	B-X
considerably	B-X
,	B-X
with	B-X
higher	B-X
estimates	B-X
in	B-X
non	B-X
-	B-X
Asian	B-X
populations	B-X
<EOS>	B-X
The	B-X
mean	B-X
age	B-X
of	B-X
Asians	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
the	B-X
mean	B-X
age	B-X
of	B-X
the	B-X
Middle	B-X
Eastern	B-X
and	B-X
Black	B-X
and	B-X
Caucasian	B-X
races	B-X
(	B-X
42	B-X
<EOS>	B-X
The	B-X
proportion	B-X
of	B-X
deaths	B-X
was	B-X
considerably	B-X
higher	B-X
amongst	B-X
Asians	B-X
(	B-X
5	B-X
<EOS>	B-X
Association	B-X
of	B-X
working	B-X
shifts	B-X
,	B-X
inside	B-X
and	B-X
outside	B-X
of	B-X
healthcare	B-X
,	B-X
with	B-X
severe	B-X
COVID	B-X
-	B-X
19	B-X
:	B-X
an	B-X
observational	B-X
study	B-X
.	B-X

The	O
novel	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O
<EOS>	B-X
The	B-X
novel	B-X
single	B-X
nucleotide	B-X
deletion	B-X
,	B-X
2304delC	B-X
,	B-X
was	B-X
found	B-X
in	B-X
one	B-X
patient	B-X
<EOS>	B-X
Arg778Leu	B-X
,	B-X
the	B-X
most	B-X
frequently	B-X
reported	B-X
mutation	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
was	B-X
found	B-X
in	B-X
six	B-X
of	B-X
eight	B-X
unrelated	B-X
patients	B-X
studied	B-X
,	B-X
an	B-X
allele	B-X
frequency	B-X
of	B-X
37	B-X
<EOS>	B-X
Identification	B-X
of	B-X
three	B-X
novel	B-X
mutations	B-X
and	B-X
a	B-X
high	B-X
frequency	B-X
of	B-X
the	B-X
Arg778Leu	B-X
mutation	B-X
in	B-X
Korean	B-X
patients	B-X
with	B-X
Wilson	B-X
disease	B-X
.	B-X
<EOS>	B-X
Since	B-X
a	B-X
mutation	B-X
at	B-X
cDNA	B-X
nucleotide	B-X
2302	B-X
(	B-X
2302insC	B-X
)	B-X
had	B-X
been	B-X
previously	B-X
described	B-X
,	B-X
this	B-X
region	B-X
of	B-X
the	B-X
ATP7B	B-X
gene	B-X
may	B-X
be	B-X
susceptible	B-X
to	B-X
gene	B-X
rearrangements	B-X
causing	B-X
Wilson	B-X
disease	B-X

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B-Disease
disease	I-Disease
.	O
<EOS>	B-X
Since	B-X
a	B-X
mutation	B-X
at	B-X
cDNA	B-X
nucleotide	B-X
2302	B-X
(	B-X
2302insC	B-X
)	B-X
had	B-X
been	B-X
previously	B-X
described	B-X
,	B-X
this	B-X
region	B-X
of	B-X
the	B-X
ATP7B	B-X
gene	B-X
may	B-X
be	B-X
susceptible	B-X
to	B-X
gene	B-X
rearrangements	B-X
causing	B-X
Wilson	B-X
disease	B-X
<EOS>	B-X
Identification	B-X
of	B-X
three	B-X
novel	B-X
mutations	B-X
and	B-X
a	B-X
high	B-X
frequency	B-X
of	B-X
the	B-X
Arg778Leu	B-X
mutation	B-X
in	B-X
Korean	B-X
patients	B-X
with	B-X
Wilson	B-X
disease	B-X
.	B-X
<EOS>	B-X
Four	B-X
mutations	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
R778L	B-X
,	B-X
A874V	B-X
,	B-X
L1083F	B-X
,	B-X
and	B-X
2304delC	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
in	B-X
the	B-X
copper	B-X
-	B-X
transporting	B-X
enzyme	B-X
,	B-X
P	B-X
-	B-X
type	B-X
ATPase	B-X
(	B-X
ATP7B	B-X
)	B-X
,	B-X
were	B-X
identified	B-X
in	B-X
Korean	B-X
Patients	B-X
with	B-X
Wilson	B-X
disease	B-X
<EOS>	B-X
The	B-X
novel	B-X
single	B-X
nucleotide	B-X
deletion	B-X
,	B-X
2304delC	B-X
,	B-X
was	B-X
found	B-X
in	B-X
one	B-X
patient	B-X

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
<EOS>	B-X
Aberrant	B-X
alternative	B-X
splicing	B-X
and	B-X
extracellular	B-X
matrix	B-X
gene	B-X
expression	B-X
in	B-X
mouse	B-X
models	B-X
of	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Dysfunction	B-X
of	B-X
MBNL	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
expanded	B-X
CUG	B-X
repeats	B-X
-	B-X
associated	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
<EOS>	B-X
Disrupted	B-X
prenatal	B-X
RNA	B-X
processing	B-X
and	B-X
myogenesis	B-X
in	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Colocalization	B-X
of	B-X
muscleblind	B-X
with	B-X
RNA	B-X
foci	B-X
is	B-X
separable	B-X
from	B-X
mis	B-X
-	B-X
regulation	B-X
of	B-X
alternative	B-X
splicing	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
.	B-X

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B-Disease
gene	O
.	O
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
(	B-X
CTG	B-X
)	B-X
(	B-X
n	B-X
)	B-X
expansion	B-X
in	B-X
the	B-X
3'	B-X
-	B-X
untranslated	B-X
region	B-X
of	B-X
DMPK	B-X
gene	B-X
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
CTG	B-X
expansion	B-X
in	B-X
the	B-X
3'	B-X
-	B-X
untranslated	B-X
region	B-X
of	B-X
a	B-X
protein	B-X
kinase	B-X
gene	B-X
(	B-X
DMPK	B-X
)	B-X
<EOS>	B-X
DM1	B-X
,	B-X
which	B-X
constitutes	B-X
98	B-X
%	B-X
of	B-X
cases	B-X
,	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
CTG	B-X
expansion	B-X
in	B-X
the	B-X
3	B-X
'	B-X
untranslated	B-X
region	B-X
(	B-X
UTR	B-X
)	B-X
of	B-X
the	B-X
DMPK	B-X
gene	B-X
<EOS>	B-X
DM2	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
CCTG	B-X
expansion	B-X
in	B-X
the	B-X
first	B-X
intron	B-X
of	B-X
the	B-X
ZNF9	B-X
gene	B-X

One	O
model	O
of	O
DM	B-Disease
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

Data	O
presented	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O
<EOS>	B-X
Data	B-X
presented	B-X
here	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
heterogeneous	B-X
nuclear	B-X
ribonucleoprotein	B-X
,	B-X
CUG	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CUG	B-X
-	B-X
BP	B-X
)	B-X
,	B-X
may	B-X
mediate	B-X
the	B-X
trans	B-X
-	B-X
dominant	B-X
effect	B-X
of	B-X
the	B-X
RNA	B-X
<EOS>	B-X
Disruption	B-X
of	B-X
splicing	B-X
regulated	B-X
by	B-X
a	B-X
CUG	B-X
-	B-X
binding	B-X
protein	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
CUG	B-X
-	B-X
BP	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
human	B-X
cardiac	B-X
troponin	B-X
T	B-X
(	B-X
cTNT	B-X
)	B-X
pre	B-X
-	B-X
messenger	B-X
RNA	B-X
and	B-X
regulate	B-X
its	B-X
alternative	B-X
splicing	B-X
<EOS>	B-X
Altered	B-X
expression	B-X
of	B-X
genes	B-X
regulated	B-X
posttranscriptionally	B-X
by	B-X
CUG	B-X
-	B-X
BP	B-X
therefore	B-X
may	B-X
contribute	B-X
to	B-X
DM	B-X
pathogenesis	B-X

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B-Disease
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O
<EOS>	B-X
Splicing	B-X
of	B-X
cTNT	B-X
was	B-X
disrupted	B-X
in	B-X
DM	B-X
striated	B-X
muscle	B-X
and	B-X
in	B-X
normal	B-X
cells	B-X
expressing	B-X
transcripts	B-X
that	B-X
contain	B-X
CUG	B-X
repeats	B-X
<EOS>	B-X
One	B-X
model	B-X
of	B-X
DM	B-X
pathogenesis	B-X
suggests	B-X
that	B-X
RNAs	B-X
from	B-X
the	B-X
expanded	B-X
allele	B-X
create	B-X
a	B-X
gain	B-X
-	B-X
of	B-X
-	B-X
function	B-X
mutation	B-X
by	B-X
the	B-X
inappropriate	B-X
binding	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
CUG	B-X
repeats	B-X
<EOS>	B-X
Disruption	B-X
of	B-X
splicing	B-X
regulated	B-X
by	B-X
a	B-X
CUG	B-X
-	B-X
binding	B-X
protein	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
CTG	B-X
expansion	B-X
in	B-X
the	B-X
3	B-X
'	B-X
untranslated	B-X
region	B-X
of	B-X
the	B-X
DM	B-X
gene	B-X

Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B-Disease
pathogenesis	O
.	O
.	O

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

Familial	B-Disease
neurohypophyseal	I-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
FNDI	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O
<EOS>	B-X
Familial	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
(	B-X
FNDI	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
disease	B-X
caused	B-X
by	B-X
deficiency	B-X
in	B-X
the	B-X
antidiuretic	B-X
hormone	B-X
arginine	B-X
vasopressin	B-X
(	B-X
AVP	B-X
)	B-X
encoded	B-X
by	B-X
the	B-X
AVP	B-X
-	B-X
neurophysin	B-X
II	B-X
(	B-X
AVP	B-X
-	B-X
NPII	B-X
)	B-X
gene	B-X
on	B-X
chromosome	B-X
20p13	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
two	B-X
families	B-X
with	B-X
FNDI	B-X
using	B-X
direct	B-X
automated	B-X
fluorescent	B-X
,	B-X
solid	B-X
phase	B-X
,	B-X
single	B-X
-	B-X
stranded	B-X
DNA	B-X
sequencing	B-X
of	B-X
PCR	B-X
-	B-X
amplified	B-X
AVP	B-X
-	B-X
NPII	B-X
DNA	B-X
<EOS>	B-X
The	B-X
premature	B-X
termination	B-X
eliminates	B-X
part	B-X
of	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
domain	B-X
of	B-X
NPII	B-X
,	B-X
including	B-X
a	B-X
cysteine	B-X
residue	B-X
in	B-X
position	B-X
85	B-X
,	B-X
which	B-X
could	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
correct	B-X
folding	B-X
of	B-X
the	B-X
prohormone	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
nonsense	B-X
mutation	B-X
and	B-X
a	B-X
missense	B-X
substitution	B-X
in	B-X
the	B-X
vasopressin	B-X
-	B-X
neurophysin	B-X
II	B-X
gene	B-X
in	B-X
two	B-X
Spanish	B-X
kindreds	B-X
with	B-X
familial	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	B-Disease
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
two	B-X
families	B-X
with	B-X
FNDI	B-X
using	B-X
direct	B-X
automated	B-X
fluorescent	B-X
,	B-X
solid	B-X
phase	B-X
,	B-X
single	B-X
-	B-X
stranded	B-X
DNA	B-X
sequencing	B-X
of	B-X
PCR	B-X
-	B-X
amplified	B-X
AVP	B-X
-	B-X
NPII	B-X
DNA	B-X
<EOS>	B-X
In	B-X
the	B-X
second	B-X
family	B-X
,	B-X
a	B-X
G279A	B-X
substitution	B-X
at	B-X
position	B-X
	B-X
-	B-X
1	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
affected	B-X
individuals	B-X
<EOS>	B-X
Familial	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
(	B-X
FNDI	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
disease	B-X
caused	B-X
by	B-X
deficiency	B-X
in	B-X
the	B-X
antidiuretic	B-X
hormone	B-X
arginine	B-X
vasopressin	B-X
(	B-X
AVP	B-X
)	B-X
encoded	B-X
by	B-X
the	B-X
AVP	B-X
-	B-X
neurophysin	B-X
II	B-X
(	B-X
AVP	B-X
-	B-X
NPII	B-X
)	B-X
gene	B-X
on	B-X
chromosome	B-X
20p13	B-X
<EOS>	B-X
This	B-X
missense	B-X
mutation	B-X
,	B-X
which	B-X
replaces	B-X
Ala	B-X
with	B-X
Thr	B-X
,	B-X
is	B-X
frequent	B-X
among	B-X
FNDI	B-X
patients	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
cleavage	B-X
by	B-X
signal	B-X
peptidases	B-X

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B-Disease
patients	O
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O
<EOS>	B-X
This	B-X
missense	B-X
mutation	B-X
,	B-X
which	B-X
replaces	B-X
Ala	B-X
with	B-X
Thr	B-X
,	B-X
is	B-X
frequent	B-X
among	B-X
FNDI	B-X
patients	B-X
and	B-X
is	B-X
thought	B-X
to	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
cleavage	B-X
by	B-X
signal	B-X
peptidases	B-X
<EOS>	B-X
In	B-X
one	B-X
of	B-X
the	B-X
families	B-X
,	B-X
affected	B-X
individuals	B-X
presented	B-X
a	B-X
novel	B-X
nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
3	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
consisting	B-X
in	B-X
a	B-X
G	B-X
to	B-X
T	B-X
transition	B-X
at	B-X
nucleotide	B-X
2101	B-X
,	B-X
which	B-X
produces	B-X
a	B-X
stop	B-X
signal	B-X
in	B-X
codon	B-X
82	B-X
(	B-X
Glu	B-X
)	B-X
of	B-X
NPII	B-X
<EOS>	B-X
In	B-X
the	B-X
second	B-X
family	B-X
,	B-X
a	B-X
G279A	B-X
substitution	B-X
at	B-X
position	B-X
	B-X
-	B-X
1	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
affected	B-X
individuals	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
nonsense	B-X
mutation	B-X
and	B-X
a	B-X
missense	B-X
substitution	B-X
in	B-X
the	B-X
vasopressin	B-X
-	B-X
neurophysin	B-X
II	B-X
gene	B-X
in	B-X
two	B-X
Spanish	B-X
kindreds	B-X
with	B-X
familial	B-X
neurohypophyseal	B-X
diabetes	B-X
insipidus	B-X
.	B-X

Genetic	O
heterogeneity	O
of	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
syndrome	I-Disease
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
due	B-X
to	B-X
TWIST	B-X
and	B-X
FGFR	B-X
mutations	B-X
.	B-X
<EOS>	B-X
Q289P	B-X
mutation	B-X
in	B-X
FGFR2	B-X
gene	B-X
causes	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
:	B-X
some	B-X
considerations	B-X
about	B-X
familial	B-X
heterogeneity	B-X
.	B-X
<EOS>	B-X
The	B-X
FGFR2	B-X
mutation	B-X
in	B-X
the	B-X
family	B-X
with	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
herein	B-X
reported	B-X
reinforces	B-X
the	B-X
idea	B-X
of	B-X
an	B-X
interaction	B-X
among	B-X
TWIST	B-X
and	B-X
FGFR	B-X
genes	B-X
during	B-X
development	B-X
<EOS>	B-X
Significant	B-X
intra	B-X
-	B-X
	B-X
and	B-X
interfamilial	B-X
phenotypic	B-X
variability	B-X
is	B-X
present	B-X
for	B-X
either	B-X
TWIST	B-X
mutations	B-X
or	B-X
FGFR	B-X
mutations	B-X

Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
syndrome	I-Disease
,	O
a	O
common	O
autosomal	B-Disease
dominant	I-Disease
condition	I-Disease
of	O
craniosynostosis	B-Disease
and	O
limb	B-Disease
anomalies	I-Disease
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O
<EOS>	B-X
Thirty	B-X
-	B-X
two	B-X
unrelated	B-X
patients	B-X
with	B-X
features	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
a	B-X
common	B-X
autosomal	B-X
dominant	B-X
condition	B-X
of	B-X
craniosynostosis	B-X
and	B-X
limb	B-X
anomalies	B-X
,	B-X
were	B-X
screened	B-X
for	B-X
mutations	B-X
in	B-X
TWIST	B-X
,	B-X
FGFR2	B-X
,	B-X
and	B-X
FGFR3	B-X
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
due	B-X
to	B-X
TWIST	B-X
and	B-X
FGFR	B-X
mutations	B-X
.	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
our	B-X
detection	B-X
rate	B-X
for	B-X
TWIST	B-X
or	B-X
FGFR	B-X
mutations	B-X
is	B-X
68	B-X
%	B-X
in	B-X
our	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
patients	B-X
,	B-X
including	B-X
our	B-X
five	B-X
patients	B-X
elsewhere	B-X
reported	B-X
with	B-X
TWIST	B-X
mutations	B-X
<EOS>	B-X
The	B-X
overlap	B-X
in	B-X
clinical	B-X
features	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
in	B-X
the	B-X
same	B-X
genes	B-X
,	B-X
of	B-X
mutations	B-X
for	B-X
more	B-X
than	B-X
one	B-X
craniosynostotic	B-X
condition	B-X
-	B-X
such	B-X
as	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
,	B-X
Crouzon	B-X
,	B-X
and	B-X
Pfeiffer	B-X
syndromes	B-X
-	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
TWIST	B-X
and	B-X
FGFRs	B-X
are	B-X
components	B-X
of	B-X
the	B-X
same	B-X
molecular	B-X
pathway	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
craniofacial	B-X
and	B-X
limb	B-X
development	B-X
in	B-X
humans	B-X

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O
.	O
<EOS>	B-X
Nine	B-X
novel	B-X
and	B-X
three	B-X
recurrent	B-X
TWIST	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
12	B-X
families	B-X
<EOS>	B-X
More	B-X
than	B-X
35	B-X
different	B-X
TWIST	B-X
mutations	B-X
are	B-X
now	B-X
known	B-X
in	B-X
the	B-X
literature	B-X
<EOS>	B-X
Seven	B-X
families	B-X
were	B-X
found	B-X
to	B-X
have	B-X
the	B-X
FGFR3	B-X
P250R	B-X
mutation	B-X
,	B-X
and	B-X
one	B-X
individual	B-X
was	B-X
found	B-X
to	B-X
have	B-X
an	B-X
FGFR2	B-X
VV269	B-X
-	B-X
270	B-X
deletion	B-X
<EOS>	B-X
Significant	B-X
intra	B-X
-	B-X
	B-X
and	B-X
interfamilial	B-X
phenotypic	B-X
variability	B-X
is	B-X
present	B-X
for	B-X
either	B-X
TWIST	B-X
mutations	B-X
or	B-X
FGFR	B-X
mutations	B-X

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
deletion	O
.	O
<EOS>	B-X
Seven	B-X
families	B-X
were	B-X
found	B-X
to	B-X
have	B-X
the	B-X
FGFR3	B-X
P250R	B-X
mutation	B-X
,	B-X
and	B-X
one	B-X
individual	B-X
was	B-X
found	B-X
to	B-X
have	B-X
an	B-X
FGFR2	B-X
VV269	B-X
-	B-X
270	B-X
deletion	B-X
<EOS>	B-X
Nine	B-X
novel	B-X
and	B-X
three	B-X
recurrent	B-X
TWIST	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
12	B-X
families	B-X
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
due	B-X
to	B-X
TWIST	B-X
and	B-X
FGFR	B-X
mutations	B-X
.	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
our	B-X
detection	B-X
rate	B-X
for	B-X
TWIST	B-X
or	B-X
FGFR	B-X
mutations	B-X
is	B-X
68	B-X
%	B-X
in	B-X
our	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
patients	B-X
,	B-X
including	B-X
our	B-X
five	B-X
patients	B-X
elsewhere	B-X
reported	B-X
with	B-X
TWIST	B-X
mutations	B-X

To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
syndrome	I-Disease
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
our	B-X
detection	B-X
rate	B-X
for	B-X
TWIST	B-X
or	B-X
FGFR	B-X
mutations	B-X
is	B-X
68	B-X
%	B-X
in	B-X
our	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
patients	B-X
,	B-X
including	B-X
our	B-X
five	B-X
patients	B-X
elsewhere	B-X
reported	B-X
with	B-X
TWIST	B-X
mutations	B-X
<EOS>	B-X
Genetic	B-X
heterogeneity	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
due	B-X
to	B-X
TWIST	B-X
and	B-X
FGFR	B-X
mutations	B-X
.	B-X
<EOS>	B-X
The	B-X
overlap	B-X
in	B-X
clinical	B-X
features	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
in	B-X
the	B-X
same	B-X
genes	B-X
,	B-X
of	B-X
mutations	B-X
for	B-X
more	B-X
than	B-X
one	B-X
craniosynostotic	B-X
condition	B-X
-	B-X
such	B-X
as	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
,	B-X
Crouzon	B-X
,	B-X
and	B-X
Pfeiffer	B-X
syndromes	B-X
-	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
TWIST	B-X
and	B-X
FGFRs	B-X
are	B-X
components	B-X
of	B-X
the	B-X
same	B-X
molecular	B-X
pathway	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
craniofacial	B-X
and	B-X
limb	B-X
development	B-X
in	B-X
humans	B-X
<EOS>	B-X
More	B-X
than	B-X
35	B-X
different	B-X
TWIST	B-X
mutations	B-X
are	B-X
now	B-X
known	B-X
in	B-X
the	B-X
literature	B-X

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O
<EOS>	B-X
More	B-X
than	B-X
35	B-X
different	B-X
TWIST	B-X
mutations	B-X
are	B-X
now	B-X
known	B-X
in	B-X
the	B-X
literature	B-X
<EOS>	B-X
Nine	B-X
novel	B-X
and	B-X
three	B-X
recurrent	B-X
TWIST	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
12	B-X
families	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
our	B-X
detection	B-X
rate	B-X
for	B-X
TWIST	B-X
or	B-X
FGFR	B-X
mutations	B-X
is	B-X
68	B-X
%	B-X
in	B-X
our	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
patients	B-X
,	B-X
including	B-X
our	B-X
five	B-X
patients	B-X
elsewhere	B-X
reported	B-X
with	B-X
TWIST	B-X
mutations	B-X
<EOS>	B-X
Seven	B-X
families	B-X
were	B-X
found	B-X
to	B-X
have	B-X
the	B-X
FGFR3	B-X
P250R	B-X
mutation	B-X
,	B-X
and	B-X
one	B-X
individual	B-X
was	B-X
found	B-X
to	B-X
have	B-X
an	B-X
FGFR2	B-X
VV269	B-X
-	B-X
270	B-X
deletion	B-X

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B-Disease
synostosis	I-Disease
,	O
brachycephaly	B-Disease
,	O
low	B-Disease
frontal	I-Disease
hairline	I-Disease
,	O
facial	B-Disease
asymmetry	I-Disease
,	O
ptosis	B-Disease
,	O
hypertelorism	B-Disease
,	O
broad	B-Disease
great	I-Disease
toes	I-Disease
,	O
and	O
clinodactyly	B-Disease
.	O
<EOS>	B-X
The	B-X
most	B-X
common	B-X
phenotypic	B-X
features	B-X
,	B-X
present	B-X
in	B-X
more	B-X
than	B-X
a	B-X
third	B-X
of	B-X
our	B-X
patients	B-X
with	B-X
TWIST	B-X
mutations	B-X
,	B-X
are	B-X
coronal	B-X
synostosis	B-X
,	B-X
brachycephaly	B-X
,	B-X
low	B-X
frontal	B-X
hairline	B-X
,	B-X
facial	B-X
asymmetry	B-X
,	B-X
ptosis	B-X
,	B-X
hypertelorism	B-X
,	B-X
broad	B-X
great	B-X
toes	B-X
,	B-X
and	B-X
clinodactyly	B-X
<EOS>	B-X
The	B-X
overlap	B-X
in	B-X
clinical	B-X
features	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
in	B-X
the	B-X
same	B-X
genes	B-X
,	B-X
of	B-X
mutations	B-X
for	B-X
more	B-X
than	B-X
one	B-X
craniosynostotic	B-X
condition	B-X
-	B-X
such	B-X
as	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
,	B-X
Crouzon	B-X
,	B-X
and	B-X
Pfeiffer	B-X
syndromes	B-X
-	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
TWIST	B-X
and	B-X
FGFRs	B-X
are	B-X
components	B-X
of	B-X
the	B-X
same	B-X
molecular	B-X
pathway	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
craniofacial	B-X
and	B-X
limb	B-X
development	B-X
in	B-X
humans	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
our	B-X
detection	B-X
rate	B-X
for	B-X
TWIST	B-X
or	B-X
FGFR	B-X
mutations	B-X
is	B-X
68	B-X
%	B-X
in	B-X
our	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
patients	B-X
,	B-X
including	B-X
our	B-X
five	B-X
patients	B-X
elsewhere	B-X
reported	B-X
with	B-X
TWIST	B-X
mutations	B-X
<EOS>	B-X
Thirty	B-X
-	B-X
two	B-X
unrelated	B-X
patients	B-X
with	B-X
features	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
a	B-X
common	B-X
autosomal	B-X
dominant	B-X
condition	B-X
of	B-X
craniosynostosis	B-X
and	B-X
limb	B-X
anomalies	B-X
,	B-X
were	B-X
screened	B-X
for	B-X
mutations	B-X
in	B-X
TWIST	B-X
,	B-X
FGFR2	B-X
,	B-X
and	B-X
FGFR3	B-X

Significant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O
<EOS>	B-X
We	B-X
identified	B-X
a	B-X
low	B-X
rate	B-X
of	B-X
incidental	B-X
germline	B-X
mutations	B-X
in	B-X
all	B-X
tumors	B-X
(	B-X
5	B-X
<EOS>	B-X
Intestinal	B-X
rotation	B-X
anomalies	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
occur	B-X
more	B-X
frequently	B-X
in	B-X
animals	B-X
with	B-X
FGFR	B-X
-	B-X
2	B-X
mutations	B-X
<EOS>	B-X
It	B-X
is	B-X
critical	B-X
to	B-X
analyze	B-X
their	B-X
target	B-X
selectivity	B-X
and	B-X
their	B-X
abilities	B-X
to	B-X
overcome	B-X
gatekeeper	B-X
mutations	B-X
<EOS>	B-X
Structural	B-X
insights	B-X
into	B-X
the	B-X
potency	B-X
and	B-X
selectivity	B-X
of	B-X
covalent	B-X
pan	B-X
-	B-X
FGFR	B-X
inhibitors	B-X
.	B-X

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B-Disease
condition	I-Disease
-	O
such	O
as	O
Saethre	B-Disease
-	I-Disease
Chotzen	I-Disease
,	I-Disease
Crouzon	I-Disease
,	I-Disease
and	I-Disease
Pfeiffer	I-Disease
syndromes	I-Disease
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
.	O
<EOS>	B-X
The	B-X
overlap	B-X
in	B-X
clinical	B-X
features	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
in	B-X
the	B-X
same	B-X
genes	B-X
,	B-X
of	B-X
mutations	B-X
for	B-X
more	B-X
than	B-X
one	B-X
craniosynostotic	B-X
condition	B-X
-	B-X
such	B-X
as	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
,	B-X
Crouzon	B-X
,	B-X
and	B-X
Pfeiffer	B-X
syndromes	B-X
-	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
TWIST	B-X
and	B-X
FGFRs	B-X
are	B-X
components	B-X
of	B-X
the	B-X
same	B-X
molecular	B-X
pathway	B-X
involved	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
craniofacial	B-X
and	B-X
limb	B-X
development	B-X
in	B-X
humans	B-X
<EOS>	B-X
The	B-X
most	B-X
common	B-X
phenotypic	B-X
features	B-X
,	B-X
present	B-X
in	B-X
more	B-X
than	B-X
a	B-X
third	B-X
of	B-X
our	B-X
patients	B-X
with	B-X
TWIST	B-X
mutations	B-X
,	B-X
are	B-X
coronal	B-X
synostosis	B-X
,	B-X
brachycephaly	B-X
,	B-X
low	B-X
frontal	B-X
hairline	B-X
,	B-X
facial	B-X
asymmetry	B-X
,	B-X
ptosis	B-X
,	B-X
hypertelorism	B-X
,	B-X
broad	B-X
great	B-X
toes	B-X
,	B-X
and	B-X
clinodactyly	B-X
<EOS>	B-X
Thirty	B-X
-	B-X
two	B-X
unrelated	B-X
patients	B-X
with	B-X
features	B-X
of	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
,	B-X
a	B-X
common	B-X
autosomal	B-X
dominant	B-X
condition	B-X
of	B-X
craniosynostosis	B-X
and	B-X
limb	B-X
anomalies	B-X
,	B-X
were	B-X
screened	B-X
for	B-X
mutations	B-X
in	B-X
TWIST	B-X
,	B-X
FGFR2	B-X
,	B-X
and	B-X
FGFR3	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
our	B-X
detection	B-X
rate	B-X
for	B-X
TWIST	B-X
or	B-X
FGFR	B-X
mutations	B-X
is	B-X
68	B-X
%	B-X
in	B-X
our	B-X
Saethre	B-X
-	B-X
Chotzen	B-X
syndrome	B-X
patients	B-X
,	B-X
including	B-X
our	B-X
five	B-X
patients	B-X
elsewhere	B-X
reported	B-X
with	B-X
TWIST	B-X
mutations	B-X

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B-Disease
syndrome	I-Disease
patients	O
.	O
<EOS>	B-X
Mutation	B-X
Update	B-X
for	B-X
UBE3A	B-X
variants	B-X
in	B-X
Angelman	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Molecular	B-X
and	B-X
clinical	B-X
characterization	B-X
of	B-X
Angelman	B-X
syndrome	B-X
in	B-X
Chinese	B-X
patients	B-X
.	B-X
<EOS>	B-X
Ube3a	B-X
imprinting	B-X
impairs	B-X
circadian	B-X
robustness	B-X
in	B-X
Angelman	B-X
syndrome	B-X
models	B-X
.	B-X
<EOS>	B-X
[	B-X
Clinical	B-X
and	B-X
genetic	B-X
analysis	B-X
of	B-X
two	B-X
unrelated	B-X
patients	B-X
with	B-X
Angelman	B-X
syndrome	B-X
and	B-X
novel	B-X
UBE3A	B-X
mutations	B-X
]	B-X
.	B-X

Angelman	B-Disease
syndrome	I-Disease
(	O
AS	B-Disease
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B-Disease
disomy	I-Disease
(	O
UPD	B-Disease
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
brain	O
-	O
specific	O
imprinting	O
.	O
<EOS>	B-X
UBE3A	B-X
encodes	B-X
a	B-X
ubiquitin	B-X
-	B-X
protein	B-X
ligase	B-X
and	B-X
shows	B-X
brain	B-X
-	B-X
specific	B-X
imprinting	B-X
<EOS>	B-X
UBE3A	B-X
encodes	B-X
an	B-X
ubiquitin	B-X
-	B-X
protein	B-X
ligase	B-X
and	B-X
shows	B-X
brain	B-X
-	B-X
specific	B-X
imprinting	B-X
<EOS>	B-X
UBE3A	B-X
encodes	B-X
UBE3A	B-X
/	B-X
E6	B-X
-	B-X
AP	B-X
,	B-X
a	B-X
ubiquitin	B-X
-	B-X
protein	B-X
ligase	B-X
,	B-X
and	B-X
shows	B-X
brain	B-X
-	B-X
specific	B-X
imprinting	B-X
,	B-X
with	B-X
brain	B-X
expression	B-X
predominantly	B-X
from	B-X
the	B-X
maternal	B-X
allele	B-X
<EOS>	B-X
The	B-X
inactive	B-X
allele	B-X
contains	B-X
a	B-X
lacZ	B-X
reporter	B-X
gene	B-X
for	B-X
analysis	B-X
of	B-X
brain	B-X
-	B-X
specific	B-X
imprinting	B-X

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B-Disease
individuals	O
or	O
families	O
.	O
<EOS>	B-X
After	B-X
two	B-X
embryo	B-X
transfers	B-X
without	B-X
achieving	B-X
pregnancy	B-X
,	B-X
the	B-X
couple	B-X
was	B-X
directed	B-X
to	B-X
the	B-X
Preimplantation	B-X
Genetic	B-X
Testing	B-X
for	B-X
Aneuploidies	B-X
(	B-X
PGT	B-X
-	B-X
A	B-X
)	B-X
<EOS>	B-X
Safety	B-X
and	B-X
effectiveness	B-X
of	B-X
a	B-X
novel	B-X
home	B-X
-	B-X
use	B-X
therapeutic	B-X
ultrasound	B-X
device	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
vaginal	B-X
dryness	B-X
in	B-X
postmenopausal	B-X
women	B-X
:	B-X
a	B-X
pilot	B-X
study	B-X
.	B-X
<EOS>	B-X
Maternal	B-X
age	B-X
at	B-X
birth	B-X
of	B-X
last	B-X
child	B-X
and	B-X
cardiovascular	B-X
disease	B-X
mortality	B-X
later	B-X
in	B-X
life	B-X
among	B-X
a	B-X
national	B-X
cohort	B-X
of	B-X
postmenopausal	B-X
women	B-X
from	B-X
the	B-X
United	B-X
States	B-X
.	B-X
<EOS>	B-X
This	B-X
work	B-X
provides	B-X
indications	B-X
on	B-X
the	B-X
domains	B-X
and	B-X
ideal	B-X
pertinent	B-X
measurement	B-X
instruments	B-X
that	B-X
clinicians	B-X
may	B-X
wish	B-X
to	B-X
use	B-X
to	B-X
follow	B-X
patients	B-X
with	B-X
cognitive	B-X
impairment	B-X

Two	O
identical	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
in	O
exon	O
16	O
were	O
found	O
.	O
<EOS>	B-X
Two	B-X
identical	B-X
de	B-X
novo	B-X
5	B-X
-	B-X
bp	B-X
duplications	B-X
in	B-X
exon	B-X
16	B-X
were	B-X
found	B-X
<EOS>	B-X
Eight	B-X
of	B-X
the	B-X
cases	B-X
were	B-X
familial	B-X
,	B-X
and	B-X
five	B-X
were	B-X
sporadic	B-X
<EOS>	B-X
The	B-X
frequencies	B-X
with	B-X
which	B-X
we	B-X
detected	B-X
mutations	B-X
were	B-X
5	B-X
(	B-X
14	B-X
%	B-X
)	B-X
of	B-X
35	B-X
in	B-X
sporadic	B-X
cases	B-X
and	B-X
8	B-X
(	B-X
80	B-X
%	B-X
)	B-X
of	B-X
10	B-X
in	B-X
familial	B-X
cases	B-X
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
UBE3A	B-X
coding	B-X
-	B-X
region	B-X
mutations	B-X
detected	B-X
by	B-X
SSCP	B-X
analysis	B-X
in	B-X
13	B-X
AS	B-X
individuals	B-X
or	B-X
families	B-X

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
other	B-X
11	B-X
unique	B-X
mutations	B-X
,	B-X
8	B-X
were	B-X
small	B-X
deletions	B-X
or	B-X
insertions	B-X
predicted	B-X
to	B-X
cause	B-X
frameshifts	B-X
,	B-X
1	B-X
was	B-X
a	B-X
mutation	B-X
to	B-X
a	B-X
stop	B-X
codon	B-X
,	B-X
1	B-X
was	B-X
a	B-X
missense	B-X
mutation	B-X
,	B-X
and	B-X
1	B-X
was	B-X
predicted	B-X
to	B-X
cause	B-X
insertion	B-X
of	B-X
an	B-X
isoleucine	B-X
in	B-X
the	B-X
hect	B-X
domain	B-X
of	B-X
the	B-X
UBE3A	B-X
protein	B-X
,	B-X
which	B-X
functions	B-X
in	B-X
E2	B-X
binding	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
<EOS>	B-X
The	B-X
three	B-X
species	B-X
of	B-X
section	B-X
Luxuriantes	B-X
of	B-X
Zea	B-X
were	B-X
identical	B-X
to	B-X
one	B-X
another	B-X
for	B-X
each	B-X
of	B-X
the	B-X
four	B-X
length	B-X
mutations	B-X
,	B-X
and	B-X
they	B-X
were	B-X
consistently	B-X
distinguished	B-X
from	B-X
the	B-X
taxa	B-X
of	B-X
section	B-X
Zea	B-X
by	B-X
these	B-X
mutations	B-X
<EOS>	B-X
Of	B-X
the	B-X
35	B-X
identified	B-X
intragenic	B-X
mutations	B-X
,	B-X
all	B-X
were	B-X
unique	B-X
,	B-X
with	B-X
the	B-X
exceptions	B-X
of	B-X
a	B-X
5	B-X
-	B-X
bp	B-X
deletion	B-X
in	B-X
exon	B-X
16	B-X
,	B-X
seen	B-X
in	B-X
two	B-X
unrelated	B-X
patients	B-X
,	B-X
and	B-X
a	B-X
C	B-X
insertion	B-X
at	B-X
base	B-X
1618	B-X
in	B-X
exon	B-X
9	B-X
,	B-X
also	B-X
seen	B-X
in	B-X
two	B-X
unrelated	B-X
patients	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
221	B-X
(	B-X
87	B-X
%	B-X
)	B-X
of	B-X
all	B-X
mutations	B-X
or	B-X
107	B-X
(	B-X
81	B-X
%	B-X
)	B-X
of	B-X
the	B-X
unique	B-X
mutations	B-X
are	B-X
small	B-X
deletions	B-X
,	B-X
insertions	B-X
,	B-X
nonsense	B-X
point	B-X
mutations	B-X
,	B-X
splice	B-X
variants	B-X
,	B-X
and	B-X
regulatory	B-X
mutations	B-X
that	B-X
result	B-X
in	B-X
truncation	B-X
or	B-X
absence	B-X
of	B-X
the	B-X
BRCA1	B-X
protein	B-X

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O
<EOS>	B-X
E864K	B-X
)	B-X
known	B-X
to	B-X
cause	B-X
Wolfram	B-X
-	B-X
like	B-X
syndrome	B-X
,	B-X
and	B-X
five	B-X
were	B-X
novel	B-X
mutations	B-X
<EOS>	B-X
Two	B-X
of	B-X
these	B-X
were	B-X
family	B-X
/	B-X
dietary	B-X
-	B-X
related	B-X
and	B-X
spatially	B-X
linked	B-X
to	B-X
a	B-X
third	B-X
<EOS>	B-X
From	B-X
these	B-X
cases	B-X
,	B-X
four	B-X
hereditary	B-X
families	B-X
and	B-X
10	B-X
cases	B-X
with	B-X
sporadic	B-X
occurrences	B-X
were	B-X
found	B-X
<EOS>	B-X
9	B-X
%	B-X
and	B-X
14	B-X
cases	B-X
were	B-X
familial	B-X

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B-Disease
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B-Disease
first	O
cousins	O
,	O
and	O
in	O
the	O
mother	O
of	O
an	O
AS	B-Disease
daughter	O
.	O
<EOS>	B-X
In	B-X
two	B-X
familial	B-X
cases	B-X
and	B-X
one	B-X
sporadic	B-X
case	B-X
,	B-X
mosaicism	B-X
for	B-X
UBE3A	B-X
mutations	B-X
was	B-X
detected	B-X
:	B-X
in	B-X
the	B-X
mother	B-X
of	B-X
three	B-X
AS	B-X
sons	B-X
,	B-X
in	B-X
the	B-X
maternal	B-X
grandfather	B-X
of	B-X
two	B-X
AS	B-X
first	B-X
cousins	B-X
,	B-X
and	B-X
in	B-X
the	B-X
mother	B-X
of	B-X
an	B-X
AS	B-X
daughter	B-X
<EOS>	B-X
Among	B-X
the	B-X
other	B-X
11	B-X
unique	B-X
mutations	B-X
,	B-X
8	B-X
were	B-X
small	B-X
deletions	B-X
or	B-X
insertions	B-X
predicted	B-X
to	B-X
cause	B-X
frameshifts	B-X
,	B-X
1	B-X
was	B-X
a	B-X
mutation	B-X
to	B-X
a	B-X
stop	B-X
codon	B-X
,	B-X
1	B-X
was	B-X
a	B-X
missense	B-X
mutation	B-X
,	B-X
and	B-X
1	B-X
was	B-X
predicted	B-X
to	B-X
cause	B-X
insertion	B-X
of	B-X
an	B-X
isoleucine	B-X
in	B-X
the	B-X
hect	B-X
domain	B-X
of	B-X
the	B-X
UBE3A	B-X
protein	B-X
,	B-X
which	B-X
functions	B-X
in	B-X
E2	B-X
binding	B-X
and	B-X
ubiquitin	B-X
transfer	B-X
<EOS>	B-X
The	B-X
frequencies	B-X
with	B-X
which	B-X
we	B-X
detected	B-X
mutations	B-X
were	B-X
5	B-X
(	B-X
14	B-X
%	B-X
)	B-X
of	B-X
35	B-X
in	B-X
sporadic	B-X
cases	B-X
and	B-X
8	B-X
(	B-X
80	B-X
%	B-X
)	B-X
of	B-X
10	B-X
in	B-X
familial	B-X
cases	B-X
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
UBE3A	B-X
coding	B-X
-	B-X
region	B-X
mutations	B-X
detected	B-X
by	B-X
SSCP	B-X
analysis	B-X
in	B-X
13	B-X
AS	B-X
individuals	B-X
or	B-X
families	B-X

The	O
frequencies	O
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
.	O

The	O
hemochromatosis	B-Disease
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O
populations	O
.	O

Hemochromatosis	B-Disease
,	O
the	O
inherited	B-Disease
disorder	I-Disease
of	I-Disease
iron	I-Disease
metabolism	I-Disease
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B-Disease
overload	I-Disease
and	O
premature	B-Disease
death	I-Disease
.	O
<EOS>	B-X
Hemochromatosis	B-X
,	B-X
the	B-X
inherited	B-X
disorder	B-X
of	B-X
iron	B-X
metabolism	B-X
,	B-X
leads	B-X
,	B-X
if	B-X
untreated	B-X
,	B-X
to	B-X
progressive	B-X
iron	B-X
overload	B-X
and	B-X
premature	B-X
death	B-X
<EOS>	B-X
The	B-X
hemochromatosis	B-X
gene	B-X
,	B-X
HFE	B-X
,	B-X
recently	B-X
has	B-X
been	B-X
identified	B-X
,	B-X
and	B-X
characterization	B-X
of	B-X
this	B-X
gene	B-X
has	B-X
shown	B-X
that	B-X
it	B-X
contains	B-X
two	B-X
mutations	B-X
that	B-X
result	B-X
in	B-X
amino	B-X
acid	B-X
substitutions	B-X
-	B-X
cDNA	B-X
nucleotides	B-X
845	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
A	B-X
(	B-X
C282Y	B-X
)	B-X
and	B-X
187	B-X
C	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
G	B-X
(	B-X
H63D	B-X
)	B-X
<EOS>	B-X
The	B-X
hemochromatosis	B-X
845	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
A	B-X
and	B-X
187	B-X
C	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
G	B-X
mutations	B-X
:	B-X
prevalence	B-X
in	B-X
non	B-X
-	B-X
Caucasian	B-X
populations	B-X
.	B-X
<EOS>	B-X
Although	B-X
hemochromatosis	B-X
is	B-X
common	B-X
in	B-X
Caucasians	B-X
,	B-X
affecting	B-X
>	B-X
=1	B-X
/	B-X
300	B-X
individuals	B-X
of	B-X
northern	B-X
European	B-X
origin	B-X
,	B-X
it	B-X
has	B-X
not	B-X
been	B-X
recognized	B-X
in	B-X
other	B-X
populations	B-X

The	O
hemochromatosis	B-Disease
gene	O
,	O
HFE	O
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
H63D	O
)	O
.	O

Although	O
hemochromatosis	B-Disease
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G	O
-	O
-	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
.	O

187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O

68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O
<EOS>	B-X
68	B-X
%	B-X
in	B-X
the	B-X
two	B-X
populations	B-X
analyzed	B-X
(	B-X
Australian	B-X
Aboriginal	B-X
and	B-X
Chinese	B-X
)	B-X
<EOS>	B-X
Hemochromatosis	B-X
,	B-X
the	B-X
inherited	B-X
disorder	B-X
of	B-X
iron	B-X
metabolism	B-X
,	B-X
leads	B-X
,	B-X
if	B-X
untreated	B-X
,	B-X
to	B-X
progressive	B-X
iron	B-X
overload	B-X
and	B-X
premature	B-X
death	B-X
<EOS>	B-X
Results	B-X
showed	B-X
that	B-X
the	B-X
845	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
A	B-X
mutation	B-X
was	B-X
present	B-X
in	B-X
these	B-X
populations	B-X
(	B-X
allele	B-X
frequency	B-X
0	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
used	B-X
PCR	B-X
and	B-X
restriction	B-X
-	B-X
enzyme	B-X
digestion	B-X
to	B-X
analyze	B-X
the	B-X
frequency	B-X
of	B-X
the	B-X
845	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
A	B-X
and	B-X
187	B-X
C	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
G	B-X
mutations	B-X
in	B-X
HLA	B-X
-	B-X
typed	B-X
samples	B-X
from	B-X
non	B-X
-	B-X
Caucasian	B-X
populations	B-X
,	B-X
comprising	B-X
Australian	B-X
Aboriginal	B-X
,	B-X
Chinese	B-X
,	B-X
and	B-X
Pacific	B-X
Islanders	B-X

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
.	O
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
as	B-X
a	B-X
guide	B-X
in	B-X
the	B-X
management	B-X
of	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
.	B-X
<EOS>	B-X
Mutations	B-X
of	B-X
APC	B-X
and	B-X
MYH	B-X
in	B-X
unrelated	B-X
Italian	B-X
patients	B-X
with	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
.	B-X
<EOS>	B-X
Clinical	B-X
and	B-X
molecular	B-X
features	B-X
of	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
in	B-X
northern	B-X
Italy	B-X
.	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
19	B-X
Dutch	B-X
cases	B-X
with	B-X
APC	B-X
gene	B-X
deletions	B-X
and	B-X
a	B-X
literature	B-X
review	B-X
.	B-X

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B-Disease
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
AAPC	B-Disease
)	O
,	O
a	O
variant	O
of	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
.	O
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
mutations	B-X
of	B-X
the	B-X
tumor	B-X
suppressor	B-X
APC	B-X
are	B-X
implicated	B-X
in	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
(	B-X
AAPC	B-X
)	B-X
,	B-X
a	B-X
variant	B-X
of	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
.	B-X
<EOS>	B-X
In	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
region	B-X
2	B-X
or	B-X
region	B-X
3	B-X
,	B-X
the	B-X
average	B-X
number	B-X
of	B-X
adenomas	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
although	B-X
age	B-X
at	B-X
diagnosis	B-X
was	B-X
similar	B-X
<EOS>	B-X
This	B-X
should	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
tailored	B-X
clinical	B-X
-	B-X
management	B-X
protocols	B-X
in	B-X
this	B-X
subset	B-X
of	B-X
FAP	B-X
patients	B-X

AAPC	B-Disease
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B-Disease
adenomas	I-Disease
and	O
a	O
later	O
onset	O
of	O
colorectal	B-Disease
cancer	I-Disease
(	O
age	O
>	O
40	O
years	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B-Disease
families	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
AAPC	B-X
families	B-X
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
mutations	B-X
of	B-X
the	B-X
tumor	B-X
suppressor	B-X
APC	B-X
are	B-X
implicated	B-X
in	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
(	B-X
AAPC	B-X
)	B-X
,	B-X
a	B-X
variant	B-X
of	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
<EOS>	B-X
This	B-X
should	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
tailored	B-X
clinical	B-X
-	B-X
management	B-X
protocols	B-X
in	B-X
this	B-X
subset	B-X
of	B-X
FAP	B-X
patients	B-X
<EOS>	B-X
Variability	B-X
in	B-X
the	B-X
number	B-X
of	B-X
colorectal	B-X
adenomas	B-X
was	B-X
most	B-X
apparent	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
and	B-X
upper	B-X
-	B-X
gastrointestinal	B-X
manifestations	B-X
were	B-X
more	B-X
severe	B-X
in	B-X
them	B-X

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B-Disease
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	B-Disease
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O
<EOS>	B-X
By	B-X
protein	B-X
-	B-X
truncation	B-X
test	B-X
(	B-X
PTT	B-X
)	B-X
assay	B-X
,	B-X
the	B-X
entire	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
screened	B-X
in	B-X
affected	B-X
individuals	B-X
from	B-X
11	B-X
AAPC	B-X
kindreds	B-X
,	B-X
and	B-X
their	B-X
phenotypic	B-X
differences	B-X
were	B-X
examined	B-X
<EOS>	B-X
Mutations	B-X
were	B-X
located	B-X
in	B-X
three	B-X
different	B-X
regions	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
:	B-X
(	B-X
1	B-X
)	B-X
at	B-X
the	B-X
5	B-X
'	B-X
end	B-X
spanning	B-X
exons	B-X
4	B-X
and	B-X
5	B-X
,	B-X
(	B-X
2	B-X
)	B-X
within	B-X
exon	B-X
9	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
at	B-X
the	B-X
3	B-X
'	B-X
distal	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
AAPC	B-X
families	B-X
,	B-X
the	B-X
location	B-X
of	B-X
the	B-X
APC	B-X
mutation	B-X
may	B-X
partially	B-X
predict	B-X
specific	B-X
phenotypic	B-X
expression	B-X
<EOS>	B-X
In	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
region	B-X
2	B-X
or	B-X
region	B-X
3	B-X
,	B-X
the	B-X
average	B-X
number	B-X
of	B-X
adenomas	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
although	B-X
age	B-X
at	B-X
diagnosis	B-X
was	B-X
similar	B-X

Five	O
novel	O
germ	O
-	O
line	O
APC	B-Disease
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O
<EOS>	B-X
Five	B-X
novel	B-X
germ	B-X
-	B-X
line	B-X
APC	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
seven	B-X
kindreds	B-X
<EOS>	B-X
No	B-X
desmoid	B-X
tumors	B-X
were	B-X
found	B-X
in	B-X
these	B-X
kindreds	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
AAPC	B-X
families	B-X
,	B-X
the	B-X
location	B-X
of	B-X
the	B-X
APC	B-X
mutation	B-X
may	B-X
partially	B-X
predict	B-X
specific	B-X
phenotypic	B-X
expression	B-X
<EOS>	B-X
Variability	B-X
in	B-X
the	B-X
number	B-X
of	B-X
colorectal	B-X
adenomas	B-X
was	B-X
most	B-X
apparent	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
and	B-X
upper	B-X
-	B-X
gastrointestinal	B-X
manifestations	B-X
were	B-X
more	B-X
severe	B-X
in	B-X
them	B-X

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B-Disease
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B-Disease
adenomas	I-Disease
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O
<EOS>	B-X
Variability	B-X
in	B-X
the	B-X
number	B-X
of	B-X
colorectal	B-X
adenomas	B-X
was	B-X
most	B-X
apparent	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
and	B-X
upper	B-X
-	B-X
gastrointestinal	B-X
manifestations	B-X
were	B-X
more	B-X
severe	B-X
in	B-X
them	B-X
<EOS>	B-X
In	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
region	B-X
2	B-X
or	B-X
region	B-X
3	B-X
,	B-X
the	B-X
average	B-X
number	B-X
of	B-X
adenomas	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
although	B-X
age	B-X
at	B-X
diagnosis	B-X
was	B-X
similar	B-X
<EOS>	B-X
In	B-X
all	B-X
AAPC	B-X
kindreds	B-X
,	B-X
a	B-X
predominance	B-X
of	B-X
right	B-X
-	B-X
sided	B-X
colorectal	B-X
adenomas	B-X
and	B-X
rectal	B-X
polyp	B-X
sparing	B-X
was	B-X
observed	B-X
<EOS>	B-X
This	B-X
should	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
tailored	B-X
clinical	B-X
-	B-X
management	B-X
protocols	B-X
in	B-X
this	B-X
subset	B-X
of	B-X
FAP	B-X
patients	B-X

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B-Disease
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O
<EOS>	B-X
Under	B-X
the	B-X
conditions	B-X
we	B-X
studied	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
detect	B-X
an	B-X
individual	B-X
contribution	B-X
of	B-X
either	B-X
Pdk1	B-X
or	B-X
Itga6	B-X
to	B-X
body	B-X
weight	B-X
<EOS>	B-X
Outcome	B-X
measures	B-X
included	B-X
prevalence	B-X
of	B-X
somatic	B-X
UBA1	B-X
variation	B-X
;	B-X
presence	B-X
of	B-X
rheumatologic	B-X
,	B-X
hematologic	B-X
,	B-X
pulmonary	B-X
,	B-X
dermatologic	B-X
,	B-X
and	B-X
other	B-X
findings	B-X
in	B-X
individuals	B-X
with	B-X
somatic	B-X
UBA1	B-X
variation	B-X
on	B-X
review	B-X
of	B-X
the	B-X
electronic	B-X
health	B-X
record	B-X
;	B-X
review	B-X
of	B-X
laboratory	B-X
data	B-X
;	B-X
bone	B-X
marrow	B-X
biopsy	B-X
pathology	B-X
analysis	B-X
;	B-X
and	B-X
in	B-X
vitro	B-X
enzymatic	B-X
assays	B-X
<EOS>	B-X
Individuals	B-X
with	B-X
full	B-X
mutation	B-X
alleles	B-X
develop	B-X
fragile	B-X
X	B-X
syndrome	B-X
,	B-X
which	B-X
causes	B-X
autism	B-X
and	B-X
intellectual	B-X
disability	B-X
,	B-X
whereas	B-X
those	B-X
with	B-X
premutation	B-X
alleles	B-X
,	B-X
which	B-X
have	B-X
shorter	B-X
CGG	B-X
expansions	B-X
,	B-X
can	B-X
develop	B-X
fragile	B-X
X	B-X
-	B-X
associated	B-X
tremor	B-X
/	B-X
ataxia	B-X
syndrome	B-X
,	B-X
a	B-X
progressive	B-X
neurodegenerative	B-X
disease	B-X
<EOS>	B-X
High	B-X
Drug	B-X
Resistance	B-X
Levels	B-X
Compromise	B-X
the	B-X
Control	B-X
of	B-X
HIV	B-X
Infection	B-X
in	B-X
Pediatric	B-X
and	B-X
Adult	B-X
Populations	B-X
in	B-X
Bata	B-X
,	B-X
Equatorial	B-X
Guinea	B-X
.	B-X

In	O
all	O
AAPC	B-Disease
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B-Disease
adenomas	I-Disease
and	O
rectal	B-Disease
polyp	I-Disease
sparing	O
was	O
observed	O
.	O
<EOS>	B-X
In	B-X
all	B-X
AAPC	B-X
kindreds	B-X
,	B-X
a	B-X
predominance	B-X
of	B-X
right	B-X
-	B-X
sided	B-X
colorectal	B-X
adenomas	B-X
and	B-X
rectal	B-X
polyp	B-X
sparing	B-X
was	B-X
observed	B-X
<EOS>	B-X
Variability	B-X
in	B-X
the	B-X
number	B-X
of	B-X
colorectal	B-X
adenomas	B-X
was	B-X
most	B-X
apparent	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
and	B-X
upper	B-X
-	B-X
gastrointestinal	B-X
manifestations	B-X
were	B-X
more	B-X
severe	B-X
in	B-X
them	B-X
<EOS>	B-X
In	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
region	B-X
2	B-X
or	B-X
region	B-X
3	B-X
,	B-X
the	B-X
average	B-X
number	B-X
of	B-X
adenomas	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
although	B-X
age	B-X
at	B-X
diagnosis	B-X
was	B-X
similar	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
.	B-X

No	O
desmoid	B-Disease
tumors	I-Disease
were	O
found	O
in	O
these	O
kindreds	O
.	O
<EOS>	B-X
No	B-X
desmoid	B-X
tumors	B-X
were	B-X
found	B-X
in	B-X
these	B-X
kindreds	B-X
<EOS>	B-X
The	B-X
penetrance	B-X
of	B-X
desmoid	B-X
tumors	B-X
was	B-X
near	B-X
100	B-X
%	B-X
in	B-X
this	B-X
kindred	B-X
<EOS>	B-X
Five	B-X
novel	B-X
germ	B-X
-	B-X
line	B-X
APC	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
seven	B-X
kindreds	B-X
<EOS>	B-X
Desmoid	B-X
tumors	B-X
and	B-X
mesenteric	B-X
fibromatosis	B-X
in	B-X
Gardner	B-X
's	B-X
syndrome	B-X
:	B-X
report	B-X
of	B-X
kindred	B-X
109	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B-Disease
families	O
,	O
the	O
location	O
of	O
the	O
APC	B-Disease
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
AAPC	B-X
families	B-X
,	B-X
the	B-X
location	B-X
of	B-X
the	B-X
APC	B-X
mutation	B-X
may	B-X
partially	B-X
predict	B-X
specific	B-X
phenotypic	B-X
expression	B-X
<EOS>	B-X
By	B-X
protein	B-X
-	B-X
truncation	B-X
test	B-X
(	B-X
PTT	B-X
)	B-X
assay	B-X
,	B-X
the	B-X
entire	B-X
coding	B-X
region	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
screened	B-X
in	B-X
affected	B-X
individuals	B-X
from	B-X
11	B-X
AAPC	B-X
kindreds	B-X
,	B-X
and	B-X
their	B-X
phenotypic	B-X
differences	B-X
were	B-X
examined	B-X
<EOS>	B-X
Five	B-X
novel	B-X
germ	B-X
-	B-X
line	B-X
APC	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
seven	B-X
kindreds	B-X
<EOS>	B-X
In	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
region	B-X
2	B-X
or	B-X
region	B-X
3	B-X
,	B-X
the	B-X
average	B-X
number	B-X
of	B-X
adenomas	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
although	B-X
age	B-X
at	B-X
diagnosis	B-X
was	B-X
similar	B-X

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B-Disease
patients	O
.	O
.	O
<EOS>	B-X
This	B-X
should	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
tailored	B-X
clinical	B-X
-	B-X
management	B-X
protocols	B-X
in	B-X
this	B-X
subset	B-X
of	B-X
FAP	B-X
patients	B-X
<EOS>	B-X
Mutations	B-X
were	B-X
located	B-X
in	B-X
three	B-X
different	B-X
regions	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
:	B-X
(	B-X
1	B-X
)	B-X
at	B-X
the	B-X
5	B-X
'	B-X
end	B-X
spanning	B-X
exons	B-X
4	B-X
and	B-X
5	B-X
,	B-X
(	B-X
2	B-X
)	B-X
within	B-X
exon	B-X
9	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
at	B-X
the	B-X
3	B-X
'	B-X
distal	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
mutations	B-X
of	B-X
the	B-X
tumor	B-X
suppressor	B-X
APC	B-X
are	B-X
implicated	B-X
in	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
(	B-X
AAPC	B-X
)	B-X
,	B-X
a	B-X
variant	B-X
of	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
<EOS>	B-X
In	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
region	B-X
2	B-X
or	B-X
region	B-X
3	B-X
,	B-X
the	B-X
average	B-X
number	B-X
of	B-X
adenomas	B-X
tended	B-X
to	B-X
be	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
individuals	B-X
with	B-X
mutations	B-X
in	B-X
region	B-X
1	B-X
,	B-X
although	B-X
age	B-X
at	B-X
diagnosis	B-X
was	B-X
similar	B-X

Wilms	B-Disease
'	I-Disease
tumor	I-Disease
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
modulate	B-X
the	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
SF	B-X
-	B-X
1	B-X
in	B-X
sex	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
WT1	B-X
	B-X
-	B-X
KTS	B-X
isoforms	B-X
associate	B-X
and	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
MIS	B-X
expression	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
WT1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
functionally	B-X
oppose	B-X
each	B-X
other	B-X
in	B-X
testis	B-X
development	B-X
by	B-X
modulating	B-X
SF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
Products	B-X
of	B-X
steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF	B-X
-	B-X
1	B-X
)	B-X
and	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
WT1	B-X
)	B-X
genes	B-X
are	B-X
essential	B-X
for	B-X
mammalian	B-X
gonadogenesis	B-X
prior	B-X
to	B-X
sexual	B-X
differentiation	B-X

Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B-Disease
tumor	I-Disease
1	O
(	O
WT1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O
<EOS>	B-X
Products	B-X
of	B-X
steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF	B-X
-	B-X
1	B-X
)	B-X
and	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
WT1	B-X
)	B-X
genes	B-X
are	B-X
essential	B-X
for	B-X
mammalian	B-X
gonadogenesis	B-X
prior	B-X
to	B-X
sexual	B-X
differentiation	B-X
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
modulate	B-X
the	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
SF	B-X
-	B-X
1	B-X
in	B-X
sex	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
WT1	B-X
	B-X
-	B-X
KTS	B-X
isoforms	B-X
associate	B-X
and	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
MIS	B-X
expression	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
WT1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
functionally	B-X
oppose	B-X
each	B-X
other	B-X
in	B-X
testis	B-X
development	B-X
by	B-X
modulating	B-X
SF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
transactivation	B-X

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O
<EOS>	B-X
In	B-X
males	B-X
,	B-X
SF	B-X
-	B-X
1	B-X
participates	B-X
in	B-X
sexual	B-X
development	B-X
by	B-X
regulating	B-X
expression	B-X
of	B-X
the	B-X
polypeptide	B-X
hormone	B-X
MÃ¼llerian	B-X
inhibiting	B-X
substance	B-X
(	B-X
MIS	B-X
)	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
WT1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
functionally	B-X
oppose	B-X
each	B-X
other	B-X
in	B-X
testis	B-X
development	B-X
by	B-X
modulating	B-X
SF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
,	B-X
candidate	B-X
dosage	B-X
-	B-X
sensitive	B-X
sex	B-X
-	B-X
reversal	B-X
gene	B-X
,	B-X
Dax	B-X
-	B-X
1	B-X
,	B-X
antagonizes	B-X
synergy	B-X
between	B-X
SF	B-X
-	B-X
1	B-X
and	B-X
WT1	B-X
,	B-X
most	B-X
likely	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
modulate	B-X
the	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
SF	B-X
-	B-X
1	B-X
in	B-X
sex	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
MIS	O
expression	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
WT1	B-X
	B-X
-	B-X
KTS	B-X
isoforms	B-X
associate	B-X
and	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
MIS	B-X
expression	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
,	B-X
candidate	B-X
dosage	B-X
-	B-X
sensitive	B-X
sex	B-X
-	B-X
reversal	B-X
gene	B-X
,	B-X
Dax	B-X
-	B-X
1	B-X
,	B-X
antagonizes	B-X
synergy	B-X
between	B-X
SF	B-X
-	B-X
1	B-X
and	B-X
WT1	B-X
,	B-X
most	B-X
likely	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
modulate	B-X
the	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
SF	B-X
-	B-X
1	B-X
in	B-X
sex	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
WT1	B-X
missense	B-X
mutations	B-X
,	B-X
associated	B-X
with	B-X
male	B-X
pseudohermaphroditism	B-X
in	B-X
Denys	B-X
-	B-X
Drash	B-X
syndrome	B-X
,	B-X
fail	B-X
to	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B-Disease
pseudohermaphroditism	I-Disease
in	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
,	O
fail	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
WT1	B-X
missense	B-X
mutations	B-X
,	B-X
associated	B-X
with	B-X
male	B-X
pseudohermaphroditism	B-X
in	B-X
Denys	B-X
-	B-X
Drash	B-X
syndrome	B-X
,	B-X
fail	B-X
to	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
,	B-X
candidate	B-X
dosage	B-X
-	B-X
sensitive	B-X
sex	B-X
-	B-X
reversal	B-X
gene	B-X
,	B-X
Dax	B-X
-	B-X
1	B-X
,	B-X
antagonizes	B-X
synergy	B-X
between	B-X
SF	B-X
-	B-X
1	B-X
and	B-X
WT1	B-X
,	B-X
most	B-X
likely	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
WT1	B-X
	B-X
-	B-X
KTS	B-X
isoforms	B-X
associate	B-X
and	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
MIS	B-X
expression	B-X
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
modulate	B-X
the	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
SF	B-X
-	B-X
1	B-X
in	B-X
sex	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
.	B-X

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	O
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
SF	O
-	O
1	O
.	O
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
,	B-X
candidate	B-X
dosage	B-X
-	B-X
sensitive	B-X
sex	B-X
-	B-X
reversal	B-X
gene	B-X
,	B-X
Dax	B-X
-	B-X
1	B-X
,	B-X
antagonizes	B-X
synergy	B-X
between	B-X
SF	B-X
-	B-X
1	B-X
and	B-X
WT1	B-X
,	B-X
most	B-X
likely	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
WT1	B-X
missense	B-X
mutations	B-X
,	B-X
associated	B-X
with	B-X
male	B-X
pseudohermaphroditism	B-X
in	B-X
Denys	B-X
-	B-X
Drash	B-X
syndrome	B-X
,	B-X
fail	B-X
to	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
<EOS>	B-X
In	B-X
males	B-X
,	B-X
SF	B-X
-	B-X
1	B-X
participates	B-X
in	B-X
sexual	B-X
development	B-X
by	B-X
regulating	B-X
expression	B-X
of	B-X
the	B-X
polypeptide	B-X
hormone	B-X
MÃ¼llerian	B-X
inhibiting	B-X
substance	B-X
(	B-X
MIS	B-X
)	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
WT1	B-X
	B-X
-	B-X
KTS	B-X
isoforms	B-X
associate	B-X
and	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
MIS	B-X
expression	B-X

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
WT1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
functionally	B-X
oppose	B-X
each	B-X
other	B-X
in	B-X
testis	B-X
development	B-X
by	B-X
modulating	B-X
SF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
and	B-X
Dax	B-X
-	B-X
1	B-X
modulate	B-X
the	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
SF	B-X
-	B-X
1	B-X
in	B-X
sex	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
WT1	B-X
	B-X
-	B-X
KTS	B-X
isoforms	B-X
associate	B-X
and	B-X
synergize	B-X
with	B-X
SF	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
MIS	B-X
expression	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
,	B-X
candidate	B-X
dosage	B-X
-	B-X
sensitive	B-X
sex	B-X
-	B-X
reversal	B-X
gene	B-X
,	B-X
Dax	B-X
-	B-X
1	B-X
,	B-X
antagonizes	B-X
synergy	B-X
between	B-X
SF	B-X
-	B-X
1	B-X
and	B-X
WT1	B-X
,	B-X
most	B-X
likely	B-X
through	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
SF	B-X
-	B-X
1	B-X

A	O
mouse	O
model	O
for	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
imprinting	O
-	O
centre	O
mutations	O
.	O
<EOS>	B-X
A	B-X
mouse	B-X
model	B-X
of	B-X
Angelman	B-X
syndrome	B-X
imprinting	B-X
defects	B-X
.	B-X
<EOS>	B-X
An	B-X
unexpected	B-X
function	B-X
of	B-X
the	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
imprinting	B-X
center	B-X
in	B-X
maternal	B-X
imprinting	B-X
in	B-X
mice	B-X
.	B-X
<EOS>	B-X
Influence	B-X
of	B-X
the	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
imprinting	B-X
center	B-X
on	B-X
the	B-X
DNA	B-X
methylation	B-X
landscape	B-X
in	B-X
the	B-X
mouse	B-X
brain	B-X
.	B-X
<EOS>	B-X
7	B-X
Mb	B-X
imprinted	B-X
Angelman	B-X
/	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
(	B-X
AS	B-X
/	B-X
PWS	B-X
)	B-X
domain	B-X
,	B-X
254	B-X
CpG	B-X
sites	B-X
were	B-X
interrogated	B-X
for	B-X
changes	B-X
in	B-X
methylation	B-X
due	B-X
to	B-X
PWS	B-X
-	B-X
IC	B-X
deletion	B-X

Imprinting	O
in	O
the	O
15q11	O
-	O
q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O
<EOS>	B-X
Deletion	B-X
of	B-X
this	B-X
IC	B-X
abolishes	B-X
local	B-X
paternally	B-X
derived	B-X
gene	B-X
expression	B-X
and	B-X
results	B-X
in	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
(	B-X
PWS	B-X
)	B-X
<EOS>	B-X
Mice	B-X
with	B-X
a	B-X
larger	B-X
deletion	B-X
involving	B-X
both	B-X
Snrpn	B-X
and	B-X
the	B-X
putative	B-X
PWS	B-X
-	B-X
IC	B-X
lack	B-X
expression	B-X
of	B-X
the	B-X
imprinted	B-X
genes	B-X
Zfp127	B-X
(	B-X
mouse	B-X
homologue	B-X
of	B-X
ZNF127	B-X
)	B-X
,	B-X
Ndn	B-X
and	B-X
Ipw	B-X
,	B-X
and	B-X
manifest	B-X
several	B-X
phenotypes	B-X
common	B-X
to	B-X
PWS	B-X
infants	B-X
<EOS>	B-X
We	B-X
have	B-X
created	B-X
two	B-X
deletion	B-X
mutations	B-X
in	B-X
mice	B-X
to	B-X
understand	B-X
PWS	B-X
and	B-X
the	B-X
mechanism	B-X
of	B-X
this	B-X
IC	B-X
<EOS>	B-X
A	B-X
mouse	B-X
model	B-X
for	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
imprinting	B-X
-	B-X
centre	B-X
mutations	B-X
.	B-X

We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B-Disease
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O
<EOS>	B-X
We	B-X
have	B-X
created	B-X
two	B-X
deletion	B-X
mutations	B-X
in	B-X
mice	B-X
to	B-X
understand	B-X
PWS	B-X
and	B-X
the	B-X
mechanism	B-X
of	B-X
this	B-X
IC	B-X
<EOS>	B-X
Mice	B-X
harbouring	B-X
an	B-X
intragenic	B-X
deletion	B-X
in	B-X
Snrpn	B-X
are	B-X
phenotypically	B-X
normal	B-X
,	B-X
suggesting	B-X
that	B-X
mutations	B-X
of	B-X
SNRPN	B-X
are	B-X
not	B-X
sufficient	B-X
to	B-X
induce	B-X
PWS	B-X
<EOS>	B-X
Imprinting	B-X
in	B-X
the	B-X
15q11	B-X
-	B-X
q13	B-X
region	B-X
involves	B-X
an	B-X
'imprinting	B-X
centre	B-X
'	B-X
(	B-X
IC	B-X
)	B-X
,	B-X
mapping	B-X
in	B-X
part	B-X
to	B-X
the	B-X
promoter	B-X
and	B-X
first	B-X
exon	B-X
of	B-X
SNRPN	B-X
<EOS>	B-X
A	B-X
mouse	B-X
model	B-X
for	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
imprinting	B-X
-	B-X
centre	B-X
mutations	B-X
.	B-X

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	B-Disease
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	B-Disease
infants	O
.	O
<EOS>	B-X
Mice	B-X
with	B-X
a	B-X
larger	B-X
deletion	B-X
involving	B-X
both	B-X
Snrpn	B-X
and	B-X
the	B-X
putative	B-X
PWS	B-X
-	B-X
IC	B-X
lack	B-X
expression	B-X
of	B-X
the	B-X
imprinted	B-X
genes	B-X
Zfp127	B-X
(	B-X
mouse	B-X
homologue	B-X
of	B-X
ZNF127	B-X
)	B-X
,	B-X
Ndn	B-X
and	B-X
Ipw	B-X
,	B-X
and	B-X
manifest	B-X
several	B-X
phenotypes	B-X
common	B-X
to	B-X
PWS	B-X
infants	B-X
<EOS>	B-X
Mice	B-X
harbouring	B-X
an	B-X
intragenic	B-X
deletion	B-X
in	B-X
Snrpn	B-X
are	B-X
phenotypically	B-X
normal	B-X
,	B-X
suggesting	B-X
that	B-X
mutations	B-X
of	B-X
SNRPN	B-X
are	B-X
not	B-X
sufficient	B-X
to	B-X
induce	B-X
PWS	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
both	B-X
the	B-X
position	B-X
of	B-X
the	B-X
IC	B-X
and	B-X
its	B-X
role	B-X
in	B-X
the	B-X
coordinate	B-X
expression	B-X
of	B-X
genes	B-X
is	B-X
conserved	B-X
between	B-X
mouse	B-X
and	B-X
human	B-X
,	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
mouse	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
system	B-X
in	B-X
which	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
imprinting	B-X
in	B-X
this	B-X
region	B-X
of	B-X
the	B-X
genome	B-X
<EOS>	B-X
Imprinting	B-X
in	B-X
the	B-X
15q11	B-X
-	B-X
q13	B-X
region	B-X
involves	B-X
an	B-X
'imprinting	B-X
centre	B-X
'	B-X
(	B-X
IC	B-X
)	B-X
,	B-X
mapping	B-X
in	B-X
part	B-X
to	B-X
the	B-X
promoter	B-X
and	B-X
first	B-X
exon	B-X
of	B-X
SNRPN	B-X

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O
<EOS>	B-X
Mutations	B-X
of	B-X
the	B-X
ATM	B-X
gene	B-X
detected	B-X
in	B-X
Japanese	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
patients	B-X
:	B-X
possible	B-X
preponderance	B-X
of	B-X
the	B-X
two	B-X
founder	B-X
mutations	B-X
4612del165	B-X
and	B-X
7883del5	B-X
.	B-X
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
these	B-X
two	B-X
founder	B-X
mutations	B-X
may	B-X
be	B-X
predominant	B-X
among	B-X
Japanese	B-X
ATM	B-X
mutant	B-X
alleles	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
define	B-X
the	B-X
types	B-X
of	B-X
disease	B-X
-	B-X
causing	B-X
ATM	B-X
mutations	B-X
in	B-X
Japanese	B-X
A	B-X
-	B-X
T	B-X
patients	B-X
as	B-X
well	B-X
as	B-X
to	B-X
look	B-X
for	B-X
possible	B-X
mutational	B-X
hotspots	B-X
,	B-X
reverse	B-X
-	B-X
transcribed	B-X
RNA	B-X
derived	B-X
from	B-X
ten	B-X
patients	B-X
belonging	B-X
to	B-X
eight	B-X
unrelated	B-X
Japanese	B-X
A	B-X
-	B-X
T	B-X
families	B-X
was	B-X
analyzed	B-X
for	B-X
mutations	B-X
by	B-X
the	B-X
restriction	B-X
endonuclease	B-X
fingerprinting	B-X
method	B-X
<EOS>	B-X
Four	B-X
were	B-X
deletions	B-X
involving	B-X
a	B-X
loss	B-X
of	B-X
a	B-X
single	B-X
exon	B-X
:	B-X
exon	B-X
7	B-X
,	B-X
exon	B-X
16	B-X
,	B-X
exon	B-X
33	B-X
or	B-X
exon	B-X
35	B-X

The	O
ATM	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
.	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
ATM	O
mutations	O
in	O
Japanese	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B-Disease
-	I-Disease
T	I-Disease
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O
<EOS>	B-X
As	B-X
has	B-X
been	B-X
reported	B-X
by	B-X
others	B-X
,	B-X
mutations	B-X
that	B-X
lead	B-X
to	B-X
exon	B-X
skipping	B-X
or	B-X
premature	B-X
protein	B-X
truncation	B-X
were	B-X
also	B-X
predominant	B-X
in	B-X
our	B-X
mutants	B-X
<EOS>	B-X
However	B-X
,	B-X
we	B-X
had	B-X
shown	B-X
previously	B-X
that	B-X
a	B-X
defect	B-X
in	B-X
intron	B-X
4	B-X
can	B-X
lead	B-X
to	B-X
the	B-X
skipping	B-X
of	B-X
exon	B-X
4	B-X
,	B-X
and	B-X
that	B-X
the	B-X
resulting	B-X
truncated	B-X
protein	B-X
retains	B-X
the	B-X
capacity	B-X
to	B-X
activate	B-X
HLA	B-X
-	B-X
DR	B-X
expression	B-X
<EOS>	B-X
Alternative	B-X
splicing	B-X
might	B-X
represent	B-X
a	B-X
mechanism	B-X
for	B-X
regulation	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
the	B-X
lower	B-X
level	B-X
of	B-X
exon	B-X
4	B-X
skipping	B-X
in	B-X
the	B-X
patient	B-X
might	B-X
be	B-X
a	B-X
response	B-X
to	B-X
intracellular	B-X
accumulation	B-X
of	B-X
iduronidase	B-X
substrates	B-X
<EOS>	B-X
A	B-X
possible	B-X
site	B-X
for	B-X
reinitiation	B-X
of	B-X
translation	B-X
overlapping	B-X
the	B-X
premature	B-X
stop	B-X
codon	B-X
in	B-X
the	B-X
mutant	B-X
expressing	B-X
the	B-X
truncated	B-X
glycophorin	B-X
C	B-X
can	B-X
be	B-X
discerned	B-X

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O
<EOS>	B-X
Six	B-X
different	B-X
mutations	B-X
were	B-X
identified	B-X
on	B-X
12	B-X
of	B-X
the	B-X
16	B-X
alleles	B-X
examined	B-X
<EOS>	B-X
The	B-X
highest	B-X
mutation	B-X
detection	B-X
rate	B-X
was	B-X
on	B-X
exon	B-X
8	B-X
(	B-X
43	B-X
<EOS>	B-X
No	B-X
ATP7B	B-X
gene	B-X
mutation	B-X
was	B-X
found	B-X
in	B-X
healthy	B-X
patients	B-X
<EOS>	B-X
The	B-X
total	B-X
mutation	B-X
detection	B-X
rate	B-X
on	B-X
exon	B-X
8	B-X
,	B-X
12	B-X
,	B-X
and	B-X
16	B-X
was	B-X
85	B-X

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O
<EOS>	B-X
However	B-X
,	B-X
considering	B-X
the	B-X
AT	B-X
truncation	B-X
protein	B-X
resulting	B-X
from	B-X
the	B-X
p	B-X
<EOS>	B-X
Genome	B-X
-	B-X
Wide	B-X
Identification	B-X
and	B-X
Characterization	B-X
of	B-X
Auxin	B-X
Response	B-X
Factor	B-X
(	B-X
ARF	B-X
)	B-X
Gene	B-X
Family	B-X
Involved	B-X
in	B-X
Wood	B-X
Formation	B-X
and	B-X
Response	B-X
to	B-X
Exogenous	B-X
Hormone	B-X
Treatment	B-X
in	B-X
<EOS>	B-X
After	B-X
lentiviral	B-X
plasmid	B-X
transfection	B-X
into	B-X
HEK293T	B-X
cells	B-X
,	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
AT	B-X
protein	B-X
decreased	B-X
in	B-X
the	B-X
constructed	B-X
c	B-X
<EOS>	B-X
Genetic	B-X
sequence	B-X
panel	B-X
identified	B-X
an	B-X
undescribed	B-X
mutation	B-X
in	B-X
the	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
gene	B-X
(	B-X
deletion	B-X
,	B-X
exons	B-X
2	B-X
-	B-X
30	B-X
)	B-X

The	O
others	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O
<EOS>	B-X
The	B-X
others	B-X
were	B-X
minute	B-X
deletions	B-X
,	B-X
4649delA	B-X
in	B-X
exon	B-X
33	B-X
and	B-X
7883del5	B-X
in	B-X
exon	B-X
55	B-X
<EOS>	B-X
Four	B-X
were	B-X
deletions	B-X
involving	B-X
a	B-X
loss	B-X
of	B-X
a	B-X
single	B-X
exon	B-X
:	B-X
exon	B-X
7	B-X
,	B-X
exon	B-X
16	B-X
,	B-X
exon	B-X
33	B-X
or	B-X
exon	B-X
35	B-X
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
these	B-X
two	B-X
founder	B-X
mutations	B-X
may	B-X
be	B-X
predominant	B-X
among	B-X
Japanese	B-X
ATM	B-X
mutant	B-X
alleles	B-X
<EOS>	B-X
Six	B-X
different	B-X
mutations	B-X
were	B-X
identified	B-X
on	B-X
12	B-X
of	B-X
the	B-X
16	B-X
alleles	B-X
examined	B-X

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O
<EOS>	B-X
The	B-X
mutations	B-X
4612del165	B-X
and	B-X
7883del5	B-X
were	B-X
found	B-X
in	B-X
more	B-X
than	B-X
two	B-X
unrelated	B-X
families	B-X
;	B-X
44	B-X
%	B-X
(	B-X
7	B-X
of	B-X
16	B-X
)	B-X
of	B-X
the	B-X
mutant	B-X
alleles	B-X
had	B-X
one	B-X
of	B-X
the	B-X
two	B-X
mutations	B-X
<EOS>	B-X
Microsatellite	B-X
genotyping	B-X
around	B-X
the	B-X
ATM	B-X
locus	B-X
also	B-X
indicated	B-X
that	B-X
a	B-X
common	B-X
haplotype	B-X
was	B-X
shared	B-X
by	B-X
the	B-X
mutant	B-X
alleles	B-X
in	B-X
both	B-X
mutations	B-X
<EOS>	B-X
The	B-X
4612del165	B-X
mutations	B-X
in	B-X
three	B-X
different	B-X
families	B-X
were	B-X
all	B-X
ascribed	B-X
to	B-X
the	B-X
same	B-X
T	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
A	B-X
substitution	B-X
at	B-X
the	B-X
splice	B-X
donor	B-X
site	B-X
in	B-X
intron	B-X
33	B-X
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
these	B-X
two	B-X
founder	B-X
mutations	B-X
may	B-X
be	B-X
predominant	B-X
among	B-X
Japanese	B-X
ATM	B-X
mutant	B-X
alleles	B-X

The	O
4612del165	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
33	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O
<EOS>	B-X
Microsatellite	B-X
genotyping	B-X
around	B-X
the	B-X
ATM	B-X
locus	B-X
also	B-X
indicated	B-X
that	B-X
a	B-X
common	B-X
haplotype	B-X
was	B-X
shared	B-X
by	B-X
the	B-X
mutant	B-X
alleles	B-X
in	B-X
both	B-X
mutations	B-X
<EOS>	B-X
The	B-X
mutations	B-X
4612del165	B-X
and	B-X
7883del5	B-X
were	B-X
found	B-X
in	B-X
more	B-X
than	B-X
two	B-X
unrelated	B-X
families	B-X
;	B-X
44	B-X
%	B-X
(	B-X
7	B-X
of	B-X
16	B-X
)	B-X
of	B-X
the	B-X
mutant	B-X
alleles	B-X
had	B-X
one	B-X
of	B-X
the	B-X
two	B-X
mutations	B-X
<EOS>	B-X
Six	B-X
different	B-X
mutations	B-X
were	B-X
identified	B-X
on	B-X
12	B-X
of	B-X
the	B-X
16	B-X
alleles	B-X
examined	B-X
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
these	B-X
two	B-X
founder	B-X
mutations	B-X
may	B-X
be	B-X
predominant	B-X
among	B-X
Japanese	B-X
ATM	B-X
mutant	B-X
alleles	B-X

This	O
suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
these	B-X
two	B-X
founder	B-X
mutations	B-X
may	B-X
be	B-X
predominant	B-X
among	B-X
Japanese	B-X
ATM	B-X
mutant	B-X
alleles	B-X
<EOS>	B-X
The	B-X
others	B-X
were	B-X
minute	B-X
deletions	B-X
,	B-X
4649delA	B-X
in	B-X
exon	B-X
33	B-X
and	B-X
7883del5	B-X
in	B-X
exon	B-X
55	B-X
<EOS>	B-X
The	B-X
mutations	B-X
4612del165	B-X
and	B-X
7883del5	B-X
were	B-X
found	B-X
in	B-X
more	B-X
than	B-X
two	B-X
unrelated	B-X
families	B-X
;	B-X
44	B-X
%	B-X
(	B-X
7	B-X
of	B-X
16	B-X
)	B-X
of	B-X
the	B-X
mutant	B-X
alleles	B-X
had	B-X
one	B-X
of	B-X
the	B-X
two	B-X
mutations	B-X
<EOS>	B-X
Microsatellite	B-X
genotyping	B-X
around	B-X
the	B-X
ATM	B-X
locus	B-X
also	B-X
indicated	B-X
that	B-X
a	B-X
common	B-X
haplotype	B-X
was	B-X
shared	B-X
by	B-X
the	B-X
mutant	B-X
alleles	B-X
in	B-X
both	B-X
mutations	B-X

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	B-Disease
(	I-Disease
M2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
.	O
<EOS>	B-X
W474C	B-X
amino	B-X
acid	B-X
substitution	B-X
affects	B-X
early	B-X
processing	B-X
of	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
subacute	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
.	B-X
<EOS>	B-X
We	B-X
identified	B-X
a	B-X
1422	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
C	B-X
(	B-X
amino	B-X
acid	B-X
W474C	B-X
)	B-X
substitution	B-X
in	B-X
the	B-X
first	B-X
position	B-X
of	B-X
exon	B-X
13	B-X
of	B-X
HEXA	B-X
of	B-X
a	B-X
non	B-X
-	B-X
Jewish	B-X
proband	B-X
who	B-X
manifested	B-X
a	B-X
subacute	B-X
variant	B-X
of	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
HEXA	B-X
gene	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
(	B-X
Hex	B-X
A	B-X
)	B-X
,	B-X
that	B-X
abolish	B-X
Hex	B-X
A	B-X
enzyme	B-X
activity	B-X
cause	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
,	B-X
the	B-X
fatal	B-X
infantile	B-X
form	B-X
of	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
,	B-X
Type	B-X
1	B-X
<EOS>	B-X
The	B-X
resulting	B-X
W474C	B-X
substitution	B-X
clearly	B-X
interferes	B-X
with	B-X
alpha	B-X
-	B-X
subunit	B-X
processing	B-X
,	B-X
but	B-X
because	B-X
the	B-X
base	B-X
substitution	B-X
falls	B-X
at	B-X
the	B-X
first	B-X
position	B-X
of	B-X
exon	B-X
13	B-X
,	B-X
aberrant	B-X
splicing	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
Hex	B-X
A	B-X
deficiency	B-X
in	B-X
this	B-X
proband	B-X

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	B-Disease
)	O
,	O
the	O
fatal	O
infantile	B-Disease
form	I-Disease
of	I-Disease
G	I-Disease
(	I-Disease
M2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
,	I-Disease
Type	I-Disease
1	I-Disease
.	O
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
HEXA	B-X
gene	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
(	B-X
Hex	B-X
A	B-X
)	B-X
,	B-X
that	B-X
abolish	B-X
Hex	B-X
A	B-X
enzyme	B-X
activity	B-X
cause	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
,	B-X
the	B-X
fatal	B-X
infantile	B-X
form	B-X
of	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
,	B-X
Type	B-X
1	B-X
<EOS>	B-X
W474C	B-X
amino	B-X
acid	B-X
substitution	B-X
affects	B-X
early	B-X
processing	B-X
of	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
subacute	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
.	B-X
<EOS>	B-X
We	B-X
identified	B-X
a	B-X
1422	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
C	B-X
(	B-X
amino	B-X
acid	B-X
W474C	B-X
)	B-X
substitution	B-X
in	B-X
the	B-X
first	B-X
position	B-X
of	B-X
exon	B-X
13	B-X
of	B-X
HEXA	B-X
of	B-X
a	B-X
non	B-X
-	B-X
Jewish	B-X
proband	B-X
who	B-X
manifested	B-X
a	B-X
subacute	B-X
variant	B-X
of	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
<EOS>	B-X
When	B-X
the	B-X
W474C	B-X
-	B-X
containing	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
transiently	B-X
co	B-X
-	B-X
expressed	B-X
with	B-X
the	B-X
beta	B-X
-	B-X
subunit	B-X
to	B-X
produce	B-X
Hex	B-X
A	B-X
(	B-X
alphabeta	B-X
)	B-X
in	B-X
COS	B-X
-	B-X
7	B-X
cells	B-X
,	B-X
the	B-X
mature	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
present	B-X
,	B-X
but	B-X
its	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
than	B-X
that	B-X
from	B-X
normal	B-X
alpha	B-X
-	B-X
subunit	B-X
transfections	B-X
,	B-X
although	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
cells	B-X
transfected	B-X
with	B-X
an	B-X
alpha	B-X
-	B-X
subunit	B-X
associated	B-X
with	B-X
infantile	B-X
TSD	B-X

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O
<EOS>	B-X
Less	B-X
severe	B-X
,	B-X
subacute	B-X
(	B-X
juvenile	B-X
-	B-X
onset	B-X
)	B-X
and	B-X
chronic	B-X
(	B-X
adult	B-X
-	B-X
onset	B-X
)	B-X
variants	B-X
are	B-X
characterized	B-X
by	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
clinical	B-X
manifestations	B-X
and	B-X
are	B-X
associated	B-X
with	B-X
residual	B-X
levels	B-X
of	B-X
Hex	B-X
A	B-X
enzyme	B-X
activity	B-X
<EOS>	B-X
W474C	B-X
amino	B-X
acid	B-X
substitution	B-X
affects	B-X
early	B-X
processing	B-X
of	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
subacute	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
.	B-X
<EOS>	B-X
When	B-X
the	B-X
W474C	B-X
-	B-X
containing	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
transiently	B-X
co	B-X
-	B-X
expressed	B-X
with	B-X
the	B-X
beta	B-X
-	B-X
subunit	B-X
to	B-X
produce	B-X
Hex	B-X
A	B-X
(	B-X
alphabeta	B-X
)	B-X
in	B-X
COS	B-X
-	B-X
7	B-X
cells	B-X
,	B-X
the	B-X
mature	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
present	B-X
,	B-X
but	B-X
its	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
than	B-X
that	B-X
from	B-X
normal	B-X
alpha	B-X
-	B-X
subunit	B-X
transfections	B-X
,	B-X
although	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
cells	B-X
transfected	B-X
with	B-X
an	B-X
alpha	B-X
-	B-X
subunit	B-X
associated	B-X
with	B-X
infantile	B-X
TSD	B-X
<EOS>	B-X
On	B-X
the	B-X
second	B-X
maternally	B-X
inherited	B-X
allele	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
common	B-X
infantile	B-X
disease	B-X
-	B-X
causing	B-X
4	B-X
-	B-X
bp	B-X
insertion	B-X
,	B-X
+TATC	B-X
1278	B-X
,	B-X
in	B-X
exon	B-X
11	B-X

We	O
identified	O
a	O
1422	O
G	O
-	O
-	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	B-Disease
(	I-Disease
M2	I-Disease
)	I-Disease
gangliosidosis	I-Disease
.	O

On	O
the	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4	O
-	O
bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O
.	O
<EOS>	B-X
On	B-X
the	B-X
second	B-X
maternally	B-X
inherited	B-X
allele	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
common	B-X
infantile	B-X
disease	B-X
-	B-X
causing	B-X
4	B-X
-	B-X
bp	B-X
insertion	B-X
,	B-X
+TATC	B-X
1278	B-X
,	B-X
in	B-X
exon	B-X
11	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
1422	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
C	B-X
mutation	B-X
is	B-X
the	B-X
cause	B-X
of	B-X
Hex	B-X
A	B-X
enzyme	B-X
deficiency	B-X
in	B-X
the	B-X
proband	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
HEXA	B-X
gene	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
(	B-X
Hex	B-X
A	B-X
)	B-X
,	B-X
that	B-X
abolish	B-X
Hex	B-X
A	B-X
enzyme	B-X
activity	B-X
cause	B-X
Tay	B-X
-	B-X
Sachs	B-X
disease	B-X
(	B-X
TSD	B-X
)	B-X
,	B-X
the	B-X
fatal	B-X
infantile	B-X
form	B-X
of	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
,	B-X
Type	B-X
1	B-X
<EOS>	B-X
The	B-X
resulting	B-X
W474C	B-X
substitution	B-X
clearly	B-X
interferes	B-X
with	B-X
alpha	B-X
-	B-X
subunit	B-X
processing	B-X
,	B-X
but	B-X
because	B-X
the	B-X
base	B-X
substitution	B-X
falls	B-X
at	B-X
the	B-X
first	B-X
position	B-X
of	B-X
exon	B-X
13	B-X
,	B-X
aberrant	B-X
splicing	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
Hex	B-X
A	B-X
deficiency	B-X
in	B-X
this	B-X
proband	B-X

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
lysosomal	B-X
hydrolases	B-X
,	B-X
cathepsin	B-X
D	B-X
and	B-X
Î²	B-X
-	B-X
hexosaminidase	B-X
,	B-X
were	B-X
missorted	B-X
at	B-X
the	B-X
trans	B-X
-	B-X
Golgi	B-X
network	B-X
and	B-X
secreted	B-X
into	B-X
the	B-X
extracellular	B-X
space	B-X
in	B-X
PTAR1	B-X
KO	B-X
cells	B-X
<EOS>	B-X
The	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
proteolytic	B-X
cleavage	B-X
of	B-X
the	B-X
Î±	B-X
/	B-X
Î²	B-X
-	B-X
subunit	B-X
precursor	B-X
into	B-X
mature	B-X
and	B-X
enzymatically	B-X
active	B-X
subunits	B-X
does	B-X
not	B-X
depend	B-X
on	B-X
the	B-X
cholesterol	B-X
content	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
Rab7	B-X
activity	B-X
was	B-X
also	B-X
required	B-X
for	B-X
the	B-X
sorting	B-X
of	B-X
the	B-X
mannose	B-X
-	B-X
6	B-X
-	B-X
phosphate	B-X
receptor	B-X
,	B-X
the	B-X
interferon	B-X
alpha	B-X
-	B-X
receptor	B-X
and	B-X
the	B-X
Shiga	B-X
toxin	B-X
B	B-X
-	B-X
subunit	B-X
<EOS>	B-X
Further	B-X
investigation	B-X
revealed	B-X
that	B-X
impairment	B-X
of	B-X
synaptic	B-X
ultra	B-X
-	B-X
structures	B-X
,	B-X
accompanied	B-X
by	B-X
dysfunctional	B-X
lysosomal	B-X
storage	B-X
,	B-X
may	B-X
result	B-X
from	B-X
a	B-X
failure	B-X
in	B-X
dynamic	B-X
turnover	B-X
of	B-X
synaptic	B-X
proteins	B-X

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
TSD	B-Disease
.	O
<EOS>	B-X
When	B-X
the	B-X
W474C	B-X
-	B-X
containing	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
transiently	B-X
co	B-X
-	B-X
expressed	B-X
with	B-X
the	B-X
beta	B-X
-	B-X
subunit	B-X
to	B-X
produce	B-X
Hex	B-X
A	B-X
(	B-X
alphabeta	B-X
)	B-X
in	B-X
COS	B-X
-	B-X
7	B-X
cells	B-X
,	B-X
the	B-X
mature	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
present	B-X
,	B-X
but	B-X
its	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
than	B-X
that	B-X
from	B-X
normal	B-X
alpha	B-X
-	B-X
subunit	B-X
transfections	B-X
,	B-X
although	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
cells	B-X
transfected	B-X
with	B-X
an	B-X
alpha	B-X
-	B-X
subunit	B-X
associated	B-X
with	B-X
infantile	B-X
TSD	B-X
<EOS>	B-X
The	B-X
resulting	B-X
W474C	B-X
substitution	B-X
clearly	B-X
interferes	B-X
with	B-X
alpha	B-X
-	B-X
subunit	B-X
processing	B-X
,	B-X
but	B-X
because	B-X
the	B-X
base	B-X
substitution	B-X
falls	B-X
at	B-X
the	B-X
first	B-X
position	B-X
of	B-X
exon	B-X
13	B-X
,	B-X
aberrant	B-X
splicing	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
Hex	B-X
A	B-X
deficiency	B-X
in	B-X
this	B-X
proband	B-X
<EOS>	B-X
Pulse	B-X
-	B-X
chase	B-X
analysis	B-X
using	B-X
proband	B-X
fibroblasts	B-X
revealed	B-X
that	B-X
the	B-X
W474C	B-X
-	B-X
containing	B-X
alpha	B-X
-	B-X
subunit	B-X
precursor	B-X
was	B-X
normally	B-X
synthesized	B-X
,	B-X
but	B-X
not	B-X
phosphorylated	B-X
or	B-X
secreted	B-X
,	B-X
and	B-X
the	B-X
mature	B-X
lysosomal	B-X
alpha	B-X
-	B-X
subunit	B-X
was	B-X
not	B-X
detected	B-X
<EOS>	B-X
W474C	B-X
amino	B-X
acid	B-X
substitution	B-X
affects	B-X
early	B-X
processing	B-X
of	B-X
the	B-X
alpha	B-X
-	B-X
subunit	B-X
of	B-X
beta	B-X
-	B-X
hexosaminidase	B-X
A	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
subacute	B-X
G	B-X
(	B-X
M2	B-X
)	B-X
gangliosidosis	B-X
.	B-X

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B-Disease
A	I-Disease
enzyme	I-Disease
deficiency	I-Disease
in	O
the	O
proband	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B-Disease
A	I-Disease
deficiency	I-Disease
in	O
this	O
proband	O
.	O
.	O

Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B-Disease
syndrome	I-Disease
.	O
<EOS>	B-X
Two	B-X
frequent	B-X
missense	B-X
mutations	B-X
in	B-X
Pendred	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Two	B-X
common	B-X
and	B-X
three	B-X
novel	B-X
PDS	B-X
mutations	B-X
in	B-X
Thai	B-X
patients	B-X
with	B-X
Pendred	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
two	B-X
frequent	B-X
PDS	B-X
mutations	B-X
will	B-X
facilitate	B-X
the	B-X
molecular	B-X
diagnosis	B-X
of	B-X
Pendred	B-X
syndrome	B-X
<EOS>	B-X
It	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
PDS	B-X
gene	B-X

Pendred	B-Disease
syndrome	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
early	O
childhood	O
deafness	B-Disease
and	O
goiter	B-Disease
.	O
<EOS>	B-X
Pendred	B-X
syndrome	B-X
is	B-X
an	B-X
autosomal	B-X
recessive	B-X
disorder	B-X
characterized	B-X
by	B-X
early	B-X
childhood	B-X
deafness	B-X
and	B-X
goiter	B-X
<EOS>	B-X
Pendred	B-X
syndrome	B-X
(	B-X
PDS	B-X
,	B-X
MIM	B-X
#	B-X
274600	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
recessive	B-X
disorder	B-X
characterized	B-X
by	B-X
congenital	B-X
sensorineural	B-X
hearing	B-X
loss	B-X
and	B-X
goiter	B-X
<EOS>	B-X
All	B-X
the	B-X
candidate	B-X
mutations	B-X
were	B-X
predicted	B-X
deleterious	B-X
by	B-X
in	B-X
silico	B-X
tools	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
describing	B-X
the	B-X
possible	B-X
PDS	B-X
causal	B-X
mutations	B-X
in	B-X
a	B-X
Malaysian	B-X
family	B-X
with	B-X
2	B-X
daughters	B-X
diagnosed	B-X
with	B-X
bilateral	B-X
hearing	B-X
loss	B-X
and	B-X
hypothyroidism	B-X

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O
<EOS>	B-X
A	B-X
century	B-X
after	B-X
its	B-X
recognition	B-X
as	B-X
a	B-X
syndrome	B-X
by	B-X
Vaughan	B-X
Pendred	B-X
,	B-X
the	B-X
disease	B-X
gene	B-X
(	B-X
PDS	B-X
)	B-X
was	B-X
mapped	B-X
to	B-X
chromosome	B-X
7q22	B-X
-	B-X
q31	B-X
<EOS>	B-X
The	B-X
mutations	B-X
include	B-X
three	B-X
single	B-X
base	B-X
deletions	B-X
,	B-X
one	B-X
splice	B-X
site	B-X
mutation	B-X
and	B-X
10	B-X
missense	B-X
mutations	B-X
<EOS>	B-X
We	B-X
performed	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
PDS	B-X
gene	B-X
in	B-X
patients	B-X
from	B-X
14	B-X
Pendred	B-X
families	B-X
originating	B-X
from	B-X
seven	B-X
countries	B-X
and	B-X
identified	B-X
all	B-X
mutations	B-X
<EOS>	B-X
Pendred	B-X
syndrome	B-X
is	B-X
an	B-X
autosomal	B-X
recessive	B-X
disorder	B-X
characterized	B-X
by	B-X
early	B-X
childhood	B-X
deafness	B-X
and	B-X
goiter	B-X

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O
<EOS>	B-X
1	B-X
and	B-X
,	B-X
recently	B-X
,	B-X
found	B-X
to	B-X
encode	B-X
a	B-X
putative	B-X
sulfate	B-X
transporter	B-X
<EOS>	B-X
The	B-X
gene	B-X
mutated	B-X
in	B-X
Pendred	B-X
's	B-X
syndrome	B-X
,	B-X
PDS	B-X
(	B-X
Pendred	B-X
's	B-X
syndrome	B-X
gene	B-X
)	B-X
,	B-X
was	B-X
cloned	B-X
very	B-X
recently	B-X
and	B-X
encodes	B-X
the	B-X
putative	B-X
sulfate	B-X
transporter	B-X
pendrin	B-X
<EOS>	B-X
The	B-X
function	B-X
of	B-X
pendrin	B-X
in	B-X
the	B-X
inner	B-X
ear	B-X
is	B-X
not	B-X
well	B-X
understood	B-X
,	B-X
but	B-X
it	B-X
seems	B-X
to	B-X
function	B-X
also	B-X
at	B-X
this	B-X
level	B-X
as	B-X
an	B-X
anion	B-X
transporter	B-X
<EOS>	B-X
This	B-X
alteration	B-X
resulted	B-X
in	B-X
truncation	B-X
of	B-X
the	B-X
protein	B-X
in	B-X
the	B-X
first	B-X
transmembrane	B-X
domain	B-X

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B-Disease
gene	O
in	O
patients	O
from	O
14	O
Pendred	B-Disease
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
PDS	B-X
gene	B-X
in	B-X
patients	B-X
from	B-X
14	B-X
Pendred	B-X
families	B-X
originating	B-X
from	B-X
seven	B-X
countries	B-X
and	B-X
identified	B-X
all	B-X
mutations	B-X
<EOS>	B-X
The	B-X
mutations	B-X
include	B-X
three	B-X
single	B-X
base	B-X
deletions	B-X
,	B-X
one	B-X
splice	B-X
site	B-X
mutation	B-X
and	B-X
10	B-X
missense	B-X
mutations	B-X
<EOS>	B-X
One	B-X
missense	B-X
mutation	B-X
(	B-X
L236P	B-X
)	B-X
was	B-X
found	B-X
in	B-X
a	B-X
homozygous	B-X
state	B-X
in	B-X
two	B-X
consanguineous	B-X
families	B-X
and	B-X
in	B-X
a	B-X
heterozygous	B-X
state	B-X
in	B-X
five	B-X
additional	B-X
non	B-X
-	B-X
consanguineous	B-X
families	B-X
<EOS>	B-X
In	B-X
total	B-X
,	B-X
one	B-X
or	B-X
both	B-X
of	B-X
these	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
nine	B-X
of	B-X
the	B-X
14	B-X
families	B-X
analyzed	B-X

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O
<EOS>	B-X
The	B-X
mutations	B-X
include	B-X
three	B-X
single	B-X
base	B-X
deletions	B-X
,	B-X
one	B-X
splice	B-X
site	B-X
mutation	B-X
and	B-X
10	B-X
missense	B-X
mutations	B-X
<EOS>	B-X
These	B-X
included	B-X
one	B-X
medium	B-X
-	B-X
sized	B-X
deletion	B-X
involving	B-X
exon	B-X
49	B-X
-	B-X
51	B-X
,	B-X
one	B-X
single	B-X
base	B-X
pair	B-X
deletion	B-X
,	B-X
one	B-X
nonsense	B-X
point	B-X
mutation	B-X
,	B-X
one	B-X
splice	B-X
site	B-X
mutation	B-X
,	B-X
and	B-X
six	B-X
missense	B-X
point	B-X
mutations	B-X
<EOS>	B-X
The	B-X
intragenic	B-X
mutations	B-X
consisted	B-X
of	B-X
14	B-X
missense	B-X
mutations	B-X
,	B-X
seven	B-X
microdeletions	B-X
or	B-X
insertions	B-X
and	B-X
two	B-X
splice	B-X
-	B-X
site	B-X
mutations	B-X
<EOS>	B-X
The	B-X
mutations	B-X
found	B-X
in	B-X
our	B-X
study	B-X
broaden	B-X
the	B-X
spectrum	B-X
of	B-X
USH2A	B-X
mutations	B-X

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families	O
.	O

Pendred	B-Disease
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O
<EOS>	B-X
Pendred	B-X
patients	B-X
in	B-X
three	B-X
non	B-X
-	B-X
consanguineous	B-X
families	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
compound	B-X
heterozygotes	B-X
for	B-X
L236P	B-X
and	B-X
T416P	B-X
<EOS>	B-X
One	B-X
missense	B-X
mutation	B-X
(	B-X
L236P	B-X
)	B-X
was	B-X
found	B-X
in	B-X
a	B-X
homozygous	B-X
state	B-X
in	B-X
two	B-X
consanguineous	B-X
families	B-X
and	B-X
in	B-X
a	B-X
heterozygous	B-X
state	B-X
in	B-X
five	B-X
additional	B-X
non	B-X
-	B-X
consanguineous	B-X
families	B-X
<EOS>	B-X
We	B-X
performed	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
PDS	B-X
gene	B-X
in	B-X
patients	B-X
from	B-X
14	B-X
Pendred	B-X
families	B-X
originating	B-X
from	B-X
seven	B-X
countries	B-X
and	B-X
identified	B-X
all	B-X
mutations	B-X
<EOS>	B-X
Pendred	B-X
syndrome	B-X
is	B-X
an	B-X
autosomal	B-X
recessive	B-X
disorder	B-X
characterized	B-X
by	B-X
early	B-X
childhood	B-X
deafness	B-X
and	B-X
goiter	B-X

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O
<EOS>	B-X
A	B-X
total	B-X
of	B-X
22	B-X
studies	B-X
were	B-X
included	B-X
in	B-X
the	B-X
review	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
436,955	B-X
cases	B-X
were	B-X
included	B-X
in	B-X
this	B-X
study	B-X
<EOS>	B-X
Factors	B-X
associated	B-X
with	B-X
progression	B-X
to	B-X
knee	B-X
arthroplasty	B-X
were	B-X
examined	B-X
using	B-X
t	B-X
-	B-X
tests	B-X
and	B-X
chi	B-X
-	B-X
square	B-X
analyses	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
2441	B-X
mothers	B-X
have	B-X
been	B-X
considered	B-X
who	B-X
delivered	B-X
their	B-X
last	B-X
live	B-X
birth	B-X
at	B-X
home	B-X
within	B-X
three	B-X
years	B-X
preceding	B-X
the	B-X
survey	B-X

The	O
identification	O
of	O
two	O
frequent	O
PDS	B-Disease
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B-Disease
syndrome	I-Disease
.	O
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
two	B-X
frequent	B-X
PDS	B-X
mutations	B-X
will	B-X
facilitate	B-X
the	B-X
molecular	B-X
diagnosis	B-X
of	B-X
Pendred	B-X
syndrome	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
these	B-X
two	B-X
frequent	B-X
PDS	B-X
mutations	B-X
will	B-X
facilitate	B-X
the	B-X
molecular	B-X
diagnosis	B-X
of	B-X
Pendred	B-X
syndrome	B-X
in	B-X
Thai	B-X
populations	B-X
<EOS>	B-X
Two	B-X
common	B-X
and	B-X
three	B-X
novel	B-X
PDS	B-X
mutations	B-X
in	B-X
Thai	B-X
patients	B-X
with	B-X
Pendred	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Two	B-X
frequent	B-X
missense	B-X
mutations	B-X
in	B-X
Pendred	B-X
syndrome	B-X
.	B-X

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B-Disease
gene	O
results	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
(	O
XLDCM	B-Disease
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B-Disease
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B-Disease
involvement	I-Disease
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B-Disease
myopathy	I-Disease
.	O
<EOS>	B-X
X	B-X
-	B-X
linked	B-X
dilated	B-X
cardiomyopathy	B-X
(	B-X
XLDCM	B-X
)	B-X
is	B-X
a	B-X
clinical	B-X
phenotype	B-X
of	B-X
dystrophinopathy	B-X
which	B-X
is	B-X
characterized	B-X
by	B-X
preferential	B-X
myocardial	B-X
involvement	B-X
without	B-X
any	B-X
overt	B-X
clinical	B-X
signs	B-X
of	B-X
skeletal	B-X
myopathy	B-X
<EOS>	B-X
Insertional	B-X
mutation	B-X
by	B-X
transposable	B-X
element	B-X
,	B-X
L1	B-X
,	B-X
in	B-X
the	B-X
DMD	B-X
gene	B-X
results	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
dilated	B-X
cardiomyopathy	B-X
.	B-X
<EOS>	B-X
The	B-X
insertion	B-X
was	B-X
a	B-X
5'	B-X
-	B-X
truncated	B-X
form	B-X
of	B-X
human	B-X
L1	B-X
inversely	B-X
integrated	B-X
in	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
region	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
,	B-X
which	B-X
affected	B-X
the	B-X
transcription	B-X
or	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
muscle	B-X
form	B-X
of	B-X
dystrophin	B-X
transcripts	B-X
but	B-X
not	B-X
that	B-X
of	B-X
the	B-X
brain	B-X
or	B-X
Purkinje	B-X
cell	B-X
form	B-X
,	B-X
probably	B-X
due	B-X
to	B-X
its	B-X
unique	B-X
site	B-X
of	B-X
integration	B-X
<EOS>	B-X
We	B-X
speculate	B-X
that	B-X
this	B-X
insertion	B-X
of	B-X
an	B-X
L1	B-X
sequence	B-X
in	B-X
DMD	B-X
is	B-X
responsible	B-X
for	B-X
some	B-X
of	B-X
the	B-X
population	B-X
of	B-X
Japanese	B-X
patients	B-X
with	B-X
XLDCM	B-X

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B-Disease
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B-Disease
phenotype	O
has	O
remained	O
to	O
be	O
elucidated	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
several	B-X
mutations	B-X
in	B-X
the	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
gene	B-X
,	B-X
DMD	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
patients	B-X
with	B-X
XLDCM	B-X
,	B-X
but	B-X
a	B-X
pathogenic	B-X
correlation	B-X
of	B-X
these	B-X
cardiospecific	B-X
mutations	B-X
in	B-X
DMD	B-X
with	B-X
the	B-X
XLDCM	B-X
phenotype	B-X
has	B-X
remained	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
unique	B-X
de	B-X
novo	B-X
L1	B-X
insertion	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
in	B-X
DMD	B-X
in	B-X
three	B-X
XLDCM	B-X
patients	B-X
from	B-X
two	B-X
unrelated	B-X
Japanese	B-X
families	B-X
<EOS>	B-X
We	B-X
speculate	B-X
that	B-X
this	B-X
insertion	B-X
of	B-X
an	B-X
L1	B-X
sequence	B-X
in	B-X
DMD	B-X
is	B-X
responsible	B-X
for	B-X
some	B-X
of	B-X
the	B-X
population	B-X
of	B-X
Japanese	B-X
patients	B-X
with	B-X
XLDCM	B-X
<EOS>	B-X
The	B-X
insertion	B-X
was	B-X
a	B-X
5'	B-X
-	B-X
truncated	B-X
form	B-X
of	B-X
human	B-X
L1	B-X
inversely	B-X
integrated	B-X
in	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
region	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
,	B-X
which	B-X
affected	B-X
the	B-X
transcription	B-X
or	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
muscle	B-X
form	B-X
of	B-X
dystrophin	B-X
transcripts	B-X
but	B-X
not	B-X
that	B-X
of	B-X
the	B-X
brain	B-X
or	B-X
Purkinje	B-X
cell	B-X
form	B-X
,	B-X
probably	B-X
due	B-X
to	B-X
its	B-X
unique	B-X
site	B-X
of	B-X
integration	B-X

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	B-Disease
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
unique	B-X
de	B-X
novo	B-X
L1	B-X
insertion	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
in	B-X
DMD	B-X
in	B-X
three	B-X
XLDCM	B-X
patients	B-X
from	B-X
two	B-X
unrelated	B-X
Japanese	B-X
families	B-X
<EOS>	B-X
We	B-X
speculate	B-X
that	B-X
this	B-X
insertion	B-X
of	B-X
an	B-X
L1	B-X
sequence	B-X
in	B-X
DMD	B-X
is	B-X
responsible	B-X
for	B-X
some	B-X
of	B-X
the	B-X
population	B-X
of	B-X
Japanese	B-X
patients	B-X
with	B-X
XLDCM	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
several	B-X
mutations	B-X
in	B-X
the	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
gene	B-X
,	B-X
DMD	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
patients	B-X
with	B-X
XLDCM	B-X
,	B-X
but	B-X
a	B-X
pathogenic	B-X
correlation	B-X
of	B-X
these	B-X
cardiospecific	B-X
mutations	B-X
in	B-X
DMD	B-X
with	B-X
the	B-X
XLDCM	B-X
phenotype	B-X
has	B-X
remained	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
The	B-X
insertion	B-X
was	B-X
a	B-X
5'	B-X
-	B-X
truncated	B-X
form	B-X
of	B-X
human	B-X
L1	B-X
inversely	B-X
integrated	B-X
in	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
region	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
,	B-X
which	B-X
affected	B-X
the	B-X
transcription	B-X
or	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
muscle	B-X
form	B-X
of	B-X
dystrophin	B-X
transcripts	B-X
but	B-X
not	B-X
that	B-X
of	B-X
the	B-X
brain	B-X
or	B-X
Purkinje	B-X
cell	B-X
form	B-X
,	B-X
probably	B-X
due	B-X
to	B-X
its	B-X
unique	B-X
site	B-X
of	B-X
integration	B-X

The	O
insertion	O
was	O
a	O
5	O
-	O
truncated	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O
<EOS>	B-X
The	B-X
insertion	B-X
was	B-X
a	B-X
5'	B-X
-	B-X
truncated	B-X
form	B-X
of	B-X
human	B-X
L1	B-X
inversely	B-X
integrated	B-X
in	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
region	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
,	B-X
which	B-X
affected	B-X
the	B-X
transcription	B-X
or	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
muscle	B-X
form	B-X
of	B-X
dystrophin	B-X
transcripts	B-X
but	B-X
not	B-X
that	B-X
of	B-X
the	B-X
brain	B-X
or	B-X
Purkinje	B-X
cell	B-X
form	B-X
,	B-X
probably	B-X
due	B-X
to	B-X
its	B-X
unique	B-X
site	B-X
of	B-X
integration	B-X
<EOS>	B-X
We	B-X
report	B-X
in	B-X
the	B-X
present	B-X
study	B-X
that	B-X
the	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
utrophin	B-X
,	B-X
the	B-X
autosomal	B-X
homologue	B-X
of	B-X
dystrophin	B-X
in	B-X
the	B-X
mouse	B-X
C2C12	B-X
and	B-X
rat	B-X
L8	B-X
myoblastic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
unique	B-X
de	B-X
novo	B-X
L1	B-X
insertion	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
in	B-X
DMD	B-X
in	B-X
three	B-X
XLDCM	B-X
patients	B-X
from	B-X
two	B-X
unrelated	B-X
Japanese	B-X
families	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
dystrophin	B-X
gene	B-X
cause	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
and	B-X
result	B-X
in	B-X
the	B-X
loss	B-X
of	B-X
dystrophin	B-X
and	B-X
the	B-X
entire	B-X
dystrophin	B-X
-	B-X
glycoprotein	B-X
complex	B-X
(	B-X
DGC	B-X
)	B-X
from	B-X
the	B-X
sarcolemma	B-X

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B-Disease
.	O
.	O
<EOS>	B-X
We	B-X
speculate	B-X
that	B-X
this	B-X
insertion	B-X
of	B-X
an	B-X
L1	B-X
sequence	B-X
in	B-X
DMD	B-X
is	B-X
responsible	B-X
for	B-X
some	B-X
of	B-X
the	B-X
population	B-X
of	B-X
Japanese	B-X
patients	B-X
with	B-X
XLDCM	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
unique	B-X
de	B-X
novo	B-X
L1	B-X
insertion	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
in	B-X
DMD	B-X
in	B-X
three	B-X
XLDCM	B-X
patients	B-X
from	B-X
two	B-X
unrelated	B-X
Japanese	B-X
families	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
several	B-X
mutations	B-X
in	B-X
the	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
gene	B-X
,	B-X
DMD	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
patients	B-X
with	B-X
XLDCM	B-X
,	B-X
but	B-X
a	B-X
pathogenic	B-X
correlation	B-X
of	B-X
these	B-X
cardiospecific	B-X
mutations	B-X
in	B-X
DMD	B-X
with	B-X
the	B-X
XLDCM	B-X
phenotype	B-X
has	B-X
remained	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
The	B-X
insertion	B-X
was	B-X
a	B-X
5'	B-X
-	B-X
truncated	B-X
form	B-X
of	B-X
human	B-X
L1	B-X
inversely	B-X
integrated	B-X
in	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
region	B-X
in	B-X
the	B-X
muscle	B-X
exon	B-X
1	B-X
,	B-X
which	B-X
affected	B-X
the	B-X
transcription	B-X
or	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
muscle	B-X
form	B-X
of	B-X
dystrophin	B-X
transcripts	B-X
but	B-X
not	B-X
that	B-X
of	B-X
the	B-X
brain	B-X
or	B-X
Purkinje	B-X
cell	B-X
form	B-X
,	B-X
probably	B-X
due	B-X
to	B-X
its	B-X
unique	B-X
site	B-X
of	B-X
integration	B-X

Severe	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
adrenal	B-Disease
insufficiency	I-Disease
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O
<EOS>	B-X
Severe	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
caused	B-X
by	B-X
POMC	B-X
mutations	B-X
in	B-X
humans	B-X
.	B-X
<EOS>	B-X
Severe	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
caused	B-X
by	B-X
POMC	B-X
mutations	B-X
in	B-X
humans	B-X
<EOS>	B-X
Laboratory	B-X
testing	B-X
demonstrated	B-X
central	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
genetic	B-X
testing	B-X
confirmed	B-X
a	B-X
homozygous	B-X
mutation	B-X
(	B-X
nucleotide	B-X
change	B-X
c	B-X
<EOS>	B-X
The	B-X
symptoms	B-X
of	B-X
severe	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
,	B-X
and	B-X
red	B-X
hair	B-X
define	B-X
the	B-X
proopiomelanocortin	B-X
(	B-X
POMC	B-X
)	B-X
deficiency	B-X
syndrome	B-X
as	B-X
described	B-X
so	B-X
far	B-X
in	B-X
two	B-X
children	B-X
with	B-X
complete	B-X
loss	B-X
-	B-X
of	B-X
-	B-X
function	B-X
mutations	B-X
of	B-X
the	B-X
human	B-X
POMC	B-X
gene	B-X

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O
<EOS>	B-X
Sequential	B-X
cleavage	B-X
of	B-X
the	B-X
precursor	B-X
protein	B-X
pre	B-X
-	B-X
pro	B-X
-	B-X
opiomelanocortin	B-X
(	B-X
POMC	B-X
)	B-X
generates	B-X
the	B-X
melanocortin	B-X
peptides	B-X
adrenocorticotrophin	B-X
(	B-X
ACTH	B-X
)	B-X
,	B-X
melanocyte	B-X
-	B-X
stimulating	B-X
hormones	B-X
(	B-X
MSH	B-X
)	B-X
alpha	B-X
,	B-X
beta	B-X
and	B-X
gamma	B-X
as	B-X
well	B-X
as	B-X
the	B-X
opioid	B-X
-	B-X
receptor	B-X
ligand	B-X
beta	B-X
-	B-X
endorphin	B-X
<EOS>	B-X
These	B-X
findings	B-X
represent	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
a	B-X
genetic	B-X
defect	B-X
within	B-X
the	B-X
POMC	B-X
gene	B-X
and	B-X
define	B-X
a	B-X
new	B-X
monogenic	B-X
endocrine	B-X
disorder	B-X
resulting	B-X
in	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
in	B-X
animal	B-X
models	B-X
elucidated	B-X
a	B-X
central	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
food	B-X
intake	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
brain	B-X
melanocortin	B-X
-	B-X
4	B-X
-	B-X
receptor	B-X
(	B-X
MC4	B-X
-	B-X
R	B-X
;	B-X
refs	B-X
3	B-X
-	B-X
5	B-X
)	B-X
and	B-X
the	B-X
linkage	B-X
of	B-X
human	B-X
obesity	B-X
to	B-X
chromosome	B-X
2	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
POMC	B-X
locus	B-X
,	B-X
led	B-X
to	B-X
the	B-X
proposal	B-X
of	B-X
an	B-X
association	B-X
of	B-X
POMC	B-X
with	B-X
human	B-X
obesity	B-X
<EOS>	B-X
The	B-X
dual	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
regulating	B-X
food	B-X
intake	B-X
and	B-X
influencing	B-X
hair	B-X
pigmentation	B-X
predicts	B-X
that	B-X
the	B-X
phenotype	B-X
associated	B-X
with	B-X
a	B-X
defect	B-X
in	B-X
POMC	B-X
function	B-X
would	B-X
include	B-X
obesity	B-X
,	B-X
alteration	B-X
in	B-X
pigmentation	B-X
and	B-X
ACTH	B-X
deficiency	B-X

While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	B-Disease
deficiency	I-Disease
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	B-Disease
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	B-Disease
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B-Disease
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B-Disease
deficiency	I-Disease
.	O
<EOS>	B-X
The	B-X
dual	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
regulating	B-X
food	B-X
intake	B-X
and	B-X
influencing	B-X
hair	B-X
pigmentation	B-X
predicts	B-X
that	B-X
the	B-X
phenotype	B-X
associated	B-X
with	B-X
a	B-X
defect	B-X
in	B-X
POMC	B-X
function	B-X
would	B-X
include	B-X
obesity	B-X
,	B-X
alteration	B-X
in	B-X
pigmentation	B-X
and	B-X
ACTH	B-X
deficiency	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
in	B-X
animal	B-X
models	B-X
elucidated	B-X
a	B-X
central	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
food	B-X
intake	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
brain	B-X
melanocortin	B-X
-	B-X
4	B-X
-	B-X
receptor	B-X
(	B-X
MC4	B-X
-	B-X
R	B-X
;	B-X
refs	B-X
3	B-X
-	B-X
5	B-X
)	B-X
and	B-X
the	B-X
linkage	B-X
of	B-X
human	B-X
obesity	B-X
to	B-X
chromosome	B-X
2	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
POMC	B-X
locus	B-X
,	B-X
led	B-X
to	B-X
the	B-X
proposal	B-X
of	B-X
an	B-X
association	B-X
of	B-X
POMC	B-X
with	B-X
human	B-X
obesity	B-X
<EOS>	B-X
Severe	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
caused	B-X
by	B-X
POMC	B-X
mutations	B-X
in	B-X
humans	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
represent	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
a	B-X
genetic	B-X
defect	B-X
within	B-X
the	B-X
POMC	B-X
gene	B-X
and	B-X
define	B-X
a	B-X
new	B-X
monogenic	B-X
endocrine	B-X
disorder	B-X
resulting	B-X
in	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
.	O
<EOS>	B-X
The	B-X
observation	B-X
of	B-X
these	B-X
symptoms	B-X
in	B-X
two	B-X
probands	B-X
prompted	B-X
us	B-X
to	B-X
search	B-X
for	B-X
mutations	B-X
within	B-X
their	B-X
POMC	B-X
genes	B-X
<EOS>	B-X
These	B-X
findings	B-X
represent	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
a	B-X
genetic	B-X
defect	B-X
within	B-X
the	B-X
POMC	B-X
gene	B-X
and	B-X
define	B-X
a	B-X
new	B-X
monogenic	B-X
endocrine	B-X
disorder	B-X
resulting	B-X
in	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
<EOS>	B-X
The	B-X
dual	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
regulating	B-X
food	B-X
intake	B-X
and	B-X
influencing	B-X
hair	B-X
pigmentation	B-X
predicts	B-X
that	B-X
the	B-X
phenotype	B-X
associated	B-X
with	B-X
a	B-X
defect	B-X
in	B-X
POMC	B-X
function	B-X
would	B-X
include	B-X
obesity	B-X
,	B-X
alteration	B-X
in	B-X
pigmentation	B-X
and	B-X
ACTH	B-X
deficiency	B-X
<EOS>	B-X
Patient	B-X
1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
compound	B-X
heterozygote	B-X
for	B-X
two	B-X
mutations	B-X
in	B-X
exon	B-X
3	B-X
(	B-X
G7013T	B-X
,	B-X
C7133delta	B-X
)	B-X
which	B-X
interfere	B-X
with	B-X
appropriate	B-X
synthesis	B-X
of	B-X
ACTH	B-X
and	B-X
alpha	B-X
-	B-X
MSH	B-X

Patient	O
1	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	O
<EOS>	B-X
Patient	B-X
1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
compound	B-X
heterozygote	B-X
for	B-X
two	B-X
mutations	B-X
in	B-X
exon	B-X
3	B-X
(	B-X
G7013T	B-X
,	B-X
C7133delta	B-X
)	B-X
which	B-X
interfere	B-X
with	B-X
appropriate	B-X
synthesis	B-X
of	B-X
ACTH	B-X
and	B-X
alpha	B-X
-	B-X
MSH	B-X
<EOS>	B-X
Patient	B-X
2	B-X
was	B-X
homozygous	B-X
for	B-X
a	B-X
mutation	B-X
in	B-X
exon	B-X
2	B-X
(	B-X
C3804A	B-X
)	B-X
which	B-X
abolishes	B-X
POMC	B-X
translation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
in	B-X
animal	B-X
models	B-X
elucidated	B-X
a	B-X
central	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
food	B-X
intake	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
brain	B-X
melanocortin	B-X
-	B-X
4	B-X
-	B-X
receptor	B-X
(	B-X
MC4	B-X
-	B-X
R	B-X
;	B-X
refs	B-X
3	B-X
-	B-X
5	B-X
)	B-X
and	B-X
the	B-X
linkage	B-X
of	B-X
human	B-X
obesity	B-X
to	B-X
chromosome	B-X
2	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
POMC	B-X
locus	B-X
,	B-X
led	B-X
to	B-X
the	B-X
proposal	B-X
of	B-X
an	B-X
association	B-X
of	B-X
POMC	B-X
with	B-X
human	B-X
obesity	B-X
<EOS>	B-X
These	B-X
findings	B-X
represent	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
a	B-X
genetic	B-X
defect	B-X
within	B-X
the	B-X
POMC	B-X
gene	B-X
and	B-X
define	B-X
a	B-X
new	B-X
monogenic	B-X
endocrine	B-X
disorder	B-X
resulting	B-X
in	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X

Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
.	O
<EOS>	B-X
Patient	B-X
2	B-X
was	B-X
homozygous	B-X
for	B-X
a	B-X
mutation	B-X
in	B-X
exon	B-X
2	B-X
(	B-X
C3804A	B-X
)	B-X
which	B-X
abolishes	B-X
POMC	B-X
translation	B-X
<EOS>	B-X
Patient	B-X
1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
compound	B-X
heterozygote	B-X
for	B-X
two	B-X
mutations	B-X
in	B-X
exon	B-X
3	B-X
(	B-X
G7013T	B-X
,	B-X
C7133delta	B-X
)	B-X
which	B-X
interfere	B-X
with	B-X
appropriate	B-X
synthesis	B-X
of	B-X
ACTH	B-X
and	B-X
alpha	B-X
-	B-X
MSH	B-X
<EOS>	B-X
Severe	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
caused	B-X
by	B-X
POMC	B-X
mutations	B-X
in	B-X
humans	B-X
.	B-X
<EOS>	B-X
While	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
isolated	B-X
ACTH	B-X
deficiency	B-X
have	B-X
been	B-X
reported	B-X
(	B-X
OMIM	B-X
201400	B-X
)	B-X
,	B-X
an	B-X
inherited	B-X
POMC	B-X
defect	B-X
has	B-X
not	B-X
been	B-X
described	B-X
so	B-X
far	B-X

These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B-Disease
defect	I-Disease
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B-Disease
endocrine	I-Disease
disorder	I-Disease
resulting	O
in	O
early	O
-	O
onset	O
obesity	B-Disease
,	O
adrenal	B-Disease
insufficiency	I-Disease
and	O
red	O
hair	O
pigmentation	O
.	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
represent	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
a	B-X
genetic	B-X
defect	B-X
within	B-X
the	B-X
POMC	B-X
gene	B-X
and	B-X
define	B-X
a	B-X
new	B-X
monogenic	B-X
endocrine	B-X
disorder	B-X
resulting	B-X
in	B-X
early	B-X
-	B-X
onset	B-X
obesity	B-X
,	B-X
adrenal	B-X
insufficiency	B-X
and	B-X
red	B-X
hair	B-X
pigmentation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
in	B-X
animal	B-X
models	B-X
elucidated	B-X
a	B-X
central	B-X
role	B-X
of	B-X
alpha	B-X
-	B-X
MSH	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
food	B-X
intake	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
brain	B-X
melanocortin	B-X
-	B-X
4	B-X
-	B-X
receptor	B-X
(	B-X
MC4	B-X
-	B-X
R	B-X
;	B-X
refs	B-X
3	B-X
-	B-X
5	B-X
)	B-X
and	B-X
the	B-X
linkage	B-X
of	B-X
human	B-X
obesity	B-X
to	B-X
chromosome	B-X
2	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
POMC	B-X
locus	B-X
,	B-X
led	B-X
to	B-X
the	B-X
proposal	B-X
of	B-X
an	B-X
association	B-X
of	B-X
POMC	B-X
with	B-X
human	B-X
obesity	B-X
<EOS>	B-X
While	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
isolated	B-X
ACTH	B-X
deficiency	B-X
have	B-X
been	B-X
reported	B-X
(	B-X
OMIM	B-X
201400	B-X
)	B-X
,	B-X
an	B-X
inherited	B-X
POMC	B-X
defect	B-X
has	B-X
not	B-X
been	B-X
described	B-X
so	B-X
far	B-X
<EOS>	B-X
Sequential	B-X
cleavage	B-X
of	B-X
the	B-X
precursor	B-X
protein	B-X
pre	B-X
-	B-X
pro	B-X
-	B-X
opiomelanocortin	B-X
(	B-X
POMC	B-X
)	B-X
generates	B-X
the	B-X
melanocortin	B-X
peptides	B-X
adrenocorticotrophin	B-X
(	B-X
ACTH	B-X
)	B-X
,	B-X
melanocyte	B-X
-	B-X
stimulating	B-X
hormones	B-X
(	B-X
MSH	B-X
)	B-X
alpha	B-X
,	B-X
beta	B-X
and	B-X
gamma	B-X
as	B-X
well	B-X
as	B-X
the	B-X
opioid	B-X
-	B-X
receptor	B-X
ligand	B-X
beta	B-X
-	B-X
endorphin	B-X

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B-Disease
hydroxylase	I-Disease
deficiency	I-Disease
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

Phenylketonuria	B-Disease
(	O
PKU	B-Disease
)	O
and	O
mild	B-Disease
hyperphenylalaninemia	I-Disease
(	O
MHP	B-Disease
)	O
are	O
allelic	B-Disease
disorders	I-Disease
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O
<EOS>	B-X
Phenylketonuria	B-X
(	B-X
PKU	B-X
)	B-X
and	B-X
mild	B-X
hyperphenylalaninemia	B-X
(	B-X
MHP	B-X
)	B-X
are	B-X
allelic	B-X
disorders	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
phenylalanine	B-X
hydroxylase	B-X
(	B-X
PAH	B-X
)	B-X
<EOS>	B-X
We	B-X
proposed	B-X
and	B-X
tested	B-X
a	B-X
simple	B-X
model	B-X
for	B-X
correlation	B-X
between	B-X
genotype	B-X
and	B-X
phenotypic	B-X
outcome	B-X
<EOS>	B-X
,	B-X
in	B-X
functionally	B-X
hemizygous	B-X
patients	B-X
and	B-X
using	B-X
the	B-X
assigned	B-X
value	B-X
(	B-X
AV	B-X
)	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
severity	B-X
of	B-X
both	B-X
common	B-X
and	B-X
rare	B-X
mutant	B-X
alleles	B-X
,	B-X
as	B-X
well	B-X
as	B-X
to	B-X
check	B-X
a	B-X
model	B-X
to	B-X
predict	B-X
the	B-X
combined	B-X
phenotypic	B-X
effect	B-X
of	B-X
two	B-X
mutant	B-X
PAH	B-X
alleles	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
a	B-X
total	B-X
of	B-X
218	B-X
independent	B-X
PAH	B-X
chromosomes	B-X
(	B-X
109	B-X
unrelated	B-X
patients	B-X
with	B-X
PKU	B-X
residing	B-X
in	B-X
Lithuania	B-X
)	B-X
were	B-X
investigated	B-X

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B-Disease
deficiency	I-Disease
correlate	O
with	O
PAH	O
genotypes	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
the	B-X
highly	B-X
variable	B-X
metabolic	B-X
phenotypes	B-X
of	B-X
PAH	B-X
deficiency	B-X
correlate	B-X
with	B-X
PAH	B-X
genotypes	B-X
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
PAH	B-X
-	B-X
mutation	B-X
genotype	B-X
is	B-X
the	B-X
main	B-X
determinant	B-X
of	B-X
metabolic	B-X
phenotype	B-X
in	B-X
most	B-X
patients	B-X
with	B-X
PAH	B-X
deficiency	B-X
<EOS>	B-X
0001	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
differences	B-X
in	B-X
methods	B-X
used	B-X
for	B-X
mutation	B-X
detection	B-X
or	B-X
phenotype	B-X
classification	B-X
may	B-X
account	B-X
for	B-X
a	B-X
considerable	B-X
proportion	B-X
of	B-X
genotype	B-X
-	B-X
phenotype	B-X
inconsistencies	B-X
<EOS>	B-X
We	B-X
identified	B-X
both	B-X
causative	B-X
mutations	B-X
in	B-X
686	B-X
patients	B-X
from	B-X
seven	B-X
European	B-X
centers	B-X

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O
.	O
<EOS>	B-X
We	B-X
identified	B-X
both	B-X
causative	B-X
mutations	B-X
in	B-X
686	B-X
patients	B-X
from	B-X
seven	B-X
European	B-X
centers	B-X
<EOS>	B-X
Among	B-X
the	B-X
seven	B-X
contributing	B-X
centers	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
patients	B-X
for	B-X
whom	B-X
the	B-X
observed	B-X
phenotype	B-X
did	B-X
not	B-X
match	B-X
the	B-X
predicted	B-X
phenotype	B-X
was	B-X
4	B-X
%	B-X
	B-X
-	B-X
23	B-X
%	B-X
(	B-X
P	B-X
<	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
297	B-X
functionally	B-X
hemizygous	B-X
patients	B-X
,	B-X
105	B-X
of	B-X
the	B-X
mutations	B-X
were	B-X
assigned	B-X
to	B-X
one	B-X
of	B-X
four	B-X
arbitrary	B-X
phenotype	B-X
categories	B-X
<EOS>	B-X
The	B-X
observed	B-X
phenotype	B-X
matched	B-X
the	B-X
predicted	B-X
phenotype	B-X
in	B-X
79	B-X
%	B-X
of	B-X
the	B-X
cases	B-X
,	B-X
and	B-X
in	B-X
only	B-X
5	B-X
of	B-X
184	B-X
patients	B-X
was	B-X
the	B-X
observed	B-X
phenotype	B-X
more	B-X
than	B-X
one	B-X
category	B-X
away	B-X
from	B-X
that	B-X
expected	B-X

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
297	B-X
functionally	B-X
hemizygous	B-X
patients	B-X
,	B-X
105	B-X
of	B-X
the	B-X
mutations	B-X
were	B-X
assigned	B-X
to	B-X
one	B-X
of	B-X
four	B-X
arbitrary	B-X
phenotype	B-X
categories	B-X
<EOS>	B-X
Among	B-X
the	B-X
seven	B-X
contributing	B-X
centers	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
patients	B-X
for	B-X
whom	B-X
the	B-X
observed	B-X
phenotype	B-X
did	B-X
not	B-X
match	B-X
the	B-X
predicted	B-X
phenotype	B-X
was	B-X
4	B-X
%	B-X
	B-X
-	B-X
23	B-X
%	B-X
(	B-X
P	B-X
<	B-X
<EOS>	B-X
We	B-X
proposed	B-X
and	B-X
tested	B-X
a	B-X
simple	B-X
model	B-X
for	B-X
correlation	B-X
between	B-X
genotype	B-X
and	B-X
phenotypic	B-X
outcome	B-X
<EOS>	B-X
We	B-X
identified	B-X
both	B-X
causative	B-X
mutations	B-X
in	B-X
686	B-X
patients	B-X
from	B-X
seven	B-X
European	B-X
centers	B-X

We	O
proposed	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O
<EOS>	B-X
We	B-X
proposed	B-X
and	B-X
tested	B-X
a	B-X
simple	B-X
model	B-X
for	B-X
correlation	B-X
between	B-X
genotype	B-X
and	B-X
phenotypic	B-X
outcome	B-X
<EOS>	B-X
A	B-X
European	B-X
multicenter	B-X
study	B-X
of	B-X
phenylalanine	B-X
hydroxylase	B-X
deficiency	B-X
:	B-X
classification	B-X
of	B-X
105	B-X
mutations	B-X
and	B-X
a	B-X
general	B-X
system	B-X
for	B-X
genotype	B-X
-	B-X
based	B-X
prediction	B-X
of	B-X
metabolic	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
Genetic	B-X
risk	B-X
modifiers	B-X
alter	B-X
the	B-X
risk	B-X
conferred	B-X
by	B-X
inherited	B-X
Lynch	B-X
syndrome	B-X
mutations	B-X
,	B-X
and	B-X
their	B-X
identification	B-X
can	B-X
improve	B-X
genetic	B-X
counseling	B-X
<EOS>	B-X
Phenylketonuria	B-X
(	B-X
PKU	B-X
)	B-X
and	B-X
mild	B-X
hyperphenylalaninemia	B-X
(	B-X
MHP	B-X
)	B-X
are	B-X
allelic	B-X
disorders	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
phenylalanine	B-X
hydroxylase	B-X
(	B-X
PAH	B-X
)	B-X

The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O
<EOS>	B-X
The	B-X
observed	B-X
phenotype	B-X
matched	B-X
the	B-X
predicted	B-X
phenotype	B-X
in	B-X
79	B-X
%	B-X
of	B-X
the	B-X
cases	B-X
,	B-X
and	B-X
in	B-X
only	B-X
5	B-X
of	B-X
184	B-X
patients	B-X
was	B-X
the	B-X
observed	B-X
phenotype	B-X
more	B-X
than	B-X
one	B-X
category	B-X
away	B-X
from	B-X
that	B-X
expected	B-X
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
PAH	B-X
-	B-X
mutation	B-X
genotype	B-X
is	B-X
the	B-X
main	B-X
determinant	B-X
of	B-X
metabolic	B-X
phenotype	B-X
in	B-X
most	B-X
patients	B-X
with	B-X
PAH	B-X
deficiency	B-X
<EOS>	B-X
Among	B-X
the	B-X
seven	B-X
contributing	B-X
centers	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
patients	B-X
for	B-X
whom	B-X
the	B-X
observed	B-X
phenotype	B-X
did	B-X
not	B-X
match	B-X
the	B-X
predicted	B-X
phenotype	B-X
was	B-X
4	B-X
%	B-X
	B-X
-	B-X
23	B-X
%	B-X
(	B-X
P	B-X
<	B-X
<EOS>	B-X
We	B-X
proposed	B-X
and	B-X
tested	B-X
a	B-X
simple	B-X
model	B-X
for	B-X
correlation	B-X
between	B-X
genotype	B-X
and	B-X
phenotypic	B-X
outcome	B-X

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O
<EOS>	B-X
0001	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
differences	B-X
in	B-X
methods	B-X
used	B-X
for	B-X
mutation	B-X
detection	B-X
or	B-X
phenotype	B-X
classification	B-X
may	B-X
account	B-X
for	B-X
a	B-X
considerable	B-X
proportion	B-X
of	B-X
genotype	B-X
-	B-X
phenotype	B-X
inconsistencies	B-X
<EOS>	B-X
Among	B-X
the	B-X
seven	B-X
contributing	B-X
centers	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
patients	B-X
for	B-X
whom	B-X
the	B-X
observed	B-X
phenotype	B-X
did	B-X
not	B-X
match	B-X
the	B-X
predicted	B-X
phenotype	B-X
was	B-X
4	B-X
%	B-X
	B-X
-	B-X
23	B-X
%	B-X
(	B-X
P	B-X
<	B-X
<EOS>	B-X
The	B-X
observed	B-X
phenotype	B-X
matched	B-X
the	B-X
predicted	B-X
phenotype	B-X
in	B-X
79	B-X
%	B-X
of	B-X
the	B-X
cases	B-X
,	B-X
and	B-X
in	B-X
only	B-X
5	B-X
of	B-X
184	B-X
patients	B-X
was	B-X
the	B-X
observed	B-X
phenotype	B-X
more	B-X
than	B-X
one	B-X
category	B-X
away	B-X
from	B-X
that	B-X
expected	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
297	B-X
functionally	B-X
hemizygous	B-X
patients	B-X
,	B-X
105	B-X
of	B-X
the	B-X
mutations	B-X
were	B-X
assigned	B-X
to	B-X
one	B-X
of	B-X
four	B-X
arbitrary	B-X
phenotype	B-X
categories	B-X

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B-Disease
deficiency	I-Disease
.	O
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
PAH	B-X
-	B-X
mutation	B-X
genotype	B-X
is	B-X
the	B-X
main	B-X
determinant	B-X
of	B-X
metabolic	B-X
phenotype	B-X
in	B-X
most	B-X
patients	B-X
with	B-X
PAH	B-X
deficiency	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
the	B-X
highly	B-X
variable	B-X
metabolic	B-X
phenotypes	B-X
of	B-X
PAH	B-X
deficiency	B-X
correlate	B-X
with	B-X
PAH	B-X
genotypes	B-X
<EOS>	B-X
The	B-X
observed	B-X
phenotype	B-X
matched	B-X
the	B-X
predicted	B-X
phenotype	B-X
in	B-X
79	B-X
%	B-X
of	B-X
the	B-X
cases	B-X
,	B-X
and	B-X
in	B-X
only	B-X
5	B-X
of	B-X
184	B-X
patients	B-X
was	B-X
the	B-X
observed	B-X
phenotype	B-X
more	B-X
than	B-X
one	B-X
category	B-X
away	B-X
from	B-X
that	B-X
expected	B-X
<EOS>	B-X
0001	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
differences	B-X
in	B-X
methods	B-X
used	B-X
for	B-X
mutation	B-X
detection	B-X
or	B-X
phenotype	B-X
classification	B-X
may	B-X
account	B-X
for	B-X
a	B-X
considerable	B-X
proportion	B-X
of	B-X
genotype	B-X
-	B-X
phenotype	B-X
inconsistencies	B-X

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B-Disease
in	O
newborns	O
.	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O
<EOS>	B-X
Somatic	B-X
instability	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
region	B-X
is	B-X
age	B-X
dependent	B-X
but	B-X
not	B-X
correlated	B-X
to	B-X
the	B-X
relative	B-X
intertissue	B-X
transcription	B-X
levels	B-X
and	B-X
proliferative	B-X
capacities	B-X
.	B-X
<EOS>	B-X
Transgenic	B-X
mice	B-X
carrying	B-X
large	B-X
human	B-X
genomic	B-X
sequences	B-X
with	B-X
expanded	B-X
CTG	B-X
repeat	B-X
mimic	B-X
closely	B-X
the	B-X
DM	B-X
CTG	B-X
repeat	B-X
intergenerational	B-X
and	B-X
somatic	B-X
instability	B-X
.	B-X
<EOS>	B-X
Major	B-X
instability	B-X
,	B-X
with	B-X
very	B-X
large	B-X
expansions	B-X
between	B-X
generations	B-X
and	B-X
high	B-X
levels	B-X
of	B-X
somatic	B-X
mosaicism	B-X
,	B-X
is	B-X
observed	B-X
in	B-X
patients	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
somatic	B-X
mutation	B-X
rate	B-X
and	B-X
tissue	B-X
proliferation	B-X
capacity	B-X

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
in	O
patients	O
.	O
<EOS>	B-X
Major	B-X
instability	B-X
,	B-X
with	B-X
very	B-X
large	B-X
expansions	B-X
between	B-X
generations	B-X
and	B-X
high	B-X
levels	B-X
of	B-X
somatic	B-X
mosaicism	B-X
,	B-X
is	B-X
observed	B-X
in	B-X
patients	B-X
<EOS>	B-X
Somatic	B-X
instability	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
region	B-X
is	B-X
age	B-X
dependent	B-X
but	B-X
not	B-X
correlated	B-X
to	B-X
the	B-X
relative	B-X
intertissue	B-X
transcription	B-X
levels	B-X
and	B-X
proliferative	B-X
capacities	B-X
.	B-X
<EOS>	B-X
As	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
tissues	B-X
of	B-X
DM	B-X
patients	B-X
,	B-X
there	B-X
is	B-X
a	B-X
tendency	B-X
for	B-X
repeat	B-X
length	B-X
and	B-X
somatic	B-X
mosaicism	B-X
to	B-X
increase	B-X
with	B-X
the	B-X
age	B-X
of	B-X
the	B-X
mouse	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
repeat	B-X
size	B-X
(	B-X
at	B-X
least	B-X
in	B-X
leucocytes	B-X
)	B-X
,	B-X
clinical	B-X
severity	B-X
and	B-X
age	B-X
of	B-X
onset	B-X

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O
<EOS>	B-X
There	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
repeat	B-X
size	B-X
(	B-X
at	B-X
least	B-X
in	B-X
leucocytes	B-X
)	B-X
,	B-X
clinical	B-X
severity	B-X
and	B-X
age	B-X
of	B-X
onset	B-X
<EOS>	B-X
As	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
tissues	B-X
of	B-X
DM	B-X
patients	B-X
,	B-X
there	B-X
is	B-X
a	B-X
tendency	B-X
for	B-X
repeat	B-X
length	B-X
and	B-X
somatic	B-X
mosaicism	B-X
to	B-X
increase	B-X
with	B-X
the	B-X
age	B-X
of	B-X
the	B-X
mouse	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
somatic	B-X
mutation	B-X
rate	B-X
and	B-X
tissue	B-X
proliferation	B-X
capacity	B-X
<EOS>	B-X
These	B-X
mice	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
reproduce	B-X
the	B-X
intergenerational	B-X
and	B-X
somatic	B-X
instability	B-X
of	B-X
the	B-X
55	B-X
CTG	B-X
repeat	B-X
suggesting	B-X
that	B-X
surrounding	B-X
sequences	B-X
and	B-X
the	B-X
chromatin	B-X
environment	B-X
are	B-X
involved	B-X
in	B-X
instability	B-X
mechanisms	B-X

The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B-Disease
and	O
other	O
human	O
genetic	B-Disease
diseases	I-Disease
are	O
unknown	O
.	O
<EOS>	B-X
The	B-X
trinucleotide	B-X
repeat	B-X
instability	B-X
mechanisms	B-X
involved	B-X
in	B-X
DM	B-X
and	B-X
other	B-X
human	B-X
genetic	B-X
diseases	B-X
are	B-X
unknown	B-X
<EOS>	B-X
Somatic	B-X
instability	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
region	B-X
is	B-X
age	B-X
dependent	B-X
but	B-X
not	B-X
correlated	B-X
to	B-X
the	B-X
relative	B-X
intertissue	B-X
transcription	B-X
levels	B-X
and	B-X
proliferative	B-X
capacities	B-X
.	B-X
<EOS>	B-X
These	B-X
mice	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
reproduce	B-X
the	B-X
intergenerational	B-X
and	B-X
somatic	B-X
instability	B-X
of	B-X
the	B-X
55	B-X
CTG	B-X
repeat	B-X
suggesting	B-X
that	B-X
surrounding	B-X
sequences	B-X
and	B-X
the	B-X
chromatin	B-X
environment	B-X
are	B-X
involved	B-X
in	B-X
instability	B-X
mechanisms	B-X
<EOS>	B-X
As	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
tissues	B-X
of	B-X
DM	B-X
patients	B-X
,	B-X
there	B-X
is	B-X
a	B-X
tendency	B-X
for	B-X
repeat	B-X
length	B-X
and	B-X
somatic	B-X
mosaicism	B-X
to	B-X
increase	B-X
with	B-X
the	B-X
age	B-X
of	B-X
the	B-X
mouse	B-X

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B-Disease
region	O
,	O
using	O
small	O
-	O
pool	O
PCR	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
somatic	B-X
instability	B-X
by	B-X
measuring	B-X
the	B-X
CTG	B-X
repeat	B-X
length	B-X
at	B-X
several	B-X
ages	B-X
in	B-X
various	B-X
tissues	B-X
of	B-X
transgenic	B-X
mice	B-X
carrying	B-X
a	B-X
(	B-X
CTG	B-X
)	B-X
55expansion	B-X
surrounded	B-X
by	B-X
45	B-X
kb	B-X
of	B-X
the	B-X
human	B-X
DM	B-X
region	B-X
,	B-X
using	B-X
small	B-X
-	B-X
pool	B-X
PCR	B-X
<EOS>	B-X
Somatic	B-X
instability	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
region	B-X
is	B-X
age	B-X
dependent	B-X
but	B-X
not	B-X
correlated	B-X
to	B-X
the	B-X
relative	B-X
intertissue	B-X
transcription	B-X
levels	B-X
and	B-X
proliferative	B-X
capacities	B-X
.	B-X
<EOS>	B-X
Major	B-X
instability	B-X
,	B-X
with	B-X
very	B-X
large	B-X
expansions	B-X
between	B-X
generations	B-X
and	B-X
high	B-X
levels	B-X
of	B-X
somatic	B-X
mosaicism	B-X
,	B-X
is	B-X
observed	B-X
in	B-X
patients	B-X
<EOS>	B-X
The	B-X
trinucleotide	B-X
repeat	B-X
instability	B-X
mechanisms	B-X
involved	B-X
in	B-X
DM	B-X
and	B-X
other	B-X
human	B-X
genetic	B-X
diseases	B-X
are	B-X
unknown	B-X

These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O
<EOS>	B-X
These	B-X
mice	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
reproduce	B-X
the	B-X
intergenerational	B-X
and	B-X
somatic	B-X
instability	B-X
of	B-X
the	B-X
55	B-X
CTG	B-X
repeat	B-X
suggesting	B-X
that	B-X
surrounding	B-X
sequences	B-X
and	B-X
the	B-X
chromatin	B-X
environment	B-X
are	B-X
involved	B-X
in	B-X
instability	B-X
mechanisms	B-X
<EOS>	B-X
As	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
tissues	B-X
of	B-X
DM	B-X
patients	B-X
,	B-X
there	B-X
is	B-X
a	B-X
tendency	B-X
for	B-X
repeat	B-X
length	B-X
and	B-X
somatic	B-X
mosaicism	B-X
to	B-X
increase	B-X
with	B-X
the	B-X
age	B-X
of	B-X
the	B-X
mouse	B-X
<EOS>	B-X
The	B-X
trinucleotide	B-X
repeat	B-X
instability	B-X
mechanisms	B-X
involved	B-X
in	B-X
DM	B-X
and	B-X
other	B-X
human	B-X
genetic	B-X
diseases	B-X
are	B-X
unknown	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
repeat	B-X
size	B-X
(	B-X
at	B-X
least	B-X
in	B-X
leucocytes	B-X
)	B-X
,	B-X
clinical	B-X
severity	B-X
and	B-X
age	B-X
of	B-X
onset	B-X

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	B-Disease
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O
<EOS>	B-X
As	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
tissues	B-X
of	B-X
DM	B-X
patients	B-X
,	B-X
there	B-X
is	B-X
a	B-X
tendency	B-X
for	B-X
repeat	B-X
length	B-X
and	B-X
somatic	B-X
mosaicism	B-X
to	B-X
increase	B-X
with	B-X
the	B-X
age	B-X
of	B-X
the	B-X
mouse	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
repeat	B-X
size	B-X
(	B-X
at	B-X
least	B-X
in	B-X
leucocytes	B-X
)	B-X
,	B-X
clinical	B-X
severity	B-X
and	B-X
age	B-X
of	B-X
onset	B-X
<EOS>	B-X
Major	B-X
instability	B-X
,	B-X
with	B-X
very	B-X
large	B-X
expansions	B-X
between	B-X
generations	B-X
and	B-X
high	B-X
levels	B-X
of	B-X
somatic	B-X
mosaicism	B-X
,	B-X
is	B-X
observed	B-X
in	B-X
patients	B-X
<EOS>	B-X
Somatic	B-X
instability	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
region	B-X
is	B-X
age	B-X
dependent	B-X
but	B-X
not	B-X
correlated	B-X
to	B-X
the	B-X
relative	B-X
intertissue	B-X
transcription	B-X
levels	B-X
and	B-X
proliferative	B-X
capacities	B-X
.	B-X

Furthermore	O
,	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
somatic	B-X
mutation	B-X
rate	B-X
and	B-X
tissue	B-X
proliferation	B-X
capacity	B-X
<EOS>	B-X
Somatic	B-X
instability	B-X
of	B-X
the	B-X
CTG	B-X
repeat	B-X
in	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
region	B-X
is	B-X
age	B-X
dependent	B-X
but	B-X
not	B-X
correlated	B-X
to	B-X
the	B-X
relative	B-X
intertissue	B-X
transcription	B-X
levels	B-X
and	B-X
proliferative	B-X
capacities	B-X
.	B-X
<EOS>	B-X
As	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
tissues	B-X
of	B-X
DM	B-X
patients	B-X
,	B-X
there	B-X
is	B-X
a	B-X
tendency	B-X
for	B-X
repeat	B-X
length	B-X
and	B-X
somatic	B-X
mosaicism	B-X
to	B-X
increase	B-X
with	B-X
the	B-X
age	B-X
of	B-X
the	B-X
mouse	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
repeat	B-X
size	B-X
(	B-X
at	B-X
least	B-X
in	B-X
leucocytes	B-X
)	B-X
,	B-X
clinical	B-X
severity	B-X
and	B-X
age	B-X
of	B-X
onset	B-X

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
.	O
.	O
<EOS>	B-X
The	B-X
prediction	B-X
model	B-X
is	B-X
also	B-X
related	B-X
to	B-X
the	B-X
infiltration	B-X
of	B-X
immune	B-X
cells	B-X
and	B-X
human	B-X
leukocyte	B-X
antigen	B-X
family	B-X
expression	B-X
in	B-X
the	B-X
immune	B-X
microenvironment	B-X
<EOS>	B-X
To	B-X
estimate	B-X
the	B-X
somatic	B-X
mutation	B-X
accumulation	B-X
and	B-X
inheritance	B-X
among	B-X
a	B-X
clonal	B-X
population	B-X
of	B-X
plant	B-X
,	B-X
here	B-X
we	B-X
assess	B-X
somatic	B-X
mutation	B-X
accumulation	B-X
in	B-X
Musa	B-X
basjoo	B-X
,	B-X
a	B-X
diploid	B-X
banana	B-X
wild	B-X
relative	B-X
,	B-X
using	B-X
30	B-X
whole	B-X
-	B-X
genome	B-X
resequenced	B-X
samples	B-X
collected	B-X
from	B-X
five	B-X
structures	B-X
,	B-X
including	B-X
leaves	B-X
,	B-X
sheaths	B-X
,	B-X
panicle	B-X
,	B-X
roots	B-X
and	B-X
underground	B-X
rhizome	B-X
connecting	B-X
three	B-X
clonal	B-X
individuals	B-X
<EOS>	B-X
Clinicopathological	B-X
patient	B-X
characteristics	B-X
were	B-X
obtained	B-X
from	B-X
medical	B-X
records	B-X
,	B-X
and	B-X
formalin	B-X
-	B-X
fixed	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
specimens	B-X
were	B-X
analyzed	B-X
for	B-X
histological	B-X
markers	B-X
,	B-X
mutations	B-X
of	B-X
126	B-X
genes	B-X
,	B-X
BRCA1	B-X
methylation	B-X
,	B-X
and	B-X
stromal	B-X
tumor	B-X
-	B-X
infiltrating	B-X
lymphocytes	B-X
<EOS>	B-X
The	B-X
imbalance	B-X
of	B-X
tumor	B-X
intrinsic	B-X
growth	B-X
potential	B-X
and	B-X
immune	B-X
function	B-X
orchestrate	B-X
the	B-X
progression	B-X
of	B-X
LUAD	B-X
,	B-X
which	B-X
can	B-X
be	B-X
measured	B-X
by	B-X
TP	B-X
index	B-X

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B-Disease
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B-Disease
phenotype	O
.	O
<EOS>	B-X
A	B-X
novel	B-X
missense	B-X
mutation	B-X
in	B-X
patients	B-X
from	B-X
a	B-X
retinoblastoma	B-X
pedigree	B-X
showing	B-X
only	B-X
mild	B-X
expression	B-X
of	B-X
the	B-X
tumor	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
single	B-X
strand	B-X
conformation	B-X
polymorphism	B-X
analysis	B-X
to	B-X
study	B-X
the	B-X
27	B-X
exons	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
in	B-X
individuals	B-X
from	B-X
a	B-X
family	B-X
showing	B-X
'mild	B-X
'	B-X
expression	B-X
of	B-X
the	B-X
retinoblastoma	B-X
phenotype	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
all	B-X
family	B-X
members	B-X
demonstrated	B-X
that	B-X
the	B-X
missense	B-X
mutation	B-X
co	B-X
-	B-X
segregated	B-X
with	B-X
patients	B-X
with	B-X
tumors	B-X
or	B-X
who	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
had	B-X
been	B-X
predicted	B-X
to	B-X
carry	B-X
the	B-X
predisposing	B-X
mutation	B-X
<EOS>	B-X
These	B-X
observations	B-X
point	B-X
to	B-X
another	B-X
region	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
where	B-X
mutations	B-X
only	B-X
modify	B-X
the	B-X
function	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
raise	B-X
important	B-X
questions	B-X
for	B-X
genetic	B-X
counseling	B-X
in	B-X
families	B-X
with	B-X
these	B-X
distinctive	B-X
phenotypes	B-X

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B-Disease
phenotype	O
.	O

In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B-Disease
tumors	I-Disease
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O
<EOS>	B-X
In	B-X
this	B-X
family	B-X
affected	B-X
individuals	B-X
developed	B-X
unilateral	B-X
tumors	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
,	B-X
unaffected	B-X
mutation	B-X
carriers	B-X
were	B-X
also	B-X
identified	B-X
within	B-X
the	B-X
pedigree	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
all	B-X
family	B-X
members	B-X
demonstrated	B-X
that	B-X
the	B-X
missense	B-X
mutation	B-X
co	B-X
-	B-X
segregated	B-X
with	B-X
patients	B-X
with	B-X
tumors	B-X
or	B-X
who	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
had	B-X
been	B-X
predicted	B-X
to	B-X
carry	B-X
the	B-X
predisposing	B-X
mutation	B-X
<EOS>	B-X
These	B-X
observations	B-X
point	B-X
to	B-X
another	B-X
region	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
where	B-X
mutations	B-X
only	B-X
modify	B-X
the	B-X
function	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
raise	B-X
important	B-X
questions	B-X
for	B-X
genetic	B-X
counseling	B-X
in	B-X
families	B-X
with	B-X
these	B-X
distinctive	B-X
phenotypes	B-X
<EOS>	B-X
A	B-X
single	B-X
band	B-X
shift	B-X
using	B-X
SSCP	B-X
was	B-X
identified	B-X
in	B-X
exon	B-X
21	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
missense	B-X
mutation	B-X
converting	B-X
a	B-X
cys	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
arg	B-X
at	B-X
nucleotide	B-X
position	B-X
28	B-X
in	B-X
the	B-X
exon	B-X

A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
.	O
<EOS>	B-X
The	B-X
mutation	B-X
destroyed	B-X
an	B-X
NdeI	B-X
restriction	B-X
enzyme	B-X
site	B-X
<EOS>	B-X
A	B-X
novel	B-X
missense	B-X
mutation	B-X
in	B-X
patients	B-X
from	B-X
a	B-X
retinoblastoma	B-X
pedigree	B-X
showing	B-X
only	B-X
mild	B-X
expression	B-X
of	B-X
the	B-X
tumor	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
A	B-X
single	B-X
band	B-X
shift	B-X
using	B-X
SSCP	B-X
was	B-X
identified	B-X
in	B-X
exon	B-X
21	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
missense	B-X
mutation	B-X
converting	B-X
a	B-X
cys	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
arg	B-X
at	B-X
nucleotide	B-X
position	B-X
28	B-X
in	B-X
the	B-X
exon	B-X
<EOS>	B-X
In	B-X
this	B-X
family	B-X
affected	B-X
individuals	B-X
developed	B-X
unilateral	B-X
tumors	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
,	B-X
unaffected	B-X
mutation	B-X
carriers	B-X
were	B-X
also	B-X
identified	B-X
within	B-X
the	B-X
pedigree	B-X

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B-Disease
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
all	B-X
family	B-X
members	B-X
demonstrated	B-X
that	B-X
the	B-X
missense	B-X
mutation	B-X
co	B-X
-	B-X
segregated	B-X
with	B-X
patients	B-X
with	B-X
tumors	B-X
or	B-X
who	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
had	B-X
been	B-X
predicted	B-X
to	B-X
carry	B-X
the	B-X
predisposing	B-X
mutation	B-X
<EOS>	B-X
In	B-X
this	B-X
family	B-X
affected	B-X
individuals	B-X
developed	B-X
unilateral	B-X
tumors	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
,	B-X
unaffected	B-X
mutation	B-X
carriers	B-X
were	B-X
also	B-X
identified	B-X
within	B-X
the	B-X
pedigree	B-X
<EOS>	B-X
FSGS	B-X
is	B-X
considered	B-X
a	B-X
podocyte	B-X
disease	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
provenâ€‘FSGS	B-X
,	B-X
the	B-X
lesion	B-X
results	B-X
from	B-X
defects	B-X
in	B-X
the	B-X
podocyte	B-X
structure	B-X
or	B-X
function	B-X
<EOS>	B-X
A	B-X
novel	B-X
missense	B-X
mutation	B-X
in	B-X
patients	B-X
from	B-X
a	B-X
retinoblastoma	B-X
pedigree	B-X
showing	B-X
only	B-X
mild	B-X
expression	B-X
of	B-X
the	B-X
tumor	B-X
phenotype	B-X
.	B-X

These	O
observations	O
point	O
to	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
.	O
<EOS>	B-X
These	B-X
observations	B-X
point	B-X
to	B-X
another	B-X
region	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
where	B-X
mutations	B-X
only	B-X
modify	B-X
the	B-X
function	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
raise	B-X
important	B-X
questions	B-X
for	B-X
genetic	B-X
counseling	B-X
in	B-X
families	B-X
with	B-X
these	B-X
distinctive	B-X
phenotypes	B-X
<EOS>	B-X
A	B-X
novel	B-X
missense	B-X
mutation	B-X
in	B-X
patients	B-X
from	B-X
a	B-X
retinoblastoma	B-X
pedigree	B-X
showing	B-X
only	B-X
mild	B-X
expression	B-X
of	B-X
the	B-X
tumor	B-X
phenotype	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
single	B-X
strand	B-X
conformation	B-X
polymorphism	B-X
analysis	B-X
to	B-X
study	B-X
the	B-X
27	B-X
exons	B-X
of	B-X
the	B-X
RB1	B-X
gene	B-X
in	B-X
individuals	B-X
from	B-X
a	B-X
family	B-X
showing	B-X
'mild	B-X
'	B-X
expression	B-X
of	B-X
the	B-X
retinoblastoma	B-X
phenotype	B-X
<EOS>	B-X
In	B-X
this	B-X
family	B-X
affected	B-X
individuals	B-X
developed	B-X
unilateral	B-X
tumors	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
linkage	B-X
analysis	B-X
,	B-X
unaffected	B-X
mutation	B-X
carriers	B-X
were	B-X
also	B-X
identified	B-X
within	B-X
the	B-X
pedigree	B-X

Maternal	B-Disease
disomy	I-Disease
and	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

Maternal	B-Disease
uniparental	I-Disease
disomy	I-Disease
(	I-Disease
UPD	I-Disease
)	I-Disease
for	I-Disease
chromosome	I-Disease
15	I-Disease
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B-Disease
-	I-Disease
Willi	I-Disease
syndrome	I-Disease
(	O
PWS	B-Disease
)	O
.	O
<EOS>	B-X
Maternal	B-X
uniparental	B-X
disomy	B-X
(	B-X
UPD	B-X
)	B-X
for	B-X
chromosome	B-X
15	B-X
is	B-X
responsible	B-X
for	B-X
an	B-X
estimated	B-X
30	B-X
%	B-X
of	B-X
cases	B-X
of	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
(	B-X
PWS	B-X
)	B-X
<EOS>	B-X
)	B-X
,	B-X
a	B-X
17	B-X
-	B-X
year	B-X
-	B-X
old	B-X
white	B-X
male	B-X
with	B-X
PWS	B-X
,	B-X
was	B-X
found	B-X
to	B-X
have	B-X
47	B-X
chromosomes	B-X
with	B-X
a	B-X
supernumerary	B-X
,	B-X
paternal	B-X
der	B-X
(	B-X
15	B-X
)	B-X
consisting	B-X
of	B-X
the	B-X
short	B-X
arm	B-X
and	B-X
the	B-X
proximal	B-X
long	B-X
arm	B-X
of	B-X
chromosome	B-X
15	B-X
,	B-X
and	B-X
distal	B-X
chromosome	B-X
arm	B-X
3p	B-X
<EOS>	B-X
Uniparental	B-X
disomy	B-X
associated	B-X
with	B-X
unbalanced	B-X
segregation	B-X
of	B-X
non	B-X
-	B-X
Robertsonian	B-X
translocations	B-X
has	B-X
been	B-X
reported	B-X
previously	B-X
but	B-X
has	B-X
not	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
been	B-X
observed	B-X
in	B-X
a	B-X
case	B-X
of	B-X
PWS	B-X
<EOS>	B-X
Methylation	B-X
analysis	B-X
at	B-X
exon	B-X
alpha	B-X
of	B-X
the	B-X
small	B-X
nuclear	B-X
ribonucleoprotein	B-X
-	B-X
associated	B-X
polypeptide	B-X
N	B-X
(	B-X
SNRPN	B-X
)	B-X
gene	B-X
showed	B-X
a	B-X
pattern	B-X
characteristic	B-X
of	B-X
only	B-X
the	B-X
maternal	B-X
chromosome	B-X
15	B-X
in	B-X
J	B-X

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B-Disease
disomy	I-Disease
15	I-Disease
in	O
PWS	B-Disease
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

The	O
patient	O
(	O
J	O
.	O
B	O
.	O
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	O
PWS	B-Disease
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B-Disease
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	B-Disease
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J	O
.	O

B	O
.	O
<EOS>	B-X
8	B-X
%	B-X
vs	B-X
<EOS>	B-X
7	B-X
Â±	B-X
0	B-X
<EOS>	B-X
6	B-X
Â±	B-X
1	B-X
<EOS>	B-X
6	B-X
Â±	B-X
0	B-X

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
.	O

Maternal	B-Disease
disomy	I-Disease
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locus	O
.	O
<EOS>	B-X
Maternal	B-X
disomy	B-X
was	B-X
confirmed	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
of	B-X
microsatellite	B-X
repeats	B-X
at	B-X
the	B-X
gamma	B-X
-	B-X
aminobutyric	B-X
acid	B-X
receptor	B-X
beta3	B-X
subunit	B-X
(	B-X
GABRB3	B-X
)	B-X
locus	B-X
<EOS>	B-X
Maternal	B-X
disomy	B-X
and	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
consistent	B-X
with	B-X
gamete	B-X
complementation	B-X
in	B-X
a	B-X
case	B-X
of	B-X
familial	B-X
translocation	B-X
(	B-X
3	B-X
;	B-X
15	B-X
)	B-X
(	B-X
p25	B-X
;	B-X
q11.2	B-X
)	B-X
.	B-X
<EOS>	B-X
Uniparental	B-X
disomy	B-X
associated	B-X
with	B-X
unbalanced	B-X
segregation	B-X
of	B-X
non	B-X
-	B-X
Robertsonian	B-X
translocations	B-X
has	B-X
been	B-X
reported	B-X
previously	B-X
but	B-X
has	B-X
not	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
been	B-X
observed	B-X
in	B-X
a	B-X
case	B-X
of	B-X
PWS	B-X
<EOS>	B-X
Fluorescent	B-X
in	B-X
situ	B-X
hybridization	B-X
analysis	B-X
demonstrated	B-X
that	B-X
the	B-X
PWS	B-X
critical	B-X
region	B-X
resided	B-X
on	B-X
the	B-X
derivative	B-X
chromosome	B-X
3	B-X
and	B-X
that	B-X
there	B-X
was	B-X
no	B-X
deletion	B-X
of	B-X
the	B-X
PWS	B-X
region	B-X
on	B-X
the	B-X
normal	B-X
pair	B-X
of	B-X
15s	B-X
present	B-X
in	B-X
J	B-X

A	O
niece	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
.	O

Uniparental	B-Disease
disomy	I-Disease
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B-Disease
.	O
<EOS>	B-X
Uniparental	B-X
disomy	B-X
associated	B-X
with	B-X
unbalanced	B-X
segregation	B-X
of	B-X
non	B-X
-	B-X
Robertsonian	B-X
translocations	B-X
has	B-X
been	B-X
reported	B-X
previously	B-X
but	B-X
has	B-X
not	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
been	B-X
observed	B-X
in	B-X
a	B-X
case	B-X
of	B-X
PWS	B-X
<EOS>	B-X
Maternal	B-X
disomy	B-X
was	B-X
confirmed	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
of	B-X
microsatellite	B-X
repeats	B-X
at	B-X
the	B-X
gamma	B-X
-	B-X
aminobutyric	B-X
acid	B-X
receptor	B-X
beta3	B-X
subunit	B-X
(	B-X
GABRB3	B-X
)	B-X
locus	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
our	B-X
findings	B-X
are	B-X
best	B-X
interpreted	B-X
as	B-X
true	B-X
gamete	B-X
complementation	B-X
resulting	B-X
in	B-X
maternal	B-X
UPD	B-X
15	B-X
and	B-X
PWS	B-X
<EOS>	B-X
Maternal	B-X
uniparental	B-X
disomy	B-X
(	B-X
UPD	B-X
)	B-X
for	B-X
chromosome	B-X
15	B-X
is	B-X
responsible	B-X
for	B-X
an	B-X
estimated	B-X
30	B-X
%	B-X
of	B-X
cases	B-X
of	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
(	B-X
PWS	B-X
)	B-X

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B-Disease
UPD	I-Disease
15	I-Disease
and	O
PWS	B-Disease
<EOS>	B-X
Furthermore	B-X
,	B-X
our	B-X
findings	B-X
are	B-X
best	B-X
interpreted	B-X
as	B-X
true	B-X
gamete	B-X
complementation	B-X
resulting	B-X
in	B-X
maternal	B-X
UPD	B-X
15	B-X
and	B-X
PWS	B-X
<EOS>	B-X
Maternal	B-X
disomy	B-X
and	B-X
Prader	B-X
-	B-X
Willi	B-X
syndrome	B-X
consistent	B-X
with	B-X
gamete	B-X
complementation	B-X
in	B-X
a	B-X
case	B-X
of	B-X
familial	B-X
translocation	B-X
(	B-X
3	B-X
;	B-X
15	B-X
)	B-X
(	B-X
p25	B-X
;	B-X
q11.2	B-X
)	B-X
.	B-X
<EOS>	B-X
Fluorescent	B-X
in	B-X
situ	B-X
hybridization	B-X
analysis	B-X
demonstrated	B-X
that	B-X
the	B-X
PWS	B-X
critical	B-X
region	B-X
resided	B-X
on	B-X
the	B-X
derivative	B-X
chromosome	B-X
3	B-X
and	B-X
that	B-X
there	B-X
was	B-X
no	B-X
deletion	B-X
of	B-X
the	B-X
PWS	B-X
region	B-X
on	B-X
the	B-X
normal	B-X
pair	B-X
of	B-X
15s	B-X
present	B-X
in	B-X
J	B-X
<EOS>	B-X
We	B-X
report	B-X
on	B-X
an	B-X
unusual	B-X
case	B-X
of	B-X
maternal	B-X
disomy	B-X
15	B-X
in	B-X
PWS	B-X
that	B-X
is	B-X
most	B-X
consistent	B-X
with	B-X
adjacent	B-X
-	B-X
1	B-X
segregation	B-X
of	B-X
a	B-X
paternal	B-X
t	B-X
(	B-X
3	B-X
;	B-X
15	B-X
)	B-X
(	B-X
p25	B-X
;	B-X
q11	B-X

Schwartz	B-Disease
-	I-Disease
Jampel	I-Disease
syndrome	I-Disease
type	I-Disease
2	I-Disease
and	O
Stuve	B-Disease
-	I-Disease
Wiedemann	I-Disease
syndrome	I-Disease
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
.	O
<EOS>	B-X
Schwartz	B-X
-	B-X
Jampel	B-X
syndrome	B-X
type	B-X
2	B-X
and	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
:	B-X
a	B-X
case	B-X
for	B-X
``	B-X
lumping	B-X
''	B-X
.	B-X
<EOS>	B-X
This	B-X
disorder	B-X
is	B-X
reminiscent	B-X
of	B-X
another	B-X
rare	B-X
condition	B-X
,	B-X
the	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
(	B-X
SWS	B-X
)	B-X
,	B-X
which	B-X
comprises	B-X
campomelia	B-X
at	B-X
birth	B-X
with	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
contractures	B-X
,	B-X
and	B-X
early	B-X
death	B-X
<EOS>	B-X
The	B-X
hypothesis	B-X
that	B-X
SWS	B-X
and	B-X
SJS	B-X
type	B-X
2	B-X
are	B-X
the	B-X
same	B-X
disorder	B-X
should	B-X
be	B-X
testable	B-X
by	B-X
molecular	B-X
methods	B-X
<EOS>	B-X
The	B-X
similarity	B-X
of	B-X
the	B-X
clinical	B-X
and	B-X
radiographic	B-X
findings	B-X
is	B-X
so	B-X
extensive	B-X
that	B-X
these	B-X
disorders	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
single	B-X
entity	B-X

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B-Disease
-	I-Disease
Jampel	I-Disease
syndrome	I-Disease
(	O
SJS	B-Disease
)	O
of	O
myotonia	B-Disease
and	O
skeletal	B-Disease
dysplasia	I-Disease
,	O
which	O
we	O
called	O
SJS	B-Disease
type	I-Disease
2	I-Disease
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
demonstrated	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
genetically	B-X
distinct	B-X
,	B-X
usually	B-X
lethal	B-X
form	B-X
of	B-X
the	B-X
Schwartz	B-X
-	B-X
Jampel	B-X
syndrome	B-X
(	B-X
SJS	B-X
)	B-X
of	B-X
myotonia	B-X
and	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
which	B-X
we	B-X
called	B-X
SJS	B-X
type	B-X
2	B-X
<EOS>	B-X
This	B-X
disorder	B-X
is	B-X
reminiscent	B-X
of	B-X
another	B-X
rare	B-X
condition	B-X
,	B-X
the	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
(	B-X
SWS	B-X
)	B-X
,	B-X
which	B-X
comprises	B-X
campomelia	B-X
at	B-X
birth	B-X
with	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
contractures	B-X
,	B-X
and	B-X
early	B-X
death	B-X
<EOS>	B-X
Patients	B-X
reported	B-X
as	B-X
having	B-X
either	B-X
neonatal	B-X
SJS	B-X
or	B-X
SWS	B-X
presented	B-X
a	B-X
combination	B-X
of	B-X
a	B-X
severe	B-X
,	B-X
prenatal	B-X
-	B-X
onset	B-X
neuromuscular	B-X
disorder	B-X
(	B-X
with	B-X
congenital	B-X
joint	B-X
contractures	B-X
,	B-X
respiratory	B-X
and	B-X
feeding	B-X
difficulties	B-X
,	B-X
tendency	B-X
to	B-X
hyperthermia	B-X
,	B-X
and	B-X
frequent	B-X
death	B-X
in	B-X
infancy	B-X
)	B-X
with	B-X
a	B-X
distinct	B-X
campomelic	B-X
-	B-X
metaphyseal	B-X
skeletal	B-X
dysplasia	B-X
<EOS>	B-X
To	B-X
test	B-X
for	B-X
possible	B-X
nosologic	B-X
identity	B-X
between	B-X
these	B-X
disorders	B-X
,	B-X
we	B-X
reviewed	B-X
the	B-X
literature	B-X
and	B-X
obtained	B-X
a	B-X
follow	B-X
-	B-X
up	B-X
of	B-X
the	B-X
only	B-X
two	B-X
surviving	B-X
patients	B-X
,	B-X
one	B-X
with	B-X
SJS	B-X
type	B-X
2	B-X
at	B-X
age	B-X
10	B-X
years	B-X
and	B-X
another	B-X
with	B-X
SWS	B-X
at	B-X
age	B-X
7	B-X
years	B-X

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B-Disease
-	I-Disease
Wiedemann	I-Disease
syndrome	I-Disease
(	O
SWS	B-Disease
)	O
,	O
which	O
comprises	O
campomelia	B-Disease
at	O
birth	O
with	O
skeletal	B-Disease
dysplasia	I-Disease
,	O
contractures	B-Disease
,	O
and	O
early	B-Disease
death	I-Disease
.	O
<EOS>	B-X
This	B-X
disorder	B-X
is	B-X
reminiscent	B-X
of	B-X
another	B-X
rare	B-X
condition	B-X
,	B-X
the	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
(	B-X
SWS	B-X
)	B-X
,	B-X
which	B-X
comprises	B-X
campomelia	B-X
at	B-X
birth	B-X
with	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
contractures	B-X
,	B-X
and	B-X
early	B-X
death	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
demonstrated	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
genetically	B-X
distinct	B-X
,	B-X
usually	B-X
lethal	B-X
form	B-X
of	B-X
the	B-X
Schwartz	B-X
-	B-X
Jampel	B-X
syndrome	B-X
(	B-X
SJS	B-X
)	B-X
of	B-X
myotonia	B-X
and	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
which	B-X
we	B-X
called	B-X
SJS	B-X
type	B-X
2	B-X
<EOS>	B-X
The	B-X
similarity	B-X
of	B-X
the	B-X
clinical	B-X
and	B-X
radiographic	B-X
findings	B-X
is	B-X
so	B-X
extensive	B-X
that	B-X
these	B-X
disorders	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
single	B-X
entity	B-X
<EOS>	B-X
The	B-X
hypothesis	B-X
that	B-X
SWS	B-X
and	B-X
SJS	B-X
type	B-X
2	B-X
are	B-X
the	B-X
same	B-X
disorder	B-X
should	B-X
be	B-X
testable	B-X
by	B-X
molecular	B-X
methods	B-X

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B-Disease
type	I-Disease
2	I-Disease
at	O
age	O
10	O
years	O
and	O
another	O
with	O
SWS	B-Disease
at	O
age	O
7	O
years	O
.	O
<EOS>	B-X
To	B-X
test	B-X
for	B-X
possible	B-X
nosologic	B-X
identity	B-X
between	B-X
these	B-X
disorders	B-X
,	B-X
we	B-X
reviewed	B-X
the	B-X
literature	B-X
and	B-X
obtained	B-X
a	B-X
follow	B-X
-	B-X
up	B-X
of	B-X
the	B-X
only	B-X
two	B-X
surviving	B-X
patients	B-X
,	B-X
one	B-X
with	B-X
SJS	B-X
type	B-X
2	B-X
at	B-X
age	B-X
10	B-X
years	B-X
and	B-X
another	B-X
with	B-X
SWS	B-X
at	B-X
age	B-X
7	B-X
years	B-X
<EOS>	B-X
This	B-X
disorder	B-X
is	B-X
reminiscent	B-X
of	B-X
another	B-X
rare	B-X
condition	B-X
,	B-X
the	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
(	B-X
SWS	B-X
)	B-X
,	B-X
which	B-X
comprises	B-X
campomelia	B-X
at	B-X
birth	B-X
with	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
contractures	B-X
,	B-X
and	B-X
early	B-X
death	B-X
<EOS>	B-X
The	B-X
follow	B-X
-	B-X
up	B-X
observation	B-X
of	B-X
an	B-X
identical	B-X
and	B-X
unique	B-X
pattern	B-X
of	B-X
progressive	B-X
bone	B-X
dysplasia	B-X
in	B-X
the	B-X
two	B-X
patients	B-X
(	B-X
one	B-X
with	B-X
SJS	B-X
type	B-X
2	B-X
,	B-X
one	B-X
with	B-X
SWS	B-X
)	B-X
surviving	B-X
beyond	B-X
infancy	B-X
adds	B-X
to	B-X
the	B-X
evidence	B-X
in	B-X
favor	B-X
of	B-X
identity	B-X
<EOS>	B-X
The	B-X
similarity	B-X
of	B-X
the	B-X
clinical	B-X
and	B-X
radiographic	B-X
findings	B-X
is	B-X
so	B-X
extensive	B-X
that	B-X
these	B-X
disorders	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
single	B-X
entity	B-X

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B-Disease
or	O
SWS	B-Disease
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B-Disease
disorder	I-Disease
(	O
with	O
congenital	B-Disease
joint	I-Disease
contractures	I-Disease
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B-Disease
,	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B-Disease
-	I-Disease
metaphyseal	I-Disease
skeletal	I-Disease
dysplasia	I-Disease
.	O
<EOS>	B-X
Patients	B-X
reported	B-X
as	B-X
having	B-X
either	B-X
neonatal	B-X
SJS	B-X
or	B-X
SWS	B-X
presented	B-X
a	B-X
combination	B-X
of	B-X
a	B-X
severe	B-X
,	B-X
prenatal	B-X
-	B-X
onset	B-X
neuromuscular	B-X
disorder	B-X
(	B-X
with	B-X
congenital	B-X
joint	B-X
contractures	B-X
,	B-X
respiratory	B-X
and	B-X
feeding	B-X
difficulties	B-X
,	B-X
tendency	B-X
to	B-X
hyperthermia	B-X
,	B-X
and	B-X
frequent	B-X
death	B-X
in	B-X
infancy	B-X
)	B-X
with	B-X
a	B-X
distinct	B-X
campomelic	B-X
-	B-X
metaphyseal	B-X
skeletal	B-X
dysplasia	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
perlecan	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
neuromuscular	B-X
function	B-X
and	B-X
cartilage	B-X
formation	B-X
,	B-X
and	B-X
they	B-X
define	B-X
the	B-X
molecular	B-X
basis	B-X
involved	B-X
in	B-X
the	B-X
difference	B-X
in	B-X
the	B-X
phenotypic	B-X
severity	B-X
between	B-X
DDSH	B-X
and	B-X
SJS	B-X
<EOS>	B-X
Pulmonary	B-X
sequestration	B-X
(	B-X
PS	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
congenital	B-X
malformation	B-X
where	B-X
non	B-X
-	B-X
functioning	B-X
lung	B-X
tissue	B-X
is	B-X
separated	B-X
from	B-X
the	B-X
bronchial	B-X
tree	B-X
and	B-X
vascularised	B-X
with	B-X
an	B-X
aberrant	B-X
artery	B-X
from	B-X
the	B-X
systemic	B-X
circulation	B-X
<EOS>	B-X
ADR	B-X
reports	B-X
received	B-X
from	B-X
2006	B-X
to	B-X
2015	B-X
of	B-X
the	B-X
system	B-X
organ	B-X
class	B-X
``	B-X
Skin	B-X
and	B-X
Appendages	B-X
Disorders	B-X
''	B-X
were	B-X
analyzed	B-X
based	B-X
on	B-X
patient	B-X
demographics	B-X
,	B-X
the	B-X
types	B-X
of	B-X
CADRs	B-X
,	B-X
suspected	B-X
drugs	B-X
,	B-X
outcome	B-X
,	B-X
and	B-X
latency	B-X
period	B-X

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity	O
.	O
<EOS>	B-X
The	B-X
similarity	B-X
of	B-X
the	B-X
clinical	B-X
and	B-X
radiographic	B-X
findings	B-X
is	B-X
so	B-X
extensive	B-X
that	B-X
these	B-X
disorders	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
single	B-X
entity	B-X
<EOS>	B-X
The	B-X
follow	B-X
-	B-X
up	B-X
observation	B-X
of	B-X
an	B-X
identical	B-X
and	B-X
unique	B-X
pattern	B-X
of	B-X
progressive	B-X
bone	B-X
dysplasia	B-X
in	B-X
the	B-X
two	B-X
patients	B-X
(	B-X
one	B-X
with	B-X
SJS	B-X
type	B-X
2	B-X
,	B-X
one	B-X
with	B-X
SWS	B-X
)	B-X
surviving	B-X
beyond	B-X
infancy	B-X
adds	B-X
to	B-X
the	B-X
evidence	B-X
in	B-X
favor	B-X
of	B-X
identity	B-X
<EOS>	B-X
The	B-X
hypothesis	B-X
that	B-X
SWS	B-X
and	B-X
SJS	B-X
type	B-X
2	B-X
are	B-X
the	B-X
same	B-X
disorder	B-X
should	B-X
be	B-X
testable	B-X
by	B-X
molecular	B-X
methods	B-X
<EOS>	B-X
This	B-X
disorder	B-X
is	B-X
reminiscent	B-X
of	B-X
another	B-X
rare	B-X
condition	B-X
,	B-X
the	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
(	B-X
SWS	B-X
)	B-X
,	B-X
which	B-X
comprises	B-X
campomelia	B-X
at	B-X
birth	B-X
with	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
contractures	B-X
,	B-X
and	B-X
early	B-X
death	B-X

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B-Disease
dysplasia	I-Disease
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B-Disease
type	I-Disease
2	I-Disease
,	O
one	O
with	O
SWS	B-Disease
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O

The	O
hypothesis	O
that	O
SWS	B-Disease
and	O
SJS	B-Disease
type	I-Disease
2	I-Disease
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O
<EOS>	B-X
The	B-X
hypothesis	B-X
that	B-X
SWS	B-X
and	B-X
SJS	B-X
type	B-X
2	B-X
are	B-X
the	B-X
same	B-X
disorder	B-X
should	B-X
be	B-X
testable	B-X
by	B-X
molecular	B-X
methods	B-X
<EOS>	B-X
Schwartz	B-X
-	B-X
Jampel	B-X
syndrome	B-X
type	B-X
2	B-X
and	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
:	B-X
a	B-X
case	B-X
for	B-X
``	B-X
lumping	B-X
''	B-X
.	B-X
<EOS>	B-X
This	B-X
disorder	B-X
is	B-X
reminiscent	B-X
of	B-X
another	B-X
rare	B-X
condition	B-X
,	B-X
the	B-X
StÃ¼ve	B-X
-	B-X
Wiedemann	B-X
syndrome	B-X
(	B-X
SWS	B-X
)	B-X
,	B-X
which	B-X
comprises	B-X
campomelia	B-X
at	B-X
birth	B-X
with	B-X
skeletal	B-X
dysplasia	B-X
,	B-X
contractures	B-X
,	B-X
and	B-X
early	B-X
death	B-X
<EOS>	B-X
The	B-X
follow	B-X
-	B-X
up	B-X
observation	B-X
of	B-X
an	B-X
identical	B-X
and	B-X
unique	B-X
pattern	B-X
of	B-X
progressive	B-X
bone	B-X
dysplasia	B-X
in	B-X
the	B-X
two	B-X
patients	B-X
(	B-X
one	B-X
with	B-X
SJS	B-X
type	B-X
2	B-X
,	B-X
one	B-X
with	B-X
SWS	B-X
)	B-X
surviving	B-X
beyond	B-X
infancy	B-X
adds	B-X
to	B-X
the	B-X
evidence	B-X
in	B-X
favor	B-X
of	B-X
identity	B-X

A	O
mouse	O
model	O
of	O
severe	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B-Disease
.	O
<EOS>	B-X
A	B-X
mouse	B-X
model	B-X
of	B-X
severe	B-X
von	B-X
Willebrand	B-X
disease	B-X
:	B-X
defects	B-X
in	B-X
hemostasis	B-X
and	B-X
thrombosis	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
mice	B-X
very	B-X
closely	B-X
mimic	B-X
severe	B-X
human	B-X
von	B-X
Willebrand	B-X
disease	B-X
and	B-X
will	B-X
be	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
vWf	B-X
in	B-X
normal	B-X
physiology	B-X
and	B-X
in	B-X
disease	B-X
models	B-X
<EOS>	B-X
Neither	B-X
vWf	B-X
nor	B-X
vWf	B-X
propolypeptide	B-X
(	B-X
von	B-X
Willebrand	B-X
antigen	B-X
II	B-X
)	B-X
were	B-X
detectable	B-X
in	B-X
plasma	B-X
,	B-X
platelets	B-X
,	B-X
or	B-X
endothelial	B-X
cells	B-X
of	B-X
the	B-X
homozygous	B-X
mutant	B-X
mice	B-X
<EOS>	B-X
We	B-X
generated	B-X
a	B-X
mouse	B-X
model	B-X
for	B-X
this	B-X
disease	B-X
by	B-X
using	B-X
gene	B-X
targeting	B-X

von	B-Disease
Willebrand	I-Disease
factor	I-Disease
(	I-Disease
vWf	I-Disease
)	I-Disease
deficiency	I-Disease
causes	O
severe	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
in	O
humans	O
.	O
<EOS>	B-X
,	B-X
VWF	B-X
inhibitors	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
von	B-X
Willebrand	B-X
disease	B-X
(	B-X
VWD	B-X
)	B-X
<EOS>	B-X
It	B-X
is	B-X
especially	B-X
related	B-X
to	B-X
a	B-X
severe	B-X
deficiency	B-X
of	B-X
ADAMTS13	B-X
,	B-X
the	B-X
specific	B-X
von	B-X
Willebrand	B-X
factor	B-X
-	B-X
cleaving	B-X
protease	B-X
<EOS>	B-X
Correction	B-X
of	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
deficiency	B-X
with	B-X
replacement	B-X
products	B-X
containing	B-X
VWF	B-X
can	B-X
lead	B-X
to	B-X
the	B-X
development	B-X
of	B-X
anti	B-X
-	B-X
VWF	B-X
alloantibodies	B-X
(	B-X
i	B-X
<EOS>	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
forms	B-X
high	B-X
-	B-X
molecular	B-X
-	B-X
weight	B-X
multimers	B-X
and	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
hemostasis	B-X
,	B-X
and	B-X
thus	B-X
its	B-X
deficiency	B-X
leads	B-X
to	B-X
bleeding	B-X
symptoms	B-X

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O
<EOS>	B-X
We	B-X
generated	B-X
and	B-X
validated	B-X
the	B-X
function	B-X
of	B-X
an	B-X
autosomal	B-X
<EOS>	B-X
To	B-X
generate	B-X
robust	B-X
HD	B-X
-	B-X
like	B-X
symptoms	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
,	B-X
the	B-X
neomycin	B-X
resistance	B-X
cassette	B-X
was	B-X
excised	B-X
from	B-X
zQ175	B-X
mice	B-X
,	B-X
generating	B-X
a	B-X
new	B-X
line	B-X
:	B-X
zQ175	B-X
<EOS>	B-X
Pluripotent	B-X
stem	B-X
cells	B-X
(	B-X
PSCs	B-X
)	B-X
hold	B-X
great	B-X
promise	B-X
for	B-X
cell	B-X
-	B-X
based	B-X
therapies	B-X
,	B-X
disease	B-X
modeling	B-X
,	B-X
and	B-X
drug	B-X
discovery	B-X
<EOS>	B-X
We	B-X
tested	B-X
this	B-X
signature	B-X
among	B-X
others	B-X

vWf	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O
<EOS>	B-X
vWf	B-X
-	B-X
deficient	B-X
mice	B-X
appeared	B-X
normal	B-X
at	B-X
birth	B-X
;	B-X
they	B-X
were	B-X
viable	B-X
and	B-X
fertile	B-X
<EOS>	B-X
As	B-X
in	B-X
the	B-X
human	B-X
disease	B-X
,	B-X
the	B-X
factor	B-X
VIII	B-X
level	B-X
in	B-X
these	B-X
mice	B-X
was	B-X
reduced	B-X
strongly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
lack	B-X
of	B-X
protection	B-X
provided	B-X
by	B-X
vWf	B-X
<EOS>	B-X
We	B-X
generated	B-X
a	B-X
mouse	B-X
model	B-X
for	B-X
this	B-X
disease	B-X
by	B-X
using	B-X
gene	B-X
targeting	B-X
<EOS>	B-X
Neither	B-X
vWf	B-X
nor	B-X
vWf	B-X
propolypeptide	B-X
(	B-X
von	B-X
Willebrand	B-X
antigen	B-X
II	B-X
)	B-X
were	B-X
detectable	B-X
in	B-X
plasma	B-X
,	B-X
platelets	B-X
,	B-X
or	B-X
endothelial	B-X
cells	B-X
of	B-X
the	B-X
homozygous	B-X
mutant	B-X
mice	B-X

Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B-Disease
Willebrand	I-Disease
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O
<EOS>	B-X
In	B-X
the	B-X
case	B-X
of	B-X
organ	B-X
transplantation	B-X
accompanied	B-X
by	B-X
vascular	B-X
anastomosis	B-X
,	B-X
major	B-X
histocompatibility	B-X
complex	B-X
mismatched	B-X
vascular	B-X
endothelial	B-X
cells	B-X
become	B-X
a	B-X
target	B-X
for	B-X
graft	B-X
rejection	B-X
<EOS>	B-X
To	B-X
generate	B-X
pluripotent	B-X
stem	B-X
cell	B-X
(	B-X
PSC	B-X
)	B-X
	B-X
-	B-X
derived	B-X
vascular	B-X
endothelial	B-X
cells	B-X
,	B-X
we	B-X
performed	B-X
blastocyst	B-X
complementation	B-X
with	B-X
a	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
-	B-X
2	B-X
homozygous	B-X
mutant	B-X
blastocyst	B-X
<EOS>	B-X
As	B-X
such	B-X
,	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
epithelial	B-X
cells	B-X
relies	B-X
heavily	B-X
on	B-X
the	B-X
spatiotemporal	B-X
recruitment	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
embryonic	B-X
pancreas	B-X
<EOS>	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
imply	B-X
a	B-X
role	B-X
for	B-X
FAK	B-X
in	B-X
controlling	B-X
the	B-X
timing	B-X
of	B-X
pancreatic	B-X
lineage	B-X
commitment	B-X
and	B-X
/	B-X
or	B-X
differentiation	B-X
in	B-X
the	B-X
embryonic	B-X
pancreas	B-X
by	B-X
preventing	B-X
endothelial	B-X
recruitment	B-X
to	B-X
the	B-X
embryonic	B-X
pancreatic	B-X
epithelium	B-X

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O
neonates	O
.	O
<EOS>	B-X
The	B-X
mutant	B-X
mice	B-X
exhibited	B-X
defects	B-X
in	B-X
hemostasis	B-X
with	B-X
a	B-X
highly	B-X
prolonged	B-X
bleeding	B-X
time	B-X
and	B-X
spontaneous	B-X
bleeding	B-X
events	B-X
in	B-X
approximately	B-X
10	B-X
%	B-X
of	B-X
neonates	B-X
<EOS>	B-X
In	B-X
this	B-X
model	B-X
,	B-X
the	B-X
exteriorized	B-X
mesentery	B-X
was	B-X
superfused	B-X
with	B-X
ferric	B-X
chloride	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
fluorescently	B-X
labeled	B-X
platelets	B-X
was	B-X
observed	B-X
by	B-X
intravital	B-X
microscopy	B-X
<EOS>	B-X
Defective	B-X
thrombosis	B-X
in	B-X
mutant	B-X
mice	B-X
was	B-X
also	B-X
evident	B-X
in	B-X
an	B-X
in	B-X
vivo	B-X
model	B-X
of	B-X
vascular	B-X
injury	B-X
<EOS>	B-X
A	B-X
mouse	B-X
model	B-X
of	B-X
severe	B-X
von	B-X
Willebrand	B-X
disease	B-X
:	B-X
defects	B-X
in	B-X
hemostasis	B-X
and	B-X
thrombosis	B-X
.	B-X

As	O
in	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf	O
.	O
<EOS>	B-X
As	B-X
in	B-X
the	B-X
human	B-X
disease	B-X
,	B-X
the	B-X
factor	B-X
VIII	B-X
level	B-X
in	B-X
these	B-X
mice	B-X
was	B-X
reduced	B-X
strongly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
lack	B-X
of	B-X
protection	B-X
provided	B-X
by	B-X
vWf	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
mice	B-X
very	B-X
closely	B-X
mimic	B-X
severe	B-X
human	B-X
von	B-X
Willebrand	B-X
disease	B-X
and	B-X
will	B-X
be	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
role	B-X
of	B-X
vWf	B-X
in	B-X
normal	B-X
physiology	B-X
and	B-X
in	B-X
disease	B-X
models	B-X
<EOS>	B-X
Defective	B-X
thrombosis	B-X
in	B-X
mutant	B-X
mice	B-X
was	B-X
also	B-X
evident	B-X
in	B-X
an	B-X
in	B-X
vivo	B-X
model	B-X
of	B-X
vascular	B-X
injury	B-X
<EOS>	B-X
In	B-X
this	B-X
model	B-X
,	B-X
the	B-X
exteriorized	B-X
mesentery	B-X
was	B-X
superfused	B-X
with	B-X
ferric	B-X
chloride	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
fluorescently	B-X
labeled	B-X
platelets	B-X
was	B-X
observed	B-X
by	B-X
intravital	B-X
microscopy	B-X

Defective	O
thrombosis	B-Disease
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B-Disease
injury	I-Disease
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O
<EOS>	B-X
In	B-X
this	B-X
model	B-X
,	B-X
the	B-X
exteriorized	B-X
mesentery	B-X
was	B-X
superfused	B-X
with	B-X
ferric	B-X
chloride	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
fluorescently	B-X
labeled	B-X
platelets	B-X
was	B-X
observed	B-X
by	B-X
intravital	B-X
microscopy	B-X
<EOS>	B-X
The	B-X
mutant	B-X
mice	B-X
exhibited	B-X
defects	B-X
in	B-X
hemostasis	B-X
with	B-X
a	B-X
highly	B-X
prolonged	B-X
bleeding	B-X
time	B-X
and	B-X
spontaneous	B-X
bleeding	B-X
events	B-X
in	B-X
approximately	B-X
10	B-X
%	B-X
of	B-X
neonates	B-X
<EOS>	B-X
As	B-X
in	B-X
the	B-X
human	B-X
disease	B-X
,	B-X
the	B-X
factor	B-X
VIII	B-X
level	B-X
in	B-X
these	B-X
mice	B-X
was	B-X
reduced	B-X
strongly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
lack	B-X
of	B-X
protection	B-X
provided	B-X
by	B-X
vWf	B-X
<EOS>	B-X
A	B-X
mouse	B-X
model	B-X
of	B-X
severe	B-X
von	B-X
Willebrand	B-X
disease	B-X
:	B-X
defects	B-X
in	B-X
hemostasis	B-X
and	B-X
thrombosis	B-X
.	B-X

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B-Disease
Willebrand	I-Disease
disease	I-Disease
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
.	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Beyond	B-X
the	B-X
pill	B-X
:	B-X
contraception	B-X
and	B-X
the	B-X
prevention	B-X
of	B-X
hereditary	B-X
ovarian	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Timing	B-X
of	B-X
oral	B-X
contraceptive	B-X
use	B-X
and	B-X
the	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
BRCA1	B-X
mutation	B-X
carriers	B-X
.	B-X
<EOS>	B-X
Contraception	B-X
options	B-X
for	B-X
patients	B-X
with	B-X
known	B-X
hereditary	B-X
risk	B-X
for	B-X
ovarian	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Oral	B-X
contraceptive	B-X
use	B-X
in	B-X
women	B-X
at	B-X
increased	B-X
risk	B-X
of	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
:	B-X
knowledge	B-X
and	B-X
attitudes	B-X
.	B-X

Hereditary	B-Disease
Ovarian	I-Disease
Cancer	I-Disease
Clinical	O
Study	O
Group	O
.	O
<EOS>	B-X
Identifying	B-X
Sequence	B-X
Variants	B-X
of	B-X
18	B-X
Hereditary	B-X
Ovarian	B-X
Cancer	B-X
-	B-X
Associated	B-X
Genes	B-X
in	B-X
Chinese	B-X
Epithelial	B-X
Ovarian	B-X
Cancer	B-X
Patients	B-X
.	B-X
<EOS>	B-X
Contraceptive	B-X
use	B-X
and	B-X
the	B-X
risk	B-X
of	B-X
ovarian	B-X
cancer	B-X
among	B-X
women	B-X
with	B-X
a	B-X
BRCA1	B-X
or	B-X
BRCA2	B-X
mutation	B-X
.	B-X
<EOS>	B-X
At	B-X
a	B-X
prespecified	B-X
event	B-X
-	B-X
driven	B-X
interim	B-X
analysis	B-X
with	B-X
a	B-X
median	B-X
follow	B-X
-	B-X
up	B-X
of	B-X
2	B-X
<EOS>	B-X
The	B-X
annual	B-X
risk	B-X
for	B-X
ovarian	B-X
or	B-X
fallopian	B-X
tube	B-X
cancer	B-X
was	B-X
0	B-X

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Germline	B-X
pathogenic	B-X
variants	B-X
mutations	B-X
)	B-X
in	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
genes	B-X
cause	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
and	B-X
ovarian	B-X
cancer	B-X
<EOS>	B-X
PGV	B-X
rates	B-X
were	B-X
significantly	B-X
higher	B-X
among	B-X
15	B-X
patients	B-X
with	B-X
a	B-X
positive	B-X
family	B-X
history	B-X
of	B-X
ovarian	B-X
cancer	B-X
(	B-X
60	B-X
<EOS>	B-X
Ethnically	B-X
distinct	B-X
mutations	B-X
in	B-X
gBRCA1	B-X
/	B-X
2	B-X
genes	B-X
were	B-X
noted	B-X
,	B-X
with	B-X
higher	B-X
frequencies	B-X
of	B-X
Val1833Ser	B-X
(	B-X
14	B-X
<EOS>	B-X
Patients	B-X
with	B-X
pathogenic	B-X
and	B-X
likely	B-X
-	B-X
pathogenic	B-X
germline	B-X
variants	B-X
(	B-X
PGVs	B-X
)	B-X
in	B-X
BRCA1	B-X
or	B-X
BRCA2	B-X
harbor	B-X
elevated	B-X
risk	B-X
of	B-X
developing	B-X
both	B-X
ovarian	B-X
and	B-X
breast	B-X
cancers	B-X

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B-Disease
cancer	I-Disease
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B-Disease
forms	I-Disease
of	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Oral	B-X
contraceptives	B-X
protect	B-X
against	B-X
ovarian	B-X
cancer	B-X
in	B-X
general	B-X
,	B-X
but	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
they	B-X
protect	B-X
against	B-X
the	B-X
disease	B-X
in	B-X
carriers	B-X
of	B-X
these	B-X
mutations	B-X
<EOS>	B-X
Oral	B-X
contraceptive	B-X
use	B-X
and	B-X
ovarian	B-X
cancer	B-X
risk	B-X
among	B-X
carriers	B-X
of	B-X
BRCA1	B-X
or	B-X
BRCA2	B-X
mutations	B-X
.	B-X
<EOS>	B-X
81	B-X
%	B-X
were	B-X
unaware	B-X
of	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
OCs	B-X
against	B-X
uterine	B-X
cancer	B-X
and	B-X
77	B-X
%	B-X
did	B-X
not	B-X
know	B-X
they	B-X
have	B-X
a	B-X
protective	B-X
effect	B-X
against	B-X
ovarian	B-X
cancer	B-X
<EOS>	B-X
Since	B-X
OCs	B-X
shorten	B-X
the	B-X
menstrual	B-X
period	B-X
and	B-X
amount	B-X
of	B-X
blood	B-X
loss	B-X
,	B-X
they	B-X
protect	B-X
against	B-X
iron	B-X
-	B-X
deficiency	B-X
anemia	B-X

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O
)	O
.	O
<EOS>	B-X
Of	B-X
the	B-X
240	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
60	B-X
carried	B-X
a	B-X
BRCA	B-X
mutation	B-X
(	B-X
43	B-X
patients	B-X
(	B-X
72	B-X
%	B-X
)	B-X
with	B-X
a	B-X
BRCA1	B-X
mutation	B-X
and	B-X
17	B-X
patients	B-X
(	B-X
28	B-X
%	B-X
)	B-X
with	B-X
a	B-X
BRCA2	B-X
mutation	B-X
)	B-X
<EOS>	B-X
Identification	B-X
and	B-X
Management	B-X
of	B-X
Pathogenic	B-X
Variants	B-X
in	B-X
BRCA1	B-X
,	B-X
BRCA2	B-X
,	B-X
and	B-X
PALB2	B-X
in	B-X
a	B-X
Tumor	B-X
-	B-X
Only	B-X
Genomic	B-X
Testing	B-X
Program	B-X
.	B-X
<EOS>	B-X
7	B-X
%	B-X
)	B-X
patients	B-X
received	B-X
a	B-X
platinum	B-X
-	B-X
containing	B-X
chemotherapy	B-X
regimen	B-X
<EOS>	B-X
Overall	B-X
,	B-X
patients	B-X
with	B-X
deleterious	B-X
gBRCA1	B-X
/	B-X
2	B-X
mutation	B-X
have	B-X
significantly	B-X
higher	B-X
pCR	B-X
rate	B-X
than	B-X
non	B-X
-	B-X
carrier	B-X
patients	B-X
(	B-X
23	B-X
[	B-X
59	B-X
%	B-X
]	B-X
of	B-X
39	B-X
vs	B-X

The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation	O
.	O
<EOS>	B-X
The	B-X
whole	B-X
exome	B-X
sequencing	B-X
confirmed	B-X
a	B-X
heterozygous	B-X
missense	B-X
mutation	B-X
c	B-X
<EOS>	B-X
The	B-X
difference	B-X
in	B-X
target	B-X
height	B-X
to	B-X
final	B-X
height	B-X
ranged	B-X
between	B-X
1	B-X
<EOS>	B-X
The	B-X
patient	B-X
was	B-X
an	B-X
8	B-X
-	B-X
year	B-X
-	B-X
old	B-X
girl	B-X
with	B-X
normal	B-X
growth	B-X
and	B-X
development	B-X
<EOS>	B-X
Vaccinated	B-X
samples	B-X
were	B-X
collected	B-X
prior	B-X
to	B-X
the	B-X
first	B-X
dose	B-X
,	B-X
one	B-X
week	B-X
after	B-X
the	B-X
first	B-X
dose	B-X
,	B-X
one	B-X
week	B-X
after	B-X
the	B-X
second	B-X
dose	B-X
,	B-X
and	B-X
monthly	B-X
thereafter	B-X

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O
<EOS>	B-X
Lifetime	B-X
histories	B-X
of	B-X
oral	B-X
-	B-X
contraceptive	B-X
use	B-X
were	B-X
obtained	B-X
by	B-X
interview	B-X
or	B-X
by	B-X
written	B-X
questionnaire	B-X
and	B-X
were	B-X
compared	B-X
between	B-X
patients	B-X
and	B-X
control	B-X
women	B-X
,	B-X
after	B-X
adjustment	B-X
for	B-X
year	B-X
of	B-X
birth	B-X
and	B-X
parity	B-X
<EOS>	B-X
Further	B-X
,	B-X
if	B-X
oral	B-X
contraceptive	B-X
users	B-X
continue	B-X
to	B-X
be	B-X
regularly	B-X
screened	B-X
,	B-X
their	B-X
risk	B-X
of	B-X
developing	B-X
the	B-X
more	B-X
invasive	B-X
lesions	B-X
should	B-X
be	B-X
very	B-X
low	B-X
<EOS>	B-X
Women	B-X
who	B-X
reported	B-X
oral	B-X
contraceptive	B-X
use	B-X
within	B-X
6	B-X
months	B-X
before	B-X
disease	B-X
onset	B-X
were	B-X
at	B-X
increased	B-X
risk	B-X
for	B-X
both	B-X
diseases	B-X
compared	B-X
with	B-X
never	B-X
users	B-X
(	B-X
relative	B-X
risk	B-X
(	B-X
RR	B-X
)	B-X
of	B-X
ulcerative	B-X
colitis	B-X
=	B-X
2	B-X
<EOS>	B-X
The	B-X
contraceptive	B-X
and	B-X
reproductive	B-X
histories	B-X
in	B-X
972	B-X
women	B-X
seeking	B-X
contraceptive	B-X
advice	B-X
were	B-X
noted	B-X
and	B-X
screening	B-X
conducted	B-X
for	B-X
human	B-X
papillomavirus	B-X
infection	B-X

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B-Disease
cancer	I-Disease
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O

5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
8	O
)	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
.	O
<EOS>	B-X
For	B-X
the	B-X
treatment	B-X
groups	B-X
with	B-X
significant	B-X
mortality	B-X
risk	B-X
reduction	B-X
,	B-X
the	B-X
percent	B-X
of	B-X
mortality	B-X
reduction	B-X
mediated	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
bone	B-X
loss	B-X
was	B-X
estimated	B-X
using	B-X
a	B-X
causal	B-X
mediation	B-X
analysis	B-X
<EOS>	B-X
Hypertension	B-X
and	B-X
frequent	B-X
UTI	B-X
were	B-X
observed	B-X
to	B-X
be	B-X
strongly	B-X
associated	B-X
with	B-X
progression	B-X
of	B-X
CKD	B-X
<EOS>	B-X
Bisphosphonates	B-X
,	B-X
potent	B-X
antiresorptive	B-X
agents	B-X
,	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
mortality	B-X
reduction	B-X
<EOS>	B-X
A	B-X
pain	B-X
score	B-X
that	B-X
exhibits	B-X
no	B-X
or	B-X
minimal	B-X
change	B-X
from	B-X
2	B-X
to	B-X
4	B-X
weeks	B-X
after	B-X
nonoperative	B-X
treatment	B-X
of	B-X
a	B-X
displaced	B-X
midshaft	B-X
fracture	B-X
of	B-X
the	B-X
clavicle	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
high	B-X
risk	B-X
that	B-X
symptomatic	B-X
nonunion	B-X
will	B-X
develop	B-X

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B-Disease
cancer	I-Disease
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
.	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B-Disease
cancer	I-Disease
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
gene	O
<EOS>	B-X
Germline	B-X
mutations	B-X
in	B-X
cancer	B-X
susceptibility	B-X
genes	B-X
were	B-X
identified	B-X
in	B-X
pancreatic	B-X
cancer	B-X
(	B-X
PanC	B-X
)	B-X
patients	B-X
with	B-X
a	B-X
sporadic	B-X
disease	B-X
and	B-X
in	B-X
those	B-X
unselected	B-X
for	B-X
family	B-X
cancer	B-X
history	B-X
<EOS>	B-X
Five	B-X
patients	B-X
carried	B-X
more	B-X
than	B-X
one	B-X
variant	B-X
in	B-X
the	B-X
same	B-X
gene	B-X
or	B-X
in	B-X
different	B-X
genes	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
large	B-X
,	B-X
real	B-X
-	B-X
world	B-X
cohort	B-X
to	B-X
comprehensively	B-X
investigate	B-X
the	B-X
incidence	B-X
of	B-X
genetic	B-X
alterations	B-X
with	B-X
potential	B-X
therapeutic	B-X
implications	B-X
at	B-X
all	B-X
stages	B-X
of	B-X
bladder	B-X
cancer	B-X
<EOS>	B-X
We	B-X
identified	B-X
a	B-X
low	B-X
rate	B-X
of	B-X
incidental	B-X
germline	B-X
mutations	B-X
in	B-X
all	B-X
tumors	B-X
(	B-X
5	B-X

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B-Disease
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O
<EOS>	B-X
A	B-X
Japanese	B-X
family	B-X
with	B-X
adrenoleukodystrophy	B-X
with	B-X
a	B-X
codon	B-X
291	B-X
deletion	B-X
:	B-X
a	B-X
clinical	B-X
,	B-X
biochemical	B-X
,	B-X
pathological	B-X
,	B-X
and	B-X
genetic	B-X
report	B-X
.	B-X
<EOS>	B-X
We	B-X
report	B-X
a	B-X
Japanese	B-X
family	B-X
with	B-X
adrenoleukodystrophy	B-X
(	B-X
ALD	B-X
)	B-X
with	B-X
a	B-X
three	B-X
base	B-X
pair	B-X
deletion	B-X
(	B-X
delGAG	B-X
291	B-X
)	B-X
in	B-X
the	B-X
ALD	B-X
gene	B-X
<EOS>	B-X
In	B-X
patients	B-X
2	B-X
and	B-X
3	B-X
,	B-X
the	B-X
autopsy	B-X
findings	B-X
showed	B-X
massive	B-X
demyelination	B-X
of	B-X
the	B-X
cerebral	B-X
white	B-X
matter	B-X
with	B-X
sparing	B-X
of	B-X
the	B-X
U	B-X
-	B-X
fibers	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
findings	B-X
of	B-X
childhood	B-X
ALD	B-X
<EOS>	B-X
Another	B-X
nephew	B-X
(	B-X
patient	B-X
4	B-X
)	B-X
of	B-X
patient	B-X
1	B-X
was	B-X
classified	B-X
as	B-X
having	B-X
an	B-X
adolescent	B-X
form	B-X

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B-Disease
gene	O
.	O
<EOS>	B-X
We	B-X
report	B-X
a	B-X
Japanese	B-X
family	B-X
with	B-X
adrenoleukodystrophy	B-X
(	B-X
ALD	B-X
)	B-X
with	B-X
a	B-X
three	B-X
base	B-X
pair	B-X
deletion	B-X
(	B-X
delGAG	B-X
291	B-X
)	B-X
in	B-X
the	B-X
ALD	B-X
gene	B-X
<EOS>	B-X
A	B-X
Japanese	B-X
family	B-X
with	B-X
adrenoleukodystrophy	B-X
with	B-X
a	B-X
codon	B-X
291	B-X
deletion	B-X
:	B-X
a	B-X
clinical	B-X
,	B-X
biochemical	B-X
,	B-X
pathological	B-X
,	B-X
and	B-X
genetic	B-X
report	B-X
.	B-X
<EOS>	B-X
While	B-X
the	B-X
proband	B-X
(	B-X
patient	B-X
1	B-X
)	B-X
was	B-X
classified	B-X
as	B-X
having	B-X
a	B-X
rare	B-X
intermediate	B-X
type	B-X
of	B-X
adult	B-X
cerebral	B-X
and	B-X
cerebello	B-X
-	B-X
brain	B-X
stem	B-X
forms	B-X
,	B-X
his	B-X
younger	B-X
brother	B-X
(	B-X
patient	B-X
2	B-X
)	B-X
and	B-X
nephew	B-X
(	B-X
patient	B-X
3	B-X
)	B-X
had	B-X
a	B-X
childhood	B-X
ALD	B-X
type	B-X
<EOS>	B-X
In	B-X
patients	B-X
2	B-X
and	B-X
3	B-X
,	B-X
the	B-X
autopsy	B-X
findings	B-X
showed	B-X
massive	B-X
demyelination	B-X
of	B-X
the	B-X
cerebral	B-X
white	B-X
matter	B-X
with	B-X
sparing	B-X
of	B-X
the	B-X
U	B-X
-	B-X
fibers	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
findings	B-X
of	B-X
childhood	B-X
ALD	B-X

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	B-Disease
type	O
.	O
<EOS>	B-X
While	B-X
the	B-X
proband	B-X
(	B-X
patient	B-X
1	B-X
)	B-X
was	B-X
classified	B-X
as	B-X
having	B-X
a	B-X
rare	B-X
intermediate	B-X
type	B-X
of	B-X
adult	B-X
cerebral	B-X
and	B-X
cerebello	B-X
-	B-X
brain	B-X
stem	B-X
forms	B-X
,	B-X
his	B-X
younger	B-X
brother	B-X
(	B-X
patient	B-X
2	B-X
)	B-X
and	B-X
nephew	B-X
(	B-X
patient	B-X
3	B-X
)	B-X
had	B-X
a	B-X
childhood	B-X
ALD	B-X
type	B-X
<EOS>	B-X
In	B-X
patients	B-X
2	B-X
and	B-X
3	B-X
,	B-X
the	B-X
autopsy	B-X
findings	B-X
showed	B-X
massive	B-X
demyelination	B-X
of	B-X
the	B-X
cerebral	B-X
white	B-X
matter	B-X
with	B-X
sparing	B-X
of	B-X
the	B-X
U	B-X
-	B-X
fibers	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
findings	B-X
of	B-X
childhood	B-X
ALD	B-X
<EOS>	B-X
We	B-X
report	B-X
a	B-X
Japanese	B-X
family	B-X
with	B-X
adrenoleukodystrophy	B-X
(	B-X
ALD	B-X
)	B-X
with	B-X
a	B-X
three	B-X
base	B-X
pair	B-X
deletion	B-X
(	B-X
delGAG	B-X
291	B-X
)	B-X
in	B-X
the	B-X
ALD	B-X
gene	B-X
<EOS>	B-X
The	B-X
tau	B-X
level	B-X
in	B-X
the	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
in	B-X
patient	B-X
1	B-X
was	B-X
as	B-X
high	B-X
as	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O
<EOS>	B-X
Another	B-X
nephew	B-X
(	B-X
patient	B-X
4	B-X
)	B-X
of	B-X
patient	B-X
1	B-X
was	B-X
classified	B-X
as	B-X
having	B-X
an	B-X
adolescent	B-X
form	B-X
<EOS>	B-X
The	B-X
tau	B-X
level	B-X
in	B-X
the	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
in	B-X
patient	B-X
1	B-X
was	B-X
as	B-X
high	B-X
as	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
<EOS>	B-X
Outcomes	B-X
and	B-X
Return	B-X
to	B-X
Sport	B-X
After	B-X
Revision	B-X
Anterior	B-X
Cruciate	B-X
Ligament	B-X
Reconstruction	B-X
in	B-X
Adolescent	B-X
Athletes	B-X
.	B-X
<EOS>	B-X
4	B-X
%	B-X
of	B-X
patients	B-X
participated	B-X
in	B-X
collision	B-X
sports	B-X

The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B-Disease
in	I-Disease
the	I-Disease
bilateral	I-Disease
cerebellar	I-Disease
hemispheres	I-Disease
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

In	O
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B-Disease
of	I-Disease
the	I-Disease
cerebral	I-Disease
white	I-Disease
matter	I-Disease
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	B-Disease
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B-Disease
with	O
phenotypic	O
variations	O
.	O
<EOS>	B-X
The	B-X
findings	B-X
in	B-X
this	B-X
family	B-X
suggest	B-X
that	B-X
delGAG291	B-X
is	B-X
part	B-X
of	B-X
the	B-X
cause	B-X
of	B-X
Japanese	B-X
ALD	B-X
with	B-X
phenotypic	B-X
variations	B-X
<EOS>	B-X
In	B-X
patients	B-X
2	B-X
and	B-X
3	B-X
,	B-X
the	B-X
autopsy	B-X
findings	B-X
showed	B-X
massive	B-X
demyelination	B-X
of	B-X
the	B-X
cerebral	B-X
white	B-X
matter	B-X
with	B-X
sparing	B-X
of	B-X
the	B-X
U	B-X
-	B-X
fibers	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
findings	B-X
of	B-X
childhood	B-X
ALD	B-X
<EOS>	B-X
The	B-X
tau	B-X
level	B-X
in	B-X
the	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
in	B-X
patient	B-X
1	B-X
was	B-X
as	B-X
high	B-X
as	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
<EOS>	B-X
While	B-X
the	B-X
proband	B-X
(	B-X
patient	B-X
1	B-X
)	B-X
was	B-X
classified	B-X
as	B-X
having	B-X
a	B-X
rare	B-X
intermediate	B-X
type	B-X
of	B-X
adult	B-X
cerebral	B-X
and	B-X
cerebello	B-X
-	B-X
brain	B-X
stem	B-X
forms	B-X
,	B-X
his	B-X
younger	B-X
brother	B-X
(	B-X
patient	B-X
2	B-X
)	B-X
and	B-X
nephew	B-X
(	B-X
patient	B-X
3	B-X
)	B-X
had	B-X
a	B-X
childhood	B-X
ALD	B-X
type	B-X

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	B-Disease
lesion	I-Disease
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B-Disease
degeneration	I-Disease
in	O
ALD	B-Disease
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
although	B-X
the	B-X
scale	B-X
of	B-X
the	B-X
study	B-X
is	B-X
limited	B-X
,	B-X
there	B-X
is	B-X
a	B-X
possibility	B-X
that	B-X
PET	B-X
can	B-X
detect	B-X
an	B-X
insidious	B-X
lesion	B-X
which	B-X
is	B-X
undetectable	B-X
by	B-X
computed	B-X
tomogram	B-X
(	B-X
CT	B-X
)	B-X
or	B-X
MRI	B-X
analysis	B-X
,	B-X
and	B-X
that	B-X
the	B-X
higher	B-X
level	B-X
of	B-X
tau	B-X
reflects	B-X
the	B-X
process	B-X
of	B-X
neuronal	B-X
degeneration	B-X
in	B-X
ALD	B-X
<EOS>	B-X
In	B-X
patients	B-X
2	B-X
and	B-X
3	B-X
,	B-X
the	B-X
autopsy	B-X
findings	B-X
showed	B-X
massive	B-X
demyelination	B-X
of	B-X
the	B-X
cerebral	B-X
white	B-X
matter	B-X
with	B-X
sparing	B-X
of	B-X
the	B-X
U	B-X
-	B-X
fibers	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
findings	B-X
of	B-X
childhood	B-X
ALD	B-X
<EOS>	B-X
While	B-X
the	B-X
proband	B-X
(	B-X
patient	B-X
1	B-X
)	B-X
was	B-X
classified	B-X
as	B-X
having	B-X
a	B-X
rare	B-X
intermediate	B-X
type	B-X
of	B-X
adult	B-X
cerebral	B-X
and	B-X
cerebello	B-X
-	B-X
brain	B-X
stem	B-X
forms	B-X
,	B-X
his	B-X
younger	B-X
brother	B-X
(	B-X
patient	B-X
2	B-X
)	B-X
and	B-X
nephew	B-X
(	B-X
patient	B-X
3	B-X
)	B-X
had	B-X
a	B-X
childhood	B-X
ALD	B-X
type	B-X
<EOS>	B-X
The	B-X
tau	B-X
level	B-X
in	B-X
the	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
in	B-X
patient	B-X
1	B-X
was	B-X
as	B-X
high	B-X
as	B-X
that	B-X
of	B-X
patients	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
.	O
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B-Disease
C9	I-Disease
deficiency	I-Disease
.	O
<EOS>	B-X
Nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
of	B-X
human	B-X
complement	B-X
C9	B-X
gene	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
Japanese	B-X
complement	B-X
C9	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
The	B-X
common	B-X
mutation	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
might	B-X
be	B-X
responsible	B-X
for	B-X
most	B-X
Japanese	B-X
C9	B-X
deficiency	B-X
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
ninth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C9	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
complement	B-X
deficiency	B-X
in	B-X
Japan	B-X
but	B-X
is	B-X
rare	B-X
in	B-X
other	B-X
countries	B-X
<EOS>	B-X
Direct	B-X
sequencing	B-X
of	B-X
amplified	B-X
C9	B-X
cDNA	B-X
and	B-X
DNA	B-X
revealed	B-X
a	B-X
nonsense	B-X
substitution	B-X
(	B-X
CGA	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
TGA	B-X
)	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
in	B-X
the	B-X
four	B-X
C9	B-X
-	B-X
deficient	B-X
individuals	B-X

Deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	I-Disease
in	O
Japan	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
ninth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C9	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
complement	B-X
deficiency	B-X
in	B-X
Japan	B-X
but	B-X
is	B-X
rare	B-X
in	B-X
other	B-X
countries	B-X
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
ninth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C9	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
complement	B-X
deficiency	B-X
in	B-X
Japan	B-X
,	B-X
with	B-X
an	B-X
incidence	B-X
of	B-X
approximately	B-X
one	B-X
homozygote	B-X
in	B-X
1000	B-X
,	B-X
but	B-X
is	B-X
very	B-X
rare	B-X
in	B-X
other	B-X
countries	B-X
<EOS>	B-X
Nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
of	B-X
human	B-X
complement	B-X
C9	B-X
gene	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
Japanese	B-X
complement	B-X
C9	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
The	B-X
common	B-X
mutation	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
might	B-X
be	B-X
responsible	B-X
for	B-X
most	B-X
Japanese	B-X
C9	B-X
deficiency	B-X

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B-Disease
deficiency	I-Disease
in	O
four	O
Japanese	O
C9	B-Disease
-	I-Disease
deficient	I-Disease
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B-Disease
meningitis	I-Disease
.	O
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
C9	B-X
deficiency	B-X
in	B-X
four	B-X
Japanese	B-X
C9	B-X
-	B-X
deficient	B-X
patients	B-X
who	B-X
had	B-X
suffered	B-X
from	B-X
meningococcal	B-X
meningitis	B-X
<EOS>	B-X
Nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
of	B-X
human	B-X
complement	B-X
C9	B-X
gene	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
Japanese	B-X
complement	B-X
C9	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
An	B-X
allele	B-X
-	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
system	B-X
designed	B-X
to	B-X
detect	B-X
exclusively	B-X
only	B-X
one	B-X
of	B-X
the	B-X
normal	B-X
and	B-X
mutant	B-X
alleles	B-X
indicated	B-X
that	B-X
all	B-X
the	B-X
four	B-X
patients	B-X
were	B-X
homozygous	B-X
for	B-X
the	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
and	B-X
that	B-X
the	B-X
parents	B-X
of	B-X
patient	B-X
2	B-X
were	B-X
heterozygous	B-X
<EOS>	B-X
The	B-X
common	B-X
mutation	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
might	B-X
be	B-X
responsible	B-X
for	B-X
most	B-X
Japanese	B-X
C9	B-X
deficiency	B-X

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9	B-Disease
-	I-Disease
deficient	I-Disease
individuals	O
.	O
<EOS>	B-X
Direct	B-X
sequencing	B-X
of	B-X
amplified	B-X
C9	B-X
cDNA	B-X
and	B-X
DNA	B-X
revealed	B-X
a	B-X
nonsense	B-X
substitution	B-X
(	B-X
CGA	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
TGA	B-X
)	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
in	B-X
the	B-X
four	B-X
C9	B-X
-	B-X
deficient	B-X
individuals	B-X
<EOS>	B-X
Nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
of	B-X
human	B-X
complement	B-X
C9	B-X
gene	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
Japanese	B-X
complement	B-X
C9	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
The	B-X
common	B-X
mutation	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
might	B-X
be	B-X
responsible	B-X
for	B-X
most	B-X
Japanese	B-X
C9	B-X
deficiency	B-X
<EOS>	B-X
An	B-X
allele	B-X
-	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
system	B-X
designed	B-X
to	B-X
detect	B-X
exclusively	B-X
only	B-X
one	B-X
of	B-X
the	B-X
normal	B-X
and	B-X
mutant	B-X
alleles	B-X
indicated	B-X
that	B-X
all	B-X
the	B-X
four	B-X
patients	B-X
were	B-X
homozygous	B-X
for	B-X
the	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
and	B-X
that	B-X
the	B-X
parents	B-X
of	B-X
patient	B-X
2	B-X
were	B-X
heterozygous	B-X

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O
<EOS>	B-X
An	B-X
allele	B-X
-	B-X
specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
system	B-X
designed	B-X
to	B-X
detect	B-X
exclusively	B-X
only	B-X
one	B-X
of	B-X
the	B-X
normal	B-X
and	B-X
mutant	B-X
alleles	B-X
indicated	B-X
that	B-X
all	B-X
the	B-X
four	B-X
patients	B-X
were	B-X
homozygous	B-X
for	B-X
the	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
and	B-X
that	B-X
the	B-X
parents	B-X
of	B-X
patient	B-X
2	B-X
were	B-X
heterozygous	B-X
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
ninth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C9	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
complement	B-X
deficiency	B-X
in	B-X
Japan	B-X
but	B-X
is	B-X
rare	B-X
in	B-X
other	B-X
countries	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
C9	B-X
deficiency	B-X
in	B-X
four	B-X
Japanese	B-X
C9	B-X
-	B-X
deficient	B-X
patients	B-X
who	B-X
had	B-X
suffered	B-X
from	B-X
meningococcal	B-X
meningitis	B-X
<EOS>	B-X
Nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
of	B-X
human	B-X
complement	B-X
C9	B-X
gene	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
Japanese	B-X
complement	B-X
C9	B-X
deficiency	B-X
.	B-X

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B-Disease
deficiency	I-Disease
.	O
.	O
<EOS>	B-X
The	B-X
common	B-X
mutation	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
might	B-X
be	B-X
responsible	B-X
for	B-X
most	B-X
Japanese	B-X
C9	B-X
deficiency	B-X
<EOS>	B-X
Nonsense	B-X
mutation	B-X
in	B-X
exon	B-X
4	B-X
of	B-X
human	B-X
complement	B-X
C9	B-X
gene	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
Japanese	B-X
complement	B-X
C9	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
ninth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C9	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
complement	B-X
deficiency	B-X
in	B-X
Japan	B-X
but	B-X
is	B-X
rare	B-X
in	B-X
other	B-X
countries	B-X
<EOS>	B-X
Direct	B-X
sequencing	B-X
of	B-X
amplified	B-X
C9	B-X
cDNA	B-X
and	B-X
DNA	B-X
revealed	B-X
a	B-X
nonsense	B-X
substitution	B-X
(	B-X
CGA	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
TGA	B-X
)	B-X
at	B-X
codon	B-X
95	B-X
in	B-X
exon	B-X
4	B-X
in	B-X
the	B-X
four	B-X
C9	B-X
-	B-X
deficient	B-X
individuals	B-X

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O
<EOS>	B-X
BRCA1	B-X
required	B-X
for	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
BRCA1	B-X
participates	B-X
,	B-X
directly	B-X
or	B-X
indirectly	B-X
,	B-X
in	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
develop	B-X
a	B-X
human	B-X
genetic	B-X
system	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
BRCA1	B-X
in	B-X
oxidative	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
Instead	B-X
,	B-X
it	B-X
functions	B-X
in	B-X
transcription	B-X
-	B-X
coupled	B-X
DNA	B-X
repair	B-X
(	B-X
TCR	B-X
)	B-X

The	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O
<EOS>	B-X
The	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
susceptibility	B-X
gene	B-X
BRCA1	B-X
encodes	B-X
a	B-X
zinc	B-X
finger	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
<EOS>	B-X
The	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
susceptibility	B-X
gene	B-X
,	B-X
BRCA1	B-X
,	B-X
has	B-X
been	B-X
cloned	B-X
and	B-X
shown	B-X
to	B-X
encode	B-X
a	B-X
zinc	B-X
-	B-X
finger	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
BRCA1	B-X
in	B-X
normal	B-X
tissue	B-X
growth	B-X
and	B-X
differentiation	B-X
,	B-X
and	B-X
to	B-X
generate	B-X
a	B-X
potential	B-X
model	B-X
for	B-X
the	B-X
cancer	B-X
susceptibility	B-X
associated	B-X
with	B-X
loss	B-X
of	B-X
BRCA1	B-X
function	B-X
,	B-X
we	B-X
have	B-X
created	B-X
a	B-X
mouse	B-X
line	B-X
carrying	B-X
a	B-X
mutation	B-X
in	B-X
one	B-X
Brca1	B-X
allele	B-X
<EOS>	B-X
The	B-X
loss	B-X
of	B-X
wild	B-X
-	B-X
type	B-X
BRCA1	B-X
in	B-X
tumours	B-X
of	B-X
individuals	B-X
carrying	B-X
one	B-X
nonfunctional	B-X
BRCA1	B-X
allele	B-X
suggests	B-X
that	B-X
BRCA1	B-X
encodes	B-X
a	B-X
tumour	B-X
suppressor	B-X
that	B-X
may	B-X
inhibit	B-X
the	B-X
proliferation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
in	O
DNA	O
repair	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
BRCA1	B-X
protein	B-X
with	B-X
the	B-X
DNA	B-X
repair	B-X
protein	B-X
Rad51	B-X
and	B-X
changes	B-X
in	B-X
the	B-X
phosphorylation	B-X
and	B-X
cellular	B-X
localization	B-X
of	B-X
the	B-X
protein	B-X
after	B-X
exposure	B-X
to	B-X
DNA	B-X
-	B-X
damaging	B-X
agents	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
BRCA1	B-X
in	B-X
DNA	B-X
repair	B-X
<EOS>	B-X
Here	B-X
,	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
mouse	B-X
embryonic	B-X
stem	B-X
cells	B-X
deficient	B-X
in	B-X
BRCA1	B-X
are	B-X
defective	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
carry	B-X
out	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
are	B-X
hypersensitive	B-X
to	B-X
ionizing	B-X
radiation	B-X
and	B-X
hydrogen	B-X
peroxide	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
BRCA1	B-X
participates	B-X
,	B-X
directly	B-X
or	B-X
indirectly	B-X
,	B-X
in	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
The	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
susceptibility	B-X
gene	B-X
BRCA1	B-X
encodes	B-X
a	B-X
zinc	B-X
finger	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B-Disease
in	I-Disease
BRCA1	I-Disease
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
mouse	B-X
embryonic	B-X
stem	B-X
cells	B-X
deficient	B-X
in	B-X
BRCA1	B-X
are	B-X
defective	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
carry	B-X
out	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
are	B-X
hypersensitive	B-X
to	B-X
ionizing	B-X
radiation	B-X
and	B-X
hydrogen	B-X
peroxide	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
BRCA1	B-X
participates	B-X
,	B-X
directly	B-X
or	B-X
indirectly	B-X
,	B-X
in	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
BRCA1	B-X
required	B-X
for	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
BRCA1	B-X
protein	B-X
with	B-X
the	B-X
DNA	B-X
repair	B-X
protein	B-X
Rad51	B-X
and	B-X
changes	B-X
in	B-X
the	B-X
phosphorylation	B-X
and	B-X
cellular	B-X
localization	B-X
of	B-X
the	B-X
protein	B-X
after	B-X
exposure	B-X
to	B-X
DNA	B-X
-	B-X
damaging	B-X
agents	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
BRCA1	B-X
in	B-X
DNA	B-X
repair	B-X

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
BRCA1	B-X
participates	B-X
,	B-X
directly	B-X
or	B-X
indirectly	B-X
,	B-X
in	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
BRCA1	B-X
required	B-X
for	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
<EOS>	B-X
It	B-X
also	B-X
contributes	B-X
indirectly	B-X
to	B-X
the	B-X
global	B-X
repair	B-X
of	B-X
some	B-X
forms	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
Increasing	B-X
evidence	B-X
suggests	B-X
that	B-X
BRCA1	B-X
regulates	B-X
cell	B-X
cycle	B-X
checkpoints	B-X
and	B-X
DNA	B-X
repair	B-X
after	B-X
DNA	B-X
damage	B-X

Truncation	O
mutations	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O
<EOS>	B-X
Truncation	B-X
mutations	B-X
in	B-X
the	B-X
transactivation	B-X
region	B-X
of	B-X
PAX6	B-X
result	B-X
in	B-X
dominant	B-X
-	B-X
negative	B-X
mutants	B-X
.	B-X
<EOS>	B-X
Heterozygous	B-X
mutations	B-X
in	B-X
the	B-X
human	B-X
PAX6	B-X
gene	B-X
result	B-X
in	B-X
various	B-X
phenotypes	B-X
,	B-X
including	B-X
aniridia	B-X
,	B-X
Peter	B-X
's	B-X
anomaly	B-X
,	B-X
autosomal	B-X
dominant	B-X
keratitis	B-X
,	B-X
and	B-X
familial	B-X
foveal	B-X
dysplasia	B-X
<EOS>	B-X
However	B-X
,	B-X
several	B-X
truncation	B-X
mutations	B-X
have	B-X
been	B-X
found	B-X
to	B-X
occur	B-X
in	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
half	B-X
of	B-X
PAX6	B-X
in	B-X
patients	B-X
with	B-X
Aniridia	B-X
resulting	B-X
in	B-X
mutant	B-X
proteins	B-X
that	B-X
retain	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
domains	B-X
but	B-X
have	B-X
lost	B-X
most	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
this	B-X
theory	B-X
,	B-X
our	B-X
data	B-X
showed	B-X
that	B-X
these	B-X
mutants	B-X
are	B-X
dominant	B-X
-	B-X
negative	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
when	B-X
they	B-X
are	B-X
coexpressed	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
.	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans	O
.	O
<EOS>	B-X
PAX6	B-X
regulates	B-X
eye	B-X
development	B-X
in	B-X
animals	B-X
ranging	B-X
from	B-X
jellyfish	B-X
to	B-X
Drosophila	B-X
to	B-X
humans	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
this	B-X
theory	B-X
,	B-X
our	B-X
data	B-X
showed	B-X
that	B-X
these	B-X
mutants	B-X
are	B-X
dominant	B-X
-	B-X
negative	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
when	B-X
they	B-X
are	B-X
coexpressed	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X
<EOS>	B-X
Heterozygous	B-X
mutations	B-X
in	B-X
the	B-X
human	B-X
PAX6	B-X
gene	B-X
result	B-X
in	B-X
various	B-X
phenotypes	B-X
,	B-X
including	B-X
aniridia	B-X
,	B-X
Peter	B-X
's	B-X
anomaly	B-X
,	B-X
autosomal	B-X
dominant	B-X
keratitis	B-X
,	B-X
and	B-X
familial	B-X
foveal	B-X
dysplasia	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
effects	B-X
result	B-X
from	B-X
the	B-X
enhanced	B-X
DNA	B-X
binding	B-X
ability	B-X
of	B-X
these	B-X
mutants	B-X

Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B-Disease
,	O
Peters	B-Disease
anomaly	I-Disease
,	O
autosomal	B-Disease
dominant	I-Disease
keratitis	I-Disease
,	O
and	O
familial	B-Disease
foveal	I-Disease
dysplasia	I-Disease
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B-Disease
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O
<EOS>	B-X
It	B-X
is	B-X
believed	B-X
that	B-X
the	B-X
mutated	B-X
allele	B-X
of	B-X
PAX6	B-X
produces	B-X
an	B-X
inactive	B-X
protein	B-X
and	B-X
aniridia	B-X
is	B-X
caused	B-X
due	B-X
to	B-X
genetic	B-X
haploinsufficiency	B-X
<EOS>	B-X
It	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
such	B-X
mutants	B-X
really	B-X
behave	B-X
as	B-X
loss	B-X
-	B-X
of	B-X
-	B-X
function	B-X
mutants	B-X
as	B-X
predicted	B-X
by	B-X
haploinsufficiency	B-X
<EOS>	B-X
However	B-X
,	B-X
several	B-X
truncation	B-X
mutations	B-X
have	B-X
been	B-X
found	B-X
to	B-X
occur	B-X
in	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
half	B-X
of	B-X
PAX6	B-X
in	B-X
patients	B-X
with	B-X
Aniridia	B-X
resulting	B-X
in	B-X
mutant	B-X
proteins	B-X
that	B-X
retain	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
domains	B-X
but	B-X
have	B-X
lost	B-X
most	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
this	B-X
theory	B-X
,	B-X
our	B-X
data	B-X
showed	B-X
that	B-X
these	B-X
mutants	B-X
are	B-X
dominant	B-X
-	B-X
negative	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
when	B-X
they	B-X
are	B-X
coexpressed	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B-Disease
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O
<EOS>	B-X
Contrary	B-X
to	B-X
this	B-X
theory	B-X
,	B-X
our	B-X
data	B-X
showed	B-X
that	B-X
these	B-X
mutants	B-X
are	B-X
dominant	B-X
-	B-X
negative	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
when	B-X
they	B-X
are	B-X
coexpressed	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X
<EOS>	B-X
It	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
such	B-X
mutants	B-X
really	B-X
behave	B-X
as	B-X
loss	B-X
-	B-X
of	B-X
-	B-X
function	B-X
mutants	B-X
as	B-X
predicted	B-X
by	B-X
haploinsufficiency	B-X
<EOS>	B-X
Kinetic	B-X
studies	B-X
of	B-X
binding	B-X
and	B-X
dissociation	B-X
revealed	B-X
that	B-X
various	B-X
truncation	B-X
mutants	B-X
have	B-X
3	B-X
-	B-X
5	B-X
-	B-X
fold	B-X
higher	B-X
affinity	B-X
to	B-X
various	B-X
DNA	B-X
-	B-X
binding	B-X
sites	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
effects	B-X
result	B-X
from	B-X
the	B-X
enhanced	B-X
DNA	B-X
binding	B-X
ability	B-X
of	B-X
these	B-X
mutants	B-X

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
.	O
<EOS>	B-X
C	B-X
/	B-X
EBP	B-X
beta	B-X
contributed	B-X
to	B-X
C2	B-X
-	B-X
enhanced	B-X
DNA	B-X
binding	B-X
activity	B-X
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
effects	B-X
of	B-X
GGA	B-X
on	B-X
other	B-X
HSP	B-X
families	B-X
of	B-X
molecules	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
monocyte	B-X
adhesion	B-X
to	B-X
human	B-X
endothelial	B-X
cells	B-X
stimulated	B-X
by	B-X
pcTat	B-X
is	B-X
mediated	B-X
via	B-X
an	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
mechanism	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
-	B-X
13	B-X
(	B-X
MMP	B-X
-	B-X
13	B-X
)	B-X
mRNA	B-X
,	B-X
protein	B-X
and	B-X
secretion	B-X
increase	B-X
in	B-X
response	B-X
to	B-X
GDNF	B-X
stimulation	B-X

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O
<EOS>	B-X
Kinetic	B-X
studies	B-X
of	B-X
binding	B-X
and	B-X
dissociation	B-X
revealed	B-X
that	B-X
various	B-X
truncation	B-X
mutants	B-X
have	B-X
3	B-X
-	B-X
5	B-X
-	B-X
fold	B-X
higher	B-X
affinity	B-X
to	B-X
various	B-X
DNA	B-X
-	B-X
binding	B-X
sites	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
this	B-X
theory	B-X
,	B-X
our	B-X
data	B-X
showed	B-X
that	B-X
these	B-X
mutants	B-X
are	B-X
dominant	B-X
-	B-X
negative	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
when	B-X
they	B-X
are	B-X
coexpressed	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
effects	B-X
result	B-X
from	B-X
the	B-X
enhanced	B-X
DNA	B-X
binding	B-X
ability	B-X
of	B-X
these	B-X
mutants	B-X
<EOS>	B-X
However	B-X
,	B-X
several	B-X
truncation	B-X
mutations	B-X
have	B-X
been	B-X
found	B-X
to	B-X
occur	B-X
in	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
half	B-X
of	B-X
PAX6	B-X
in	B-X
patients	B-X
with	B-X
Aniridia	B-X
resulting	B-X
in	B-X
mutant	B-X
proteins	B-X
that	B-X
retain	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
domains	B-X
but	B-X
have	B-X
lost	B-X
most	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B-Disease
.	O
.	O
<EOS>	B-X
These	B-X
results	B-X
provide	B-X
a	B-X
new	B-X
insight	B-X
into	B-X
the	B-X
role	B-X
of	B-X
mutant	B-X
PAX6	B-X
in	B-X
causing	B-X
aniridia	B-X
<EOS>	B-X
Kinetic	B-X
studies	B-X
of	B-X
binding	B-X
and	B-X
dissociation	B-X
revealed	B-X
that	B-X
various	B-X
truncation	B-X
mutants	B-X
have	B-X
3	B-X
-	B-X
5	B-X
-	B-X
fold	B-X
higher	B-X
affinity	B-X
to	B-X
various	B-X
DNA	B-X
-	B-X
binding	B-X
sites	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X
<EOS>	B-X
Heterozygous	B-X
mutations	B-X
in	B-X
the	B-X
human	B-X
PAX6	B-X
gene	B-X
result	B-X
in	B-X
various	B-X
phenotypes	B-X
,	B-X
including	B-X
aniridia	B-X
,	B-X
Peter	B-X
's	B-X
anomaly	B-X
,	B-X
autosomal	B-X
dominant	B-X
keratitis	B-X
,	B-X
and	B-X
familial	B-X
foveal	B-X
dysplasia	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
this	B-X
theory	B-X
,	B-X
our	B-X
data	B-X
showed	B-X
that	B-X
these	B-X
mutants	B-X
are	B-X
dominant	B-X
-	B-X
negative	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
when	B-X
they	B-X
are	B-X
coexpressed	B-X
with	B-X
wild	B-X
-	B-X
type	B-X
PAX6	B-X

Reversal	O
of	O
severe	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coenzyme	I-Disease
A	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
.	O
<EOS>	B-X
Reversal	B-X
of	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
and	B-X
excellent	B-X
neuropsychologic	B-X
outcome	B-X
in	B-X
very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
Her	B-X
ventricular	B-X
hypertrophy	B-X
resolved	B-X
significantly	B-X
over	B-X
1	B-X
year	B-X
,	B-X
and	B-X
cognitively	B-X
,	B-X
she	B-X
is	B-X
in	B-X
the	B-X
superior	B-X
range	B-X
for	B-X
age	B-X
<EOS>	B-X
After	B-X
initial	B-X
treatment	B-X
with	B-X
intravenous	B-X
glucose	B-X
and	B-X
carnitine	B-X
,	B-X
the	B-X
patient	B-X
has	B-X
thrived	B-X
on	B-X
a	B-X
low	B-X
-	B-X
fat	B-X
diet	B-X
supplemented	B-X
with	B-X
medium	B-X
-	B-X
chain	B-X
triglyceride	B-X
oil	B-X
and	B-X
carnitine	B-X
and	B-X
avoidance	B-X
of	B-X
fasting	B-X
<EOS>	B-X
We	B-X
describe	B-X
the	B-X
outcome	B-X
of	B-X
a	B-X
5	B-X
-	B-X
year	B-X
-	B-X
old	B-X
girl	B-X
with	B-X
VLCAD	B-X
deficiency	B-X
who	B-X
was	B-X
first	B-X
seen	B-X
at	B-X
5	B-X
months	B-X
of	B-X
age	B-X
with	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
,	B-X
hepatomegaly	B-X
,	B-X
encephalopathy	B-X
,	B-X
and	B-X
hypotonia	B-X

Very	B-Disease
-	I-Disease
long	I-Disease
-	I-Disease
chain	I-Disease
acyl	I-Disease
-	I-Disease
coenzyme	I-Disease
A	I-Disease
dehydrogenase	I-Disease
(	I-Disease
VLCAD	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O
<EOS>	B-X
Very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
(	B-X
VLCAD	B-X
)	B-X
deficiency	B-X
is	B-X
a	B-X
disorder	B-X
of	B-X
fatty	B-X
acid	B-X
beta	B-X
oxidation	B-X
that	B-X
reportedly	B-X
has	B-X
high	B-X
rates	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
<EOS>	B-X
Clinical	B-X
recognition	B-X
of	B-X
VLCAD	B-X
deficiency	B-X
is	B-X
important	B-X
because	B-X
it	B-X
is	B-X
one	B-X
of	B-X
the	B-X
few	B-X
directly	B-X
treatable	B-X
causes	B-X
of	B-X
cardiomyopathy	B-X
in	B-X
children	B-X
<EOS>	B-X
Biochemical	B-X
studies	B-X
indicated	B-X
VLCAD	B-X
deficiency	B-X
caused	B-X
by	B-X
a	B-X
stable	B-X
yet	B-X
inactive	B-X
enzyme	B-X
<EOS>	B-X
Her	B-X
ventricular	B-X
hypertrophy	B-X
resolved	B-X
significantly	B-X
over	B-X
1	B-X
year	B-X
,	B-X
and	B-X
cognitively	B-X
,	B-X
she	B-X
is	B-X
in	B-X
the	B-X
superior	B-X
range	B-X
for	B-X
age	B-X

We	O
describe	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B-Disease
deficiency	I-Disease
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
,	O
hepatomegaly	B-Disease
,	O
encephalopathy	B-Disease
,	O
and	O
hypotonia	B-Disease
.	O
<EOS>	B-X
We	B-X
describe	B-X
the	B-X
outcome	B-X
of	B-X
a	B-X
5	B-X
-	B-X
year	B-X
-	B-X
old	B-X
girl	B-X
with	B-X
VLCAD	B-X
deficiency	B-X
who	B-X
was	B-X
first	B-X
seen	B-X
at	B-X
5	B-X
months	B-X
of	B-X
age	B-X
with	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
,	B-X
hepatomegaly	B-X
,	B-X
encephalopathy	B-X
,	B-X
and	B-X
hypotonia	B-X
<EOS>	B-X
Clinical	B-X
recognition	B-X
of	B-X
VLCAD	B-X
deficiency	B-X
is	B-X
important	B-X
because	B-X
it	B-X
is	B-X
one	B-X
of	B-X
the	B-X
few	B-X
directly	B-X
treatable	B-X
causes	B-X
of	B-X
cardiomyopathy	B-X
in	B-X
children	B-X
<EOS>	B-X
Very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
(	B-X
VLCAD	B-X
)	B-X
deficiency	B-X
is	B-X
a	B-X
disorder	B-X
of	B-X
fatty	B-X
acid	B-X
beta	B-X
oxidation	B-X
that	B-X
reportedly	B-X
has	B-X
high	B-X
rates	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
<EOS>	B-X
Biochemical	B-X
studies	B-X
indicated	B-X
VLCAD	B-X
deficiency	B-X
caused	B-X
by	B-X
a	B-X
stable	B-X
yet	B-X
inactive	B-X
enzyme	B-X

Biochemical	O
studies	O
indicated	O
VLCAD	B-Disease
deficiency	I-Disease
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O
<EOS>	B-X
Biochemical	B-X
studies	B-X
indicated	B-X
VLCAD	B-X
deficiency	B-X
caused	B-X
by	B-X
a	B-X
stable	B-X
yet	B-X
inactive	B-X
enzyme	B-X
<EOS>	B-X
Very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
(	B-X
VLCAD	B-X
)	B-X
deficiency	B-X
is	B-X
a	B-X
disorder	B-X
of	B-X
fatty	B-X
acid	B-X
beta	B-X
oxidation	B-X
that	B-X
reportedly	B-X
has	B-X
high	B-X
rates	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
<EOS>	B-X
Clinical	B-X
recognition	B-X
of	B-X
VLCAD	B-X
deficiency	B-X
is	B-X
important	B-X
because	B-X
it	B-X
is	B-X
one	B-X
of	B-X
the	B-X
few	B-X
directly	B-X
treatable	B-X
causes	B-X
of	B-X
cardiomyopathy	B-X
in	B-X
children	B-X
<EOS>	B-X
We	B-X
describe	B-X
the	B-X
outcome	B-X
of	B-X
a	B-X
5	B-X
-	B-X
year	B-X
-	B-X
old	B-X
girl	B-X
with	B-X
VLCAD	B-X
deficiency	B-X
who	B-X
was	B-X
first	B-X
seen	B-X
at	B-X
5	B-X
months	B-X
of	B-X
age	B-X
with	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
,	B-X
hepatomegaly	B-X
,	B-X
encephalopathy	B-X
,	B-X
and	B-X
hypotonia	B-X

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O
<EOS>	B-X
After	B-X
initial	B-X
treatment	B-X
with	B-X
intravenous	B-X
glucose	B-X
and	B-X
carnitine	B-X
,	B-X
the	B-X
patient	B-X
has	B-X
thrived	B-X
on	B-X
a	B-X
low	B-X
-	B-X
fat	B-X
diet	B-X
supplemented	B-X
with	B-X
medium	B-X
-	B-X
chain	B-X
triglyceride	B-X
oil	B-X
and	B-X
carnitine	B-X
and	B-X
avoidance	B-X
of	B-X
fasting	B-X
<EOS>	B-X
Reversal	B-X
of	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
and	B-X
excellent	B-X
neuropsychologic	B-X
outcome	B-X
in	B-X
very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
Her	B-X
ventricular	B-X
hypertrophy	B-X
resolved	B-X
significantly	B-X
over	B-X
1	B-X
year	B-X
,	B-X
and	B-X
cognitively	B-X
,	B-X
she	B-X
is	B-X
in	B-X
the	B-X
superior	B-X
range	B-X
for	B-X
age	B-X
<EOS>	B-X
Clinical	B-X
recognition	B-X
of	B-X
VLCAD	B-X
deficiency	B-X
is	B-X
important	B-X
because	B-X
it	B-X
is	B-X
one	B-X
of	B-X
the	B-X
few	B-X
directly	B-X
treatable	B-X
causes	B-X
of	B-X
cardiomyopathy	B-X
in	B-X
children	B-X

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age	O
.	O
<EOS>	B-X
Her	B-X
ventricular	B-X
hypertrophy	B-X
resolved	B-X
significantly	B-X
over	B-X
1	B-X
year	B-X
,	B-X
and	B-X
cognitively	B-X
,	B-X
she	B-X
is	B-X
in	B-X
the	B-X
superior	B-X
range	B-X
for	B-X
age	B-X
<EOS>	B-X
Very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
(	B-X
VLCAD	B-X
)	B-X
deficiency	B-X
is	B-X
a	B-X
disorder	B-X
of	B-X
fatty	B-X
acid	B-X
beta	B-X
oxidation	B-X
that	B-X
reportedly	B-X
has	B-X
high	B-X
rates	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
<EOS>	B-X
Reversal	B-X
of	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
and	B-X
excellent	B-X
neuropsychologic	B-X
outcome	B-X
in	B-X
very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
deficiency	B-X
.	B-X
<EOS>	B-X
After	B-X
initial	B-X
treatment	B-X
with	B-X
intravenous	B-X
glucose	B-X
and	B-X
carnitine	B-X
,	B-X
the	B-X
patient	B-X
has	B-X
thrived	B-X
on	B-X
a	B-X
low	B-X
-	B-X
fat	B-X
diet	B-X
supplemented	B-X
with	B-X
medium	B-X
-	B-X
chain	B-X
triglyceride	B-X
oil	B-X
and	B-X
carnitine	B-X
and	B-X
avoidance	B-X
of	B-X
fasting	B-X

Clinical	O
recognition	O
of	O
VLCAD	B-Disease
deficiency	I-Disease
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B-Disease
in	O
children	O
.	O
.	O
<EOS>	B-X
Clinical	B-X
recognition	B-X
of	B-X
VLCAD	B-X
deficiency	B-X
is	B-X
important	B-X
because	B-X
it	B-X
is	B-X
one	B-X
of	B-X
the	B-X
few	B-X
directly	B-X
treatable	B-X
causes	B-X
of	B-X
cardiomyopathy	B-X
in	B-X
children	B-X
<EOS>	B-X
Very	B-X
-	B-X
long	B-X
-	B-X
chain	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
dehydrogenase	B-X
(	B-X
VLCAD	B-X
)	B-X
deficiency	B-X
is	B-X
a	B-X
disorder	B-X
of	B-X
fatty	B-X
acid	B-X
beta	B-X
oxidation	B-X
that	B-X
reportedly	B-X
has	B-X
high	B-X
rates	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
<EOS>	B-X
We	B-X
describe	B-X
the	B-X
outcome	B-X
of	B-X
a	B-X
5	B-X
-	B-X
year	B-X
-	B-X
old	B-X
girl	B-X
with	B-X
VLCAD	B-X
deficiency	B-X
who	B-X
was	B-X
first	B-X
seen	B-X
at	B-X
5	B-X
months	B-X
of	B-X
age	B-X
with	B-X
severe	B-X
hypertrophic	B-X
cardiomyopathy	B-X
,	B-X
hepatomegaly	B-X
,	B-X
encephalopathy	B-X
,	B-X
and	B-X
hypotonia	B-X
<EOS>	B-X
Biochemical	B-X
studies	B-X
indicated	B-X
VLCAD	B-X
deficiency	B-X
caused	B-X
by	B-X
a	B-X
stable	B-X
yet	B-X
inactive	B-X
enzyme	B-X

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O
<EOS>	B-X
It	B-X
is	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
gene	B-X
family	B-X
<EOS>	B-X
LRP7	B-X
(	B-X
the	B-X
HGMW	B-X
-	B-X
approved	B-X
gene	B-X
symbol	B-X
for	B-X
LR3	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
(	B-X
LDLR	B-X
)	B-X
family	B-X
<EOS>	B-X
We	B-X
report	B-X
molecular	B-X
cloning	B-X
and	B-X
initial	B-X
functional	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
low	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
(	B-X
LDLR	B-X
)	B-X
gene	B-X
family	B-X
<EOS>	B-X
An	B-X
insect	B-X
homolog	B-X
of	B-X
the	B-X
vertebrate	B-X
very	B-X
low	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
mediates	B-X
endocytosis	B-X
of	B-X
lipophorins	B-X
.	B-X

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
(	O
IDDM	B-Disease
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
novel	B-X
transmembrane	B-X
protein	B-X
was	B-X
identified	B-X
by	B-X
DNA	B-X
sequence	B-X
analysis	B-X
within	B-X
the	B-X
insulin	B-X
-	B-X
dependent	B-X
diabetes	B-X
mellitus	B-X
(	B-X
IDDM	B-X
)	B-X
locus	B-X
IDDM4	B-X
on	B-X
chromosome	B-X
11q13	B-X
<EOS>	B-X
The	B-X
gene	B-X
,	B-X
termed	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
related	B-X
protein	B-X
5	B-X
(	B-X
LRP5	B-X
)	B-X
,	B-X
encodes	B-X
a	B-X
protein	B-X
of	B-X
1615	B-X
amino	B-X
acids	B-X
that	B-X
contains	B-X
conserved	B-X
modules	B-X
which	B-X
are	B-X
characteristic	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
family	B-X
<EOS>	B-X
The	B-X
encoded	B-X
protein	B-X
has	B-X
a	B-X
unique	B-X
organization	B-X
of	B-X
EGF	B-X
and	B-X
LDLR	B-X
repeats	B-X
;	B-X
therefore	B-X
,	B-X
LRP5	B-X
likely	B-X
represents	B-X
a	B-X
new	B-X
category	B-X
of	B-X
the	B-X
LDLR	B-X
family	B-X
<EOS>	B-X
These	B-X
modules	B-X
include	B-X
a	B-X
putative	B-X
signal	B-X
peptide	B-X
for	B-X
protein	B-X
export	B-X
,	B-X
four	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
repeats	B-X
with	B-X
associated	B-X
spacer	B-X
domains	B-X
,	B-X
three	B-X
LDL	B-X
-	B-X
receptor	B-X
(	B-X
LDLR	B-X
)	B-X
repeats	B-X
,	B-X
a	B-X
single	B-X
transmembrane	B-X
spanning	B-X
domain	B-X
,	B-X
and	B-X
a	B-X
cytoplasmic	B-X
domain	B-X

Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B-Disease
.	O
<EOS>	B-X
Based	B-X
on	B-X
its	B-X
chromosomal	B-X
position	B-X
,	B-X
this	B-X
gene	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
conferring	B-X
susceptibility	B-X
to	B-X
diabetes	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
35	B-X
reports	B-X
were	B-X
collected	B-X
,	B-X
among	B-X
of	B-X
them	B-X
only	B-X
16	B-X
studies	B-X
(	B-X
including	B-X
24,407	B-X
cases	B-X
and	B-X
33,937	B-X
controls	B-X
)	B-X
match	B-X
the	B-X
inclusion	B-X
criteria	B-X
and	B-X
were	B-X
selected	B-X
for	B-X
the	B-X
statistical	B-X
test	B-X
<EOS>	B-X
Cloning	B-X
of	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
family	B-X
.	B-X
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
novel	B-X
transmembrane	B-X
protein	B-X
was	B-X
identified	B-X
by	B-X
DNA	B-X
sequence	B-X
analysis	B-X
within	B-X
the	B-X
insulin	B-X
-	B-X
dependent	B-X
diabetes	B-X
mellitus	B-X
(	B-X
IDDM	B-X
)	B-X
locus	B-X
IDDM4	B-X
on	B-X
chromosome	B-X
11q13	B-X

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
family	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
,	B-X
termed	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
related	B-X
protein	B-X
5	B-X
(	B-X
LRP5	B-X
)	B-X
,	B-X
encodes	B-X
a	B-X
protein	B-X
of	B-X
1615	B-X
amino	B-X
acids	B-X
that	B-X
contains	B-X
conserved	B-X
modules	B-X
which	B-X
are	B-X
characteristic	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
family	B-X
<EOS>	B-X
The	B-X
encoded	B-X
protein	B-X
has	B-X
a	B-X
unique	B-X
organization	B-X
of	B-X
EGF	B-X
and	B-X
LDLR	B-X
repeats	B-X
;	B-X
therefore	B-X
,	B-X
LRP5	B-X
likely	B-X
represents	B-X
a	B-X
new	B-X
category	B-X
of	B-X
the	B-X
LDLR	B-X
family	B-X
<EOS>	B-X
Cloning	B-X
of	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
family	B-X
.	B-X
<EOS>	B-X
Both	B-X
human	B-X
and	B-X
mouse	B-X
LRP5	B-X
cDNAs	B-X
have	B-X
been	B-X
isolated	B-X
and	B-X
the	B-X
encoded	B-X
mature	B-X
proteins	B-X
are	B-X
95	B-X
%	B-X
identical	B-X
,	B-X
indicating	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
evolutionary	B-X
conservation	B-X

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O
LDLR	O
family	O
.	O

Both	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O
<EOS>	B-X
Both	B-X
human	B-X
and	B-X
mouse	B-X
LRP5	B-X
cDNAs	B-X
have	B-X
been	B-X
isolated	B-X
and	B-X
the	B-X
encoded	B-X
mature	B-X
proteins	B-X
are	B-X
95	B-X
%	B-X
identical	B-X
,	B-X
indicating	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
evolutionary	B-X
conservation	B-X
<EOS>	B-X
The	B-X
gene	B-X
,	B-X
termed	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
related	B-X
protein	B-X
5	B-X
(	B-X
LRP5	B-X
)	B-X
,	B-X
encodes	B-X
a	B-X
protein	B-X
of	B-X
1615	B-X
amino	B-X
acids	B-X
that	B-X
contains	B-X
conserved	B-X
modules	B-X
which	B-X
are	B-X
characteristic	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
(	B-X
LDL	B-X
)	B-X
receptor	B-X
family	B-X
<EOS>	B-X
Cloning	B-X
of	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
receptor	B-X
family	B-X
.	B-X
<EOS>	B-X
Based	B-X
on	B-X
its	B-X
chromosomal	B-X
position	B-X
,	B-X
this	B-X
gene	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
conferring	B-X
susceptibility	B-X
to	B-X
diabetes	B-X

The	O
APC	B-Disease
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B-Disease
tumors	I-Disease
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
APC	B-X
I1307K	B-X
and	B-X
E1317Q	B-X
polymorphisms	B-X
with	B-X
colorectal	B-X
cancer	B-X
among	B-X
Egyptian	B-X
subjects	B-X
.	B-X
<EOS>	B-X
APC	B-X
I1307K	B-X
variant	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
CRC	B-X
among	B-X
Egyptian	B-X
subjects	B-X
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
(	B-X
APC	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
risk	B-X
in	B-X
several	B-X
ethnic	B-X
populations	B-X
<EOS>	B-X
In	B-X
Jewish	B-X
CRC	B-X
patients	B-X
the	B-X
E1317Q	B-X
variant	B-X
plays	B-X
little	B-X
if	B-X
any	B-X
role	B-X
in	B-X
colorectal	B-X
cancer	B-X
susceptibility	B-X
and	B-X
genetic	B-X
testing	B-X
for	B-X
this	B-X
variant	B-X
is	B-X
not	B-X
warranted	B-X

Classical	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
carcinoma	I-Disease
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
.	O
<EOS>	B-X
Classical	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
is	B-X
a	B-X
high	B-X
-	B-X
penetrance	B-X
autosomal	B-X
dominant	B-X
disease	B-X
that	B-X
predisposes	B-X
to	B-X
hundreds	B-X
or	B-X
thousands	B-X
of	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
and	B-X
that	B-X
results	B-X
from	B-X
truncating	B-X
mutations	B-X
in	B-X
the	B-X
APC	B-X
gene	B-X
<EOS>	B-X
In	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
syndrome	B-X
,	B-X
autosomal	B-X
dominant	B-X
inheritance	B-X
of	B-X
the	B-X
mutated	B-X
APC	B-X
(	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
)	B-X
gene	B-X
on	B-X
chromosome	B-X
5q21	B-X
typically	B-X
results	B-X
in	B-X
thousands	B-X
of	B-X
adenomas	B-X
in	B-X
the	B-X
colorectum	B-X
and	B-X
in	B-X
lesser	B-X
numbers	B-X
in	B-X
the	B-X
proximal	B-X
small	B-X
bowel	B-X
<EOS>	B-X
A	B-X
variant	B-X
of	B-X
FAP	B-X
is	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
,	B-X
which	B-X
results	B-X
from	B-X
germ	B-X
-	B-X
line	B-X
mutations	B-X
in	B-X
the	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
regions	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
<EOS>	B-X
There	B-X
is	B-X
increasing	B-X
evidence	B-X
that	B-X
there	B-X
exist	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
that	B-X
predispose	B-X
to	B-X
the	B-X
development	B-X
of	B-X
multiple	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
,	B-X
but	B-X
without	B-X
the	B-X
florid	B-X
phenotype	B-X
of	B-X
classical	B-X
FAP	B-X
,	B-X
and	B-X
possibly	B-X
with	B-X
importance	B-X
for	B-X
colorectal	B-X
cancer	B-X
risk	B-X
in	B-X
the	B-X
general	B-X
population	B-X

A	O
variant	O
of	O
FAP	B-Disease
is	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
APC	B-Disease
gene	O
.	O
<EOS>	B-X
A	B-X
variant	B-X
of	B-X
FAP	B-X
is	B-X
attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
,	B-X
which	B-X
results	B-X
from	B-X
germ	B-X
-	B-X
line	B-X
mutations	B-X
in	B-X
the	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
regions	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
<EOS>	B-X
Classical	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
is	B-X
a	B-X
high	B-X
-	B-X
penetrance	B-X
autosomal	B-X
dominant	B-X
disease	B-X
that	B-X
predisposes	B-X
to	B-X
hundreds	B-X
or	B-X
thousands	B-X
of	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
and	B-X
that	B-X
results	B-X
from	B-X
truncating	B-X
mutations	B-X
in	B-X
the	B-X
APC	B-X
gene	B-X
<EOS>	B-X
Another	B-X
group	B-X
of	B-X
patients	B-X
with	B-X
multiple	B-X
adenomas	B-X
has	B-X
no	B-X
mutations	B-X
in	B-X
the	B-X
APC	B-X
gene	B-X
,	B-X
and	B-X
their	B-X
phenotype	B-X
probably	B-X
results	B-X
from	B-X
variation	B-X
at	B-X
a	B-X
locus	B-X
,	B-X
or	B-X
loci	B-X
,	B-X
elsewhere	B-X
in	B-X
the	B-X
genome	B-X
<EOS>	B-X
Attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
patients	B-X
have	B-X
``	B-X
multiple	B-X
''	B-X
colorectal	B-X
adenomas	B-X
(	B-X
typically	B-X
fewer	B-X
than	B-X
100	B-X
)	B-X
without	B-X
the	B-X
florid	B-X
phenotype	B-X
of	B-X
classical	B-X
FAP	B-X

Attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B-Disease
adenomas	I-Disease
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B-Disease
.	O
<EOS>	B-X
Attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
patients	B-X
have	B-X
``	B-X
multiple	B-X
''	B-X
colorectal	B-X
adenomas	B-X
(	B-X
typically	B-X
fewer	B-X
than	B-X
100	B-X
)	B-X
without	B-X
the	B-X
florid	B-X
phenotype	B-X
of	B-X
classical	B-X
FAP	B-X
<EOS>	B-X
There	B-X
is	B-X
increasing	B-X
evidence	B-X
that	B-X
there	B-X
exist	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
that	B-X
predispose	B-X
to	B-X
the	B-X
development	B-X
of	B-X
multiple	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
,	B-X
but	B-X
without	B-X
the	B-X
florid	B-X
phenotype	B-X
of	B-X
classical	B-X
FAP	B-X
,	B-X
and	B-X
possibly	B-X
with	B-X
importance	B-X
for	B-X
colorectal	B-X
cancer	B-X
risk	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
Classical	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
is	B-X
a	B-X
high	B-X
-	B-X
penetrance	B-X
autosomal	B-X
dominant	B-X
disease	B-X
that	B-X
predisposes	B-X
to	B-X
hundreds	B-X
or	B-X
thousands	B-X
of	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
and	B-X
that	B-X
results	B-X
from	B-X
truncating	B-X
mutations	B-X
in	B-X
the	B-X
APC	B-X
gene	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
set	B-X
of	B-X
164	B-X
patients	B-X
with	B-X
multiple	B-X
colorectal	B-X
adenomas	B-X
and	B-X
/	B-X
or	B-X
carcinoma	B-X
and	B-X
analyzed	B-X
codons	B-X
1263	B-X
-	B-X
1377	B-X
(	B-X
exon	B-X
15G	B-X
)	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
for	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B-Disease
has	O
no	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O
<EOS>	B-X
Sorghum	B-X
is	B-X
a	B-X
feed	B-X
/	B-X
industrial	B-X
crop	B-X
in	B-X
developed	B-X
countries	B-X
and	B-X
a	B-X
staple	B-X
food	B-X
elsewhere	B-X
in	B-X
the	B-X
world	B-X
<EOS>	B-X
Although	B-X
it	B-X
is	B-X
known	B-X
that	B-X
the	B-X
mutation	B-X
rate	B-X
varies	B-X
across	B-X
the	B-X
genome	B-X
,	B-X
previous	B-X
estimates	B-X
were	B-X
based	B-X
on	B-X
averaging	B-X
across	B-X
various	B-X
numbers	B-X
of	B-X
positions	B-X
<EOS>	B-X
Approximate	B-X
equations	B-X
for	B-X
the	B-X
boundaries	B-X
of	B-X
the	B-X
set	B-X
of	B-X
polymorphic	B-X
evolutionary	B-X
outcomes	B-X
were	B-X
derived	B-X
by	B-X
Bulmer	B-X
(	B-X
<EOS>	B-X
Long	B-X
-	B-X
term	B-X
monitoring	B-X
of	B-X
Pca	B-X
in	B-X
Australia	B-X
,	B-X
North	B-X
America	B-X
and	B-X
elsewhere	B-X
has	B-X
shown	B-X
that	B-X
it	B-X
is	B-X
highly	B-X
variable	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
sexual	B-X
recombination	B-X
,	B-X
likely	B-X
due	B-X
to	B-X
large	B-X
pathogen	B-X
populations	B-X
that	B-X
cycle	B-X
between	B-X
wild	B-X
oat	B-X
communities	B-X
and	B-X
oat	B-X
crops	B-X

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	B-Disease
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B-Disease
tumors	I-Disease
,	O
including	O
multiple	O
adenomas	B-Disease
,	O
in	O
Ashkenazim	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
however	B-X
,	B-X
a	B-X
missense	B-X
variant	B-X
of	B-X
APC	B-X
(	B-X
I1307K	B-X
)	B-X
was	B-X
described	B-X
that	B-X
confers	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
colorectal	B-X
tumors	B-X
,	B-X
including	B-X
multiple	B-X
adenomas	B-X
,	B-X
in	B-X
Ashkenazim	B-X
<EOS>	B-X
The	B-X
APC	B-X
variants	B-X
I1307K	B-X
and	B-X
E1317Q	B-X
are	B-X
associated	B-X
with	B-X
colorectal	B-X
tumors	B-X
,	B-X
but	B-X
not	B-X
always	B-X
with	B-X
a	B-X
family	B-X
history	B-X
.	B-X
<EOS>	B-X
Four	B-X
patients	B-X
had	B-X
a	B-X
germ	B-X
-	B-X
line	B-X
E1317Q	B-X
missense	B-X
variant	B-X
of	B-X
APC	B-X
that	B-X
was	B-X
not	B-X
present	B-X
in	B-X
controls	B-X
;	B-X
one	B-X
of	B-X
these	B-X
individuals	B-X
had	B-X
an	B-X
unusually	B-X
large	B-X
number	B-X
of	B-X
metaplastic	B-X
polyps	B-X
of	B-X
the	B-X
colorectum	B-X
<EOS>	B-X
Classical	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
is	B-X
a	B-X
high	B-X
-	B-X
penetrance	B-X
autosomal	B-X
dominant	B-X
disease	B-X
that	B-X
predisposes	B-X
to	B-X
hundreds	B-X
or	B-X
thousands	B-X
of	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
and	B-X
that	B-X
results	B-X
from	B-X
truncating	B-X
mutations	B-X
in	B-X
the	B-X
APC	B-X
gene	B-X

We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
carcinoma	I-Disease
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B-Disease
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
set	B-X
of	B-X
164	B-X
patients	B-X
with	B-X
multiple	B-X
colorectal	B-X
adenomas	B-X
and	B-X
/	B-X
or	B-X
carcinoma	B-X
and	B-X
analyzed	B-X
codons	B-X
1263	B-X
-	B-X
1377	B-X
(	B-X
exon	B-X
15G	B-X
)	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
for	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X
<EOS>	B-X
Attenuated	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
patients	B-X
have	B-X
``	B-X
multiple	B-X
''	B-X
colorectal	B-X
adenomas	B-X
(	B-X
typically	B-X
fewer	B-X
than	B-X
100	B-X
)	B-X
without	B-X
the	B-X
florid	B-X
phenotype	B-X
of	B-X
classical	B-X
FAP	B-X
<EOS>	B-X
There	B-X
is	B-X
increasing	B-X
evidence	B-X
that	B-X
there	B-X
exist	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
that	B-X
predispose	B-X
to	B-X
the	B-X
development	B-X
of	B-X
multiple	B-X
colorectal	B-X
adenomas	B-X
and	B-X
carcinoma	B-X
,	B-X
but	B-X
without	B-X
the	B-X
florid	B-X
phenotype	B-X
of	B-X
classical	B-X
FAP	B-X
,	B-X
and	B-X
possibly	B-X
with	B-X
importance	B-X
for	B-X
colorectal	B-X
cancer	B-X
risk	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
Another	B-X
group	B-X
of	B-X
patients	B-X
with	B-X
multiple	B-X
adenomas	B-X
has	B-X
no	B-X
mutations	B-X
in	B-X
the	B-X
APC	B-X
gene	B-X
,	B-X
and	B-X
their	B-X
phenotype	B-X
probably	B-X
results	B-X
from	B-X
variation	B-X
at	B-X
a	B-X
locus	B-X
,	B-X
or	B-X
loci	B-X
,	B-X
elsewhere	B-X
in	B-X
the	B-X
genome	B-X

Three	O
patients	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O
<EOS>	B-X
Three	B-X
patients	B-X
with	B-X
the	B-X
I1307K	B-X
allele	B-X
were	B-X
detected	B-X
,	B-X
each	B-X
of	B-X
Ashkenazi	B-X
descent	B-X
<EOS>	B-X
The	B-X
APC	B-X
variants	B-X
I1307K	B-X
and	B-X
E1317Q	B-X
are	B-X
associated	B-X
with	B-X
colorectal	B-X
tumors	B-X
,	B-X
but	B-X
not	B-X
always	B-X
with	B-X
a	B-X
family	B-X
history	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
however	B-X
,	B-X
a	B-X
missense	B-X
variant	B-X
of	B-X
APC	B-X
(	B-X
I1307K	B-X
)	B-X
was	B-X
described	B-X
that	B-X
confers	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
colorectal	B-X
tumors	B-X
,	B-X
including	B-X
multiple	B-X
adenomas	B-X
,	B-X
in	B-X
Ashkenazim	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
set	B-X
of	B-X
164	B-X
patients	B-X
with	B-X
multiple	B-X
colorectal	B-X
adenomas	B-X
and	B-X
/	B-X
or	B-X
carcinoma	B-X
and	B-X
analyzed	B-X
codons	B-X
1263	B-X
-	B-X
1377	B-X
(	B-X
exon	B-X
15G	B-X
)	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
for	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B-Disease
polyps	I-Disease
of	I-Disease
the	I-Disease
colorectum	I-Disease
.	O
<EOS>	B-X
Nontruncating	B-X
APC	B-X
germ	B-X
-	B-X
line	B-X
mutations	B-X
and	B-X
mismatch	B-X
repair	B-X
deficiency	B-X
play	B-X
a	B-X
minor	B-X
role	B-X
in	B-X
APC	B-X
mutation	B-X
-	B-X
negative	B-X
polyposis	B-X
.	B-X
<EOS>	B-X
Few	B-X
studies	B-X
have	B-X
determined	B-X
whether	B-X
or	B-X
not	B-X
the	B-X
same	B-X
genes	B-X
harbour	B-X
other	B-X
,	B-X
more	B-X
common	B-X
variants	B-X
,	B-X
which	B-X
might	B-X
have	B-X
a	B-X
lower	B-X
penetrance	B-X
and	B-X
/	B-X
or	B-X
cause	B-X
mild	B-X
disease	B-X
,	B-X
perhaps	B-X
indistinguishable	B-X
from	B-X
sporadic	B-X
disease	B-X
and	B-X
accounting	B-X
for	B-X
a	B-X
considerable	B-X
proportion	B-X
of	B-X
the	B-X
unexplained	B-X
inherited	B-X
risk	B-X
of	B-X
tumours	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
We	B-X
argue	B-X
that	B-X
it	B-X
is	B-X
worthwhile	B-X
to	B-X
screen	B-X
multiple	B-X
adenoma	B-X
patients	B-X
for	B-X
a	B-X
restricted	B-X
number	B-X
of	B-X
germline	B-X
APC	B-X
variants	B-X
,	B-X
namely	B-X
the	B-X
missense	B-X
changes	B-X
E1317Q	B-X
and	B-X
I1307K	B-X
(	B-X
if	B-X
of	B-X
Ashkenazi	B-X
descent	B-X
)	B-X
,	B-X
and	B-X
,	B-X
if	B-X
there	B-X
is	B-X
a	B-X
family	B-X
history	B-X
of	B-X
colorectal	B-X
tumours	B-X
,	B-X
for	B-X
truncating	B-X
mutations	B-X
5	B-X
'	B-X
to	B-X
exon	B-X
5	B-X
,	B-X
in	B-X
exon	B-X
9	B-X
and	B-X
3	B-X
'	B-X
to	B-X
codon	B-X
1580	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
four	B-X
patients	B-X
with	B-X
truncating	B-X
APC	B-X
variants	B-X
in	B-X
exon	B-X
9	B-X
or	B-X
in	B-X
the	B-X
3	B-X
'	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
were	B-X
identified	B-X

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	B-Disease
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	I-Disease
carcinoma	I-Disease
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B-Disease
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B-Disease
cancer	I-Disease
risk	O
in	O
the	O
general	O
population	O
.	O
.	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B-Disease
chloride	I-Disease
diarrhea	I-Disease
(	O
CLD	B-Disease
)	O
gene	O
.	O
<EOS>	B-X
Genomic	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
congenital	B-X
chloride	B-X
diarrhea	B-X
(	B-X
CLD	B-X
)	B-X
gene	B-X
.	B-X
<EOS>	B-X
The	B-X
diagnoses	B-X
were	B-X
confirmed	B-X
by	B-X
fecal	B-X
chloride	B-X
measurements	B-X
<EOS>	B-X
The	B-X
genomic	B-X
structure	B-X
was	B-X
determined	B-X
using	B-X
DNA	B-X
from	B-X
several	B-X
sources	B-X
including	B-X
multiple	B-X
large	B-X
-	B-X
insert	B-X
libaries	B-X
and	B-X
genomic	B-X
DNA	B-X
from	B-X
Finnish	B-X
CLD	B-X
patients	B-X
and	B-X
controls	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
genomic	B-X
organization	B-X
of	B-X
the	B-X
human	B-X
CLD	B-X
gene	B-X
which	B-X
spans	B-X
approximately	B-X
39kb	B-X
,	B-X
and	B-X
comprises	B-X
21	B-X
exons	B-X

Congenital	B-Disease
chloride	I-Disease
diarrhea	I-Disease
(	O
CLD	B-Disease
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B-Disease
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
genomic	B-X
organization	B-X
of	B-X
the	B-X
human	B-X
CLD	B-X
gene	B-X
which	B-X
spans	B-X
approximately	B-X
39kb	B-X
,	B-X
and	B-X
comprises	B-X
21	B-X
exons	B-X
<EOS>	B-X
Genomic	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
congenital	B-X
chloride	B-X
diarrhea	B-X
(	B-X
CLD	B-X
)	B-X
gene	B-X
.	B-X
<EOS>	B-X
The	B-X
genomic	B-X
structure	B-X
was	B-X
determined	B-X
using	B-X
DNA	B-X
from	B-X
several	B-X
sources	B-X
including	B-X
multiple	B-X
large	B-X
-	B-X
insert	B-X
libaries	B-X
and	B-X
genomic	B-X
DNA	B-X
from	B-X
Finnish	B-X
CLD	B-X
patients	B-X
and	B-X
controls	B-X
<EOS>	B-X
Genomic	B-X
sequencing	B-X
of	B-X
a	B-X
BAC	B-X
clone	B-X
H_RG364P16	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
another	B-X
,	B-X
highly	B-X
homologous	B-X
gene	B-X
3	B-X
'	B-X
of	B-X
the	B-X
CLD	B-X
gene	B-X
,	B-X
with	B-X
a	B-X
similar	B-X
genomic	B-X
structure	B-X
,	B-X
recently	B-X
identified	B-X
as	B-X
the	B-X
Pendred	B-X
syndrome	B-X
gene	B-X
(	B-X
PDS	B-X
)	B-X

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	B-Disease
patients	O
and	O
controls	O
.	O
<EOS>	B-X
The	B-X
genomic	B-X
structure	B-X
was	B-X
determined	B-X
using	B-X
DNA	B-X
from	B-X
several	B-X
sources	B-X
including	B-X
multiple	B-X
large	B-X
-	B-X
insert	B-X
libaries	B-X
and	B-X
genomic	B-X
DNA	B-X
from	B-X
Finnish	B-X
CLD	B-X
patients	B-X
and	B-X
controls	B-X
<EOS>	B-X
Exon	B-X
-	B-X
specific	B-X
primers	B-X
developed	B-X
in	B-X
this	B-X
study	B-X
will	B-X
facilitate	B-X
mutation	B-X
screening	B-X
studies	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
disease	B-X
<EOS>	B-X
Genomic	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
congenital	B-X
chloride	B-X
diarrhea	B-X
(	B-X
CLD	B-X
)	B-X
gene	B-X
.	B-X
<EOS>	B-X
Congenital	B-X
chloride	B-X
diarrhea	B-X
(	B-X
CLD	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
which	B-X
encodes	B-X
an	B-X
intestinal	B-X
anion	B-X
transporter	B-X

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O
<EOS>	B-X
Exon	B-X
-	B-X
specific	B-X
primers	B-X
developed	B-X
in	B-X
this	B-X
study	B-X
will	B-X
facilitate	B-X
mutation	B-X
screening	B-X
studies	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
disease	B-X
<EOS>	B-X
The	B-X
genomic	B-X
structure	B-X
was	B-X
determined	B-X
using	B-X
DNA	B-X
from	B-X
several	B-X
sources	B-X
including	B-X
multiple	B-X
large	B-X
-	B-X
insert	B-X
libaries	B-X
and	B-X
genomic	B-X
DNA	B-X
from	B-X
Finnish	B-X
CLD	B-X
patients	B-X
and	B-X
controls	B-X
<EOS>	B-X
Genomic	B-X
sequencing	B-X
of	B-X
a	B-X
BAC	B-X
clone	B-X
H_RG364P16	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
another	B-X
,	B-X
highly	B-X
homologous	B-X
gene	B-X
3	B-X
'	B-X
of	B-X
the	B-X
CLD	B-X
gene	B-X
,	B-X
with	B-X
a	B-X
similar	B-X
genomic	B-X
structure	B-X
,	B-X
recently	B-X
identified	B-X
as	B-X
the	B-X
Pendred	B-X
syndrome	B-X
gene	B-X
(	B-X
PDS	B-X
)	B-X
<EOS>	B-X
Congenital	B-X
chloride	B-X
diarrhea	B-X
(	B-X
CLD	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
which	B-X
encodes	B-X
an	B-X
intestinal	B-X
anion	B-X
transporter	B-X

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	B-Disease
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B-Disease
syndrome	I-Disease
gene	O
(	O
PDS	B-Disease
)	O
.	O
.	O
<EOS>	B-X
Genomic	B-X
sequencing	B-X
of	B-X
a	B-X
BAC	B-X
clone	B-X
H_RG364P16	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
another	B-X
,	B-X
highly	B-X
homologous	B-X
gene	B-X
3	B-X
'	B-X
of	B-X
the	B-X
CLD	B-X
gene	B-X
,	B-X
with	B-X
a	B-X
similar	B-X
genomic	B-X
structure	B-X
,	B-X
recently	B-X
identified	B-X
as	B-X
the	B-X
Pendred	B-X
syndrome	B-X
gene	B-X
(	B-X
PDS	B-X
)	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
genomic	B-X
organization	B-X
of	B-X
the	B-X
human	B-X
CLD	B-X
gene	B-X
which	B-X
spans	B-X
approximately	B-X
39kb	B-X
,	B-X
and	B-X
comprises	B-X
21	B-X
exons	B-X
<EOS>	B-X
The	B-X
genomic	B-X
structure	B-X
was	B-X
determined	B-X
using	B-X
DNA	B-X
from	B-X
several	B-X
sources	B-X
including	B-X
multiple	B-X
large	B-X
-	B-X
insert	B-X
libaries	B-X
and	B-X
genomic	B-X
DNA	B-X
from	B-X
Finnish	B-X
CLD	B-X
patients	B-X
and	B-X
controls	B-X
<EOS>	B-X
Congenital	B-X
chloride	B-X
diarrhea	B-X
(	B-X
CLD	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
which	B-X
encodes	B-X
an	B-X
intestinal	B-X
anion	B-X
transporter	B-X

The	O
APCI1307K	O
allele	O
and	O
cancer	B-Disease
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
characterized	O
by	O
multiple	O
intestinal	O
polyps	B-Disease
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	B-Disease
)	O
.	O
<EOS>	B-X
Mutations	B-X
in	B-X
APC	B-X
are	B-X
classically	B-X
associated	B-X
with	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
penetrant	B-X
autosomal	B-X
dominant	B-X
disorder	B-X
characterized	B-X
by	B-X
multiple	B-X
intestinal	B-X
polyps	B-X
and	B-X
,	B-X
without	B-X
surgical	B-X
intervention	B-X
,	B-X
the	B-X
development	B-X
of	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
<EOS>	B-X
Risk	B-X
of	B-X
developing	B-X
colorectal	B-X
,	B-X
breast	B-X
and	B-X
other	B-X
cancers	B-X
were	B-X
compared	B-X
between	B-X
genotyped	B-X
I1307K	B-X
carriers	B-X
and	B-X
non	B-X
-	B-X
carriers	B-X
and	B-X
their	B-X
first	B-X
-	B-X
degree	B-X
relatives	B-X
<EOS>	B-X
The	B-X
germline	B-X
T	B-X
-	B-X
to	B-X
-	B-X
A	B-X
transversion	B-X
responsible	B-X
for	B-X
the	B-X
APC	B-X
I1307K	B-X
allele	B-X
converts	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
sequence	B-X
to	B-X
a	B-X
homopolymer	B-X
tract	B-X
(	B-X
A8	B-X
)	B-X
that	B-X
is	B-X
genetically	B-X
unstable	B-X
and	B-X
prone	B-X
to	B-X
somatic	B-X
mutation	B-X
<EOS>	B-X
1	B-X
%	B-X
of	B-X
unselected	B-X
Ashkenazi	B-X
Jews	B-X
and	B-X
higher	B-X
proportions	B-X
of	B-X
Ashkenazim	B-X
with	B-X
family	B-X
or	B-X
personal	B-X
histories	B-X
of	B-X
CRC	B-X
(	B-X
ref	B-X

APC	B-Disease
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B-Disease
.	O
<EOS>	B-X
Recent	B-X
progress	B-X
in	B-X
mouse	B-X
models	B-X
for	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
its	B-X
implications	B-X
in	B-X
human	B-X
cancer	B-X
.	B-X
<EOS>	B-X
All	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
-	B-X
associated	B-X
adenomas	B-X
and	B-X
some	B-X
sporadic	B-X
lesions	B-X
had	B-X
polyclonal	B-X
genetic	B-X
defects	B-X
<EOS>	B-X
Cancer	B-X
arises	B-X
through	B-X
successive	B-X
somatic	B-X
mutations	B-X
/	B-X
epimutations	B-X
of	B-X
oncogenes	B-X
and	B-X
tumor	B-X
-	B-X
suppressor	B-X
genes	B-X
<EOS>	B-X
Germline	B-X
defects	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
lead	B-X
to	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
,	B-X
and	B-X
its	B-X
somatic	B-X
mutations	B-X
occur	B-X
in	B-X
multiple	B-X
tumor	B-X
types	B-X

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
.	O

The	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	O
<EOS>	B-X
The	B-X
APC	B-X
I1307K	B-X
allele	B-X
was	B-X
identified	B-X
in	B-X
48	B-X
(	B-X
10	B-X
<EOS>	B-X
The	B-X
I1307K	B-X
APC	B-X
gene	B-X
variant	B-X
was	B-X
found	B-X
in	B-X
6	B-X
<EOS>	B-X
APC	B-X
I1307K	B-X
was	B-X
found	B-X
in	B-X
7	B-X
<EOS>	B-X
The	B-X
APC	B-X
I1307K	B-X
variant	B-X
was	B-X
detected	B-X
in	B-X
189	B-X
(	B-X
11	B-X

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B-Disease
(	O
ref	O
.	O
2	O
)	O
.	O
<EOS>	B-X
1	B-X
%	B-X
of	B-X
unselected	B-X
Ashkenazi	B-X
Jews	B-X
and	B-X
higher	B-X
proportions	B-X
of	B-X
Ashkenazim	B-X
with	B-X
family	B-X
or	B-X
personal	B-X
histories	B-X
of	B-X
CRC	B-X
(	B-X
ref	B-X
<EOS>	B-X
Risk	B-X
of	B-X
developing	B-X
colorectal	B-X
,	B-X
breast	B-X
and	B-X
other	B-X
cancers	B-X
were	B-X
compared	B-X
between	B-X
genotyped	B-X
I1307K	B-X
carriers	B-X
and	B-X
non	B-X
-	B-X
carriers	B-X
and	B-X
their	B-X
first	B-X
-	B-X
degree	B-X
relatives	B-X
<EOS>	B-X
Positive	B-X
family	B-X
history	B-X
promotes	B-X
participation	B-X
in	B-X
colorectal	B-X
cancer	B-X
screening	B-X
.	B-X
<EOS>	B-X
The	B-X
findings	B-X
will	B-X
be	B-X
disseminated	B-X
to	B-X
academic	B-X
and	B-X
clinical	B-X
audiences	B-X
through	B-X
journal	B-X
articles	B-X
and	B-X
conference	B-X
presentations	B-X
and	B-X
to	B-X
the	B-X
autistic	B-X
and	B-X
autism	B-X
communities	B-X
through	B-X
accessible	B-X
reports	B-X

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B-Disease
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O

Risk	O
of	O
developing	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O
<EOS>	B-X
Risk	B-X
of	B-X
developing	B-X
colorectal	B-X
,	B-X
breast	B-X
and	B-X
other	B-X
cancers	B-X
were	B-X
compared	B-X
between	B-X
genotyped	B-X
I1307K	B-X
carriers	B-X
and	B-X
non	B-X
-	B-X
carriers	B-X
and	B-X
their	B-X
first	B-X
-	B-X
degree	B-X
relatives	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
I1307K	B-X
in	B-X
cancer	B-X
,	B-X
we	B-X
genotyped	B-X
5,081	B-X
Ashkenazi	B-X
volunteers	B-X
in	B-X
a	B-X
community	B-X
survey	B-X
<EOS>	B-X
1	B-X
%	B-X
of	B-X
unselected	B-X
Ashkenazi	B-X
Jews	B-X
and	B-X
higher	B-X
proportions	B-X
of	B-X
Ashkenazim	B-X
with	B-X
family	B-X
or	B-X
personal	B-X
histories	B-X
of	B-X
CRC	B-X
(	B-X
ref	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
APC	B-X
are	B-X
classically	B-X
associated	B-X
with	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
penetrant	B-X
autosomal	B-X
dominant	B-X
disorder	B-X
characterized	B-X
by	B-X
multiple	B-X
intestinal	B-X
polyps	B-X
and	B-X
,	B-X
without	B-X
surgical	B-X
intervention	B-X
,	B-X
the	B-X
development	B-X
of	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B-Disease
ataxia	I-Disease
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B-Disease
gene	O
.	O

Friedreich	B-Disease
ataxia	I-Disease
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	B-Disease
gene	O
.	O
<EOS>	B-X
Friedreich	B-X
ataxia	B-X
is	B-X
usually	B-X
caused	B-X
by	B-X
an	B-X
expansion	B-X
of	B-X
a	B-X
GAA	B-X
trinucleotide	B-X
repeat	B-X
in	B-X
intron	B-X
1	B-X
of	B-X
the	B-X
FRDA	B-X
gene	B-X
<EOS>	B-X
It	B-X
is	B-X
caused	B-X
by	B-X
hyperexpansion	B-X
of	B-X
GAA	B-X
repeats	B-X
in	B-X
the	B-X
first	B-X
intron	B-X
of	B-X
the	B-X
frataxin	B-X
gene	B-X
<EOS>	B-X
It	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
homozygous	B-X
guanine	B-X
-	B-X
adenine	B-X
-	B-X
adenine	B-X
(	B-X
GAA	B-X
)	B-X
trinucleotide	B-X
repeat	B-X
expansion	B-X
in	B-X
intron	B-X
1	B-X
of	B-X
the	B-X
frataxin	B-X
gene	B-X
(	B-X
FXN	B-X
)	B-X
on	B-X
chromosome	B-X
9q13	B-X
-	B-X
q21	B-X
<EOS>	B-X
Molecular	B-X
analysis	B-X
showed	B-X
a	B-X
210	B-X
-	B-X
	B-X
and	B-X
230	B-X
-	B-X
trinucleotide	B-X
GAA	B-X
repeat	B-X
expansion	B-X
in	B-X
the	B-X
two	B-X
alleles	B-X
of	B-X
the	B-X
FXN	B-X
gene	B-X

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O
repeats	O
.	O
<EOS>	B-X
Functional	B-X
characterization	B-X
of	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
using	B-X
a	B-X
transgene	B-X
approach	B-X
in	B-X
a	B-X
human	B-X
cell	B-X
line	B-X
or	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
generally	B-X
poses	B-X
limitations	B-X
due	B-X
to	B-X
persistent	B-X
transgene	B-X
overexpression	B-X
<EOS>	B-X
Expansion	B-X
in	B-X
somatic	B-X
cells	B-X
affects	B-X
age	B-X
of	B-X
onset	B-X
and	B-X
disease	B-X
severity	B-X
in	B-X
some	B-X
of	B-X
these	B-X
disorders	B-X
<EOS>	B-X
These	B-X
include	B-X
age	B-X
of	B-X
clinical	B-X
onset	B-X
and	B-X
rate	B-X
of	B-X
initial	B-X
progression	B-X
of	B-X
disease	B-X
severity	B-X
<EOS>	B-X
Huntington	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
condition	B-X
caused	B-X
by	B-X
CAG	B-X
-	B-X
triplet	B-X
repeat	B-X
expansions	B-X

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
sperm	B-X
DNA	B-X
of	B-X
a	B-X
premutation	B-X
carrier	B-X
<EOS>	B-X
Occasionally	B-X
,	B-X
a	B-X
fully	B-X
expanded	B-X
allele	B-X
has	B-X
been	B-X
found	B-X
to	B-X
arise	B-X
from	B-X
a	B-X
premutation	B-X
of	B-X
100	B-X
or	B-X
less	B-X
triplet	B-X
repeats	B-X
<EOS>	B-X
His	B-X
sperm	B-X
showed	B-X
an	B-X
expanded	B-X
allele	B-X
in	B-X
a	B-X
tight	B-X
range	B-X
centering	B-X
on	B-X
a	B-X
size	B-X
of	B-X
approximately	B-X
320	B-X
trinucleotide	B-X
repeats	B-X
<EOS>	B-X
This	B-X
man	B-X
's	B-X
leucocyte	B-X
DNA	B-X
showed	B-X
one	B-X
normal	B-X
allele	B-X
and	B-X
one	B-X
allele	B-X
of	B-X
approximately	B-X
100	B-X
repeats	B-X

This	O
mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O
<EOS>	B-X
His	B-X
affected	B-X
son	B-X
has	B-X
repeat	B-X
sizes	B-X
of	B-X
1040	B-X
and	B-X
540	B-X
<EOS>	B-X
This	B-X
man	B-X
's	B-X
leucocyte	B-X
DNA	B-X
showed	B-X
one	B-X
normal	B-X
allele	B-X
and	B-X
one	B-X
allele	B-X
of	B-X
approximately	B-X
100	B-X
repeats	B-X
<EOS>	B-X
Occasionally	B-X
,	B-X
a	B-X
fully	B-X
expanded	B-X
allele	B-X
has	B-X
been	B-X
found	B-X
to	B-X
arise	B-X
from	B-X
a	B-X
premutation	B-X
of	B-X
100	B-X
or	B-X
less	B-X
triplet	B-X
repeats	B-X
<EOS>	B-X
His	B-X
sperm	B-X
showed	B-X
an	B-X
expanded	B-X
allele	B-X
in	B-X
a	B-X
tight	B-X
range	B-X
centering	B-X
on	B-X
a	B-X
size	B-X
of	B-X
approximately	B-X
320	B-X
trinucleotide	B-X
repeats	B-X

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
expansion	B-X
occurs	B-X
in	B-X
two	B-X
stages	B-X
,	B-X
the	B-X
first	B-X
during	B-X
meiosis	B-X
followed	B-X
by	B-X
a	B-X
second	B-X
mitotic	B-X
expansion	B-X
<EOS>	B-X
His	B-X
sperm	B-X
showed	B-X
an	B-X
expanded	B-X
allele	B-X
in	B-X
a	B-X
tight	B-X
range	B-X
centering	B-X
on	B-X
a	B-X
size	B-X
of	B-X
approximately	B-X
320	B-X
trinucleotide	B-X
repeats	B-X
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
in	B-X
all	B-X
informative	B-X
carrier	B-X
father	B-X
to	B-X
affected	B-X
child	B-X
transmissions	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
the	B-X
premutation	B-X
carrier	B-X
,	B-X
the	B-X
expansion	B-X
size	B-X
decreases	B-X
<EOS>	B-X
This	B-X
man	B-X
's	B-X
leucocyte	B-X
DNA	B-X
showed	B-X
one	B-X
normal	B-X
allele	B-X
and	B-X
one	B-X
allele	B-X
of	B-X
approximately	B-X
100	B-X
repeats	B-X

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
in	B-X
all	B-X
informative	B-X
carrier	B-X
father	B-X
to	B-X
affected	B-X
child	B-X
transmissions	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
the	B-X
premutation	B-X
carrier	B-X
,	B-X
the	B-X
expansion	B-X
size	B-X
decreases	B-X
<EOS>	B-X
Sperm	B-X
DNA	B-X
analysis	B-X
in	B-X
a	B-X
Friedreich	B-X
ataxia	B-X
premutation	B-X
carrier	B-X
suggests	B-X
both	B-X
meiotic	B-X
and	B-X
mitotic	B-X
expansion	B-X
in	B-X
the	B-X
FRDA	B-X
gene	B-X
.	B-X
<EOS>	B-X
Occasionally	B-X
,	B-X
a	B-X
fully	B-X
expanded	B-X
allele	B-X
has	B-X
been	B-X
found	B-X
to	B-X
arise	B-X
from	B-X
a	B-X
premutation	B-X
of	B-X
100	B-X
or	B-X
less	B-X
triplet	B-X
repeats	B-X
<EOS>	B-X
His	B-X
sperm	B-X
showed	B-X
an	B-X
expanded	B-X
allele	B-X
in	B-X
a	B-X
tight	B-X
range	B-X
centering	B-X
on	B-X
a	B-X
size	B-X
of	B-X
approximately	B-X
320	B-X
trinucleotide	B-X
repeats	B-X

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B-Disease
leukodystrophy	I-Disease
.	O

Deficiency	B-Disease
of	I-Disease
arylsulfatase	I-Disease
A	I-Disease
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
.	O
<EOS>	B-X
A	B-X
deficiency	B-X
of	B-X
the	B-X
enzyme	B-X
arylsulfatase	B-X
A	B-X
(	B-X
ARSA	B-X
)	B-X
causes	B-X
a	B-X
progressive	B-X
neurodegenerative	B-X
lysosomal	B-X
storage	B-X
disease	B-X
known	B-X
as	B-X
metachromatic	B-X
leukodystrophy	B-X
(	B-X
MLD	B-X
)	B-X
<EOS>	B-X
Population	B-X
carrier	B-X
rates	B-X
of	B-X
pathogenic	B-X
ARSA	B-X
gene	B-X
mutations	B-X
:	B-X
is	B-X
metachromatic	B-X
leukodystrophy	B-X
underdiagnosed	B-X
?	B-X
<EOS>	B-X
His	B-X
investigations	B-X
were	B-X
suggestive	B-X
of	B-X
metachromatic	B-X
leukodystrophy	B-X
<EOS>	B-X
Critical	B-X
issues	B-X
for	B-X
the	B-X
proper	B-X
diagnosis	B-X
of	B-X
Metachromatic	B-X
Leukodystrophy	B-X
.	B-X

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B-Disease
have	O
been	O
identified	O
.	O
<EOS>	B-X
A	B-X
number	B-X
of	B-X
ARSA	B-X
gene	B-X
mutations	B-X
responsible	B-X
for	B-X
MLD	B-X
have	B-X
been	B-X
identified	B-X
<EOS>	B-X
It	B-X
is	B-X
therefore	B-X
concluded	B-X
that	B-X
the	B-X
R496H	B-X
mutation	B-X
of	B-X
ARSA	B-X
does	B-X
not	B-X
negatively	B-X
influence	B-X
the	B-X
activity	B-X
of	B-X
ARSA	B-X
and	B-X
is	B-X
not	B-X
a	B-X
cause	B-X
of	B-X
MLD	B-X
<EOS>	B-X
Recently	B-X
,	B-X
the	B-X
R496H	B-X
mutation	B-X
of	B-X
ARSA	B-X
was	B-X
proposed	B-X
to	B-X
be	B-X
a	B-X
cause	B-X
of	B-X
MLD	B-X
(	B-X
Draghia	B-X
et	B-X
al	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
R496H	B-X
mutation	B-X
and	B-X
found	B-X
this	B-X
mutation	B-X
at	B-X
a	B-X
relatively	B-X
high	B-X
frequency	B-X
in	B-X
an	B-X
African	B-X
American	B-X
population	B-X
(	B-X
f=0	B-X

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B-Disease
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
the	B-X
R496H	B-X
mutation	B-X
of	B-X
ARSA	B-X
was	B-X
proposed	B-X
to	B-X
be	B-X
a	B-X
cause	B-X
of	B-X
MLD	B-X
(	B-X
Draghia	B-X
et	B-X
al	B-X
<EOS>	B-X
It	B-X
is	B-X
therefore	B-X
concluded	B-X
that	B-X
the	B-X
R496H	B-X
mutation	B-X
of	B-X
ARSA	B-X
does	B-X
not	B-X
negatively	B-X
influence	B-X
the	B-X
activity	B-X
of	B-X
ARSA	B-X
and	B-X
is	B-X
not	B-X
a	B-X
cause	B-X
of	B-X
MLD	B-X
<EOS>	B-X
The	B-X
R496H	B-X
mutation	B-X
of	B-X
arylsulfatase	B-X
A	B-X
does	B-X
not	B-X
cause	B-X
metachromatic	B-X
leukodystrophy	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
R496H	B-X
mutation	B-X
and	B-X
found	B-X
this	B-X
mutation	B-X
at	B-X
a	B-X
relatively	B-X
high	B-X
frequency	B-X
in	B-X
an	B-X
African	B-X
American	B-X
population	B-X
(	B-X
f=0	B-X

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O
<EOS>	B-X
The	B-X
ARSA	B-X
enzyme	B-X
activity	B-X
in	B-X
subjects	B-X
with	B-X
and	B-X
without	B-X
the	B-X
R496H	B-X
mutation	B-X
was	B-X
determined	B-X
and	B-X
found	B-X
to	B-X
be	B-X
normal	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
R496H	B-X
mutation	B-X
and	B-X
found	B-X
this	B-X
mutation	B-X
at	B-X
a	B-X
relatively	B-X
high	B-X
frequency	B-X
in	B-X
an	B-X
African	B-X
American	B-X
population	B-X
(	B-X
f=0	B-X
<EOS>	B-X
The	B-X
R496H	B-X
mutation	B-X
of	B-X
arylsulfatase	B-X
A	B-X
does	B-X
not	B-X
cause	B-X
metachromatic	B-X
leukodystrophy	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
the	B-X
R496H	B-X
mutation	B-X
of	B-X
ARSA	B-X
was	B-X
proposed	B-X
to	B-X
be	B-X
a	B-X
cause	B-X
of	B-X
MLD	B-X
(	B-X
Draghia	B-X
et	B-X
al	B-X

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	B-Disease

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
in	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	B-Disease
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	O

Large	O
-	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O
CA12	O
.	O
<EOS>	B-X
Large	B-X
-	B-X
scale	B-X
RNA	B-X
differential	B-X
display	B-X
technology	B-X
applied	B-X
to	B-X
these	B-X
cell	B-X
lines	B-X
identified	B-X
several	B-X
differentially	B-X
expressed	B-X
genes	B-X
,	B-X
including	B-X
an	B-X
alpha	B-X
carbonic	B-X
anhydrase	B-X
gene	B-X
,	B-X
termed	B-X
CA12	B-X
<EOS>	B-X
Reintroduced	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
strongly	B-X
inhibited	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
CA12	B-X
gene	B-X
in	B-X
the	B-X
parental	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
transmembrane	B-X
carbonic	B-X
anhydrases	B-X
in	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
by	B-X
wild	B-X
-	B-X
type	B-X
von	B-X
Hippel	B-X
-	B-X
Lindau	B-X
transgenes	B-X
.	B-X
<EOS>	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
CA9	B-X
,	B-X
encoding	B-X
another	B-X
transmembrane	B-X
CA	B-X
with	B-X
an	B-X
intact	B-X
catalytic	B-X
domain	B-X

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O
<EOS>	B-X
The	B-X
deduced	B-X
protein	B-X
sequence	B-X
was	B-X
classified	B-X
as	B-X
a	B-X
one	B-X
-	B-X
pass	B-X
transmembrane	B-X
CA	B-X
possessing	B-X
an	B-X
apparently	B-X
intact	B-X
catalytic	B-X
domain	B-X
in	B-X
the	B-X
extracellular	B-X
CA	B-X
module	B-X
<EOS>	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
CA9	B-X
,	B-X
encoding	B-X
another	B-X
transmembrane	B-X
CA	B-X
with	B-X
an	B-X
intact	B-X
catalytic	B-X
domain	B-X
<EOS>	B-X
Reintroduced	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
strongly	B-X
inhibited	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
CA12	B-X
gene	B-X
in	B-X
the	B-X
parental	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
2	B-X
respectively	B-X
,	B-X
regions	B-X
prone	B-X
to	B-X
amplification	B-X
in	B-X
some	B-X
human	B-X
cancers	B-X

Reintroduced	O
wild	O
-	O
type	O
VHL	B-Disease
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
cell	O
lines	O
.	O
<EOS>	B-X
Reintroduced	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
strongly	B-X
inhibited	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
CA12	B-X
gene	B-X
in	B-X
the	B-X
parental	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Although	B-X
both	B-X
domains	B-X
of	B-X
the	B-X
VHL	B-X
protein	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
CA12	B-X
expression	B-X
,	B-X
the	B-X
elongin	B-X
binding	B-X
domain	B-X
alone	B-X
could	B-X
effectively	B-X
regulate	B-X
CA9	B-X
expression	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
are	B-X
needed	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
CA	B-X
IX	B-X
and	B-X
CA	B-X
XII	B-X
enzymes	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pH	B-X
in	B-X
the	B-X
extracellular	B-X
microenvironment	B-X
and	B-X
its	B-X
potential	B-X
impact	B-X
on	B-X
cancer	B-X
cell	B-X
growth	B-X
<EOS>	B-X
The	B-X
deduced	B-X
protein	B-X
sequence	B-X
was	B-X
classified	B-X
as	B-X
a	B-X
one	B-X
-	B-X
pass	B-X
transmembrane	B-X
CA	B-X
possessing	B-X
an	B-X
apparently	B-X
intact	B-X
catalytic	B-X
domain	B-X
in	B-X
the	B-X
extracellular	B-X
CA	B-X
module	B-X

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O
<EOS>	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
CA9	B-X
,	B-X
encoding	B-X
another	B-X
transmembrane	B-X
CA	B-X
with	B-X
an	B-X
intact	B-X
catalytic	B-X
domain	B-X
<EOS>	B-X
The	B-X
deduced	B-X
protein	B-X
sequence	B-X
was	B-X
classified	B-X
as	B-X
a	B-X
one	B-X
-	B-X
pass	B-X
transmembrane	B-X
CA	B-X
possessing	B-X
an	B-X
apparently	B-X
intact	B-X
catalytic	B-X
domain	B-X
in	B-X
the	B-X
extracellular	B-X
CA	B-X
module	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
are	B-X
needed	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
CA	B-X
IX	B-X
and	B-X
CA	B-X
XII	B-X
enzymes	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pH	B-X
in	B-X
the	B-X
extracellular	B-X
microenvironment	B-X
and	B-X
its	B-X
potential	B-X
impact	B-X
on	B-X
cancer	B-X
cell	B-X
growth	B-X
<EOS>	B-X
Large	B-X
-	B-X
scale	B-X
RNA	B-X
differential	B-X
display	B-X
technology	B-X
applied	B-X
to	B-X
these	B-X
cell	B-X
lines	B-X
identified	B-X
several	B-X
differentially	B-X
expressed	B-X
genes	B-X
,	B-X
including	B-X
an	B-X
alpha	B-X
carbonic	B-X
anhydrase	B-X
gene	B-X
,	B-X
termed	B-X
CA12	B-X

Although	O
both	O
domains	O
of	O
the	O
VHL	B-Disease
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O
.	O
<EOS>	B-X
Although	B-X
both	B-X
domains	B-X
of	B-X
the	B-X
VHL	B-X
protein	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
CA12	B-X
expression	B-X
,	B-X
the	B-X
elongin	B-X
binding	B-X
domain	B-X
alone	B-X
could	B-X
effectively	B-X
regulate	B-X
CA9	B-X
expression	B-X
<EOS>	B-X
Reintroduced	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
strongly	B-X
inhibited	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
CA12	B-X
gene	B-X
in	B-X
the	B-X
parental	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
are	B-X
needed	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
CA	B-X
IX	B-X
and	B-X
CA	B-X
XII	B-X
enzymes	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pH	B-X
in	B-X
the	B-X
extracellular	B-X
microenvironment	B-X
and	B-X
its	B-X
potential	B-X
impact	B-X
on	B-X
cancer	B-X
cell	B-X
growth	B-X
<EOS>	B-X
2	B-X
respectively	B-X
,	B-X
regions	B-X
prone	B-X
to	B-X
amplification	B-X
in	B-X
some	B-X
human	B-X
cancers	B-X

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O
<EOS>	B-X
We	B-X
mapped	B-X
CA12	B-X
and	B-X
CA9	B-X
loci	B-X
to	B-X
chromosome	B-X
bands	B-X
15q22	B-X
and	B-X
17q21	B-X
<EOS>	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
CA9	B-X
,	B-X
encoding	B-X
another	B-X
transmembrane	B-X
CA	B-X
with	B-X
an	B-X
intact	B-X
catalytic	B-X
domain	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
are	B-X
needed	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
CA	B-X
IX	B-X
and	B-X
CA	B-X
XII	B-X
enzymes	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pH	B-X
in	B-X
the	B-X
extracellular	B-X
microenvironment	B-X
and	B-X
its	B-X
potential	B-X
impact	B-X
on	B-X
cancer	B-X
cell	B-X
growth	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
transmembrane	B-X
carbonic	B-X
anhydrases	B-X
in	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
by	B-X
wild	B-X
-	B-X
type	B-X
von	B-X
Hippel	B-X
-	B-X
Lindau	B-X
transgenes	B-X
.	B-X

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B-Disease
.	O
<EOS>	B-X
2	B-X
respectively	B-X
,	B-X
regions	B-X
prone	B-X
to	B-X
amplification	B-X
in	B-X
some	B-X
human	B-X
cancers	B-X
<EOS>	B-X
Individual	B-X
signatures	B-X
demonstrate	B-X
amplification	B-X
or	B-X
deletion	B-X
dominance	B-X
<EOS>	B-X
Common	B-X
fragile	B-X
sites	B-X
(	B-X
cFS	B-X
)	B-X
represent	B-X
chromosomal	B-X
regions	B-X
that	B-X
are	B-X
prone	B-X
to	B-X
breakage	B-X
after	B-X
partial	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
<EOS>	B-X
1	B-X
,	B-X
whereas	B-X
in	B-X
distal	B-X
CRC	B-X
the	B-X
region	B-X
of	B-X
AI	B-X
frequently	B-X
included	B-X
all	B-X
the	B-X
informative	B-X
markers	B-X

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B-Disease
cell	O
growth	O
.	O
<EOS>	B-X
Additional	B-X
experiments	B-X
are	B-X
needed	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
CA	B-X
IX	B-X
and	B-X
CA	B-X
XII	B-X
enzymes	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pH	B-X
in	B-X
the	B-X
extracellular	B-X
microenvironment	B-X
and	B-X
its	B-X
potential	B-X
impact	B-X
on	B-X
cancer	B-X
cell	B-X
growth	B-X
<EOS>	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
CA9	B-X
,	B-X
encoding	B-X
another	B-X
transmembrane	B-X
CA	B-X
with	B-X
an	B-X
intact	B-X
catalytic	B-X
domain	B-X
<EOS>	B-X
Reintroduced	B-X
wild	B-X
-	B-X
type	B-X
VHL	B-X
strongly	B-X
inhibited	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
CA12	B-X
gene	B-X
in	B-X
the	B-X
parental	B-X
renal	B-X
cell	B-X
carcinoma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Although	B-X
both	B-X
domains	B-X
of	B-X
the	B-X
VHL	B-X
protein	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
CA12	B-X
expression	B-X
,	B-X
the	B-X
elongin	B-X
binding	B-X
domain	B-X
alone	B-X
could	B-X
effectively	B-X
regulate	B-X
CA9	B-X
expression	B-X

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B-Disease
mellitus	I-Disease
and	O
optic	B-Disease
atrophy	I-Disease
(	O
Wolfram	B-Disease
syndrome	I-Disease
)	O
.	O
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
transmembrane	B-X
protein	B-X
is	B-X
mutated	B-X
in	B-X
patients	B-X
with	B-X
diabetes	B-X
mellitus	B-X
and	B-X
optic	B-X
atrophy	B-X
(	B-X
Wolfram	B-X
syndrome	B-X
)	B-X
.	B-X
<EOS>	B-X
WFS1	B-X
mutations	B-X
in	B-X
Spanish	B-X
patients	B-X
with	B-X
diabetes	B-X
mellitus	B-X
and	B-X
deafness	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
presence	B-X
of	B-X
WFS1	B-X
variants	B-X
in	B-X
three	B-X
groups	B-X
of	B-X
individuals	B-X
:	B-X
patients	B-X
with	B-X
diabetes	B-X
mellitus	B-X
,	B-X
patients	B-X
with	B-X
deafness	B-X
and	B-X
patients	B-X
with	B-X
both	B-X
conditions	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
a	B-X
novel	B-X
gene	B-X
(	B-X
WFS1	B-X
)	B-X
encoding	B-X
a	B-X
putative	B-X
transmembrane	B-X
protein	B-X
were	B-X
found	B-X
in	B-X
all	B-X
affected	B-X
individuals	B-X
in	B-X
six	B-X
WFS	B-X
families	B-X
,	B-X
and	B-X
these	B-X
mutations	B-X
were	B-X
associated	B-X
with	B-X
the	B-X
disease	B-X
phenotype	B-X

Wolfram	B-Disease
syndrome	I-Disease
(	O
WFS	B-Disease
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disorder	I-Disease
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
progressive	O
optic	B-Disease
atrophy	I-Disease
.	O
<EOS>	B-X
Wolfram	B-X
syndrome	B-X
(	B-X
WFS	B-X
;	B-X
OMIM	B-X
222300	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
recessive	B-X
neurodegenerative	B-X
disorder	B-X
defined	B-X
by	B-X
young	B-X
-	B-X
onset	B-X
non	B-X
-	B-X
immune	B-X
insulin	B-X
-	B-X
dependent	B-X
diabetes	B-X
mellitus	B-X
and	B-X
progressive	B-X
optic	B-X
atrophy	B-X
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
transmembrane	B-X
protein	B-X
is	B-X
mutated	B-X
in	B-X
patients	B-X
with	B-X
diabetes	B-X
mellitus	B-X
and	B-X
optic	B-X
atrophy	B-X
(	B-X
Wolfram	B-X
syndrome	B-X
)	B-X
.	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
meiotic	B-X
recombinants	B-X
and	B-X
disease	B-X
-	B-X
associated	B-X
haplotypes	B-X
,	B-X
the	B-X
WFS	B-X
gene	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
BAC	B-X
/	B-X
P1	B-X
contig	B-X
of	B-X
less	B-X
than	B-X
250	B-X
kb	B-X
<EOS>	B-X
WFS1	B-X
appears	B-X
to	B-X
function	B-X
in	B-X
survival	B-X
of	B-X
islet	B-X
beta	B-X
-	B-X
cells	B-X
and	B-X
neurons	B-X

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O
<EOS>	B-X
Linkage	B-X
to	B-X
markers	B-X
on	B-X
chromosome	B-X
4p	B-X
was	B-X
confirmed	B-X
in	B-X
five	B-X
families	B-X
<EOS>	B-X
Additional	B-X
ASP	B-X
analyses	B-X
on	B-X
chromosomes	B-X
18	B-X
and	B-X
21q	B-X
marker	B-X
data	B-X
were	B-X
performed	B-X
using	B-X
disease	B-X
phenotype	B-X
models	B-X
defined	B-X
previously	B-X
<EOS>	B-X
5	B-X
)	B-X
occurred	B-X
on	B-X
chromosome	B-X
1p	B-X
between	B-X
markers	B-X
D1S1597	B-X
and	B-X
D1S407	B-X
(	B-X
1p36	B-X
<EOS>	B-X
The	B-X
highest	B-X
maximum	B-X
likelihood	B-X
scores	B-X
(	B-X
MLS	B-X
)	B-X
were	B-X
obtained	B-X
on	B-X
chromosomes	B-X
3q	B-X
(	B-X
MLS	B-X
=	B-X
2	B-X

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	B-Disease
gene	O
was	O
localized	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
meiotic	B-X
recombinants	B-X
and	B-X
disease	B-X
-	B-X
associated	B-X
haplotypes	B-X
,	B-X
the	B-X
WFS	B-X
gene	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
BAC	B-X
/	B-X
P1	B-X
contig	B-X
of	B-X
less	B-X
than	B-X
250	B-X
kb	B-X
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
transmembrane	B-X
protein	B-X
is	B-X
mutated	B-X
in	B-X
patients	B-X
with	B-X
diabetes	B-X
mellitus	B-X
and	B-X
optic	B-X
atrophy	B-X
(	B-X
Wolfram	B-X
syndrome	B-X
)	B-X
.	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
a	B-X
novel	B-X
gene	B-X
(	B-X
WFS1	B-X
)	B-X
encoding	B-X
a	B-X
putative	B-X
transmembrane	B-X
protein	B-X
were	B-X
found	B-X
in	B-X
all	B-X
affected	B-X
individuals	B-X
in	B-X
six	B-X
WFS	B-X
families	B-X
,	B-X
and	B-X
these	B-X
mutations	B-X
were	B-X
associated	B-X
with	B-X
the	B-X
disease	B-X
phenotype	B-X
<EOS>	B-X
Linkage	B-X
to	B-X
markers	B-X
on	B-X
chromosome	B-X
4p	B-X
was	B-X
confirmed	B-X
in	B-X
five	B-X
families	B-X

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B-Disease
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

WFS1	O
appears	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O
<EOS>	B-X
WFS1	B-X
appears	B-X
to	B-X
function	B-X
in	B-X
survival	B-X
of	B-X
islet	B-X
beta	B-X
-	B-X
cells	B-X
and	B-X
neurons	B-X
<EOS>	B-X
The	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
important	B-X
in	B-X
the	B-X
survival	B-X
and	B-X
maintenance	B-X
of	B-X
normal	B-X
pancreatic	B-X
beta	B-X
-	B-X
cells	B-X
and	B-X
neurons	B-X
<EOS>	B-X
By	B-X
haplotype	B-X
analysis	B-X
and	B-X
recombination	B-X
mapping	B-X
in	B-X
5	B-X
families	B-X
,	B-X
we	B-X
localized	B-X
the	B-X
gene	B-X
within	B-X
a	B-X
region	B-X
less	B-X
than	B-X
250	B-X
kb	B-X
on	B-X
chromosome	B-X
6p	B-X
<EOS>	B-X
3	B-X
kDa	B-X
with	B-X
9	B-X
to	B-X
10	B-X
putative	B-X
transmembrane	B-X
domains	B-X

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B-Disease
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O
<EOS>	B-X
Stable	B-X
interaction	B-X
between	B-X
the	B-X
products	B-X
of	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
tumor	B-X
suppressor	B-X
genes	B-X
in	B-X
mitotic	B-X
and	B-X
meiotic	B-X
cells	B-X
.	B-X
<EOS>	B-X
(	B-X
1998	B-X
)	B-X
Stable	B-X
interaction	B-X
between	B-X
the	B-X
products	B-X
of	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
tumor	B-X
suppressor	B-X
genes	B-X
in	B-X
mitotic	B-X
and	B-X
meiotic	B-X
cells	B-X
<EOS>	B-X
(	B-X
1997	B-X
)	B-X
Association	B-X
of	B-X
BRCA1	B-X
with	B-X
Rad51	B-X
in	B-X
mitotic	B-X
and	B-X
meiotic	B-X
cells	B-X
<EOS>	B-X
Heritable	B-X
mutations	B-X
in	B-X
the	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
the	B-X
DNA	B-X
double	B-X
-	B-X
strand	B-X
break	B-X
(	B-X
DSB	B-X
)	B-X
repair	B-X
pathway	B-X
disrupt	B-X
binding	B-X
of	B-X
the	B-X
encoded	B-X
proteins	B-X
,	B-X
transport	B-X
into	B-X
the	B-X
nucleus	B-X
and	B-X
initiation	B-X
of	B-X
homologous	B-X
recombination	B-X
,	B-X
thereby	B-X
increasing	B-X
cancer	B-X
risk	B-X
[	B-X
Scully	B-X
,	B-X
R	B-X

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O
<EOS>	B-X
Both	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutation	B-X
carriers	B-X
were	B-X
significantly	B-X
more	B-X
likely	B-X
to	B-X
be	B-X
early	B-X
-	B-X
onset	B-X
and	B-X
bilateral	B-X
breast	B-X
cancers	B-X
,	B-X
high	B-X
-	B-X
grade	B-X
cancer	B-X
,	B-X
and	B-X
to	B-X
have	B-X
a	B-X
family	B-X
history	B-X
of	B-X
breast	B-X
cancer	B-X
compared	B-X
with	B-X
non	B-X
-	B-X
carriers	B-X
<EOS>	B-X
Currently	B-X
,	B-X
their	B-X
contribution	B-X
to	B-X
familial	B-X
breast	B-X
cancer	B-X
(	B-X
BC	B-X
)	B-X
and	B-X
ovarian	B-X
cancer	B-X
(	B-X
OVC	B-X
)	B-X
in	B-X
South	B-X
Africa	B-X
(	B-X
SA	B-X
)	B-X
is	B-X
unknown	B-X
<EOS>	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
germline	B-X
variants	B-X
in	B-X
breast	B-X
cancer	B-X
patients	B-X
from	B-X
the	B-X
Republic	B-X
of	B-X
Macedonia	B-X
.	B-X
<EOS>	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
genes	B-X
mutations	B-X
among	B-X
high	B-X
risk	B-X
breast	B-X
cancer	B-X
patients	B-X
in	B-X
Jordan	B-X
.	B-X

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O
<EOS>	B-X
LD	B-X
-	B-X
Cu	B-X
offered	B-X
a	B-X
lower	B-X
activation	B-X
energy	B-X
for	B-X
WGSR	B-X
to	B-X
H2	B-X
under	B-X
UV	B-X
-	B-X
Vis	B-X
irradiation	B-X
(	B-X
1	B-X
<EOS>	B-X
5	B-X
%	B-X
,	B-X
regardless	B-X
the	B-X
plates	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
chitosan	B-X
induce	B-X
a	B-X
faster	B-X
osteogenic	B-X
differentiation	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
water	B-X
molecules	B-X
in	B-X
thermal	B-X
catalysis	B-X
typically	B-X
requires	B-X
high	B-X
temperatures	B-X
,	B-X
representing	B-X
an	B-X
obstacle	B-X
to	B-X
catalyst	B-X
development	B-X
for	B-X
the	B-X
low	B-X
-	B-X
temperature	B-X
water	B-X
-	B-X
gas	B-X
shift	B-X
reaction	B-X
(	B-X
WGSR	B-X
)	B-X
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
Vickers	B-X
microhardness	B-X
,	B-X
surface	B-X
roughness	B-X
,	B-X
initial	B-X
adhesion	B-X
,	B-X
and	B-X
osteogenic	B-X
differentiation	B-X
on	B-X
titanium	B-X
(	B-X
Ti	B-X
)	B-X
and	B-X
nitrurized	B-X
titanium	B-X
(	B-X
NTi	B-X
)	B-X
plates	B-X
were	B-X
treated	B-X
by	B-X
UV	B-X
irradiation	B-X
and	B-X
chitosan	B-X

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O
<EOS>	B-X
BMAL1	B-X
collaborates	B-X
with	B-X
CLOCK	B-X
to	B-X
directly	B-X
promote	B-X
DNA	B-X
double	B-X
-	B-X
strand	B-X
break	B-X
repair	B-X
and	B-X
tumor	B-X
chemoresistance	B-X
.	B-X
<EOS>	B-X
The	B-X
multi	B-X
-	B-X
BRCT	B-X
domain	B-X
protein	B-X
DDRM2	B-X
promotes	B-X
the	B-X
recruitment	B-X
of	B-X
RAD51	B-X
to	B-X
DNA	B-X
damage	B-X
sites	B-X
to	B-X
facilitate	B-X
homologous	B-X
recombination	B-X
.	B-X
<EOS>	B-X
The	B-X
nucleolytic	B-X
processing	B-X
(	B-X
resection	B-X
)	B-X
of	B-X
a	B-X
DNA	B-X
double	B-X
-	B-X
strand	B-X
break	B-X
(	B-X
DSB	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
step	B-X
to	B-X
repair	B-X
the	B-X
lesion	B-X
by	B-X
homologous	B-X
recombination	B-X
(	B-X
HR	B-X
)	B-X
<EOS>	B-X
Two	B-X
error	B-X
-	B-X
free	B-X
pathways	B-X
can	B-X
bypass	B-X
the	B-X
lesions	B-X
:	B-X
the	B-X
template	B-X
switching	B-X
pathway	B-X
,	B-X
which	B-X
uses	B-X
the	B-X
sister	B-X
chromatid	B-X
as	B-X
a	B-X
template	B-X
,	B-X
and	B-X
the	B-X
homologous	B-X
recombination	B-X
pathway	B-X
(	B-X
HR	B-X
)	B-X
,	B-X
which	B-X
also	B-X
can	B-X
use	B-X
the	B-X
homologous	B-X
chromosome	B-X
as	B-X
template	B-X

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
.	O
<EOS>	B-X
The	B-X
most	B-X
relevant	B-X
findings	B-X
were	B-X
in	B-X
patients	B-X
belonging	B-X
to	B-X
hereditary	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
syndrome	B-X
<EOS>	B-X
The	B-X
most	B-X
frequent	B-X
condition	B-X
was	B-X
hereditary	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
syndrome	B-X
(	B-X
60	B-X
%	B-X
)	B-X
<EOS>	B-X
The	B-X
data	B-X
indicated	B-X
that	B-X
ZHX2	B-X
may	B-X
be	B-X
considered	B-X
a	B-X
promising	B-X
biomarker	B-X
in	B-X
ovarian	B-X
cancer	B-X
and	B-X
that	B-X
inhibition	B-X
of	B-X
its	B-X
expression	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
in	B-X
ovarian	B-X
cancer	B-X
treatment	B-X
<EOS>	B-X
SLFN5	B-X
promotes	B-X
reversible	B-X
epithelial	B-X
and	B-X
mesenchymal	B-X
transformation	B-X
in	B-X
ovarian	B-X
cancer	B-X
.	B-X

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O
<EOS>	B-X
A	B-X
novel	B-X
Arg362Ser	B-X
mutation	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
gene	B-X
(	B-X
CYP27	B-X
)	B-X
:	B-X
its	B-X
effects	B-X
on	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
and	B-X
enzyme	B-X
activity	B-X
.	B-X
<EOS>	B-X
A	B-X
novel	B-X
C	B-X
to	B-X
A	B-X
mutation	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
gene	B-X
(	B-X
CYP27	B-X
)	B-X
was	B-X
identified	B-X
by	B-X
sequencing	B-X
amplified	B-X
CYP27	B-X
gene	B-X
products	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
cerebrotendinous	B-X
xanthomatosis	B-X
(	B-X
CTX	B-X
)	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
C	B-X
to	B-X
A	B-X
mutation	B-X
at	B-X
the	B-X
penultimate	B-X
nucleotide	B-X
of	B-X
exon	B-X
6	B-X
of	B-X
the	B-X
CYP27	B-X
gene	B-X
not	B-X
only	B-X
causes	B-X
the	B-X
deficiency	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
activity	B-X
,	B-X
but	B-X
also	B-X
partially	B-X
leads	B-X
to	B-X
alternative	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
CYP27	B-X
gene	B-X
mRNA	B-X
in	B-X
the	B-X
patient	B-X
represented	B-X
52	B-X

A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B-Disease
xanthomatosis	I-Disease
(	O
CTX	B-Disease
)	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O
.	O
<EOS>	B-X
The	B-X
mutation	B-X
changed	B-X
the	B-X
adrenodoxin	B-X
cofactor	B-X
binding	B-X
residue	B-X
362Arg	B-X
to	B-X
362Ser	B-X
(	B-X
CGT	B-X
362Arg	B-X
to	B-X
AGT	B-X
362Ser	B-X
)	B-X
,	B-X
and	B-X
was	B-X
responsible	B-X
for	B-X
deficiency	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
activity	B-X
,	B-X
as	B-X
confirmed	B-X
by	B-X
expression	B-X
of	B-X
mutant	B-X
cDNA	B-X
into	B-X
COS	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
C	B-X
to	B-X
A	B-X
mutation	B-X
at	B-X
the	B-X
penultimate	B-X
nucleotide	B-X
of	B-X
exon	B-X
6	B-X
of	B-X
the	B-X
CYP27	B-X
gene	B-X
not	B-X
only	B-X
causes	B-X
the	B-X
deficiency	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
activity	B-X
,	B-X
but	B-X
also	B-X
partially	B-X
leads	B-X
to	B-X
alternative	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
As	B-X
the	B-X
mutation	B-X
occurred	B-X
at	B-X
the	B-X
penultimate	B-X
nucleotide	B-X
of	B-X
exon	B-X
6	B-X
(	B-X
	B-X
-	B-X
2	B-X
position	B-X
of	B-X
exon	B-X
6	B-X
-	B-X
intron	B-X
6	B-X
splice	B-X
site	B-X
)	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
the	B-X
mutation	B-X
may	B-X
partially	B-X
affect	B-X
the	B-X
normal	B-X
splicing	B-X
efficiency	B-X
in	B-X
exon	B-X
6	B-X
and	B-X
cause	B-X
alternative	B-X
splicing	B-X
elsewhere	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
decreased	B-X
transcript	B-X
in	B-X
the	B-X
patient	B-X
<EOS>	B-X
Transfection	B-X
of	B-X
constructed	B-X
minigenes	B-X
,	B-X
with	B-X
or	B-X
without	B-X
the	B-X
mutation	B-X
,	B-X
into	B-X
COS	B-X
-	B-X
1	B-X
cells	B-X
confirmed	B-X
that	B-X
the	B-X
mutant	B-X
minigene	B-X
was	B-X
responsible	B-X
for	B-X
a	B-X
mRNA	B-X
species	B-X
alternatively	B-X
spliced	B-X
at	B-X
an	B-X
activated	B-X
cryptic	B-X
5	B-X
'	B-X
splice	B-X
site	B-X
88	B-X
bp	B-X
upstream	B-X
from	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
exon	B-X
6	B-X

Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
.	O
<EOS>	B-X
Quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
CYP27	B-X
gene	B-X
mRNA	B-X
in	B-X
the	B-X
patient	B-X
represented	B-X
52	B-X
<EOS>	B-X
A	B-X
novel	B-X
C	B-X
to	B-X
A	B-X
mutation	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
gene	B-X
(	B-X
CYP27	B-X
)	B-X
was	B-X
identified	B-X
by	B-X
sequencing	B-X
amplified	B-X
CYP27	B-X
gene	B-X
products	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
cerebrotendinous	B-X
xanthomatosis	B-X
(	B-X
CTX	B-X
)	B-X
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
regarding	B-X
effects	B-X
on	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
of	B-X
a	B-X
mutation	B-X
at	B-X
the	B-X
	B-X
-	B-X
2	B-X
position	B-X
of	B-X
a	B-X
5	B-X
'	B-X
splice	B-X
site	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
C	B-X
to	B-X
A	B-X
mutation	B-X
at	B-X
the	B-X
penultimate	B-X
nucleotide	B-X
of	B-X
exon	B-X
6	B-X
of	B-X
the	B-X
CYP27	B-X
gene	B-X
not	B-X
only	B-X
causes	B-X
the	B-X
deficiency	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
activity	B-X
,	B-X
but	B-X
also	B-X
partially	B-X
leads	B-X
to	B-X
alternative	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
of	B-X
the	B-X
gene	B-X

5	O
%	O
of	O
the	O
normal	O
level	O
.	O
<EOS>	B-X
1	B-X
%	B-X
men	B-X
;	B-X
mean	B-X
glycated	B-X
hemoglobin	B-X
level	B-X
7	B-X
<EOS>	B-X
021	B-X
)	B-X
confectionery	B-X
intake	B-X
,	B-X
respectively	B-X
<EOS>	B-X
52	B-X
mm	B-X
in	B-X
the	B-X
healthy	B-X
group	B-X
and	B-X
4	B-X
<EOS>	B-X
7	B-X
%	B-X
)	B-X
had	B-X
normal	B-X
postoperative	B-X
amylase	B-X
(	B-X
non	B-X
-	B-X
POH	B-X
)	B-X
levels	B-X

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	O
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O
<EOS>	B-X
As	B-X
the	B-X
mutation	B-X
occurred	B-X
at	B-X
the	B-X
penultimate	B-X
nucleotide	B-X
of	B-X
exon	B-X
6	B-X
(	B-X
	B-X
-	B-X
2	B-X
position	B-X
of	B-X
exon	B-X
6	B-X
-	B-X
intron	B-X
6	B-X
splice	B-X
site	B-X
)	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
the	B-X
mutation	B-X
may	B-X
partially	B-X
affect	B-X
the	B-X
normal	B-X
splicing	B-X
efficiency	B-X
in	B-X
exon	B-X
6	B-X
and	B-X
cause	B-X
alternative	B-X
splicing	B-X
elsewhere	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
decreased	B-X
transcript	B-X
in	B-X
the	B-X
patient	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
C	B-X
to	B-X
A	B-X
mutation	B-X
at	B-X
the	B-X
penultimate	B-X
nucleotide	B-X
of	B-X
exon	B-X
6	B-X
of	B-X
the	B-X
CYP27	B-X
gene	B-X
not	B-X
only	B-X
causes	B-X
the	B-X
deficiency	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
activity	B-X
,	B-X
but	B-X
also	B-X
partially	B-X
leads	B-X
to	B-X
alternative	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Transfection	B-X
of	B-X
constructed	B-X
minigenes	B-X
,	B-X
with	B-X
or	B-X
without	B-X
the	B-X
mutation	B-X
,	B-X
into	B-X
COS	B-X
-	B-X
1	B-X
cells	B-X
confirmed	B-X
that	B-X
the	B-X
mutant	B-X
minigene	B-X
was	B-X
responsible	B-X
for	B-X
a	B-X
mRNA	B-X
species	B-X
alternatively	B-X
spliced	B-X
at	B-X
an	B-X
activated	B-X
cryptic	B-X
5	B-X
'	B-X
splice	B-X
site	B-X
88	B-X
bp	B-X
upstream	B-X
from	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
exon	B-X
6	B-X
<EOS>	B-X
The	B-X
mutation	B-X
changed	B-X
the	B-X
adrenodoxin	B-X
cofactor	B-X
binding	B-X
residue	B-X
362Arg	B-X
to	B-X
362Ser	B-X
(	B-X
CGT	B-X
362Arg	B-X
to	B-X
AGT	B-X
362Ser	B-X
)	B-X
,	B-X
and	B-X
was	B-X
responsible	B-X
for	B-X
deficiency	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
activity	B-X
,	B-X
as	B-X
confirmed	B-X
by	B-X
expression	B-X
of	B-X
mutant	B-X
cDNA	B-X
into	B-X
COS	B-X
-	B-X
1	B-X
cells	B-X

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	O
6	O
.	O
<EOS>	B-X
Transfection	B-X
of	B-X
cells	B-X
with	B-X
either	B-X
of	B-X
the	B-X
blockers	B-X
significantly	B-X
decreased	B-X
both	B-X
Î²	B-X
-	B-X
catenin	B-X
protein	B-X
levels	B-X
and	B-X
Î²	B-X
-	B-X
catenin	B-X
-	B-X
mediated	B-X
transcriptional	B-X
activities	B-X
<EOS>	B-X
Wild	B-X
type	B-X
and	B-X
mutant	B-X
minigene	B-X
vectors	B-X
containing	B-X
exon	B-X
23	B-X
,	B-X
intron	B-X
23	B-X
and	B-X
exon	B-X
24	B-X
of	B-X
the	B-X
UNC13D	B-X
gene	B-X
were	B-X
constructed	B-X
and	B-X
transfected	B-X
into	B-X
HEK293T	B-X
cells	B-X
by	B-X
lipofectamine	B-X
reagent	B-X
<EOS>	B-X
We	B-X
reproduced	B-X
gene	B-X
mutations	B-X
by	B-X
mutagenesis	B-X
,	B-X
inserted	B-X
the	B-X
mutated	B-X
genes	B-X
into	B-X
minigene	B-X
vectors	B-X
,	B-X
and	B-X
investigated	B-X
the	B-X
pathogenicity	B-X
and	B-X
onset	B-X
mechanisms	B-X
of	B-X
these	B-X
variants	B-X
<EOS>	B-X
The	B-X
studies	B-X
were	B-X
reviewed	B-X
with	B-X
regard	B-X
to	B-X
the	B-X
investigated	B-X
splicing	B-X
regulatory	B-X
events	B-X
and	B-X
the	B-X
experimental	B-X
strategy	B-X
to	B-X
construct	B-X
and	B-X
perform	B-X
a	B-X
splicing	B-X
reporter	B-X
minigene	B-X
assay	B-X

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
sterol	I-Disease
27	I-Disease
-	I-Disease
hydroxylase	I-Disease
activity	I-Disease
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O
the	O
gene	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
.	O
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
regarding	B-X
effects	B-X
on	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
of	B-X
a	B-X
mutation	B-X
at	B-X
the	B-X
	B-X
-	B-X
2	B-X
position	B-X
of	B-X
a	B-X
5	B-X
'	B-X
splice	B-X
site	B-X
<EOS>	B-X
Transfection	B-X
of	B-X
constructed	B-X
minigenes	B-X
,	B-X
with	B-X
or	B-X
without	B-X
the	B-X
mutation	B-X
,	B-X
into	B-X
COS	B-X
-	B-X
1	B-X
cells	B-X
confirmed	B-X
that	B-X
the	B-X
mutant	B-X
minigene	B-X
was	B-X
responsible	B-X
for	B-X
a	B-X
mRNA	B-X
species	B-X
alternatively	B-X
spliced	B-X
at	B-X
an	B-X
activated	B-X
cryptic	B-X
5	B-X
'	B-X
splice	B-X
site	B-X
88	B-X
bp	B-X
upstream	B-X
from	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
exon	B-X
6	B-X
<EOS>	B-X
A	B-X
novel	B-X
Arg362Ser	B-X
mutation	B-X
in	B-X
the	B-X
sterol	B-X
27	B-X
-	B-X
hydroxylase	B-X
gene	B-X
(	B-X
CYP27	B-X
)	B-X
:	B-X
its	B-X
effects	B-X
on	B-X
pre	B-X
-	B-X
mRNA	B-X
splicing	B-X
and	B-X
enzyme	B-X
activity	B-X
.	B-X
<EOS>	B-X
Quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
CYP27	B-X
gene	B-X
mRNA	B-X
in	B-X
the	B-X
patient	B-X
represented	B-X
52	B-X

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
in	O
the	O
Dutch	O
population	O
.	O
<EOS>	B-X
ATM	B-X
germline	B-X
mutations	B-X
in	B-X
classical	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
patients	B-X
in	B-X
the	B-X
Dutch	B-X
population	B-X
.	B-X
<EOS>	B-X
In	B-X
our	B-X
study	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
ATM	B-X
mutation	B-X
spectrum	B-X
in	B-X
19	B-X
classical	B-X
A	B-X
-	B-X
T	B-X
patients	B-X
,	B-X
including	B-X
some	B-X
immigrant	B-X
populations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
12	B-X
of	B-X
Dutch	B-X
ethnic	B-X
origin	B-X
<EOS>	B-X
Germline	B-X
mutations	B-X
in	B-X
the	B-X
ATM	B-X
gene	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
autosomal	B-X
recessive	B-X
disorder	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
(	B-X
A	B-X
-	B-X
T	B-X
)	B-X
<EOS>	B-X
All	B-X
patients	B-X
manifested	B-X
classical	B-X
A	B-X
-	B-X
T	B-X
and	B-X
increased	B-X
cellular	B-X
radioresistant	B-X
DNA	B-X
synthesis	B-X

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	O
.	O
<EOS>	B-X
Both	B-X
the	B-X
protein	B-X
truncation	B-X
test	B-X
(	B-X
PTT	B-X
)	B-X
and	B-X
the	B-X
restriction	B-X
endonuclease	B-X
fingerprinting	B-X
(	B-X
REF	B-X
)	B-X
method	B-X
were	B-X
used	B-X
and	B-X
compared	B-X
for	B-X
their	B-X
detection	B-X
efficiency	B-X
,	B-X
identifying	B-X
76	B-X
%	B-X
and	B-X
60	B-X
%	B-X
of	B-X
the	B-X
mutations	B-X
,	B-X
respectively	B-X
<EOS>	B-X
The	B-X
observed	B-X
genetic	B-X
heterogeneity	B-X
including	B-X
the	B-X
relative	B-X
high	B-X
percentage	B-X
of	B-X
splice	B-X
-	B-X
site	B-X
mutations	B-X
had	B-X
no	B-X
reflection	B-X
on	B-X
the	B-X
phenotype	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
founder	B-X
mutation	B-X
among	B-X
relatively	B-X
small	B-X
ethnic	B-X
population	B-X
groups	B-X
in	B-X
Western	B-X
Europe	B-X
could	B-X
indicate	B-X
a	B-X
high	B-X
carrier	B-X
frequency	B-X
in	B-X
such	B-X
communities	B-X
<EOS>	B-X
7	B-X
-	B-X
kb	B-X
genomic	B-X
deletion	B-X
of	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
most	B-X
likely	B-X
a	B-X
result	B-X
of	B-X
recombination	B-X
between	B-X
two	B-X
LINE	B-X
elements	B-X
,	B-X
was	B-X
identified	B-X

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O
<EOS>	B-X
Fifteen	B-X
cases	B-X
were	B-X
heterozygous	B-X
and	B-X
two	B-X
were	B-X
compound	B-X
heterozygous	B-X
for	B-X
Î²Â°	B-X
-	B-X
thal	B-X
SEA	B-X
deletion	B-X
<EOS>	B-X
This	B-X
finding	B-X
of	B-X
a	B-X
compound	B-X
heterozygote	B-X
with	B-X
a	B-X
1	B-X
<EOS>	B-X
Three	B-X
variants	B-X
in	B-X
leucine	B-X
-	B-X
rich	B-X
repeat	B-X
containing	B-X
6	B-X
(	B-X
LRRC6	B-X
)	B-X
[	B-X
patient	B-X
1	B-X
(	B-X
compound	B-X
heterozygote	B-X
)	B-X
:	B-X
NM_012472	B-X
:	B-X
c	B-X
<EOS>	B-X
Deleterious	B-X
DYNC2H1	B-X
variants	B-X
were	B-X
found	B-X
in	B-X
six	B-X
sporadic	B-X
patients	B-X
and	B-X
two	B-X
monozygotic	B-X
(	B-X
MZ	B-X
)	B-X
twins	B-X

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O
.	O
<EOS>	B-X
Seventeen	B-X
distinct	B-X
RHD	B-X
mutation	B-X
alleles	B-X
were	B-X
detected	B-X
,	B-X
with	B-X
11	B-X
weak	B-X
D	B-X
,	B-X
four	B-X
partial	B-X
D	B-X
and	B-X
two	B-X
DEL	B-X
alleles	B-X
<EOS>	B-X
Seventeen	B-X
patients	B-X
received	B-X
radiotherapy	B-X
,	B-X
five	B-X
received	B-X
chemotherapy	B-X
,	B-X
and	B-X
six	B-X
underwent	B-X
cerebrospinal	B-X
fluid	B-X
diversion	B-X
<EOS>	B-X
Six	B-X
of	B-X
these	B-X
deletions	B-X
were	B-X
associated	B-X
with	B-X
chromosomal	B-X
crossovers	B-X
generated	B-X
during	B-X
mitosis	B-X
<EOS>	B-X
Seventeen	B-X
pediatric	B-X
GISTs	B-X
were	B-X
investigated	B-X
for	B-X
KIT	B-X
/	B-X
PDGFRA	B-X
genotype	B-X
and	B-X
biochemical	B-X
activation	B-X
of	B-X
KIT	B-X
downstream	B-X
targets	B-X

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O
<EOS>	B-X
Missense	B-X
mutations	B-X
were	B-X
the	B-X
most	B-X
common	B-X
(	B-X
12	B-X
/	B-X
19	B-X
,	B-X
63	B-X
%	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
small	B-X
deletions	B-X
,	B-X
nonsense	B-X
mutations	B-X
,	B-X
an	B-X
insertion	B-X
,	B-X
and	B-X
a	B-X
splice	B-X
site	B-X
mutation	B-X
<EOS>	B-X
In	B-X
four	B-X
patients	B-X
we	B-X
detected	B-X
small	B-X
deletions	B-X
/	B-X
frameshift	B-X
variants	B-X
and	B-X
in	B-X
one	B-X
patient	B-X
a	B-X
splicing	B-X
variant	B-X
,	B-X
predicted	B-X
to	B-X
disturb	B-X
the	B-X
splicing	B-X
process	B-X
<EOS>	B-X
Mutational	B-X
signatures	B-X
are	B-X
characteristic	B-X
patterns	B-X
of	B-X
mutations	B-X
caused	B-X
by	B-X
endogenous	B-X
or	B-X
exogenous	B-X
mutational	B-X
processes	B-X
<EOS>	B-X
Point	B-X
mutations	B-X
detected	B-X
in	B-X
6	B-X
%	B-X
,	B-X
small	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
1	B-X

Moreover	O
,	O
a	O
16	O
.	O
<EOS>	B-X
5	B-X
%	B-X
were	B-X
positive	B-X
for	B-X
Hepatozoon	B-X
spp	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
risk	B-X
was	B-X
increased	B-X
in	B-X
the	B-X
second	B-X
(	B-X
OR	B-X
1	B-X
<EOS>	B-X
From	B-X
the	B-X
total	B-X
number	B-X
of	B-X
sampled	B-X
cats	B-X
,	B-X
19	B-X
<EOS>	B-X
For	B-X
the	B-X
characterization	B-X
of	B-X
K	B-X

7	O
-	O
kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O
<EOS>	B-X
7	B-X
-	B-X
kb	B-X
genomic	B-X
deletion	B-X
of	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
most	B-X
likely	B-X
a	B-X
result	B-X
of	B-X
recombination	B-X
between	B-X
two	B-X
LINE	B-X
elements	B-X
,	B-X
was	B-X
identified	B-X
<EOS>	B-X
In	B-X
patients	B-X
of	B-X
Dutch	B-X
ethnic	B-X
origin	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
founder	B-X
effect	B-X
could	B-X
be	B-X
identified	B-X
<EOS>	B-X
ATM	B-X
germline	B-X
mutations	B-X
in	B-X
classical	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
patients	B-X
in	B-X
the	B-X
Dutch	B-X
population	B-X
.	B-X
<EOS>	B-X
Both	B-X
the	B-X
protein	B-X
truncation	B-X
test	B-X
(	B-X
PTT	B-X
)	B-X
and	B-X
the	B-X
restriction	B-X
endonuclease	B-X
fingerprinting	B-X
(	B-X
REF	B-X
)	B-X
method	B-X
were	B-X
used	B-X
and	B-X
compared	B-X
for	B-X
their	B-X
detection	B-X
efficiency	B-X
,	B-X
identifying	B-X
76	B-X
%	B-X
and	B-X
60	B-X
%	B-X
of	B-X
the	B-X
mutations	B-X
,	B-X
respectively	B-X

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B-Disease
-	I-Disease
T	I-Disease
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A	B-Disease
-	I-Disease
T	I-Disease
founder	O
mutation	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
founder	B-X
mutation	B-X
among	B-X
relatively	B-X
small	B-X
ethnic	B-X
population	B-X
groups	B-X
in	B-X
Western	B-X
Europe	B-X
could	B-X
indicate	B-X
a	B-X
high	B-X
carrier	B-X
frequency	B-X
in	B-X
such	B-X
communities	B-X
<EOS>	B-X
ATM	B-X
germline	B-X
mutations	B-X
in	B-X
classical	B-X
ataxia	B-X
-	B-X
telangiectasia	B-X
patients	B-X
in	B-X
the	B-X
Dutch	B-X
population	B-X
.	B-X
<EOS>	B-X
Mutations	B-X
are	B-X
small	B-X
deletions	B-X
or	B-X
point	B-X
mutations	B-X
frequently	B-X
affecting	B-X
splice	B-X
sites	B-X
<EOS>	B-X
The	B-X
observed	B-X
genetic	B-X
heterogeneity	B-X
including	B-X
the	B-X
relative	B-X
high	B-X
percentage	B-X
of	B-X
splice	B-X
-	B-X
site	B-X
mutations	B-X
had	B-X
no	B-X
reflection	B-X
on	B-X
the	B-X
phenotype	B-X

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
.	O
<EOS>	B-X
In	B-X
patients	B-X
of	B-X
Dutch	B-X
ethnic	B-X
origin	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
founder	B-X
effect	B-X
could	B-X
be	B-X
identified	B-X
<EOS>	B-X
Mutations	B-X
are	B-X
small	B-X
deletions	B-X
or	B-X
point	B-X
mutations	B-X
frequently	B-X
affecting	B-X
splice	B-X
sites	B-X
<EOS>	B-X
7	B-X
-	B-X
kb	B-X
genomic	B-X
deletion	B-X
of	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
most	B-X
likely	B-X
a	B-X
result	B-X
of	B-X
recombination	B-X
between	B-X
two	B-X
LINE	B-X
elements	B-X
,	B-X
was	B-X
identified	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
founder	B-X
mutation	B-X
among	B-X
relatively	B-X
small	B-X
ethnic	B-X
population	B-X
groups	B-X
in	B-X
Western	B-X
Europe	B-X
could	B-X
indicate	B-X
a	B-X
high	B-X
carrier	B-X
frequency	B-X
in	B-X
such	B-X
communities	B-X

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O
phenotype	O
.	O
<EOS>	B-X
The	B-X
observed	B-X
genetic	B-X
heterogeneity	B-X
including	B-X
the	B-X
relative	B-X
high	B-X
percentage	B-X
of	B-X
splice	B-X
-	B-X
site	B-X
mutations	B-X
had	B-X
no	B-X
reflection	B-X
on	B-X
the	B-X
phenotype	B-X
<EOS>	B-X
Both	B-X
the	B-X
protein	B-X
truncation	B-X
test	B-X
(	B-X
PTT	B-X
)	B-X
and	B-X
the	B-X
restriction	B-X
endonuclease	B-X
fingerprinting	B-X
(	B-X
REF	B-X
)	B-X
method	B-X
were	B-X
used	B-X
and	B-X
compared	B-X
for	B-X
their	B-X
detection	B-X
efficiency	B-X
,	B-X
identifying	B-X
76	B-X
%	B-X
and	B-X
60	B-X
%	B-X
of	B-X
the	B-X
mutations	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Mutations	B-X
are	B-X
small	B-X
deletions	B-X
or	B-X
point	B-X
mutations	B-X
frequently	B-X
affecting	B-X
splice	B-X
sites	B-X
<EOS>	B-X
In	B-X
patients	B-X
of	B-X
Dutch	B-X
ethnic	B-X
origin	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
founder	B-X
effect	B-X
could	B-X
be	B-X
identified	B-X

All	O
patients	O
manifested	O
classical	O
A	B-Disease
-	I-Disease
T	I-Disease
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B-Disease
recessive	I-Disease
Alport	I-Disease
syndrome	I-Disease
.	O
<EOS>	B-X
Determination	B-X
of	B-X
the	B-X
genomic	B-X
structure	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
and	B-X
of	B-X
novel	B-X
mutations	B-X
causing	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
characterization	B-X
of	B-X
the	B-X
48	B-X
exons	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
,	B-X
a	B-X
comprehensive	B-X
gene	B-X
screen	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
detection	B-X
of	B-X
10	B-X
novel	B-X
mutations	B-X
in	B-X
eight	B-X
patients	B-X
diagnosed	B-X
with	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
<EOS>	B-X
Somatic	B-X
mutations	B-X
in	B-X
COL4A5	B-X
(	B-X
X	B-X
-	B-X
linked	B-X
)	B-X
,	B-X
COL4A3	B-X
and	B-X
COL4A4	B-X
genes	B-X
(	B-X
both	B-X
autosomal	B-X
recessive	B-X
and	B-X
autosomal	B-X
dominant	B-X
)	B-X
cause	B-X
Alport	B-X
syndrome	B-X
<EOS>	B-X
Affected	B-X
dogs	B-X
were	B-X
not	B-X
clinically	B-X
deaf	B-X
,	B-X
and	B-X
did	B-X
not	B-X
have	B-X
the	B-X
ocular	B-X
abnormalities	B-X
seen	B-X
in	B-X
human	B-X
X	B-X
-	B-X
linked	B-X
or	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X

Autosomal	B-Disease
recessive	I-Disease
Alport	I-Disease
syndrome	I-Disease
is	O
a	O
progressive	O
hematuric	B-Disease
glomerulonephritis	I-Disease
characterized	O
by	O
glomerular	B-Disease
basement	I-Disease
membrane	I-Disease
abnormalities	I-Disease
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains	O
,	O
respectively	O
.	O
<EOS>	B-X
Autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
is	B-X
a	B-X
progressive	B-X
hematuric	B-X
glomerulonephritis	B-X
characterized	B-X
by	B-X
glomerular	B-X
basement	B-X
membrane	B-X
abnormalities	B-X
and	B-X
associated	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
the	B-X
COL4A3	B-X
or	B-X
the	B-X
COL4A4	B-X
gene	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha3	B-X
and	B-X
alpha4	B-X
type	B-X
IV	B-X
collagen	B-X
chains	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Most	B-X
cases	B-X
are	B-X
X	B-X
-	B-X
linked	B-X
and	B-X
involve	B-X
the	B-X
COL4A5	B-X
gene	B-X
with	B-X
a	B-X
minority	B-X
of	B-X
patients	B-X
having	B-X
autosomal	B-X
recessive	B-X
mutations	B-X
in	B-X
the	B-X
COL4A3	B-X
or	B-X
COL4A4	B-X
genes	B-X
encoding	B-X
the	B-X
Î±3	B-X
(	B-X
IV	B-X
)	B-X
or	B-X
Î±4	B-X
(	B-X
IV	B-X
)	B-X
chain	B-X
respectively	B-X
<EOS>	B-X
We	B-X
first	B-X
isolated	B-X
and	B-X
characterized	B-X
genomic	B-X
DNA	B-X
fragments	B-X
that	B-X
cover	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
sequences	B-X
of	B-X
COL4A3	B-X
and	B-X
COL4A4	B-X
encoding	B-X
the	B-X
human	B-X
basement	B-X
membrane	B-X
alpha3	B-X
(	B-X
IV	B-X
)	B-X
and	B-X
alpha4	B-X
(	B-X
IV	B-X
)	B-X
collagen	B-X
chains	B-X
,	B-X
respectively	B-X
<EOS>	B-X
XLAS	B-X
is	B-X
caused	B-X
by	B-X
pathogenic	B-X
variants	B-X
in	B-X
COL4A5	B-X
,	B-X
which	B-X
encodes	B-X
type	B-X
IV	B-X
collagen	B-X
Î±5	B-X
chain	B-X
,	B-X
while	B-X
ADAS	B-X
and	B-X
ARAS	B-X
are	B-X
caused	B-X
by	B-X
variants	B-X
in	B-X
COL4A3	B-X
or	B-X
COL4A4	B-X
,	B-X
which	B-X
encode	B-X
type	B-X
IV	B-X
collagen	B-X
Î±3	B-X
or	B-X
Î±4	B-X
chain	B-X
,	B-X
respectively	B-X

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
mutation	B-X
screening	B-X
in	B-X
the	B-X
two	B-X
genes	B-X
has	B-X
been	B-X
hampered	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
genomic	B-X
structure	B-X
information	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
glycine	B-X
to	B-X
alanine	B-X
substitution	B-X
in	B-X
the	B-X
collagenous	B-X
domain	B-X
that	B-X
is	B-X
apparently	B-X
silent	B-X
in	B-X
the	B-X
heterozygous	B-X
carriers	B-X
,	B-X
in	B-X
11	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
characterization	B-X
of	B-X
the	B-X
48	B-X
exons	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
,	B-X
a	B-X
comprehensive	B-X
gene	B-X
screen	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
detection	B-X
of	B-X
10	B-X
novel	B-X
mutations	B-X
in	B-X
eight	B-X
patients	B-X
diagnosed	B-X
with	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
<EOS>	B-X
Determination	B-X
of	B-X
the	B-X
genomic	B-X
structure	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
and	B-X
of	B-X
novel	B-X
mutations	B-X
causing	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
.	B-X

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B-Disease
recessive	I-Disease
Alport	I-Disease
syndrome	I-Disease
.	O
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
characterization	B-X
of	B-X
the	B-X
48	B-X
exons	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
,	B-X
a	B-X
comprehensive	B-X
gene	B-X
screen	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
detection	B-X
of	B-X
10	B-X
novel	B-X
mutations	B-X
in	B-X
eight	B-X
patients	B-X
diagnosed	B-X
with	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
<EOS>	B-X
Determination	B-X
of	B-X
the	B-X
genomic	B-X
structure	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
and	B-X
of	B-X
novel	B-X
mutations	B-X
causing	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
mutation	B-X
screening	B-X
in	B-X
the	B-X
two	B-X
genes	B-X
has	B-X
been	B-X
hampered	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
genomic	B-X
structure	B-X
information	B-X
<EOS>	B-X
Autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X
is	B-X
a	B-X
progressive	B-X
hematuric	B-X
glomerulonephritis	B-X
characterized	B-X
by	B-X
glomerular	B-X
basement	B-X
membrane	B-X
abnormalities	B-X
and	B-X
associated	B-X
with	B-X
mutations	B-X
in	B-X
either	B-X
the	B-X
COL4A3	B-X
or	B-X
the	B-X
COL4A4	B-X
gene	B-X
,	B-X
which	B-X
encode	B-X
the	B-X
alpha3	B-X
and	B-X
alpha4	B-X
type	B-X
IV	B-X
collagen	B-X
chains	B-X
,	B-X
respectively	B-X

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
glycine	B-X
to	B-X
alanine	B-X
substitution	B-X
in	B-X
the	B-X
collagenous	B-X
domain	B-X
that	B-X
is	B-X
apparently	B-X
silent	B-X
in	B-X
the	B-X
heterozygous	B-X
carriers	B-X
,	B-X
in	B-X
11	B-X
<EOS>	B-X
There	B-X
has	B-X
been	B-X
no	B-X
previous	B-X
finding	B-X
of	B-X
a	B-X
glycine	B-X
substitution	B-X
that	B-X
is	B-X
not	B-X
associated	B-X
with	B-X
any	B-X
obvious	B-X
phenotype	B-X
in	B-X
homozygous	B-X
individuals	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
mutation	B-X
screening	B-X
in	B-X
the	B-X
two	B-X
genes	B-X
has	B-X
been	B-X
hampered	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
genomic	B-X
structure	B-X
information	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
complete	B-X
characterization	B-X
of	B-X
the	B-X
48	B-X
exons	B-X
of	B-X
the	B-X
COL4A4	B-X
gene	B-X
,	B-X
a	B-X
comprehensive	B-X
gene	B-X
screen	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
detection	B-X
of	B-X
10	B-X
novel	B-X
mutations	B-X
in	B-X
eight	B-X
patients	B-X
diagnosed	B-X
with	B-X
autosomal	B-X
recessive	B-X
Alport	B-X
syndrome	B-X

5	O
%	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O
<EOS>	B-X
5	B-X
%	B-X
of	B-X
all	B-X
control	B-X
individuals	B-X
,	B-X
and	B-X
in	B-X
one	B-X
control	B-X
individual	B-X
homozygous	B-X
for	B-X
this	B-X
glycine	B-X
substitution	B-X
<EOS>	B-X
One	B-X
patient	B-X
and	B-X
a	B-X
normal	B-X
control	B-X
had	B-X
two	B-X
previously	B-X
undescribed	B-X
mutations	B-X
<EOS>	B-X
In	B-X
three	B-X
patients	B-X
a	B-X
homozygous	B-X
mutation	B-X
was	B-X
present	B-X
at	B-X
nucleotide	B-X
position	B-X
229	B-X
,	B-X
causing	B-X
a	B-X
glycine	B-X
to	B-X
serine	B-X
amino	B-X
acid	B-X
substitution	B-X
<EOS>	B-X
Here	B-X
we	B-X
performed	B-X
genomic	B-X
DNA	B-X
analyses	B-X
from	B-X
individuals	B-X
bearing	B-X
the	B-X
enzyme	B-X
deficiency	B-X
in	B-X
order	B-X
to	B-X
detect	B-X
the	B-X
molecular	B-X
abnormalities	B-X

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O
<EOS>	B-X
Gly741Ser	B-X
,	B-X
a	B-X
glycine	B-X
substitution	B-X
mutation	B-X
,	B-X
has	B-X
been	B-X
previously	B-X
reported	B-X
,	B-X
whereas	B-X
p	B-X
<EOS>	B-X
Finally	B-X
,	B-X
our	B-X
data	B-X
agree	B-X
with	B-X
previous	B-X
findings	B-X
,	B-X
suggesting	B-X
a	B-X
key	B-X
role	B-X
of	B-X
peripherin	B-X
in	B-X
the	B-X
ALS	B-X
pathogenesis	B-X
,	B-X
thus	B-X
highlighting	B-X
that	B-X
DRG	B-X
neurons	B-X
mirror	B-X
some	B-X
dysfunctions	B-X
found	B-X
in	B-X
motor	B-X
neurons	B-X
<EOS>	B-X
Despite	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
mechanism	B-X
of	B-X
glycinergic	B-X
dis	B-X
-	B-X
inhibition	B-X
associated	B-X
with	B-X
dysfunctional	B-X
Î±3GlyRs	B-X
,	B-X
our	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
events	B-X
involved	B-X
is	B-X
limited	B-X
<EOS>	B-X
The	B-X
new	B-X
work	B-X
more	B-X
broadly	B-X
characterizes	B-X
the	B-X
effect	B-X
of	B-X
Î³	B-X
residue	B-X
substitution	B-X
on	B-X
helix	B-X
stability	B-X
,	B-X
based	B-X
on	B-X
circular	B-X
dichroism	B-X
and	B-X
two	B-X
-	B-X
dimensional	B-X
NMR	B-X
measurements	B-X

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
<EOS>	B-X
Founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
Founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
in	B-X
French	B-X
Canadian	B-X
ovarian	B-X
cancer	B-X
cases	B-X
unselected	B-X
for	B-X
family	B-X
history	B-X
.	B-X
<EOS>	B-X
Founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
in	B-X
early	B-X
-	B-X
onset	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
cases	B-X
unselected	B-X
for	B-X
family	B-X
history	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
Canadian	B-X
breast	B-X
cancer	B-X
and	B-X
breast	B-X
-	B-X
ovarian	B-X
cancer	B-X
families	B-X
of	B-X
French	B-X
ancestry	B-X

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B-Disease
cancer	I-Disease
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B-Disease
cancer	I-Disease
and	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
from	O
Quebec	O
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
four	B-X
mutations	B-X
in	B-X
each	B-X
of	B-X
the	B-X
breast	B-X
cancer	B-X
-	B-X
susceptibility	B-X
genes	B-X
,	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
,	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
and	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
from	B-X
Quebec	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
common	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
will	B-X
facilitate	B-X
carrier	B-X
detection	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
and	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
<EOS>	B-X
Germline	B-X
mutations	B-X
in	B-X
the	B-X
breast	B-X
cancer	B-X
susceptibility	B-X
gene	B-X
PTEN	B-X
are	B-X
rare	B-X
in	B-X
high	B-X
-	B-X
risk	B-X
non	B-X
-	B-X
BRCA1	B-X
/	B-X
2	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
Founder	B-X
mutations	B-X
have	B-X
been	B-X
found	B-X
in	B-X
four	B-X
breast	B-X
-	B-X
cancer	B-X
-	B-X
predisposing	B-X
genes	B-X
in	B-X
French	B-X
-	B-X
Canadian	B-X
breast	B-X
cancer	B-X
families	B-X

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B-Disease
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
founder	B-X
effects	B-X
,	B-X
we	B-X
examined	B-X
independently	B-X
ascertained	B-X
French	B-X
Canadian	B-X
cancer	B-X
families	B-X
for	B-X
the	B-X
distribution	B-X
of	B-X
these	B-X
eight	B-X
mutations	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
28	B-X
of	B-X
41	B-X
families	B-X
identified	B-X
to	B-X
have	B-X
a	B-X
mutation	B-X
<EOS>	B-X
Founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
7x	B-X
greater	B-X
if	B-X
one	B-X
or	B-X
more	B-X
cases	B-X
of	B-X
ovarian	B-X
cancer	B-X
were	B-X
also	B-X
present	B-X
in	B-X
the	B-X
family	B-X

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
.	O
<EOS>	B-X
28	B-X
%	B-X
)	B-X
were	B-X
found	B-X
and	B-X
the	B-X
major	B-X
c	B-X
<EOS>	B-X
Fourteen	B-X
possible	B-X
disease	B-X
-	B-X
causing	B-X
variants	B-X
were	B-X
identified	B-X
in	B-X
13	B-X
of	B-X
27	B-X
BC	B-X
families	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
73	B-X
patients	B-X
were	B-X
only	B-X
diagnosed	B-X
due	B-X
to	B-X
family	B-X
history	B-X
(	B-X
delay	B-X
15	B-X
<EOS>	B-X
Germline	B-X
P	B-X
/	B-X
LP	B-X
variants	B-X
were	B-X
identified	B-X
in	B-X
41	B-X
patients	B-X
(	B-X
17	B-X

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
.	O
<EOS>	B-X
Six	B-X
of	B-X
eight	B-X
mutations	B-X
were	B-X
observed	B-X
at	B-X
least	B-X
twice	B-X
<EOS>	B-X
Nearly	B-X
80	B-X
%	B-X
of	B-X
the	B-X
identified	B-X
p53	B-X
mutations	B-X
were	B-X
G	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
A	B-X
and	B-X
C	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
T	B-X
transitions	B-X
<EOS>	B-X
Mutations	B-X
were	B-X
found	B-X
in	B-X
41	B-X
of	B-X
97	B-X
families	B-X
<EOS>	B-X
Founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
families	B-X
.	B-X

The	O
BRCA1	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O
<EOS>	B-X
The	B-X
BRCA1	B-X
C4446T	B-X
mutation	B-X
was	B-X
the	B-X
most	B-X
common	B-X
mutation	B-X
found	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
BRCA2	B-X
8765delAG	B-X
mutation	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
28	B-X
of	B-X
41	B-X
families	B-X
identified	B-X
to	B-X
have	B-X
a	B-X
mutation	B-X
<EOS>	B-X
The	B-X
odds	B-X
of	B-X
detection	B-X
of	B-X
any	B-X
of	B-X
the	B-X
four	B-X
BRCA2	B-X
mutations	B-X
was	B-X
5	B-X
<EOS>	B-X
The	B-X
odds	B-X
of	B-X
detection	B-X
of	B-X
any	B-X
of	B-X
the	B-X
four	B-X
BRCA1	B-X
mutations	B-X
was	B-X
18	B-X

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
28	B-X
of	B-X
41	B-X
families	B-X
identified	B-X
to	B-X
have	B-X
a	B-X
mutation	B-X
<EOS>	B-X
Mutations	B-X
were	B-X
found	B-X
in	B-X
41	B-X
of	B-X
97	B-X
families	B-X
<EOS>	B-X
To	B-X
identify	B-X
founder	B-X
effects	B-X
,	B-X
we	B-X
examined	B-X
independently	B-X
ascertained	B-X
French	B-X
Canadian	B-X
cancer	B-X
families	B-X
for	B-X
the	B-X
distribution	B-X
of	B-X
these	B-X
eight	B-X
mutations	B-X
<EOS>	B-X
Six	B-X
of	B-X
eight	B-X
mutations	B-X
were	B-X
observed	B-X
at	B-X
least	B-X
twice	B-X

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18	O
.	O
<EOS>	B-X
The	B-X
odds	B-X
of	B-X
detection	B-X
of	B-X
any	B-X
of	B-X
the	B-X
four	B-X
BRCA1	B-X
mutations	B-X
was	B-X
18	B-X
<EOS>	B-X
The	B-X
odds	B-X
of	B-X
detection	B-X
of	B-X
any	B-X
of	B-X
the	B-X
four	B-X
BRCA2	B-X
mutations	B-X
was	B-X
5	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
result	B-X
of	B-X
the	B-X
meta	B-X
-	B-X
analysis	B-X
also	B-X
discards	B-X
the	B-X
involvement	B-X
of	B-X
BRCA1	B-X
mutations	B-X
in	B-X
the	B-X
development	B-X
of	B-X
prostate	B-X
cancer	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
breast	B-X
cancer	B-X
case	B-X
<	B-X
36	B-X
years	B-X
of	B-X
age	B-X
was	B-X
strongly	B-X
predictive	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
any	B-X
of	B-X
the	B-X
eight	B-X
mutations	B-X
screened	B-X

7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B-Disease
cancer	I-Disease
were	O
also	O
present	O
in	O
the	O
family	O
.	O
<EOS>	B-X
Self	B-X
-	B-X
reported	B-X
use	B-X
of	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
risk	B-X
assessments	B-X
was	B-X
low	B-X
(	B-X
34	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
whether	B-X
other	B-X
germline	B-X
pathogenic	B-X
variants	B-X
of	B-X
hereditary	B-X
cancer	B-X
genes	B-X
are	B-X
present	B-X
in	B-X
patients	B-X
with	B-X
LS	B-X
<EOS>	B-X
Out	B-X
of	B-X
21,410	B-X
new	B-X
cases	B-X
of	B-X
ovarian	B-X
cancer	B-X
in	B-X
the	B-X
United	B-X
States	B-X
in	B-X
2021	B-X
,	B-X
more	B-X
than	B-X
half	B-X
were	B-X
fatal	B-X
<EOS>	B-X
7X	B-X
greater	B-X
for	B-X
the	B-X
six	B-X
source	B-X
collimated	B-X
configuration	B-X
than	B-X
the	B-X
six	B-X
source	B-X
overlapping	B-X
configuration	B-X

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O
<EOS>	B-X
The	B-X
odds	B-X
of	B-X
detection	B-X
of	B-X
any	B-X
of	B-X
the	B-X
four	B-X
BRCA2	B-X
mutations	B-X
was	B-X
5	B-X
<EOS>	B-X
The	B-X
odds	B-X
of	B-X
detection	B-X
of	B-X
any	B-X
of	B-X
the	B-X
four	B-X
BRCA1	B-X
mutations	B-X
was	B-X
18	B-X
<EOS>	B-X
The	B-X
probability	B-X
of	B-X
testing	B-X
positive	B-X
for	B-X
deleterious	B-X
mutations	B-X
in	B-X
any	B-X
of	B-X
the	B-X
four	B-X
genes	B-X
ranges	B-X
up	B-X
to	B-X
10	B-X
<EOS>	B-X
For	B-X
the	B-X
revised	B-X
analysis	B-X
,	B-X
we	B-X
included	B-X
822	B-X
BRCA1	B-X
/	B-X
2	B-X
mutation	B-X
carriers	B-X

3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
in	O
the	O
family	O
.	O
<EOS>	B-X
3x	B-X
greater	B-X
if	B-X
there	B-X
were	B-X
at	B-X
least	B-X
five	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
the	B-X
family	B-X
<EOS>	B-X
7x	B-X
greater	B-X
if	B-X
one	B-X
or	B-X
more	B-X
cases	B-X
of	B-X
ovarian	B-X
cancer	B-X
were	B-X
also	B-X
present	B-X
in	B-X
the	B-X
family	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
breast	B-X
cancer	B-X
case	B-X
<	B-X
36	B-X
years	B-X
of	B-X
age	B-X
was	B-X
strongly	B-X
predictive	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
any	B-X
of	B-X
the	B-X
eight	B-X
mutations	B-X
screened	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
common	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
will	B-X
facilitate	B-X
carrier	B-X
detection	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
and	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X

Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B-Disease
cancer	I-Disease
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
breast	B-X
cancer	B-X
case	B-X
<	B-X
36	B-X
years	B-X
of	B-X
age	B-X
was	B-X
strongly	B-X
predictive	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
any	B-X
of	B-X
the	B-X
eight	B-X
mutations	B-X
screened	B-X
<EOS>	B-X
3x	B-X
greater	B-X
if	B-X
there	B-X
were	B-X
at	B-X
least	B-X
five	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
the	B-X
family	B-X
<EOS>	B-X
To	B-X
identify	B-X
founder	B-X
effects	B-X
,	B-X
we	B-X
examined	B-X
independently	B-X
ascertained	B-X
French	B-X
Canadian	B-X
cancer	B-X
families	B-X
for	B-X
the	B-X
distribution	B-X
of	B-X
these	B-X
eight	B-X
mutations	B-X
<EOS>	B-X
7x	B-X
greater	B-X
if	B-X
one	B-X
or	B-X
more	B-X
cases	B-X
of	B-X
ovarian	B-X
cancer	B-X
were	B-X
also	B-X
present	B-X
in	B-X
the	B-X
family	B-X

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O
<EOS>	B-X
Carriers	B-X
of	B-X
the	B-X
same	B-X
mutation	B-X
,	B-X
from	B-X
different	B-X
families	B-X
,	B-X
shared	B-X
similar	B-X
haplotypes	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
mutant	B-X
alleles	B-X
were	B-X
likely	B-X
to	B-X
be	B-X
identical	B-X
by	B-X
descent	B-X
for	B-X
a	B-X
mutation	B-X
in	B-X
the	B-X
founder	B-X
population	B-X
<EOS>	B-X
To	B-X
identify	B-X
founder	B-X
effects	B-X
,	B-X
we	B-X
examined	B-X
independently	B-X
ascertained	B-X
French	B-X
Canadian	B-X
cancer	B-X
families	B-X
for	B-X
the	B-X
distribution	B-X
of	B-X
these	B-X
eight	B-X
mutations	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
28	B-X
of	B-X
41	B-X
families	B-X
identified	B-X
to	B-X
have	B-X
a	B-X
mutation	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
breast	B-X
cancer	B-X
case	B-X
<	B-X
36	B-X
years	B-X
of	B-X
age	B-X
was	B-X
strongly	B-X
predictive	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
any	B-X
of	B-X
the	B-X
eight	B-X
mutations	B-X
screened	B-X

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B-Disease
cancer	I-Disease
and	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
families	O
.	O
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
common	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
will	B-X
facilitate	B-X
carrier	B-X
detection	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
and	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
<EOS>	B-X
Founder	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutations	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
families	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
four	B-X
mutations	B-X
in	B-X
each	B-X
of	B-X
the	B-X
breast	B-X
cancer	B-X
-	B-X
susceptibility	B-X
genes	B-X
,	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
,	B-X
in	B-X
French	B-X
Canadian	B-X
breast	B-X
cancer	B-X
and	B-X
breast	B-X
/	B-X
ovarian	B-X
cancer	B-X
families	B-X
from	B-X
Quebec	B-X
<EOS>	B-X
3x	B-X
greater	B-X
if	B-X
there	B-X
were	B-X
at	B-X
least	B-X
five	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
the	B-X
family	B-X

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B-Disease
impairment	I-Disease
in	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
?	O
<EOS>	B-X
Are	B-X
Dp71	B-X
and	B-X
Dp140	B-X
brain	B-X
dystrophin	B-X
isoforms	B-X
related	B-X
to	B-X
cognitive	B-X
impairment	B-X
in	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
?	B-X
<EOS>	B-X
This	B-X
finding	B-X
may	B-X
be	B-X
relevant	B-X
to	B-X
the	B-X
cognitive	B-X
dysfunction	B-X
affecting	B-X
many	B-X
patients	B-X
with	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
<EOS>	B-X
Combining	B-X
genetics	B-X
,	B-X
neuropsychology	B-X
and	B-X
neuroimaging	B-X
to	B-X
improve	B-X
understanding	B-X
of	B-X
brain	B-X
involvement	B-X
in	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
	B-X
-	B-X
	B-X
a	B-X
narrative	B-X
review	B-X
.	B-X
<EOS>	B-X
Language	B-X
Development	B-X
in	B-X
Preschool	B-X
Duchenne	B-X
Muscular	B-X
Dystrophy	B-X
Boys	B-X
.	B-X

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	B-Disease
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B-Disease
impairment	I-Disease
observed	O
in	O
most	O
DMD	B-Disease
patients	O
.	O
<EOS>	B-X
Molecular	B-X
study	B-X
and	B-X
neuropsychological	B-X
analysis	B-X
were	B-X
performed	B-X
concurrently	B-X
on	B-X
49	B-X
patients	B-X
with	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
(	B-X
DMD	B-X
)	B-X
in	B-X
order	B-X
to	B-X
find	B-X
a	B-X
molecular	B-X
explanation	B-X
for	B-X
the	B-X
cognitive	B-X
impairment	B-X
observed	B-X
in	B-X
most	B-X
DMD	B-X
patients	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
some	B-X
sequences	B-X
located	B-X
in	B-X
the	B-X
distal	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
some	B-X
DMD	B-X
isoforms	B-X
expressed	B-X
in	B-X
the	B-X
brain	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
cognitive	B-X
impairment	B-X
associated	B-X
with	B-X
DMD	B-X
<EOS>	B-X
Complete	B-X
analysis	B-X
of	B-X
the	B-X
dystrophin	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
define	B-X
the	B-X
localization	B-X
of	B-X
deletions	B-X
and	B-X
duplications	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
different	B-X
DMD	B-X
promoters	B-X
<EOS>	B-X
Neuropsychological	B-X
analysis	B-X
assessed	B-X
verbal	B-X
and	B-X
visuospatial	B-X
intelligence	B-X
,	B-X
verbal	B-X
memory	B-X
,	B-X
and	B-X
reading	B-X
skills	B-X

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	B-Disease
promoters	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O
<EOS>	B-X
Qualitative	B-X
analysis	B-X
of	B-X
the	B-X
Dp71	B-X
transcript	B-X
and	B-X
testing	B-X
for	B-X
the	B-X
specific	B-X
first	B-X
exon	B-X
of	B-X
Dp140	B-X
were	B-X
also	B-X
carried	B-X
out	B-X
<EOS>	B-X
Complete	B-X
analysis	B-X
of	B-X
the	B-X
dystrophin	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
define	B-X
the	B-X
localization	B-X
of	B-X
deletions	B-X
and	B-X
duplications	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
different	B-X
DMD	B-X
promoters	B-X
<EOS>	B-X
Two	B-X
altered	B-X
Dp71	B-X
transcripts	B-X
and	B-X
two	B-X
deleted	B-X
Dp140	B-X
DNA	B-X
sequences	B-X
were	B-X
found	B-X
in	B-X
four	B-X
patients	B-X
with	B-X
severe	B-X
cerebral	B-X
dysfunction	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
molecular	B-X
and	B-X
psychometric	B-X
findings	B-X
demonstrated	B-X
that	B-X
deletions	B-X
and	B-X
duplications	B-X
that	B-X
were	B-X
localized	B-X
in	B-X
the	B-X
distal	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
seemed	B-X
to	B-X
be	B-X
preferentially	B-X
associated	B-X
with	B-X
cognitive	B-X
impairment	B-X

Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
skills	O
.	O
<EOS>	B-X
Neuropsychological	B-X
analysis	B-X
assessed	B-X
verbal	B-X
and	B-X
visuospatial	B-X
intelligence	B-X
,	B-X
verbal	B-X
memory	B-X
,	B-X
and	B-X
reading	B-X
skills	B-X
<EOS>	B-X
Neuropsychological	B-X
abilities	B-X
underpinning	B-X
academic	B-X
attainment	B-X
in	B-X
children	B-X
born	B-X
extremely	B-X
preterm	B-X
.	B-X
<EOS>	B-X
All	B-X
five	B-X
neuropsychological	B-X
variables	B-X
mediated	B-X
the	B-X
relationship	B-X
between	B-X
EP	B-X
birth	B-X
and	B-X
attainment	B-X
in	B-X
mathematics	B-X
,	B-X
but	B-X
a	B-X
direct	B-X
effect	B-X
of	B-X
EP	B-X
birth	B-X
on	B-X
mathematics	B-X
remained	B-X
in	B-X
the	B-X
mediated	B-X
model	B-X
<EOS>	B-X
Controlling	B-X
for	B-X
sex	B-X
and	B-X
socio	B-X
-	B-X
economic	B-X
status	B-X
we	B-X
evaluated	B-X
the	B-X
following	B-X
mediators	B-X
:	B-X
verbal	B-X
working	B-X
memory	B-X
,	B-X
visuospatial	B-X
working	B-X
memory	B-X
,	B-X
verbal	B-X
processing	B-X
speed	B-X
,	B-X
attention	B-X
,	B-X
and	B-X
visuospatial	B-X
processing	B-X

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B-Disease
impairment	I-Disease
.	O
<EOS>	B-X
Comparison	B-X
of	B-X
molecular	B-X
and	B-X
psychometric	B-X
findings	B-X
demonstrated	B-X
that	B-X
deletions	B-X
and	B-X
duplications	B-X
that	B-X
were	B-X
localized	B-X
in	B-X
the	B-X
distal	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
seemed	B-X
to	B-X
be	B-X
preferentially	B-X
associated	B-X
with	B-X
cognitive	B-X
impairment	B-X
<EOS>	B-X
Complete	B-X
analysis	B-X
of	B-X
the	B-X
dystrophin	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
define	B-X
the	B-X
localization	B-X
of	B-X
deletions	B-X
and	B-X
duplications	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
different	B-X
DMD	B-X
promoters	B-X
<EOS>	B-X
Two	B-X
altered	B-X
Dp71	B-X
transcripts	B-X
and	B-X
two	B-X
deleted	B-X
Dp140	B-X
DNA	B-X
sequences	B-X
were	B-X
found	B-X
in	B-X
four	B-X
patients	B-X
with	B-X
severe	B-X
cerebral	B-X
dysfunction	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
some	B-X
sequences	B-X
located	B-X
in	B-X
the	B-X
distal	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
some	B-X
DMD	B-X
isoforms	B-X
expressed	B-X
in	B-X
the	B-X
brain	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
cognitive	B-X
impairment	B-X
associated	B-X
with	B-X
DMD	B-X

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B-Disease
dysfunction	I-Disease
.	O
<EOS>	B-X
Two	B-X
altered	B-X
Dp71	B-X
transcripts	B-X
and	B-X
two	B-X
deleted	B-X
Dp140	B-X
DNA	B-X
sequences	B-X
were	B-X
found	B-X
in	B-X
four	B-X
patients	B-X
with	B-X
severe	B-X
cerebral	B-X
dysfunction	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
molecular	B-X
and	B-X
psychometric	B-X
findings	B-X
demonstrated	B-X
that	B-X
deletions	B-X
and	B-X
duplications	B-X
that	B-X
were	B-X
localized	B-X
in	B-X
the	B-X
distal	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
seemed	B-X
to	B-X
be	B-X
preferentially	B-X
associated	B-X
with	B-X
cognitive	B-X
impairment	B-X
<EOS>	B-X
Are	B-X
Dp71	B-X
and	B-X
Dp140	B-X
brain	B-X
dystrophin	B-X
isoforms	B-X
related	B-X
to	B-X
cognitive	B-X
impairment	B-X
in	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
?	B-X
<EOS>	B-X
Molecular	B-X
study	B-X
and	B-X
neuropsychological	B-X
analysis	B-X
were	B-X
performed	B-X
concurrently	B-X
on	B-X
49	B-X
patients	B-X
with	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
(	B-X
DMD	B-X
)	B-X
in	B-X
order	B-X
to	B-X
find	B-X
a	B-X
molecular	B-X
explanation	B-X
for	B-X
the	B-X
cognitive	B-X
impairment	B-X
observed	B-X
in	B-X
most	B-X
DMD	B-X
patients	B-X

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B-Disease
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
DMD	B-Disease
.	O
.	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
(	O
HNPCC	B-Disease
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
French	B-X
Canadian	B-X
hereditary	B-X
non	B-X
-	B-X
polyposis	B-X
colorectal	B-X
cancer	B-X
(	B-X
HNPCC	B-X
)	B-X
kindred	B-X
which	B-X
carries	B-X
a	B-X
novel	B-X
truncating	B-X
mutation	B-X
in	B-X
hMLH1	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
I1307K	B-X
APC	B-X
polymorphism	B-X
,	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
is	B-X
also	B-X
present	B-X
in	B-X
this	B-X
family	B-X
<EOS>	B-X
I1307K	B-X
APC	B-X
and	B-X
hMLH1	B-X
mutations	B-X
in	B-X
a	B-X
non	B-X
-	B-X
Jewish	B-X
family	B-X
with	B-X
hereditary	B-X
non	B-X
-	B-X
polyposis	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
The	B-X
I1307K	B-X
polymorphism	B-X
has	B-X
previously	B-X
only	B-X
been	B-X
identified	B-X
in	B-X
individuals	B-X
of	B-X
self	B-X
-	B-X
reported	B-X
Ashkenazi	B-X
Jewish	B-X
origins	B-X

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
,	O
is	O
also	O
present	O
in	O
this	O
family	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
I1307K	B-X
APC	B-X
polymorphism	B-X
,	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
is	B-X
also	B-X
present	B-X
in	B-X
this	B-X
family	B-X
<EOS>	B-X
The	B-X
I1307K	B-X
polymorphism	B-X
has	B-X
previously	B-X
only	B-X
been	B-X
identified	B-X
in	B-X
individuals	B-X
of	B-X
self	B-X
-	B-X
reported	B-X
Ashkenazi	B-X
Jewish	B-X
origins	B-X
<EOS>	B-X
I1307K	B-X
APC	B-X
and	B-X
hMLH1	B-X
mutations	B-X
in	B-X
a	B-X
non	B-X
-	B-X
Jewish	B-X
family	B-X
with	B-X
hereditary	B-X
non	B-X
-	B-X
polyposis	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
in	B-X
this	B-X
family	B-X
,	B-X
there	B-X
appears	B-X
to	B-X
be	B-X
no	B-X
relationship	B-X
between	B-X
the	B-X
I1307K	B-X
polymorphism	B-X
and	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
cancer	B-X

The	O
I1307K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O
<EOS>	B-X
The	B-X
I1307K	B-X
polymorphism	B-X
has	B-X
previously	B-X
only	B-X
been	B-X
identified	B-X
in	B-X
individuals	B-X
of	B-X
self	B-X
-	B-X
reported	B-X
Ashkenazi	B-X
Jewish	B-X
origins	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
I1307K	B-X
APC	B-X
polymorphism	B-X
,	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
is	B-X
also	B-X
present	B-X
in	B-X
this	B-X
family	B-X
<EOS>	B-X
I1307K	B-X
APC	B-X
and	B-X
hMLH1	B-X
mutations	B-X
in	B-X
a	B-X
non	B-X
-	B-X
Jewish	B-X
family	B-X
with	B-X
hereditary	B-X
non	B-X
-	B-X
polyposis	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
French	B-X
Canadian	B-X
hereditary	B-X
non	B-X
-	B-X
polyposis	B-X
colorectal	B-X
cancer	B-X
(	B-X
HNPCC	B-X
)	B-X
kindred	B-X
which	B-X
carries	B-X
a	B-X
novel	B-X
truncating	B-X
mutation	B-X
in	B-X
hMLH1	B-X

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B-Disease
.	O
.	O
<EOS>	B-X
We	B-X
hypothesised	B-X
that	B-X
high	B-X
activation	B-X
of	B-X
an	B-X
innate	B-X
response	B-X
relative	B-X
to	B-X
the	B-X
adaptive	B-X
response	B-X
may	B-X
prevent	B-X
proper	B-X
tumour	B-X
neoantigen	B-X
identification	B-X
and	B-X
decrease	B-X
the	B-X
specific	B-X
anticancer	B-X
response	B-X
,	B-X
both	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
immunotherapy	B-X
<EOS>	B-X
This	B-X
special	B-X
edition	B-X
included	B-X
original	B-X
articles	B-X
,	B-X
reviews	B-X
and	B-X
commentaries	B-X
relevant	B-X
to	B-X
the	B-X
research	B-X
goals	B-X
of	B-X
this	B-X
new	B-X
project	B-X
which	B-X
was	B-X
titled	B-X
Researching	B-X
the	B-X
Effects	B-X
of	B-X
the	B-X
Presence	B-X
and	B-X
Absence	B-X
of	B-X
Ionizing	B-X
Radiation	B-X
(	B-X
REPAIR	B-X
)	B-X
<EOS>	B-X
RNA	B-X
modification	B-X
writers	B-X
pattern	B-X
in	B-X
relation	B-X
to	B-X
tumor	B-X
microenvironment	B-X
and	B-X
prognosis	B-X
in	B-X
prostate	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Tumor	B-X
immunotherapy	B-X
brings	B-X
opportunities	B-X
and	B-X
progress	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
pancreatic	B-X
cancer	B-X

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B-Disease
coproporphyria	I-Disease
family	O
.	O

Hereditary	B-Disease
coproporphyria	I-Disease
(	O
HCP	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
characterized	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
coproporphyrinogen	I-Disease
oxidase	I-Disease
(	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O
<EOS>	B-X
Hereditary	B-X
coproporphyria	B-X
(	B-X
HCP	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
disease	B-X
characterized	B-X
by	B-X
a	B-X
deficiency	B-X
of	B-X
coproporphyrinogen	B-X
oxidase	B-X
(	B-X
CPO	B-X
)	B-X
caused	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
the	B-X
CPO	B-X
gene	B-X
<EOS>	B-X
Polymerase	B-X
chain	B-X
reaction	B-X
-	B-X
single	B-X
strand	B-X
conformational	B-X
polymorphism	B-X
and	B-X
direct	B-X
sequence	B-X
analyses	B-X
demonstrated	B-X
a	B-X
C	B-X
to	B-X
T	B-X
substitution	B-X
in	B-X
exon	B-X
1	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
at	B-X
nucleotide	B-X
position	B-X
85	B-X
,	B-X
which	B-X
lies	B-X
in	B-X
the	B-X
putative	B-X
presequence	B-X
for	B-X
targeting	B-X
to	B-X
mitochondria	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
mutation	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
in	B-X
a	B-X
Japanese	B-X
hereditary	B-X
coproporphyria	B-X
family	B-X
.	B-X
<EOS>	B-X
This	B-X
mutation	B-X
changes	B-X
the	B-X
codon	B-X
for	B-X
glutamine	B-X
to	B-X
a	B-X
termination	B-X
codon	B-X
at	B-X
amino	B-X
acid	B-X
position	B-X
29	B-X

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	B-Disease
patients	O
.	O
<EOS>	B-X
Only	B-X
11	B-X
mutations	B-X
of	B-X
the	B-X
gene	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
HCP	B-X
patients	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
mutation	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
in	B-X
a	B-X
Japanese	B-X
hereditary	B-X
coproporphyria	B-X
family	B-X
.	B-X
<EOS>	B-X
This	B-X
mutation	B-X
changes	B-X
the	B-X
codon	B-X
for	B-X
glutamine	B-X
to	B-X
a	B-X
termination	B-X
codon	B-X
at	B-X
amino	B-X
acid	B-X
position	B-X
29	B-X
<EOS>	B-X
The	B-X
C	B-X
-	B-X
T	B-X
mutation	B-X
is	B-X
located	B-X
within	B-X
a	B-X
recently	B-X
proposed	B-X
putative	B-X
alternative	B-X
translation	B-X
initiation	B-X
codon	B-X
(	B-X
TIC	B-X
-	B-X
1	B-X
)	B-X
,	B-X
supporting	B-X
that	B-X
TIC	B-X
-	B-X
1	B-X
is	B-X
the	B-X
real	B-X
TIC	B-X
rather	B-X
than	B-X
TIC	B-X
-	B-X
2	B-X

We	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
mitochondria	O
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O
<EOS>	B-X
This	B-X
mutation	B-X
changes	B-X
the	B-X
codon	B-X
for	B-X
glutamine	B-X
to	B-X
a	B-X
termination	B-X
codon	B-X
at	B-X
amino	B-X
acid	B-X
position	B-X
29	B-X
<EOS>	B-X
The	B-X
C	B-X
-	B-X
T	B-X
mutation	B-X
is	B-X
located	B-X
within	B-X
a	B-X
recently	B-X
proposed	B-X
putative	B-X
alternative	B-X
translation	B-X
initiation	B-X
codon	B-X
(	B-X
TIC	B-X
-	B-X
1	B-X
)	B-X
,	B-X
supporting	B-X
that	B-X
TIC	B-X
-	B-X
1	B-X
is	B-X
the	B-X
real	B-X
TIC	B-X
rather	B-X
than	B-X
TIC	B-X
-	B-X
2	B-X
<EOS>	B-X
Only	B-X
11	B-X
mutations	B-X
of	B-X
the	B-X
gene	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
HCP	B-X
patients	B-X
<EOS>	B-X
We	B-X
report	B-X
another	B-X
mutation	B-X
in	B-X
a	B-X
Japanese	B-X
family	B-X

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O
<EOS>	B-X
MaeI	B-X
restriction	B-X
analysis	B-X
showed	B-X
two	B-X
other	B-X
carriers	B-X
in	B-X
the	B-X
family	B-X
<EOS>	B-X
We	B-X
report	B-X
another	B-X
mutation	B-X
in	B-X
a	B-X
Japanese	B-X
family	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
mutation	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
in	B-X
a	B-X
Japanese	B-X
hereditary	B-X
coproporphyria	B-X
family	B-X
.	B-X
<EOS>	B-X
The	B-X
C	B-X
-	B-X
to	B-X
-	B-X
T	B-X
transition	B-X
creates	B-X
a	B-X
NlaIII	B-X
site	B-X
and	B-X
permits	B-X
rapid	B-X
restriction	B-X
analysis	B-X
of	B-X
the	B-X
mutation	B-X

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
.	O
.	O

Human	B-Disease
complement	I-Disease
factor	I-Disease
H	I-Disease
deficiency	I-Disease
associated	O
with	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O
<EOS>	B-X
Deletion	B-X
of	B-X
complement	B-X
factor	B-X
H	B-X
-	B-X
related	B-X
genes	B-X
CFHR1	B-X
and	B-X
CFHR3	B-X
is	B-X
associated	B-X
with	B-X
atypical	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
complement	B-X
factor	B-X
H	B-X
mutations	B-X
associated	B-X
with	B-X
atypical	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
(	B-X
HUS	B-X
)	B-X
are	B-X
heterozygous	B-X
<EOS>	B-X
Variant	B-X
-	B-X
specific	B-X
quantification	B-X
of	B-X
factor	B-X
H	B-X
in	B-X
plasma	B-X
identifies	B-X
null	B-X
alleles	B-X
associated	B-X
with	B-X
atypical	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Total	B-X
deficiency	B-X
of	B-X
complement	B-X
factor	B-X
H	B-X
(	B-X
CFH	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
dense	B-X
deposit	B-X
disease	B-X
and	B-X
atypical	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X

This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B-Disease
in	I-Disease
the	I-Disease
human	I-Disease
complement	I-Disease
regulatory	I-Disease
protein	I-Disease
Factor	I-Disease
H	I-Disease
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B-Disease
renal	I-Disease
disease	I-Disease
.	O
<EOS>	B-X
This	B-X
study	B-X
reports	B-X
on	B-X
six	B-X
cases	B-X
of	B-X
deficiency	B-X
in	B-X
the	B-X
human	B-X
complement	B-X
regulatory	B-X
protein	B-X
Factor	B-X
H	B-X
(	B-X
FH	B-X
)	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
acute	B-X
renal	B-X
disease	B-X
<EOS>	B-X
Factor	B-X
H	B-X
deficiency	B-X
is	B-X
the	B-X
only	B-X
complement	B-X
deficiency	B-X
associated	B-X
with	B-X
HUS	B-X
<EOS>	B-X
Southern	B-X
blot	B-X
and	B-X
PCR	B-X
analysis	B-X
of	B-X
DNA	B-X
of	B-X
one	B-X
patient	B-X
with	B-X
homozygous	B-X
deficiency	B-X
ruled	B-X
out	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
deletion	B-X
of	B-X
the	B-X
FH	B-X
gene	B-X
as	B-X
the	B-X
underlying	B-X
defect	B-X
for	B-X
the	B-X
deficiency	B-X
<EOS>	B-X
Five	B-X
of	B-X
the	B-X
cases	B-X
were	B-X
observed	B-X
in	B-X
children	B-X
presenting	B-X
with	B-X
idiopathic	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
(	B-X
HUS	B-X
)	B-X

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
(	O
HUS	B-Disease
)	O
.	O
<EOS>	B-X
Five	B-X
of	B-X
the	B-X
cases	B-X
were	B-X
observed	B-X
in	B-X
children	B-X
presenting	B-X
with	B-X
idiopathic	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
(	B-X
HUS	B-X
)	B-X
<EOS>	B-X
Human	B-X
complement	B-X
factor	B-X
H	B-X
deficiency	B-X
associated	B-X
with	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
The	B-X
other	B-X
four	B-X
children	B-X
presented	B-X
with	B-X
heterozygous	B-X
deficiency	B-X
and	B-X
exhibited	B-X
a	B-X
normal	B-X
immunoblotting	B-X
pattern	B-X
of	B-X
proteins	B-X
of	B-X
the	B-X
FH	B-X
family	B-X
<EOS>	B-X
This	B-X
study	B-X
reports	B-X
on	B-X
six	B-X
cases	B-X
of	B-X
deficiency	B-X
in	B-X
the	B-X
human	B-X
complement	B-X
regulatory	B-X
protein	B-X
Factor	B-X
H	B-X
(	B-X
FH	B-X
)	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
acute	B-X
renal	B-X
disease	B-X

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O
.	O
<EOS>	B-X
Two	B-X
of	B-X
the	B-X
children	B-X
exhibited	B-X
a	B-X
homozygous	B-X
deficiency	B-X
characterized	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
150	B-X
-	B-X
kD	B-X
form	B-X
of	B-X
Factor	B-X
H	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
upon	B-X
immunoblotting	B-X
,	B-X
of	B-X
the	B-X
42	B-X
-	B-X
kD	B-X
Factor	B-X
H	B-X
-	B-X
like	B-X
protein	B-X
1	B-X
(	B-X
FHL	B-X
-	B-X
1	B-X
)	B-X
and	B-X
other	B-X
FH	B-X
-	B-X
related	B-X
protein	B-X
(	B-X
FHR	B-X
)	B-X
bands	B-X
<EOS>	B-X
The	B-X
other	B-X
four	B-X
children	B-X
presented	B-X
with	B-X
heterozygous	B-X
deficiency	B-X
and	B-X
exhibited	B-X
a	B-X
normal	B-X
immunoblotting	B-X
pattern	B-X
of	B-X
proteins	B-X
of	B-X
the	B-X
FH	B-X
family	B-X
<EOS>	B-X
This	B-X
study	B-X
reports	B-X
on	B-X
six	B-X
cases	B-X
of	B-X
deficiency	B-X
in	B-X
the	B-X
human	B-X
complement	B-X
regulatory	B-X
protein	B-X
Factor	B-X
H	B-X
(	B-X
FH	B-X
)	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
acute	B-X
renal	B-X
disease	B-X
<EOS>	B-X
Southern	B-X
blot	B-X
and	B-X
PCR	B-X
analysis	B-X
of	B-X
DNA	B-X
of	B-X
one	B-X
patient	B-X
with	B-X
homozygous	B-X
deficiency	B-X
ruled	B-X
out	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
deletion	B-X
of	B-X
the	B-X
FH	B-X
gene	B-X
as	B-X
the	B-X
underlying	B-X
defect	B-X
for	B-X
the	B-X
deficiency	B-X

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O
<EOS>	B-X
Southern	B-X
blot	B-X
and	B-X
PCR	B-X
analysis	B-X
of	B-X
DNA	B-X
of	B-X
one	B-X
patient	B-X
with	B-X
homozygous	B-X
deficiency	B-X
ruled	B-X
out	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
deletion	B-X
of	B-X
the	B-X
FH	B-X
gene	B-X
as	B-X
the	B-X
underlying	B-X
defect	B-X
for	B-X
the	B-X
deficiency	B-X
<EOS>	B-X
The	B-X
other	B-X
four	B-X
children	B-X
presented	B-X
with	B-X
heterozygous	B-X
deficiency	B-X
and	B-X
exhibited	B-X
a	B-X
normal	B-X
immunoblotting	B-X
pattern	B-X
of	B-X
proteins	B-X
of	B-X
the	B-X
FH	B-X
family	B-X
<EOS>	B-X
This	B-X
study	B-X
reports	B-X
on	B-X
six	B-X
cases	B-X
of	B-X
deficiency	B-X
in	B-X
the	B-X
human	B-X
complement	B-X
regulatory	B-X
protein	B-X
Factor	B-X
H	B-X
(	B-X
FH	B-X
)	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
acute	B-X
renal	B-X
disease	B-X
<EOS>	B-X
Two	B-X
of	B-X
the	B-X
children	B-X
exhibited	B-X
a	B-X
homozygous	B-X
deficiency	B-X
characterized	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
150	B-X
-	B-X
kD	B-X
form	B-X
of	B-X
Factor	B-X
H	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
upon	B-X
immunoblotting	B-X
,	B-X
of	B-X
the	B-X
42	B-X
-	B-X
kD	B-X
Factor	B-X
H	B-X
-	B-X
like	B-X
protein	B-X
1	B-X
(	B-X
FHL	B-X
-	B-X
1	B-X
)	B-X
and	B-X
other	B-X
FH	B-X
-	B-X
related	B-X
protein	B-X
(	B-X
FHR	B-X
)	B-X
bands	B-X

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O
<EOS>	B-X
The	B-X
other	B-X
four	B-X
children	B-X
presented	B-X
with	B-X
heterozygous	B-X
deficiency	B-X
and	B-X
exhibited	B-X
a	B-X
normal	B-X
immunoblotting	B-X
pattern	B-X
of	B-X
proteins	B-X
of	B-X
the	B-X
FH	B-X
family	B-X
<EOS>	B-X
Two	B-X
of	B-X
the	B-X
children	B-X
exhibited	B-X
a	B-X
homozygous	B-X
deficiency	B-X
characterized	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
150	B-X
-	B-X
kD	B-X
form	B-X
of	B-X
Factor	B-X
H	B-X
and	B-X
the	B-X
presence	B-X
,	B-X
upon	B-X
immunoblotting	B-X
,	B-X
of	B-X
the	B-X
42	B-X
-	B-X
kD	B-X
Factor	B-X
H	B-X
-	B-X
like	B-X
protein	B-X
1	B-X
(	B-X
FHL	B-X
-	B-X
1	B-X
)	B-X
and	B-X
other	B-X
FH	B-X
-	B-X
related	B-X
protein	B-X
(	B-X
FHR	B-X
)	B-X
bands	B-X
<EOS>	B-X
Southern	B-X
blot	B-X
and	B-X
PCR	B-X
analysis	B-X
of	B-X
DNA	B-X
of	B-X
one	B-X
patient	B-X
with	B-X
homozygous	B-X
deficiency	B-X
ruled	B-X
out	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
deletion	B-X
of	B-X
the	B-X
FH	B-X
gene	B-X
as	B-X
the	B-X
underlying	B-X
defect	B-X
for	B-X
the	B-X
deficiency	B-X
<EOS>	B-X
Human	B-X
complement	B-X
factor	B-X
H	B-X
deficiency	B-X
associated	B-X
with	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
.	B-X

Factor	B-Disease
H	I-Disease
deficiency	I-Disease
is	O
the	O
only	O
complement	B-Disease
deficiency	I-Disease
associated	O
with	O
HUS	B-Disease
.	O
<EOS>	B-X
Factor	B-X
H	B-X
deficiency	B-X
is	B-X
the	B-X
only	B-X
complement	B-X
deficiency	B-X
associated	B-X
with	B-X
HUS	B-X
<EOS>	B-X
Factor	B-X
H	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
renal	B-X
diseases	B-X
.	B-X
<EOS>	B-X
Complete	B-X
factor	B-X
H	B-X
deficiency	B-X
-	B-X
associated	B-X
atypical	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
in	B-X
a	B-X
neonate	B-X
.	B-X
<EOS>	B-X
Factor	B-X
H	B-X
(	B-X
FH	B-X
)	B-X
deficiency	B-X
-	B-X
associated	B-X
aHUS	B-X
usually	B-X
occurs	B-X
in	B-X
infants	B-X
to	B-X
middle	B-X
-	B-X
aged	B-X
adults	B-X
and	B-X
only	B-X
rarely	B-X
in	B-X
neonates	B-X

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B-Disease
.	O
.	O
<EOS>	B-X
There	B-X
are	B-X
several	B-X
theories	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
preterm	B-X
birth	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
fibroids	B-X
<EOS>	B-X
Our	B-X
findings	B-X
suggest	B-X
a	B-X
role	B-X
of	B-X
NLR	B-X
in	B-X
predicting	B-X
PCSK9	B-X
-	B-X
i	B-X
effect	B-X
in	B-X
FH	B-X
subjects	B-X
with	B-X
ASCVD	B-X
<EOS>	B-X
These	B-X
outcomes	B-X
mainly	B-X
occurred	B-X
in	B-X
patients	B-X
with	B-X
positive	B-X
ACPA	B-X
,	B-X
with	B-X
a	B-X
mean	B-X
AUC	B-X
of	B-X
0	B-X
<EOS>	B-X
The	B-X
objective	B-X
response	B-X
rate	B-X
(	B-X
ORR	B-X
)	B-X
in	B-X
all	B-X
randomized	B-X
patients	B-X
was	B-X
41	B-X

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B-Disease
dystrophy	I-Disease
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	B-Disease
chromosomes	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B-Disease
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B-Disease
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
a	B-X
founder	B-X
chromosome	B-X
for	B-X
the	B-X
DM	B-X
mutation	B-X
exists	B-X
in	B-X
the	B-X
Japanese	B-X
population	B-X
,	B-X
we	B-X
genotyped	B-X
families	B-X
using	B-X
polymorphic	B-X
markers	B-X
near	B-X
the	B-X
(	B-X
CTG	B-X
)	B-X
n	B-X
repeat	B-X
region	B-X
and	B-X
constructed	B-X
haplotypes	B-X
<EOS>	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
few	B-X
common	B-X
ancestral	B-X
mutations	B-X
in	B-X
both	B-X
Caucasian	B-X
and	B-X
Japanese	B-X
populations	B-X
have	B-X
originated	B-X
by	B-X
expansion	B-X
of	B-X
an	B-X
ancestral	B-X
n	B-X
=	B-X
5	B-X
repeat	B-X
to	B-X
n	B-X
=	B-X
19	B-X
-	B-X
37	B-X
copies	B-X
<EOS>	B-X
To	B-X
find	B-X
an	B-X
origin	B-X
of	B-X
the	B-X
(	B-X
CTG	B-X
)	B-X
n	B-X
repeat	B-X
mutation	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
the	B-X
expansion	B-X
mutation	B-X
in	B-X
the	B-X
Japanese	B-X
population	B-X
we	B-X
have	B-X
studied	B-X
90	B-X
Japanese	B-X
DM	B-X
families	B-X
comprising	B-X
190	B-X
affected	B-X
and	B-X
130	B-X
unaffected	B-X
members	B-X
<EOS>	B-X
These	B-X
data	B-X
support	B-X
multistep	B-X
models	B-X
of	B-X
triplet	B-X
repeat	B-X
expansion	B-X
that	B-X
have	B-X
been	B-X
proposed	B-X
for	B-X
both	B-X
DM	B-X
and	B-X
Friedreich	B-X
's	B-X
ataxia	B-X

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B-Disease
alleles	O
were	O
always	O
haplotype	O
A	O
.	O
<EOS>	B-X
Six	B-X
different	B-X
haplotypes	B-X
were	B-X
found	B-X
and	B-X
DM	B-X
alleles	B-X
were	B-X
always	B-X
haplotype	B-X
A	B-X
<EOS>	B-X
Four	B-X
different	B-X
DMA	B-X
alleles	B-X
and	B-X
six	B-X
different	B-X
DMB	B-X
alleles	B-X
were	B-X
detected	B-X
<EOS>	B-X
4	B-X
%	B-X
)	B-X
of	B-X
34	B-X
monkeys	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
the	B-X
MHC	B-X
-	B-X
DMA	B-X
and	B-X
	B-X
-	B-X
DMB	B-X
alleles	B-X
was	B-X
probably	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
the	B-X
Chinese	B-X
rhesus	B-X
macaques	B-X
<EOS>	B-X
All	B-X
loci	B-X
met	B-X
the	B-X
Hardy	B-X
-	B-X
Weinberg	B-X
equilibrium	B-X
principle	B-X
that	B-X
both	B-X
allele	B-X
and	B-X
genotype	B-X
frequencies	B-X
in	B-X
a	B-X
population	B-X
remain	B-X
constant	B-X

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B-Disease
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O
<EOS>	B-X
To	B-X
find	B-X
an	B-X
origin	B-X
of	B-X
the	B-X
(	B-X
CTG	B-X
)	B-X
n	B-X
repeat	B-X
mutation	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
the	B-X
expansion	B-X
mutation	B-X
in	B-X
the	B-X
Japanese	B-X
population	B-X
we	B-X
have	B-X
studied	B-X
90	B-X
Japanese	B-X
DM	B-X
families	B-X
comprising	B-X
190	B-X
affected	B-X
and	B-X
130	B-X
unaffected	B-X
members	B-X
<EOS>	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
few	B-X
common	B-X
ancestral	B-X
mutations	B-X
in	B-X
both	B-X
Caucasian	B-X
and	B-X
Japanese	B-X
populations	B-X
have	B-X
originated	B-X
by	B-X
expansion	B-X
of	B-X
an	B-X
ancestral	B-X
n	B-X
=	B-X
5	B-X
repeat	B-X
to	B-X
n	B-X
=	B-X
19	B-X
-	B-X
37	B-X
copies	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
a	B-X
founder	B-X
chromosome	B-X
for	B-X
the	B-X
DM	B-X
mutation	B-X
exists	B-X
in	B-X
the	B-X
Japanese	B-X
population	B-X
,	B-X
we	B-X
genotyped	B-X
families	B-X
using	B-X
polymorphic	B-X
markers	B-X
near	B-X
the	B-X
(	B-X
CTG	B-X
)	B-X
n	B-X
repeat	B-X
region	B-X
and	B-X
constructed	B-X
haplotypes	B-X
<EOS>	B-X
Further	B-X
evidence	B-X
for	B-X
a	B-X
major	B-X
ancient	B-X
mutation	B-X
underlying	B-X
myotonic	B-X
dystrophy	B-X
from	B-X
linkage	B-X
disequilibrium	B-X
studies	B-X
in	B-X
the	B-X
Japanese	B-X
population	B-X
.	B-X

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B-Disease
and	O
Friedreichs	B-Disease
ataxia	I-Disease
.	O
.	O

The	O
molecular	O
basis	O
of	O
C6	B-Disease
deficiency	I-Disease
in	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O
<EOS>	B-X
The	B-X
molecular	B-X
basis	B-X
of	B-X
C6	B-X
deficiency	B-X
in	B-X
the	B-X
western	B-X
Cape	B-X
,	B-X
South	B-X
Africa	B-X
.	B-X
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
sixth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C6	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
a	B-X
number	B-X
of	B-X
families	B-X
from	B-X
the	B-X
western	B-X
Cape	B-X
,	B-X
South	B-X
Africa	B-X
<EOS>	B-X
Meningococcal	B-X
disease	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
almost	B-X
all	B-X
pedigrees	B-X
of	B-X
total	B-X
C6	B-X
deficiency	B-X
(	B-X
C6Q0	B-X
)	B-X
have	B-X
been	B-X
ascertained	B-X
because	B-X
of	B-X
recurrent	B-X
disease	B-X
<EOS>	B-X
The	B-X
1936delG	B-X
defect	B-X
was	B-X
observed	B-X
only	B-X
once	B-X
in	B-X
the	B-X
Cape	B-X
,	B-X
but	B-X
its	B-X
associated	B-X
haplotype	B-X
could	B-X
be	B-X
deduced	B-X

Deficiency	B-Disease
of	I-Disease
the	I-Disease
sixth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Meningococcal	B-Disease
disease	I-Disease
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B-Disease
deficiency	I-Disease
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O
<EOS>	B-X
Meningococcal	B-X
disease	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
almost	B-X
all	B-X
pedigrees	B-X
of	B-X
total	B-X
C6	B-X
deficiency	B-X
(	B-X
C6Q0	B-X
)	B-X
have	B-X
been	B-X
ascertained	B-X
because	B-X
of	B-X
recurrent	B-X
disease	B-X
<EOS>	B-X
The	B-X
molecular	B-X
basis	B-X
of	B-X
C6	B-X
deficiency	B-X
in	B-X
the	B-X
western	B-X
Cape	B-X
,	B-X
South	B-X
Africa	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
sequenced	B-X
the	B-X
expressed	B-X
exons	B-X
of	B-X
the	B-X
C6	B-X
gene	B-X
from	B-X
selected	B-X
cases	B-X
and	B-X
have	B-X
found	B-X
three	B-X
molecular	B-X
defects	B-X
leading	B-X
to	B-X
total	B-X
deficiency	B-X
:	B-X
879delG	B-X
,	B-X
which	B-X
is	B-X
the	B-X
common	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
hitherto	B-X
unreported	B-X
,	B-X
and	B-X
1195delC	B-X
and	B-X
1936delG	B-X
,	B-X
which	B-X
have	B-X
been	B-X
previously	B-X
reported	B-X
in	B-X
African	B-X
-	B-X
Americans	B-X
<EOS>	B-X
The	B-X
1936delG	B-X
defect	B-X
was	B-X
observed	B-X
only	B-X
once	B-X
in	B-X
the	B-X
Cape	B-X
,	B-X
but	B-X
its	B-X
associated	B-X
haplotype	B-X
could	B-X
be	B-X
deduced	B-X

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O
<EOS>	B-X
We	B-X
have	B-X
sequenced	B-X
the	B-X
expressed	B-X
exons	B-X
of	B-X
the	B-X
C6	B-X
gene	B-X
from	B-X
selected	B-X
cases	B-X
and	B-X
have	B-X
found	B-X
three	B-X
molecular	B-X
defects	B-X
leading	B-X
to	B-X
total	B-X
deficiency	B-X
:	B-X
879delG	B-X
,	B-X
which	B-X
is	B-X
the	B-X
common	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
hitherto	B-X
unreported	B-X
,	B-X
and	B-X
1195delC	B-X
and	B-X
1936delG	B-X
,	B-X
which	B-X
have	B-X
been	B-X
previously	B-X
reported	B-X
in	B-X
African	B-X
-	B-X
Americans	B-X
<EOS>	B-X
The	B-X
data	B-X
from	B-X
the	B-X
haplotypes	B-X
indicate	B-X
that	B-X
these	B-X
three	B-X
molecular	B-X
defects	B-X
account	B-X
for	B-X
the	B-X
defects	B-X
in	B-X
all	B-X
the	B-X
38	B-X
unrelated	B-X
C6Q0	B-X
individuals	B-X
we	B-X
have	B-X
studied	B-X
from	B-X
the	B-X
Cape	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
observed	B-X
the	B-X
879delG	B-X
defect	B-X
in	B-X
two	B-X
Dutch	B-X
C6	B-X
-	B-X
deficient	B-X
kindreds	B-X
,	B-X
but	B-X
the	B-X
879delG	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
probably	B-X
did	B-X
not	B-X
come	B-X
from	B-X
The	B-X
Netherlands	B-X
<EOS>	B-X
Meningococcal	B-X
disease	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
almost	B-X
all	B-X
pedigrees	B-X
of	B-X
total	B-X
C6	B-X
deficiency	B-X
(	B-X
C6Q0	B-X
)	B-X
have	B-X
been	B-X
ascertained	B-X
because	B-X
of	B-X
recurrent	B-X
disease	B-X

We	O
also	O
show	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
the	B-X
879delG	B-X
and	B-X
1195delC	B-X
defects	B-X
are	B-X
associated	B-X
with	B-X
characteristic	B-X
C6	B-X
/	B-X
C7	B-X
region	B-X
DNA	B-X
marker	B-X
haplotypes	B-X
,	B-X
although	B-X
small	B-X
variations	B-X
were	B-X
observed	B-X
<EOS>	B-X
The	B-X
1936delG	B-X
defect	B-X
was	B-X
observed	B-X
only	B-X
once	B-X
in	B-X
the	B-X
Cape	B-X
,	B-X
but	B-X
its	B-X
associated	B-X
haplotype	B-X
could	B-X
be	B-X
deduced	B-X
<EOS>	B-X
We	B-X
have	B-X
sequenced	B-X
the	B-X
expressed	B-X
exons	B-X
of	B-X
the	B-X
C6	B-X
gene	B-X
from	B-X
selected	B-X
cases	B-X
and	B-X
have	B-X
found	B-X
three	B-X
molecular	B-X
defects	B-X
leading	B-X
to	B-X
total	B-X
deficiency	B-X
:	B-X
879delG	B-X
,	B-X
which	B-X
is	B-X
the	B-X
common	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
hitherto	B-X
unreported	B-X
,	B-X
and	B-X
1195delC	B-X
and	B-X
1936delG	B-X
,	B-X
which	B-X
have	B-X
been	B-X
previously	B-X
reported	B-X
in	B-X
African	B-X
-	B-X
Americans	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
observed	B-X
the	B-X
879delG	B-X
defect	B-X
in	B-X
two	B-X
Dutch	B-X
C6	B-X
-	B-X
deficient	B-X
kindreds	B-X
,	B-X
but	B-X
the	B-X
879delG	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
probably	B-X
did	B-X
not	B-X
come	B-X
from	B-X
The	B-X
Netherlands	B-X

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
.	O
<EOS>	B-X
The	B-X
1936delG	B-X
defect	B-X
was	B-X
observed	B-X
only	B-X
once	B-X
in	B-X
the	B-X
Cape	B-X
,	B-X
but	B-X
its	B-X
associated	B-X
haplotype	B-X
could	B-X
be	B-X
deduced	B-X
<EOS>	B-X
The	B-X
molecular	B-X
basis	B-X
of	B-X
C6	B-X
deficiency	B-X
in	B-X
the	B-X
western	B-X
Cape	B-X
,	B-X
South	B-X
Africa	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
observed	B-X
the	B-X
879delG	B-X
defect	B-X
in	B-X
two	B-X
Dutch	B-X
C6	B-X
-	B-X
deficient	B-X
kindreds	B-X
,	B-X
but	B-X
the	B-X
879delG	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
probably	B-X
did	B-X
not	B-X
come	B-X
from	B-X
The	B-X
Netherlands	B-X
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
the	B-X
879delG	B-X
and	B-X
1195delC	B-X
defects	B-X
are	B-X
associated	B-X
with	B-X
characteristic	B-X
C6	B-X
/	B-X
C7	B-X
region	B-X
DNA	B-X
marker	B-X
haplotypes	B-X
,	B-X
although	B-X
small	B-X
variations	B-X
were	B-X
observed	B-X

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O
<EOS>	B-X
The	B-X
data	B-X
from	B-X
the	B-X
haplotypes	B-X
indicate	B-X
that	B-X
these	B-X
three	B-X
molecular	B-X
defects	B-X
account	B-X
for	B-X
the	B-X
defects	B-X
in	B-X
all	B-X
the	B-X
38	B-X
unrelated	B-X
C6Q0	B-X
individuals	B-X
we	B-X
have	B-X
studied	B-X
from	B-X
the	B-X
Cape	B-X
<EOS>	B-X
We	B-X
have	B-X
sequenced	B-X
the	B-X
expressed	B-X
exons	B-X
of	B-X
the	B-X
C6	B-X
gene	B-X
from	B-X
selected	B-X
cases	B-X
and	B-X
have	B-X
found	B-X
three	B-X
molecular	B-X
defects	B-X
leading	B-X
to	B-X
total	B-X
deficiency	B-X
:	B-X
879delG	B-X
,	B-X
which	B-X
is	B-X
the	B-X
common	B-X
defect	B-X
in	B-X
the	B-X
Cape	B-X
and	B-X
hitherto	B-X
unreported	B-X
,	B-X
and	B-X
1195delC	B-X
and	B-X
1936delG	B-X
,	B-X
which	B-X
have	B-X
been	B-X
previously	B-X
reported	B-X
in	B-X
African	B-X
-	B-X
Americans	B-X
<EOS>	B-X
The	B-X
1936delG	B-X
defect	B-X
was	B-X
observed	B-X
only	B-X
once	B-X
in	B-X
the	B-X
Cape	B-X
,	B-X
but	B-X
its	B-X
associated	B-X
haplotype	B-X
could	B-X
be	B-X
deduced	B-X
<EOS>	B-X
Deficiency	B-X
of	B-X
the	B-X
sixth	B-X
component	B-X
of	B-X
human	B-X
complement	B-X
(	B-X
C6	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
a	B-X
number	B-X
of	B-X
families	B-X
from	B-X
the	B-X
western	B-X
Cape	B-X
,	B-X
South	B-X
Africa	B-X

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6	B-Disease
-	I-Disease
deficient	I-Disease
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
.	O

Complement	B-Disease
C7	I-Disease
deficiency	I-Disease
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O
<EOS>	B-X
Complement	B-X
C7	B-X
deficiency	B-X
:	B-X
seven	B-X
further	B-X
molecular	B-X
defects	B-X
and	B-X
their	B-X
associated	B-X
marker	B-X
haplotypes	B-X
.	B-X
<EOS>	B-X
Seven	B-X
further	B-X
molecular	B-X
bases	B-X
of	B-X
C7	B-X
deficiency	B-X
are	B-X
described	B-X
<EOS>	B-X
Seven	B-X
different	B-X
C7	B-X
deficient	B-X
haplotypes	B-X
were	B-X
found	B-X
for	B-X
C7	B-X
markers	B-X
alone	B-X
,	B-X
but	B-X
all	B-X
the	B-X
four	B-X
Israelis	B-X
share	B-X
one	B-X
and	B-X
three	B-X
out	B-X
of	B-X
four	B-X
Irish	B-X
haplotypes	B-X
share	B-X
another	B-X
<EOS>	B-X
Five	B-X
of	B-X
the	B-X
nine	B-X
C7	B-X
deficient	B-X
probands	B-X
(	B-X
resident	B-X
in	B-X
Ireland	B-X
,	B-X
South	B-X
Africa	B-X
,	B-X
Russia	B-X
and	B-X
Israel	B-X
)	B-X
are	B-X
heterozygous	B-X
for	B-X
C6	B-X
/	B-X
C7	B-X
haplotypes	B-X

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B-Disease
deficiency	I-Disease
are	O
described	O
.	O
<EOS>	B-X
Seven	B-X
further	B-X
molecular	B-X
bases	B-X
of	B-X
C7	B-X
deficiency	B-X
are	B-X
described	B-X
<EOS>	B-X
Complement	B-X
C7	B-X
deficiency	B-X
:	B-X
seven	B-X
further	B-X
molecular	B-X
defects	B-X
and	B-X
their	B-X
associated	B-X
marker	B-X
haplotypes	B-X
.	B-X
<EOS>	B-X
The	B-X
C6	B-X
/	B-X
C7	B-X
marker	B-X
haplotypes	B-X
associated	B-X
with	B-X
most	B-X
C7	B-X
defects	B-X
are	B-X
tabulated	B-X
<EOS>	B-X
All	B-X
these	B-X
new	B-X
molecular	B-X
defects	B-X
involve	B-X
single	B-X
-	B-X
nucleotide	B-X
events	B-X
,	B-X
deletions	B-X
and	B-X
substitutions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
alter	B-X
splice	B-X
sites	B-X
,	B-X
and	B-X
others	B-X
codons	B-X

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O
<EOS>	B-X
All	B-X
these	B-X
new	B-X
molecular	B-X
defects	B-X
involve	B-X
single	B-X
-	B-X
nucleotide	B-X
events	B-X
,	B-X
deletions	B-X
and	B-X
substitutions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
alter	B-X
splice	B-X
sites	B-X
,	B-X
and	B-X
others	B-X
codons	B-X
<EOS>	B-X
Complement	B-X
C7	B-X
deficiency	B-X
:	B-X
seven	B-X
further	B-X
molecular	B-X
defects	B-X
and	B-X
their	B-X
associated	B-X
marker	B-X
haplotypes	B-X
.	B-X
<EOS>	B-X
They	B-X
are	B-X
distributed	B-X
along	B-X
the	B-X
C7	B-X
gene	B-X
,	B-X
but	B-X
predominantly	B-X
towards	B-X
the	B-X
3	B-X
'	B-X
end	B-X
<EOS>	B-X
Seven	B-X
further	B-X
molecular	B-X
bases	B-X
of	B-X
C7	B-X
deficiency	B-X
are	B-X
described	B-X

They	O
are	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O
<EOS>	B-X
They	B-X
are	B-X
distributed	B-X
along	B-X
the	B-X
C7	B-X
gene	B-X
,	B-X
but	B-X
predominantly	B-X
towards	B-X
the	B-X
3	B-X
'	B-X
end	B-X
<EOS>	B-X
All	B-X
these	B-X
new	B-X
molecular	B-X
defects	B-X
involve	B-X
single	B-X
-	B-X
nucleotide	B-X
events	B-X
,	B-X
deletions	B-X
and	B-X
substitutions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
alter	B-X
splice	B-X
sites	B-X
,	B-X
and	B-X
others	B-X
codons	B-X
<EOS>	B-X
Seven	B-X
further	B-X
molecular	B-X
bases	B-X
of	B-X
C7	B-X
deficiency	B-X
are	B-X
described	B-X
<EOS>	B-X
The	B-X
C6	B-X
/	B-X
C7	B-X
marker	B-X
haplotypes	B-X
associated	B-X
with	B-X
most	B-X
C7	B-X
defects	B-X
are	B-X
tabulated	B-X

All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O
<EOS>	B-X
We	B-X
identified	B-X
compound	B-X
heterozygous	B-X
variants	B-X
of	B-X
<EOS>	B-X
Patient	B-X
AY078	B-X
had	B-X
novel	B-X
compound	B-X
heterozygous	B-X
splice	B-X
variants	B-X
(	B-X
c	B-X
<EOS>	B-X
This	B-X
finding	B-X
of	B-X
a	B-X
compound	B-X
heterozygote	B-X
with	B-X
a	B-X
1	B-X
<EOS>	B-X
A347T	B-X
)	B-X
compound	B-X
heterozygous	B-X
variants	B-X
,	B-X
and	B-X
c	B-X

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	B-Disease
defects	I-Disease
are	O
tabulated	O
.	O
.	O
<EOS>	B-X
The	B-X
C6	B-X
/	B-X
C7	B-X
marker	B-X
haplotypes	B-X
associated	B-X
with	B-X
most	B-X
C7	B-X
defects	B-X
are	B-X
tabulated	B-X
<EOS>	B-X
Seven	B-X
further	B-X
molecular	B-X
bases	B-X
of	B-X
C7	B-X
deficiency	B-X
are	B-X
described	B-X
<EOS>	B-X
Complement	B-X
C7	B-X
deficiency	B-X
:	B-X
seven	B-X
further	B-X
molecular	B-X
defects	B-X
and	B-X
their	B-X
associated	B-X
marker	B-X
haplotypes	B-X
.	B-X
<EOS>	B-X
All	B-X
these	B-X
new	B-X
molecular	B-X
defects	B-X
involve	B-X
single	B-X
-	B-X
nucleotide	B-X
events	B-X
,	B-X
deletions	B-X
and	B-X
substitutions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
alter	B-X
splice	B-X
sites	B-X
,	B-X
and	B-X
others	B-X
codons	B-X

A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B-Disease
affective	I-Disease
disorder	I-Disease
among	O
the	O
Old	O
Order	O
Amish	O
.	O
<EOS>	B-X
A	B-X
genome	B-X
-	B-X
wide	B-X
search	B-X
for	B-X
chromosomal	B-X
loci	B-X
linked	B-X
to	B-X
mental	B-X
health	B-X
wellness	B-X
in	B-X
relatives	B-X
at	B-X
high	B-X
risk	B-X
for	B-X
bipolar	B-X
affective	B-X
disorder	B-X
among	B-X
the	B-X
Old	B-X
Order	B-X
Amish	B-X
.	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
there	B-X
could	B-X
be	B-X
protective	B-X
alleles	B-X
that	B-X
prevent	B-X
or	B-X
reduce	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
BPAD	B-X
,	B-X
similar	B-X
to	B-X
what	B-X
is	B-X
observed	B-X
in	B-X
other	B-X
genetic	B-X
disorders	B-X
,	B-X
we	B-X
used	B-X
mental	B-X
health	B-X
wellness	B-X
(	B-X
absence	B-X
of	B-X
any	B-X
psychiatric	B-X
disorder	B-X
)	B-X
as	B-X
the	B-X
phenotype	B-X
in	B-X
our	B-X
genome	B-X
-	B-X
wide	B-X
linkage	B-X
scan	B-X
of	B-X
several	B-X
large	B-X
multigeneration	B-X
Old	B-X
Order	B-X
Amish	B-X
pedigrees	B-X
exhibiting	B-X
an	B-X
extremely	B-X
high	B-X
incidence	B-X
of	B-X
BPAD	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
linkage	B-X
studies	B-X
have	B-X
attempted	B-X
only	B-X
to	B-X
identify	B-X
chromosomal	B-X
loci	B-X
that	B-X
cause	B-X
or	B-X
increase	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
BPAD	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
strong	B-X
evidence	B-X
for	B-X
a	B-X
locus	B-X
on	B-X
chromosome	B-X
4p	B-X
at	B-X
D4S2949	B-X
(	B-X
maximum	B-X
GENEHUNTER	B-X
-	B-X
PLUS	B-X
nonparametric	B-X
linkage	B-X
score	B-X
=	B-X
4	B-X

Bipolar	B-Disease
affective	I-Disease
disorder	I-Disease
(	O
BPAD	B-Disease
;	O
manic	B-Disease
-	I-Disease
depressive	I-Disease
illness	I-Disease
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B-Disease
and	O
/	O
or	O
hypomania	B-Disease
interspersed	O
with	O
periods	O
of	O
depression	B-Disease
.	O
<EOS>	B-X
Bipolar	B-X
disorder	B-X
(	B-X
BD	B-X
)	B-X
is	B-X
a	B-X
psychiatric	B-X
disorder	B-X
characterized	B-X
by	B-X
episodes	B-X
of	B-X
depression	B-X
and	B-X
mania	B-X
,	B-X
associated	B-X
with	B-X
impaired	B-X
emotion	B-X
processing	B-X
<EOS>	B-X
Bipolar	B-X
disorder	B-X
(	B-X
BPD	B-X
)	B-X
is	B-X
a	B-X
severe	B-X
mental	B-X
illness	B-X
characterized	B-X
by	B-X
episodes	B-X
of	B-X
depression	B-X
and	B-X
mania	B-X
<EOS>	B-X
Bipolar	B-X
Disorder	B-X
(	B-X
BD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
mental	B-X
disease	B-X
characterized	B-X
by	B-X
recurrent	B-X
episodes	B-X
of	B-X
mania	B-X
and	B-X
depression	B-X
<EOS>	B-X
Bipolar	B-X
disorder	B-X
(	B-X
BD	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
major	B-X
psychiatric	B-X
disorders	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
recurrent	B-X
episodes	B-X
of	B-X
depression	B-X
and	B-X
mania	B-X
(	B-X
or	B-X
hypomania	B-X
)	B-X
,	B-X
leading	B-X
to	B-X
seriously	B-X
adverse	B-X
outcomes	B-X
with	B-X
unclear	B-X
pathogenesis	B-X

Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	B-Disease
.	O
<EOS>	B-X
Compelling	B-X
evidence	B-X
supports	B-X
a	B-X
significant	B-X
genetic	B-X
component	B-X
in	B-X
the	B-X
susceptibility	B-X
to	B-X
develop	B-X
BPAD	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
linkage	B-X
studies	B-X
have	B-X
attempted	B-X
only	B-X
to	B-X
identify	B-X
chromosomal	B-X
loci	B-X
that	B-X
cause	B-X
or	B-X
increase	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
BPAD	B-X
<EOS>	B-X
These	B-X
findings	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
certain	B-X
alleles	B-X
could	B-X
prevent	B-X
or	B-X
modify	B-X
the	B-X
clinical	B-X
manifestations	B-X
of	B-X
BPAD	B-X
and	B-X
perhaps	B-X
other	B-X
related	B-X
affective	B-X
disorders	B-X
<EOS>	B-X
A	B-X
genome	B-X
-	B-X
wide	B-X
search	B-X
for	B-X
chromosomal	B-X
loci	B-X
linked	B-X
to	B-X
mental	B-X
health	B-X
wellness	B-X
in	B-X
relatives	B-X
at	B-X
high	B-X
risk	B-X
for	B-X
bipolar	B-X
affective	B-X
disorder	B-X
among	B-X
the	B-X
Old	B-X
Order	B-X
Amish	B-X
.	B-X

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	B-Disease
.	O
<EOS>	B-X
Two	B-X
weeks	B-X
later	B-X
,	B-X
she	B-X
presented	B-X
with	B-X
insomnia	B-X
,	B-X
anxiety	B-X
,	B-X
nausea	B-X
,	B-X
headaches	B-X
and	B-X
palpitations	B-X
<EOS>	B-X
Offspring	B-X
of	B-X
parents	B-X
with	B-X
bipolar	B-X
disorder	B-X
(	B-X
BD	B-X
-	B-X
I	B-X
/	B-X
II	B-X
)	B-X
are	B-X
at	B-X
increased	B-X
risk	B-X
to	B-X
develop	B-X
the	B-X
disorder	B-X
<EOS>	B-X
Most	B-X
published	B-X
studies	B-X
have	B-X
used	B-X
domperidone	B-X
in	B-X
a	B-X
dosage	B-X
of	B-X
10	B-X
mg	B-X
3	B-X
times	B-X
daily	B-X
for	B-X
4	B-X
to	B-X
10	B-X
days	B-X
<EOS>	B-X
[	B-X
1	B-X
]	B-X
Data	B-X
available	B-X
from	B-X
4	B-X
small	B-X
studies	B-X
on	B-X
the	B-X
excretion	B-X
of	B-X
domperidone	B-X
into	B-X
breastmilk	B-X
are	B-X
somewhat	B-X
inconsistent	B-X
,	B-X
but	B-X
infants	B-X
would	B-X
probably	B-X
receive	B-X
less	B-X
than	B-X
0	B-X

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	B-Disease
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B-Disease
disorders	I-Disease
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B-Disease
disorder	I-Disease
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	B-Disease
.	O
<EOS>	B-X
To	B-X
test	B-X
whether	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
PACAP	B-X
are	B-X
direct	B-X
on	B-X
the	B-X
PAC1	B-X
receptor	B-X
subtype	B-X
on	B-X
neurons	B-X
,	B-X
we	B-X
delete	B-X
PAC1	B-X
receptors	B-X
from	B-X
neurons	B-X
and	B-X
investigate	B-X
neuropathologigical	B-X
changes	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
of	B-X
MS	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
there	B-X
was	B-X
evidence	B-X
of	B-X
statistical	B-X
interaction	B-X
between	B-X
alcohol	B-X
consumption	B-X
and	B-X
HLA	B-X
-	B-X
DRB1	B-X
*	B-X
15:01	B-X
genotype	B-X
,	B-X
we	B-X
calculated	B-X
interaction	B-X
on	B-X
the	B-X
additive	B-X
and	B-X
multiplicative	B-X
scales	B-X
<EOS>	B-X
To	B-X
determine	B-X
if	B-X
PAC1	B-X
receptors	B-X
protect	B-X
neurons	B-X
in	B-X
a	B-X
cell	B-X
-	B-X
autonomous	B-X
manner	B-X
,	B-X
we	B-X
used	B-X
adeno	B-X
-	B-X
associated	B-X
virus	B-X
(	B-X
AAV2	B-X
)	B-X
to	B-X
deliver	B-X
Cre	B-X
recombinase	B-X
to	B-X
the	B-X
retina	B-X
of	B-X
mice	B-X
harboring	B-X
floxed	B-X
PAC1	B-X
alleles	B-X
<EOS>	B-X
Brain	B-X
Age	B-X
Gap	B-X
(	B-X
BAG	B-X
)	B-X
is	B-X
a	B-X
concept	B-X
used	B-X
increasingly	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
brain	B-X
health	B-X
;	B-X
BAG	B-X
is	B-X
defined	B-X
as	B-X
the	B-X
difference	B-X
between	B-X
predicted	B-X
age	B-X
(	B-X
based	B-X
on	B-X
structural	B-X
MRI	B-X
)	B-X
and	B-X
chronological	B-X
age	B-X
,	B-X
with	B-X
negative	B-X
values	B-X
reflecting	B-X
preserved	B-X
brain	B-X
health	B-X
with	B-X
age	B-X

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B-Disease
and	O
perhaps	O
other	O
related	O
affective	B-Disease
disorders	I-Disease
.	O
<EOS>	B-X
These	B-X
findings	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
certain	B-X
alleles	B-X
could	B-X
prevent	B-X
or	B-X
modify	B-X
the	B-X
clinical	B-X
manifestations	B-X
of	B-X
BPAD	B-X
and	B-X
perhaps	B-X
other	B-X
related	B-X
affective	B-X
disorders	B-X
<EOS>	B-X
The	B-X
present	B-X
report	B-X
concerns	B-X
the	B-X
clinical	B-X
and	B-X
temperamental	B-X
features	B-X
of	B-X
104	B-X
manic	B-X
patients	B-X
during	B-X
the	B-X
acute	B-X
hospital	B-X
phase	B-X
<EOS>	B-X
This	B-X
research	B-X
derives	B-X
from	B-X
the	B-X
French	B-X
national	B-X
multisite	B-X
collaborative	B-X
study	B-X
on	B-X
the	B-X
clinical	B-X
epidemiology	B-X
of	B-X
mania	B-X
(	B-X
EPIMAN	B-X
)	B-X
<EOS>	B-X
Because	B-X
men	B-X
have	B-X
higher	B-X
rates	B-X
of	B-X
this	B-X
temperament	B-X
,	B-X
pure	B-X
mania	B-X
is	B-X
overrepresented	B-X
in	B-X
men	B-X
;	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
depressive	B-X
temperament	B-X
in	B-X
manic	B-X
women	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
clinical	B-X
marker	B-X
for	B-X
the	B-X
well	B-X
-	B-X
known	B-X
female	B-X
tendency	B-X
for	B-X
depression	B-X
,	B-X
hence	B-X
the	B-X
higher	B-X
prevalence	B-X
of	B-X
mixed	B-X
mania	B-X
in	B-X
women	B-X

Segregation	O
distortion	O
in	O
myotonic	B-Disease
dystrophy	I-Disease
.	O
<EOS>	B-X
Segregation	B-X
distortion	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Segregation	B-X
distortion	B-X
of	B-X
the	B-X
CTG	B-X
repeats	B-X
at	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
locus	B-X
.	B-X
<EOS>	B-X
Dynamic	B-X
balance	B-X
of	B-X
segregation	B-X
distortion	B-X
and	B-X
selection	B-X
maintains	B-X
normal	B-X
allele	B-X
sizes	B-X
at	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
locus	B-X
.	B-X
<EOS>	B-X
Segregation	B-X
distortion	B-X
of	B-X
the	B-X
CTG	B-X
repeats	B-X
at	B-X
the	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
locus	B-X
:	B-X
new	B-X
data	B-X
from	B-X
Brazilian	B-X
DM	B-X
families	B-X
.	B-X

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O

This	O
results	O
in	O
infertility	B-Disease
and	O
congenital	B-Disease
myotonic	I-Disease
dystrophy	I-Disease
(	O
CDM	B-Disease
)	O
with	O
the	O
disappearance	O
of	O
DM	B-Disease
in	O
that	O
pedigree	O
.	O
<EOS>	B-X
This	B-X
results	B-X
in	B-X
infertility	B-X
and	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
CDM	B-X
)	B-X
with	B-X
the	B-X
disappearance	B-X
of	B-X
DM	B-X
in	B-X
that	B-X
pedigree	B-X
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
segregation	B-X
distortion	B-X
,	B-X
where	B-X
there	B-X
is	B-X
preferential	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
,	B-X
has	B-X
been	B-X
put	B-X
forward	B-X
to	B-X
explain	B-X
partially	B-X
the	B-X
maintenance	B-X
of	B-X
DM	B-X
in	B-X
the	B-X
population	B-X
<EOS>	B-X
Segregation	B-X
distortion	B-X
in	B-X
myotonic	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Sibships	B-X
where	B-X
the	B-X
status	B-X
of	B-X
all	B-X
the	B-X
members	B-X
had	B-X
been	B-X
identified	B-X
were	B-X
examined	B-X
to	B-X
determine	B-X
the	B-X
transmission	B-X
of	B-X
the	B-X
DM	B-X
expansion	B-X
from	B-X
affected	B-X
parents	B-X
to	B-X
their	B-X
offspring	B-X

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B-Disease
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	B-Disease
in	O
the	O
population	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
segregation	B-X
distortion	B-X
,	B-X
where	B-X
there	B-X
is	B-X
preferential	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
,	B-X
has	B-X
been	B-X
put	B-X
forward	B-X
to	B-X
explain	B-X
partially	B-X
the	B-X
maintenance	B-X
of	B-X
DM	B-X
in	B-X
the	B-X
population	B-X
<EOS>	B-X
Studies	B-X
on	B-X
meiotic	B-X
drive	B-X
in	B-X
DM	B-X
have	B-X
shown	B-X
increased	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
in	B-X
non	B-X
-	B-X
DM	B-X
heterozygotes	B-X
for	B-X
CTGn	B-X
<EOS>	B-X
This	B-X
results	B-X
in	B-X
infertility	B-X
and	B-X
congenital	B-X
myotonic	B-X
dystrophy	B-X
(	B-X
CDM	B-X
)	B-X
with	B-X
the	B-X
disappearance	B-X
of	B-X
DM	B-X
in	B-X
that	B-X
pedigree	B-X
<EOS>	B-X
Myotonic	B-X
dystrophy	B-X
(	B-X
DM	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
disease	B-X
which	B-X
,	B-X
in	B-X
the	B-X
typical	B-X
pedigree	B-X
,	B-X
shows	B-X
a	B-X
three	B-X
generation	B-X
anticipation	B-X
cascade	B-X

In	O
a	O
survey	O
of	O
DM	B-Disease
in	O
Northern	O
Ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	B-Disease
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O
<EOS>	B-X
Sibships	B-X
where	B-X
the	B-X
status	B-X
of	B-X
all	B-X
the	B-X
members	B-X
had	B-X
been	B-X
identified	B-X
were	B-X
examined	B-X
to	B-X
determine	B-X
the	B-X
transmission	B-X
of	B-X
the	B-X
DM	B-X
expansion	B-X
from	B-X
affected	B-X
parents	B-X
to	B-X
their	B-X
offspring	B-X
<EOS>	B-X
This	B-X
study	B-X
provides	B-X
further	B-X
evidence	B-X
that	B-X
the	B-X
DM	B-X
expansion	B-X
tends	B-X
to	B-X
be	B-X
transmitted	B-X
preferentially	B-X
<EOS>	B-X
Studies	B-X
on	B-X
meiotic	B-X
drive	B-X
in	B-X
DM	B-X
have	B-X
shown	B-X
increased	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
in	B-X
non	B-X
-	B-X
DM	B-X
heterozygotes	B-X
for	B-X
CTGn	B-X
<EOS>	B-X
3	B-X
%	B-X
of	B-X
the	B-X
offspring	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
female	B-X
transmitting	B-X
parent	B-X
,	B-X
68	B-X

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
.	O
<EOS>	B-X
Where	B-X
the	B-X
transmitting	B-X
parent	B-X
was	B-X
male	B-X
,	B-X
58	B-X
<EOS>	B-X
Ten	B-X
percent	B-X
of	B-X
the	B-X
urine	B-X
filtration	B-X
slides	B-X
were	B-X
read	B-X
twice	B-X
<EOS>	B-X
These	B-X
ultra	B-X
-	B-X
light	B-X
infections	B-X
impose	B-X
a	B-X
major	B-X
challenge	B-X
for	B-X
accurate	B-X
diagnosis	B-X
<EOS>	B-X
haematobium	B-X
transmission	B-X
and	B-X
control	B-X
soil	B-X
-	B-X
transmitted	B-X
helminthiasis	B-X

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O
<EOS>	B-X
3	B-X
%	B-X
of	B-X
the	B-X
offspring	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
female	B-X
transmitting	B-X
parent	B-X
,	B-X
68	B-X
<EOS>	B-X
Sibships	B-X
where	B-X
the	B-X
status	B-X
of	B-X
all	B-X
the	B-X
members	B-X
had	B-X
been	B-X
identified	B-X
were	B-X
examined	B-X
to	B-X
determine	B-X
the	B-X
transmission	B-X
of	B-X
the	B-X
DM	B-X
expansion	B-X
from	B-X
affected	B-X
parents	B-X
to	B-X
their	B-X
offspring	B-X
<EOS>	B-X
Studies	B-X
on	B-X
meiotic	B-X
drive	B-X
in	B-X
DM	B-X
have	B-X
shown	B-X
increased	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
in	B-X
non	B-X
-	B-X
DM	B-X
heterozygotes	B-X
for	B-X
CTGn	B-X
<EOS>	B-X
Where	B-X
the	B-X
transmitting	B-X
parent	B-X
was	B-X
male	B-X
,	B-X
58	B-X

7	O
%	O
were	O
affected	O
.	O
<EOS>	B-X
Ruminal	B-X
pH	B-X
was	B-X
not	B-X
affected	B-X
(	B-X
P	B-X
â‰¥	B-X
0	B-X
<EOS>	B-X
Dry	B-X
matter	B-X
intake	B-X
was	B-X
not	B-X
affected	B-X
(	B-X
P	B-X
â‰¥	B-X
0	B-X
<EOS>	B-X
7	B-X
%	B-X
of	B-X
children	B-X
after	B-X
PGT	B-X
and	B-X
in	B-X
7	B-X
<EOS>	B-X
1	B-X
million	B-X
affected	B-X
individuals	B-X

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B-Disease
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B-Disease
locus	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O
<EOS>	B-X
Studies	B-X
on	B-X
meiotic	B-X
drive	B-X
in	B-X
DM	B-X
have	B-X
shown	B-X
increased	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
in	B-X
non	B-X
-	B-X
DM	B-X
heterozygotes	B-X
for	B-X
CTGn	B-X
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
segregation	B-X
distortion	B-X
,	B-X
where	B-X
there	B-X
is	B-X
preferential	B-X
transmission	B-X
of	B-X
the	B-X
larger	B-X
allele	B-X
at	B-X
the	B-X
DM	B-X
locus	B-X
,	B-X
has	B-X
been	B-X
put	B-X
forward	B-X
to	B-X
explain	B-X
partially	B-X
the	B-X
maintenance	B-X
of	B-X
DM	B-X
in	B-X
the	B-X
population	B-X
<EOS>	B-X
Sibships	B-X
where	B-X
the	B-X
status	B-X
of	B-X
all	B-X
the	B-X
members	B-X
had	B-X
been	B-X
identified	B-X
were	B-X
examined	B-X
to	B-X
determine	B-X
the	B-X
transmission	B-X
of	B-X
the	B-X
DM	B-X
expansion	B-X
from	B-X
affected	B-X
parents	B-X
to	B-X
their	B-X
offspring	B-X
<EOS>	B-X
3	B-X
%	B-X
of	B-X
the	B-X
offspring	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
female	B-X
transmitting	B-X
parent	B-X
,	B-X
68	B-X

This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	B-Disease
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O
<EOS>	B-X
This	B-X
study	B-X
provides	B-X
further	B-X
evidence	B-X
that	B-X
the	B-X
DM	B-X
expansion	B-X
tends	B-X
to	B-X
be	B-X
transmitted	B-X
preferentially	B-X
<EOS>	B-X
3	B-X
%	B-X
of	B-X
the	B-X
offspring	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
female	B-X
transmitting	B-X
parent	B-X
,	B-X
68	B-X
<EOS>	B-X
Sibships	B-X
where	B-X
the	B-X
status	B-X
of	B-X
all	B-X
the	B-X
members	B-X
had	B-X
been	B-X
identified	B-X
were	B-X
examined	B-X
to	B-X
determine	B-X
the	B-X
transmission	B-X
of	B-X
the	B-X
DM	B-X
expansion	B-X
from	B-X
affected	B-X
parents	B-X
to	B-X
their	B-X
offspring	B-X
<EOS>	B-X
In	B-X
a	B-X
survey	B-X
of	B-X
DM	B-X
in	B-X
Northern	B-X
Ireland	B-X
,	B-X
59	B-X
pedigrees	B-X
were	B-X
ascertained	B-X

Diagnosis	O
of	O
hemochromatosis	B-Disease
.	O
<EOS>	B-X
Hemochromatosis	B-X
.	B-X
<EOS>	B-X
Diagnosis	B-X
and	B-X
Management	B-X
of	B-X
Hereditary	B-X
Hemochromatosis	B-X
.	B-X
<EOS>	B-X
What	B-X
Is	B-X
Hereditary	B-X
Hemochromatosis	B-X
?	B-X
<EOS>	B-X
These	B-X
findings	B-X
led	B-X
to	B-X
the	B-X
diagnosis	B-X
of	B-X
hemochromatosis	B-X

If	O
untreated	O
,	O
hemochromatosis	B-Disease
can	O
cause	O
serious	O
illness	O
and	O
early	B-Disease
death	I-Disease
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O
<EOS>	B-X
If	B-X
untreated	B-X
,	B-X
hemochromatosis	B-X
can	B-X
cause	B-X
serious	B-X
illness	B-X
and	B-X
early	B-X
death	B-X
,	B-X
but	B-X
the	B-X
disease	B-X
is	B-X
still	B-X
substantially	B-X
under	B-X
-	B-X
diagnosed	B-X
<EOS>	B-X
It	B-X
is	B-X
crucial	B-X
to	B-X
diagnose	B-X
hemochromatosis	B-X
before	B-X
hepatic	B-X
cirrhosis	B-X
develops	B-X
because	B-X
phlebotomy	B-X
therapy	B-X
can	B-X
avert	B-X
serious	B-X
chronic	B-X
disease	B-X
and	B-X
can	B-X
even	B-X
lead	B-X
to	B-X
normal	B-X
life	B-X
expectancy	B-X
<EOS>	B-X
Once	B-X
the	B-X
diagnosis	B-X
is	B-X
suspected	B-X
,	B-X
physicians	B-X
must	B-X
use	B-X
serum	B-X
ferritin	B-X
levels	B-X
and	B-X
hepatic	B-X
iron	B-X
stores	B-X
on	B-X
liver	B-X
biopsy	B-X
specimens	B-X
to	B-X
assess	B-X
patients	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
iron	B-X
overload	B-X
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
most	B-X
useful	B-X
role	B-X
for	B-X
this	B-X
test	B-X
is	B-X
in	B-X
the	B-X
detection	B-X
of	B-X
hemochromatosis	B-X
in	B-X
the	B-X
family	B-X
members	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
proven	B-X
case	B-X
of	B-X
the	B-X
disease	B-X

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O
<EOS>	B-X
The	B-X
cornerstone	B-X
of	B-X
screening	B-X
and	B-X
case	B-X
detection	B-X
is	B-X
the	B-X
measurement	B-X
of	B-X
serum	B-X
transferrin	B-X
saturation	B-X
and	B-X
the	B-X
serum	B-X
ferritin	B-X
level	B-X
<EOS>	B-X
Once	B-X
the	B-X
diagnosis	B-X
is	B-X
suspected	B-X
,	B-X
physicians	B-X
must	B-X
use	B-X
serum	B-X
ferritin	B-X
levels	B-X
and	B-X
hepatic	B-X
iron	B-X
stores	B-X
on	B-X
liver	B-X
biopsy	B-X
specimens	B-X
to	B-X
assess	B-X
patients	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
iron	B-X
overload	B-X
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
most	B-X
useful	B-X
role	B-X
for	B-X
this	B-X
test	B-X
is	B-X
in	B-X
the	B-X
detection	B-X
of	B-X
hemochromatosis	B-X
in	B-X
the	B-X
family	B-X
members	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
proven	B-X
case	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
It	B-X
is	B-X
crucial	B-X
to	B-X
diagnose	B-X
hemochromatosis	B-X
before	B-X
hepatic	B-X
cirrhosis	B-X
develops	B-X
because	B-X
phlebotomy	B-X
therapy	B-X
can	B-X
avert	B-X
serious	B-X
chronic	B-X
disease	B-X
and	B-X
can	B-X
even	B-X
lead	B-X
to	B-X
normal	B-X
life	B-X
expectancy	B-X

Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B-Disease
overload	I-Disease
.	O
<EOS>	B-X
Once	B-X
the	B-X
diagnosis	B-X
is	B-X
suspected	B-X
,	B-X
physicians	B-X
must	B-X
use	B-X
serum	B-X
ferritin	B-X
levels	B-X
and	B-X
hepatic	B-X
iron	B-X
stores	B-X
on	B-X
liver	B-X
biopsy	B-X
specimens	B-X
to	B-X
assess	B-X
patients	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
iron	B-X
overload	B-X
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
most	B-X
useful	B-X
role	B-X
for	B-X
this	B-X
test	B-X
is	B-X
in	B-X
the	B-X
detection	B-X
of	B-X
hemochromatosis	B-X
in	B-X
the	B-X
family	B-X
members	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
proven	B-X
case	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
The	B-X
cornerstone	B-X
of	B-X
screening	B-X
and	B-X
case	B-X
detection	B-X
is	B-X
the	B-X
measurement	B-X
of	B-X
serum	B-X
transferrin	B-X
saturation	B-X
and	B-X
the	B-X
serum	B-X
ferritin	B-X
level	B-X
<EOS>	B-X
If	B-X
untreated	B-X
,	B-X
hemochromatosis	B-X
can	B-X
cause	B-X
serious	B-X
illness	B-X
and	B-X
early	B-X
death	B-X
,	B-X
but	B-X
the	B-X
disease	B-X
is	B-X
still	B-X
substantially	B-X
under	B-X
-	B-X
diagnosed	B-X

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B-Disease
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O
<EOS>	B-X
The	B-X
model	B-X
was	B-X
established	B-X
based	B-X
on	B-X
the	B-X
4	B-X
indexes	B-X
,	B-X
with	B-X
the	B-X
area	B-X
under	B-X
the	B-X
curve	B-X
of	B-X
0	B-X
<EOS>	B-X
Since	B-X
it	B-X
is	B-X
rare	B-X
,	B-X
no	B-X
established	B-X
chemotherapy	B-X
or	B-X
radiation	B-X
protocols	B-X
exist	B-X
<EOS>	B-X
A	B-X
clinical	B-X
prediction	B-X
model	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
brain	B-X
metastases	B-X
from	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
The	B-X
worse	B-X
prognosis	B-X
is	B-X
also	B-X
due	B-X
to	B-X
limited	B-X
surveillance	B-X
strategies	B-X
and	B-X
a	B-X
lower	B-X
efficacy	B-X
of	B-X
standard	B-X
treatments	B-X

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B-Disease
is	O
still	O
being	O
evaluated	O
.	O
<EOS>	B-X
A	B-X
DNA	B-X
-	B-X
based	B-X
test	B-X
for	B-X
the	B-X
HFE	B-X
gene	B-X
is	B-X
commercially	B-X
available	B-X
,	B-X
but	B-X
its	B-X
place	B-X
in	B-X
the	B-X
diagnosis	B-X
of	B-X
hemochromatosis	B-X
is	B-X
still	B-X
being	B-X
evaluated	B-X
<EOS>	B-X
Liver	B-X
biopsy	B-X
is	B-X
also	B-X
used	B-X
to	B-X
establish	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
cirrhosis	B-X
,	B-X
which	B-X
can	B-X
affect	B-X
prognosis	B-X
and	B-X
management	B-X
<EOS>	B-X
If	B-X
untreated	B-X
,	B-X
hemochromatosis	B-X
can	B-X
cause	B-X
serious	B-X
illness	B-X
and	B-X
early	B-X
death	B-X
,	B-X
but	B-X
the	B-X
disease	B-X
is	B-X
still	B-X
substantially	B-X
under	B-X
-	B-X
diagnosed	B-X
<EOS>	B-X
Once	B-X
the	B-X
diagnosis	B-X
is	B-X
suspected	B-X
,	B-X
physicians	B-X
must	B-X
use	B-X
serum	B-X
ferritin	B-X
levels	B-X
and	B-X
hepatic	B-X
iron	B-X
stores	B-X
on	B-X
liver	B-X
biopsy	B-X
specimens	B-X
to	B-X
assess	B-X
patients	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
iron	B-X
overload	B-X

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B-Disease
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
most	B-X
useful	B-X
role	B-X
for	B-X
this	B-X
test	B-X
is	B-X
in	B-X
the	B-X
detection	B-X
of	B-X
hemochromatosis	B-X
in	B-X
the	B-X
family	B-X
members	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
proven	B-X
case	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
Once	B-X
the	B-X
diagnosis	B-X
is	B-X
suspected	B-X
,	B-X
physicians	B-X
must	B-X
use	B-X
serum	B-X
ferritin	B-X
levels	B-X
and	B-X
hepatic	B-X
iron	B-X
stores	B-X
on	B-X
liver	B-X
biopsy	B-X
specimens	B-X
to	B-X
assess	B-X
patients	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
iron	B-X
overload	B-X
<EOS>	B-X
The	B-X
cornerstone	B-X
of	B-X
screening	B-X
and	B-X
case	B-X
detection	B-X
is	B-X
the	B-X
measurement	B-X
of	B-X
serum	B-X
transferrin	B-X
saturation	B-X
and	B-X
the	B-X
serum	B-X
ferritin	B-X
level	B-X
<EOS>	B-X
Liver	B-X
biopsy	B-X
is	B-X
also	B-X
used	B-X
to	B-X
establish	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
cirrhosis	B-X
,	B-X
which	B-X
can	B-X
affect	B-X
prognosis	B-X
and	B-X
management	B-X

It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B-Disease
before	O
hepatic	B-Disease
cirrhosis	I-Disease
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O
expectancy	O
.	O
.	O
<EOS>	B-X
It	B-X
is	B-X
crucial	B-X
to	B-X
diagnose	B-X
hemochromatosis	B-X
before	B-X
hepatic	B-X
cirrhosis	B-X
develops	B-X
because	B-X
phlebotomy	B-X
therapy	B-X
can	B-X
avert	B-X
serious	B-X
chronic	B-X
disease	B-X
and	B-X
can	B-X
even	B-X
lead	B-X
to	B-X
normal	B-X
life	B-X
expectancy	B-X
<EOS>	B-X
If	B-X
untreated	B-X
,	B-X
hemochromatosis	B-X
can	B-X
cause	B-X
serious	B-X
illness	B-X
and	B-X
early	B-X
death	B-X
,	B-X
but	B-X
the	B-X
disease	B-X
is	B-X
still	B-X
substantially	B-X
under	B-X
-	B-X
diagnosed	B-X
<EOS>	B-X
The	B-X
cornerstone	B-X
of	B-X
screening	B-X
and	B-X
case	B-X
detection	B-X
is	B-X
the	B-X
measurement	B-X
of	B-X
serum	B-X
transferrin	B-X
saturation	B-X
and	B-X
the	B-X
serum	B-X
ferritin	B-X
level	B-X
<EOS>	B-X
Liver	B-X
biopsy	B-X
is	B-X
also	B-X
used	B-X
to	B-X
establish	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
cirrhosis	B-X
,	B-X
which	B-X
can	B-X
affect	B-X
prognosis	B-X
and	B-X
management	B-X

Prevalence	O
of	O
the	O
I1307K	O
APC	B-Disease
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Prevalence	B-X
of	B-X
the	B-X
I1307K	B-X
APC	B-X
gene	B-X
variant	B-X
in	B-X
Israeli	B-X
Jews	B-X
of	B-X
differing	B-X
ethnic	B-X
origin	B-X
and	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
We	B-X
assessed	B-X
the	B-X
I1307K	B-X
prevalence	B-X
in	B-X
Israeli	B-X
Jews	B-X
of	B-X
differing	B-X
ethnic	B-X
origin	B-X
and	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
I1307K	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
(	B-X
APC	B-X
)	B-X
gene	B-X
variant	B-X
,	B-X
prevalent	B-X
among	B-X
Ashkenazi	B-X
Jews	B-X
,	B-X
may	B-X
increase	B-X
the	B-X
risk	B-X
for	B-X
colorectal	B-X
neoplasia	B-X
<EOS>	B-X
Clinical	B-X
and	B-X
screening	B-X
implications	B-X
of	B-X
the	B-X
I1307K	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
gene	B-X
variant	B-X
in	B-X
Israeli	B-X
Ashkenazi	B-X
Jews	B-X
with	B-X
familial	B-X
colorectal	B-X
neoplasia	B-X
.	B-X
Evidence	B-X
for	B-X
a	B-X
founder	B-X
effect	B-X
.	B-X

BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B-Disease
cancer	I-Disease
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O
.	O

The	O
I1307K	O
APC	B-Disease
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O
<EOS>	B-X
The	B-X
I1307K	B-X
APC	B-X
gene	B-X
variant	B-X
was	B-X
found	B-X
in	B-X
6	B-X
<EOS>	B-X
Only	B-X
1309	B-X
APC	B-X
gene	B-X
mutation	B-X
was	B-X
detected	B-X
in	B-X
our	B-X
samples	B-X
<EOS>	B-X
The	B-X
APC	B-X
I1307K	B-X
variant	B-X
was	B-X
detected	B-X
in	B-X
189	B-X
(	B-X
11	B-X
<EOS>	B-X
The	B-X
APC	B-X
I1307K	B-X
allele	B-X
was	B-X
identified	B-X
in	B-X
48	B-X
(	B-X
10	B-X

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B-Disease
cancer	I-Disease
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
We	B-X
assessed	B-X
the	B-X
I1307K	B-X
prevalence	B-X
in	B-X
Israeli	B-X
Jews	B-X
of	B-X
differing	B-X
ethnic	B-X
origin	B-X
and	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Prevalence	B-X
of	B-X
the	B-X
I1307K	B-X
APC	B-X
gene	B-X
variant	B-X
in	B-X
Israeli	B-X
Jews	B-X
of	B-X
differing	B-X
ethnic	B-X
origin	B-X
and	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
The	B-X
I1307K	B-X
APC	B-X
variant	B-X
may	B-X
represent	B-X
a	B-X
susceptibility	B-X
gene	B-X
for	B-X
colorectal	B-X
,	B-X
or	B-X
other	B-X
,	B-X
cancers	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
,	B-X
and	B-X
partially	B-X
explains	B-X
the	B-X
higher	B-X
incidence	B-X
of	B-X
colorectal	B-X
cancer	B-X
in	B-X
European	B-X
Israelis	B-X
<EOS>	B-X
02	B-X
)	B-X
and	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
51	B-X
non	B-X
-	B-X
European	B-X
Jews	B-X
at	B-X
increased	B-X
cancer	B-X
risk	B-X

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B-Disease
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O
<EOS>	B-X
Compared	B-X
with	B-X
prepandemic	B-X
years	B-X
,	B-X
during	B-X
the	B-X
pandemic	B-X
,	B-X
rhinoviruses	B-X
and	B-X
/	B-X
or	B-X
enteroviruses	B-X
were	B-X
detected	B-X
in	B-X
patients	B-X
who	B-X
were	B-X
slightly	B-X
older	B-X
,	B-X
although	B-X
most	B-X
(	B-X
74	B-X
<EOS>	B-X
The	B-X
most	B-X
frequent	B-X
adverse	B-X
drug	B-X
events	B-X
after	B-X
the	B-X
second	B-X
dose	B-X
of	B-X
vaccine	B-X
were	B-X
pain	B-X
at	B-X
the	B-X
site	B-X
of	B-X
inoculation	B-X
of	B-X
the	B-X
vaccine	B-X
(	B-X
70	B-X
<EOS>	B-X
Overall	B-X
,	B-X
19	B-X
consultations	B-X
between	B-X
parents	B-X
of	B-X
preterm	B-X
infants	B-X
and	B-X
pediatricians	B-X
were	B-X
observed	B-X
to	B-X
determine	B-X
which	B-X
themes	B-X
are	B-X
discussed	B-X
the	B-X
most	B-X
and	B-X
the	B-X
number	B-X
of	B-X
questions	B-X
asked	B-X
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
examine	B-X
whether	B-X
access	B-X
to	B-X
treatment	B-X
for	B-X
major	B-X
morbidity	B-X
conditions	B-X
is	B-X
determined	B-X
by	B-X
the	B-X
social	B-X
class	B-X
of	B-X
the	B-X
person	B-X
who	B-X
needs	B-X
treatment	B-X

RESULTS	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B-Disease
cancer	I-Disease
,	O
I1307K	O
was	O
found	O
in	O
5	O
.	O
<EOS>	B-X
In	B-X
persons	B-X
at	B-X
average	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
,	B-X
I1307K	B-X
was	B-X
found	B-X
in	B-X
5	B-X
<EOS>	B-X
I1307K	B-X
gene	B-X
variant	B-X
is	B-X
an	B-X
important	B-X
risk	B-X
factor	B-X
for	B-X
colorectal	B-X
neoplasia	B-X
in	B-X
average	B-X
risk	B-X
Ashkenazi	B-X
Jews	B-X
<EOS>	B-X
When	B-X
an	B-X
individual	B-X
at	B-X
average	B-X
risk	B-X
would	B-X
initiate	B-X
colonoscopy	B-X
at	B-X
age	B-X
45	B-X
years	B-X
,	B-X
a	B-X
CRC	B-X
risk	B-X
of	B-X
0	B-X
<EOS>	B-X
1	B-X
%	B-X
of	B-X
American	B-X
Jews	B-X
,	B-X
28	B-X
%	B-X
of	B-X
their	B-X
familial	B-X
colorectal	B-X
cancer	B-X
cases	B-X
,	B-X
but	B-X
not	B-X
in	B-X
non	B-X
-	B-X
Jews	B-X

0	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O

6	O
%	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

It	O
occurred	O
in	O
15	O
.	O
<EOS>	B-X
005	B-X
]	B-X
compared	B-X
with	B-X
PCV	B-X
<EOS>	B-X
Union	B-X
was	B-X
achieved	B-X
in	B-X
all	B-X
patients	B-X
<EOS>	B-X
2	B-X
to	B-X
not	B-X
reached	B-X
)	B-X
and	B-X
4	B-X
<EOS>	B-X
The	B-X
study	B-X
included	B-X
US	B-X
nursing	B-X
homes	B-X

4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B-Disease
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B-Disease
risk	O
.	O

Colorectal	B-Disease
neoplasia	I-Disease
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B-Disease
.	O
<EOS>	B-X
Consequently	B-X
,	B-X
a	B-X
large	B-X
peristomal	B-X
skin	B-X
defect	B-X
occurred	B-X
,	B-X
resulting	B-X
in	B-X
difficulty	B-X
achieving	B-X
a	B-X
good	B-X
seal	B-X
of	B-X
the	B-X
ostomy	B-X
pouching	B-X
system	B-X
<EOS>	B-X
Colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
leading	B-X
causes	B-X
of	B-X
cancer	B-X
deaths	B-X
worldwide	B-X
<EOS>	B-X
Colonoscopic	B-X
biopsy	B-X
obtained	B-X
from	B-X
the	B-X
lesion	B-X
in	B-X
the	B-X
colon	B-X
was	B-X
reported	B-X
as	B-X
adenocarcinoma	B-X
<EOS>	B-X
We	B-X
used	B-X
samples	B-X
of	B-X
surgical	B-X
material	B-X
from	B-X
310	B-X
patients	B-X
with	B-X
a	B-X
verified	B-X
diagnosis	B-X
of	B-X
gastric	B-X
cancer	B-X

CONCLUSIONS	O
The	O
I1307K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B-Disease
,	I-Disease
or	I-Disease
other	I-Disease
,	I-Disease
cancers	I-Disease
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B-Disease
cancer	I-Disease
in	O
European	O
Israelis	O
.	O
<EOS>	B-X
The	B-X
I1307K	B-X
APC	B-X
variant	B-X
may	B-X
represent	B-X
a	B-X
susceptibility	B-X
gene	B-X
for	B-X
colorectal	B-X
,	B-X
or	B-X
other	B-X
,	B-X
cancers	B-X
in	B-X
Ashkenazi	B-X
Jews	B-X
,	B-X
and	B-X
partially	B-X
explains	B-X
the	B-X
higher	B-X
incidence	B-X
of	B-X
colorectal	B-X
cancer	B-X
in	B-X
European	B-X
Israelis	B-X
<EOS>	B-X
The	B-X
I1307K	B-X
mutation	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
is	B-X
found	B-X
in	B-X
approximately	B-X
6	B-X
%	B-X
of	B-X
the	B-X
Ashkenazi	B-X
Jewish	B-X
population	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
elevated	B-X
risk	B-X
of	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Phenotypic	B-X
characteristics	B-X
associated	B-X
with	B-X
the	B-X
APC	B-X
gene	B-X
I1307K	B-X
mutation	B-X
in	B-X
Ashkenazi	B-X
Jewish	B-X
patients	B-X
with	B-X
colorectal	B-X
polyps	B-X
.	B-X
<EOS>	B-X
Although	B-X
their	B-X
genotypic	B-X
risks	B-X
are	B-X
modest	B-X
,	B-X
their	B-X
high	B-X
frequency	B-X
in	B-X
the	B-X
population	B-X
implies	B-X
that	B-X
they	B-X
may	B-X
well	B-X
have	B-X
considerable	B-X
impact	B-X
on	B-X
colorectal	B-X
cancer	B-X
incidence	B-X

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B-Disease
coproporphyria	I-Disease
and	O
mutation	O
update	O
.	O
<EOS>	B-X
Systematic	B-X
analysis	B-X
of	B-X
coproporphyrinogen	B-X
oxidase	B-X
gene	B-X
defects	B-X
in	B-X
hereditary	B-X
coproporphyria	B-X
and	B-X
mutation	B-X
update	B-X
.	B-X
<EOS>	B-X
Hereditary	B-X
coproporphyria	B-X
(	B-X
HC	B-X
)	B-X
is	B-X
an	B-X
acute	B-X
hepatic	B-X
porphyria	B-X
with	B-X
autosomal	B-X
dominant	B-X
inheritance	B-X
caused	B-X
by	B-X
deficient	B-X
activity	B-X
of	B-X
coproporphyrinogen	B-X
III	B-X
oxidase	B-X
(	B-X
CPO	B-X
)	B-X
<EOS>	B-X
Clinical	B-X
manifestations	B-X
of	B-X
the	B-X
disease	B-X
are	B-X
characterized	B-X
by	B-X
acute	B-X
attacks	B-X
of	B-X
neurological	B-X
dysfunction	B-X
often	B-X
precipitated	B-X
by	B-X
drugs	B-X
,	B-X
fasting	B-X
,	B-X
cyclical	B-X
hormonal	B-X
changes	B-X
,	B-X
or	B-X
infectious	B-X
diseases	B-X
<EOS>	B-X
The	B-X
pathological	B-X
significance	B-X
of	B-X
the	B-X
point	B-X
mutations	B-X
G197W	B-X
,	B-X
W427R	B-X
,	B-X
and	B-X
the	B-X
in	B-X
-	B-X
frame	B-X
deletion	B-X
390delGly	B-X
were	B-X
assessed	B-X
by	B-X
their	B-X
respective	B-X
expression	B-X
in	B-X
a	B-X
prokaryotic	B-X
system	B-X
using	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X

Hereditary	B-Disease
coproporphyria	I-Disease
(	O
HC	B-Disease
)	O
is	O
an	O
acute	O
hepatic	B-Disease
porphyria	I-Disease
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B-Disease
activity	I-Disease
of	I-Disease
coproporphyrinogen	I-Disease
III	I-Disease
oxidase	I-Disease
(	O
CPO	O
)	O
.	O
<EOS>	B-X
Hereditary	B-X
coproporphyria	B-X
(	B-X
HC	B-X
)	B-X
is	B-X
an	B-X
acute	B-X
hepatic	B-X
porphyria	B-X
with	B-X
autosomal	B-X
dominant	B-X
inheritance	B-X
caused	B-X
by	B-X
deficient	B-X
activity	B-X
of	B-X
coproporphyrinogen	B-X
III	B-X
oxidase	B-X
(	B-X
CPO	B-X
)	B-X
<EOS>	B-X
Systematic	B-X
analysis	B-X
of	B-X
coproporphyrinogen	B-X
oxidase	B-X
gene	B-X
defects	B-X
in	B-X
hereditary	B-X
coproporphyria	B-X
and	B-X
mutation	B-X
update	B-X
.	B-X
<EOS>	B-X
Five	B-X
intragenic	B-X
dimorphisms	B-X
are	B-X
now	B-X
well	B-X
characterized	B-X
and	B-X
the	B-X
high	B-X
degree	B-X
of	B-X
allelic	B-X
heterogeneity	B-X
in	B-X
HC	B-X
is	B-X
demonstrated	B-X
with	B-X
seven	B-X
new	B-X
different	B-X
mutations	B-X
making	B-X
a	B-X
total	B-X
of	B-X
nineteen	B-X
CPO	B-X
gene	B-X
defects	B-X
reported	B-X
so	B-X
far	B-X
<EOS>	B-X
The	B-X
seven	B-X
exons	B-X
,	B-X
the	B-X
exon	B-X
/	B-X
intron	B-X
boundaries	B-X
and	B-X
part	B-X
of	B-X
3	B-X
'	B-X
noncoding	B-X
sequence	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
were	B-X
systematically	B-X
analyzed	B-X
by	B-X
an	B-X
exon	B-X
-	B-X
by	B-X
-	B-X
exon	B-X
denaturing	B-X
gradient	B-X
gel	B-X
electrophoresis	B-X
(	B-X
DGGE	B-X
)	B-X
strategy	B-X
followed	B-X
by	B-X
direct	B-X
sequencing	B-X
in	B-X
seven	B-X
unrelated	B-X
heterozygous	B-X
HC	B-X
patients	B-X
from	B-X
France	B-X
,	B-X
Holland	B-X
,	B-X
and	B-X
Czech	B-X
Republic	B-X

Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B-Disease
dysfunction	I-Disease
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B-Disease
diseases	I-Disease
.	O
<EOS>	B-X
These	B-X
results	B-X
are	B-X
crucial	B-X
for	B-X
understanding	B-X
the	B-X
physiological	B-X
functions	B-X
of	B-X
taurine	B-X
/	B-X
androgen	B-X
and	B-X
their	B-X
interacting	B-X
mechanisms	B-X
in	B-X
liver	B-X
<EOS>	B-X
In	B-X
this	B-X
cross	B-X
-	B-X
sectional	B-X
study	B-X
,	B-X
maternal	B-X
peripheral	B-X
blood	B-X
(	B-X
PB	B-X
)	B-X
and	B-X
uterine	B-X
IVB	B-X
(	B-X
obtained	B-X
from	B-X
the	B-X
surgical	B-X
sponge	B-X
used	B-X
to	B-X
clean	B-X
the	B-X
placental	B-X
bed	B-X
during	B-X
cesarean	B-X
delivery	B-X
)	B-X
were	B-X
collected	B-X
from	B-X
participants	B-X
with	B-X
and	B-X
without	B-X
preeclampsia	B-X
<EOS>	B-X
Our	B-X
study	B-X
indicated	B-X
that	B-X
H9N2	B-X
circulating	B-X
in	B-X
the	B-X
Chinese	B-X
poultry	B-X
have	B-X
experienced	B-X
frequent	B-X
mutations	B-X
at	B-X
HA	B-X
residue	B-X
193	B-X
since	B-X
2013	B-X
,	B-X
with	B-X
viruses	B-X
that	B-X
carried	B-X
asparagine	B-X
(	B-X
N	B-X
)	B-X
being	B-X
replaced	B-X
by	B-X
those	B-X
with	B-X
alanine	B-X
(	B-X
A	B-X
)	B-X
,	B-X
aspartic	B-X
acid	B-X
(	B-X
D	B-X
)	B-X
,	B-X
glutamic	B-X
acid	B-X
(	B-X
E	B-X
)	B-X
,	B-X
glycine	B-X
(	B-X
G	B-X
)	B-X
,	B-X
and	B-X
serine	B-X
(	B-X
S	B-X
)	B-X
,	B-X
etc	B-X
<EOS>	B-X
Yet	B-X
detailed	B-X
characterization	B-X
of	B-X
rhinovirus	B-X
and	B-X
/	B-X
or	B-X
enterovirus	B-X
detection	B-X
over	B-X
time	B-X
is	B-X
limited	B-X
,	B-X
especially	B-X
by	B-X
age	B-X
group	B-X
and	B-X
health	B-X
care	B-X
setting	B-X

Skin	O
photosensitivity	O
may	O
also	O
be	O
present	O
.	O
<EOS>	B-X
A	B-X
Case	B-X
Study	B-X
of	B-X
Photosensitivity	B-X
Associated	B-X
with	B-X
<EOS>	B-X
Photosensitive	B-X
rash	B-X
and	B-X
dermatitis	B-X
may	B-X
be	B-X
caused	B-X
by	B-X
many	B-X
conditions	B-X
<EOS>	B-X
Multisystemic	B-X
involvement	B-X
was	B-X
also	B-X
reported	B-X
in	B-X
a	B-X
case	B-X
<EOS>	B-X
It	B-X
was	B-X
generally	B-X
well	B-X
tolerated	B-X
other	B-X
than	B-X
skin	B-X
photosensitivity	B-X
in	B-X
all	B-X
patients	B-X

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B-Disease
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
Czech	O
Republic	O
.	O
<EOS>	B-X
The	B-X
seven	B-X
exons	B-X
,	B-X
the	B-X
exon	B-X
/	B-X
intron	B-X
boundaries	B-X
and	B-X
part	B-X
of	B-X
3	B-X
'	B-X
noncoding	B-X
sequence	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
were	B-X
systematically	B-X
analyzed	B-X
by	B-X
an	B-X
exon	B-X
-	B-X
by	B-X
-	B-X
exon	B-X
denaturing	B-X
gradient	B-X
gel	B-X
electrophoresis	B-X
(	B-X
DGGE	B-X
)	B-X
strategy	B-X
followed	B-X
by	B-X
direct	B-X
sequencing	B-X
in	B-X
seven	B-X
unrelated	B-X
heterozygous	B-X
HC	B-X
patients	B-X
from	B-X
France	B-X
,	B-X
Holland	B-X
,	B-X
and	B-X
Czech	B-X
Republic	B-X
<EOS>	B-X
The	B-X
pathological	B-X
significance	B-X
of	B-X
the	B-X
point	B-X
mutations	B-X
G197W	B-X
,	B-X
W427R	B-X
,	B-X
and	B-X
the	B-X
in	B-X
-	B-X
frame	B-X
deletion	B-X
390delGly	B-X
were	B-X
assessed	B-X
by	B-X
their	B-X
respective	B-X
expression	B-X
in	B-X
a	B-X
prokaryotic	B-X
system	B-X
using	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
<EOS>	B-X
Five	B-X
intragenic	B-X
dimorphisms	B-X
are	B-X
now	B-X
well	B-X
characterized	B-X
and	B-X
the	B-X
high	B-X
degree	B-X
of	B-X
allelic	B-X
heterogeneity	B-X
in	B-X
HC	B-X
is	B-X
demonstrated	B-X
with	B-X
seven	B-X
new	B-X
different	B-X
mutations	B-X
making	B-X
a	B-X
total	B-X
of	B-X
nineteen	B-X
CPO	B-X
gene	B-X
defects	B-X
reported	B-X
so	B-X
far	B-X
<EOS>	B-X
Clinical	B-X
manifestations	B-X
of	B-X
the	B-X
disease	B-X
are	B-X
characterized	B-X
by	B-X
acute	B-X
attacks	B-X
of	B-X
neurological	B-X
dysfunction	B-X
often	B-X
precipitated	B-X
by	B-X
drugs	B-X
,	B-X
fasting	B-X
,	B-X
cyclical	B-X
hormonal	B-X
changes	B-X
,	B-X
or	B-X
infectious	B-X
diseases	B-X

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
.	O
<EOS>	B-X
Seven	B-X
previously	B-X
reported	B-X
polymorphisms	B-X
and	B-X
additional	B-X
three	B-X
novel	B-X
allele	B-X
variants	B-X
of	B-X
GDNF	B-X
were	B-X
detected	B-X
<EOS>	B-X
Seven	B-X
novel	B-X
genetic	B-X
variants	B-X
in	B-X
a	B-X
North	B-X
Indian	B-X
cohort	B-X
with	B-X
classical	B-X
homocystinuria	B-X
.	B-X
<EOS>	B-X
Seven	B-X
different	B-X
polymorphisms	B-X
and	B-X
three	B-X
new	B-X
variants	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
intron	B-X
regions	B-X
of	B-X
PAH	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
68	B-X
NEB	B-X
mutations	B-X
,	B-X
mainly	B-X
small	B-X
deletions	B-X
or	B-X
point	B-X
mutations	B-X
have	B-X
been	B-X
published	B-X

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
.	O
<EOS>	B-X
Among	B-X
these	B-X
mutations	B-X
:	B-X
two	B-X
are	B-X
missense	B-X
(	B-X
G197W	B-X
,	B-X
W427R	B-X
)	B-X
,	B-X
two	B-X
are	B-X
nonsense	B-X
(	B-X
Q306X	B-X
,	B-X
Q385X	B-X
)	B-X
,	B-X
two	B-X
are	B-X
small	B-X
deletions	B-X
(	B-X
662de14bp	B-X
;	B-X
1168del3bp	B-X
removing	B-X
a	B-X
glycine	B-X
at	B-X
position	B-X
390	B-X
)	B-X
,	B-X
and	B-X
one	B-X
is	B-X
a	B-X
splicing	B-X
mutation	B-X
(	B-X
IVS1	B-X
-	B-X
15c	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
g	B-X
)	B-X
which	B-X
creates	B-X
a	B-X
new	B-X
acceptor	B-X
splice	B-X
site	B-X
<EOS>	B-X
The	B-X
pathological	B-X
significance	B-X
of	B-X
the	B-X
point	B-X
mutations	B-X
G197W	B-X
,	B-X
W427R	B-X
,	B-X
and	B-X
the	B-X
in	B-X
-	B-X
frame	B-X
deletion	B-X
390delGly	B-X
were	B-X
assessed	B-X
by	B-X
their	B-X
respective	B-X
expression	B-X
in	B-X
a	B-X
prokaryotic	B-X
system	B-X
using	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
<EOS>	B-X
Five	B-X
intragenic	B-X
dimorphisms	B-X
are	B-X
now	B-X
well	B-X
characterized	B-X
and	B-X
the	B-X
high	B-X
degree	B-X
of	B-X
allelic	B-X
heterogeneity	B-X
in	B-X
HC	B-X
is	B-X
demonstrated	B-X
with	B-X
seven	B-X
new	B-X
different	B-X
mutations	B-X
making	B-X
a	B-X
total	B-X
of	B-X
nineteen	B-X
CPO	B-X
gene	B-X
defects	B-X
reported	B-X
so	B-X
far	B-X
<EOS>	B-X
Clinical	B-X
manifestations	B-X
of	B-X
the	B-X
disease	B-X
are	B-X
characterized	B-X
by	B-X
acute	B-X
attacks	B-X
of	B-X
neurological	B-X
dysfunction	B-X
often	B-X
precipitated	B-X
by	B-X
drugs	B-X
,	B-X
fasting	B-X
,	B-X
cyclical	B-X
hormonal	B-X
changes	B-X
,	B-X
or	B-X
infectious	B-X
diseases	B-X

The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity	O
.	O
<EOS>	B-X
The	B-X
risk	B-X
model	B-X
was	B-X
constructed	B-X
using	B-X
the	B-X
least	B-X
absolute	B-X
shrinkage	B-X
and	B-X
selection	B-X
operator	B-X
(	B-X
LASSO	B-X
)	B-X
regression	B-X
analysis	B-X
<EOS>	B-X
The	B-X
gene	B-X
mutation	B-X
frequency	B-X
and	B-X
tumor	B-X
immune	B-X
microenvironment	B-X
in	B-X
the	B-X
high	B-X
-	B-X
	B-X
and	B-X
low	B-X
-	B-X
risk	B-X
score	B-X
groups	B-X
were	B-X
significantly	B-X
different	B-X
<EOS>	B-X
The	B-X
evaluation	B-X
of	B-X
HRAS	B-X
expression	B-X
in	B-X
the	B-X
tumor	B-X
tissue	B-X
might	B-X
improve	B-X
patient	B-X
selection	B-X
and	B-X
optimize	B-X
therapeutic	B-X
outcome	B-X
<EOS>	B-X
The	B-X
significantly	B-X
upregulated	B-X
ULBP2	B-X
was	B-X
a	B-X
poor	B-X
prognostic	B-X
biomarker	B-X
of	B-X
colon	B-X
cancer	B-X

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B-Disease
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B-Disease
defects	I-Disease
reported	O
so	O
far	O
.	O
.	O
<EOS>	B-X
Five	B-X
intragenic	B-X
dimorphisms	B-X
are	B-X
now	B-X
well	B-X
characterized	B-X
and	B-X
the	B-X
high	B-X
degree	B-X
of	B-X
allelic	B-X
heterogeneity	B-X
in	B-X
HC	B-X
is	B-X
demonstrated	B-X
with	B-X
seven	B-X
new	B-X
different	B-X
mutations	B-X
making	B-X
a	B-X
total	B-X
of	B-X
nineteen	B-X
CPO	B-X
gene	B-X
defects	B-X
reported	B-X
so	B-X
far	B-X
<EOS>	B-X
Hereditary	B-X
coproporphyria	B-X
(	B-X
HC	B-X
)	B-X
is	B-X
an	B-X
acute	B-X
hepatic	B-X
porphyria	B-X
with	B-X
autosomal	B-X
dominant	B-X
inheritance	B-X
caused	B-X
by	B-X
deficient	B-X
activity	B-X
of	B-X
coproporphyrinogen	B-X
III	B-X
oxidase	B-X
(	B-X
CPO	B-X
)	B-X
<EOS>	B-X
Clinical	B-X
manifestations	B-X
of	B-X
the	B-X
disease	B-X
are	B-X
characterized	B-X
by	B-X
acute	B-X
attacks	B-X
of	B-X
neurological	B-X
dysfunction	B-X
often	B-X
precipitated	B-X
by	B-X
drugs	B-X
,	B-X
fasting	B-X
,	B-X
cyclical	B-X
hormonal	B-X
changes	B-X
,	B-X
or	B-X
infectious	B-X
diseases	B-X
<EOS>	B-X
The	B-X
two	B-X
polymorphisms	B-X
were	B-X
localized	B-X
in	B-X
noncoding	B-X
part	B-X
of	B-X
the	B-X
gene	B-X
:	B-X
1	B-X
)	B-X
a	B-X
C	B-X
/	B-X
G	B-X
polymorphism	B-X
in	B-X
the	B-X
promotor	B-X
region	B-X
,	B-X
142	B-X
bp	B-X
upstream	B-X
from	B-X
the	B-X
transcriptional	B-X
initiation	B-X
site	B-X
(	B-X
	B-X
-	B-X
142C	B-X
/	B-X
G	B-X
)	B-X
,	B-X
and	B-X
2	B-X
)	B-X
a	B-X
6	B-X
bp	B-X
deletion	B-X
polymorphism	B-X
in	B-X
the	B-X
3	B-X
'	B-X
noncoding	B-X
part	B-X
of	B-X
the	B-X
CPO	B-X
gene	B-X
,	B-X
574	B-X
bp	B-X
downstream	B-X
of	B-X
the	B-X
last	B-X
base	B-X
of	B-X
the	B-X
normal	B-X
termination	B-X
codon	B-X
(	B-X
+574	B-X
delATTCTT	B-X
)	B-X

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B-Disease
leukodystrophy	I-Disease
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O
<EOS>	B-X
Coincidence	B-X
of	B-X
two	B-X
novel	B-X
arylsulfatase	B-X
A	B-X
alleles	B-X
and	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
within	B-X
a	B-X
family	B-X
with	B-X
metachromatic	B-X
leukodystrophy	B-X
:	B-X
molecular	B-X
basis	B-X
of	B-X
phenotypic	B-X
heterogeneity	B-X
.	B-X
<EOS>	B-X
Mutation	B-X
screening	B-X
and	B-X
sequence	B-X
analysis	B-X
disclosed	B-X
the	B-X
involvement	B-X
of	B-X
three	B-X
different	B-X
ARSA	B-X
mutations	B-X
being	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
intrafamilial	B-X
phenotypic	B-X
heterogeneity	B-X
<EOS>	B-X
The	B-X
two	B-X
clinically	B-X
unaffected	B-X
siblings	B-X
carried	B-X
the	B-X
maternal	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
and	B-X
,	B-X
on	B-X
their	B-X
paternal	B-X
allele	B-X
,	B-X
a	B-X
novel	B-X
cytosine	B-X
to	B-X
thymidine	B-X
transition	B-X
at	B-X
nucleotide	B-X
2435	B-X
in	B-X
exon	B-X
8	B-X
,	B-X
resulting	B-X
in	B-X
substitution	B-X
of	B-X
alanine	B-X
464	B-X
by	B-X
valine	B-X
(	B-X
A464V	B-X
)	B-X
<EOS>	B-X
The	B-X
late	B-X
infantile	B-X
patient	B-X
inherited	B-X
from	B-X
his	B-X
mother	B-X
the	B-X
frequent	B-X
0	B-X
-	B-X
type	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
,	B-X
and	B-X
from	B-X
his	B-X
father	B-X
a	B-X
novel	B-X
,	B-X
single	B-X
basepair	B-X
microdeletion	B-X
of	B-X
guanine	B-X
at	B-X
nucleotide	B-X
7	B-X
in	B-X
exon	B-X
1	B-X
(	B-X
7delG	B-X
)	B-X

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
range	O
of	O
MLD	B-Disease
patients	O
.	O
<EOS>	B-X
The	B-X
two	B-X
other	B-X
siblings	B-X
,	B-X
apparently	B-X
healthy	B-X
at	B-X
12	B-X
(	B-X
1	B-X
/	B-X
2	B-X
)	B-X
and	B-X
15	B-X
years	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
their	B-X
father	B-X
,	B-X
apparently	B-X
healthy	B-X
as	B-X
well	B-X
,	B-X
presented	B-X
ARSA	B-X
and	B-X
GS	B-X
values	B-X
within	B-X
the	B-X
range	B-X
of	B-X
MLD	B-X
patients	B-X
<EOS>	B-X
The	B-X
two	B-X
clinically	B-X
unaffected	B-X
siblings	B-X
carried	B-X
the	B-X
maternal	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
and	B-X
,	B-X
on	B-X
their	B-X
paternal	B-X
allele	B-X
,	B-X
a	B-X
novel	B-X
cytosine	B-X
to	B-X
thymidine	B-X
transition	B-X
at	B-X
nucleotide	B-X
2435	B-X
in	B-X
exon	B-X
8	B-X
,	B-X
resulting	B-X
in	B-X
substitution	B-X
of	B-X
alanine	B-X
464	B-X
by	B-X
valine	B-X
(	B-X
A464V	B-X
)	B-X
<EOS>	B-X
The	B-X
late	B-X
infantile	B-X
patient	B-X
inherited	B-X
from	B-X
his	B-X
mother	B-X
the	B-X
frequent	B-X
0	B-X
-	B-X
type	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
,	B-X
and	B-X
from	B-X
his	B-X
father	B-X
a	B-X
novel	B-X
,	B-X
single	B-X
basepair	B-X
microdeletion	B-X
of	B-X
guanine	B-X
at	B-X
nucleotide	B-X
7	B-X
in	B-X
exon	B-X
1	B-X
(	B-X
7delG	B-X
)	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
further	B-X
ARSA	B-X
alleles	B-X
functionally	B-X
similar	B-X
to	B-X
A464V	B-X
might	B-X
exist	B-X
which	B-X
,	B-X
together	B-X
with	B-X
0	B-X
-	B-X
type	B-X
mutations	B-X
,	B-X
may	B-X
cause	B-X
pathological	B-X
ARSA	B-X
and	B-X
GS	B-X
levels	B-X
,	B-X
but	B-X
not	B-X
clinical	B-X
outbreak	B-X
of	B-X
the	B-X
disease	B-X

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O
<EOS>	B-X
Mutation	B-X
screening	B-X
and	B-X
sequence	B-X
analysis	B-X
disclosed	B-X
the	B-X
involvement	B-X
of	B-X
three	B-X
different	B-X
ARSA	B-X
mutations	B-X
being	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
intrafamilial	B-X
phenotypic	B-X
heterogeneity	B-X
<EOS>	B-X
Coincidence	B-X
of	B-X
two	B-X
novel	B-X
arylsulfatase	B-X
A	B-X
alleles	B-X
and	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
within	B-X
a	B-X
family	B-X
with	B-X
metachromatic	B-X
leukodystrophy	B-X
:	B-X
molecular	B-X
basis	B-X
of	B-X
phenotypic	B-X
heterogeneity	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
further	B-X
ARSA	B-X
alleles	B-X
functionally	B-X
similar	B-X
to	B-X
A464V	B-X
might	B-X
exist	B-X
which	B-X
,	B-X
together	B-X
with	B-X
0	B-X
-	B-X
type	B-X
mutations	B-X
,	B-X
may	B-X
cause	B-X
pathological	B-X
ARSA	B-X
and	B-X
GS	B-X
levels	B-X
,	B-X
but	B-X
not	B-X
clinical	B-X
outbreak	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
In	B-X
a	B-X
family	B-X
with	B-X
three	B-X
siblings	B-X
,	B-X
one	B-X
developed	B-X
classical	B-X
late	B-X
infantile	B-X
metachromatic	B-X
leukodystrophy	B-X
(	B-X
MLD	B-X
)	B-X
,	B-X
fatal	B-X
at	B-X
age	B-X
5	B-X
years	B-X
,	B-X
with	B-X
deficient	B-X
arylsulfatase	B-X
A	B-X
(	B-X
ARSA	B-X
)	B-X
activity	B-X
and	B-X
increased	B-X
galactosylsulfatide	B-X
(	B-X
GS	B-X
)	B-X
excretion	B-X

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O
<EOS>	B-X
The	B-X
two	B-X
clinically	B-X
unaffected	B-X
siblings	B-X
carried	B-X
the	B-X
maternal	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
and	B-X
,	B-X
on	B-X
their	B-X
paternal	B-X
allele	B-X
,	B-X
a	B-X
novel	B-X
cytosine	B-X
to	B-X
thymidine	B-X
transition	B-X
at	B-X
nucleotide	B-X
2435	B-X
in	B-X
exon	B-X
8	B-X
,	B-X
resulting	B-X
in	B-X
substitution	B-X
of	B-X
alanine	B-X
464	B-X
by	B-X
valine	B-X
(	B-X
A464V	B-X
)	B-X
<EOS>	B-X
The	B-X
late	B-X
infantile	B-X
patient	B-X
inherited	B-X
from	B-X
his	B-X
mother	B-X
the	B-X
frequent	B-X
0	B-X
-	B-X
type	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
,	B-X
and	B-X
from	B-X
his	B-X
father	B-X
a	B-X
novel	B-X
,	B-X
single	B-X
basepair	B-X
microdeletion	B-X
of	B-X
guanine	B-X
at	B-X
nucleotide	B-X
7	B-X
in	B-X
exon	B-X
1	B-X
(	B-X
7delG	B-X
)	B-X
<EOS>	B-X
The	B-X
two	B-X
other	B-X
siblings	B-X
,	B-X
apparently	B-X
healthy	B-X
at	B-X
12	B-X
(	B-X
1	B-X
/	B-X
2	B-X
)	B-X
and	B-X
15	B-X
years	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
their	B-X
father	B-X
,	B-X
apparently	B-X
healthy	B-X
as	B-X
well	B-X
,	B-X
presented	B-X
ARSA	B-X
and	B-X
GS	B-X
values	B-X
within	B-X
the	B-X
range	B-X
of	B-X
MLD	B-X
patients	B-X
<EOS>	B-X
Coincidence	B-X
of	B-X
two	B-X
novel	B-X
arylsulfatase	B-X
A	B-X
alleles	B-X
and	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
within	B-X
a	B-X
family	B-X
with	B-X
metachromatic	B-X
leukodystrophy	B-X
:	B-X
molecular	B-X
basis	B-X
of	B-X
phenotypic	B-X
heterogeneity	B-X
.	B-X

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
.	O
<EOS>	B-X
The	B-X
fathers	B-X
genotype	B-X
thus	B-X
was	B-X
7delG	B-X
/	B-X
A464V	B-X
<EOS>	B-X
The	B-X
late	B-X
infantile	B-X
patient	B-X
inherited	B-X
from	B-X
his	B-X
mother	B-X
the	B-X
frequent	B-X
0	B-X
-	B-X
type	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
,	B-X
and	B-X
from	B-X
his	B-X
father	B-X
a	B-X
novel	B-X
,	B-X
single	B-X
basepair	B-X
microdeletion	B-X
of	B-X
guanine	B-X
at	B-X
nucleotide	B-X
7	B-X
in	B-X
exon	B-X
1	B-X
(	B-X
7delG	B-X
)	B-X
<EOS>	B-X
The	B-X
two	B-X
other	B-X
siblings	B-X
,	B-X
apparently	B-X
healthy	B-X
at	B-X
12	B-X
(	B-X
1	B-X
/	B-X
2	B-X
)	B-X
and	B-X
15	B-X
years	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
their	B-X
father	B-X
,	B-X
apparently	B-X
healthy	B-X
as	B-X
well	B-X
,	B-X
presented	B-X
ARSA	B-X
and	B-X
GS	B-X
values	B-X
within	B-X
the	B-X
range	B-X
of	B-X
MLD	B-X
patients	B-X
<EOS>	B-X
Mutation	B-X
A464V	B-X
was	B-X
not	B-X
found	B-X
in	B-X
18	B-X
unrelated	B-X
MLD	B-X
patients	B-X
and	B-X
50	B-X
controls	B-X

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B-Disease
patients	O
and	O
50	O
controls	O
.	O

A464V	O
,	O
although	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	B-Disease
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele	O
.	O
<EOS>	B-X
A464V	B-X
,	B-X
although	B-X
clearly	B-X
modifying	B-X
ARSA	B-X
and	B-X
GS	B-X
levels	B-X
,	B-X
apparently	B-X
bears	B-X
little	B-X
significance	B-X
for	B-X
clinical	B-X
manifestation	B-X
of	B-X
MLD	B-X
,	B-X
mimicking	B-X
the	B-X
frequent	B-X
ARSA	B-X
pseudodeficiency	B-X
allele	B-X
<EOS>	B-X
The	B-X
two	B-X
clinically	B-X
unaffected	B-X
siblings	B-X
carried	B-X
the	B-X
maternal	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
and	B-X
,	B-X
on	B-X
their	B-X
paternal	B-X
allele	B-X
,	B-X
a	B-X
novel	B-X
cytosine	B-X
to	B-X
thymidine	B-X
transition	B-X
at	B-X
nucleotide	B-X
2435	B-X
in	B-X
exon	B-X
8	B-X
,	B-X
resulting	B-X
in	B-X
substitution	B-X
of	B-X
alanine	B-X
464	B-X
by	B-X
valine	B-X
(	B-X
A464V	B-X
)	B-X
<EOS>	B-X
In	B-X
a	B-X
family	B-X
with	B-X
three	B-X
siblings	B-X
,	B-X
one	B-X
developed	B-X
classical	B-X
late	B-X
infantile	B-X
metachromatic	B-X
leukodystrophy	B-X
(	B-X
MLD	B-X
)	B-X
,	B-X
fatal	B-X
at	B-X
age	B-X
5	B-X
years	B-X
,	B-X
with	B-X
deficient	B-X
arylsulfatase	B-X
A	B-X
(	B-X
ARSA	B-X
)	B-X
activity	B-X
and	B-X
increased	B-X
galactosylsulfatide	B-X
(	B-X
GS	B-X
)	B-X
excretion	B-X
<EOS>	B-X
The	B-X
late	B-X
infantile	B-X
patient	B-X
inherited	B-X
from	B-X
his	B-X
mother	B-X
the	B-X
frequent	B-X
0	B-X
-	B-X
type	B-X
mutation	B-X
459+1G	B-X
>	B-X
A	B-X
,	B-X
and	B-X
from	B-X
his	B-X
father	B-X
a	B-X
novel	B-X
,	B-X
single	B-X
basepair	B-X
microdeletion	B-X
of	B-X
guanine	B-X
at	B-X
nucleotide	B-X
7	B-X
in	B-X
exon	B-X
1	B-X
(	B-X
7delG	B-X
)	B-X

Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	B-Disease
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B-Disease
malignancy	I-Disease
and	O
neurofibromatosis	B-Disease
type	I-Disease
1	I-Disease
.	O
<EOS>	B-X
Human	B-X
MLH1	B-X
deficiency	B-X
predisposes	B-X
to	B-X
hematological	B-X
malignancy	B-X
and	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
three	B-X
offspring	B-X
in	B-X
a	B-X
hereditary	B-X
nonpolyposis	B-X
colorectal	B-X
cancer	B-X
family	B-X
who	B-X
developed	B-X
hematological	B-X
malignancy	B-X
at	B-X
a	B-X
very	B-X
early	B-X
age	B-X
,	B-X
and	B-X
at	B-X
least	B-X
two	B-X
of	B-X
them	B-X
displayed	B-X
signs	B-X
of	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
(	B-X
NF1	B-X
)	B-X
<EOS>	B-X
Thus	B-X
,	B-X
a	B-X
homozygous	B-X
germ	B-X
-	B-X
line	B-X
MLH1	B-X
mutation	B-X
and	B-X
consequent	B-X
mismatch	B-X
repair	B-X
deficiency	B-X
results	B-X
in	B-X
a	B-X
mutator	B-X
phenotype	B-X
characterized	B-X
by	B-X
leukemia	B-X
and	B-X
/	B-X
or	B-X
lymphoma	B-X
associated	B-X
with	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
<EOS>	B-X
Malignant	B-X
brain	B-X
tumors	B-X
are	B-X
at	B-X
least	B-X
as	B-X
frequent	B-X
as	B-X
gastrointestinal	B-X
tumors	B-X
and	B-X
in	B-X
more	B-X
than	B-X
a	B-X
third	B-X
of	B-X
cases	B-X
haematological	B-X
malignancies	B-X
were	B-X
also	B-X
reported	B-X

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
<EOS>	B-X
Heterozygous	B-X
germ	B-X
-	B-X
line	B-X
mutations	B-X
in	B-X
the	B-X
DNA	B-X
mismatch	B-X
repair	B-X
genes	B-X
lead	B-X
to	B-X
hereditary	B-X
nonpolyposis	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Heterozygous	B-X
germ	B-X
-	B-X
line	B-X
variants	B-X
of	B-X
DNA	B-X
mismatch	B-X
repair	B-X
(	B-X
MMR	B-X
)	B-X
genes	B-X
predispose	B-X
individuals	B-X
to	B-X
hereditary	B-X
non	B-X
-	B-X
polyposis	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Six	B-X
novel	B-X
heterozygous	B-X
MLH1	B-X
,	B-X
MSH2	B-X
,	B-X
and	B-X
MSH6	B-X
and	B-X
one	B-X
homozygous	B-X
MLH1	B-X
germline	B-X
mutations	B-X
in	B-X
hereditary	B-X
nonpolyposis	B-X
colorectal	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
mutations	B-X
in	B-X
MLH1	B-X
lead	B-X
to	B-X
the	B-X
cancer	B-X
susceptibility	B-X
syndrome	B-X
hereditary	B-X
nonpolyposis	B-X
colorectal	B-X
cancer	B-X
(	B-X
HNPCC	B-X
)	B-X

The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O
<EOS>	B-X
The	B-X
disease	B-X
susceptibility	B-X
of	B-X
individuals	B-X
who	B-X
constitutionally	B-X
lack	B-X
both	B-X
wild	B-X
-	B-X
type	B-X
alleles	B-X
is	B-X
unknown	B-X
<EOS>	B-X
Human	B-X
MLH1	B-X
deficiency	B-X
predisposes	B-X
to	B-X
hematological	B-X
malignancy	B-X
and	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
a	B-X
homozygous	B-X
germ	B-X
-	B-X
line	B-X
MLH1	B-X
mutation	B-X
and	B-X
consequent	B-X
mismatch	B-X
repair	B-X
deficiency	B-X
results	B-X
in	B-X
a	B-X
mutator	B-X
phenotype	B-X
characterized	B-X
by	B-X
leukemia	B-X
and	B-X
/	B-X
or	B-X
lymphoma	B-X
associated	B-X
with	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
three	B-X
offspring	B-X
in	B-X
a	B-X
hereditary	B-X
nonpolyposis	B-X
colorectal	B-X
cancer	B-X
family	B-X
who	B-X
developed	B-X
hematological	B-X
malignancy	B-X
at	B-X
a	B-X
very	B-X
early	B-X
age	B-X
,	B-X
and	B-X
at	B-X
least	B-X
two	B-X
of	B-X
them	B-X
displayed	B-X
signs	B-X
of	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
(	B-X
NF1	B-X
)	B-X

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
family	O
who	O
developed	O
hematological	B-Disease
malignancy	I-Disease
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B-Disease
type	I-Disease
1	I-Disease
(	O
NF1	B-Disease
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O
<EOS>	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
allele	B-X
-	B-X
specific	B-X
amplification	B-X
in	B-X
two	B-X
siblings	B-X
revealed	B-X
a	B-X
homozygous	B-X
MLH1	B-X
mutation	B-X
(	B-X
C676T	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
Arg226Stop	B-X
)	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
three	B-X
offspring	B-X
in	B-X
a	B-X
hereditary	B-X
nonpolyposis	B-X
colorectal	B-X
cancer	B-X
family	B-X
who	B-X
developed	B-X
hematological	B-X
malignancy	B-X
at	B-X
a	B-X
very	B-X
early	B-X
age	B-X
,	B-X
and	B-X
at	B-X
least	B-X
two	B-X
of	B-X
them	B-X
displayed	B-X
signs	B-X
of	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
(	B-X
NF1	B-X
)	B-X
<EOS>	B-X
Thus	B-X
,	B-X
a	B-X
homozygous	B-X
germ	B-X
-	B-X
line	B-X
MLH1	B-X
mutation	B-X
and	B-X
consequent	B-X
mismatch	B-X
repair	B-X
deficiency	B-X
results	B-X
in	B-X
a	B-X
mutator	B-X
phenotype	B-X
characterized	B-X
by	B-X
leukemia	B-X
and	B-X
/	B-X
or	B-X
lymphoma	B-X
associated	B-X
with	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
<EOS>	B-X
Human	B-X
MLH1	B-X
deficiency	B-X
predisposes	B-X
to	B-X
hematological	B-X
malignancy	B-X
and	B-X
neurofibromatosis	B-X
type	B-X
1	B-X
.	B-X

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B-Disease
and	O
/	O
or	O
lymphoma	B-Disease
associated	O
with	O
neurofibromatosis	B-Disease
type	I-Disease
1	I-Disease
.	O
.	O
<EOS>	B-X
Hodgkin	B-X
lymphoma	B-X
should	B-X
be	B-X
kept	B-X
in	B-X
mind	B-X
in	B-X
cervical	B-X
/	B-X
supraclavicular	B-X
lymphadenomegalies	B-X
when	B-X
evaluating	B-X
patients	B-X
with	B-X
neurofibromatosis	B-X
1	B-X
<EOS>	B-X
Role	B-X
of	B-X
the	B-X
parental	B-X
NF1	B-X
carrier	B-X
in	B-X
effects	B-X
of	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
anaplastic	B-X
lymphoma	B-X
kinase	B-X
in	B-X
Neurofibromatosis	B-X
1	B-X
mutant	B-X
mice	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
inhibition	B-X
of	B-X
Alk	B-X
may	B-X
cognitively	B-X
benefit	B-X
patients	B-X
with	B-X
Neurofibromatosis	B-X
1	B-X
<EOS>	B-X
Central	B-X
nervous	B-X
system	B-X
and	B-X
soft	B-X
tissue	B-X
tumors	B-X
are	B-X
common	B-X
non	B-X
-	B-X
hematological	B-X
malignancies	B-X
in	B-X
individuals	B-X
with	B-X
neurofibromatosis	B-X
1	B-X

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B-Disease
eye	I-Disease
malformations	I-Disease
.	O
<EOS>	B-X
Missense	B-X
mutations	B-X
in	B-X
the	B-X
most	B-X
ancient	B-X
residues	B-X
of	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
underlie	B-X
a	B-X
spectrum	B-X
of	B-X
human	B-X
congenital	B-X
eye	B-X
malformations	B-X
.	B-X
<EOS>	B-X
Strikingly	B-X
,	B-X
all	B-X
four	B-X
mutations	B-X
are	B-X
located	B-X
within	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
and	B-X
affect	B-X
amino	B-X
acids	B-X
which	B-X
are	B-X
highly	B-X
conserved	B-X
in	B-X
all	B-X
known	B-X
paired	B-X
domain	B-X
proteins	B-X
<EOS>	B-X
Mutations	B-X
of	B-X
the	B-X
human	B-X
PAX6	B-X
gene	B-X
underlie	B-X
aniridia	B-X
(	B-X
congenital	B-X
absence	B-X
of	B-X
the	B-X
iris	B-X
)	B-X
,	B-X
a	B-X
rare	B-X
dominant	B-X
malformation	B-X
of	B-X
the	B-X
eye	B-X
<EOS>	B-X
This	B-X
indicates	B-X
that	B-X
there	B-X
is	B-X
a	B-X
heavy	B-X
ascertainment	B-X
bias	B-X
in	B-X
the	B-X
selection	B-X
of	B-X
patients	B-X
for	B-X
PAX6	B-X
mutation	B-X
analysis	B-X
and	B-X
that	B-X
the	B-X
'missing	B-X
'	B-X
PAX6	B-X
missense	B-X
mutations	B-X
frequently	B-X
may	B-X
underlie	B-X
phenotypes	B-X
distinct	B-X
from	B-X
textbook	B-X
aniridia	B-X

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B-Disease
(	O
congenital	B-Disease
absence	I-Disease
of	I-Disease
the	I-Disease
iris	I-Disease
)	O
,	O
a	O
rare	O
dominant	O
malformation	B-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
.	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B-Disease
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O
<EOS>	B-X
The	B-X
spectrum	B-X
of	B-X
PAX6	B-X
mutations	B-X
in	B-X
aniridia	B-X
patients	B-X
is	B-X
highly	B-X
biased	B-X
,	B-X
with	B-X
92	B-X
%	B-X
of	B-X
all	B-X
reported	B-X
mutations	B-X
leading	B-X
to	B-X
premature	B-X
truncation	B-X
of	B-X
the	B-X
protein	B-X
(	B-X
nonsense	B-X
,	B-X
splicing	B-X
,	B-X
insertions	B-X
and	B-X
deletions	B-X
)	B-X
and	B-X
just	B-X
2	B-X
%	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
one	B-X
amino	B-X
acid	B-X
by	B-X
another	B-X
(	B-X
missense	B-X
)	B-X
<EOS>	B-X
The	B-X
extraordinary	B-X
conservation	B-X
of	B-X
the	B-X
PAX6	B-X
protein	B-X
at	B-X
the	B-X
amino	B-X
acid	B-X
level	B-X
amongst	B-X
vertebrates	B-X
predicts	B-X
that	B-X
pathological	B-X
missense	B-X
mutations	B-X
should	B-X
in	B-X
fact	B-X
be	B-X
common	B-X
even	B-X
though	B-X
they	B-X
are	B-X
hardly	B-X
ever	B-X
seen	B-X
in	B-X
aniridia	B-X
patients	B-X
<EOS>	B-X
Strikingly	B-X
,	B-X
all	B-X
four	B-X
mutations	B-X
are	B-X
located	B-X
within	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
and	B-X
affect	B-X
amino	B-X
acids	B-X
which	B-X
are	B-X
highly	B-X
conserved	B-X
in	B-X
all	B-X
known	B-X
paired	B-X
domain	B-X
proteins	B-X
<EOS>	B-X
This	B-X
indicates	B-X
that	B-X
there	B-X
is	B-X
a	B-X
heavy	B-X
ascertainment	B-X
bias	B-X
in	B-X
the	B-X
selection	B-X
of	B-X
patients	B-X
for	B-X
PAX6	B-X
mutation	B-X
analysis	B-X
and	B-X
that	B-X
the	B-X
'missing	B-X
'	B-X
PAX6	B-X
missense	B-X
mutations	B-X
frequently	B-X
may	B-X
underlie	B-X
phenotypes	B-X
distinct	B-X
from	B-X
textbook	B-X
aniridia	B-X

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B-Disease
patients	O
.	O
<EOS>	B-X
The	B-X
extraordinary	B-X
conservation	B-X
of	B-X
the	B-X
PAX6	B-X
protein	B-X
at	B-X
the	B-X
amino	B-X
acid	B-X
level	B-X
amongst	B-X
vertebrates	B-X
predicts	B-X
that	B-X
pathological	B-X
missense	B-X
mutations	B-X
should	B-X
in	B-X
fact	B-X
be	B-X
common	B-X
even	B-X
though	B-X
they	B-X
are	B-X
hardly	B-X
ever	B-X
seen	B-X
in	B-X
aniridia	B-X
patients	B-X
<EOS>	B-X
Missense	B-X
mutations	B-X
in	B-X
the	B-X
most	B-X
ancient	B-X
residues	B-X
of	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
underlie	B-X
a	B-X
spectrum	B-X
of	B-X
human	B-X
congenital	B-X
eye	B-X
malformations	B-X
.	B-X
<EOS>	B-X
Mutations	B-X
of	B-X
the	B-X
human	B-X
PAX6	B-X
gene	B-X
underlie	B-X
aniridia	B-X
(	B-X
congenital	B-X
absence	B-X
of	B-X
the	B-X
iris	B-X
)	B-X
,	B-X
a	B-X
rare	B-X
dominant	B-X
malformation	B-X
of	B-X
the	B-X
eye	B-X
<EOS>	B-X
The	B-X
spectrum	B-X
of	B-X
PAX6	B-X
mutations	B-X
in	B-X
aniridia	B-X
patients	B-X
is	B-X
highly	B-X
biased	B-X
,	B-X
with	B-X
92	B-X
%	B-X
of	B-X
all	B-X
reported	B-X
mutations	B-X
leading	B-X
to	B-X
premature	B-X
truncation	B-X
of	B-X
the	B-X
protein	B-X
(	B-X
nonsense	B-X
,	B-X
splicing	B-X
,	B-X
insertions	B-X
and	B-X
deletions	B-X
)	B-X
and	B-X
just	B-X
2	B-X
%	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
one	B-X
amino	B-X
acid	B-X
by	B-X
another	B-X
(	B-X
missense	B-X
)	B-X

This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B-Disease
.	O
<EOS>	B-X
This	B-X
indicates	B-X
that	B-X
there	B-X
is	B-X
a	B-X
heavy	B-X
ascertainment	B-X
bias	B-X
in	B-X
the	B-X
selection	B-X
of	B-X
patients	B-X
for	B-X
PAX6	B-X
mutation	B-X
analysis	B-X
and	B-X
that	B-X
the	B-X
'missing	B-X
'	B-X
PAX6	B-X
missense	B-X
mutations	B-X
frequently	B-X
may	B-X
underlie	B-X
phenotypes	B-X
distinct	B-X
from	B-X
textbook	B-X
aniridia	B-X
<EOS>	B-X
Missense	B-X
mutations	B-X
in	B-X
the	B-X
most	B-X
ancient	B-X
residues	B-X
of	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
underlie	B-X
a	B-X
spectrum	B-X
of	B-X
human	B-X
congenital	B-X
eye	B-X
malformations	B-X
.	B-X
<EOS>	B-X
Strikingly	B-X
,	B-X
all	B-X
four	B-X
mutations	B-X
are	B-X
located	B-X
within	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
and	B-X
affect	B-X
amino	B-X
acids	B-X
which	B-X
are	B-X
highly	B-X
conserved	B-X
in	B-X
all	B-X
known	B-X
paired	B-X
domain	B-X
proteins	B-X
<EOS>	B-X
Our	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
under	B-X
-	B-X
representation	B-X
of	B-X
missense	B-X
mutations	B-X
is	B-X
caused	B-X
by	B-X
ascertainment	B-X
bias	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
substantial	B-X
burden	B-X
of	B-X
PAX6	B-X
	B-X
-	B-X
related	B-X
disease	B-X
remains	B-X
to	B-X
be	B-X
uncovered	B-X

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B-Disease
pupillae	I-Disease
(	O
displaced	B-Disease
pupils	I-Disease
)	O
and	O
congenital	B-Disease
nystagmus	I-Disease
(	O
searching	B-Disease
gaze	I-Disease
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B-Disease
phenotypes	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
present	B-X
four	B-X
novel	B-X
PAX6	B-X
missense	B-X
mutations	B-X
,	B-X
two	B-X
in	B-X
association	B-X
with	B-X
atypical	B-X
phenotypes	B-X
:	B-X
ectopia	B-X
pupillae	B-X
(	B-X
displaced	B-X
pupils	B-X
)	B-X
and	B-X
congenital	B-X
nystagmus	B-X
(	B-X
searching	B-X
gaze	B-X
)	B-X
,	B-X
and	B-X
two	B-X
in	B-X
association	B-X
with	B-X
more	B-X
recognizable	B-X
aniridia	B-X
phenotypes	B-X
<EOS>	B-X
Strikingly	B-X
,	B-X
all	B-X
four	B-X
mutations	B-X
are	B-X
located	B-X
within	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
and	B-X
affect	B-X
amino	B-X
acids	B-X
which	B-X
are	B-X
highly	B-X
conserved	B-X
in	B-X
all	B-X
known	B-X
paired	B-X
domain	B-X
proteins	B-X
<EOS>	B-X
Missense	B-X
mutations	B-X
in	B-X
the	B-X
most	B-X
ancient	B-X
residues	B-X
of	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
underlie	B-X
a	B-X
spectrum	B-X
of	B-X
human	B-X
congenital	B-X
eye	B-X
malformations	B-X
.	B-X
<EOS>	B-X
The	B-X
spectrum	B-X
of	B-X
PAX6	B-X
mutations	B-X
in	B-X
aniridia	B-X
patients	B-X
is	B-X
highly	B-X
biased	B-X
,	B-X
with	B-X
92	B-X
%	B-X
of	B-X
all	B-X
reported	B-X
mutations	B-X
leading	B-X
to	B-X
premature	B-X
truncation	B-X
of	B-X
the	B-X
protein	B-X
(	B-X
nonsense	B-X
,	B-X
splicing	B-X
,	B-X
insertions	B-X
and	B-X
deletions	B-X
)	B-X
and	B-X
just	B-X
2	B-X
%	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
one	B-X
amino	B-X
acid	B-X
by	B-X
another	B-X
(	B-X
missense	B-X
)	B-X

Strikingly	O
,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O
<EOS>	B-X
Strikingly	B-X
,	B-X
all	B-X
four	B-X
mutations	B-X
are	B-X
located	B-X
within	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
and	B-X
affect	B-X
amino	B-X
acids	B-X
which	B-X
are	B-X
highly	B-X
conserved	B-X
in	B-X
all	B-X
known	B-X
paired	B-X
domain	B-X
proteins	B-X
<EOS>	B-X
Missense	B-X
mutations	B-X
in	B-X
the	B-X
most	B-X
ancient	B-X
residues	B-X
of	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
underlie	B-X
a	B-X
spectrum	B-X
of	B-X
human	B-X
congenital	B-X
eye	B-X
malformations	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
present	B-X
four	B-X
novel	B-X
PAX6	B-X
missense	B-X
mutations	B-X
,	B-X
two	B-X
in	B-X
association	B-X
with	B-X
atypical	B-X
phenotypes	B-X
:	B-X
ectopia	B-X
pupillae	B-X
(	B-X
displaced	B-X
pupils	B-X
)	B-X
and	B-X
congenital	B-X
nystagmus	B-X
(	B-X
searching	B-X
gaze	B-X
)	B-X
,	B-X
and	B-X
two	B-X
in	B-X
association	B-X
with	B-X
more	B-X
recognizable	B-X
aniridia	B-X
phenotypes	B-X
<EOS>	B-X
The	B-X
spectrum	B-X
of	B-X
PAX6	B-X
mutations	B-X
in	B-X
aniridia	B-X
patients	B-X
is	B-X
highly	B-X
biased	B-X
,	B-X
with	B-X
92	B-X
%	B-X
of	B-X
all	B-X
reported	B-X
mutations	B-X
leading	B-X
to	B-X
premature	B-X
truncation	B-X
of	B-X
the	B-X
protein	B-X
(	B-X
nonsense	B-X
,	B-X
splicing	B-X
,	B-X
insertions	B-X
and	B-X
deletions	B-X
)	B-X
and	B-X
just	B-X
2	B-X
%	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
one	B-X
amino	B-X
acid	B-X
by	B-X
another	B-X
(	B-X
missense	B-X
)	B-X

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B-Disease
-	I-Disease
related	I-Disease
disease	I-Disease
remains	O
to	O
be	O
uncovered	O
.	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
under	B-X
-	B-X
representation	B-X
of	B-X
missense	B-X
mutations	B-X
is	B-X
caused	B-X
by	B-X
ascertainment	B-X
bias	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
substantial	B-X
burden	B-X
of	B-X
PAX6	B-X
	B-X
-	B-X
related	B-X
disease	B-X
remains	B-X
to	B-X
be	B-X
uncovered	B-X
<EOS>	B-X
The	B-X
spectrum	B-X
of	B-X
PAX6	B-X
mutations	B-X
in	B-X
aniridia	B-X
patients	B-X
is	B-X
highly	B-X
biased	B-X
,	B-X
with	B-X
92	B-X
%	B-X
of	B-X
all	B-X
reported	B-X
mutations	B-X
leading	B-X
to	B-X
premature	B-X
truncation	B-X
of	B-X
the	B-X
protein	B-X
(	B-X
nonsense	B-X
,	B-X
splicing	B-X
,	B-X
insertions	B-X
and	B-X
deletions	B-X
)	B-X
and	B-X
just	B-X
2	B-X
%	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
one	B-X
amino	B-X
acid	B-X
by	B-X
another	B-X
(	B-X
missense	B-X
)	B-X
<EOS>	B-X
Missense	B-X
mutations	B-X
in	B-X
the	B-X
most	B-X
ancient	B-X
residues	B-X
of	B-X
the	B-X
PAX6	B-X
paired	B-X
domain	B-X
underlie	B-X
a	B-X
spectrum	B-X
of	B-X
human	B-X
congenital	B-X
eye	B-X
malformations	B-X
.	B-X
<EOS>	B-X
Mutations	B-X
of	B-X
the	B-X
human	B-X
PAX6	B-X
gene	B-X
underlie	B-X
aniridia	B-X
(	B-X
congenital	B-X
absence	B-X
of	B-X
the	B-X
iris	B-X
)	B-X
,	B-X
a	B-X
rare	B-X
dominant	B-X
malformation	B-X
of	B-X
the	B-X
eye	B-X

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
second	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
.	O
<EOS>	B-X
The	B-X
chromosomal	B-X
order	B-X
of	B-X
genes	B-X
controlling	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
,	B-X
properdin	B-X
factor	B-X
B	B-X
,	B-X
and	B-X
deficiency	B-X
of	B-X
the	B-X
second	B-X
component	B-X
of	B-X
complement	B-X
.	B-X
<EOS>	B-X
The	B-X
relationship	B-X
of	B-X
the	B-X
genes	B-X
coding	B-X
for	B-X
HLA	B-X
to	B-X
those	B-X
coding	B-X
for	B-X
properdin	B-X
Factor	B-X
B	B-X
allotypes	B-X
and	B-X
for	B-X
deficiency	B-X
of	B-X
the	B-X
second	B-X
component	B-X
of	B-X
complement	B-X
(	B-X
C2	B-X
)	B-X
was	B-X
studied	B-X
in	B-X
families	B-X
of	B-X
patients	B-X
with	B-X
connective	B-X
tissue	B-X
disorders	B-X
<EOS>	B-X
18	B-X
families	B-X
with	B-X
21	B-X
informative	B-X
matings	B-X
for	B-X
both	B-X
properdin	B-X
Factor	B-X
B	B-X
allotype	B-X
and	B-X
HLA	B-X
-	B-X
B	B-X
were	B-X
found	B-X
<EOS>	B-X
A	B-X
crossover	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
occurred	B-X
between	B-X
genes	B-X
for	B-X
Factor	B-X
B	B-X
and	B-X
HLA	B-X
-	B-X
D	B-X
,	B-X
in	B-X
which	B-X
HLA	B-X
-	B-X
D	B-X
segregared	B-X
with	B-X
HLA	B-X
-	B-X
A	B-X
and	B-X
B	B-X

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
second	I-Disease
component	I-Disease
of	I-Disease
complement	I-Disease
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O
<EOS>	B-X
The	B-X
relationship	B-X
of	B-X
the	B-X
genes	B-X
coding	B-X
for	B-X
HLA	B-X
to	B-X
those	B-X
coding	B-X
for	B-X
properdin	B-X
Factor	B-X
B	B-X
allotypes	B-X
and	B-X
for	B-X
deficiency	B-X
of	B-X
the	B-X
second	B-X
component	B-X
of	B-X
complement	B-X
(	B-X
C2	B-X
)	B-X
was	B-X
studied	B-X
in	B-X
families	B-X
of	B-X
patients	B-X
with	B-X
connective	B-X
tissue	B-X
disorders	B-X
<EOS>	B-X
The	B-X
chromosomal	B-X
order	B-X
of	B-X
genes	B-X
controlling	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
,	B-X
properdin	B-X
factor	B-X
B	B-X
,	B-X
and	B-X
deficiency	B-X
of	B-X
the	B-X
second	B-X
component	B-X
of	B-X
complement	B-X
.	B-X
<EOS>	B-X
A	B-X
lod	B-X
score	B-X
of	B-X
16	B-X
between	B-X
HLA	B-X
-	B-X
B	B-X
and	B-X
Factor	B-X
B	B-X
allotypes	B-X
was	B-X
calculated	B-X
at	B-X
a	B-X
maximum	B-X
likelihood	B-X
value	B-X
of	B-X
the	B-X
recombinant	B-X
fraction	B-X
of	B-X
0	B-X
<EOS>	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
the	B-X
genes	B-X
for	B-X
Factor	B-X
B	B-X
and	B-X
C2	B-X
deficiency	B-X
are	B-X
located	B-X
outside	B-X
those	B-X
for	B-X
HLA	B-X
,	B-X
that	B-X
the	B-X
order	B-X
of	B-X
genese	B-X
is	B-X
HLA	B-X
-	B-X
A	B-X
,	B-X
	B-X
-	B-X
B	B-X
,	B-X
	B-X
-	B-X
D	B-X
,	B-X
Factor	B-X
B	B-X
allotype	B-X
,	B-X
C2	B-X
deficiency	B-X
,	B-X
that	B-X
the	B-X
genes	B-X
coding	B-X
for	B-X
C2	B-X
deficiency	B-X
and	B-X
Factor	B-X
B	B-X
allotypes	B-X
are	B-X
approximately	B-X
3	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
5	B-X
centimorgans	B-X
from	B-X
the	B-X
HLA	B-X
-	B-X
A	B-X
and	B-X
HLA	B-X
-	B-X
B	B-X
loci	B-X
,	B-X
and	B-X
that	B-X
the	B-X
apparent	B-X
lack	B-X
of	B-X
recombinants	B-X
between	B-X
the	B-X
Factor	B-X
B	B-X
gene	B-X
and	B-X
C2	B-X
deficiency	B-X
gene	B-X
suggests	B-X
that	B-X
these	B-X
two	B-X
genes	B-X
lie	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
one	B-X
another	B-X

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B-Disease
deficiency	I-Disease
.	O
<EOS>	B-X
Statins	B-X
are	B-X
the	B-X
primary	B-X
therapy	B-X
in	B-X
patient	B-X
with	B-X
heterozygous	B-X
familial	B-X
hypercholesterolemia	B-X
(	B-X
HeFH	B-X
)	B-X
<EOS>	B-X
The	B-X
prenatal	B-X
gene	B-X
test	B-X
results	B-X
indicated	B-X
that	B-X
there	B-X
was	B-X
heterozygous	B-X
mutation	B-X
of	B-X
NSD1	B-X
gene	B-X
c	B-X
<EOS>	B-X
We	B-X
identified	B-X
compound	B-X
heterozygous	B-X
variants	B-X
of	B-X
<EOS>	B-X
The	B-X
phenotype	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
compound	B-X
heterozygous	B-X
genotype	B-X
of	B-X
one	B-X
p	B-X

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B-Disease
deficiency	I-Disease
were	O
found	O
.	O
<EOS>	B-X
12	B-X
families	B-X
with	B-X
15	B-X
matings	B-X
informative	B-X
for	B-X
C2	B-X
deficiency	B-X
were	B-X
found	B-X
<EOS>	B-X
18	B-X
families	B-X
with	B-X
21	B-X
informative	B-X
matings	B-X
for	B-X
both	B-X
properdin	B-X
Factor	B-X
B	B-X
allotype	B-X
and	B-X
HLA	B-X
-	B-X
B	B-X
were	B-X
found	B-X
<EOS>	B-X
The	B-X
chromosomal	B-X
order	B-X
of	B-X
genes	B-X
controlling	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
,	B-X
properdin	B-X
factor	B-X
B	B-X
,	B-X
and	B-X
deficiency	B-X
of	B-X
the	B-X
second	B-X
component	B-X
of	B-X
complement	B-X
.	B-X
<EOS>	B-X
Of	B-X
57	B-X
informative	B-X
meioses	B-X
,	B-X
two	B-X
crossovers	B-X
were	B-X
noted	B-X
between	B-X
the	B-X
C2	B-X
deficiency	B-X
gene	B-X
and	B-X
the	B-X
HLA	B-X
-	B-X
B	B-X
gene	B-X
,	B-X
with	B-X
a	B-X
recombinant	B-X
fraction	B-X
of	B-X
0	B-X

Of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B-Disease
deficiency	I-Disease
gene	O
and	O
the	O
HLA	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

035	O
.	O
<EOS>	B-X
Lorazepam	B-X
in	B-X
sexual	B-X
disorders	B-X
.	B-X

A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B-Disease
deficiency	I-Disease
and	O
HLA	O
-	O
B	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

04	O
.	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
.	O
<EOS>	B-X
18	B-X
families	B-X
with	B-X
21	B-X
informative	B-X
matings	B-X
for	B-X
both	B-X
properdin	B-X
Factor	B-X
B	B-X
allotype	B-X
and	B-X
HLA	B-X
-	B-X
B	B-X
were	B-X
found	B-X
<EOS>	B-X
12	B-X
families	B-X
with	B-X
15	B-X
matings	B-X
informative	B-X
for	B-X
C2	B-X
deficiency	B-X
were	B-X
found	B-X
<EOS>	B-X
The	B-X
chromosomal	B-X
order	B-X
of	B-X
genes	B-X
controlling	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
,	B-X
properdin	B-X
factor	B-X
B	B-X
,	B-X
and	B-X
deficiency	B-X
of	B-X
the	B-X
second	B-X
component	B-X
of	B-X
complement	B-X
.	B-X
<EOS>	B-X
A	B-X
crossover	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
occurred	B-X
between	B-X
genes	B-X
for	B-X
Factor	B-X
B	B-X
and	B-X
HLA	B-X
-	B-X
D	B-X
,	B-X
in	B-X
which	B-X
HLA	B-X
-	B-X
D	B-X
segregared	B-X
with	B-X
HLA	B-X
-	B-X
A	B-X
and	B-X
B	B-X

Of	O
72	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

042	O
.	O
<EOS>	B-X
Determinants	B-X
of	B-X
intracellular	B-X
pH	B-X
in	B-X
the	B-X
erythrocyte	B-X
.	B-X

A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B-Disease
deficiency	I-Disease
are	O
located	O
outside	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B-Disease
deficiency	I-Disease
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B-Disease
deficiency	I-Disease
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	B-Disease
deficiency	I-Disease
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
<EOS>	B-X
Distribution	B-X
of	B-X
emerin	B-X
and	B-X
lamins	B-X
in	B-X
the	B-X
heart	B-X
and	B-X
implications	B-X
for	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Activation	B-X
of	B-X
MAPK	B-X
in	B-X
hearts	B-X
of	B-X
EMD	B-X
null	B-X
mice	B-X
:	B-X
similarities	B-X
between	B-X
mouse	B-X
models	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
and	B-X
autosomal	B-X
dominant	B-X
Emery	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Emerin	B-X
is	B-X
a	B-X
nuclear	B-X
membrane	B-X
protein	B-X
which	B-X
is	B-X
missing	B-X
or	B-X
defective	B-X
in	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
(	B-X
EDMD	B-X
)	B-X
<EOS>	B-X
This	B-X
distribution	B-X
of	B-X
emerin	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
lamin	B-X
A	B-X
,	B-X
a	B-X
candidate	B-X
gene	B-X
for	B-X
an	B-X
autosomal	B-X
form	B-X
of	B-X
EDMD	B-X

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
EDMD	B-Disease
)	O
.	O
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
emerin	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
majority	B-X
of	B-X
cases	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
(	B-X
X	B-X
-	B-X
EDMD	B-X
)	B-X
<EOS>	B-X
Muscle	B-X
cell	B-X
differentiation	B-X
and	B-X
development	B-X
pathway	B-X
defects	B-X
in	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Heart	B-X
disease	B-X
is	B-X
an	B-X
under	B-X
-	B-X
recognized	B-X
cause	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
in	B-X
patients	B-X
with	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
(	B-X
EDMD	B-X
)	B-X
<EOS>	B-X
Muscle	B-X
MRI	B-X
as	B-X
a	B-X
Diagnostic	B-X
Challenge	B-X
in	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
Muscular	B-X
Dystrophy	B-X
.	B-X

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O
<EOS>	B-X
It	B-X
is	B-X
one	B-X
member	B-X
of	B-X
a	B-X
family	B-X
of	B-X
lamina	B-X
-	B-X
associated	B-X
proteins	B-X
which	B-X
includes	B-X
LAP1	B-X
,	B-X
LAP2	B-X
and	B-X
lamin	B-X
B	B-X
receptor	B-X
(	B-X
LBR	B-X
)	B-X
<EOS>	B-X
In	B-X
EDMD	B-X
,	B-X
the	B-X
additional	B-X
absence	B-X
of	B-X
lamin	B-X
B1	B-X
from	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
nuclei	B-X
which	B-X
already	B-X
lack	B-X
emerin	B-X
may	B-X
offer	B-X
an	B-X
alternative	B-X
explanation	B-X
of	B-X
why	B-X
these	B-X
tissues	B-X
are	B-X
particularly	B-X
affected	B-X
<EOS>	B-X
Several	B-X
mAbs	B-X
against	B-X
different	B-X
emerin	B-X
epitopes	B-X
did	B-X
not	B-X
recognize	B-X
intercalated	B-X
discs	B-X
in	B-X
the	B-X
heart	B-X
,	B-X
though	B-X
they	B-X
recognized	B-X
cardiomyocyte	B-X
nuclei	B-X
strongly	B-X
,	B-X
both	B-X
at	B-X
the	B-X
rim	B-X
and	B-X
in	B-X
intranuclear	B-X
spots	B-X
or	B-X
channels	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart	O
.	O
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
16	B-X
monoclonal	B-X
antibodies	B-X
(	B-X
mAbs	B-X
)	B-X
has	B-X
been	B-X
mapped	B-X
to	B-X
six	B-X
specific	B-X
sites	B-X
throughout	B-X
the	B-X
emerin	B-X
molecule	B-X
using	B-X
phage	B-X
-	B-X
displayed	B-X
peptide	B-X
libraries	B-X
and	B-X
has	B-X
been	B-X
used	B-X
to	B-X
localize	B-X
emerin	B-X
in	B-X
human	B-X
and	B-X
rabbit	B-X
heart	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X
<EOS>	B-X
These	B-X
results	B-X
would	B-X
not	B-X
be	B-X
expected	B-X
if	B-X
immunostaining	B-X
at	B-X
intercalated	B-X
discs	B-X
were	B-X
due	B-X
to	B-X
a	B-X
product	B-X
of	B-X
the	B-X
emerin	B-X
gene	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
cast	B-X
some	B-X
doubt	B-X
upon	B-X
the	B-X
hypothesis	B-X
that	B-X
cardiac	B-X
defects	B-X
in	B-X
EDMD	B-X
are	B-X
caused	B-X
by	B-X
absence	B-X
of	B-X
emerin	B-X
from	B-X
intercalated	B-X
discs	B-X
<EOS>	B-X
Although	B-X
emerin	B-X
was	B-X
abundant	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
it	B-X
was	B-X
absent	B-X
from	B-X
many	B-X
non	B-X
-	B-X
myocyte	B-X
cells	B-X
in	B-X
the	B-X
heart	B-X

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O
<EOS>	B-X
Sbh1	B-X
,	B-X
the	B-X
most	B-X
divergent	B-X
,	B-X
contains	B-X
multiple	B-X
phosphorylation	B-X
sites	B-X
,	B-X
which	B-X
may	B-X
allow	B-X
it	B-X
to	B-X
regulate	B-X
entry	B-X
into	B-X
the	B-X
secretory	B-X
pathway	B-X
in	B-X
a	B-X
species	B-X
-	B-X
	B-X
and	B-X
protein	B-X
-	B-X
specific	B-X
manner	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
work	B-X
was	B-X
to	B-X
identify	B-X
previously	B-X
unknown	B-X
functions	B-X
of	B-X
APOE	B-X
based	B-X
on	B-X
the	B-X
detection	B-X
of	B-X
novel	B-X
APOE	B-X
protein	B-X
-	B-X
protein	B-X
interaction	B-X
candidates	B-X
<EOS>	B-X
Following	B-X
this	B-X
idea	B-X
,	B-X
this	B-X
paper	B-X
proposes	B-X
a	B-X
novel	B-X
and	B-X
simple	B-X
shadow	B-X
removal	B-X
method	B-X
based	B-X
on	B-X
a	B-X
differential	B-X
correction	B-X
calculation	B-X
between	B-X
the	B-X
pixel	B-X
values	B-X
of	B-X
Red	B-X
,	B-X
Green	B-X
and	B-X
Blue	B-X
channels	B-X
<EOS>	B-X
Notably	B-X
,	B-X
reactions	B-X
with	B-X
neutral	B-X
ozone	B-X
and	B-X
OH	B-X
radical	B-X
proceed	B-X
through	B-X
low	B-X
-	B-X
energy	B-X
concerted	B-X
mechanisms	B-X
involving	B-X
asynchronous	B-X
transition	B-X
structures	B-X

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
.	O
<EOS>	B-X
A	B-X
polyclonal	B-X
rabbit	B-X
antiserum	B-X
against	B-X
emerin	B-X
did	B-X
recognize	B-X
both	B-X
nuclear	B-X
membrane	B-X
and	B-X
intercalated	B-X
discs	B-X
but	B-X
,	B-X
after	B-X
affinity	B-X
purification	B-X
against	B-X
a	B-X
pure	B-X
-	B-X
emerin	B-X
band	B-X
on	B-X
a	B-X
western	B-X
blot	B-X
,	B-X
it	B-X
stained	B-X
only	B-X
the	B-X
nuclear	B-X
membrane	B-X
<EOS>	B-X
Several	B-X
mAbs	B-X
against	B-X
different	B-X
emerin	B-X
epitopes	B-X
did	B-X
not	B-X
recognize	B-X
intercalated	B-X
discs	B-X
in	B-X
the	B-X
heart	B-X
,	B-X
though	B-X
they	B-X
recognized	B-X
cardiomyocyte	B-X
nuclei	B-X
strongly	B-X
,	B-X
both	B-X
at	B-X
the	B-X
rim	B-X
and	B-X
in	B-X
intranuclear	B-X
spots	B-X
or	B-X
channels	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X
<EOS>	B-X
Although	B-X
emerin	B-X
was	B-X
abundant	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
it	B-X
was	B-X
absent	B-X
from	B-X
many	B-X
non	B-X
-	B-X
myocyte	B-X
cells	B-X
in	B-X
the	B-X
heart	B-X

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B-Disease
defects	I-Disease
in	O
EDMD	B-Disease
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O
<EOS>	B-X
These	B-X
results	B-X
support	B-X
the	B-X
feasibility	B-X
of	B-X
developing	B-X
a	B-X
pBCI	B-X
for	B-X
detecting	B-X
not	B-X
only	B-X
the	B-X
level	B-X
,	B-X
but	B-X
also	B-X
the	B-X
type	B-X
,	B-X
of	B-X
attentional	B-X
resources	B-X
being	B-X
required	B-X
of	B-X
the	B-X
user	B-X
at	B-X
a	B-X
given	B-X
time	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
multipatient	B-X
simulations	B-X
may	B-X
be	B-X
an	B-X
effective	B-X
strategy	B-X
to	B-X
better	B-X
prepare	B-X
students	B-X
for	B-X
the	B-X
health	B-X
care	B-X
system	B-X
's	B-X
demands	B-X
<EOS>	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
generated	B-X
pressures	B-X
are	B-X
sufficient	B-X
to	B-X
produce	B-X
acoustic	B-X
cavitation	B-X
due	B-X
to	B-X
resonance	B-X
in	B-X
the	B-X
irradiated	B-X
object	B-X
<EOS>	B-X
While	B-X
metal	B-X
sulfides	B-X
have	B-X
extensively	B-X
investigated	B-X
as	B-X
electrode	B-X
materials	B-X
for	B-X
supercapacitors	B-X
,	B-X
the	B-X
further	B-X
optimization	B-X
of	B-X
their	B-X
material	B-X
system	B-X
is	B-X
still	B-X
necessary	B-X
to	B-X
achieve	B-X
satisfied	B-X
performance	B-X

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O
<EOS>	B-X
Although	B-X
emerin	B-X
was	B-X
abundant	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
it	B-X
was	B-X
absent	B-X
from	B-X
many	B-X
non	B-X
-	B-X
myocyte	B-X
cells	B-X
in	B-X
the	B-X
heart	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X
<EOS>	B-X
Several	B-X
mAbs	B-X
against	B-X
different	B-X
emerin	B-X
epitopes	B-X
did	B-X
not	B-X
recognize	B-X
intercalated	B-X
discs	B-X
in	B-X
the	B-X
heart	B-X
,	B-X
though	B-X
they	B-X
recognized	B-X
cardiomyocyte	B-X
nuclei	B-X
strongly	B-X
,	B-X
both	B-X
at	B-X
the	B-X
rim	B-X
and	B-X
in	B-X
intranuclear	B-X
spots	B-X
or	B-X
channels	B-X
<EOS>	B-X
A	B-X
polyclonal	B-X
rabbit	B-X
antiserum	B-X
against	B-X
emerin	B-X
did	B-X
recognize	B-X
both	B-X
nuclear	B-X
membrane	B-X
and	B-X
intercalated	B-X
discs	B-X
but	B-X
,	B-X
after	B-X
affinity	B-X
purification	B-X
against	B-X
a	B-X
pure	B-X
-	B-X
emerin	B-X
band	B-X
on	B-X
a	B-X
western	B-X
blot	B-X
,	B-X
it	B-X
stained	B-X
only	B-X
the	B-X
nuclear	B-X
membrane	B-X

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	B-Disease
.	O
<EOS>	B-X
This	B-X
distribution	B-X
of	B-X
emerin	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
lamin	B-X
A	B-X
,	B-X
a	B-X
candidate	B-X
gene	B-X
for	B-X
an	B-X
autosomal	B-X
form	B-X
of	B-X
EDMD	B-X
<EOS>	B-X
Distribution	B-X
of	B-X
emerin	B-X
and	B-X
lamins	B-X
in	B-X
the	B-X
heart	B-X
and	B-X
implications	B-X
for	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Several	B-X
mAbs	B-X
against	B-X
different	B-X
emerin	B-X
epitopes	B-X
did	B-X
not	B-X
recognize	B-X
intercalated	B-X
discs	B-X
in	B-X
the	B-X
heart	B-X
,	B-X
though	B-X
they	B-X
recognized	B-X
cardiomyocyte	B-X
nuclei	B-X
strongly	B-X
,	B-X
both	B-X
at	B-X
the	B-X
rim	B-X
and	B-X
in	B-X
intranuclear	B-X
spots	B-X
or	B-X
channels	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X

In	O
contrast	O
,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X
<EOS>	B-X
In	B-X
EDMD	B-X
,	B-X
the	B-X
additional	B-X
absence	B-X
of	B-X
lamin	B-X
B1	B-X
from	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
nuclei	B-X
which	B-X
already	B-X
lack	B-X
emerin	B-X
may	B-X
offer	B-X
an	B-X
alternative	B-X
explanation	B-X
of	B-X
why	B-X
these	B-X
tissues	B-X
are	B-X
particularly	B-X
affected	B-X
<EOS>	B-X
Although	B-X
emerin	B-X
was	B-X
abundant	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
it	B-X
was	B-X
absent	B-X
from	B-X
many	B-X
non	B-X
-	B-X
myocyte	B-X
cells	B-X
in	B-X
the	B-X
heart	B-X
<EOS>	B-X
A	B-X
polyclonal	B-X
rabbit	B-X
antiserum	B-X
against	B-X
emerin	B-X
did	B-X
recognize	B-X
both	B-X
nuclear	B-X
membrane	B-X
and	B-X
intercalated	B-X
discs	B-X
but	B-X
,	B-X
after	B-X
affinity	B-X
purification	B-X
against	B-X
a	B-X
pure	B-X
-	B-X
emerin	B-X
band	B-X
on	B-X
a	B-X
western	B-X
blot	B-X
,	B-X
it	B-X
stained	B-X
only	B-X
the	B-X
nuclear	B-X
membrane	B-X

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O
<EOS>	B-X
Lamin	B-X
B1	B-X
is	B-X
also	B-X
almost	B-X
completely	B-X
absent	B-X
from	B-X
skeletal	B-X
muscle	B-X
nuclei	B-X
<EOS>	B-X
Although	B-X
emerin	B-X
was	B-X
abundant	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
it	B-X
was	B-X
absent	B-X
from	B-X
many	B-X
non	B-X
-	B-X
myocyte	B-X
cells	B-X
in	B-X
the	B-X
heart	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X
<EOS>	B-X
Distribution	B-X
of	B-X
emerin	B-X
and	B-X
lamins	B-X
in	B-X
the	B-X
heart	B-X
and	B-X
implications	B-X
for	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
.	B-X

In	O
EDMD	B-Disease
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
.	O
<EOS>	B-X
In	B-X
EDMD	B-X
,	B-X
the	B-X
additional	B-X
absence	B-X
of	B-X
lamin	B-X
B1	B-X
from	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
nuclei	B-X
which	B-X
already	B-X
lack	B-X
emerin	B-X
may	B-X
offer	B-X
an	B-X
alternative	B-X
explanation	B-X
of	B-X
why	B-X
these	B-X
tissues	B-X
are	B-X
particularly	B-X
affected	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
lamin	B-X
B1	B-X
was	B-X
absent	B-X
from	B-X
cardiomyocyte	B-X
nuclei	B-X
,	B-X
showing	B-X
that	B-X
lamin	B-X
B1	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
localization	B-X
of	B-X
emerin	B-X
to	B-X
the	B-X
nuclear	B-X
lamina	B-X
<EOS>	B-X
Distribution	B-X
of	B-X
emerin	B-X
and	B-X
lamins	B-X
in	B-X
the	B-X
heart	B-X
and	B-X
implications	B-X
for	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
.	B-X
<EOS>	B-X
Emerin	B-X
is	B-X
a	B-X
nuclear	B-X
membrane	B-X
protein	B-X
which	B-X
is	B-X
missing	B-X
or	B-X
defective	B-X
in	B-X
Emery	B-X
-	B-X
Dreifuss	B-X
muscular	B-X
dystrophy	B-X
(	B-X
EDMD	B-X
)	B-X

Genetic	O
mapping	O
of	O
the	O
copper	B-Disease
toxicosis	I-Disease
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O

Abnormal	O
hepatic	B-Disease
copper	I-Disease
accumulation	I-Disease
is	O
recognized	O
as	O
an	O
inherited	B-Disease
disorder	I-Disease
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O
<EOS>	B-X
Abnormal	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
inherited	B-X
disorder	B-X
in	B-X
man	B-X
,	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
dog	B-X
<EOS>	B-X
The	B-X
major	B-X
cause	B-X
of	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
in	B-X
man	B-X
is	B-X
a	B-X
dysfunctional	B-X
ATP7B	B-X
gene	B-X
,	B-X
causing	B-X
Wilson	B-X
disease	B-X
(	B-X
WD	B-X
)	B-X
<EOS>	B-X
Genetic	B-X
mapping	B-X
of	B-X
the	B-X
copper	B-X
toxicosis	B-X
locus	B-X
in	B-X
Bedlington	B-X
terriers	B-X
to	B-X
dog	B-X
chromosome	B-X
10	B-X
,	B-X
in	B-X
a	B-X
region	B-X
syntenic	B-X
to	B-X
human	B-X
chromosome	B-X
region	B-X
2p13	B-X
-	B-X
p16	B-X
.	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
ATP7B	B-X
genes	B-X
have	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
mouse	B-X
and	B-X
rat	B-X

The	O
major	O
cause	O
of	O
hepatic	B-Disease
copper	I-Disease
accumulation	I-Disease
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B-Disease
disease	I-Disease
(	O
WD	B-Disease
)	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
ATP7B	B-X
genes	B-X
have	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
mouse	B-X
and	B-X
rat	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
genes	B-X
encoding	B-X
ATP7A	B-X
and	B-X
ATP7B	B-X
lead	B-X
to	B-X
copper	B-X
deficiency	B-X
and	B-X
copper	B-X
toxicity	B-X
disorders	B-X
,	B-X
Menkes	B-X
and	B-X
Wilson	B-X
diseases	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Clusterin	B-X
and	B-X
COMMD1	B-X
independently	B-X
regulate	B-X
degradation	B-X
of	B-X
the	B-X
mammalian	B-X
copper	B-X
ATPases	B-X
ATP7A	B-X
and	B-X
ATP7B	B-X
.	B-X
<EOS>	B-X
Abnormal	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
inherited	B-X
disorder	B-X
in	B-X
man	B-X
,	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
dog	B-X

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B-Disease
overload	I-Disease
disease	O
non	B-Disease
-	I-Disease
Indian	I-Disease
childhood	I-Disease
cirrhosis	I-Disease
,	O
indicating	O
genetic	O
heterogeneity	O
.	O
<EOS>	B-X
The	B-X
ATP7B	B-X
gene	B-X
has	B-X
been	B-X
excluded	B-X
in	B-X
the	B-X
much	B-X
rarer	B-X
human	B-X
copper	B-X
overload	B-X
disease	B-X
non	B-X
-	B-X
Indian	B-X
childhood	B-X
cirrhosis	B-X
,	B-X
indicating	B-X
genetic	B-X
heterogeneity	B-X
<EOS>	B-X
The	B-X
major	B-X
cause	B-X
of	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
in	B-X
man	B-X
is	B-X
a	B-X
dysfunctional	B-X
ATP7B	B-X
gene	B-X
,	B-X
causing	B-X
Wilson	B-X
disease	B-X
(	B-X
WD	B-X
)	B-X
<EOS>	B-X
Abnormal	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
inherited	B-X
disorder	B-X
in	B-X
man	B-X
,	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
dog	B-X
<EOS>	B-X
A	B-X
transcribed	B-X
sequence	B-X
identified	B-X
from	B-X
the	B-X
C04107	B-X
-	B-X
containing	B-X
BAC	B-X
was	B-X
found	B-X
to	B-X
be	B-X
homologous	B-X
to	B-X
a	B-X
gene	B-X
expressed	B-X
from	B-X
human	B-X
chromosome	B-X
2p13	B-X
-	B-X
p16	B-X
,	B-X
a	B-X
region	B-X
devoid	B-X
of	B-X
any	B-X
positional	B-X
candidate	B-X
genes	B-X

By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B-Disease
toxicosis	I-Disease
(	O
CT	B-Disease
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B-Disease
disease	I-Disease
.	O
<EOS>	B-X
By	B-X
investigating	B-X
the	B-X
common	B-X
autosomal	B-X
recessive	B-X
copper	B-X
toxicosis	B-X
(	B-X
CT	B-X
)	B-X
in	B-X
Bedlington	B-X
terriers	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
new	B-X
locus	B-X
involved	B-X
in	B-X
progressive	B-X
liver	B-X
disease	B-X
<EOS>	B-X
Genetic	B-X
mapping	B-X
of	B-X
the	B-X
copper	B-X
toxicosis	B-X
locus	B-X
in	B-X
Bedlington	B-X
terriers	B-X
to	B-X
dog	B-X
chromosome	B-X
10	B-X
,	B-X
in	B-X
a	B-X
region	B-X
syntenic	B-X
to	B-X
human	B-X
chromosome	B-X
region	B-X
2p13	B-X
-	B-X
p16	B-X
.	B-X
<EOS>	B-X
The	B-X
major	B-X
cause	B-X
of	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
in	B-X
man	B-X
is	B-X
a	B-X
dysfunctional	B-X
ATP7B	B-X
gene	B-X
,	B-X
causing	B-X
Wilson	B-X
disease	B-X
(	B-X
WD	B-X
)	B-X
<EOS>	B-X
Abnormal	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
inherited	B-X
disorder	B-X
in	B-X
man	B-X
,	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
dog	B-X

We	O
examined	O
whether	O
the	O
WD	B-Disease
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	B-Disease
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
<EOS>	B-X
We	B-X
examined	B-X
whether	B-X
the	B-X
WD	B-X
gene	B-X
ATP7B	B-X
was	B-X
also	B-X
causative	B-X
for	B-X
CT	B-X
by	B-X
investigating	B-X
the	B-X
chromosomal	B-X
co	B-X
-	B-X
localization	B-X
of	B-X
ATP7B	B-X
and	B-X
C04107	B-X
,	B-X
using	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
(	B-X
FISH	B-X
)	B-X
<EOS>	B-X
Genetic	B-X
mapping	B-X
of	B-X
the	B-X
copper	B-X
toxicosis	B-X
locus	B-X
in	B-X
Bedlington	B-X
terriers	B-X
to	B-X
dog	B-X
chromosome	B-X
10	B-X
,	B-X
in	B-X
a	B-X
region	B-X
syntenic	B-X
to	B-X
human	B-X
chromosome	B-X
region	B-X
2p13	B-X
-	B-X
p16	B-X
.	B-X
<EOS>	B-X
The	B-X
major	B-X
cause	B-X
of	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
in	B-X
man	B-X
is	B-X
a	B-X
dysfunctional	B-X
ATP7B	B-X
gene	B-X
,	B-X
causing	B-X
Wilson	B-X
disease	B-X
(	B-X
WD	B-X
)	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
ATP7B	B-X
genes	B-X
have	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
mouse	B-X
and	B-X
rat	B-X

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	B-Disease
.	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	O
WD	B-Disease
cannot	O
be	O
homologous	O
to	O
CT	B-Disease
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B-Disease
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O
.	O
<EOS>	B-X
The	B-X
copper	B-X
transport	B-X
genes	B-X
CTR1	B-X
and	B-X
CTR2	B-X
were	B-X
also	B-X
excluded	B-X
as	B-X
candidate	B-X
genes	B-X
for	B-X
CT	B-X
since	B-X
they	B-X
both	B-X
mapped	B-X
to	B-X
canine	B-X
chromosome	B-X
region	B-X
CFA11q22	B-X
<EOS>	B-X
Genetic	B-X
mapping	B-X
of	B-X
the	B-X
copper	B-X
toxicosis	B-X
locus	B-X
in	B-X
Bedlington	B-X
terriers	B-X
to	B-X
dog	B-X
chromosome	B-X
10	B-X
,	B-X
in	B-X
a	B-X
region	B-X
syntenic	B-X
to	B-X
human	B-X
chromosome	B-X
region	B-X
2p13	B-X
-	B-X
p16	B-X
.	B-X
<EOS>	B-X
The	B-X
major	B-X
cause	B-X
of	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
in	B-X
man	B-X
is	B-X
a	B-X
dysfunctional	B-X
ATP7B	B-X
gene	B-X
,	B-X
causing	B-X
Wilson	B-X
disease	B-X
(	B-X
WD	B-X
)	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
ATP7B	B-X
genes	B-X
have	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
mouse	B-X
and	B-X
rat	B-X

2	O
-	O
22	O
.	O
<EOS>	B-X
application	B-X
of	B-X
BA	B-X
1	B-X
<EOS>	B-X
(	B-X
Contrary	B-X
to	B-X
BA	B-X
1	B-X
,	B-X
250	B-X
-	B-X
min	B-X
hyperglycemia	B-X
caused	B-X
no	B-X
further	B-X
improvement	B-X
of	B-X
the	B-X
recovery	B-X
rate	B-X
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
<EOS>	B-X
Experiments	B-X
in	B-X
214	B-X
DS	B-X
carcinosarcoma	B-X
bearing	B-X
Wistar	B-X
rats	B-X
have	B-X
shown	B-X
that	B-X
BA	B-X
1	B-X
,	B-X
at	B-X
a	B-X
dosage	B-X
of	B-X
only	B-X
about	B-X
12	B-X
percent	B-X
LD50	B-X
(	B-X
150	B-X
mg	B-X
kg	B-X
)	B-X
and	B-X
negligible	B-X
lethality	B-X
(	B-X
1	B-X

5	O
.	O
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
.	O
<EOS>	B-X
A	B-X
transcribed	B-X
sequence	B-X
identified	B-X
from	B-X
the	B-X
C04107	B-X
-	B-X
containing	B-X
BAC	B-X
was	B-X
found	B-X
to	B-X
be	B-X
homologous	B-X
to	B-X
a	B-X
gene	B-X
expressed	B-X
from	B-X
human	B-X
chromosome	B-X
2p13	B-X
-	B-X
p16	B-X
,	B-X
a	B-X
region	B-X
devoid	B-X
of	B-X
any	B-X
positional	B-X
candidate	B-X
genes	B-X
<EOS>	B-X
Genetic	B-X
mapping	B-X
of	B-X
the	B-X
copper	B-X
toxicosis	B-X
locus	B-X
in	B-X
Bedlington	B-X
terriers	B-X
to	B-X
dog	B-X
chromosome	B-X
10	B-X
,	B-X
in	B-X
a	B-X
region	B-X
syntenic	B-X
to	B-X
human	B-X
chromosome	B-X
region	B-X
2p13	B-X
-	B-X
p16	B-X
.	B-X
<EOS>	B-X
The	B-X
ATP7B	B-X
gene	B-X
has	B-X
been	B-X
excluded	B-X
in	B-X
the	B-X
much	B-X
rarer	B-X
human	B-X
copper	B-X
overload	B-X
disease	B-X
non	B-X
-	B-X
Indian	B-X
childhood	B-X
cirrhosis	B-X
,	B-X
indicating	B-X
genetic	B-X
heterogeneity	B-X
<EOS>	B-X
Abnormal	B-X
hepatic	B-X
copper	B-X
accumulation	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
inherited	B-X
disorder	B-X
in	B-X
man	B-X
,	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
dog	B-X

Molecular	O
analysis	O
of	O
the	O
APC	B-Disease
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B-Disease
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	B-Disease
amino	O
acid	O
changes	O
in	O
colorectal	B-Disease
cancer	I-Disease
predisposition	O
.	O
<EOS>	B-X
Molecular	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
in	B-X
205	B-X
families	B-X
:	B-X
extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
FAP	B-X
and	B-X
evidence	B-X
for	B-X
the	B-X
role	B-X
of	B-X
APC	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
colorectal	B-X
cancer	B-X
predisposition	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
direct	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
for	B-X
nine	B-X
extracolonic	B-X
manifestations	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
incidence	B-X
of	B-X
APC	B-X
mutations	B-X
in	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
This	B-X
study	B-X
also	B-X
provided	B-X
evidence	B-X
for	B-X
the	B-X
pathological	B-X
nature	B-X
of	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
APC	B-X
associated	B-X
with	B-X
both	B-X
FAP	B-X
and	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Amino	B-X
acid	B-X
changes	B-X
were	B-X
identified	B-X
in	B-X
four	B-X
patients	B-X
,	B-X
three	B-X
of	B-X
whom	B-X
belonged	B-X
to	B-X
the	B-X
non	B-X
-	B-X
FAP	B-X
group	B-X
of	B-X
colorectal	B-X
cancer	B-X
patients	B-X

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B-Disease
cancer	I-Disease
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
mutations	O
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B-Disease
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B-Disease
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
direct	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
for	B-X
nine	B-X
extracolonic	B-X
manifestations	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
incidence	B-X
of	B-X
APC	B-X
mutations	B-X
in	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Molecular	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
in	B-X
205	B-X
families	B-X
:	B-X
extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
FAP	B-X
and	B-X
evidence	B-X
for	B-X
the	B-X
role	B-X
of	B-X
APC	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
colorectal	B-X
cancer	B-X
predisposition	B-X
.	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
identified	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
nature	B-X
of	B-X
certain	B-X
extracolonic	B-X
manifestations	B-X
in	B-X
FAP	B-X
patients	B-X
belonging	B-X
to	B-X
three	B-X
mutation	B-X
subgroups	B-X
<EOS>	B-X
This	B-X
study	B-X
also	B-X
provided	B-X
evidence	B-X
for	B-X
the	B-X
pathological	B-X
nature	B-X
of	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
APC	B-X
associated	B-X
with	B-X
both	B-X
FAP	B-X
and	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
patients	B-X

METHODS	O
The	O
APC	B-Disease
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B-Disease
and	O
15	O
non	O
-	O
FAP	O
colorectal	B-Disease
cancer	I-Disease
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O
<EOS>	B-X
The	B-X
APC	B-X
gene	B-X
was	B-X
analysed	B-X
in	B-X
190	B-X
unrelated	B-X
FAP	B-X
and	B-X
15	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
patients	B-X
using	B-X
denaturing	B-X
gradient	B-X
gel	B-X
electrophoresis	B-X
,	B-X
the	B-X
protein	B-X
truncation	B-X
test	B-X
,	B-X
and	B-X
direct	B-X
sequencing	B-X
<EOS>	B-X
Extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
made	B-X
in	B-X
this	B-X
study	B-X
may	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
determine	B-X
the	B-X
most	B-X
appropriate	B-X
surveillance	B-X
and	B-X
prophylactic	B-X
treatment	B-X
regimens	B-X
for	B-X
those	B-X
patients	B-X
with	B-X
mutations	B-X
associated	B-X
with	B-X
life	B-X
threatening	B-X
conditions	B-X
<EOS>	B-X
Chain	B-X
terminating	B-X
signals	B-X
were	B-X
only	B-X
identified	B-X
in	B-X
patients	B-X
belonging	B-X
to	B-X
the	B-X
FAP	B-X
group	B-X
(	B-X
105	B-X
patients	B-X
)	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
direct	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
for	B-X
nine	B-X
extracolonic	B-X
manifestations	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
incidence	B-X
of	B-X
APC	B-X
mutations	B-X
in	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B-Disease
group	O
(	O
105	O
patients	O
)	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B-Disease
cancer	I-Disease
patients	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B-Disease
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
identified	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
nature	B-X
of	B-X
certain	B-X
extracolonic	B-X
manifestations	B-X
in	B-X
FAP	B-X
patients	B-X
belonging	B-X
to	B-X
three	B-X
mutation	B-X
subgroups	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
direct	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
for	B-X
nine	B-X
extracolonic	B-X
manifestations	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
incidence	B-X
of	B-X
APC	B-X
mutations	B-X
in	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
made	B-X
in	B-X
this	B-X
study	B-X
may	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
determine	B-X
the	B-X
most	B-X
appropriate	B-X
surveillance	B-X
and	B-X
prophylactic	B-X
treatment	B-X
regimens	B-X
for	B-X
those	B-X
patients	B-X
with	B-X
mutations	B-X
associated	B-X
with	B-X
life	B-X
threatening	B-X
conditions	B-X
<EOS>	B-X
Chain	B-X
terminating	B-X
signals	B-X
were	B-X
only	B-X
identified	B-X
in	B-X
patients	B-X
belonging	B-X
to	B-X
the	B-X
FAP	B-X
group	B-X
(	B-X
105	B-X
patients	B-X
)	B-X

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
.	O
<EOS>	B-X
Extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
made	B-X
in	B-X
this	B-X
study	B-X
may	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
determine	B-X
the	B-X
most	B-X
appropriate	B-X
surveillance	B-X
and	B-X
prophylactic	B-X
treatment	B-X
regimens	B-X
for	B-X
those	B-X
patients	B-X
with	B-X
mutations	B-X
associated	B-X
with	B-X
life	B-X
threatening	B-X
conditions	B-X
<EOS>	B-X
Genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
identified	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
nature	B-X
of	B-X
certain	B-X
extracolonic	B-X
manifestations	B-X
in	B-X
FAP	B-X
patients	B-X
belonging	B-X
to	B-X
three	B-X
mutation	B-X
subgroups	B-X
<EOS>	B-X
The	B-X
APC	B-X
gene	B-X
was	B-X
analysed	B-X
in	B-X
190	B-X
unrelated	B-X
FAP	B-X
and	B-X
15	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
patients	B-X
using	B-X
denaturing	B-X
gradient	B-X
gel	B-X
electrophoresis	B-X
,	B-X
the	B-X
protein	B-X
truncation	B-X
test	B-X
,	B-X
and	B-X
direct	B-X
sequencing	B-X
<EOS>	B-X
Molecular	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
in	B-X
205	B-X
families	B-X
:	B-X
extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
FAP	B-X
and	B-X
evidence	B-X
for	B-X
the	B-X
role	B-X
of	B-X
APC	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
colorectal	B-X
cancer	B-X
predisposition	B-X
.	B-X

This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	B-Disease
and	O
non	O
-	O
FAP	O
colorectal	B-Disease
cancer	I-Disease
patients	O
.	O
.	O
<EOS>	B-X
This	B-X
study	B-X
also	B-X
provided	B-X
evidence	B-X
for	B-X
the	B-X
pathological	B-X
nature	B-X
of	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
APC	B-X
associated	B-X
with	B-X
both	B-X
FAP	B-X
and	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Amino	B-X
acid	B-X
changes	B-X
were	B-X
identified	B-X
in	B-X
four	B-X
patients	B-X
,	B-X
three	B-X
of	B-X
whom	B-X
belonged	B-X
to	B-X
the	B-X
non	B-X
-	B-X
FAP	B-X
group	B-X
of	B-X
colorectal	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Molecular	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
in	B-X
205	B-X
families	B-X
:	B-X
extended	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
in	B-X
FAP	B-X
and	B-X
evidence	B-X
for	B-X
the	B-X
role	B-X
of	B-X
APC	B-X
amino	B-X
acid	B-X
changes	B-X
in	B-X
colorectal	B-X
cancer	B-X
predisposition	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
direct	B-X
mutation	B-X
analysis	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
genotype	B-X
-	B-X
phenotype	B-X
correlations	B-X
for	B-X
nine	B-X
extracolonic	B-X
manifestations	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
incidence	B-X
of	B-X
APC	B-X
mutations	B-X
in	B-X
non	B-X
-	B-X
FAP	B-X
colorectal	B-X
cancer	B-X

Inherited	B-Disease
colorectal	I-Disease
polyposis	I-Disease
and	O
cancer	B-Disease
risk	O
of	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O
<EOS>	B-X
Inherited	B-X
colorectal	B-X
polyposis	B-X
and	B-X
cancer	B-X
risk	B-X
of	B-X
the	B-X
APC	B-X
I1307K	B-X
polymorphism	B-X
.	B-X
<EOS>	B-X
or	B-X
colorectal	B-X
cancer	B-X
,	B-X
for	B-X
the	B-X
APC	B-X
I1307K	B-X
polymorphism	B-X
<EOS>	B-X
7	B-X
for	B-X
colorectal	B-X
neoplasia	B-X
(	B-X
both	B-X
P=	B-X
<EOS>	B-X
Unidentified	B-X
predisposition	B-X
genes	B-X
almost	B-X
certainly	B-X
exist	B-X

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B-Disease
tumor	I-Disease
formation	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
syndrome	I-Disease
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
and	B-X
somatic	B-X
truncating	B-X
mutations	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
are	B-X
thought	B-X
to	B-X
initiate	B-X
colorectal	B-X
tumor	B-X
formation	B-X
in	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
syndrome	B-X
and	B-X
sporadic	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
noncarriers	B-X
,	B-X
APC	B-X
I1307K	B-X
carriers	B-X
had	B-X
increased	B-X
numbers	B-X
of	B-X
adenomas	B-X
and	B-X
colorectal	B-X
cancers	B-X
per	B-X
patient	B-X
(	B-X
P=	B-X
<EOS>	B-X
The	B-X
estimated	B-X
relative	B-X
risk	B-X
for	B-X
carriers	B-X
may	B-X
justify	B-X
specific	B-X
clinical	B-X
screening	B-X
for	B-X
the	B-X
360,000	B-X
Americans	B-X
expected	B-X
to	B-X
harbor	B-X
this	B-X
allele	B-X
,	B-X
and	B-X
genetic	B-X
testing	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
long	B-X
-	B-X
term	B-X
-	B-X
outcome	B-X
studies	B-X
may	B-X
impact	B-X
significantly	B-X
on	B-X
colorectal	B-X
cancer	B-X
prevention	B-X
in	B-X
this	B-X
population	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
APC	B-X
I1307K	B-X
variant	B-X
leads	B-X
to	B-X
increased	B-X
adenoma	B-X
formation	B-X
and	B-X
directly	B-X
contributes	B-X
to	B-X
3	B-X
%	B-X
	B-X
-	B-X
4	B-X
%	B-X
of	B-X
all	B-X
Ashkenazi	B-X
Jewish	B-X
colorectal	B-X
cancer	B-X

Recently	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B-Disease
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
an	B-X
isoleucine	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
lysine	B-X
polymorphism	B-X
at	B-X
codon	B-X
1307	B-X
(	B-X
I1307K	B-X
)	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
6	B-X
%	B-X
	B-X
-	B-X
7	B-X
%	B-X
of	B-X
the	B-X
Ashkenazi	B-X
Jewish	B-X
population	B-X
<EOS>	B-X
Recently	B-X
,	B-X
an	B-X
isoleucine	B-X
-	B-X
lysine	B-X
polymorphism	B-X
at	B-X
codon	B-X
1307	B-X
(	B-X
I1307K	B-X
)	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
6	B-X
-	B-X
7	B-X
%	B-X
of	B-X
the	B-X
Ashkenazi	B-X
Jewish	B-X
population	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
APC	B-X
I1307K	B-X
variant	B-X
leads	B-X
to	B-X
increased	B-X
adenoma	B-X
formation	B-X
and	B-X
directly	B-X
contributes	B-X
to	B-X
3	B-X
%	B-X
	B-X
-	B-X
4	B-X
%	B-X
of	B-X
all	B-X
Ashkenazi	B-X
Jewish	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
The	B-X
estimated	B-X
relative	B-X
risk	B-X
for	B-X
carriers	B-X
may	B-X
justify	B-X
specific	B-X
clinical	B-X
screening	B-X
for	B-X
Turkish	B-X
people	B-X
expected	B-X
to	B-X
harbor	B-X
this	B-X
allele	B-X
,	B-X
and	B-X
genetic	B-X
testing	B-X
in	B-X
the	B-X
long	B-X
term	B-X
may	B-X
significantly	B-X
promote	B-X
colorectal	B-X
cancer	B-X
prevention	B-X
in	B-X
this	B-X
population	B-X

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B-Disease
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B-Disease
polyps	I-Disease
and	O
.	O
or	O
colorectal	B-Disease
cancer	I-Disease
,	I-Disease
for	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
risk	B-X
of	B-X
this	B-X
common	B-X
APC	B-X
allelic	B-X
variant	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
a	B-X
cohort	B-X
of	B-X
unselected	B-X
Turkish	B-X
subjects	B-X
with	B-X
stomach	B-X
or	B-X
colorectal	B-X
cancer	B-X
(	B-X
or	B-X
both	B-X
)	B-X
was	B-X
analyzed	B-X
for	B-X
the	B-X
APC	B-X
I1307K	B-X
polymorphism	B-X
<EOS>	B-X
The	B-X
probability	B-X
of	B-X
colorectal	B-X
cancer	B-X
is	B-X
moderately	B-X
increased	B-X
among	B-X
carriers	B-X
of	B-X
the	B-X
APC	B-X
I1307K	B-X
polymorphism	B-X
<EOS>	B-X
A	B-X
missense	B-X
mutation	B-X
within	B-X
the	B-X
APC	B-X
gene	B-X
,	B-X
I1307K	B-X
,	B-X
was	B-X
described	B-X
in	B-X
Ashkenazi	B-X
individuals	B-X
at	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
and	B-X
in	B-X
the	B-X
general	B-X
population	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
association	B-X
may	B-X
show	B-X
that	B-X
these	B-X
variants	B-X
selected	B-X
for	B-X
this	B-X
study	B-X
are	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
colorectal	B-X
carcinogenic	B-X
process	B-X

The	O
APC	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O
<EOS>	B-X
The	B-X
APC	B-X
I1307K	B-X
allele	B-X
was	B-X
identified	B-X
in	B-X
48	B-X
(	B-X
10	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
APC	B-X
I1307K	B-X
variant	B-X
leads	B-X
to	B-X
increased	B-X
adenoma	B-X
formation	B-X
and	B-X
directly	B-X
contributes	B-X
to	B-X
3	B-X
%	B-X
	B-X
-	B-X
4	B-X
%	B-X
of	B-X
all	B-X
Ashkenazi	B-X
Jewish	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
noncarriers	B-X
,	B-X
APC	B-X
I1307K	B-X
carriers	B-X
had	B-X
increased	B-X
numbers	B-X
of	B-X
adenomas	B-X
and	B-X
colorectal	B-X
cancers	B-X
per	B-X
patient	B-X
(	B-X
P=	B-X
<EOS>	B-X
1	B-X
%	B-X
)	B-X
of	B-X
476	B-X
patients	B-X

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O
.	O
<EOS>	B-X
Compared	B-X
with	B-X
the	B-X
frequency	B-X
in	B-X
two	B-X
separate	B-X
population	B-X
control	B-X
groups	B-X
,	B-X
the	B-X
APC	B-X
I1307K	B-X
allele	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
estimated	B-X
relative	B-X
risk	B-X
of	B-X
1	B-X
<EOS>	B-X
Comparing	B-X
the	B-X
frequencies	B-X
of	B-X
the	B-X
two	B-X
separate	B-X
population	B-X
control	B-X
groups	B-X
,	B-X
the	B-X
APC	B-X
I1307K	B-X
allele	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
estimated	B-X
relative	B-X
risk	B-X
of	B-X
1	B-X
<EOS>	B-X
Inherited	B-X
colorectal	B-X
polyposis	B-X
and	B-X
cancer	B-X
risk	B-X
of	B-X
the	B-X
APC	B-X
I1307K	B-X
polymorphism	B-X
.	B-X
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
risk	B-X
of	B-X
this	B-X
common	B-X
APC	B-X
allelic	B-X
variant	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
a	B-X
large	B-X
cohort	B-X
of	B-X
unselected	B-X
Ashkenazi	B-X
Jewish	B-X
subjects	B-X
with	B-X
adenomatous	B-X
polyps	B-X
and	B-X

5	O
-	O
1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

7	O
for	O
colorectal	B-Disease
neoplasia	I-Disease
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B-Disease
and	O
colorectal	B-Disease
cancers	I-Disease
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
noncarriers	B-X
,	B-X
APC	B-X
I1307K	B-X
carriers	B-X
had	B-X
increased	B-X
numbers	B-X
of	B-X
adenomas	B-X
and	B-X
colorectal	B-X
cancers	B-X
per	B-X
patient	B-X
(	B-X
P=	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
APC	B-X
I1307K	B-X
variant	B-X
leads	B-X
to	B-X
increased	B-X
adenoma	B-X
formation	B-X
and	B-X
directly	B-X
contributes	B-X
to	B-X
3	B-X
%	B-X
	B-X
-	B-X
4	B-X
%	B-X
of	B-X
all	B-X
Ashkenazi	B-X
Jewish	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
The	B-X
estimated	B-X
relative	B-X
risk	B-X
for	B-X
carriers	B-X
may	B-X
justify	B-X
specific	B-X
clinical	B-X
screening	B-X
for	B-X
the	B-X
360,000	B-X
Americans	B-X
expected	B-X
to	B-X
harbor	B-X
this	B-X
allele	B-X
,	B-X
and	B-X
genetic	B-X
testing	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
long	B-X
-	B-X
term	B-X
-	B-X
outcome	B-X
studies	B-X
may	B-X
impact	B-X
significantly	B-X
on	B-X
colorectal	B-X
cancer	B-X
prevention	B-X
in	B-X
this	B-X
population	B-X
<EOS>	B-X
Compared	B-X
with	B-X
the	B-X
frequency	B-X
in	B-X
two	B-X
separate	B-X
population	B-X
control	B-X
groups	B-X
,	B-X
the	B-X
APC	B-X
I1307K	B-X
allele	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
estimated	B-X
relative	B-X
risk	B-X
of	B-X
1	B-X

We	O
conclude	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	B-Disease
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-	O
4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	B-Disease
cancer	I-Disease
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
APC	B-X
I1307K	B-X
variant	B-X
leads	B-X
to	B-X
increased	B-X
adenoma	B-X
formation	B-X
and	B-X
directly	B-X
contributes	B-X
to	B-X
3	B-X
%	B-X
	B-X
-	B-X
4	B-X
%	B-X
of	B-X
all	B-X
Ashkenazi	B-X
Jewish	B-X
colorectal	B-X
cancer	B-X
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
and	B-X
somatic	B-X
truncating	B-X
mutations	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
are	B-X
thought	B-X
to	B-X
initiate	B-X
colorectal	B-X
tumor	B-X
formation	B-X
in	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
syndrome	B-X
and	B-X
sporadic	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
respectively	B-X
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
risk	B-X
of	B-X
this	B-X
common	B-X
APC	B-X
allelic	B-X
variant	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
a	B-X
large	B-X
cohort	B-X
of	B-X
unselected	B-X
Ashkenazi	B-X
Jewish	B-X
subjects	B-X
with	B-X
adenomatous	B-X
polyps	B-X
and	B-X
<EOS>	B-X
Recently	B-X
,	B-X
an	B-X
isoleucine	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
lysine	B-X
polymorphism	B-X
at	B-X
codon	B-X
1307	B-X
(	B-X
I1307K	B-X
)	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
6	B-X
%	B-X
	B-X
-	B-X
7	B-X
%	B-X
of	B-X
the	B-X
Ashkenazi	B-X
Jewish	B-X
population	B-X

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B-Disease
cancer	I-Disease
prevention	O
in	O
this	O
population	O
.	O
<EOS>	B-X
The	B-X
estimated	B-X
relative	B-X
risk	B-X
for	B-X
carriers	B-X
may	B-X
justify	B-X
specific	B-X
clinical	B-X
screening	B-X
for	B-X
the	B-X
360,000	B-X
Americans	B-X
expected	B-X
to	B-X
harbor	B-X
this	B-X
allele	B-X
,	B-X
and	B-X
genetic	B-X
testing	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
long	B-X
-	B-X
term	B-X
-	B-X
outcome	B-X
studies	B-X
may	B-X
impact	B-X
significantly	B-X
on	B-X
colorectal	B-X
cancer	B-X
prevention	B-X
in	B-X
this	B-X
population	B-X
<EOS>	B-X
Germ	B-X
-	B-X
line	B-X
and	B-X
somatic	B-X
truncating	B-X
mutations	B-X
of	B-X
the	B-X
APC	B-X
gene	B-X
are	B-X
thought	B-X
to	B-X
initiate	B-X
colorectal	B-X
tumor	B-X
formation	B-X
in	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
syndrome	B-X
and	B-X
sporadic	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
respectively	B-X
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
risk	B-X
of	B-X
this	B-X
common	B-X
APC	B-X
allelic	B-X
variant	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
a	B-X
large	B-X
cohort	B-X
of	B-X
unselected	B-X
Ashkenazi	B-X
Jewish	B-X
subjects	B-X
with	B-X
adenomatous	B-X
polyps	B-X
and	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
noncarriers	B-X
,	B-X
APC	B-X
I1307K	B-X
carriers	B-X
had	B-X
increased	B-X
numbers	B-X
of	B-X
adenomas	B-X
and	B-X
colorectal	B-X
cancers	B-X
per	B-X
patient	B-X
(	B-X
P=	B-X

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B-Disease
-	I-Disease
inherited	I-Disease
breast	I-Disease
carcinomas	I-Disease
.	O
<EOS>	B-X
Localization	B-X
of	B-X
human	B-X
BRCA1	B-X
and	B-X
its	B-X
loss	B-X
in	B-X
high	B-X
-	B-X
grade	B-X
,	B-X
non	B-X
-	B-X
inherited	B-X
breast	B-X
carcinomas	B-X
.	B-X
<EOS>	B-X
Immunohistochemical	B-X
staining	B-X
of	B-X
human	B-X
breast	B-X
specimens	B-X
also	B-X
revealed	B-X
BRCA1	B-X
nuclear	B-X
foci	B-X
in	B-X
benign	B-X
breast	B-X
,	B-X
invasive	B-X
lobular	B-X
cancers	B-X
and	B-X
low	B-X
-	B-X
grade	B-X
ductal	B-X
carcinomas	B-X
<EOS>	B-X
These	B-X
reagents	B-X
detect	B-X
a	B-X
220	B-X
-	B-X
kD	B-X
protein	B-X
localized	B-X
in	B-X
discrete	B-X
nuclear	B-X
foci	B-X
in	B-X
all	B-X
epithelial	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
those	B-X
derived	B-X
from	B-X
breast	B-X
malignancies	B-X
<EOS>	B-X
In	B-X
part	B-X
B	B-X
,	B-X
we	B-X
further	B-X
investigated	B-X
the	B-X
maximum	B-X
tolerated	B-X
dose	B-X
in	B-X
patients	B-X
with	B-X
sporadic	B-X
platinum	B-X
-	B-X
resistant	B-X
high	B-X
-	B-X
grade	B-X
serous	B-X
ovarian	B-X
cancer	B-X
and	B-X
sporadic	B-X
prostate	B-X
cancer	B-X

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	B-Disease
-	O
suppressor	O
gene	O
and	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
non	B-Disease
-	I-Disease
familial	I-Disease
cancers	I-Disease
is	O
unclear	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
link	B-X
between	B-X
the	B-X
BRCA1	B-X
tumour	B-X
-	B-X
suppressor	B-X
gene	B-X
and	B-X
hereditary	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
established	B-X
,	B-X
the	B-X
role	B-X
,	B-X
if	B-X
any	B-X
,	B-X
of	B-X
BRCA1	B-X
in	B-X
non	B-X
-	B-X
familial	B-X
cancers	B-X
is	B-X
unclear	B-X
<EOS>	B-X
Epigenetic	B-X
loss	B-X
,	B-X
however	B-X
,	B-X
has	B-X
not	B-X
received	B-X
general	B-X
acceptance	B-X
due	B-X
to	B-X
controversy	B-X
regarding	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
BRCA1	B-X
proteins	B-X
,	B-X
reports	B-X
of	B-X
which	B-X
have	B-X
ranged	B-X
from	B-X
exclusively	B-X
nuclear	B-X
,	B-X
to	B-X
conditionally	B-X
nuclear	B-X
,	B-X
to	B-X
the	B-X
ER	B-X
/	B-X
golgi	B-X
,	B-X
to	B-X
cytoplasmic	B-X
invaginations	B-X
into	B-X
the	B-X
nucleus	B-X
<EOS>	B-X
BRCA1	B-X
mutations	B-X
are	B-X
rare	B-X
in	B-X
sporadic	B-X
cancers	B-X
,	B-X
but	B-X
loss	B-X
of	B-X
BRCA1	B-X
resulting	B-X
from	B-X
reduced	B-X
expression	B-X
or	B-X
incorrect	B-X
subcellular	B-X
localization	B-X
is	B-X
postulated	B-X
to	B-X
be	B-X
important	B-X
in	B-X
non	B-X
-	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
<EOS>	B-X
These	B-X
reagents	B-X
detect	B-X
a	B-X
220	B-X
-	B-X
kD	B-X
protein	B-X
localized	B-X
in	B-X
discrete	B-X
nuclear	B-X
foci	B-X
in	B-X
all	B-X
epithelial	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
those	B-X
derived	B-X
from	B-X
breast	B-X
malignancies	B-X

BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	B-Disease
cancers	I-Disease
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	B-Disease
-	I-Disease
familial	I-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O
<EOS>	B-X
BRCA1	B-X
mutations	B-X
are	B-X
rare	B-X
in	B-X
sporadic	B-X
cancers	B-X
,	B-X
but	B-X
loss	B-X
of	B-X
BRCA1	B-X
resulting	B-X
from	B-X
reduced	B-X
expression	B-X
or	B-X
incorrect	B-X
subcellular	B-X
localization	B-X
is	B-X
postulated	B-X
to	B-X
be	B-X
important	B-X
in	B-X
non	B-X
-	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
<EOS>	B-X
BRCA1	B-X
mutations	B-X
are	B-X
rare	B-X
in	B-X
sporadic	B-X
cancers	B-X
,	B-X
but	B-X
loss	B-X
of	B-X
BRCA1	B-X
resulting	B-X
from	B-X
reduced	B-X
expression	B-X
or	B-X
incorrect	B-X
subcellular	B-X
localization	B-X
is	B-X
postulated	B-X
to	B-X
be	B-X
important	B-X
in	B-X
non	B-X
-	B-X
familial	B-X
breast	B-X
cancers	B-X
<EOS>	B-X
In	B-X
sporadic	B-X
tumors	B-X
,	B-X
although	B-X
inherent	B-X
gene	B-X
mutations	B-X
are	B-X
rare	B-X
,	B-X
loss	B-X
of	B-X
BRCA1	B-X
,	B-X
resulting	B-X
from	B-X
reduced	B-X
expression	B-X
or	B-X
incorrect	B-X
subcellular	B-X
localization	B-X
,	B-X
is	B-X
postulated	B-X
to	B-X
be	B-X
important	B-X
<EOS>	B-X
Immunohistochemical	B-X
assessment	B-X
of	B-X
BRCA1	B-X
expression	B-X
could	B-X
provide	B-X
additional	B-X
clinically	B-X
relevant	B-X
information	B-X
in	B-X
routine	B-X
classification	B-X
of	B-X
breast	B-X
cancer	B-X

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O
the	O
nucleus	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
genome	B-X
organization	B-X
and	B-X
gene	B-X
activity	B-X
with	B-X
single	B-X
-	B-X
cell	B-X
resolution	B-X
using	B-X
lineage	B-X
tracing	B-X
and	B-X
single	B-X
-	B-X
nucleus	B-X
multiomics	B-X
offers	B-X
new	B-X
insight	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
renal	B-X
injury	B-X
repair	B-X
<EOS>	B-X
Recent	B-X
decades	B-X
provide	B-X
mounting	B-X
evidence	B-X
for	B-X
the	B-X
continual	B-X
increase	B-X
in	B-X
global	B-X
temperatures	B-X
,	B-X
now	B-X
termed	B-X
``	B-X
global	B-X
warming	B-X
,	B-X
''	B-X
to	B-X
the	B-X
point	B-X
of	B-X
drastic	B-X
worldwide	B-X
change	B-X
in	B-X
the	B-X
climate	B-X
<EOS>	B-X
Mechanistically	B-X
,	B-X
our	B-X
findings	B-X
further	B-X
demonstrated	B-X
that	B-X
GPX2	B-X
was	B-X
a	B-X
downstream	B-X
gene	B-X
regulated	B-X
by	B-X
Î²	B-X
-	B-X
catenin	B-X
,	B-X
while	B-X
lenvatinib	B-X
could	B-X
prevent	B-X
nuclear	B-X
translocation	B-X
of	B-X
Î²	B-X
-	B-X
catenin	B-X
and	B-X
further	B-X
inhibit	B-X
GPX2	B-X
expression	B-X
in	B-X
HCC	B-X
cells	B-X
<EOS>	B-X
While	B-X
primary	B-X
clinical	B-X
emphasis	B-X
has	B-X
been	B-X
placed	B-X
on	B-X
motor	B-X
,	B-X
speech	B-X
and	B-X
visual	B-X
deficits	B-X
,	B-X
vascular	B-X
cognitive	B-X
decline	B-X
is	B-X
a	B-X
vastly	B-X
under	B-X
recognized	B-X
and	B-X
devastating	B-X
condition	B-X
afflicting	B-X
millions	B-X
of	B-X
Americans	B-X

In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
.	O

These	O
reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	B-Disease
malignancies	I-Disease
.	O
<EOS>	B-X
These	B-X
reagents	B-X
detect	B-X
a	B-X
220	B-X
-	B-X
kD	B-X
protein	B-X
localized	B-X
in	B-X
discrete	B-X
nuclear	B-X
foci	B-X
in	B-X
all	B-X
epithelial	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
those	B-X
derived	B-X
from	B-X
breast	B-X
malignancies	B-X
<EOS>	B-X
Localization	B-X
of	B-X
human	B-X
BRCA1	B-X
and	B-X
its	B-X
loss	B-X
in	B-X
high	B-X
-	B-X
grade	B-X
,	B-X
non	B-X
-	B-X
inherited	B-X
breast	B-X
carcinomas	B-X
.	B-X
<EOS>	B-X
BRCA1	B-X
mutations	B-X
are	B-X
rare	B-X
in	B-X
sporadic	B-X
cancers	B-X
,	B-X
but	B-X
loss	B-X
of	B-X
BRCA1	B-X
resulting	B-X
from	B-X
reduced	B-X
expression	B-X
or	B-X
incorrect	B-X
subcellular	B-X
localization	B-X
is	B-X
postulated	B-X
to	B-X
be	B-X
important	B-X
in	B-X
non	B-X
-	B-X
familial	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
BRCA1	B-X
expression	B-X
was	B-X
reduced	B-X
or	B-X
undetectable	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
high	B-X
-	B-X
grade	B-X
,	B-X
ductal	B-X
carcinomas	B-X
,	B-X
suggesting	B-X
that	B-X
absence	B-X
of	B-X
BRCA1	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
a	B-X
significant	B-X
percentage	B-X
of	B-X
sporadic	B-X
breast	B-X
cancers	B-X

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B-Disease
lobular	I-Disease
cancers	I-Disease
and	O
low	B-Disease
-	I-Disease
grade	I-Disease
ductal	I-Disease
carcinomas	I-Disease
.	O
<EOS>	B-X
Immunohistochemical	B-X
staining	B-X
of	B-X
human	B-X
breast	B-X
specimens	B-X
also	B-X
revealed	B-X
BRCA1	B-X
nuclear	B-X
foci	B-X
in	B-X
benign	B-X
breast	B-X
,	B-X
invasive	B-X
lobular	B-X
cancers	B-X
and	B-X
low	B-X
-	B-X
grade	B-X
ductal	B-X
carcinomas	B-X
<EOS>	B-X
Localization	B-X
of	B-X
human	B-X
BRCA1	B-X
and	B-X
its	B-X
loss	B-X
in	B-X
high	B-X
-	B-X
grade	B-X
,	B-X
non	B-X
-	B-X
inherited	B-X
breast	B-X
carcinomas	B-X
.	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
resolve	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
have	B-X
comprehensively	B-X
characterized	B-X
19	B-X
anti	B-X
-	B-X
BRCA1	B-X
antibodies	B-X
<EOS>	B-X
Epigenetic	B-X
loss	B-X
,	B-X
however	B-X
,	B-X
has	B-X
not	B-X
received	B-X
general	B-X
acceptance	B-X
due	B-X
to	B-X
controversy	B-X
regarding	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
BRCA1	B-X
proteins	B-X
,	B-X
reports	B-X
of	B-X
which	B-X
have	B-X
ranged	B-X
from	B-X
exclusively	B-X
nuclear	B-X
,	B-X
to	B-X
conditionally	B-X
nuclear	B-X
,	B-X
to	B-X
the	B-X
ER	B-X
/	B-X
golgi	B-X
,	B-X
to	B-X
cytoplasmic	B-X
invaginations	B-X
into	B-X
the	B-X
nucleus	B-X

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B-Disease
carcinomas	I-Disease
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B-Disease
breast	I-Disease
cancers	I-Disease
.	O
.	O
<EOS>	B-X
Microcephalin	B-X
is	B-X
an	B-X
independent	B-X
predictor	B-X
of	B-X
BCSS	B-X
in	B-X
invasive	B-X
ductal	B-X
breast	B-X
cancer	B-X
patients	B-X
and	B-X
may	B-X
prove	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
biomarker	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
aggressive	B-X
breast	B-X
cancers	B-X
<EOS>	B-X
Epigenetic	B-X
mechanisms	B-X
may	B-X
contribute	B-X
to	B-X
reduced	B-X
expression	B-X
of	B-X
the	B-X
tumor	B-X
suppressor	B-X
gene	B-X
BRCA	B-X
-	B-X
1	B-X
in	B-X
sporadic	B-X
breast	B-X
cancers	B-X
<EOS>	B-X
Expression	B-X
of	B-X
BRCA1	B-X
is	B-X
commonly	B-X
decreased	B-X
in	B-X
sporadic	B-X
breast	B-X
tumors	B-X
,	B-X
and	B-X
this	B-X
correlates	B-X
with	B-X
poor	B-X
prognosis	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
BRCA1	B-X
disease	B-X
-	B-X
associated	B-X
mutations	B-X
abrogated	B-X
the	B-X
interaction	B-X
in	B-X
yeast	B-X
,	B-X
and	B-X
BRCA1	B-X
failed	B-X
to	B-X
interact	B-X
with	B-X
MEKK3	B-X
in	B-X
BRCA1	B-X
mutant	B-X
HCC1937	B-X
breast	B-X
cancer	B-X
cells	B-X

